Page last updated: 2024-10-16

adenine and Hepatitis B, Chronic

adenine has been researched along with Hepatitis B, Chronic in 1207 studies

Hepatitis B, Chronic: INFLAMMATION of the LIVER in humans caused by HEPATITIS B VIRUS lasting six months or more. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact.

Research Excerpts

ExcerptRelevanceReference
"Entecavir (ETV) and tenofovir alafenamide fumarate (TAF) have been used widely to treat patients with chronic hepatitis B virus (HBV) infection, but it is still unclear how best to use these drugs."9.51Switching to tenofovir alafenamide versus continued therapy in chronic hepatitis B patients who were treated with entecavir: A prospective, multicenter, randomized controlled study. ( Akahane, T; Inoue, J; Iwata, T; Kisara, N; Kobayashi, T; Masamune, A; Ninomiya, M; Onuki, M; Sano, A; Sato, K; Sato, S; Tsuruoka, M, 2022)
"The aim of this study was to demonstrate how tenofovir alafenamide (TAF) and other hepatitis B treatment drugs differentially impact lipid profiles in chronic hepatitis B patients."9.41Risk of dyslipidemia in chronic hepatitis B patients taking tenofovir alafenamide: a systematic review and meta-analysis. ( Hwang, EG; Jung, EA; Kim, SG; Kim, YS; Yoo, JJ, 2023)
"Treatment with tenofovir disoproxil fumarate has been associated with renal toxicity or reductions in bone mineral density, or both, in some patients with chronic hepatitis B virus (HBV) infection."9.34Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study. ( Agarwal, K; Ahn, SH; Bae, H; Buti, M; Chan, HLY; Chen, CY; Chuang, WL; Flaherty, JF; Fung, S; Gaggar, A; Lampertico, P; Lau, A; Lim, YS; Liu, Y; Ma, X; Ramji, A; Subramanian, GM; Suri, V; Tak, WY; Tam, E; Tan, SK; Trinh, H; Wu, G; Yoon, SK, 2020)
"Tenofovir disoproxil fumarate (TDF) is a first-line treatment for chronic hepatitis B (CHB)."9.30Ten-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B virus infection. ( Buggisch, P; Buti, M; Cathcart, AL; Crans, G; Flaherty, J; Flisiak, R; Gaggar, A; Jump, B; Kaita, K; Krastev, Z; Lee, SS; Manns, M; Marcellin, P; Op den Brouw, M; Petersen, J; Sievert, W; Wong, DK, 2019)
" We divided 48 chronic hepatitis B patients who had taken entecavir (ETV) for ≥2 years into two groups: the ETV continuation (n = 24) and the TAF switching (n = 24) groups, and compared the antiviral effects and safety until 48 weeks after the start of the study."9.30Switching from entecavir to tenofovir alafenamide versus maintaining entecavir for chronic hepatitis B. ( Hagiwara, S; Ida, H; Komeda, Y; Kudo, M; Minami, Y; Nishida, N; Takita, M; Ueshima, K, 2019)
"The nucleos(t)ide analogues (NAs) entecavir (ETV), tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF) are preferred treatment options for patients with chronic hepatitis B infection (CHB)."9.22Review article: switching patients with chronic hepatitis B to tenofovir alafenamide-a review of current data. ( Agarwal, K; Flaherty, JF; Fung, S; Gordon, SC; Hou, J; Kao, JH; Kurosaki, M; Lampertico, P; Lim, YS; Seto, WK; Yee, LJ; Zhao, Y, 2022)
"To explore clinical efficacy of Yiguanjian Decoction (YD) combined Adefovir Dipivoxil Tablet (ADT) in treating HBeAg negative chronic viral hepatitis B (CVHB) active compensated liver cirrhosis (LC) patients."9.22[Efficacy Observation of Yiguanjian Decoction Combined Adefovir Dipivoxil Tablet in Treating HBeAg Negative Chronic Viral Hepatitis B Active Compensated Liver Cirrhosis Patients]. ( Bao, ZY; Duan, SH; Liu, MS; Wang, L; Yuan, XD, 2016)
"Tenofovir disoproxil fumarate (TDF) has demonstrated long-term efficacy and a high barrier to resistance in multiple chronic hepatitis B (CHB) populations outside of China."9.20Tenofovir disoproxil fumarate vs adefovir dipivoxil in Chinese patients with chronic hepatitis B after 48 weeks: a randomized controlled trial. ( Chen, CW; Chen, SJ; Cheng, J; Dong, J; Gao, ZL; Hou, JL; Ji, Y; Jia, JD; Li, J; Mao, Q; Mao, YM; Ning, Q; Niu, JQ; Pan, C; Ren, H; Sheng, JF; Tan, DM; Tang, H; Wang, H; Wu, SM; Xie, Q; Xu, M; Zhang, JM; Zhang, XX; Zhao, W, 2015)
"We evaluated the antiviral response of Asian or Pacific Islander (API) patients with chronic hepatitis B (CHB) who had baseline high viral load (HVL), defined as pre-treatment hepatitis B virus (HBV) DNA ≥9 log10 copies/ml, following up to 288 weeks of tenofovir disoproxil fumarate (TDF) treatment."9.20Tenofovir disoproxil fumarate in Asian or Pacific Islander chronic hepatitis B patients with high viral load (≥ 9 log10 copies/ml). ( Buti, M; Dinh, P; Dusheiko, G; Flaherty, JF; Flisiak, R; Fung, S; Gane, E; Gordon, SC; Horban, A; Jacobson, IM; Kitrinos, KM; Krastev, Z; Marcellin, P; Martins, EB; Petersen, J; Rustgi, VK; Sperl, J; Trinh, H; Yee, LJ, 2015)
"Non-cirrhotic, treatment-naïve subjects with chronic hepatitis B were randomized (1:1:1:1:1) to receive tenofovir alafenamide 8, 25, 40, or 120 mg, or tenofovir disoproxil fumarate 300 mg for 28 days and assessed for safety, antiviral response, and pharmacokinetics, followed-up by off-treatment for 4 weeks."9.20Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection. ( Agarwal, K; Cheng, W; Flaherty, JF; Foster, GR; Fung, SK; Gane, EJ; Lawson, E; McHutchison, JG; Nguyen, TT; Ryder, SD; Sicard, E; Subramanian, GM; Zhao, S, 2015)
"The purpose of this study was to analyze the cost-effectiveness of lamivudine (LMV), telbivudine (LdT), and entecavir (ETV) in treatment of chronic hepatitis B with adefovir dipivoxil (ADV) resistance."9.20Cost-effectiveness analysis of lamivudine, telbivudine, and entecavir in treatment of chronic hepatitis B with adefovir dipivoxil resistance. ( Liu, Y; Qiu, P; Wang, G; Wen, J; Wen, P; Xiao, X; Xu, L; Zhou, SF, 2015)
"This study aimed to research the efficiency of adefovir dipivoxil in hepatitis B e antigen (HBeAg)-negative chronic hepatitis B treatment and in combination with α-2b interferon in the treatment of HBeAg-positive chronic hepatitis B."9.20The curative effect of adefovir dipivoxil treating HBeAg negative chronic hepatitis B and treating HBeAg positive chronic hepatitis B combining interferon α-2b. ( Gu, J; Shen, S; Sun, R; Yu, Z, 2015)
"To compare the efficacies ofentecavir and adefovir in patients with chronic hepatitis B (CHB) and cirrhosis when administered as monotherapies using a 240-week course."9.20[A randomized controlled trial on 240-week monotherapy with entecavir or adefovir in patients with chronic hepatitis B and cirrhosis]. ( Gao, Y; Han, T; Lian, J; Liu, F; Lyu, H; Wang, F; Xiang, H, 2015)
"To prospectively observe the long-term antiviral efficacy and safety of telbivudine (LDT) administered as a monotherapy and as a combination therapy with adefovir dipivoxil (ADV) in patients diagnosed with chronic hepatitis B (CHB) and positivity for hepatitis B e antigen (HBeAg)."9.19[Long-term efficacy and safety of telbivudine as monotherapy and as combination therapy with adefovir dipivoxil in HBeAg-positive chronic hepatitis B patients]. ( Chang, L; Du, Y; Jia, T; Li, H; Li, W; Liu, L; Liu, Y; Peng, D, 2014)
"A 48-week PegIFN therapy was added to HBeAg positive-HIV co-infected patients on TDF and emtricitabine, or lamivudine for at least 6 months."9.19Role of a 48-week pegylated interferon therapy in hepatitis B e antigen positive HIV-co-infected patients on cART including tenofovir: EMVIPEG study. ( Barthe, Y; Bouix, C; Cacoub, P; Carrat, F; Lascoux-Combe, C; Lebossé, F; Maynard-Muet, M; Miailhes, P; Piroth, L; Pol, S; Rey, D; Sogni, P; Zoulim, F, 2014)
"A recent study compared the efficacy of tenofovir disoproxil fumarate (TDF) vs the combination of emtricitabine and TDF (FTC/TDF) in patients with lamivudine-resistant chronic hepatitis B who were treated for as long as 96 weeks."9.19No resistance to tenofovir disoproxil fumarate through 96 weeks of treatment in patients with lamivudine-resistant chronic hepatitis B. ( Corsa, AC; Flaherty, JF; Fung, SK; Gane, E; Kitrinos, KM; Liu, Y; Miller, MD; Mitchell, B, 2014)
"In a study of 266 chronic hepatitis B e antigen (HBeAg)-positive patients, 23 experienced hepatitis B surface antigen (HBsAg) loss with up to 5 years of tenofovir disoproxil fumarate (TDF) treatment."9.19Kinetics of hepatitis B surface antigen loss in patients with HBeAg-positive chronic hepatitis B treated with tenofovir disoproxil fumarate. ( Buti, M; de Man, RA; Dinh, P; Dusheiko, GM; Flaherty, JF; Flisiak, R; Gaggar, A; Gurel, S; Heathcote, EJ; Krastev, Z; Lin, L; Lou, L; Marcellin, P; Massetto, B; McHutchison, JG; Subramanian, GM; Zeuzem, S, 2014)
"The objective of this study was to compare the efficacy and safety of two rescue strategies for hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) patients with resistance to adefovir dipivoxil (ADV)."9.17Efficacy and safety of telbivudine plus adefovir dipivoxil combination therapy and entecavir monotherapy for HBeAg-positive chronic hepatitis B patients with resistance to adefovir dipivoxil. ( Chen, EQ; Liu, K; Lu, JJ; Ma, YJ; Tang, H; Wang, J, 2013)
"Telbivudine (LdT) has demonstrated potent antiviral activity in nucleos(t)ide analogue (NA)-naïve chronic hepatitis B patients (CHB), but data on its efficacy in NA-experienced patients are limited."9.17Efficacy of telbivudine treatment for hepatitis B e antigen-positive chronic hepatitis B patients with poor response to adefovir dipivoxil. ( Bai, XF; Li, Y; Lian, JQ; Wang, JP; Zhang, Y, 2013)
"In this study, we aimed to identify baseline predictors of response in chronic hepatitis B patients treated with a combination of pegylated interferon (PEG-IFN)-α2a and adefovir."9.17Baseline hepatitis B surface antigen (HBsAg) as predictor of sustained HBsAg loss in chronic hepatitis B patients treated with pegylated interferon-α2a and adefovir. ( Beld, MG; de Niet, A; Dijkgraaf, MG; Jansen, L; Jansen, PL; Janssen, HL; Koot, M; Molenkamp, R; Reesink, HW; Rijckborst, V; Takkenberg, RB; Terpstra, V; Weegink, CJ; Zaaijer, HL, 2013)
"A 1-year trial with entecavir plus adefovir resulted in a rate of virological response (VR) higher than that seen with lamivudine plus adefovir in multiple-drug-refractory chronic hepatitis B (CHB) patients."9.17Randomized trial of the virologic response during up to two years of entecavir-adefovir combination therapy in multiple-drug-refractory chronic hepatitis B virus patients. ( Lee, D; Lee, HC; Lee, JY; Lee, YS; Lim, YS; Shim, JH; Suh, DJ, 2013)
"To investigate the efficacy and safety of an extended course (96-week) of combination treatment with peginterferon alfa-2a (Peg-IFNa-2a; 40 kd] plus adefovir (ADV) for treating chronic hepatitis B (CHB) in Chinese patients with negativity for hepatitis B e antigen (HBeAg)."9.17[Efficacy and safety of peginterferon alfa-2a (40 kd) plus adefovir for 96 weeks in HBeAg-negative chronic hepatitis B patients]. ( Cao, ZH; Chen, XY; He, ZM; Jin, Y; Liu, YL; Lu, JF; Ma, LN; Zhang, YH, 2013)
"To compare the efficacy and safety of recombinant human interferon α-2b (INFα-2b) monotherapy and combined therapy with entecavir (ETV) plus adefovir dipivoxil (ADV) in chronic hepatitis B patients with poor response to combined therapy with lamivudine and ADV."9.17[Therapeutic effect of antiviral regimens for chronic hepatitis B refractory to lamivudine plus adefovir]. ( Chen, Z; Li, M; Liu, Z; Wu, J; Xu, G; Zhang, Q, 2013)
" At month 24, virological response rate [hepatitis B virus (HBV) DNA <60 IU/ml] was higher in the adefovir-lamivudine combination group compared with entecavir group (56."9.17Adding adefovir vs. switching to entecavir for lamivudine-resistant chronic hepatitis B (ACE study): a 2-year follow-up randomized controlled trial. ( Baik, SK; Chae, HB; Hong, SP; Kim, CW; Kim, JH; Kim, MY; Kim, YS; Lee, CD; Lee, JI; Lee, JW; Lee, MS; Park, CK; Park, SH; Seo, YS; Um, SH; Yim, HJ; Yoon, EL, 2013)
"Telbivudine therapy with tenofovir intensification at Week 24, where indicated by the Roadmap strategy, appears effective and well tolerated for the treatment of chronic hepatitis B."9.1752-week efficacy and safety of telbivudine with conditional tenofovir intensification at week 24 in HBeAg-positive chronic hepatitis B. ( Bessone, F; Chan, HL; Cheinquer, H; Daruich, J; Dong, Y; Fassio, E; Komolmit, P; Ono, SK; Pathan, R; Pessôa, MG; Piratvisuth, T; Sukeepaisarnjaroen, W; Tanwandee, T; Trylesinski, A; Zeuzem, S, 2013)
"In this study, we aimed to devise a simple scoring system predicting the risk of genotypic resistance (GR) to current rescue therapies for patients with lamivudine (LAM)-resistant chronic hepatitis B."9.16Simple scoring system predicting genotypic resistance during rescue therapy for Lamivudine-resistant chronic hepatitis B. ( Cho, EJ; Hwang, SY; Jang, ES; Kim, CY; Kim, YJ; Kwak, MS; Lee, CH; Lee, HS; Lee, JH; Yang, HJ; Yoon, JH; Yu, SJ, 2012)
"Adefovir dipivoxil (ADV) is a nucleotide analogue with proven efficacy in chronic hepatitis B (CHB)."9.16Five years of treatment with adefovir dipivoxil in Chinese patients with HBeAg-positive chronic hepatitis B. ( Barker, K; Daozhen, X; Dixon, J; Guangbi, Y; Hao, W; Hong, R; JinLin, H; Junqi, N; Minde, Z; Xiaqiu, Z; Yagang, C; Yaozong, W; Yimin, M; Youming, C; Yuming, W, 2012)
"In a cohort of 95 chronic hepatitis B patients, who were treated with peg-interferon and adefovir for 1 year, and who had 15% HBsAg loss (overall), no association was found between IL28B polymorphisms and HBeAg seroconversion or HBsAg clearance."9.16Genetic variation in IL28B and treatment outcome in HBeAg-positive and -negative chronic hepatitis B patients treated with Peg interferon alfa-2a and adefovir. ( Beld, MG; Benayed, R; de Niet, A; Jansen, PL; Koot, M; Lopatin, U; Reesink, HW; Riley-Gillis, B; Takkenberg, RB; Weegink, CJ; Zaaijer, HL, 2012)
"Patients with chronic hepatitis B with and without previous lamivudine therapy were randomised to receive adefovir alone (10 mg/daily) or adefovir and lamivudine (100 mg/daily) for up to 192 weeks."9.16Randomised clinical trial: the benefit of combination therapy with adefovir and lamivudine for chronic hepatitis B. ( Doo, E; Feld, JJ; Ghany, MG; Heller, T; Hoofnagle, JH; Kleiner, DE; Koh, C; Liang, TJ; Nagabhyru, P; Rotman, Y; Wright, EC; Zhao, X, 2012)
"To investigate the efficacy of 104 weeks of lamivudine (LAM) and adefovir (ADV) de novo combination therapy, as compared to optimized combination therapy administered after 48 weeks of treatment with lamivudine or adefovir mono-therapy, in chronic hepatitis B (CHB) patients."9.16[Efficacy of lamivudine and adefovir de novo combination therapy or after mono-therapy in chronic hepatitis B patients]. ( Chen, R; Chen, WL; Chen, XF; Chen, XP; Huang, J; Luo, XD; Ma, HY; Ma, XJ, 2012)
"The safety and efficacy of adefovir dipivoxil (ADV) for chronic hepatitis B infection in children was demonstrated in a randomized, placebo-controlled trial."9.16Efficacy and safety of long-term adefovir dipivoxil therapy in children with chronic hepatitis B infection. ( Frederick, D; Jonas, MM; Kelly, D; Mizerski, J; Mondou, E; Pollack, H; Rousseau, F; Sokal, E; Sorbel, J, 2012)
"Entecavir (ETV) and tenofovir disoproxil fumarate (TDF) are potent antiviral agents that might have additive or synergistic antiviral activity in treatment of patients with chronic hepatitis B (CHB)."9.16Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B. ( Akarca, US; Carosi, G; Cohen, D; Gadano, A; Habersetzer, F; Llamoso, C; Lok, AS; Lovegren, M; Sievert, W; Trinh, H; Wong, D, 2012)
"The aim of the study was to compare the virologic response to adefovir (ADV) add-on therapy with switching to entecavir (ETV) monotherapy in children and adolescents with chronic hepatitis B (CHB) who have developed lamivudine (LAM) resistance during LAM treatment."9.16Virologic responses to add-on adefovir dipivoxil treatment versus entecavir monotherapy in children with lamivudine-resistant chronic hepatitis B. ( Cho, MH; Cho, SM; Choe, BH; Chu, M; Kwon, S; Lee, WK, 2012)
"To study the changes of experimental markers of hepatic fibrosis in patients with chronic hepatitis B treated by Dahuang Zhechong Wan combined with adefovir dipivoxil."9.16[Experimental study on effect of dahuang zhechong wan combined with adefovir dipivoxil in preventing hepatic fibrosis in patients with chronic hepatitis B]. ( Chang, Y; Zhang, L, 2012)
"To observe the efficacy of adefovir dipivoxil(ADV) in combination with Anluohuaxian capsule in the treatment of chronic hepatitis B (CHB) patients."9.16[The therapeutic effect of Anluohuaxian capsule combined with adefovir dipivoxil on patients with chronic hepatitis B and influence on hepatic histology]. ( Gong, GZ; He, B; Jiang, YF; Li, NP; Ma, J; Tang, W, 2012)
"To evaluate the efficacy and safety of tenofovir disoproxil fumarate (TDF) for chronic hepatitis B (CHB) patients after multiple failures."9.16Tenofovir rescue therapy for chronic hepatitis B patients after multiple treatment failures. ( Choi, MS; Gwak, GY; Kim, YJ; Koh, KC; Lee, JH; Paik, SW; Sinn, DH; Yoo, BC, 2012)
"To determine the efficacy of tenofovir disoproxil fumarate (TDF) in adults with chronic hepatitis B virus (HBV) infection who had previously failed lamivudine (LAM) and had significant viral replication (HBV DNA >10⁵ copies/ml if HBeAg positive, > 10⁴ copies/ml if HBeAg negative) despite at least 24 weeks of treatment with adefovir dipivoxil (ADV)."9.15Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B. ( Angus, PW; Bowden, S; Desmond, PV; George, J; Lee, AU; Locarnini, S; Nicoll, AJ; Patterson, SJ; Roberts, SK; Sievert, W; Strasser, SI, 2011)
"This prospective randomized pilot study was conducted in Lok Nayak Hospital, New Delhi, involving 30 patients of chronic hepatitis B (both e antigen positive and negative); 15 were randomly selected to receive either adefovir or lamivudine for a period of 6 months."9.15Evaluation of adefovir & lamivudine in chronic hepatitis B: correlation with HBV viral kinetic, hepatic-necro inflammation & fibrosis. ( Asim, M; Das, BC; Gondal, R; Kar, P; Medhi, S; Pradeep Kumar, S, 2011)
" In two phase 3 studies (GS-US-174-0102 and GS-US-174-0103), 375 hepatitis B e antigen-negative (HBeAg(-) ) patients and 266 HBeAg(+) patients with chronic hepatitis B (some nucleoside-naive and some lamivudine-experienced) were randomized 2:1 to receive TDF (n = 426) or adefovir dipivoxil (ADV; n = 215) for 48 weeks."9.15No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus. ( Borroto-Esoda, K; Chappell, B; Curtis, M; Heathcote, J; Kitrinos, K; Marcellin, P; Miller, MD; Myrick, F; Schawalder, J; Snow-Lampart, A; Sorbel, J; Svarovskaia, ES; Zhu, Y, 2011)
"A randomized, open-label comparative study of entecavir versus adefovir therapy was performed in subjects with chronic hepatitis B who had hepatic decompensation (Child-Turcotte-Pugh score ≥7)."9.15Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study. ( Beebe, S; Bialkowska, J; Brown, RS; Cheinquer, H; Cooney, E; Jeffers, L; Leung, N; Liaw, YF; Myers, RP; Peng, CY; Raptopoulou-Gigi, M; Sarin, SK; Tang, S; Tanwandee, T; Tsai, N, 2011)
"We investigated whether intrahepatic markers could predict response in chronic hepatitis B virus (HBV) patients treated with peg-interferon and adefovir for 48 weeks."9.15Intrahepatic response markers in chronic hepatitis B patients treated with peginterferon alpha-2a and adefovir. ( Beld, M; Dijkgraaf, M; Jansen, P; Reesink, H; Takkenberg, B; Terpstra, V; Weegink, C; Zaaijer, H, 2011)
"To evaluate the safety and efficacy of the combined therapy with entecavir (ETV) and adefovir (ADV) in patients with chronic hepatitis B (CHB) who experienced failure of treatment with single or multiple nucleoside analogs, and analyze the factors that affect the patients response to the treatment."9.15[Safety and efficacy of Entecavir combined with Adefovir in patients with chronic hepatitis B who fail to respond to nucleoside analog treatment]. ( Guo, YB; Hou, JL; Peng, J; Sun, J; Wang, ZH; Yan, L; Yang, J; Zhou, B, 2011)
"In this randomised study, chronic hepatitis B patients with lamivudine resistance were treated with peginterferon alfa-2a for 48 weeks (n=155) or adefovir for 72 weeks (n=80)."9.15Randomised clinical trial: efficacy of peginterferon alfa-2a in HBeAg positive chronic hepatitis B patients with lamivudine resistance. ( Chan, HL; Chen, SJ; Hou, JL; Jia, JD; Jiang, M; Lai, JY; Li, MK; Li, XH; Popescu, M; Sheng, JF; Sun, J; Sung, JJ; Wang, H; Wang, JF; Wang, YM; Xie, Q; Zhang, JM, 2011)
"To investigate the levels of HBsAg in predicting the efficacy of peglated interferon-alpha 2a combined with adefovir dipivoxil (ADV), in HBeAg-positive chronic hepatitis B patients."9.15[The levels of HBsAg can predict the efficacy of peglated interferon-alpha 2a combined with adefovir dipivoxil, in HBeAg-positive chronic hepatitis B patients]. ( Cao, H; Li, G; Sun, HX; Xu, QH; Yang, XA; Zhang, K, 2011)
"A large clinic cohort of chronic hepatitis B cirrhotic patients were enrolled in a treatment program of lamivudine ± adefovir therapy."9.15Clinical outcomes of lamivudine-adefovir therapy in chronic hepatitis B cirrhosis. ( Aung, MO; Dan, YY; Fernandes, M; Lai, V; Lee, GH; Lee, YM; Lim, SG; Low, HC; Mak, B; Sutedja, D, 2011)
"To explore relationship between HBeAg seroconversion with HBV genotypes and HBV specific CTL in patients with chronic hepatitis B (CHB) treated with Adefovir dipivoxil."9.15[Relationship between HBeAg seroconversion with genotypes and HBV specific CTL in patients with chronic hepatitis B treated with Adefovir dipivoxil]. ( Gu, XB; Pan, JQ; Tan, YF; Tang, JM; Wang, XC; Wu, YT; Yang, ZX; Zhao, YP; Zhou, YL, 2011)
"To observe the efficacy and safety on the efficacy of HBeAg-positive chronic Hepatitis B patients treated with adefovir dipivoxil for 4 years."9.15[A clinical study on the efficacy of HBeAg-positive chronic hepatitis B patients treated with adefovir dipivoxil for 4 years]. ( Chen, LB; Liang, JY; Shu, X; Xu, QH; Yang, XA; Zhang, K, 2011)
"0 mg/d or ETV plus adefovir dipivoxil (ADV) in adults with chronic hepatitis B virus (HBV) infection who had previously resisted lamivudine (LAM) and failed with rescue treatment of LAM + ADV."9.15[Entecavir 1.0mg monotherapy or entecavir plus adefovir dipivoxil for patients with lamivudine-resistant chronic hepatitis B had suboptimal response to lamivudine plus adefovir dipivoxil]. ( Han, T; Li, J; Li, Y; Liu, L; Xiao, SX; Xing, J, 2011)
"To investigate the clinical efficacy and safety of adefovir dipivoxil (ADV) in combination with bicyclol for the treatment of chronic hepatitis B (CHB) in seniors."9.15[The clinical efficacy and safety of adefovir dipivoxil in combination with bicyclol for the treatment of senior patients with chronic hepatitis B]. ( Cai, SP; Fan, ZP; He, WP; Ji, YJ; Zhang, WJ, 2011)
"This study was undertaken to compare the early antiviral activity and viral kinetic profiles of entecavir (ETV) versus adefovir (ADV) in hepatitis B e antigen positive nucleoside-naïve adults with chronic hepatitis B (CHB)."9.14Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir. ( Cross, A; Diva, U; Hann, HW; Hsu, CW; Jeffers, L; Lao-Tan, J; Lesmana, L; Leung, N; Lopez-Talavera, J; Mencarini, K; Min, A; Peng, CY; Sherman, M; Sollano, J; Wilber, R; Yuen, MF, 2009)
"Lamivudine (3TC)-resistant chronic hepatitis B patients demonstrated a higher rate of adefovir dipivoxil (ADV) resistance compared with nucleoside-naive patients."9.14Adefovir dipivoxil resistance patterns in patients with lamivudine-resistant chronic hepatitis B. ( Barraud, L; Durantel, S; Fasano, M; Guastadisegni, A; Heichen, M; Pastore, G; Santantonio, T; Zoulim, F, 2009)
"Entecavir (ETV) is currently recommended as a rescue therapy purely for adefovir (ADV)-resistant chronic hepatitis B virus (HBV) infections."9.14Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone. ( Chung, YH; Kim, KM; Lee, HC; Lee, YS; Lim, YS; Shim, JH; Suh, DJ, 2009)
"The efficacy of adefovir dipivoxil (ADV) or entecavir (ETV) rescue monotherapy has not been directly compared in hepatitis B e antigen (HBeAg)-positive patients with lamivudine (3TC)-resistant chronic hepatitis B (CHB)."9.14Rescue monotherapy in lamivudine-resistant hepatitis B e antigen-positive chronic hepatitis B: adefovir versus entecavir. ( Ahn, SH; Chon, CY; Han, KH; Hong, SP; Kim, DY; Kim, HJ; Kim, JK; Lee, CK; Lee, HW; Lee, JM; Lee, KS; Nguyen, T; Paik, YH; Park, JY, 2009)
"Adefovir dipivoxil (ADV) is effective in lamivudine (LAM)-resistant hepatitis B e antigen-negative (HBeAg(-)) chronic hepatitis B (CHB)."9.14Adefovir plus lamivudine are more effective than adefovir alone in lamivudine-resistant HBeAg- chronic hepatitis B patients: a 4-year study. ( Eugenidis, N; Giouleme, O; Gkisakis, D; Grammatikos, N; Katsinelos, P; Koumaras, H; Koumerkeridis, G; Mpoumponaris, A; Panderi, A; Patsiaoura, K; Theodoropoulos, K; Tziomalos, K; Vassiliadis, TG, 2010)
"Entecavir is a potent inhibitor of viral replication in nucleos(t)ide analogue (NA)-naïve chronic hepatitis B patients, but data on the efficacy in NA-experienced subjects are limited."9.14Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues. ( Buti, M; Deterding, K; Hansen, BE; Janssen, HL; Petersen, J; Reijnders, JG; Santantonio, T; van Bömmel, F; Wedemeyer, H; Zoulim, F, 2010)
"Large clinical studies assessing long-term adefovir dipivoxil salvage monotherapy in patients with lamivudine-resistant chronic hepatitis B (CHB) are lacking, particularly in patients positive for hepatitis B e antigen (HBeAg)."9.14Long-term adefovir dipivoxil monotherapy for up to 5 years in lamivudine-resistant chronic hepatitis B. ( Ahn, SH; Chon, CY; Han, KH; Hong, SP; Kim, DY; Kim, SO; Lee, JM; Nguyen, T; Park, JY, 2010)
"To compare the efficacy of 48 week-Entecavir therapy with that of Adefovir therapy for chronic hepatitis B patients."9.14[Comparison of the efficacy of 48 week-Entecavir therapy with that of Adefovir therapy for chronic hepatitis B patients]. ( Hu, P; Lin, Q; Ren, H; Shi, XF; Wang, ZY; Zeng, WQ; Zhang, DZ; Zhou, Z, 2010)
"No study has reported on the comparative effect of adefovir (ADV) add-on lamivudine (LAM) versus switching to entecavir (ETV) in LAM-resistant patients with chronic hepatitis B."9.14Efficacy of adefovir add-on lamivudine rescue therapy compared with switching to entecavir monotherapy in patients with lamivudine-resistant chronic hepatitis B. ( Ahn, SH; Chon, CY; Han, KH; Kim, DY; Lee, JM; Lee, MH; Park, JY; Ryu, HJ, 2010)
"To investigate the efficacy of the 96-week antiviral therapy with adefovir dipivoxil in patients with chronic hepatitis B."9.14[Efficacy of the 96-week adefovir dipivoxil therapy in patients with chronic hepatitis B]. ( Cao, H; Chen, LB; Li, G; Shu, X; Xie, QF; Xu, QH; Xu, Z, 2010)
"To observe the efficacy and safety of PEG-interferon alpha-2a (PEG-IFNalpha-2a) treatment on lamivudine (LAM)-resistant chronic hepatitis B (CHB) patients."9.14[Observation on effect of peg interferon lphaa-2a treating lamivudine resistant chronic hepatitis B]. ( Bai, HL; Long, H; Luo, HT; Ye, YN; Zhong, RX, 2010)
"To explore the influence of adefovir dipivoxil on HBV specific CTL in patients with chronic hepatitis B (CHB)."9.14[Influence of adefovir dipivoxil on HBV specific CTL in patients with chronic hepatitis B]. ( Pan, JQ; Tan, YF; Tang, JM; Wang, XC; Wu, YT; Zhao, YP; Zhou, YL, 2010)
"Treatment of 171 patients with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) with adefovir dipivoxil (ADV) 10 mg over 48 weeks resulted in significant histological, virological, serological, and biochemical improvement compared with placebo."9.13Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. ( Arterburn, S; Borroto-Esoda, K; Chang, TT; Frederick, D; Lim, SG; Marcellin, P; Rousseau, F; Sievert, W; Tong, M, 2008)
"Thai patients enrolled in STACCATO with HIV/hepatitis B virus (HBV) co-infection and tenofovir/emtricitabine-based antiretroviral therapy (ART) were randomly assigned to continuous treatment or CD4 cell count-guided interruptions."9.13Interruptions of tenofovir/emtricitabine-based antiretroviral therapy in patients with HIV/hepatitis B virus co-infection. ( Ananworanich, J; Chetchotisakd, P; Hirschel, B; Jupimai, T; Klinbuayam, W; Mahanontharit, A; Nüesch, R; Prasithsirikul, W; Ruxrungtham, K; Srasuebkul, P, 2008)
"To evaluate the efficacy of short-term overlap lamivudine therapy with adefovir in patients with lamivudine-resistant and naive chronic hepatitis B, we compared patients receiving overlap therapy with those receiving adefovir alone."9.13Short-term overlap lamivudine treatment with adefovir dipivoxil in patients with lamivudine-resistant chronic hepatitis B. ( Bae, SH; Cho, SH; Choi, JY; Han, JY; Kang, SB; Kim, YS; Lee, SW; Lee, YS; Nam, SW; Yang, JM; Yoon, SK, 2008)
"This study investigated the efficacy, safety, and pharmacokinetics of adefovir dipivoxil (ADV) in children and adolescents with chronic hepatitis B (CHB)."9.13Safety, efficacy, and pharmacokinetics of adefovir dipivoxil in children and adolescents (age 2 to <18 years) with chronic hepatitis B. ( Frederick, D; Jonas, MM; Kelly, D; Mizerski, J; Mondou, E; Pollack, H; Rousseau, F; Sokal, E; Sorbel, J, 2008)
"Four hundred and eighty Chinese subjects with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) were enrolled in a multicenter, double-blind, randomized, placebo-controlled study of adefovir dipivoxil (ADV) 10 mg once daily."9.12A double-blind randomized trial of adefovir dipivoxil in Chinese subjects with HBeAg-positive chronic hepatitis B. ( Barker, KF; Chang, CN; Hou, J; Ji, BN; Mao, Y; Wang, H; Wang, Y; Yao, G; Zeng, M, 2006)
"Treatment with adefovir dipivoxil for 48 weeks resulted in clinical improvement in patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B that was lost when treatment was discontinued."9.12Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. ( Arterburn, S; Borroto-Esoda, K; Brosgart, CL; Chang, TT; Chuck, SL; Goodman, Z; Hadziyannis, SJ; Heathcote, EJ; Kitis, G; Lim, SG; Ma, J; Marcellin, P; Rizzetto, M; Tassopoulos, NC, 2006)
"In patients failing to respond to adefovir monotherapy or an adefovir-containing regimen for chronic hepatitis B virus, a combination of tenofovir and emtricitabine resulted in undetectable hepatitis B viral DNA levels without any renal toxicity."9.12Effect of switching to tenofovir with emtricitabine in patients with chronic hepatitis B failing to respond to an adefovir-containing regimen. ( Carriero, D; Dieterich, DT; Jaffe, D; Lucas, J; Park, JS; Santos, SA; Uriel, AJ, 2006)
"To investigate the efficacy and safety of adefovir dipivoxil (ADV, DAIDING) for Chinese chronic hepatitis B patients with lamivudine (LAM) resistance."9.12[A double-blind, randomized, lamivudine-controlled clinical trial of DAIDING (adefovir dipivoxil) for lamivudine-resistant patients with chronic hepatitis B]. ( Chen, YK; Lei, BJ; Lu, ZM; Wang, YM; Yin, YK; Yu, YS; Zhang, DZ, 2006)
"To evaluate the efficacy and safety of a China made adefovir dipivoxil (ADV) treatment for hepatitis B e antigen-positive patients with chronic hepatitis B."9.12[A clinical study of adefovir dipivoxil, made in China, for treatment of hepatitis B e antigen-positive patients with chronic hepatitis B]. ( Chen, XY; Kang, XP; Li, J; Lin, XH; Liu, P; Ren, XM; Si, CW; Yu, YY; Zhang, SL, 2006)
"We studied the long-term efficacy of adefovir dipivoxil (ADV) treatment in 42 HBeAg-negative patients with chronic hepatitis B (CHB) who had developed genotypical lamivudine (LAM) resistance with virological and clinical breakthroughs under long-term LAM treatment."9.12Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. ( Dimou, E; Hadziyannis, SJ; Mitsoula, P; Rapti, I, 2007)
"To evaluate the efficacy and safety of adefovir dipivoxil (ADV) treatment in patients with hepatitis B e antigen (HBeAg) positive chronic hepatitis B (CHB)."9.12[Three year adefovir dipivoxil treatment for hepatitis B e antigen-positive chronic hepatitis B patients]. ( Ling, N; Ren, H; Zhang, DZ; Zhou, Z, 2007)
"To evaluate the efficacy and safety of adefovir dipivoxil (ADV) in treating patients with lamivudine (LAM) refractory HBeAg-positive chronic hepatitis B."9.12[A clinical study of adefovir dipivoxil in treating lamivudine refractory HBeAg-positive chronic hepatitis B]. ( Chen, XY; Si, CW; Tang, XP; Wang, L; Zhang, YX; Zhao, H, 2007)
"To evaluate the cost effectiveness of treatment of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) with entecavir compared with lamivudine with adefovir salvage, based primarily on the results of a recent 2-year, randomised, multicentre, clinical trial (n = 709)."9.12Cost effectiveness of entecavir versus lamivudine with adefovir salvage in HBeAg-positive chronic hepatitis B. ( Clarke, L; Di Bisceglie, A; Gish, RG; Iloeje, UH; Kowdley, KV; Sullivan, SD; Tafesse, E; Veenstra, DL, 2007)
"To evaluate the effect of diammonium glycyrrhizinate on the antiviral therapy with adefovir dipivoxil (ADV) in patients with HBeAg-positive chronic hepatitis B."9.12[Diammonium glycyrrhizinate does not affect efficacy of adefovir dipivoxil therapy in patients with HBeAg-positive chronic hepatitis B]. ( Chen, XY; Lei, CL; Li, J; Si, CW; Tang, XP; Wang, L; Zhang, YX; Zhao, H, 2007)
"The safety and efficacy of 10 mg of adefovir dipivoxil was compared to placebo in 501 Asian (n = 259) or Caucasian (n = 242) HBeAg+ and HBeAg- chronic hepatitis B virus patients treated for 48 weeks in two randomized, double-blind, placebo-controlled studies."9.12Clinical trial: effects of adefovir dipivoxil therapy in Asian and Caucasian patients with chronic hepatitis B. ( Arterburn, S; Brosgart, CL; Chang, TT; Hadziyannis, S; Hu, P; Lim, SG; Marcellin, P; Sievert, W; Tassopoulos, N; Tong, M, 2007)
" We evaluated the efficacy and safety of adding adefovir dipivoxil to lamivudine in 135 patients with chronic hepatitis B (CHB) and YMDD mutant HBV."9.11Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. ( Bourne, E; Brosgart, CL; Gardner, S; Hann, HW; Lee, WM; Leung, N; Moorat, A; Mutimer, D; Perrillo, R; Schiff, E; Willems, B; Woessner, M, 2004)
" This study assessed the safety and efficacy of adefovir dipivoxil alone and in combination with lamivudine compared with ongoing lamivudine therapy in patients with chronic hepatitis B with compensated liver disease and lamivudine-resistant hepatitis B virus (HBV)."9.11Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. ( Bourliere, M; Brosgart, CL; Buggisch, P; Ebrahimi, R; Gray Df, Df; Hann Hw, Hw; Heathcote, EJ; Kleber, K; Kowdley, K; Martin, P; Peters, MG; Rubin, R; Sullivan, M; Trepo, C; Xiong, S, 2004)
"Lamivudine treatment in patients with chronic hepatitis B virus (HBV) infection may improve clinical state and suppress viral replication before liver transplantation."9.11Liver transplantation for chronic hepatitis B with lamivudine-resistant YMDD mutant using add-on adefovir dipivoxil plus lamivudine. ( Chan, SC; Fan, ST; Lau, GK; Liu, CL; Lo, CM; Ng, IO, 2005)
"Treatment with adefovir dipivoxil for 48 weeks resulted in histologic, virologic, and biochemical improvement in patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B."9.11Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. ( Arterburn, S; Brosgart, CL; Chang, TT; Currie, G; Goodman, Z; Hadziyannis, SJ; Heathcote, EJ; Kitis, G; Lim, SG; Ma, J; Marcellin, P; Rizzetto, M; Tassopoulos, NC; Xiong, S, 2005)
"Adefovir dipivoxil is safe for the treatment of chronic hepatitis B in patients with varying degrees of renal dysfunction and lamivudine-resistant HBV and results in biochemical and virological efficacy similar to that reported in the general population."9.11Efficacy and safety of adefovir dipivoxil in kidney recipients, hemodialysis patients, and patients with renal insufficiency. ( Brosgart, C; Chaix, ML; Currie, G; Fontaine, H; Morales, E; Nalpas, B; Pol, S; Serpaggi, J; Vallet-Pichard, A; Varaut, A; Verkarre, V, 2005)
" Currently available treatments for chronic hepatitis B (interferon [IFN]-alpha and lamivudine [3TC]) have limited long-term utility because of side effects or of the development of resistance."9.10Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed. ( Aberg, JA; Crippin, J; Kessels, L; Lisker-Melman, M; Powderly, WG; Ristig, MB; Tebas, P, 2002)
"We randomly assigned 515 patients with chronic hepatitis B who were positive for hepatitis B e antigen (HBeAg) to receive 10 mg of adefovir dipivoxil (172 patients), 30 mg of adefovir dipivoxil (173), or placebo (170) daily for 48 weeks."9.10Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. ( Brosgart, CL; Chang, TT; Fry, J; Goodman, Z; Jeffers, L; Lim, SG; Marcellin, P; Shiffman, ML; Sievert, W; Tong, MJ; Wulfsohn, MS; Xiong, S, 2003)
"Adefovir dipivoxil, a nucleotide analogue, demonstrated clinically significant antiviral activity in patients with chronic hepatitis B in phase 1 and 2 clinical trials."9.10Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. ( Brosgart, CL; Chang, TT; Fry, J; Goodman, Z; Hadziyannis, SJ; Heathcote, EJ; Kitis, G; Lim, SG; Marcellin, P; Rizzetto, M; Tassopoulos, NC; Wulfsohn, MS; Xiong, S, 2003)
"Seven hundred nucleoside treatment-naive patients were enrolled in two phase 3 trials of adefovir dipivoxil (ADV) for the treatment of chronic hepatitis B."9.10Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B. ( Brosgart, CL; Delaney, WE; Fry, J; Gibbs, CS; Miller, MD; Westland, CE; Wulfsohn, M; Xiong, S; Yang, H, 2003)
"In April 2017 tenofovir alafenamide (TAF) was added to the list of first-line therapies recommended for chronic hepatitis B (CHB)."8.95Tenofovir alafenamide for the treatment of chronic hepatitis B virus infection. ( Abdul Basit, S; Dawood, A; Gish, R; Ryan, J, 2017)
"Tenofovir alafenamide (TAF) has recently been approved for chronic hepatitis B (CHB)."8.95Tenofovir alafenamide as compared to tenofovir disoproxil fumarate in the management of chronic hepatitis B with recent trends in patient demographics. ( Hsu, YC; Nguyen, MH; Wei, MT, 2017)
"Tenofovir alafenamide (TAF), a novel prodrug of tenofovir (TFV), has been approved for the treatment of chronic hepatitis B virus (HBV) infection."8.95Tenofovir alafenamide in the treatment of chronic hepatitis B: design, development, and place in therapy. ( Furusyo, N; Nguyen, MH; Ogawa, E, 2017)
"Long-term adefovir dipivoxil therapy is connected to renal dysfunction in chronic hepatitis B, necessitating the monitoring of kidney function."8.93Relationship between nephrotoxicity and long-term adefovir dipivoxil therapy for chronic hepatitis B: A meta-analysis. ( Cheng, F; Deng, Y; Kang, J; Luo, Q; Zeng, W; Zhang, D; Zhong, S, 2016)
" He had been receiving low-dose adefovir dipivoxil (ADV) for the treatment of lamivudine-resistant chronic hepatitis B virus infection for eight years and subsequently developed severe hypophosphatemia and proximal renal tubule dysfunction."8.90Hypophosphatemic osteomalacia due to drug-induced Fanconi's syndrome associated with adefovir dipivoxil treatment for hepatitis B. ( Eguchi, H; Hiromatsu, Y; Kuwahara, R; Tani, J; Tsuruta, M, 2014)
"Tenofovir (TDF) and entecavir (ETV) are both potent antiviral agents for the treatment of chronic hepatitis B virus (HBV) infection."8.90Comparison of efficacy and safety of tenofovir and entecavir in chronic hepatitis B virus infection: a systematic review and meta-analysis. ( Gao, Y; Ke, W; Liu, L; Yang, Y; Ye, X; Zhang, C; Zhou, S, 2014)
" Currently, lamivudine plus adefovir combination therapy or entecavir monotherapy is usually used for the treatment of patients with lamivudine-resistant chronic hepatitis B (CHB)."8.89Comparison of the efficacy of Lamivudine plus adefovir versus entecavir in the treatment of Lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis. ( Chen, RC; Dai, XH; Fan, XG; Huang, Y; Huang, ZB; Li, N; Li, WT; Yi, PP; Zhang, BX; Zhao, SS; Zhou, RR, 2013)
"The aim of the current study was to compare the effectiveness of adefovir dipivoxil (ADV) monotherapy with that of combination ADV and lamivudine (LAM) therapy in the treatment of LAM-resistant chronic hepatitis B (CHB)."8.88Comparative meta-analysis of adefovir dipivoxil monotherapy and combination therapy of adefovir dipivoxil and lamivudine for lamivudine-resistant chronic hepatitis B. ( Chen, Y; Ju, T, 2012)
"Entecavir (ETV) and tenofovir disoproxil fumarate (TDF) are potent nucleos(t)ide analogues (NUCs) recommended as first-line monotherapies for chronic hepatitis B."8.88First-line treatment of chronic hepatitis B with entecavir or tenofovir in 'real-life' settings: from clinical trials to clinical practice. ( Lampertico, P; Pol, S, 2012)
"Although entacavir and adefovir were widely used in most Asian countries, there were few conclusions drawn from a meta-analysis for comparing the efficacy between entecavir and adefovir in nucleos(t)ide-naïve Asian patients with chronic hepatitis B (CHB)."8.87Comparison of the 48-week efficacy between entecavir and adefovir in HBeAg-positive nucleos(t)ide-naïve Asian patients with chronic hepatitis B: a meta-analysis. ( Guan, Q; Liu, W; Zhao, J; Zhao, P, 2011)
" Currently, several drugs, such as tenofovir and adefovir, are recommended for treatment of patients with chronic hepatitis B."8.87Comparison of the efficacy of tenofovir and adefovir in the treatment of chronic hepatitis B: a systematic review. ( Chen, LZ; Dai, XH; Fan, XG; Tang, LH; Wang, W; Zhao, SS; Zhou, RR, 2011)
"Chronic hepatitis B virus (HBV) infection represents a serious global health problem and resistance to lamivudine (LAM) has become a serious clinical challenge."8.87Lamivudine plus adefovir combination therapy versus entecavir monotherapy for lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis. ( Hu, HD; Hu, P; Liu, JY; Ren, H; Sheng, YJ; Tong, SW; Zhang, DZ, 2011)
" Lamivudine and adefovir dipivoxil are effective and tolerable for chronic hepatitis B by suppressing the viral load and to reduce fibrosis in the liver."8.87Lamivudine with or without adefovir dipivoxil for postoperative hepatocellular carcinoma. ( Li, le Q; Wu, LC; Zhong, JH, 2011)
"Since its approval for the treatment of chronic hepatitis B in 1998, lamivudine (LAM) has been used extensively throughout the world, because of its relatively low costs and favourable tolerability."8.86Avoiding and managing lamivudine resistance in chronic hepatitis B: current approaches and potential strategies including pegylated interferon. ( Marcellin, P; Piratvisuth, T; Sung, J, 2010)
"This paper presents a summary of the evidence review group (ERG) report into the clinical effectiveness and cost-effectiveness of tenofovir disoproxil fumarate for the treatment of chronic hepatitis B, in accordance with the licensed indication, based upon the evidence submission from Gilead to the National Institute for Health and Clinical Excellence (NICE) as part of the single technology appraisal process."8.86Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B infection. ( Colquitt, J; Cooper, K; Harris, P; Jones, J; Shepherd, J, 2010)
"Tenofovir is a nucleotide analog reverse transcriptase inhibitor approved recently by the US FDA for the treatment of chronic hepatitis B (CHB) in adult patients based on the results of two double-blind randomized trials demonstrating superiority of tenofovir compared with adefovir."8.86Tenofovir disoproxil fumarate in the treatment of chronic hepatitis B. ( Jenh, AM; Pham, PA, 2010)
"To update and extend a 2006 report on the clinical effectiveness and cost-effectiveness of adefovir dipivoxil (ADV) and pegylated interferon alpha (PEG-alpha) for the treatment of chronic hepatitis B (CHB)."8.85Adefovir dipivoxil and pegylated interferon alpha for the treatment of chronic hepatitis B: an updated systematic review and economic evaluation. ( Baxter, L; Gospodarevskaya, E; Harris, P; Hartwell, D; Jones, J; Price, A; Shepherd, J, 2009)
"Clinical trials demonstrated telbivudine to be a safe and potent antiviral agent for treatment of chronic hepatitis B."8.84A review of telbivudine for the management of chronic hepatitis B virus infection. ( Chan, HL; Lui, YY, 2008)
"Standard treatments for chronic hepatitis B (CHB) include interferon-alpha (IFN-alpha) and lamivudine (LAM), but these are associated with adverse effects and viral resistance, respectively."8.84A systematic review and economic evaluation of adefovir dipivoxil and pegylated interferon-alpha-2a for the treatment of chronic hepatitis B. ( Davidson, P; Jones, J; Price, A; Shepherd, J; Takeda, A, 2007)
"To evaluate properties of the new acyclic nucleotide analog adefovir dipivoxil in the treatment of chronic hepatitis B (CHB)."8.82Adefovir dipivoxil in the treatment of chronic hepatitis B. ( Rivkin, AM, 2004)
" To determine the effectiveness of adefovir, three populations of patients with chronic hepatitis B patients were studied: hepatitis B e antigen (HBeAg)-positive patients, HBeAg-negative patients, and patients with lamivudine-resistant tyrosine-methionine-asparate-aspartate (YMDD) mutants."8.82Treatment of patients with chronic hepatitis B with adefovir dipivoxil. ( Tong, MJ; Tu, SS, 2004)
"Adefovir dipivoxil, an acyclic nucleotide analogue, is effective for the treatment of chronic hepatitis B in both hepatitis B e antigen (HBeAg)-positive and -negative patients, with improvement in liver histology, hepatitis B virus (HBV) DNA levels, alanine aminotransferase levels, and HBeAg seroconversion (for HBeAg-positive patients)."8.82Adefovir dipivoxil in chronic hepatitis B infection. ( Lai, CL; Yuen, MF, 2004)
" Adefovir dipivoxil is indicated for the treatment of chronic hepatitis B in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (alanine [ALT] or aspartate [AST]) or histologically active disease."8.82Adefovir dipivoxil: focus on its use in the treatment of chronic hepatitis B. ( Baker, DE, 2005)
"As tenofovir disoproxil fumarate (TDF) requires long-term use, a reduction in bone density should be considered a possibility when treating patients with chronic hepatitis B (CHB) with aging and systemic diseases."8.31Tenofovir disoproxil fumarate versus tenofovir alafenamide on risk of osteoporotic fracture in patients with chronic hepatitis B: A nationwide claims study in South Korea. ( Chang, JI; Cho, YY; Jang, ES; Kim, E; Kim, HJ; Kim, SS; Lee, HW; Seo, GH; Yoon, E, 2023)
"Switching to a tenofovir alafenamide (TAF)-containing regimen has been reported to be associated with body weight gain in human immunodeficiency virus-infected subjects."8.12Body weight changes in treated hepatitis B patients switching to tenofovir alafenamide ( Chuang, WL; Dai, CY; Hsieh, MY; Huang, CF; Huang, CI; Huang, JF; Liang, PC; Nguyen, MH; Trinh, S; Yeh, ML; Yu, ML, 2022)
"Data on long-term tenofovir alafenamide (TAF) therapy for pregnant women with active chronic hepatitis B (CHB) (immune clearance and reactivation phases, currently and previously diagnosed) and their infants are lacking."8.12Tenofovir Alafenamide for Pregnant Chinese Women With Active Chronic Hepatitis B: A Multicenter Prospective Study. ( Chen, ZM; Cui, GL; Feng, YH; Huang, S; Li, GM; Li, GT; Li, J; Li, W; Li, WZ; Li, ZQ; Liang, HX; Lin, WB; Liu, N; Liu, YM; Lv, J; Pan, YJ; Song, N; Sun, CY; Wang, FS; Wang, M; Xu, GH; Xu, JH; Yu, ZJ; Zeng, QL; Zeng, YL; Zhang, DW; Zhang, GF; Zhang, GQ; Zhang, HX; Zhang, JY; Zhou, YH, 2022)
"We aimed to investigate the long-term effects of tenofovir disoproxil fumarate and entecavir treatment on bone mineral density and evaluated the fracture risk assessment tool score in patients with chronic hepatitis B."8.12Effects of Long-Term Tenofovir and Entecavir Treatment on Bone Mineral Density in Patients with Chronic Hepatitis B. ( Çalhan, T; Doğanay, L; Kahraman, R; Kanat, E; Özdil, K; Öztürk, O; Şahin, A; Sayar, S, 2022)
"HBV DNA was extracted from blood samples of two patients with HBeAg-positive chronic HBV infection and persistent viremia despite tenofovir treatment, and subsequently amplified by PCR before full-length HBV genomes were assembled by deep sequencing."8.12Novel hepatitis B virus reverse transcriptase mutations in patients with sustained viremia despite long-term tenofovir treatment. ( Bajpai, PS; Bukh, J; Dalegaard, MI; Fahnøe, U; Lundh, A; Ryom, L; Weis, N; Winckelmann, A, 2022)
"Antenatal antiviral therapy (AVT) is effective in preventing mother-to-child transmission (MTCT) in chronic hepatitis B (CHB); tenofovir disoproxil fumarate (TDF) is the preferred agent."8.12Plasma and breast milk pharmacokinetics of tenofovir alafenamide in mothers with chronic hepatitis B infection. ( Cottrell, M; Crane, H; Di Girolamo, J; Dumond, J; Gane, E; Kashuba, A; Kayes, T; Levy, MT; Lim, TH; Manandhar, S; Symonds, A, 2022)
"Tenofovir alafenamide (TAF) may be preferable to other nucleos(t)ide analogues (NA) regarding outcomes against chronic hepatitis B virus (HBV) infection."8.12Switching to tenofovir alafenamide for nucleos(t)ide analogue-experienced patients with chronic hepatitis B: week 144 results from a real-world, multi-centre cohort study. ( Amagase, H; Azuma, K; Dohmen, K; Furusyo, N; Hayashi, J; Ichiki, Y; Kajiwara, E; Kato, M; Kawano, A; Koyanagi, T; Kuniyoshi, M; Morita, C; Nakamuta, M; Nomura, H; Ogawa, E; Ooho, A; Satoh, T; Shimoda, S; Sugimoto, R; Takahashi, K; Yamashita, N, 2022)
"Non-inferior antiviral efficacy and better renal safety have been reported in chronic hepatitis B patients with tenofovir alafenamide (TAF) treatment."8.12One-year efficacy of tenofovir alafenamide in patients with chronic hepatitis B: An observational study. ( Chen, YC; Chien, RN; Hsu, CW; Tai, DI, 2022)
"Although tenofovir alafenamide (TAF) and besifovir dipivoxil maleate (BSV) are potent antiviral agents in the treatment of chronic hepatitis B (CHB) infection, their renal safety profiles have not been previously compared."8.12Similar risk of kidney function decline between tenofovir alafenamide and besifovir dipivoxil maleate in chronic hepatitis B. ( Ahn, SH; Jung, CY; Kim, BS; Kim, HW; Kim, SU; Lee, HW; Lee, JI, 2022)
"Entecavir (ETV) or adefovir dipivoxil (ADV) are not recommended during pregnancy because of embryotoxicity or teratogenicity found in animal studies; however, information on the safety of ETV or ADV in humans is limited."8.12Pregnancy outcomes for pregnant women with chronic hepatitis B exposing to entecavir or adefovir dipivoxil therapy before or in early pregnancy. ( Cai, H; Duan, X; Fu, D; Gao, X; Hu, Y; Kang, K; Liu, M; Yi, W; Zhou, M, 2022)
" This study aimed to compare the efficacy of entecavir (ETV) and tenofovir disoproxil fumarate (TDF) in relation to the adverse clinical outcomes among chronic hepatitis B (CHB) patients stratified according to adherence to medication and MVR."8.02Comparable Incidence of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated with Entecavir or Tenofovir. ( Jeong, J; Jung, SW; Kim, MJ; Lee, SB; Park, BR; Park, EJ; Park, NH; Shin, JW, 2021)
"Tenofovir alafenamide (TAF) has been newly approved for the treatment of chronic hepatitis B (CHB)."7.96Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B. ( Azuma, K; Dohmen, K; Furusyo, N; Hayashi, J; Kajiwara, E; Kato, M; Kawano, A; Koyanagi, T; Nakamuta, M; Nomura, H; Ogawa, E; Ooho, A; Satoh, T; Shimoda, S; Takahashi, K, 2020)
"Renal toxicity is a concern in patients with chronic hepatitis B taking nucleotide analogues, such as adefovir (ADV) and tenofovir disoproxil fumarate (TDF)."7.96Long-term Nucleotide Analogue Treatment Has Higher Levels of Renal Toxicities than Does Entecavir in Patients with Chronic Hepatitis B. ( Chang, Y; Cho, EJ; Cho, H; Cho, YY; Kim, YJ; Lee, JH; Nam, JY; Yoon, JH; Yu, SJ, 2020)
" He had been receiving adefovir dipivoxil (ADV) for the treatment of entecavir (ETV)-resistant chronic hepatitis B (CHB) for four years in his 8-year treatment of hepatocellular carcinoma (HCC), but was referred to our hospital after increased levels of bone pain in his ribs, knees, and ankles."7.91[Adefovir Dipivoxil-induced Fanconi's Syndrome and Osteomalacia Following Multiple Bone Fractures in a Patient with Chronic Hepatitis B]. ( Ikeda, A; Ikeda, F; Kanzaki, H; Kitamura, Y; Makita, T; Murakawa, K; Nishihara, S; Okada, H; Onishi, H; Sendo, T; Shiraha, H; Takaki, A; Takeuchi, Y; Tanaka, Y; Wada, N; Yasunaka, T, 2019)
"Adefovir dipivoxil (ADV) is one of the most important nucleostide analogues currently in use for the treatment of chronic hepatitis B virus (HBV) infection."7.91Low-dose adefovir dipivoxil-induced hypophosphatemia osteomalacia in five chronic hepatitis B virus-infected patients. Is low-dose adefovir dipivoxil-induced nephrotoxicity completely reversible? ( Dai, ZJ; Jin, J; Pan, YJ; Qian, YY; Ruan, LY; Shi, MT; Wu, CM; Zhu, YX, 2019)
"Renal toxicity of adefovir disoproxil (ADV) and tenofovir disoproxil fumarate (TDF) is a significant concern in chronic hepatitis B (CHB) patients."7.91In Vitro and In Vivo Renoprotective Effects of Telbivudine in Chronic Hepatitis B Patients Receiving Nucleotide Analogue. ( Chan, TM; Fung, J; Lai, CL; Liu, SH; Mak, LY; Seto, WK; Wong, DK; Yap, DY; Yuen, MF, 2019)
"Adefovir dipivoxil (ADV)-induced renal tubular dysfunction and hypophosphatemic osteomalacia (HO) have been given great consideration in the past few years."7.88Adefovir dipivoxil induced hypophosphatemic osteomalacia in chronic hepatitis B: a comparative study of Chinese and foreign case series. ( Chen, N; Li, LY; Liu, LW; Peng, T; Tang, KX; Yu, F; Yu, X; Zhang, JB; Zhang, Q; Zhao, YP, 2018)
"Few studies have addressed the impact of adefovir dipivoxil (ADV)-based combination therapy on the renal function of patients with chronic hepatitis B (CHB)."7.88Telbivudine and adefovir dipivoxil combination therapy improves renal function in patients with chronic hepatitis B: A STROBE-compliant article. ( Nie, ZW; Xu, Y, 2018)
"Although high potent nucleos(t)ide analogues are strongly recommended as first-line therapy for chronic hepatitis B (CHB) in China, some patients are still being treated with adefovir disoproxil (ADV), especially those low-income patients whose health insurance could not reimburse the drug cost."7.85Efficacy and safety of three adefovir-based combination therapies in HBeAg-positive chronic hepatitis B patients with suboptimal response to adefovir monotherapy. ( Chen, EQ; Du, LY; Lei, BJ; Lei, XZ; Liao, J; Lu, JJ; Tang, H; Wang, ML; Yan, LB; Zhang, DM; Zhou, TY, 2017)
"This study compared virologic response to entecavir monotherapy and de novo lamivudine plus adefovir (LAM + ADV) combination therapy in patients with chronic hepatitis B (CHB) with high viral load (HVL)."7.83Comparison of entecavir monotherapy and de novo lamivudine and adefovir combination therapy in HBeAg-positive chronic hepatitis B with high viral load: 48-week result. ( Cai, S; Jiang, Y; Lv, F; Peng, J; Yu, T; Zhang, Y, 2016)
"We investigated the long-term efficacy of adefovir add-on lamivudine rescue therapy in lamivudine-resistant chronic hepatitis B and the optimal cutoff hepatitis B virus (HBV) DNA level that predicts complete virological response (CVR) among patients without CVR after 1 year of treatment."7.83Outcome of adefovir add-on lamivudine rescue therapy of up to 5 years in patients with lamivudine-resistant chronic hepatitis B. ( Ahn, SH; Han, KH; Kim, BK; Kim, DY; Kim, SB; Kim, SU; Park, JY, 2016)
"Lamivudine (LAM) plus adefovir (ADV) combination therapy is clinically efficacious for treating chronic hepatitis B (CHB) patients in China, but no pharmacoeconomic evaluations of this strategy are available."7.83Cost-effectiveness comparison of lamivudine plus adefovir combination treatment and nucleos(t)ide analog monotherapies in Chinese chronic hepatitis B patients. ( Gao, Y; Ke, W; Liu, L; Yang, Y; Yao, Z; Ye, X; Zhang, C; Zhou, S, 2016)
" We aimed to establish if IP-10 expression in liver tissue and in plasma of chronic hepatitis B (CHB) patients correlated with each other and further to investigate if IP-10 levels before and during therapy with peginterferon and adefovir could predict treatment outcome in CHB patients."7.83Intrahepatic IP-10 mRNA and plasma IP-10 levels as response marker for HBeAg-positive chronic hepatitis B patients treated with peginterferon and adefovir. ( de Niet, A; Jansen, L; Kootstra, NA; Reesink, HW; Sinnige, MJ; Takkenberg, RB; Verheij, J; Willemse, SB, 2016)
"Tenofovir disoproxil fumarate (TDF) is newly available for treatment of chronic hepatitis B patients in China."7.83Cost-effectiveness analysis of tenofovir disoproxil fumarate for treatment of chronic hepatitis B in China. ( Gao, Y; Ke, W; Liu, L; Yang, Y; Yao, Z; Ye, X; Zhang, C; Zhou, S, 2016)
"Adefovir dipivoxil (ADV) is effective for hepatitis B virus (HBV) infection; however, ADV may provoke renal injury resulting in osteomalacia, and this side effect is seldom recognized until bone fractures emerge."7.83Urinary β-2 Microglobulin Levels Sensitively Altered in an Osteomalacia Patient Receiving Add-on Adefovir Dipivoxil Therapy for Hepatitis B Virus Infection. ( Hirase, S; Ito, K; Ito, T; Morishima, T; Morita, H; Ohashi, T; Otake, K; Takagi, J; Yoneda, M, 2016)
"Entecavir (ETV) is a potent viral replication inhibitor for chronic hepatitis B (CHB) patients."7.83A five years study of antiviral effect of entecavir in Chinese chronic hepatitis B patients. ( Bao, R; Bao, S; Chen, R; Guo, Q; Liu, K; Liu, Y; Wang, H; Xiang, X; Xie, J; Xie, Q, 2016)
"The aim of this study was to evaluate serum kidney injury molecule-1 (KIM-1) as a new diagnostic marker of renal dysfunction in chronic hepatitis B (CHB) patients receiving long-term adefovir dipivoxil (ADV) treatment."7.83Circulating kidney injury molecule-1 is a novel diagnostic biomarker for renal dysfunction during long-term adefovir therapy in chronic hepatitis B. ( Li, Z; Liu, Z; Shen, C; Wang, W; Wang, Y; Zhao, C; Zhao, Q, 2016)
"Tenofovir disoproxil fumarate (TDF) is an established nucleotide analogue in the treatment of chronic hepatitis B."7.81Assessment of bone mineral density in tenofovir-treated patients with chronic hepatitis B: can the fracture risk assessment tool identify those at greatest risk? ( Al-Shamma, S; Barr, DA; Burke, K; Foster, GR; Gill, US; Kallis, YN; Kennedy, PT; Kooner, P; Marley, RT; McPhail, MJ; Zissimopoulos, A, 2015)
"The risk of hepatocellular carcinoma (HCC) in Caucasian patients with chronic hepatitis B (CHB), treated with entecavir (ETV) or tenofovir (TDF), is unclear."7.81Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir. ( Arends, P; Buti, M; Colombo, M; Dalekos, GN; Esteban, R; Galanis, K; Gatselis, N; Goulis, J; Hansen, BE; Idilman, R; Janssen, HL; Keskın, O; Lampertico, P; Mangia, G; Manolakopoulos, S; Papaioannou, C; Papatheodoridis, GV; Savvidou, S; Sypsa, V; Yurdaydin, C, 2015)
"Increased risk of defective urinary phosphate reabsorption and osteoporosis has been reported in HIV and chronic hepatitis B (CHB) patients treated with tenofovir disoproxil fumarate (TDF)."7.81Long-term treatment with tenofovir in Asian-American chronic hepatitis B patients is associated with abnormal renal phosphate handling. ( Bae, HS; Chan, LS; Chang, M; Fong, TL; Huh, B; Lee, S; Lim, C; Shinada, S; Tien, C; Xu, JJ, 2015)
"To investigate the association between the baseline profiles and dynamics of hepatitis B virus (HBV) DNA polymerase gene mutations and the long-term virological response of lamivudine (LAM)-adefovir (ADV) combination therapy in patients with LAM-resistant chronic hepatitis B."7.81Long-term outcomes and dynamics of mutants associated with lamivudine-adefovir rescue therapy in patients with lamivudine-resistant chronic hepatitis B. ( Choi, K; Jang, JY; Jeong, SW; Kim, BS; Kim, HS; Kim, J; Kim, SG; Kim, YS; Lee, SH, 2015)
"Tenofovir disoproxil fumarate (TDF) monotherapy is a therapeutic option for chronic hepatitis B (CHB) patients infected with hepatitis B virus (HBV) variants resistant to lamivudine (LAM)."7.81Tenofovir monotherapy versus tenofovir plus lamivudine or telbivudine combination therapy in treatment of lamivudine-resistant chronic hepatitis B. ( Ahn, H; Cho, EJ; Cho, H; Cho, Y; Cho, YY; Choi, WM; Jung, EU; Kim, BH; Kim, CM; Kim, CY; Kim, YJ; Lee, DH; Lee, HS; Lee, JH; Lee, M; Lee, YB; Lee, YJ; Park, JW; Park, SJ; Yoo, JJ; Yoon, JH; Yu, SJ, 2015)
"Entecavir (ETV) plus adefovir (ADV) combination therapy is one of the useful treatment option for the patients with chronic hepatitis B (CHB) who had failed on prior nucleos(t) ide analogue (NA) treatments."7.81Comparison of the efficacies of entecavir 0.5 and 1.0 mg combined with adefovir in patients with chronic hepatitis B who had failed on prior nucleos(t)ide analogue treatments. ( Cho, Y; Kim, YJ; Lee, HS; Lee, JH; Yoon, JH; Yu, SJ, 2015)
" These pregnant females developed lamivudine (LAM)- or telbivudine (LdT)-resistant chronic hepatitis B and received tenofovir (TDF) therapy (300 mg/d), and its curative effect, maternal and perinatal adverse events, fetal growth and development, and neonatal prognosis were evaluated."7.81Tenofovir rescue therapy in pregnant females with chronic hepatitis B. ( Cai, HD; Cao, YJ; Hu, YH; Liu, M; Yi, W, 2015)
"Patients with chronic hepatitis B (HBV DNA load, >17 000 IU/mL) were treated with pegylated interferon alfa-2a and adefovir for 48 weeks."7.81Natural Killer Cell Characteristics in Patients With Chronic Hepatitis B Virus (HBV) Infection Are Associated With HBV Surface Antigen Clearance After Combination Treatment With Pegylated Interferon Alfa-2a and Adefovir. ( de Niet, A; Jansen, L; Kootstra, NA; Reesink, HW; Stelma, F; Takkenberg, RB; Tempelmans Plat-Sinnige, MJ; van Leeuwen, EM, 2015)
"Tenofovir disoproxil fumarate has been used in chronic hepatitis B patients with suboptimal virologic response to nucleos(t)ide analogues."7.81Efficacy of tenofovir switch therapy for nucleos(t)ide-experienced patients with chronic hepatitis B. ( Chan, HL; Chan, HY; Lo, AO; Tse, YK; Wong, GL; Wong, VW, 2015)
"To evaluate urine β2-microglobulin (β2-M), retinol-binding protein (RBP) excretion, and renal impairment with adefovir dipivoxil (ADV) for chronic hepatitis B."7.81Early kidney injury during long-term adefovir dipivoxil therapy for chronic hepatitis B. ( Cai, H; Chen, JY; Ding, F; Hu, JH; Jia, HY; Li, LJ; Lian, JS; Lu, YF; Xiang, DR; Yang, YD; Yu, GD; Yu, L; Zeng, LY; Zhang, YM; Zheng, L, 2015)
"We evaluated the efficacy of tenofovir (TDF)-based rescue therapy and compared the outcomes of TDF monotherapy and TDF-based nucleoside analog (NA) combination therapy in patients with suboptimal response (SOR) to adefovir (ADV) with or without NAs in lamivudine (LAM)-resistant chronic hepatitis B."7.81Tenofovir-based rescue therapy in chronic hepatitis B patients with suboptimal responses to adefovir with prior lamivudine resistance. ( Cheong, JY; Cho, HJ; Cho, SW; Kim, SS; Shin, SJ; Yoo, BM, 2015)
"In chronic hepatitis B patients, lamivudine (LAM) and adefovir (ADV) combination therapy is commonly used as a rescue therapy for LAM resistance, but it often results in incomplete viral suppression."7.81Efficacy of Tenofovir-based Rescue Therapy in Lamivudine-resistant Chronic Hepatitis B Patients With Failure of Lamivudine and Adefovir Combination. ( Bang, SJ; Jeong, ID; Jung, SW; Kim, BG; Kim, CJ; Kim, MH; Lee, BU; Park, BR; Park, JH; Park, NH; Shin, JW, 2015)
"In the past decade, many chronic hepatitis B (CHB) patients have undergone sequential treatment with lamivudine (LAM), adefovir (ADV), and entecavir (ETV) to manage antiviral resistance or insufficient suppression of HBV-DNA."7.81Tenofovir-based rescue therapy for chronic hepatitis B patients who had failed treatment with lamivudine, adefovir, and entecavir. ( Bang, SJ; Jeong, ID; Jung, SW; Kim, BG; Kim, CJ; Kim, EH; Kim, JH; Kim, MH; Lee, BU; Park, BR; Park, JH; Park, NH; Shin, JW; Sung, SJ, 2015)
"To compare the efficacy of telbivudine monotherapy and telbivudine combination therapy with adefovir in patients with nucleos(t)ide-naive chronic hepatitis B, high-level hepatitis B virus (HBV) load and hepatitis B e antigen (HBeAg)-positivity, and to explore the relationship between treatment regimen adherence and treatment outcomes."7.81[Efficacy and safety of telbivudine alone and combined with adefovir for the treatment of nucleos(t)ide-naive chronic hepatitis B in patients with high-level hepatitis B virus load]. ( Dang, B; Kang, W; Liu, Q; Sun, Y; Wang, C; Yao, N; Yu, Z; Zhao, K, 2015)
"To investigate the effects of adefovir dipivoxil (ADV) on blood phosphorus metabolism in patients with chronic hepatitis B (CHB)."7.81[Adefovir dipivoxil effects on and related factors of blood phosphorus metabolism in patients with chronic hepatitis B]. ( Ding, G; Kang, Y; Li, K; Li, W; Mao, Z; Ning, H; Shang, J; Xiao, E, 2015)
"To evaluate the long-term efficacy adefovir (ADV)-based combination therapies in entecavir (ETV)-resistant chronic hepatitis B (CHB) patients."7.81Management of entecavir-resistant chronic hepatitis B with adefovir-based combination therapies. ( Hwang, SG; Jang, MK; Jeong, SH; Jung, YK; Kim, BH; Kim, HS; Kim, IH; Kim, JH; Kim, JW; Kim, SG; Kim, TY; Kim, YS; Lee, JI; Lee, JW; Lee, SH; Park, H; Park, JW; Park, SJ; Seo, YS; Suh, SJ; Yim, HJ, 2015)
"We compared the efficacies of entecavir (ETV) plus tenofovir (TDF) and ETV plus adefovir (ADV) in chronic hepatitis B (CHB) patients with genotypic resistance to lamivudine (LAM) who showed a suboptimal response to LAM and ADV combination therapy."7.81Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy. ( Park, JG; Park, SY, 2015)
"Renal dysfunction and Fanconi's syndrome associated with hypophosphatemia caused by long-term administration of low-dose adefovir dipivoxil (ADV) has been reported in recent years."7.80Renal dysfunction and hypophosphatemia during long-term lamivudine plus adefovir dipivoxil therapy in patients with chronic hepatitis B. ( Akuta, N; Arase, Y; Hara, T; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Saitoh, S; Seko, Y; Sezaki, H; Suzuki, F; Suzuki, Y; Tanaka, M, 2014)
"Few studies have investigated the emergence of multidrug resistance to adefovir dipivoxil (ADV) plus lamivudine (LAM) combination therapy for patients with LAM-refractory chronic hepatitis B (CHB)."7.80Long-term efficacy and emergence of multidrug resistance in patients with lamivudine-refractory chronic hepatitis B treated by combination therapy with adefovir plus lamivudine. ( Akuta, N; Arase, Y; Hara, T; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Mineta, R; Saitoh, S; Sezaki, H; Suzuki, F; Suzuki, Y; Watahiki, S, 2014)
"We investigated the long-term efficacy of entecavir (ETV) + adefovir (ADV) combination therapy versus ETV monotherapy in lamivudine (LAM)-resistant chronic hepatitis B (CHB) patients who failed to respond to ADV rescue therapy."7.80Long-term efficacy of entecavir plus adefovir combination therapy versus entecavir monotherapy in adefovir refractory chronic hepatitis B patients with prior lamivudine resistance. ( Kim, DG; Kim, IH; Kim, SH; Kim, SW; Lee, S; Lee, SO; Lee, ST; Seo, SY; Sohn, JY, 2014)
"Previous studies have demonstrated that the treatment of chronic hepatitis B (CHB) infection with adefovir (ADV) can impair renal function."7.80Telbivudine protects renal function in patients with chronic hepatitis B infection in conjunction with adefovir-based combination therapy. ( Kim, HY; Kim, YJ; Lee, HJ; Lee, HS; Lee, JH; Lee, M; Oh, S; Yeum, TS; Yoon, JH; Yu, SJ, 2014)
"Entecavir (ETV) plus adefovir (ADV) combination therapy may be a promising option for chronic hepatitis B (CHB) patients who have failed on prior nucleos(t)ide analog (NA) treatment."7.80Efficacy of 2years of entecavir plus adefovir therapy in patients with chronic hepatitis B who had failed on prior nucleos(t)ide analog treatment. ( Wang, X; Wang, Y; Xiong, Y; Zhang, C; Zhu, Y, 2014)
"Entecavir (ETV) and tenofovir disoproxil fumarate (TDF) are the two first-line anti-viral therapies for chronic hepatitis B (CHB); however, there are limited studies directly comparing their effectiveness."7.80Tenofovir is superior to entecavir for achieving complete viral suppression in HBeAg-positive chronic hepatitis B patients with high HBV DNA. ( Gao, L; Li, J; Nguyen, MH; Trinh, HN, 2014)
"We investigated the efficacy and safety of tenofovir disoproxil fumarate (TDF)-based treatment in chronic hepatitis B (CHB) patients who failed previous antiviral therapies."7.80Efficacy and safety of tenofovir-based rescue therapy for chronic hepatitis B patients with previous nucleo(s/t)ide treatment failure. ( Byun, KS; Choe, WH; Kim, JH; Kim, YS; Kwon, SY; Lee, CH; Lee, CI; Yeon, JE; Yoon, EL, 2014)
"Tenofovir (TDF) has similar antiviral efficacy in both treatment-naive and lamivudine-resistant chronic hepatitis B (CHB) patients."7.80Efficacy of tenofovir in adefovir-experienced patients compared with treatment-naive patients with chronic hepatitis B. ( Akyüz, F; Badur, S; Baran, B; Bozdayi, AM; Idilman, R; Kabaçam, G; Karatayli, E; Karatayli, S; Kaymakoglu, S; Keskin, O; Onel, D; Ormeci, AC; Tüzün, A; Yurdaydin, C, 2014)
"The role of quantitative hepatitis B surface antigen (HBsAg) levels in patients receiving highly potent oral antiviral therapy is controversial, and here, we determined the HBsAg response in 121 chronic hepatitis B patients treated with tenofovir 300 mg daily."7.80Relevance of hepatitis B surface antigen levels in patients with chronic hepatitis B during 5 year of tenofovir treatment. ( Gupta, E; Hissar, SS; Sarin, SK; Sharma, MK; Singh, AK, 2014)
"The aim of the present study was to assess the long-term impact of entecavir (ETV) on T, B and natural killer (NK) cell immunity in patients with suboptimal responses to adefovir (SRA) chronic hepatitis B (CHB)."7.80Effects of entecavir on peripheral blood lymphocyte profiles in chronic hepatitis B patients with suboptimal responses to adefovir. ( Hu, X; Jiang, Y; Wang, Q; Zhang, L; Zhao, P, 2014)
"A 64-year-old woman was prescribed lamivudine and adefovir (ADV) for chronic hepatitis B."7.80[A case of chronic hepatitis B managed with continued adefovir despite treatment-related Fanconi syndrome and osteomalacia]. ( Asahina, Y; Iizuka, K; Iizuka, Y; Ito, E; Kobayashi, K; Mochizuki, N; Sakai, H; Watanabe, M, 2014)
"In chronic hepatitis B patients with kidney transplantation, sequential monotherapy with antiviral agents with low barriers to resistance should be avoided, and initial therapy with entecavir is a better option."7.80Efficacy and safety of tenofovir in a kidney transplant patient with chronic hepatitis B and nucleos(t)ide multidrug resistance: a case report. ( Shan, C; Wu, P; Yin, GQ, 2014)
"To investigate the treatment efficacy of adefovir dipivoxil combined with a corticosteroid on hepatitis B virus-associated glomerulonephritis (HBV-GN)."7.80Efficacy of adefovir dipivoxil combined with a corticosteroid in 38 cases of nephrotic syndrome induced by hepatitis B virus-associated glomerulonephritis. ( Li, H; Qiu, L; Xiao, P; Yuan, X; Zhou, Q, 2014)
"This study investigated the antiviral efficacy of adefovir (ADV) rescue therapy and the feasibility of lamivudine (LAM) discontinuation in LAM-resistant chronic hepatitis B (CH-B) patients who had attained a virological response (VR) with LAM + ADV combination therapy."7.80The feasibility of discontinuing lamivudine in lamivudine-resistant chronic hepatitis B patients on lamivudine and adefovir combination therapy. ( Byoun, YS; Chung, SM; Jang, ES; Jeong, SH; Kim, HS; Kim, JW, 2014)
"Adefovir (ADV) resistance is more frequent in lamivudine (LMV)-resistant chronic hepatitis B (CHB) patients than in nucleos(t)ide analogue-naïve patients."7.80Different mechanism of selection of adefovir-resistant mutant viruses during adefovir monotherapy in patients with lamivudine-resistant chronic hepatitis B. ( Cho, YK; Cui, XJ; Jeong, SU; Song, BC, 2014)
"This study assessed the antiviral efficacy and safety of tenofovir disoproxil fumarate (TDF) for up to 12 months in Korean treatment-naïve chronic hepatitis B (CHB) patients."7.80Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide-naïve chronic hepatitis B patients in Korea: data from the clinical practice setting in a single-center cohort. ( Ahn, SH; Ahn, SS; Chon, YE; Han, KH; Kim, BK; Kim, DY; Kim, SU; Park, JY, 2014)
"Adefovir (ADV) and lamivudine (LAM) combination therapy (ADV+LAM) has been a useful option for patients with LAM-resistant (LAM-r) chronic hepatitis B (CHB)."7.80Long-term outcomes of two rescue therapies in lamivudine-refractory patients with chronic hepatitis B: combined lamivudine and adefovir, and 1-mg entecavir. ( Ahn, DG; Baek, EK; Cho, HJ; Chung, HW; Kim, HJ; Kwon, JC; Lee, H; Lee, JJ; Ze, E, 2014)
" Here, we describe two additional patients with chronic hepatitis B (CHB) who developed a TDF-induced Fanconi syndrome that reverted after TDF withdrawal and had viral replication fully suppressed upon switching to entecavir (ETV)."7.80Tenofovir-induced Fanconi syndrome in chronic hepatitis B monoinfected patients that reverted after tenofovir withdrawal. ( Brocchieri, A; Castelli, F; Colombo, M; Facchetti, F; Fugazza, A; Lampertico, P; Mangia, G; Spinetti, A; Viganò, M; Zaltron, S, 2014)
"Tenofovir (300 mg/d) is an effective and safe rescue therapy in chronic hepatitis B patients who failed initial treatment with LAM and secondary treatment of LAM plus ADV."7.80[Tenofovir rescue therapy for chronic hepatitis B patients after suboptimal response to treatment with lamivudine plus adefovir dipivoxil]. ( Fan, H; Fan, Y; Ge, Y; Li, D; Liu, X; Liu, Z; Lyu, W; Yang, H; Zhou, B, 2014)
"There is very limited experience in the management of telbivudine (LdT)-associated virological breakthrough (VBT) and resistance in the treatment of chronic hepatitis B (CHB) patients, and the guideline recommendations are primitively based on the general principles of rescue therapy to nucleos(t)ide analog resistance."7.79Telbivudine plus adefovir therapy for chronic hepatitis B patients with virological breakthrough or genotypic resistance to telbivudine. ( Bai, XF; Huang, CX; Li, Y; Lian, JQ; Wang, JP; Zhang, Y, 2013)
"Chronic hepatitis B patients (CHB) treated with adefovir were followed up to evaluate nephrotoxicity and its outcome."7.79Resolution of adefovir-related nephrotoxicity by adefovir dose-reduction in patients with chronic hepatitis B. ( Aung, MO; Chiu, LL; Dan, YY; Gowans, M; Hartono, JL; Khoo, MJ; Koay, E; Lee, GH; Lee, YM; Lim, K; Lim, SG; Low, HC; Soon, C; Tan, PS; Thwin, MA, 2013)
"In patients with lamivudine (LAM)-resistant chronic hepatitis B (CHB) receiving adefovir (ADV) add-on LAM therapy, insufficient viral suppression or the appearance of additional ADV resistance has remained unresolved."7.79Partial virological response to adefovir add-on lamivudine rescue therapy in patients with lamivudine-resistant chronic hepatitis B. ( Ahn, SH; Choi, A; Chon, CY; Chon, YE; Han, KH; Kim, DY; Kim, SU; Park, JY, 2013)
"To evaluate the efficacy and safety of Entecavir (ETV) plus adefovir (ADV) for chronic hepatitis B (CHB) patients after multiple nucleos(t)ide analogue (NAs) failure treatment."7.79Entecavir plus adefovir rescue therapy for chronic hepatitis B patients after multiple treatment failures in real-life practice. ( Deng, JY; He, FQ; Li, GL; Li, JY; Li, Q; Pan, QR; Qin, Y; Xu, XH, 2013)
"Tenofovir disoproxil fumarate (TDF) is increasingly used in patients with chronic hepatitis B (CHB) infection."7.79Tenofovir-associated Fanconi syndrome in patients with chronic hepatitis B monoinfection. ( Gracey, DM; McKenzie, P; Snelling, P; Strasser, SI, 2013)
"The aim of this study was to compare the effect of combination lamivudine (LAM) and adefovir dipivoxil (ADV) versus entecavir (ETV) monotherapy for naïve HBeAg-positive chronic hepatitis B (CHB) patients."7.79Combination lamivudine and adefovir versus entecavir for the treatment of naïve chronic hepatitis B patients: a pilot study. ( Cai, FJ; Ding, JG; Du, QW; Fu, RQ; Hong, L; Sun, QF; Wu, YH; Zhou, QQ, 2013)
"The aim of our study was to validate the roadmap concept in the treatment of chronic hepatitis B, and to investigate the virologic efficacy and kinetics of quantitative hepatitis B surface antigen (qHBsAg) during telbivudine therapy in a real-world setting."7.79Real-world application of the roadmap model in chronic hepatitis B patients with telbivudine therapy. ( Hsu, PI; Lai, KH; Lin, KH; Tsai, TJ; Tsay, FW; Wang, HM; Yu, HC, 2013)
"Treatment strategies for entecavir (ETV)-resistant chronic hepatitis B (CHB) patients are not yet well established."7.79Efficacy of adefovir-based combination therapy for patients with Lamivudine- and entecavir-resistant chronic hepatitis B virus infection. ( Cho, Y; Cho, YY; Choi, WM; Kim, CY; Kim, YJ; Lee, DH; Lee, HS; Lee, JH; Lee, M; Lee, YB; Yoo, JJ; Yoon, JH; Yu, SJ, 2013)
"Lamivudine (LAM) plus adefovir (ADV) combination therapy has been accepted as one of the best treatments for LAM-resistant chronic hepatitis B (CHB)."7.79Lamivudine plus adefovir combination therapy for lamivudine resistance in hepatitis-B-related hepatocellular carcinoma patients. ( Choe, WH; Kim, JH; Ko, SY; Kwon, SY; Lee, CH, 2013)
"To investigate the efficacy and safety ofTelbivudine +Tenofovir combination therapy in chronic hepatitis B patients, over a period of 52 weeks, in real life clinical settings."7.79Telbivudine plus tenofovir in combination therapy in patients with chronic hepatitis B infection--an Indian experience. ( Panda, C, 2013)
"The efficacy of adefovir (ADV) plus entecavir (ETV) combination in patients with chronic hepatitis B (CHB) who developed multidrug refractoriness had not been fully evaluated."7.79The efficacy of adefovir plus entecavir combination therapy in patients with chronic hepatitis B refractory to both lamivudine and adefovir. ( Cho, EJ; Cho, Y; Chung, KH; Jeong, SH; Jin, E; Kim, CY; Kim, JW; Kim, YJ; Lee, DH; Lee, HS; Lee, JH; Yoon, JH; Yu, SJ, 2013)
"Fifty-three patients with confirmed genotypic lamivudine-resistant chronic hepatitis B were treated with entecavir."7.79The short-term efficacy of entecavir in lamivudine-resistant chronic hepatitis B: influence of sequential adefovir-refractoriness. ( Choi, DJ; Jung, YK; Kim, JH; Kim, YS; Ku, YS; Kwon, OS, 2013)
"To compare the efficacy of rescue therapies in lamivudine (LAM)-resistant chronic hepatitis B (CHB) infections including: (1) adefovir dipivoxil (ADV) monotherapy, (2) ADV plus LAM combination therapy and (3) entecavir (ETV) 1."7.79Treatment of lamivudine-resistant chronic hepatitis B infection: a multicenter retrospective study. ( Ahn, SH; Hong, SP; Hwang, SG; Kim, BH; Kim, HS; Kim, IH; Kim, JH; Lee, JI; Lee, JM; Lee, JW; Lee, SH; Lee, SJ; Park, SJ; Park, YM; Seo, YS; Yim, HJ; Yoon, EL, 2013)
"We evaluated the efficacy of tenofovir disoproxil fumarate (TDF) in patients with lamivudine failure (LAM-F) in comparison with that in nucleoside/nucleotide analogue (NA)-naïve patients with chronic hepatitis B (CHB)."7.79Efficacy of tenofovir in patients with Lamivudine failure is not different from that in nucleoside/nucleotide analogue-naive patients with chronic hepatitis B. ( Akyuz, F; Badur, S; Baran, B; Besisik, F; Bozbey, HU; Demir, K; Evirgen, S; Gokturk, S; Gulluoglu, M; Karaca, C; Kaymakoglu, S; Onel, D; Ormeci, AC; Soyer, OM, 2013)
"The impact of adefovir dipivoxil (ADV) treatment on the immune system in patients with chronic hepatitis B (CHB) is unknown."7.78Adefovir dipivoxil modulates cytokine expression in Th1/Th2 cells in patients with chronic hepatitis B. ( Liu, YY; Ma, ZH; Niu, JQ; Piao, RL; Tian, D; Zhang, M; Zhao, C, 2012)
"A male 36 years old patient diagnosed with anti HBe-positive chronic hepatitis B (CHB) had received lamivudine treatment for 7 years following an initial unsuccessfull interferon treatment."7.78Molecular characterization of a novel entecavir mutation pattern isolated from a multi-drug refractory patient with chronic hepatitis B infection. ( Bozdayi, AM; Cinar, K; Gokahmetoglu, S; Güven, K; Idilman, R; Karatayli, E; Karatayli, SC; Yurdaydin, C, 2012)
"Adefovir is usually applied for therapy of chronic hepatitis B (CHB), but its effectiveness after cessation is still unknown."7.78A prospective clinical study in hepatitis B e antigen-negative chronic hepatitis B patients with stringent cessation criteria for adefovir. ( Diao, S; Ha, M; Huang, C; Huang, Z; Kuan, C; Lin, M; She, H; Shen, L; Shen, W; Sun, L; Zhang, G, 2012)
"The optimal treatment of patients with chronic hepatitis B (CHB) who develop resistance to both lamivudine (LMV) and entecavir (ETV) after sequential monotherapy of LMV and ETV remains little known."7.78Efficacy of entecavir and adefovir combination therapy for patients with lamivudine- and entecavir-resistant chronic hepatitis B. ( Cha, JM; Jeon, JW; Joo, KR; Kim, S; Lee, JI; Lim, JU; Lim, K; Park, JJ; Shin, HP, 2012)
"The combination of entecavir, a nucleoside analogue, and adefovir, a nucleotide analogue, would be a promising salvage treatment for chronic hepatitis B (CHB) patients who fail nucleoside/nucleotide analogue (NA) regimens."7.78Entecavir plus adefovir combination treatment for chronic hepatitis B patients after failure of nucleoside/nucleotide analogues. ( Heo, NY; Lee, HC; Lee, TH; Lim, YS; Shim, JH; Suh, DJ, 2012)
"Among 141 HIV-HBV-coinfected patients treated with tenofovir in our centre, 87% were good-responders to therapy."7.78Quasispecies analysis and in vitro susceptibility of HBV strains isolated from HIV-HBV-coinfected patients with delayed response to tenofovir. ( Branger, M; Collin, G; Fraqueiro, G; Gervais, A; Lada, O; Leclerc, L; Marcellin, P; Martinot-Peignoux, M; Matheron, S; Moucari, R; Peytavin, G; Roquebert, B, 2012)
" entecavir (ETV) monotherapy in HBeAg-positive hepatitis B patients who fail to respond to sequential treatment with LAM and ADV."7.78Lamivudine plus adefovir vs. entecavir in HBeAg-positive hepatitis B with sequential treatment failure of lamivudine and adefovir. ( Ahn, SH; Chon, CY; Han, KH; Kim, DY; Lee, JM; Lee, MH; Park, JY; Ryu, HJ; Son, CY, 2012)
"Adefovir and tenofovir are nucleotide analogues used as long-term therapy of chronic hepatitis B."7.78Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B. ( Chong, WH; Collins, MT; Gara, N; Ghany, MG; Hoofnagle, JH; Jake Liang, T; Kleiner, DE; Zhao, X, 2012)
"Tenofovir is a nucleotide reverse-transcriptase inhibitor approved for treatment of human immunodeficiency virus infection, as well as chronic hepatitis B (CHB)."7.78Similar risk of renal events among patients treated with tenofovir or entecavir for chronic hepatitis B. ( Baqai, S; Clark, MD; Gish, RG; Kane, SD; Mangahas, MF; Shaw, RE, 2012)
"To evaluate the changes in the renal function of patients with chronic hepatitis B (CHB) receiving adefovir dipivoxil (ADV) or telbivudine (L-DT) monotherapy."7.78[Influence of adefovir dipivoxil or telbivudine monotherapy on renal function of patients with chronic hepatitis B]. ( Fan, R; Guo, Y; Hou, J; Li, X; Peng, J; Sun, J; Yang, S; Zhong, C, 2012)
"In the first year of treatment for chronic hepatitis B, virologic response and tolerability did not differ significantly between tenofovir and entecavir."7.78Comparison of the efficacy of tenofovir and entecavir for the treatment of nucleos(t)ide-naive patients with chronic hepatitis B. ( Akin, MS; Doğan, ÜB; Gümürdülü, Y; Kara, B; Soylu, A, 2012)
"We present a case of a 62-year-old man who underwent total hip arthroplasty for treatment of pathologic femoral neck fracture associated with adefovir dipivoxil-induced osteomalacia."7.78Pathological femoral fractures due to osteomalacia associated with adefovir dipivoxil treatment for hepatitis B: a case report. ( Arishima, Y; Hirotsu, M; Ishidou, Y; Kakoi, H; Kamizono, J; Komiya, S; Nagano, S; Nakamura, S; Saitoh, Y; Setoguchi, T; Tanaka, M; Yokouchi, M, 2012)
"There is a paucity of data on the long-term efficacy of combination lamivudine and adefovir therapy in patients with lamivudine-resistant chronic hepatitis B."7.78Outcome of lamivudine-resistant chronic hepatitis B after up to 5 years of combination therapy with adefovir. ( Fung, J; Hung, IF; Lai, CL; Liu, K; Seto, WK; Wong, DK; Yuen, JC; Yuen, MF, 2012)
"Lamivudine (LAM) resistance now poses a major problem in the management of patients with chronic hepatitis B virus (HBV) infection."7.78Comparison of rescue strategies in lamivudine-resistant patients with chronic hepatitis B. ( Huang, L; Li, T; Wang, C; Xu, D; Zhao, P, 2012)
" To evaluate the resistance to adefovir (ADV) therapy in patients with chronic hepatitis B infection, a study was conducted on 70 patients (63 males and 7 females), who had received in first line lamivudine and second line adefovir."7.78Use of ALLGIO probe assays for detection of HBV resistance to adefovir in patients with chronic hepatitis B, Kerman, Iran. ( Afshar, RM; Mollaie, HR, 2012)
"To investigate retrospectively the long-term efficacy of various treatment strategies using adefovir dipivoxil (adefovir) in patients with lamivudine-resistant chronic hepatitis B."7.78Treatment strategies using adefovir dipivoxil for individuals with lamivudine-resistant chronic hepatitis B. ( An, H; Chun, HJ; Jeen, YT; Jung, JY; Keum, B; Kim, CD; Kim, CH; Kim, JD; Kim, YS; Lee, HS; Ryu, HS; Seo, YS; Um, SH; Yim, HJ; Yun, TJ, 2012)
"Although adefovir dipivoxil (ADV) has been used for antiviral treatment of lamivudine (LAM)-resistant chronic hepatitis B (CHB) patients, the long-term efficacy of this treatment is not well understood."7.77Initial virological response and viral mutation with adefovir dipivoxil added to ongoing Lamivudine therapy in Lamivudine-resistant chronic hepatitis B. ( Arai, M; Fukai, K; Imazeki, F; Kanda, T; Wu, S; Yokosuka, O; Yonemitsu, Y, 2011)
"Tenofovir disoproxil fumarate (TDF), a nucleotide analogue and potent inhibitor of hepatitis B virus (HBV) polymerase, showed superior efficacy to adefovir dipivoxil in treatment of chronic hepatitis B through 48 weeks."7.77Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. ( Anderson, J; Borroto-Esoda, K; Buggisch, P; Buti, M; De Man, RA; Flisiak, R; Gane, E; Germanidis, G; Gurel, S; Heathcote, EJ; Kaita, K; Kotzev, I; Krastev, Z; Kurdas, OO; Lee, SS; Manns, M; Marcellin, P; Mondou, E; Rousseau, F; Shiffman, ML; Snow-Lampart, A; Sorbel, J; Tchernev, K; Trinh, H; Weilert, F, 2011)
"The study evaluated whether a liquid suspension of adefovir dipivoxil (ADV) is effective and safe when dose adjusted based on varying degrees of renal impairment in patients with chronic hepatitis B."7.77Efficacy and pharmacokinetics of adefovir dipivoxil liquid suspension in patients with chronic hepatitis B and renal impairment. ( Frederick, D; Pol, S; Rostaing, L; Rousseau, F; Schiff, E; Shiffman, ML; Thabut, D; Zeuzem, S; Zong, J, 2011)
"The aim of this study was to determine the optimal time and HBV DNA levels during the treatment period for prediction of virological breakthrough (VBT) 3 years after adefovir monotherapy in chronic hepatitis B (CHB) patients with lamivudine resistance."7.77The level of HBV DNA at month 12 is an important predictor of virological breakthrough during adefovir monotherapy in chronic hepatitis B patients with lamivudine resistance. ( Jung, SW; Kim, MC; Park, NH; Shin, JW, 2011)
"This study included 82 patients with HBeAg-negative chronic hepatitis B (CHB) who received adefovir dipivoxil therapy."7.77[Virological response to adefovir dipivoxil predicts the long-term development of resistance in previously untreated patients with HBeAg-negative chronic hepatitis B]. ( Andrade, RJ; Chueca, N; Figueruela, B; Fraga, E; García, F; Gila, A; Martín, JM; Muñoz Rueda, P; Nogales, C; Puche, B; Romero-Gómez, M; Salmerón, J; Suárez, E, 2011)
"An increasing number of patients with chronic hepatitis B infection are being treated with the newly licensed drug, adefovir."7.77Adefovir-induced Stevens-Johnson syndrome and toxic epidermal necrolysis overlap syndrome. ( Chattopadhyay, P; Sarma, N, 2011)
"To assess the long-term effectiveness and safety of adefovir (ADV) plus lamivudine (LMV) in LMV-resistant (R) kidney transplants with chronic hepatitis B, 11 such patients were treated with add-on ADV."7.77Long-term add-on therapy with adefovir in lamivudine-resistant kidney graft recipients with chronic hepatitis B. ( Aroldi, A; Colombo, M; Facchetti, F; Invernizzi, F; Lampertico, P; Lunghi, G; Messa, PG; Viganò, M, 2011)
"The aims of this study were to assess the long-term efficacy of lamivudine (LAM) plus adefovir dipivoxil (ADV) combination therapy in patients with chronic hepatitis B resistant to LAM, to identify predictive factors of complete viral response (HBV-DNA <2."7.77Clinical course and predictive factors of virological response in long-term lamivudine plus adefovir dipivoxil combination therapy for lamivudine-resistant chronic hepatitis B patients. ( Aizawa, M; Fujise, K; Hoshina, S; Kono, M; Tajiri, H; Tatsuzawa, K; Tsubota, A, 2011)
"We report a case of an immunocompromised patient affected by chronic hepatitis B virus (HBV) with high basal HBV viremia (>8 log(10) IU/ml) who failed an entecavir regimen, despite the absence of primary or secondary drug resistance mutations."7.77Successful switch to tenofovir after suboptimal response to entecavir in an immunocompromised patient with chronic hepatitis B and without genotypic hepatitis B virus resistance. ( Andreoni, M; Bertoli, A; Ceccarelli, L; Perno, CF; Salpini, R; Sarrecchia, C; Sordillo, P; Svicher, V; Volpi, A, 2011)
"An increasing number of patients with chronic hepatitis B (CHB) have experienced treatment failure to adefovir (ADV) and their management poses a growing challenge."7.77The efficacy of entecavir therapy in chronic hepatitis B patients with suboptimal response to adevofir. ( Do, ST; Garcia, RT; Nguyen, HA; Nguyen, KK; Nguyen, MH; Nguyen, TT; Sheen, E; Tran, P; Trinh, HN, 2011)
"In chronic hepatitis B (CHB) patients, adefovir is commonly used as a rescue therapy for lamivudine resistance, but often results in incomplete virological suppression."7.77Management options for lamivudine-resistant chronic hepatitis B patients with suboptimal virological suppression by adefovir. ( Chan, HL; Chan, HY; Ong, A; Tse, CH; Wong, GL; Wong, VW, 2011)
"This study aimed to evaluate the long-term efficacy of entecavir (ETV) in adefovir (ADV)-refractory chronic hepatitis B (CHB) patients with prior lamivudine (LMV) resistance."7.77Long-term efficacy of entecavir in adefovir-refractory chronic hepatitis B patients with prior lamivudine resistance. ( Jang, JS; Jang, MK; Kim, DJ; Kim, HS; Kim, HY; Kim, KH; Lee, JH; Lee, MS; Park, CK; Park, JW; Seo, DD; Shin, WG, 2011)
"To study the factors influencing the long-term usage of lamivudine (LAM) in chronic hepatitis B (CHB) patients and the management after drug-resistance."7.77[Lamivudine-resistant analysis and management for chronic hepatitis B patients with initial lamivudine therapy]. ( Chen, Y; He, LL; Lei, BJ; Lei, XZ; Xu, H, 2011)
"Previous research has demonstrated that tenofovir disoproxil fumarate (DF) is the most cost-effective nucleos(t)ide treatment for chronic hepatitis B (CHB) in the UK, Spain, Italy and France."7.77Cost effectiveness of tenofovir disoproxil fumarate for the treatment of chronic hepatitis B from a Canadian public payer perspective. ( Bentley, A; Dakin, H; Fidler, C; Fung, S; Sherman, M, 2011)
"Adefovir dipivoxil is commonly used for treatment of chronic hepatitis B."7.77[Adefovir dipivoxil-induced Fanconi syndrome and hypophosphatemic osteomalacia associated with muscular weakness in a patient with chronic hepatitis B]. ( Dong, GF; Li, L; Xie, YS; Zhang, X, 2011)
"We investigated the durability of the biochemical and virologic responses after adefovir (ADV) discontinuation in lamivudine-resistant (LMV-R) chronic hepatitis B (CHB) patients, and the outcomes of ADV discontinuation compared to that of ADV maintenance."7.77Virologic response is not durable after adefovir discontinuation in lamivudine-resistant chronic hepatitis B patients. ( Byun, KS; Jung, ES; Jung, YK; Kim, JH; Lee, KG; Ryu, HS; Seo, YS; Um, SH; Yeon, JE; Yim, HJ, 2011)
" The use of lamivudine and tenofovir resulted in arrest of proteinuria and stabilisation of renal function."7.77Hepatitis B virus related membranous glomerulonephritis and proteinuria treated with lamivudine and tenofovir. ( Das, P; Ford, M; Holt, S; Kingdon, E; Vivek, V, 2011)
" The purpose of this study was to evaluate the effect of a new therapeutic strategy combining Lamivudine (LAM) and ADV in patients with HBeAg-positive chronic hepatitis B (CHB) and poor response to ADV monotherapy."7.76Combination of Lamivudine and adefovir therapy in HBeAg-positive chronic hepatitis B patients with poor response to adefovir monotherapy. ( Cao, J; Chen, EQ; Lei, BJ; Liu, L; Tang, H; Wang, JR; Wang, LC, 2010)
"Long-term lamivudine (LAM) and adefovir (ADV) treatment has been found to induce the emergence of drug-resistant hepatitis B virus (HBV) in a significant number of patients with chronic hepatitis B (CHB) infection."7.76Lamivudine and adefovir resistance in children and young adults with chronic hepatitis B. ( Akman, SA; Halicioglu, O; Kose, S, 2010)
" In adefovir (ADV) treated chronic hepatitis B patients carrying rtA181T/rtA181V mutations, overlap with surface gene mutations such as sW172stop/sL173F has been reported."7.76Hepatitis B viral surface mutations in patients with adefovir resistant chronic hepatitis B with A181T/V polymerase mutations. ( Bak, YT; Byun, KS; Joo, MK; Jung, YK; Kim, JH; Kim, JS; Park, JJ; Yeon, JE; Yim, HJ, 2010)
"The aim of this study was to determine the evolution of full-length hepatitis B virus (HBV) sequences in chronic hepatitis B (CHB) patients with sequential lamivudine (LAM) and adefovir (ADV) resistance."7.76Evolution of full-length HBV sequences in chronic hepatitis B patients with sequential lamivudine and adefovir dipivoxil resistance. ( Changchien, CS; Chen, CH; Hu, TH; Hung, CH; Lee, CM; Lu, SN; Tung, WC; Wang, JC; Wang, JH, 2010)
" The aim of this study was to clarify the effect of molecular characteristics on the antiviral response to adefovir in patients with lamivudine-resistant chronic hepatitis B (CHB)."7.76Response to adefovir depends on mutation patterns in precore region, basal core promoter and reverse transcriptase, and on-treatment responses in Lamivudine-resistant chronic hepatitis B patients. ( Cho, YK; Choi, EK; Cui, XJ; Hyun, S; Jeong, SU; Kim, HU; Park, NH; Shin, JW; Song, BC; Song, HJ, 2010)
"There have been no reports comparing the therapeutic results of adefovir (ADV) and entecavir (ETV) rescue therapy for patients with lamivudine (LAM)-resistant chronic hepatitis B (CHB)."7.76Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy. ( Cho, YK; Jeon, WK; Kim, BI; Kim, HJ; Park, DI; Park, JH; Sohn, CI, 2010)
"The aim of this study was to assess the cost-effectiveness of tenofovir disoproxil fumarate (TDF) in the treatment of chronic hepatitis B (CHB) versus alternative nucleos(t)ides from a UK National Health Service (NHS) perspective."7.76Cost-utility analysis of tenofovir disoproxil fumarate in the treatment of chronic hepatitis B. ( Bentley, A; Dakin, H; Dusheiko, G, 2010)
"Adefovir dipivoxil treatment has significantly improved the outcome of chronic hepatitis B virus (HBV) infection."7.76Th1 and Th2 immune response in chronic hepatitis B patients during a long-term treatment with adefovir dipivoxil. ( Hao, C; Jiang, Y; Li, W; Ma, Z; Niu, J; Xin, G; Xu, H; Yan, H; Zhao, P, 2010)
" The aim was to evaluate the long-term outcome of lamivudine monoprophylaxis with adefovir salvage for liver transplantation in chronic hepatitis B."7.75Lamivudine monoprophylaxis and adefovir salvage for liver transplantation in chronic hepatitis B: a seven-year follow-up study. ( Chan, HL; Chan, HY; Kwan, KY; Lai, PB; Limquiaco, JL; Tse, CH; Wong, GL; Wong, J; Wong, VW, 2009)
"Patients with chronic hepatitis B (CHB) who will and those who will not respond to adefovir (ADV) monotherapy need to be identified at an early stage in order to adjust treatment and prevent future development of antiviral resistance."7.75On-treatment monitoring of adefovir therapy in chronic hepatitis B: virologic response can be assessed at 24 weeks. ( de Man, RA; Hansen, BE; Janssen, HL; Leemans, WF; Pas, SD; Reijnders, JG; Schutten, M, 2009)
"The aims of the study were to investigate the efficacy of rescue therapy with lamivudine (LAM) and adefovir (ADV) combination for 6 months followed by ADV monotherapy in lamivudine-resistant chronic hepatitis B (LAM-R CHB) patients, and to analyze the frequency of ADV resistance mutant development in such patients."7.75A short course of add-on adefovir dipivoxil treatment in lamivudine-resistant chronic hepatitis B patients. ( Ahishali, E; Badur, S; Bektas, M; Bozkaya, H; Cakaloglu, Y; Cinar, K; Idilman, R; Karayalcin, S; Kaymakoglu, S; Mithat Bozdayi, A; Oguz Onder, F; Okten, A; Pinarbasi, B; Yurdaydin, C, 2009)
"It has been shown that adefovir dipivoxil is an effective antiviral agent in the treatment of chronic hepatitis B (CHB), not only in wild-type hepatitis B virus (HBV) infection, but also in lamivudine-resistant (LAMV-R) cases."7.75[Virologic response to adefovir dipivoxil monotherapy is not durable in HBeAg-positive, lamivudine-resistant chronic hepatitis B patients]. ( Choi, MS; Jung, HW; Kim, KH; Koh, KC; Lee, JH; Paik, SW; Park, SH; Yeon, KK; Yoo, BC, 2009)
"The antiviral effect of adefovir dipivoxil (ADV) added to ongoing lamivudine (LAM) treatment for LAM-resistant chronic hepatitis B (CHB) differs among patients."7.75Factors contributing to antiviral effect of adefovir dipivoxil therapy added to ongoing lamivudine treatment in patients with lamivudine-resistant chronic hepatitis B. ( Doi, Y; Hagiwara, H; Hayashi, E; Hayashi, N; Hiramatsu, N; Imai, Y; Kanto, T; Kasahara, A; Kashihara, T; Kato, M; Kiso, S; Kurashige, N; Mita, E; Nagase, T; Ohkawa, K; Oshita, M; Takehara, T; Yakushijin, T; Yamada, A; Yoshihara, H, 2009)
"The aim of this study was to elucidate the antiviral efficacy of lamivudine (LMV)-adefovir (ADV) combination therapy in chronic hepatitis B patients who showed resistance to LMV and ADV consecutively."7.75[Antiviral efficacy of lamivudine/adefovir combination therapy in chronic hepatitis b patients with resistance to lamivudine and adefovir consecutively]. ( Gwak, GY; Koh, KC; Lee, HIe; Lee, JH; Paik, SW; Park, MK; Suh, HJ; Yoo, BC, 2009)
"The aim of the study was to estimate the effect of viral factors (HBV genotype, viral load and kinetics) to treatment response in chronic hepatitis B (CHB) and first-line therapy with adefovir dipivoxil (ADV)."7.75Rapid HBV DNA decrease (week 12) is an important prognostic factor for first-line treatment with adefovir dipivoxil for chronic hepatitis B. ( Bock, T; Hass, HG; Kaiser, S; Nehls, O, 2009)
"Data concerning the outcome of lamivudine-resistant (LAM-R) chronic hepatitis B (CHB) patients with compensated cirrhosis under adefovir (ADV) treatment are limited."7.75Clinical outcome of lamivudine-resistant chronic hepatitis B patients with compensated cirrhosis under adefovir salvage treatment. Importance of HCC surveillance. ( Buti, M; Elefsiniotis, I; Esteban, R; Jardi, R; Vezali, E, 2009)
"Clinical data of 233 chronic hepatitis B patients treated with lamivudine 100mg daily (91 patients were switched to Adefovir 10mg daily or Adefovir 10mg in combination with lamivudine 100mg daily) were retrospective."7.75[Factors associated with response to lamivudine: retrospective study of 233 patients with chronic hepatitis B]. ( Fu, J; Li, SG; Tan, B; Wen, FY; Wu, JL; Yang, XY; Zhou, HJ, 2009)
"To explore the mechanism for adefovir dipivoxil (ADV) resistance occurred in chronic hepatitis B patients of a series of phase III clinical trails."7.75[Dissection of mechanism for the adefovir dipivoxil resistance in chronic hepatitis B patients]. ( Cai, SF; Deng, H; Deng, XH; Guo, JJ; Huang, AL; Li, QL; Lu, P; Xin, XJ; Yang, C; Zeng, AZ, 2009)
"To study the predictive value of ALT, HBeAg and HBV DNA levels at baseline and HBV DNA levels at week 12 adefovir dipivoxil (ADV) treatment to the efficacy of it at week 52 in patients with HBeAg-positive chronic hepatitis B (CHB)."7.74[The predictive value of ALT, HBeAg and HBV DNA levels at baseline and the degree of HBV suppression at week 12 adefovir dipivoxil treatment to the efficacy of it at week 52 in patients with HBeAg-positive chronic hepatitis B]. ( Chen, YM; Gao, ZL; Li, JG; Lin, BL; Lu, WL; Xie, DY; Xu, QH, 2008)
"A 43-year-old man was treated with lamivudine for hepatitis B e antigen-positive chronic hepatitis B."7.74Selection of an entecavir-resistant mutant despite prolonged hepatitis B virus DNA suppression, in a chronic hepatitis B patient with preexistent lamivudine resistance: successful rescue therapy with tenofovir. ( de Man, RA; Janssen, HL; Leemans, WF; Niesters, HG; Schalm, SW; van der Eijk, AA, 2008)
"This longitudinal study included 41 patients with chronic hepatitis B virus (HBV) infection receiving ADV monotherapy or ADV plus lamivudine (3TC)."7.74Adefovir for chronic hepatitis B treatment: identification of virological markers linked to therapy response. ( Buti, M; Esteban, R; Ferrer-Costa, C; Homs, M; Jardi, R; Rodriguez-Frias, F; Schaper, M; Tabernero, D, 2008)
"To study the resistant rate of hepatitis B virus (HBV) to ADV and the dynamic evolution of HBV in lamivudine (Lam)-resistant chronic hepatitis B (CHB) patients."7.74[The rate of hepatitis B virus resistance to adefovir dipivoxil (ADV) and the evolution of hepatitis B virus in lamivudine-resistant chronic hepatitis B patients with ADV monotherapy]. ( Huang, YX; Mao, RC; Qin, YL; Weng, XH; Wu, XH; Yin, YK; Zhang, JM; Zhang, QB; Zhang, WQ, 2007)
"To determine the factors affecting the virological response to adefovir dipivoxil (ADV) among patients with lamivudine resistant chronic hepatitis B."7.74Early virological suppression is associated with good maintained response to adefovir dipivoxil in lamivudine resistant chronic hepatitis B. ( Chan, HL; Chan, HY; Chim, AM; Sung, JJ; Tse, CH; Wong, GL; Wong, VW, 2007)
"To determine the factors associated with virological response (VR), HBeAg loss or the emergence of adefovir (ADV)-related mutations in ADV-treated chronic hepatitis B (CHB) patients with lamivudine (LAM) resistance."7.74Viral genotype and baseline load predict the response to adefovir treatment in lamivudine-resistant chronic hepatitis B patients. ( Bonovas, S; Buti, M; Elefsiniotis, I; Esteban, R; Jardi, R; Rodriguez-Frias, F; Schapper, M; Vargas, V, 2007)
"Adefovir dipivoxil (ADV) resistance in patients with lamivudine-resistant chronic hepatitis B is not well understood."7.74[Effect of initial virologic response to adefovir on the development of resistance to adefovir in lamivudine-resistant chronic hepatitis B]. ( Kim, DG; Kim, HC; Kim, IH; Kim, SH; Kim, SW; Lee, SO; Lee, ST; Shin, KD, 2007)
"We summarize the clinical history and laboratory results following the introduction of tenofovir among 6 patients coinfected with human immunodeficiency virus (HIV) and hepatitis B virus (HBV) who presented with severe liver disease while receiving lamivudine-based highly active antiretroviral therapy."7.74Tenofovir-based rescue therapy for advanced liver disease in 6 patients coinfected with HIV and hepatitis B virus and receiving lamivudine. ( Guillemi, S; Gutiérrez, S; Harrigan, PR; Jahnke, N; Montaner, JS; Montessori, V, 2008)
" In our department, tenofovir was prescribed in addition to lamivudine for the treatment of lamivudine resistant chronic hepatitis B."7.74Switching patients with lamivudine resistant chronic hepatitis B virus from tenofovir to adefovir results in less potent HBV-DNA suppression. ( de Man, RA; Janssen, HL; Leemans, WF; Niesters, HG, 2008)
"The aims of the present study were to assess initial virological response (IVR) to adefovir (ADV) treatment for chronic hepatitis B, to identify patients with suboptimal response and to determine the incidence of ADV-resistant mutants."7.74Evaluation of initial virological response to adefovir and development of adefovir-resistant mutations in patients with chronic hepatitis B. ( Enrĺquez, J; Gallego, A; García-Samaniego, J; Hornillos, P; Margall, N; Romero, M; Sheldon, J; Soriano, V, 2008)
"In lamivudine-resistant patients with chronic hepatitis B (CHB), we compared efficacy, predictive response factors and changes in viral mutants in two antiviral approaches with adefovir."7.74Lamivudine-resistant chronic hepatitis B: an observational study on adefovir in monotherapy or in combination with lamivudine. ( Alessandria, C; Barbon, V; Carenzi, S; Gaia, S; Lagget, M; Marzano, A; Olivero, A; Rizzetto, M; Smedile, A, 2008)
"The aim of this study was to assess the therapeutic effectiveness of adefovir dipivoxil (ADV), administered in combination with lamivudine (LAM) or as monotherapy, and the rate of resistance to ADV, in hepatitis B e antigen (HBeAg)-negative adult patients with chronic hepatitis B virus (HBV) infection and clinical or virologic resistance to LAM."7.74Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study. ( Armignacco, O; Barbarini, G; Barbaro, G; Barlattani, A; Camporiondo, MP; Ferri, F; Francavilla, R; Mazzoni, E; Mecenate, F; Nauri, L; Nosotti, L; Paffetti, A; Pellicelli, AM; Romano, M; Soccorsi, F; Struglia, C; Villani, R, 2008)
"Long-term treatment with lamivudine is required to control viral replication in patients with hepatitis B e antigen-negative chronic hepatitis B, but is associated with a high rate of viral resistance."7.73Adefovir dipivoxil added to ongoing lamivudine therapy in patients with lamivudine-resistant hepatitis B e antigen-negative chronic hepatitis B. ( Eugenidis, N; Giouleme, O; Gkisakis, D; Grammatikos, N; Katsinelos, P; Nikolaidis, N; Orfanou-Koumerkeridou, E; Patsiaoura, K; Theodoropoulos, K; Tziomalos, K; Vassiliadis, T; Zezos, P, 2005)
"We determined the clinical outcome of hepatitis e antigen (HBeAg)-negative chronic hepatitis B patients treated with long-term nucleos(t)ide analog therapy starting with lamivudine."7.73Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine. ( Dimakopoulos, K; Dimou, E; Hadziyannis, SJ; Kitis, G; Manesis, E; Manolakopoulos, S; Papatheodoridis, GV; Rapti, I; Tzourmakliotis, D, 2005)
"Fifty chronic hepatitis B (CHB) patients with lamivudine resistant HBV mutants who had received lamivudine for more than 12 months were included in the study."7.73[Clinical outcomes after discontinuation of Lamivudine in chronic hepatitis B patients with Lamivudine resistant HBV mutant]. ( Cho, HJ; Choi, HY; Hong, SP; Hwang, SG; Kim, JK; Kim, NK; Ko, KH; Park, H; Park, PW; Rim, KS, 2005)
"To evaluate the efficacy and safety of adefovir dipivoxil in treatment of decompensated liver cirrhosis patients with YMDD motif mutation during lamivudine therapy."7.73[Adefovir dipivoxil in treatment of decompensated liver cirrhosis patients with YMDD mutation]. ( Su, GG; Ying, MF; Zhao, NF; Zhou, Y, 2005)
"Seven antiretroviral-naive HIV-infected individuals with chronic hepatitis B treated with adefovir for longer than 6 months were assessed."7.73Risk of selecting K65R in antiretroviral-naive HIV-infected individuals with chronic hepatitis B treated with adefovir. ( Berger, F; Corral, A; Mauss, S; Rockstroh, J; Rodés, B; Schwarze-Zander, C; Sheldon, JA; Soriano, V, 2005)
"We studied the impact of tenofovir disoproxil fumarate, given as an antiretroviral medication, on patients with chronic hepatitis B virus (HBV) co-infection."7.73Impact of tenofovir-containing antiretroviral therapy on chronic hepatitis B in a cohort co-infected with human immunodeficiency virus. ( Berger, A; Bickel, M; Carlebach, A; Klauke, S; Lutz, T; Staszewski, S; Stephan, C; Stuermer, M, 2005)
"Currently, adefovir is an effective rescue therapy that broadens the existing range of options for patients with lamivudine-resistant chronic hepatitis B infection, particularly those with decompensated cirrhosis awaiting a liver graft, and those with recurrent posttransplantation HBV."7.73Clinical and virological effects during two years of ongoing adefovir dipivoxil in the treatment of lamivudine-resistant chronic hepatitis B infection. ( Baliellas, C; Cañas, C; Casanovas, A; Casanovas, T; Chahri, N; Figueras, J; Gil-Vernet, S; Gornals, JB; Sabidó, M; Serrano, T; Verdura, B, 2005)
"To estimate the cost-effectiveness over a 4-year duration of lamivudine and adefovir dipivoxil for patients with hepatitis B 'e' antigen-negative chronic hepatitis B."7.73Cost-effectiveness analysis of lamivudine and adefovir dipivoxil in the treatment of patients with HBeAg-negative chronic hepatitis B. ( Aguilar, J; Buti, M; Calleja, JL; Casado, MA; Esteban, R; Rueda, M; Salmerón, J, 2006)
"We have studied a 49-year-old patient with a HBeAg-negative chronic hepatitis B in whom, after 34 months of treatment with lamivudine and associated with an increase in the serum hepatitis B virus (HBV) DNA, the lamivudine resistance mutations M204I and L180V were detected."7.73[Lamivudine and adefovir resistance in a patient with HBeAg negative chronic hepatitis B]. ( Mateos, ML; Moreira, V; Tato, M, 2006)
"A 56-year-old male patient received adefovir dipivoxil (10 mg/day) for chronic hepatitis B resistant to lamivudine."7.73Adefovir dipivoxil-associated thrombocytopenia in a patient with chronic hepatitis B. ( Amato, A; Gaeta, GB; Stornaiuolo, G, 2006)
"Although adefovir dipivoxil (ADV) has a unique profile of delayed and infrequent resistance in treatment-naïve chronic hepatitis B patients, the association of ADV resistance with previous lamivudine (LAM) resistance is not well understood."7.73Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. ( Chung, YH; Jung, SW; Kim, KM; Kim, SO; Lee, HC; Lee, YS; Lim, YS; Suh, DJ; Yoo, W, 2006)
"The nucleotide analog adefovir dipivoxil (ADV) is an effective antiviral treatment for chronic hepatitis B virus (HBV) infection, with resistance to ADV estimated to occur less frequently than resistance to lamivudine treatment."7.73Detection of rtN236T and rtA181V/T mutations associated with resistance to adefovir dipivoxil in samples from patients with chronic hepatitis B virus infection by the INNO-LiPA HBV DR line probe assay (version 2). ( Borlang, J; Giles, E; Heathcote, EJ; Osiowy, C; Villeneuve, JP, 2006)
"Continuation of lamivudine therapy is controversial for patients with chronic hepatitis B when viral breakthrough occurs."7.73[Comparison of clinical outcome between patients continuing and discontinuing lamivudine therapy in acute exacerbation after viral breakthrough during lamivudine therapy in chronic hepatitis B]. ( Eun, JR, 2006)
"Lamivudine is widely used for the treatment of chronic hepatitis B infection because of it's remarkable antiviral efficacy and safety."7.73[A case of severe skin eruption caused by lamivudine in a patient with chronic hepatitis B]. ( Baik, du S; Kim, BH; Kim, HJ; Kim, SB; Seo, PJ; Shin, JE; Song, IH; Yun, SY, 2006)
"Lamivudine is a treatment option for the therapy of chronic hepatitis B with an excellent safety profile."7.72Severe exacerbation of chronic hepatitis B after emergence of lamivudine resistance in a cirrhotic patient: immediate switch to adefovir dipivoxil appears to be indicated. ( Flemming, P; Klempnauer, J; Manns, MP; Nashan, B; Niemann, P; Rohde, P; Tillmann, HL; Tischendorf, JJ; Trautwein, C; Wiegand, J, 2004)
" Ninety-eight liver biopsy samples from patients in the major phases of the natural history of chronic hepatitis B and 32 pairs of samples from patients receiving adefovir dipivoxil (ADV) therapy were assessed."7.72Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. ( Bowden, S; Brosgart, CL; Chen, SS; Delaney, WE; Gibbs, CS; Goodman, Z; Lau, G; Locarnini, S; Marcellin, P; Petersen, J; Trepo, C; Werle-Lapostolle, B; Wursthorn, K; Xiong, S; Zoulim, F, 2004)
"Among 3656 highly viremic mothers treated with TDF, hepatitis B virus DNA suppression to the levels <200,000 IU/mL at delivery was achieved in 34% to 100% of mothers."7.01The Use of Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide for Preventing Vertical Transmission of Hepatitis B. ( Deng, Y; Pan, CQ; Park, J; Zhu, L, 2023)
" However, greater adverse effects on renal function were observed for TDF than ETV at 60 months compared to 12 months."7.01Renal and bone side effects of long-term use of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide fumarate in patients with Hepatitis B: a network meta-analysis. ( Liu, S; Liu, Z; Ma, X; Xin, Y; Zhao, Z, 2023)
" The treatment using NAs was well-tolerated and there was no serious drug-related adverse event reported."7.01Short-term and long-term safety and efficacy of tenofovir alafenamide, tenofovir disoproxil fumarate and entecavir treatment of acute-on-chronic liver failure associated with hepatitis B. ( Chen, T; Chen, Y; Fu, M; Fu, S; Gao, Z; He, Y; Hu, C; Li, J; Liu, J; Yan, T; Yang, Y; Zhang, R; Zhao, Y; Zhou, M, 2021)
"Pradefovir is a liver targeted novel prodrug of adefovir (PMEA) developed to provide higher antiviral activity with reduced systemic toxicities."6.94Safety, efficacy, and pharmacokinetics of pradefovir for the treatment of chronic hepatitis B infection. ( Chen, H; Ding, Y; Jin, W; Li, C; Li, X; Liu, C; Liu, J; Niu, J; Wu, M; Zhang, D; Zhang, H; Zhu, X, 2020)
"In lamivudine-treated patients with suboptimal virological response at week 24, promptly adding on ADV is necessary to prevent resistance development."6.80Randomized, three-arm study to optimize lamivudine efficacy in hepatitis B e antigen-positive chronic hepatitis B patients. ( Chen, C; Chen, S; Chen, X; Cheng, J; Dou, X; Hou, J; Jia, J; Jiang, J; Li, T; Liang, X; Long, H; Ma, H; Ning, Q; Niu, J; Ren, H; Sheng, J; Shi, G; Shi, J; Sun, J; Sun, Y; Tan, D; Tang, H; Wan, M; Wang, H; Xie, Q; Yu, Y; Zhuang, H, 2015)
" Most adverse events were mild in severity and considered unrelated to study drug."6.79Efficacy and safety of tenofovir disoproxil fumarate in Asian-Americans with chronic hepatitis B in community settings. ( Bae, H; Chan, S; Lou, L; Pan, CQ; Trinh, H; Yao, A, 2014)
"Sixty-one HBeAg-positive chronic hepatitis B patients were randomized to receive Peg-IFN alpha-2b alone (1."6.79Combination therapy with pegylated interferon alpha-2b and adefovir dipivoxil in HBeAg-positive chronic hepatitis B versus interferon alone: a prospective, randomized study. ( Dai, YR; Liu, YH; Sun, N; Wang, GL; Wu, T; Yuan, JZ; Zhou, XH, 2014)
" Tenofovir gel, when used intermittently, was safe to use in women with HBV infection."6.78Safety of coitally administered tenofovir 1% gel, a vaginal microbicide, in chronic hepatitis B virus carriers: results from the CAPRISA 004 trial. ( Abdool Karim, Q; Abdool Karim, SS; Baxter, C; Tshabalala, P; Yende-Zuma, N, 2013)
"There is no standard management of chronic hepatitis B (CHB) patients with suboptimal response to nucleoside/nucleotide analogues (NAs)."6.77Lamivudine plus adefovir or telbivudine plus adefovir for chronic hepatitis B patients with suboptimal response to adefovir. ( Bai, L; Chen, EQ; Liang, LB; Tang, H; Wang, JR; Yan, LB; Zhou, TY, 2012)
"Adefovir dipivoxil (ADV) has demonstrated activity against wild-type and lamivudine-resistant hepatitis B virus (HBV)."6.73Suboptimal response to adefovir dipivoxil therapy for chronic hepatitis B in nucleoside-naive patients is not due to pre-existing drug-resistant mutants. ( Carrouée-Durantel, S; Durantel, D; Naesens, L; Neyts, J; Pichoud, C; Trépo, C; Werle-Lapostolle, B; Zoulim, F, 2008)
"Adefovir dipivoxil (ADV) is a licensed treatment for chronic hepatitis B in adults."6.73The pharmacokinetics and safety of adefovir dipivoxil in children and adolescents with chronic hepatitis B virus infection. ( Dhawan, A; Frederick, D; Kelly, D; Mizerski, J; Sokal, EM; Wirth, S, 2008)
"Lamivudine was combined for or=6 months in 12 (group III)."6.72Overlap lamivudine treatment in patients with chronic hepatitis B receiving adefovir for lamivudine-resistant viral mutants. ( Chen, DS; Chen, PJ; Chen, TC; Kao, JH; Lai, MY; Lin, FY; Liu, CJ, 2006)
"To investigate the efficacy, safety, and the tolerability of two dosing regimens of ADV (10 mg daily or 30 mg daily), two double-blind, placebo-controlled studies were performed in patients with chronic hepatitis B and compensated liver disease who were not undergoing current treatment and who had evidence of hepatitis B virus (HBV) replication."6.71Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double-blind, randomized, placebo-controlled studies. ( Arterbrun, S; Brosgart, CL; Currie, G; Deray, G; Hadziyannis, SJ; Hulot, JS; Izzedine, H; Launay-Vacher, V; Marcellini, P; Westland, C, 2004)
"Adefovir dipivoxil (ADV) has demonstrated clinical activity against wild-type and lamivudine-resistant HBV, but it is unclear whether resistance mutations will emerge after long-term therapy with this drug."6.70Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks. ( Brosgart, C; Delaney, WE; Fry, J; Gibbs, CS; Heathcote, EJ; Ho, V; Miller, MD; Westland, CE; Xiong, S; Yang, H, 2002)
"Treatment for chronic hepatitis B as a once-daily oral dose was well tolerated and associated with significant and sustained reductions in serum HBV DNA levels during treatment."6.69A placebo-controlled phase I/II study of adefovir dipivoxil in patients with chronic hepatitis B virus infection. ( Chopra, KB; Gilson, RJ; Jaffe, HS; Murray-Lyon, IM; Nelson, MR; Newell, AM; Rice, SJ; Tedder, RS; Toole, J; Weller, IV, 1999)
"The specific drugs available for chronic hepatitis B infection include standard and pegylated IFN-α, and nucleoside/nucleotide analogs that directly inhibit the reverse transcriptase."6.48Tenofovir disoproxil fumarate in the treatment of chronic hepatitis B. ( Buti, M; Homs, M, 2012)
"Adefovir dipivoxil (Hepsera) is an oral prodrug of the nucleotide analogue adefovir."6.42Adefovir dipivoxil: a review of its use in chronic hepatitis B. ( Dando, T; Plosker, G, 2003)
"Adefovir dipivoxil is an oral prodrug of adefovir, a nucleotide analogue of adenosine monophosphate."6.42[Application and efficacy of adefovir dipivoxil in hepatitis B virus-associated chronic liver diseases]. ( Cho, YK; Kim, BI, 2003)
"Treatment with Adefovir dipivoxil is a long term treatment (48 weeks), it is well tolerated, and side effects are moderate and reversible."6.42[Adefovir dipivoxil is a new drug for treatment of chronic hepatitis B]. ( Stránský, J, 2004)
"In hepatitis B e antigen-negative chronic hepatitis B, adefovir dipivoxil was recently found to maintain its efficacy even after 3 years of therapy."6.42Adefovir dipivoxil in the treatment of chronic hepatitis B virus infection. ( Hadziyannis, SJ; Papatheodoridis, GV, 2004)
" The aim was to investigate the expression of IL-1β in CHB patients treated with Peg-IFN-α combination with TDF and TDF/Peg-IFN-α monotherapy."5.91The expression of interleukin-1β in patients with chronic hepatitis B treated with pegylated-interferon-alpha combined with tenofovir disoproxil fumarate and monotherapy. ( Hu, X; Li, Y; Luo, H; Qin, B; Tan, G, 2023)
"Fanconi syndrome with osteomalacia can develop in patients with chronic hepatitis B infection being treated with adefovir at a conventional low dosage of 10 mg/day."5.56Osteomalacia and renal failure due to Fanconi syndrome caused by long-term low-dose Adefovir Dipivoxil: a case report. ( Cen, X; Cui, Y; Liu, Z; Mu, G; Xiang, Q; Xie, Q; Yu, Y; Zhang, H; Zhang, J, 2020)
"Entecavir (ETV) and tenofovir alafenamide fumarate (TAF) have been used widely to treat patients with chronic hepatitis B virus (HBV) infection, but it is still unclear how best to use these drugs."5.51Switching to tenofovir alafenamide versus continued therapy in chronic hepatitis B patients who were treated with entecavir: A prospective, multicenter, randomized controlled study. ( Akahane, T; Inoue, J; Iwata, T; Kisara, N; Kobayashi, T; Masamune, A; Ninomiya, M; Onuki, M; Sano, A; Sato, K; Sato, S; Tsuruoka, M, 2022)
"A major hurdle in the long-term treatment of chronic hepatitis B (CHB) patients is to maintain viral suppression in the absence of drug resistance."5.46No detectable resistance to tenofovir disoproxil fumarate in HBeAg+ and HBeAg- patients with chronic hepatitis B after 8 years of treatment. ( Buti, M; Cathcart, AL; Corsa, AC; Flaherty, JF; Gane, EJ; Kitrinos, KM; Liu, Y; Marcellin, P; Miller, MD, 2017)
"Long-term TDF treatment appears to be safe and effective in patients with prior failure of LAM and a suboptimal response to ADV therapy."5.46Five-year efficacy and safety of tenofovir-based salvage therapy for patients with chronic hepatitis B who previously failed LAM/ADV therapy. ( Angus, P; Bowden, S; Desmond, P; George, J; Lee, A; Lim, L; Locarnini, S; Marion, K; Nicoll, A; Patterson, S; Roberts, S; Sievert, W; Strasser, S; Thompson, A, 2017)
"Eighty-one chronic hepatitis B patients with a viral load above 4 log 10 copies/ml and high levels of serum alanine aminotransferase were treated with ETV 0."5.43Profile of HBV polymerase gene mutations during entecavir treatment in patients with chronic hepatitis B. ( Song, J; Sun, M; Tan, G; Wang, J; Wu, X, 2016)
"This case indicates that Fanconi's syndrome with osteomalacia can be acquired by a chronic hepatitis B patient taking ADV at a conventional dosage of 10 mg/day."5.42Osteomalacia and Fanconi's syndrome caused by long-term low-dose adefovir dipivoxil. ( Chen, YS; Sun, FR; Wang, BF; Wang, BY; Wang, Y; Zhang, D, 2015)
"Charts were reviewed for LAM-resistant chronic hepatitis B (CHB) patients who visited the Zhejiang Province People's Hospital and The First Affiliated Hospital, College of Medicine, Zhejiang University, from June 2009 to May 2013."5.42Tenofovir disoproxil fumarate is superior to lamivudine plus adefovir in lamivudine-resistant chronic hepatitis B patients. ( Huang, HJ; Li, MW; Pan, HY; Xie, YJ; Yang, DH; Zhao, NF, 2015)
"The aim of this study was to demonstrate how tenofovir alafenamide (TAF) and other hepatitis B treatment drugs differentially impact lipid profiles in chronic hepatitis B patients."5.41Risk of dyslipidemia in chronic hepatitis B patients taking tenofovir alafenamide: a systematic review and meta-analysis. ( Hwang, EG; Jung, EA; Kim, SG; Kim, YS; Yoo, JJ, 2023)
"Tenofovir disoproxil fumarate (TDF) is a novel nucleotide reverse transcriptase inhibitor that is mainly used to treat human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections."5.41[Research progress on the effect of tenofovir disoproxil fumarate on blood lipid profile]. ( Duan, YQ; Hu, P, 2023)
"Twenty chronic hepatitis B (CHB) patients who had been receiving ETV for more than 6 months and developed virologic breakthrough due to ETV resistance were consecutively enrolled."5.40Adefovir and lamivudine combination therapy in patients with entecavir-resistant chronic hepatitis B: antiviral responses and evolution of mutations. ( Baik, SK; Chae, HB; Hong, SP; Kim, CW; Kim, JH; Kim, MY; Kim, YS; Lee, CD; Lee, HJ; Lee, JI; Lee, JW; Lee, MS; Park, CK; Park, SH; Seo, YS; Suh, SJ; Um, SH; Yim, HJ, 2014)
"The prevalence of chronic hepatitis B in Bangladesh is reported to be 7."5.40Efficacy of adefovir dipivoxil therapy in patients with chronic hepatitis B viral infection. ( Chowdhury, MS; Khan, MR; Mahmuduzzaman, M; Miah, AR; Rahman, KM; Raihan, MA; Roknuzzaman, SM; Roy, PK; Saha, M, 2014)
"HIV worsens the natural history of chronic hepatitis B virus (HBV) infection."5.39Influence of HIV infection on response to tenofovir in patients with chronic hepatitis B. ( Aguilera, A; Barreiro, P; del Romero, J; Mena, A; Pedreira, J; Plaza, Z; Poveda, E; Rodriguez, C; Sierra-Enguita, R; Soriano, V; Tomé, S; Vispo, E, 2013)
"To investigate 3-year antiviral efficacy and side effect of adefovir dipivoxil (ADV) on the old patients with hepatitis B chronic infection."5.38[Three-year efficacy and side effect of adefovir dipivoxil for the treatment of the old patients with chronic hepatitis B virus infection]. ( Lou, GQ; Lu, L; Qian, JC; Shi, JP; Yan, FL; Zhu, MF, 2012)
" Modification of the dosing interval or discontinuation of ADV was required in seven and three patients, respectively, and none of them showed a further decline in the eGFR."5.38Frequency and risk factors of renal impairment during long-term adefovir dipivoxil treatment in chronic hepatitis B patients. ( Cho, HC; Choi, MS; Gwak, GY; Kim, YJ; Koh, KC; Lee, JH; Paik, SW; Sinn, DH; Yoo, BC, 2012)
"The effectiveness of antiviral treatments of chronic hepatitis B has been poorly studied in Brazil."5.38Antiviral therapy against chronic hepatitis B in Brazil: high rates of lamivudine resistance mutations and correlation with HBV genotypes. ( Fernandes, CA; Gomes, Sde A; Mello, FC, 2012)
"Lamivudine (LAM) has been extensively used to treat hepatitis B, but high incidence of drug resistance has required rescue studies."5.37Add-on adefovir is superior to a switch to entecavir as rescue therapy for Lamivudine-resistant chronic hepatitis B. ( Chung, GE; Hwang, SY; Jeong, JB; Jung, YJ; Kim, BG; Kim, D; Kim, HY; Kim, W; Kim, YJ; Lee, HS; Lee, JH; Lee, KL; Yoon, JH, 2011)
"In total, 33 patients with chronic hepatitis B virus (HBV) infection with evidence of active viral replication (HBV DNA levels ≥ 10(5) copies/mL) or a history of treatment failure to lamivudine/adefovir sequential therapy between April 2007 and July 2009 were treated with entecavir (1."5.37Long-term efficacy of entecavir therapy in chronic hepatitis B patients with antiviral resistance to lamivudine and adefovir. ( Cho, YS; Choi, JW; Kim, KA; Kwak, MS; Lee, CK; Lee, JS; Park, BK; Suh, JH; Won, SY, 2011)
"Lamivudine resistance is a result of mutations in YMDD motif in which rt203-206th codons (Y: tyrosine; M: methionin; D: aspartic acid; D: aspartic acid) of reverse trancriptase; the catalytic part of hepatitis B polymerase enzyme, takes place."5.35[YMDD motif variants detected by Inno-Lipa HBV DR assay in chronic hepatitis B patients during lamivudine therapy]. ( Arslan, U; Findik, D; Ural, O, 2008)
"Adefovir dipivoxil (ADV) is a nucleotide analogue that inhibits wild-type hepatitis B virus (HBV) and lamivudine (LMV)-resistant HBV mutants."5.35[The efficacy of adefovir dipivoxil monotherapy and the incidence of genotypic resistance to adefovir dipivoxil in patients with lamivudine-resistant chronic hepatitis B infection]. ( Bae, JH; Cho, M; Heo, J; Kang, DH; Kim, GH; Moon, JH; Song, GA; Yoon, KT, 2008)
"Adefovir has a potent antiviral activity as a rescue treatment against lamivudine-resistant strains."5.35Association of lamivudine-resistant mutational patterns with the antiviral effect of adefovir in patients with chronic hepatitis B. ( Cha, CK; Cheong, JY; Cho, SW; Hong, SP; Kim, SO; Kwon, HC; Yoo, WD, 2009)
"We performed a cohort study of 290 chronic hepatitis B patients: 145 patients treated with 10 mg ADV and 145 patients unexposed to ADV at two community clinics, who were matched for age (+/-10 years), sex, and baseline eGFR."5.35Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil. ( Garcia, RT; Ha, NB; Levitt, BS; Nguyen, HA; Nguyen, KK; Nguyen, MH; Trinh, HN; Vu, AA, 2009)
"Treatment with tenofovir disoproxil fumarate has been associated with renal toxicity or reductions in bone mineral density, or both, in some patients with chronic hepatitis B virus (HBV) infection."5.34Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study. ( Agarwal, K; Ahn, SH; Bae, H; Buti, M; Chan, HLY; Chen, CY; Chuang, WL; Flaherty, JF; Fung, S; Gaggar, A; Lampertico, P; Lau, A; Lim, YS; Liu, Y; Ma, X; Ramji, A; Subramanian, GM; Suri, V; Tak, WY; Tam, E; Tan, SK; Trinh, H; Wu, G; Yoon, SK, 2020)
"Adefovir dipivoxil is a nucleotide prodrug indicated for the treatment of patients with hepatitis B e antigen positive or hepatitis B e antigen negative chronic hepatitis B, lamivudine-resistant HBV infection, HBV infection pre- or post-liver transplantation, or HlV co-infection."5.34Progress in the treatment of chronic hepatitis B: long-term experience with adefovir dipivoxil. ( Delaney, WE, 2007)
"In this report, a chronic hepatitis B case who had never received adefovir dipivoxil but had primary adefovir resistance, was presented."5.34[A case of chronic hepatitis B with primary adefovir resistance]. ( Erensoy, S; Pullukçu, H; Sertöz, R; Taşbakan, M; Ulusoy, S; Yamazhan, T, 2007)
"Forty-four patients with chronic hepatitis B (CHB) were included."5.34Antiviral efficacy of adefovir dipivoxil versus lamivudine in patients with chronic hepatitis B sequentially treated with lamivudine and adefovir due to lamivudine resistance. ( Bak, YT; Byun, KS; Kim, JH; Kim, JS; Lee, CH; Park, JJ; Seo, YS; Yeon, JE, 2007)
"Adefovir dipivoxil (ADV) is a potent nucleotide analogue against both the wild-type and lamivudine (LMV) resistant hepatitis B virus (HBV)."5.33Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil. ( Byun, KS; Chang, YJ; Chung, HJ; Hong, SP; Kim, JH; Kim, SO; Lee, CH; Moon, MS; Seo, YS; Yeon, JE; Yoo, W; Yu, SK, 2006)
"Current therapies for the treatment of chronic hepatitis B virus (HBV) infection do not eliminate viral replication once therapy is stopped, resulting in a rapid rebound of viremia in a majority of patients."5.32Use of adefovir in the treatment of the chronic hepatitis B virus infection with resistance to lamivudine. ( Barcena Marugan, R; Cid Gomez, L; Lopez Serrano, P, 2003)
"Adefovir dipivoxil is a clinically approved drug that can block the action of an anthrax toxin."5.32Selective inhibition of anthrax edema factor by adefovir, a drug for chronic hepatitis B virus infection. ( Bergson, P; Gibbs, CS; Shen, Y; Soelaiman, S; Tang, WJ; Wang, CR; Zhukovskaya, NL; Zimmer, MI, 2004)
"Tenofovir disoproxil fumarate (TDF) is a first-line treatment for chronic hepatitis B (CHB)."5.30Ten-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B virus infection. ( Buggisch, P; Buti, M; Cathcart, AL; Crans, G; Flaherty, J; Flisiak, R; Gaggar, A; Jump, B; Kaita, K; Krastev, Z; Lee, SS; Manns, M; Marcellin, P; Op den Brouw, M; Petersen, J; Sievert, W; Wong, DK, 2019)
" We divided 48 chronic hepatitis B patients who had taken entecavir (ETV) for ≥2 years into two groups: the ETV continuation (n = 24) and the TAF switching (n = 24) groups, and compared the antiviral effects and safety until 48 weeks after the start of the study."5.30Switching from entecavir to tenofovir alafenamide versus maintaining entecavir for chronic hepatitis B. ( Hagiwara, S; Ida, H; Komeda, Y; Kudo, M; Minami, Y; Nishida, N; Takita, M; Ueshima, K, 2019)
"The efficacy of switching to tenofovir disoproxil fumarate (TDF) monotherapy from lamivudine (LAM) plus adefovir dipivoxil (ADV) combination therapy (stable switching) in patients with LAM-resistant chronic hepatitis B (CHB) and undetectable hepatitis B virus (HBV) DNA is not clear."5.27Evaluating the efficacy of switching from lamivudine plus adefovir to tenofovir disoproxil fumarate monotherapy in lamivudine-resistant stable hepatitis B patients. ( Chung, WJ; Heo, J; Hwang, JS; Jang, BK; Kim, BS; Kim, SJ; Kweon, YO; Lee, CH; Lee, HJ; Park, SY; Suh, JI; Tak, WY; Woo, HY, 2018)
"In patients with chronic hepatitis B with a low viral load, combination treatment (peg-IFN plus adefovir and peg-IFN plus tenofovir) did not result in significant HBsAg loss compared with no treatment, which does not support the use of combination treatment in this population of patients."5.24Peg-interferon plus nucleotide analogue treatment versus no treatment in patients with chronic hepatitis B with a low viral load: a randomised controlled, open-label trial. ( Beuers, U; de Niet, A; Jansen, L; Koot, M; Kuiken, SD; Molenkamp, R; Reesink, HW; Stelma, F; Takkenberg, RB; van Nieuwkerk, CMJ; Verheij, J; Weijer, S; Willemse, SB; Zaaijer, HL, 2017)
"In the chronic hepatitis B patients with interferon resistance, the combined administration of entecavir and adefovir dipivoxil can significantly improve liver function, hepatic fibrosis and MELD scores."5.24Effects of the combined administration of entecavir and adefovir dipivoxil to improve hepatic fibrosis in hepatitis B patients with interferon resistance. ( Chang, S; Chen, B; Qiu, L; Shen, F; Sun, Y; Wu, K; Yu, L, 2017)
"The nucleos(t)ide analogues (NAs) entecavir (ETV), tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF) are preferred treatment options for patients with chronic hepatitis B infection (CHB)."5.22Review article: switching patients with chronic hepatitis B to tenofovir alafenamide-a review of current data. ( Agarwal, K; Flaherty, JF; Fung, S; Gordon, SC; Hou, J; Kao, JH; Kurosaki, M; Lampertico, P; Lim, YS; Seto, WK; Yee, LJ; Zhao, Y, 2022)
"To explore clinical efficacy of Yiguanjian Decoction (YD) combined Adefovir Dipivoxil Tablet (ADT) in treating HBeAg negative chronic viral hepatitis B (CVHB) active compensated liver cirrhosis (LC) patients."5.22[Efficacy Observation of Yiguanjian Decoction Combined Adefovir Dipivoxil Tablet in Treating HBeAg Negative Chronic Viral Hepatitis B Active Compensated Liver Cirrhosis Patients]. ( Bao, ZY; Duan, SH; Liu, MS; Wang, L; Yuan, XD, 2016)
"Here, we evaluated the safety and immunogenicity of hepatitis B virus (HBV) DNA vaccine, HB-110, in mice and Korean patients with chronic hepatitis B (CHB) undergoing adefovir dipivoxil (ADV) treatment."5.20Safety and immunogenicity of therapeutic DNA vaccine with antiviral drug in chronic HBV patients and its immunogenicity in mice. ( Bae, SH; Im, SJ; Jang, JW; Jeong, SH; Kim, BM; Kim, CY; Seo, YB; Song, JS; Song, MJ; Suh, YS; Sung, YC; Yang, SH; Yoon, SK; You, CR, 2015)
"In patients with hepatitis B-related HCC, adefovir antiviral therapy reduced late HCC recurrence and significantly improved overall survival after R0 hepatic resection."5.20Antiviral therapy improves postoperative survival in patients with hepatocellular carcinoma: a randomized controlled trial. ( Huang, G; Lau, WY; Pan, ZY; Shen, F; Wang, ZG; Wu, MC; Yuan, SX; Zhou, WP, 2015)
"Tenofovir disoproxil fumarate (TDF) has demonstrated long-term efficacy and a high barrier to resistance in multiple chronic hepatitis B (CHB) populations outside of China."5.20Tenofovir disoproxil fumarate vs adefovir dipivoxil in Chinese patients with chronic hepatitis B after 48 weeks: a randomized controlled trial. ( Chen, CW; Chen, SJ; Cheng, J; Dong, J; Gao, ZL; Hou, JL; Ji, Y; Jia, JD; Li, J; Mao, Q; Mao, YM; Ning, Q; Niu, JQ; Pan, C; Ren, H; Sheng, JF; Tan, DM; Tang, H; Wang, H; Wu, SM; Xie, Q; Xu, M; Zhang, JM; Zhang, XX; Zhao, W, 2015)
"We evaluated the antiviral response of Asian or Pacific Islander (API) patients with chronic hepatitis B (CHB) who had baseline high viral load (HVL), defined as pre-treatment hepatitis B virus (HBV) DNA ≥9 log10 copies/ml, following up to 288 weeks of tenofovir disoproxil fumarate (TDF) treatment."5.20Tenofovir disoproxil fumarate in Asian or Pacific Islander chronic hepatitis B patients with high viral load (≥ 9 log10 copies/ml). ( Buti, M; Dinh, P; Dusheiko, G; Flaherty, JF; Flisiak, R; Fung, S; Gane, E; Gordon, SC; Horban, A; Jacobson, IM; Kitrinos, KM; Krastev, Z; Marcellin, P; Martins, EB; Petersen, J; Rustgi, VK; Sperl, J; Trinh, H; Yee, LJ, 2015)
"Non-cirrhotic, treatment-naïve subjects with chronic hepatitis B were randomized (1:1:1:1:1) to receive tenofovir alafenamide 8, 25, 40, or 120 mg, or tenofovir disoproxil fumarate 300 mg for 28 days and assessed for safety, antiviral response, and pharmacokinetics, followed-up by off-treatment for 4 weeks."5.20Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection. ( Agarwal, K; Cheng, W; Flaherty, JF; Foster, GR; Fung, SK; Gane, EJ; Lawson, E; McHutchison, JG; Nguyen, TT; Ryder, SD; Sicard, E; Subramanian, GM; Zhao, S, 2015)
"The purpose of this study was to analyze the cost-effectiveness of lamivudine (LMV), telbivudine (LdT), and entecavir (ETV) in treatment of chronic hepatitis B with adefovir dipivoxil (ADV) resistance."5.20Cost-effectiveness analysis of lamivudine, telbivudine, and entecavir in treatment of chronic hepatitis B with adefovir dipivoxil resistance. ( Liu, Y; Qiu, P; Wang, G; Wen, J; Wen, P; Xiao, X; Xu, L; Zhou, SF, 2015)
"This study aimed to research the efficiency of adefovir dipivoxil in hepatitis B e antigen (HBeAg)-negative chronic hepatitis B treatment and in combination with α-2b interferon in the treatment of HBeAg-positive chronic hepatitis B."5.20The curative effect of adefovir dipivoxil treating HBeAg negative chronic hepatitis B and treating HBeAg positive chronic hepatitis B combining interferon α-2b. ( Gu, J; Shen, S; Sun, R; Yu, Z, 2015)
"To compare the efficacies ofentecavir and adefovir in patients with chronic hepatitis B (CHB) and cirrhosis when administered as monotherapies using a 240-week course."5.20[A randomized controlled trial on 240-week monotherapy with entecavir or adefovir in patients with chronic hepatitis B and cirrhosis]. ( Gao, Y; Han, T; Lian, J; Liu, F; Lyu, H; Wang, F; Xiang, H, 2015)
"We examined the durability of the virological response after discontinuing lamivudine (LVD) in chronic hepatitis B (CHB) patients with LVD-resistant hepatitis B virus (HBV), who responded to LVD plus adefovir (ADV) combination therapy, and the outcome of switching to ADV monotherapy compared to maintaining combination therapy."5.19Maintaining remission in lamivudine-resistant patients with a virological response to adefovir add-on lamivudine after stopping lamivudine therapy. ( Ahn, SH; Chon, CY; Han, KH; Kim, DY; Kim, HS; Kim, MN; Kim, SU; Lee, CK; Lee, S; Park, JY, 2014)
"To prospectively observe the long-term antiviral efficacy and safety of telbivudine (LDT) administered as a monotherapy and as a combination therapy with adefovir dipivoxil (ADV) in patients diagnosed with chronic hepatitis B (CHB) and positivity for hepatitis B e antigen (HBeAg)."5.19[Long-term efficacy and safety of telbivudine as monotherapy and as combination therapy with adefovir dipivoxil in HBeAg-positive chronic hepatitis B patients]. ( Chang, L; Du, Y; Jia, T; Li, H; Li, W; Liu, L; Liu, Y; Peng, D, 2014)
"A 48-week PegIFN therapy was added to HBeAg positive-HIV co-infected patients on TDF and emtricitabine, or lamivudine for at least 6 months."5.19Role of a 48-week pegylated interferon therapy in hepatitis B e antigen positive HIV-co-infected patients on cART including tenofovir: EMVIPEG study. ( Barthe, Y; Bouix, C; Cacoub, P; Carrat, F; Lascoux-Combe, C; Lebossé, F; Maynard-Muet, M; Miailhes, P; Piroth, L; Pol, S; Rey, D; Sogni, P; Zoulim, F, 2014)
"A recent study compared the efficacy of tenofovir disoproxil fumarate (TDF) vs the combination of emtricitabine and TDF (FTC/TDF) in patients with lamivudine-resistant chronic hepatitis B who were treated for as long as 96 weeks."5.19No resistance to tenofovir disoproxil fumarate through 96 weeks of treatment in patients with lamivudine-resistant chronic hepatitis B. ( Corsa, AC; Flaherty, JF; Fung, SK; Gane, E; Kitrinos, KM; Liu, Y; Miller, MD; Mitchell, B, 2014)
"In a study of 266 chronic hepatitis B e antigen (HBeAg)-positive patients, 23 experienced hepatitis B surface antigen (HBsAg) loss with up to 5 years of tenofovir disoproxil fumarate (TDF) treatment."5.19Kinetics of hepatitis B surface antigen loss in patients with HBeAg-positive chronic hepatitis B treated with tenofovir disoproxil fumarate. ( Buti, M; de Man, RA; Dinh, P; Dusheiko, GM; Flaherty, JF; Flisiak, R; Gaggar, A; Gurel, S; Heathcote, EJ; Krastev, Z; Lin, L; Lou, L; Marcellin, P; Massetto, B; McHutchison, JG; Subramanian, GM; Zeuzem, S, 2014)
"The objective of this study was to compare the efficacy and safety of two rescue strategies for hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) patients with resistance to adefovir dipivoxil (ADV)."5.17Efficacy and safety of telbivudine plus adefovir dipivoxil combination therapy and entecavir monotherapy for HBeAg-positive chronic hepatitis B patients with resistance to adefovir dipivoxil. ( Chen, EQ; Liu, K; Lu, JJ; Ma, YJ; Tang, H; Wang, J, 2013)
"Telbivudine (LdT) has demonstrated potent antiviral activity in nucleos(t)ide analogue (NA)-naïve chronic hepatitis B patients (CHB), but data on its efficacy in NA-experienced patients are limited."5.17Efficacy of telbivudine treatment for hepatitis B e antigen-positive chronic hepatitis B patients with poor response to adefovir dipivoxil. ( Bai, XF; Li, Y; Lian, JQ; Wang, JP; Zhang, Y, 2013)
"The incidence of multidrug-resistant (MDR) chronic hepatitis B (CHB) during sequential lamivudine (LAM) and adefovir dipivoxil (ADV) treatment is increasing."5.17Antiviral efficacies of currently available rescue therapies for multidrug-resistant chronic hepatitis B. ( Ahn, SH; Baartarkhuu, O; Chon, CY; Han, KH; Kim, BK; Kim, DY; Kim, JK; Kim, KS; Kim, SU; Park, JY; Park, MS, 2013)
"The study aimed to investigate the efficacy and safety of peginterferon α-2a (PEG IFNα-2a) in combination with lamivudine or adefovir in the treatment of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB)."5.17Extended treatment with peginterferon α-2a in combination with lamivudine or adefovir for 96 weeks yields high rates of HBeAg and HBsAg seroconversion. ( Cao, ZH; Chen, XY; Liu, YL; Ma, LN; Zhang, HW, 2013)
"In this study, we aimed to identify baseline predictors of response in chronic hepatitis B patients treated with a combination of pegylated interferon (PEG-IFN)-α2a and adefovir."5.17Baseline hepatitis B surface antigen (HBsAg) as predictor of sustained HBsAg loss in chronic hepatitis B patients treated with pegylated interferon-α2a and adefovir. ( Beld, MG; de Niet, A; Dijkgraaf, MG; Jansen, L; Jansen, PL; Janssen, HL; Koot, M; Molenkamp, R; Reesink, HW; Rijckborst, V; Takkenberg, RB; Terpstra, V; Weegink, CJ; Zaaijer, HL, 2013)
"A 1-year trial with entecavir plus adefovir resulted in a rate of virological response (VR) higher than that seen with lamivudine plus adefovir in multiple-drug-refractory chronic hepatitis B (CHB) patients."5.17Randomized trial of the virologic response during up to two years of entecavir-adefovir combination therapy in multiple-drug-refractory chronic hepatitis B virus patients. ( Lee, D; Lee, HC; Lee, JY; Lee, YS; Lim, YS; Shim, JH; Suh, DJ, 2013)
"To compare the efficacy and safety of the common antivirals, including adefovir dipivoxil (ADV), pegylated-interferon alpha-2a (peg-IFN) and lamivudine (LAM), used as combination therapies to treat chronic hepatitis B (CHB) patients with positivity for the hepatitis B e antigen (HBeAg) and hepatitis B virus (HBV) harboring the ADV-resistance mutation, rtN236T, and to explore the factors associated with curative outcome."5.17[Clinical efficacy of various antiviral-based strategies to treat chronic hepatitis patients with positivity for hepatitis B e antigen and rtN236T mutation]. ( Chen, L; Deng, YD; Mao, XR; Yuan, H; Yue, W, 2013)
"To investigate the efficacy and safety of an extended course (96-week) of combination treatment with peginterferon alfa-2a (Peg-IFNa-2a; 40 kd] plus adefovir (ADV) for treating chronic hepatitis B (CHB) in Chinese patients with negativity for hepatitis B e antigen (HBeAg)."5.17[Efficacy and safety of peginterferon alfa-2a (40 kd) plus adefovir for 96 weeks in HBeAg-negative chronic hepatitis B patients]. ( Cao, ZH; Chen, XY; He, ZM; Jin, Y; Liu, YL; Lu, JF; Ma, LN; Zhang, YH, 2013)
"To compare the efficacy and safety of recombinant human interferon α-2b (INFα-2b) monotherapy and combined therapy with entecavir (ETV) plus adefovir dipivoxil (ADV) in chronic hepatitis B patients with poor response to combined therapy with lamivudine and ADV."5.17[Therapeutic effect of antiviral regimens for chronic hepatitis B refractory to lamivudine plus adefovir]. ( Chen, Z; Li, M; Liu, Z; Wu, J; Xu, G; Zhang, Q, 2013)
"To examine the efficacy of telbivudine (LdT) + adefovir (ADV) vs continuation of lamivudine (LAM) + ADV in patients with LAM-resistant chronic hepatitis B (CHB) who show a suboptimal response to LAM + ADV."5.17Efficacy of switching to telbivudine plus adefovir in suboptimal responders to lamivudine plus adefovir. ( Ahn, SH; Chon, CY; Han, KH; Kim, DY; Kim, SU; Park, H; Park, JY, 2013)
" At month 24, virological response rate [hepatitis B virus (HBV) DNA <60 IU/ml] was higher in the adefovir-lamivudine combination group compared with entecavir group (56."5.17Adding adefovir vs. switching to entecavir for lamivudine-resistant chronic hepatitis B (ACE study): a 2-year follow-up randomized controlled trial. ( Baik, SK; Chae, HB; Hong, SP; Kim, CW; Kim, JH; Kim, MY; Kim, YS; Lee, CD; Lee, JI; Lee, JW; Lee, MS; Park, CK; Park, SH; Seo, YS; Um, SH; Yim, HJ; Yoon, EL, 2013)
"Telbivudine therapy with tenofovir intensification at Week 24, where indicated by the Roadmap strategy, appears effective and well tolerated for the treatment of chronic hepatitis B."5.1752-week efficacy and safety of telbivudine with conditional tenofovir intensification at week 24 in HBeAg-positive chronic hepatitis B. ( Bessone, F; Chan, HL; Cheinquer, H; Daruich, J; Dong, Y; Fassio, E; Komolmit, P; Ono, SK; Pathan, R; Pessôa, MG; Piratvisuth, T; Sukeepaisarnjaroen, W; Tanwandee, T; Trylesinski, A; Zeuzem, S, 2013)
"In this study, we aimed to devise a simple scoring system predicting the risk of genotypic resistance (GR) to current rescue therapies for patients with lamivudine (LAM)-resistant chronic hepatitis B."5.16Simple scoring system predicting genotypic resistance during rescue therapy for Lamivudine-resistant chronic hepatitis B. ( Cho, EJ; Hwang, SY; Jang, ES; Kim, CY; Kim, YJ; Kwak, MS; Lee, CH; Lee, HS; Lee, JH; Yang, HJ; Yoon, JH; Yu, SJ, 2012)
"Adefovir dipivoxil (ADV) is a nucleotide analogue with proven efficacy in chronic hepatitis B (CHB)."5.16Five years of treatment with adefovir dipivoxil in Chinese patients with HBeAg-positive chronic hepatitis B. ( Barker, K; Daozhen, X; Dixon, J; Guangbi, Y; Hao, W; Hong, R; JinLin, H; Junqi, N; Minde, Z; Xiaqiu, Z; Yagang, C; Yaozong, W; Yimin, M; Youming, C; Yuming, W, 2012)
"In a cohort of 95 chronic hepatitis B patients, who were treated with peg-interferon and adefovir for 1 year, and who had 15% HBsAg loss (overall), no association was found between IL28B polymorphisms and HBeAg seroconversion or HBsAg clearance."5.16Genetic variation in IL28B and treatment outcome in HBeAg-positive and -negative chronic hepatitis B patients treated with Peg interferon alfa-2a and adefovir. ( Beld, MG; Benayed, R; de Niet, A; Jansen, PL; Koot, M; Lopatin, U; Reesink, HW; Riley-Gillis, B; Takkenberg, RB; Weegink, CJ; Zaaijer, HL, 2012)
"Monotherapy with pegylated interferon alpha (Peg-IFNa) or adefovir dipivoxil (ADV) to HBeAg-positive chronic hepatitis B (CHB) patients has limited effects."5.16Improved efficacy by individualized combination therapy with Peg IFN-a 2a and ADV in HBeAg positive chronic hepatitis B patients. ( Lu, HZ; Shen, C; Wang, W; Wang, YD; Yan, WZ; Yu, WY; Zhang, L; Zhao, CY; Zhou, JY, 2012)
"Patients with chronic hepatitis B with and without previous lamivudine therapy were randomised to receive adefovir alone (10 mg/daily) or adefovir and lamivudine (100 mg/daily) for up to 192 weeks."5.16Randomised clinical trial: the benefit of combination therapy with adefovir and lamivudine for chronic hepatitis B. ( Doo, E; Feld, JJ; Ghany, MG; Heller, T; Hoofnagle, JH; Kleiner, DE; Koh, C; Liang, TJ; Nagabhyru, P; Rotman, Y; Wright, EC; Zhao, X, 2012)
"To investigate the efficacy of 104 weeks of lamivudine (LAM) and adefovir (ADV) de novo combination therapy, as compared to optimized combination therapy administered after 48 weeks of treatment with lamivudine or adefovir mono-therapy, in chronic hepatitis B (CHB) patients."5.16[Efficacy of lamivudine and adefovir de novo combination therapy or after mono-therapy in chronic hepatitis B patients]. ( Chen, R; Chen, WL; Chen, XF; Chen, XP; Huang, J; Luo, XD; Ma, HY; Ma, XJ, 2012)
"The safety and efficacy of adefovir dipivoxil (ADV) for chronic hepatitis B infection in children was demonstrated in a randomized, placebo-controlled trial."5.16Efficacy and safety of long-term adefovir dipivoxil therapy in children with chronic hepatitis B infection. ( Frederick, D; Jonas, MM; Kelly, D; Mizerski, J; Mondou, E; Pollack, H; Rousseau, F; Sokal, E; Sorbel, J, 2012)
"To observe the effects on patients with HBeAg positive chronic hepatitis B by Baihua Xianglian Detoxification Recipe (BXDR) combined adefovir dipivoxil (AD), and to assess its clinical efficacy."5.16[Clinical study on Baihua Xianglian detoxification recipe combined with adefovir dipivoxil in treating HBeAg positive chronic hepatitis]. ( Mao, DW; Qiu, H; Wei, AL, 2012)
"Entecavir (ETV) and tenofovir disoproxil fumarate (TDF) are potent antiviral agents that might have additive or synergistic antiviral activity in treatment of patients with chronic hepatitis B (CHB)."5.16Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B. ( Akarca, US; Carosi, G; Cohen, D; Gadano, A; Habersetzer, F; Llamoso, C; Lok, AS; Lovegren, M; Sievert, W; Trinh, H; Wong, D, 2012)
"The aim of the study was to compare the virologic response to adefovir (ADV) add-on therapy with switching to entecavir (ETV) monotherapy in children and adolescents with chronic hepatitis B (CHB) who have developed lamivudine (LAM) resistance during LAM treatment."5.16Virologic responses to add-on adefovir dipivoxil treatment versus entecavir monotherapy in children with lamivudine-resistant chronic hepatitis B. ( Cho, MH; Cho, SM; Choe, BH; Chu, M; Kwon, S; Lee, WK, 2012)
"To study the changes of experimental markers of hepatic fibrosis in patients with chronic hepatitis B treated by Dahuang Zhechong Wan combined with adefovir dipivoxil."5.16[Experimental study on effect of dahuang zhechong wan combined with adefovir dipivoxil in preventing hepatic fibrosis in patients with chronic hepatitis B]. ( Chang, Y; Zhang, L, 2012)
"To observe the efficacy of adefovir dipivoxil(ADV) in combination with Anluohuaxian capsule in the treatment of chronic hepatitis B (CHB) patients."5.16[The therapeutic effect of Anluohuaxian capsule combined with adefovir dipivoxil on patients with chronic hepatitis B and influence on hepatic histology]. ( Gong, GZ; He, B; Jiang, YF; Li, NP; Ma, J; Tang, W, 2012)
"To evaluate the efficacy and safety of tenofovir disoproxil fumarate (TDF) for chronic hepatitis B (CHB) patients after multiple failures."5.16Tenofovir rescue therapy for chronic hepatitis B patients after multiple treatment failures. ( Choi, MS; Gwak, GY; Kim, YJ; Koh, KC; Lee, JH; Paik, SW; Sinn, DH; Yoo, BC, 2012)
"To determine the efficacy of tenofovir disoproxil fumarate (TDF) in adults with chronic hepatitis B virus (HBV) infection who had previously failed lamivudine (LAM) and had significant viral replication (HBV DNA >10⁵ copies/ml if HBeAg positive, > 10⁴ copies/ml if HBeAg negative) despite at least 24 weeks of treatment with adefovir dipivoxil (ADV)."5.15Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B. ( Angus, PW; Bowden, S; Desmond, PV; George, J; Lee, AU; Locarnini, S; Nicoll, AJ; Patterson, SJ; Roberts, SK; Sievert, W; Strasser, SI, 2011)
"This prospective randomized pilot study was conducted in Lok Nayak Hospital, New Delhi, involving 30 patients of chronic hepatitis B (both e antigen positive and negative); 15 were randomly selected to receive either adefovir or lamivudine for a period of 6 months."5.15Evaluation of adefovir & lamivudine in chronic hepatitis B: correlation with HBV viral kinetic, hepatic-necro inflammation & fibrosis. ( Asim, M; Das, BC; Gondal, R; Kar, P; Medhi, S; Pradeep Kumar, S, 2011)
" This study compares cccDNA reduction with relation to liver histology in nucleoside/nucleotide-naïve chronic hepatitis B patients receiving oral antiviral monotherapy (n=35), including entecavir (ETV, n=13), adefovir dipivoxil (ADV, n=22) or placebo (n=14)."5.15Association of intrahepatic cccDNA reduction with the improvement of liver histology in chronic hepatitis B patients receiving oral antiviral agents. ( Chang, TT; Cheng, PN; Liu, WC; Tsai, HW; Wu, IC; Young, KC, 2011)
" In two phase 3 studies (GS-US-174-0102 and GS-US-174-0103), 375 hepatitis B e antigen-negative (HBeAg(-) ) patients and 266 HBeAg(+) patients with chronic hepatitis B (some nucleoside-naive and some lamivudine-experienced) were randomized 2:1 to receive TDF (n = 426) or adefovir dipivoxil (ADV; n = 215) for 48 weeks."5.15No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus. ( Borroto-Esoda, K; Chappell, B; Curtis, M; Heathcote, J; Kitrinos, K; Marcellin, P; Miller, MD; Myrick, F; Schawalder, J; Snow-Lampart, A; Sorbel, J; Svarovskaia, ES; Zhu, Y, 2011)
"A randomized, open-label comparative study of entecavir versus adefovir therapy was performed in subjects with chronic hepatitis B who had hepatic decompensation (Child-Turcotte-Pugh score ≥7)."5.15Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study. ( Beebe, S; Bialkowska, J; Brown, RS; Cheinquer, H; Cooney, E; Jeffers, L; Leung, N; Liaw, YF; Myers, RP; Peng, CY; Raptopoulou-Gigi, M; Sarin, SK; Tang, S; Tanwandee, T; Tsai, N, 2011)
"We investigated whether intrahepatic markers could predict response in chronic hepatitis B virus (HBV) patients treated with peg-interferon and adefovir for 48 weeks."5.15Intrahepatic response markers in chronic hepatitis B patients treated with peginterferon alpha-2a and adefovir. ( Beld, M; Dijkgraaf, M; Jansen, P; Reesink, H; Takkenberg, B; Terpstra, V; Weegink, C; Zaaijer, H, 2011)
"To evaluate the safety and efficacy of the combined therapy with entecavir (ETV) and adefovir (ADV) in patients with chronic hepatitis B (CHB) who experienced failure of treatment with single or multiple nucleoside analogs, and analyze the factors that affect the patients response to the treatment."5.15[Safety and efficacy of Entecavir combined with Adefovir in patients with chronic hepatitis B who fail to respond to nucleoside analog treatment]. ( Guo, YB; Hou, JL; Peng, J; Sun, J; Wang, ZH; Yan, L; Yang, J; Zhou, B, 2011)
"In this randomised study, chronic hepatitis B patients with lamivudine resistance were treated with peginterferon alfa-2a for 48 weeks (n=155) or adefovir for 72 weeks (n=80)."5.15Randomised clinical trial: efficacy of peginterferon alfa-2a in HBeAg positive chronic hepatitis B patients with lamivudine resistance. ( Chan, HL; Chen, SJ; Hou, JL; Jia, JD; Jiang, M; Lai, JY; Li, MK; Li, XH; Popescu, M; Sheng, JF; Sun, J; Sung, JJ; Wang, H; Wang, JF; Wang, YM; Xie, Q; Zhang, JM, 2011)
"To investigate the levels of HBsAg in predicting the efficacy of peglated interferon-alpha 2a combined with adefovir dipivoxil (ADV), in HBeAg-positive chronic hepatitis B patients."5.15[The levels of HBsAg can predict the efficacy of peglated interferon-alpha 2a combined with adefovir dipivoxil, in HBeAg-positive chronic hepatitis B patients]. ( Cao, H; Li, G; Sun, HX; Xu, QH; Yang, XA; Zhang, K, 2011)
"A large clinic cohort of chronic hepatitis B cirrhotic patients were enrolled in a treatment program of lamivudine ± adefovir therapy."5.15Clinical outcomes of lamivudine-adefovir therapy in chronic hepatitis B cirrhosis. ( Aung, MO; Dan, YY; Fernandes, M; Lai, V; Lee, GH; Lee, YM; Lim, SG; Low, HC; Mak, B; Sutedja, D, 2011)
"To explore relationship between HBeAg seroconversion with HBV genotypes and HBV specific CTL in patients with chronic hepatitis B (CHB) treated with Adefovir dipivoxil."5.15[Relationship between HBeAg seroconversion with genotypes and HBV specific CTL in patients with chronic hepatitis B treated with Adefovir dipivoxil]. ( Gu, XB; Pan, JQ; Tan, YF; Tang, JM; Wang, XC; Wu, YT; Yang, ZX; Zhao, YP; Zhou, YL, 2011)
"To observe the therapeutic effect and safety of entecavir and adefovir in the treatment of lamivudine-resistant HBeAg-negative chronic hepatitis B."5.15[Efficacy of two nucleoside analogs to treat resistant HBeAg-negative chronic hepatitis B]. ( Li, XJ; Shu, X; Xu, QH; Zhu, JY, 2011)
"To observe the efficacy and safety on the efficacy of HBeAg-positive chronic Hepatitis B patients treated with adefovir dipivoxil for 4 years."5.15[A clinical study on the efficacy of HBeAg-positive chronic hepatitis B patients treated with adefovir dipivoxil for 4 years]. ( Chen, LB; Liang, JY; Shu, X; Xu, QH; Yang, XA; Zhang, K, 2011)
"0 mg/d or ETV plus adefovir dipivoxil (ADV) in adults with chronic hepatitis B virus (HBV) infection who had previously resisted lamivudine (LAM) and failed with rescue treatment of LAM + ADV."5.15[Entecavir 1.0mg monotherapy or entecavir plus adefovir dipivoxil for patients with lamivudine-resistant chronic hepatitis B had suboptimal response to lamivudine plus adefovir dipivoxil]. ( Han, T; Li, J; Li, Y; Liu, L; Xiao, SX; Xing, J, 2011)
"To investigate the clinical efficacy and safety of adefovir dipivoxil (ADV) in combination with bicyclol for the treatment of chronic hepatitis B (CHB) in seniors."5.15[The clinical efficacy and safety of adefovir dipivoxil in combination with bicyclol for the treatment of senior patients with chronic hepatitis B]. ( Cai, SP; Fan, ZP; He, WP; Ji, YJ; Zhang, WJ, 2011)
"This study was undertaken to compare the early antiviral activity and viral kinetic profiles of entecavir (ETV) versus adefovir (ADV) in hepatitis B e antigen positive nucleoside-naïve adults with chronic hepatitis B (CHB)."5.14Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir. ( Cross, A; Diva, U; Hann, HW; Hsu, CW; Jeffers, L; Lao-Tan, J; Lesmana, L; Leung, N; Lopez-Talavera, J; Mencarini, K; Min, A; Peng, CY; Sherman, M; Sollano, J; Wilber, R; Yuen, MF, 2009)
"In patients with hepatitis B e antigen-negative chronic hepatitis B, adefovir dipivoxil administration selects variants bearing reverse transcriptase rtN236T and/or rtA181V/T substitutions in 29% of cases after 5 years."5.14Complex dynamics of hepatitis B virus resistance to adefovir. ( Brillet, R; Hézode, C; Nordmann, P; Pallier, C; Pawlotsky, JM; Rodriguez, C, 2009)
"Adefovir dipivoxil in combination with lamivudine or entecavir are safe and effective therapies for chronic hepatitis B patients with YMDD mutation."5.14[A study on the treatment of chronic hepatitis B with YMDD mutation]. ( Dai, YX; Ding, H; Hu, TH; Huang, LH; Jiang, XH; Jiang, YM; Qiu, YW; Zhou, M, 2009)
"Lamivudine (3TC)-resistant chronic hepatitis B patients demonstrated a higher rate of adefovir dipivoxil (ADV) resistance compared with nucleoside-naive patients."5.14Adefovir dipivoxil resistance patterns in patients with lamivudine-resistant chronic hepatitis B. ( Barraud, L; Durantel, S; Fasano, M; Guastadisegni, A; Heichen, M; Pastore, G; Santantonio, T; Zoulim, F, 2009)
"Entecavir (ETV) is currently recommended as a rescue therapy purely for adefovir (ADV)-resistant chronic hepatitis B virus (HBV) infections."5.14Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone. ( Chung, YH; Kim, KM; Lee, HC; Lee, YS; Lim, YS; Shim, JH; Suh, DJ, 2009)
"The efficacy of adefovir dipivoxil (ADV) or entecavir (ETV) rescue monotherapy has not been directly compared in hepatitis B e antigen (HBeAg)-positive patients with lamivudine (3TC)-resistant chronic hepatitis B (CHB)."5.14Rescue monotherapy in lamivudine-resistant hepatitis B e antigen-positive chronic hepatitis B: adefovir versus entecavir. ( Ahn, SH; Chon, CY; Han, KH; Hong, SP; Kim, DY; Kim, HJ; Kim, JK; Lee, CK; Lee, HW; Lee, JM; Lee, KS; Nguyen, T; Paik, YH; Park, JY, 2009)
"Adefovir dipivoxil (ADV) is effective in lamivudine (LAM)-resistant hepatitis B e antigen-negative (HBeAg(-)) chronic hepatitis B (CHB)."5.14Adefovir plus lamivudine are more effective than adefovir alone in lamivudine-resistant HBeAg- chronic hepatitis B patients: a 4-year study. ( Eugenidis, N; Giouleme, O; Gkisakis, D; Grammatikos, N; Katsinelos, P; Koumaras, H; Koumerkeridis, G; Mpoumponaris, A; Panderi, A; Patsiaoura, K; Theodoropoulos, K; Tziomalos, K; Vassiliadis, TG, 2010)
"Adefovir dipivoxil combined with bicyclol is efective in the treatment of chronic hepatitis B."5.14[The analyse of effectiveness in HBeAg-positive chronic viral hepatitis B treated by adefovir dipivoxil combined with bicyclol]. ( Sheng, JF; Xiang, DR, 2009)
"Entecavir is a potent inhibitor of viral replication in nucleos(t)ide analogue (NA)-naïve chronic hepatitis B patients, but data on the efficacy in NA-experienced subjects are limited."5.14Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues. ( Buti, M; Deterding, K; Hansen, BE; Janssen, HL; Petersen, J; Reijnders, JG; Santantonio, T; van Bömmel, F; Wedemeyer, H; Zoulim, F, 2010)
"Large clinical studies assessing long-term adefovir dipivoxil salvage monotherapy in patients with lamivudine-resistant chronic hepatitis B (CHB) are lacking, particularly in patients positive for hepatitis B e antigen (HBeAg)."5.14Long-term adefovir dipivoxil monotherapy for up to 5 years in lamivudine-resistant chronic hepatitis B. ( Ahn, SH; Chon, CY; Han, KH; Hong, SP; Kim, DY; Kim, SO; Lee, JM; Nguyen, T; Park, JY, 2010)
"To compare the efficacy of 48 week-Entecavir therapy with that of Adefovir therapy for chronic hepatitis B patients."5.14[Comparison of the efficacy of 48 week-Entecavir therapy with that of Adefovir therapy for chronic hepatitis B patients]. ( Hu, P; Lin, Q; Ren, H; Shi, XF; Wang, ZY; Zeng, WQ; Zhang, DZ; Zhou, Z, 2010)
"The aim of this study was to investigate the outcome of overlap/switch to adefovir dipivoxil (ADV) monotherapy for chronic hepatitis B (CHB) patients with lamivudine (LAM)-resistant HBV, who responded to LAM plus ADV combination therapy."5.14Overlap/switch to adefovir monotherapy for lamivudine-resistant patients who responded to combination therapy: a pilot controlled study. ( Aizawa, M; Baba, M; Fujise, K; Namiki, Y; Ohkusa, T; Sato, K; Tajiri, H; Takamatsu, M; Tsubota, A, 2010)
"We compared treatments for patients with chronic hepatitis B virus (HBV) infection who had an incomplete response to adefovir dipivoxil (ADV)."5.14Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection. ( Berg, T; Borroto-Esoda, K; Chan, S; Frederick, D; Lavocat, F; Marcellin, P; Moller, B; Oldach, D; Rousseau, F; Snow-Lampart, A; Sorbel, J; Suarez, E; Trinh, H; Zoulim, F, 2010)
"Earlier clinical studies have reported an ALT flare greater than 10 times the upper limit of normal in some patients with chronic hepatitis B when their lamivudine (LAM) treatment was switched to adefovir (ADV) therapy."5.14Question of ALT flare during switch to adefovir from lamivudine: A single center open-label, randomized, safety study (June 17, 2005 to February 5, 2009). ( Ahn, M; Dunn, SR; Hann, HW; Park, SY, 2010)
"Therapy for chronic hepatitis B with tenofovir disoproxil fumarate (TDF) and lamivudine (3TC) or emtricitabine (FTC) is currently recommended for HIV-HBV coinfection."5.14Efficacy of tenofovir disoproxil fumarate/emtricitabine compared with emtricitabine alone in antiretroviral-naive HIV-HBV coinfection in Thailand. ( Avihingsanon, A; Bowden, S; Chang, JJ; Dore, GJ; Kerr, S; Lange, J; Lewin, SR; Matthews, GV; Napissanant, N; Piyawat, K; Ruxrungtham, K, 2010)
"No study has reported on the comparative effect of adefovir (ADV) add-on lamivudine (LAM) versus switching to entecavir (ETV) in LAM-resistant patients with chronic hepatitis B."5.14Efficacy of adefovir add-on lamivudine rescue therapy compared with switching to entecavir monotherapy in patients with lamivudine-resistant chronic hepatitis B. ( Ahn, SH; Chon, CY; Han, KH; Kim, DY; Lee, JM; Lee, MH; Park, JY; Ryu, HJ, 2010)
"To investigate the efficacy of the 96-week antiviral therapy with adefovir dipivoxil in patients with chronic hepatitis B."5.14[Efficacy of the 96-week adefovir dipivoxil therapy in patients with chronic hepatitis B]. ( Cao, H; Chen, LB; Li, G; Shu, X; Xie, QF; Xu, QH; Xu, Z, 2010)
"To observe the efficacy and safety of PEG-interferon alpha-2a (PEG-IFNalpha-2a) treatment on lamivudine (LAM)-resistant chronic hepatitis B (CHB) patients."5.14[Observation on effect of peg interferon lphaa-2a treating lamivudine resistant chronic hepatitis B]. ( Bai, HL; Long, H; Luo, HT; Ye, YN; Zhong, RX, 2010)
"To explore the influence of adefovir dipivoxil on HBV specific CTL in patients with chronic hepatitis B (CHB)."5.14[Influence of adefovir dipivoxil on HBV specific CTL in patients with chronic hepatitis B]. ( Pan, JQ; Tan, YF; Tang, JM; Wang, XC; Wu, YT; Zhao, YP; Zhou, YL, 2010)
"Treatment of 171 patients with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) with adefovir dipivoxil (ADV) 10 mg over 48 weeks resulted in significant histological, virological, serological, and biochemical improvement compared with placebo."5.13Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. ( Arterburn, S; Borroto-Esoda, K; Chang, TT; Frederick, D; Lim, SG; Marcellin, P; Rousseau, F; Sievert, W; Tong, M, 2008)
"Nine patients with lamivudine-resistant chronic hepatitis B infection who had been treated with adefovir 10 mg/day and had had a suboptimal response but did not have genotypic resistance to adefovir were treated with high-dose adefovir (20 mg/day)."5.13Failure of adefovir 20 mg to improve suboptimal response in lamivudine-resistant hepatitis B patients treated with adefovir 10 mg and lamivudine. ( Colombo, M; Facchetti, F; Lampertico, P; Lunghi, G; Viganò, M, 2008)
"Thai patients enrolled in STACCATO with HIV/hepatitis B virus (HBV) co-infection and tenofovir/emtricitabine-based antiretroviral therapy (ART) were randomly assigned to continuous treatment or CD4 cell count-guided interruptions."5.13Interruptions of tenofovir/emtricitabine-based antiretroviral therapy in patients with HIV/hepatitis B virus co-infection. ( Ananworanich, J; Chetchotisakd, P; Hirschel, B; Jupimai, T; Klinbuayam, W; Mahanontharit, A; Nüesch, R; Prasithsirikul, W; Ruxrungtham, K; Srasuebkul, P, 2008)
"To evaluate the efficacy of short-term overlap lamivudine therapy with adefovir in patients with lamivudine-resistant and naive chronic hepatitis B, we compared patients receiving overlap therapy with those receiving adefovir alone."5.13Short-term overlap lamivudine treatment with adefovir dipivoxil in patients with lamivudine-resistant chronic hepatitis B. ( Bae, SH; Cho, SH; Choi, JY; Han, JY; Kang, SB; Kim, YS; Lee, SW; Lee, YS; Nam, SW; Yang, JM; Yoon, SK, 2008)
"This study investigated the efficacy, safety, and pharmacokinetics of adefovir dipivoxil (ADV) in children and adolescents with chronic hepatitis B (CHB)."5.13Safety, efficacy, and pharmacokinetics of adefovir dipivoxil in children and adolescents (age 2 to <18 years) with chronic hepatitis B. ( Frederick, D; Jonas, MM; Kelly, D; Mizerski, J; Mondou, E; Pollack, H; Rousseau, F; Sokal, E; Sorbel, J, 2008)
"Four hundred and eighty Chinese subjects with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) were enrolled in a multicenter, double-blind, randomized, placebo-controlled study of adefovir dipivoxil (ADV) 10 mg once daily."5.12A double-blind randomized trial of adefovir dipivoxil in Chinese subjects with HBeAg-positive chronic hepatitis B. ( Barker, KF; Chang, CN; Hou, J; Ji, BN; Mao, Y; Wang, H; Wang, Y; Yao, G; Zeng, M, 2006)
"We conducted a multicenter, 1: 2 matched pair analysis comparing patients with HBV/HIV-coinfection starting an antiretroviral regimen including tenofovir plus lamivudine with patients who had highly replicative, lamivudine resistant HBe-antigen positive chronic hepatitis B and started with tenofovir as the only active HBV polymerase inhibitor subsequent to lamivudine."5.12Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection. ( Berg, T; Berger, F; Bruno, R; Carlebach, A; Hoffmann, C; Jaeger, H; Lutz, T; Mauss, S; Nelson, M; Rockstroh, J; Schmutz, G; Schürmann, D; Schwarze-Zander, C; Sheldon, J; Soriano, V; Stoehr, A; von Boemmel, F; Wolf, E, 2006)
"Treatment with adefovir dipivoxil for 48 weeks resulted in clinical improvement in patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B that was lost when treatment was discontinued."5.12Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. ( Arterburn, S; Borroto-Esoda, K; Brosgart, CL; Chang, TT; Chuck, SL; Goodman, Z; Hadziyannis, SJ; Heathcote, EJ; Kitis, G; Lim, SG; Ma, J; Marcellin, P; Rizzetto, M; Tassopoulos, NC, 2006)
"In patients failing to respond to adefovir monotherapy or an adefovir-containing regimen for chronic hepatitis B virus, a combination of tenofovir and emtricitabine resulted in undetectable hepatitis B viral DNA levels without any renal toxicity."5.12Effect of switching to tenofovir with emtricitabine in patients with chronic hepatitis B failing to respond to an adefovir-containing regimen. ( Carriero, D; Dieterich, DT; Jaffe, D; Lucas, J; Park, JS; Santos, SA; Uriel, AJ, 2006)
"To investigate the efficacy and safety of adefovir dipivoxil (ADV, DAIDING) for Chinese chronic hepatitis B patients with lamivudine (LAM) resistance."5.12[A double-blind, randomized, lamivudine-controlled clinical trial of DAIDING (adefovir dipivoxil) for lamivudine-resistant patients with chronic hepatitis B]. ( Chen, YK; Lei, BJ; Lu, ZM; Wang, YM; Yin, YK; Yu, YS; Zhang, DZ, 2006)
"To evaluate the efficacy and safety of a China made adefovir dipivoxil (ADV) treatment for hepatitis B e antigen-positive patients with chronic hepatitis B."5.12[A clinical study of adefovir dipivoxil, made in China, for treatment of hepatitis B e antigen-positive patients with chronic hepatitis B]. ( Chen, XY; Kang, XP; Li, J; Lin, XH; Liu, P; Ren, XM; Si, CW; Yu, YY; Zhang, SL, 2006)
"We studied the long-term efficacy of adefovir dipivoxil (ADV) treatment in 42 HBeAg-negative patients with chronic hepatitis B (CHB) who had developed genotypical lamivudine (LAM) resistance with virological and clinical breakthroughs under long-term LAM treatment."5.12Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. ( Dimou, E; Hadziyannis, SJ; Mitsoula, P; Rapti, I, 2007)
"Forty-six consecutive lamivudine-resistant chronic hepatitis B patients treated with ADV for more than 12 months with or without 3TC overlapping were prospectively examined for virological response and adefovir resistance."5.12Virological response and incidence of adefovir resistance in lamivudine-resistant patients treated with adefovir dipivoxil. ( Changchien, CS; Chen, CH; Hu, TH; Hung, CH; Lee, CM; Lu, SN; Wang, JC; Wang, JH, 2006)
"We assessed the efficacy and safety of adefovir 20 mg daily in patients with hepatitis B e antigen-positive chronic hepatitis B resistant to lamivudine and a suboptimal virological response to adefovir 10 mg daily add-on."5.12Efficacy and safety of adefovir dipivoxil 20 mg daily in HBeAg-positive patients with lamivudine-resistant hepatitis B virus and a suboptimal virological response to adefovir dipivoxil 10 mg daily. ( Bouvier-Alias, M; Brillet, R; Chevaliez, S; Dhumeaux, D; Hézode, C; Pawlotsky, JM; Roudot-Thoraval, F; Zafrani, ES, 2007)
"To evaluate the efficacy and safety of adefovir dipivoxil (ADV) treatment in patients with hepatitis B e antigen (HBeAg) positive chronic hepatitis B (CHB)."5.12[Three year adefovir dipivoxil treatment for hepatitis B e antigen-positive chronic hepatitis B patients]. ( Ling, N; Ren, H; Zhang, DZ; Zhou, Z, 2007)
"To evaluate the efficacy and safety of adefovir dipivoxil (ADV) in treating patients with lamivudine (LAM) refractory HBeAg-positive chronic hepatitis B."5.12[A clinical study of adefovir dipivoxil in treating lamivudine refractory HBeAg-positive chronic hepatitis B]. ( Chen, XY; Si, CW; Tang, XP; Wang, L; Zhang, YX; Zhao, H, 2007)
"We investigated the impact of early viral load decline on virus-specific T-cell reactivity in 30 hepatitis B e antigen (HBeAg)-positive patients with chronic hepatitis B randomized to monotherapy with adefovir dipivoxil (ADV) or in combination with emtricitabine (ADV/FTC)."5.12Impact of early viral kinetics on T-cell reactivity during antiviral therapy in chronic hepatitis B. ( Anderson, J; Bowden, S; Cooksley, H; Hui, CK; Lau, GK; Lewin, S; Locornini, S; Mondou, E; Naoumov, NV; Perelson, AS; Powers, KA; Ribeiro, RM; Rousseau, F; Shudo, E; Sorbel, J, 2007)
"To compare the antiviral efficacy of telbivudine and adefovir dipivoxil, and the effects of switching from adefovir to telbivudine, in hepatitis B e antigen (HBeAg)-positive patients with chronic hepatitis B."5.12Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. ( Brown, NA; Bzowej, N; Chan, HL; Chao, YC; Cho, M; Harb, G; Heathcote, EJ; Jeffers, L; Kaiser, R; Lai, CL; Marcellin, P; Minuk, GY; Moon, YM; Myers, RP; Qiao, XJ; Sievert, W, 2007)
"To evaluate the cost effectiveness of treatment of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) with entecavir compared with lamivudine with adefovir salvage, based primarily on the results of a recent 2-year, randomised, multicentre, clinical trial (n = 709)."5.12Cost effectiveness of entecavir versus lamivudine with adefovir salvage in HBeAg-positive chronic hepatitis B. ( Clarke, L; Di Bisceglie, A; Gish, RG; Iloeje, UH; Kowdley, KV; Sullivan, SD; Tafesse, E; Veenstra, DL, 2007)
"To evaluate the effect of diammonium glycyrrhizinate on the antiviral therapy with adefovir dipivoxil (ADV) in patients with HBeAg-positive chronic hepatitis B."5.12[Diammonium glycyrrhizinate does not affect efficacy of adefovir dipivoxil therapy in patients with HBeAg-positive chronic hepatitis B]. ( Chen, XY; Lei, CL; Li, J; Si, CW; Tang, XP; Wang, L; Zhang, YX; Zhao, H, 2007)
"To determine the relationship between the response to adefovir dipivoxil (ADV) treatment in patients with HBV genotypes B and C of HBeAg positive chronic hepatitis B."5.12[Efficacy of adefovir dipivoxil was not related to genotypes B and C of hepatitis B virus: a randomized, double-blind, multicenter clinical study]. ( Chen, XY; Lei, CL; Li, J; Si, CW; Tang, XP; Wang, L; Zhang, YX; Zhao, H, 2007)
"The safety and efficacy of 10 mg of adefovir dipivoxil was compared to placebo in 501 Asian (n = 259) or Caucasian (n = 242) HBeAg+ and HBeAg- chronic hepatitis B virus patients treated for 48 weeks in two randomized, double-blind, placebo-controlled studies."5.12Clinical trial: effects of adefovir dipivoxil therapy in Asian and Caucasian patients with chronic hepatitis B. ( Arterburn, S; Brosgart, CL; Chang, TT; Hadziyannis, S; Hu, P; Lim, SG; Marcellin, P; Sievert, W; Tassopoulos, N; Tong, M, 2007)
"The extended treatment with lamivudine in patients with chronic hepatitis B is associated with the emergence of resistances."5.12[Adefovir dipivoxil compassionate use program in Spain: efficacy and resistance analysis]. ( Buti, M; Calleja, JL; Carnicer, F; Casanovas, T; Crespo, J; Enríquez, J; Esteban, R; García Bengoechea, M; García Samaniego, J; Jardí, R; Miras, M; Pérez Roldán, F; Pons, F; Prieto, M; Rodríguez Frías, F; Romero, M; Rueda, M, 2007)
" We evaluated the efficacy and safety of adding adefovir dipivoxil to lamivudine in 135 patients with chronic hepatitis B (CHB) and YMDD mutant HBV."5.11Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. ( Bourne, E; Brosgart, CL; Gardner, S; Hann, HW; Lee, WM; Leung, N; Moorat, A; Mutimer, D; Perrillo, R; Schiff, E; Willems, B; Woessner, M, 2004)
" This study assessed the safety and efficacy of adefovir dipivoxil alone and in combination with lamivudine compared with ongoing lamivudine therapy in patients with chronic hepatitis B with compensated liver disease and lamivudine-resistant hepatitis B virus (HBV)."5.11Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. ( Bourliere, M; Brosgart, CL; Buggisch, P; Ebrahimi, R; Gray Df, Df; Hann Hw, Hw; Heathcote, EJ; Kleber, K; Kowdley, K; Martin, P; Peters, MG; Rubin, R; Sullivan, M; Trepo, C; Xiong, S, 2004)
"Lamivudine treatment in patients with chronic hepatitis B virus (HBV) infection may improve clinical state and suppress viral replication before liver transplantation."5.11Liver transplantation for chronic hepatitis B with lamivudine-resistant YMDD mutant using add-on adefovir dipivoxil plus lamivudine. ( Chan, SC; Fan, ST; Lau, GK; Liu, CL; Lo, CM; Ng, IO, 2005)
"Treatment with adefovir dipivoxil for 48 weeks resulted in histologic, virologic, and biochemical improvement in patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B."5.11Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. ( Arterburn, S; Brosgart, CL; Chang, TT; Currie, G; Goodman, Z; Hadziyannis, SJ; Heathcote, EJ; Kitis, G; Lim, SG; Ma, J; Marcellin, P; Rizzetto, M; Tassopoulos, NC; Xiong, S, 2005)
"Adefovir dipivoxil is safe for the treatment of chronic hepatitis B in patients with varying degrees of renal dysfunction and lamivudine-resistant HBV and results in biochemical and virological efficacy similar to that reported in the general population."5.11Efficacy and safety of adefovir dipivoxil in kidney recipients, hemodialysis patients, and patients with renal insufficiency. ( Brosgart, C; Chaix, ML; Currie, G; Fontaine, H; Morales, E; Nalpas, B; Pol, S; Serpaggi, J; Vallet-Pichard, A; Varaut, A; Verkarre, V, 2005)
" Currently available treatments for chronic hepatitis B (interferon [IFN]-alpha and lamivudine [3TC]) have limited long-term utility because of side effects or of the development of resistance."5.10Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed. ( Aberg, JA; Crippin, J; Kessels, L; Lisker-Melman, M; Powderly, WG; Ristig, MB; Tebas, P, 2002)
"We randomly assigned 515 patients with chronic hepatitis B who were positive for hepatitis B e antigen (HBeAg) to receive 10 mg of adefovir dipivoxil (172 patients), 30 mg of adefovir dipivoxil (173), or placebo (170) daily for 48 weeks."5.10Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. ( Brosgart, CL; Chang, TT; Fry, J; Goodman, Z; Jeffers, L; Lim, SG; Marcellin, P; Shiffman, ML; Sievert, W; Tong, MJ; Wulfsohn, MS; Xiong, S, 2003)
"Adefovir dipivoxil, a nucleotide analogue, demonstrated clinically significant antiviral activity in patients with chronic hepatitis B in phase 1 and 2 clinical trials."5.10Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. ( Brosgart, CL; Chang, TT; Fry, J; Goodman, Z; Hadziyannis, SJ; Heathcote, EJ; Kitis, G; Lim, SG; Marcellin, P; Rizzetto, M; Tassopoulos, NC; Wulfsohn, MS; Xiong, S, 2003)
"Seven hundred nucleoside treatment-naive patients were enrolled in two phase 3 trials of adefovir dipivoxil (ADV) for the treatment of chronic hepatitis B."5.10Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B. ( Brosgart, CL; Delaney, WE; Fry, J; Gibbs, CS; Miller, MD; Westland, CE; Wulfsohn, M; Xiong, S; Yang, H, 2003)
"In a recent phase II clinical study, 13 chronic hepatitis B-infected patients treated daily with 30 mg adefovir dipivoxil for 12 weeks displayed a median 4."5.09Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy. ( Gibbs, CS; Rooney, JF; Toole, JJ; Tsiang, M, 1999)
"Tenofovir disoproxil fumarate (TDF), an ester prodrug of tenofovir (TFV), is one of the recommended drugs for chronic hepatitis B (CHB) patients."4.98Tenofovir alafenamide (TAF) treatment of HBV, what are the unanswered questions? ( Grossi, G; Lampertico, P; Loglio, A; Viganò, M, 2018)
"We aimed to evaluate the efficacy of five oral nucleos(t)ide analogues (NAs), including lamivudine, entecavir, adefovir, telbivudine and tenofovir, for the prevention of hepatitis B virus (HBV) reactivation and HBV-related complications in chronic hepatitis B virus (CHB) infected patients with hematological malignancies receiving chemotherapy or hematopoietic stem cell transplantation (HSCT) by network meta-analysis."4.95Nucleos(t)ide analogues for preventing HBV reactivation in immunosuppressed patients with hematological malignancies: a network meta-analysis. ( Chen, FY; Cheng, Z; Huang, HH; Shi, KQ; Van Poucke, S; Zhang, MY; Zheng, JN; Zheng, MH; Zhu, GQ, 2017)
"In April 2017 tenofovir alafenamide (TAF) was added to the list of first-line therapies recommended for chronic hepatitis B (CHB)."4.95Tenofovir alafenamide for the treatment of chronic hepatitis B virus infection. ( Abdul Basit, S; Dawood, A; Gish, R; Ryan, J, 2017)
"Tenofovir alafenamide (TAF) has recently been approved for chronic hepatitis B (CHB)."4.95Tenofovir alafenamide as compared to tenofovir disoproxil fumarate in the management of chronic hepatitis B with recent trends in patient demographics. ( Hsu, YC; Nguyen, MH; Wei, MT, 2017)
"Tenofovir alafenamide (TAF), a novel prodrug of tenofovir (TFV), has been approved for the treatment of chronic hepatitis B virus (HBV) infection."4.95Tenofovir alafenamide in the treatment of chronic hepatitis B: design, development, and place in therapy. ( Furusyo, N; Nguyen, MH; Ogawa, E, 2017)
"Conventional interferon alfa and nucleos(t)ide analogues, such as lamivudine, are frequently used for chronic hepatitis B (CHB) treatment, but are associated with adverse effects and viral resistance."4.93Pegylated interferon alfa for chronic hepatitis B: systematic review and meta-analysis. ( Abreu, RM; Baldassare, RM; Carrilho, FJ; Kim, V; Nakagawa, DM; Ono, SK, 2016)
"Long-term adefovir dipivoxil therapy is connected to renal dysfunction in chronic hepatitis B, necessitating the monitoring of kidney function."4.93Relationship between nephrotoxicity and long-term adefovir dipivoxil therapy for chronic hepatitis B: A meta-analysis. ( Cheng, F; Deng, Y; Kang, J; Luo, Q; Zeng, W; Zhang, D; Zhong, S, 2016)
"The treatment of chronic hepatitis B (CHB) in patients with chronic kidney disease (CKD) is based on nucleoside (lamivudine, telbivudine, entecavir) or nucleotide (adefovir, tenofovir) analogues (NAs), but it may be complex and the information is scarce."4.90Review article: nucleos(t)ide analogues in patients with chronic hepatitis B virus infection and chronic kidney disease. ( Cholongitas, E; Papatheodoridis, G; Pipili, C, 2014)
" He had been receiving low-dose adefovir dipivoxil (ADV) for the treatment of lamivudine-resistant chronic hepatitis B virus infection for eight years and subsequently developed severe hypophosphatemia and proximal renal tubule dysfunction."4.90Hypophosphatemic osteomalacia due to drug-induced Fanconi's syndrome associated with adefovir dipivoxil treatment for hepatitis B. ( Eguchi, H; Hiromatsu, Y; Kuwahara, R; Tani, J; Tsuruta, M, 2014)
"Tenofovir (TDF) and entecavir (ETV) are both potent antiviral agents for the treatment of chronic hepatitis B virus (HBV) infection."4.90Comparison of efficacy and safety of tenofovir and entecavir in chronic hepatitis B virus infection: a systematic review and meta-analysis. ( Gao, Y; Ke, W; Liu, L; Yang, Y; Ye, X; Zhang, C; Zhou, S, 2014)
" Currently, lamivudine plus adefovir combination therapy or entecavir monotherapy is usually used for the treatment of patients with lamivudine-resistant chronic hepatitis B (CHB)."4.89Comparison of the efficacy of Lamivudine plus adefovir versus entecavir in the treatment of Lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis. ( Chen, RC; Dai, XH; Fan, XG; Huang, Y; Huang, ZB; Li, N; Li, WT; Yi, PP; Zhang, BX; Zhao, SS; Zhou, RR, 2013)
"To conduct a meta-analysis to determine the efficacy of peginterferon alpha (PEG-IFN α) therapy versus IFN α, adefovir dipivoxil (ADV) and entecavir (ETV) for HBeAg-positive chronic hepatitis B patients in China."4.89Peginterferon alpha versus other antiviral regimes for Chinese HBeAg-positive chronic hepatitis B patients. ( Deng, Z; Li, B; Li, Z; Liu, S; Wang, C, 2013)
"The aim of this study was to systematically review the quality of cost-effectiveness evidence on first-line treatment with entecavir (ETV) or tenofovir difumarate (TDF) for patients with chronic hepatitis B."4.89Cost effectiveness of first-line oral antiviral therapies for chronic hepatitis B : a systematic review. ( Buti, M; Casado, MA; Lozano, V; Oyagüez, I, 2013)
"The aim of the current study was to compare the effectiveness of adefovir dipivoxil (ADV) monotherapy with that of combination ADV and lamivudine (LAM) therapy in the treatment of LAM-resistant chronic hepatitis B (CHB)."4.88Comparative meta-analysis of adefovir dipivoxil monotherapy and combination therapy of adefovir dipivoxil and lamivudine for lamivudine-resistant chronic hepatitis B. ( Chen, Y; Ju, T, 2012)
"Entecavir (ETV) and tenofovir disoproxil fumarate (TDF) are potent nucleos(t)ide analogues (NUCs) recommended as first-line monotherapies for chronic hepatitis B."4.88First-line treatment of chronic hepatitis B with entecavir or tenofovir in 'real-life' settings: from clinical trials to clinical practice. ( Lampertico, P; Pol, S, 2012)
"First-line treatment options for chronic hepatitis B (CHB) consist of nucleos(t)ide analogues with a high barrier to resistance (entecavir and tenofovir) or the immunomodulatory agent peginterferon (PEG-IFN)."4.87Review article: chronic hepatitis B - anti-viral or immunomodulatory therapy? ( Janssen, HL; Rijckborst, V; Sonneveld, MJ, 2011)
"Although entacavir and adefovir were widely used in most Asian countries, there were few conclusions drawn from a meta-analysis for comparing the efficacy between entecavir and adefovir in nucleos(t)ide-naïve Asian patients with chronic hepatitis B (CHB)."4.87Comparison of the 48-week efficacy between entecavir and adefovir in HBeAg-positive nucleos(t)ide-naïve Asian patients with chronic hepatitis B: a meta-analysis. ( Guan, Q; Liu, W; Zhao, J; Zhao, P, 2011)
" Currently, several drugs, such as tenofovir and adefovir, are recommended for treatment of patients with chronic hepatitis B."4.87Comparison of the efficacy of tenofovir and adefovir in the treatment of chronic hepatitis B: a systematic review. ( Chen, LZ; Dai, XH; Fan, XG; Tang, LH; Wang, W; Zhao, SS; Zhou, RR, 2011)
"Chronic hepatitis B virus (HBV) infection represents a serious global health problem and resistance to lamivudine (LAM) has become a serious clinical challenge."4.87Lamivudine plus adefovir combination therapy versus entecavir monotherapy for lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis. ( Hu, HD; Hu, P; Liu, JY; Ren, H; Sheng, YJ; Tong, SW; Zhang, DZ, 2011)
" Combination therapy with Interferon-α and ribavirin remains the backbone treatment for chronic hepatitis C; the addition of serine protease inhibitors improves the treatment outcome of patients infected with hepatitis C virus genotype 1."4.87Antiviral drugs for viruses other than human immunodeficiency virus. ( Razonable, RR, 2011)
" Lamivudine and adefovir dipivoxil are effective and tolerable for chronic hepatitis B by suppressing the viral load and to reduce fibrosis in the liver."4.87Lamivudine with or without adefovir dipivoxil for postoperative hepatocellular carcinoma. ( Li, le Q; Wu, LC; Zhong, JH, 2011)
"Since its approval for the treatment of chronic hepatitis B in 1998, lamivudine (LAM) has been used extensively throughout the world, because of its relatively low costs and favourable tolerability."4.86Avoiding and managing lamivudine resistance in chronic hepatitis B: current approaches and potential strategies including pegylated interferon. ( Marcellin, P; Piratvisuth, T; Sung, J, 2010)
"This paper presents a summary of the evidence review group (ERG) report into the clinical effectiveness and cost-effectiveness of tenofovir disoproxil fumarate for the treatment of chronic hepatitis B, in accordance with the licensed indication, based upon the evidence submission from Gilead to the National Institute for Health and Clinical Excellence (NICE) as part of the single technology appraisal process."4.86Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B infection. ( Colquitt, J; Cooper, K; Harris, P; Jones, J; Shepherd, J, 2010)
"Tenofovir is a nucleotide analog reverse transcriptase inhibitor approved recently by the US FDA for the treatment of chronic hepatitis B (CHB) in adult patients based on the results of two double-blind randomized trials demonstrating superiority of tenofovir compared with adefovir."4.86Tenofovir disoproxil fumarate in the treatment of chronic hepatitis B. ( Jenh, AM; Pham, PA, 2010)
"To update and extend a 2006 report on the clinical effectiveness and cost-effectiveness of adefovir dipivoxil (ADV) and pegylated interferon alpha (PEG-alpha) for the treatment of chronic hepatitis B (CHB)."4.85Adefovir dipivoxil and pegylated interferon alpha for the treatment of chronic hepatitis B: an updated systematic review and economic evaluation. ( Baxter, L; Gospodarevskaya, E; Harris, P; Hartwell, D; Jones, J; Price, A; Shepherd, J, 2009)
"Tenofovir disoproxil fumarate is a nucleotide analog reverse transcriptase inhibitor recently approved by the United States Food and Drug Administration (FDA) for the treatment of chronic hepatitis B virus (HBV) infection in adults."4.85Tenofovir for the treatment of hepatitis B virus. ( Jenh, AM; Pham, PA; Thio, CL, 2009)
"Currently, there are no conclusive results on the efficacy of adefovir dipivoxil (ADV) plus lamivudine (LAM) in LAM-resistant patients with chronic hepatitis B (CHB)."4.85Meta-analysis: adefovir dipivoxil in combination with lamivudine in patients with lamivudine-resistant hepatitis B virus. ( Chen, EQ; Lei, J; Tang, H; Wang, LC; Xu, L, 2009)
"Clinical trials demonstrated telbivudine to be a safe and potent antiviral agent for treatment of chronic hepatitis B."4.84A review of telbivudine for the management of chronic hepatitis B virus infection. ( Chan, HL; Lui, YY, 2008)
" Interferon alfa-2b, lamivudine, adefovir, entecavir, peginterferon alfa-2a, telbivudine, and tenofovir are approved as initial therapy for chronic hepatitis B and have certain advantages and disadvantages."4.84A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. ( Dieterich, DT; Han, SH; Jacobson, IM; Keeffe, EB; Martin, P; Schiff, ER; Tobias, H, 2008)
" In the last few years the therapeutic options in chronic hepatitis B have increased and currently six treatments are authorized: standard interferon (IFN)-alpha, pegylated interferon-alpha (PEG-IFNalpha), lamivudine, adefovir, entecavir, and telbivudine."4.84[Interferon in hepatitis B]. ( García Buey, L; González Mateos, F; Moreno Otero, R, 2008)
"At least 4 nucleos(t)ide analogs have been approved for the treatment of chronic hepatitis B: lamivudine, adefovir dipivoxil, entecavir, and telbivudine."4.84[Nucleoside and nucleotide analogs in the treatment of chronic hepatitis B]. ( Buti, M, 2008)
"The practising clinician is currently faced with a number of effective treatment options for chronic hepatitis B, including two formulations of interferon (standard IFN and pegylated IFN) and five nucleos(t)ide analogues (lamivudine, adefovir, entecavir, telbivudine and tenofovir)."4.84Peginterferon for the treatment of chronic hepatitis B in the era of nucleos(t)ide analogues. ( Buster, EH; Janssen, HL; Schalm, SW, 2008)
" Treatment options for chronic hepatitis B include pegylated interferon and 4 licensed oral nucleosides/nucleotides (lamivudine, adefovir entecavir and tenofovir)."4.84[Chronic hepatitis B: current therapy]. ( Buffet, C, 2008)
"Lamivudine and adefovir were approved for treatment of chronic hepatitis B virus (HBV) infection based on placebo-controlled trials, and entecavir was recently approved on the basis of its superiority over lamivudine in phase II/III trials; however, to date, these three therapies have not been compared head to head."4.84Cross-study analysis of the relative efficacies of oral antiviral therapies for chronic hepatitis B infection in nucleoside-naive patients. ( Dienstag, JL; Kreter, B; Wei, LJ; Xu, D, 2007)
"Standard treatments for chronic hepatitis B (CHB) include interferon-alpha (IFN-alpha) and lamivudine (LAM), but these are associated with adverse effects and viral resistance, respectively."4.84A systematic review and economic evaluation of adefovir dipivoxil and pegylated interferon-alpha-2a for the treatment of chronic hepatitis B. ( Davidson, P; Jones, J; Price, A; Shepherd, J; Takeda, A, 2007)
"Among the six drugs licensed for the treatment of chronic hepatitis B in the US, the preferred agents in 2008 will include entecavir, peginterferon alfa-2a, possibly telbivudine, and tenofovir following licensure."4.84Review article: current antiviral therapy of chronic hepatitis B. ( Ayoub, WS; Keeffe, EB, 2008)
"Five agents are currently approved for the treatment of chronic hepatitis B: standard interferon-alpha (IFN-alpha), pegylated interferon-alpha 2a (PEG-IFN-alpha 2a), lamivudine, adefovir and entecavir."4.83Medical therapy of patients affected by HBeAg-negative chronic hepatitis B. ( Asselah, T; Boyer, N; Marcellin, P, 2006)
"There are two new nucleoside analogues available for the management of chronic hepatitis B, adefovir and entecavir, and several more in development."4.83Personal view: the management of chronic hepatitis B infection. ( Sherman, M, 2006)
" The treatment of choice in chronic hepatitis C currently is pegylated interferon plus ribavirin."4.83Chronic Hepatitis B and C--current treatment and future therapeutic prospects. ( Müller, C, 2006)
" Chronic hepatitis C can be treated preferably with a combination therapy (pegylated interferons + Ribavirin)."4.82[Hepatitis: associated diseases. Risk groups -- prevention -- treatment]. ( Maier, KP, 2003)
"To evaluate properties of the new acyclic nucleotide analog adefovir dipivoxil in the treatment of chronic hepatitis B (CHB)."4.82Adefovir dipivoxil in the treatment of chronic hepatitis B. ( Rivkin, AM, 2004)
" To determine the effectiveness of adefovir, three populations of patients with chronic hepatitis B patients were studied: hepatitis B e antigen (HBeAg)-positive patients, HBeAg-negative patients, and patients with lamivudine-resistant tyrosine-methionine-asparate-aspartate (YMDD) mutants."4.82Treatment of patients with chronic hepatitis B with adefovir dipivoxil. ( Tong, MJ; Tu, SS, 2004)
"Adefovir dipivoxil, an acyclic nucleotide analogue, is effective for the treatment of chronic hepatitis B in both hepatitis B e antigen (HBeAg)-positive and -negative patients, with improvement in liver histology, hepatitis B virus (HBV) DNA levels, alanine aminotransferase levels, and HBeAg seroconversion (for HBeAg-positive patients)."4.82Adefovir dipivoxil in chronic hepatitis B infection. ( Lai, CL; Yuen, MF, 2004)
"Adefovir dipivoxil (ADF) is a novel acyclic nucleoside analogue that has recently been approved for the treatment of chronic hepatitis B virus (HBV)."4.82Adefovir dipivoxil: review of a novel acyclic nucleoside analogue. ( Danta, M; Dusheiko, G, 2004)
"Although the management of chronic hepatitis B has improved over the last decade, none of the available therapeutic agents, IFN-alpha, lamivudine and adefovir dipivoxil, can achieve sustained off-therapy responses in most cases."4.82Emerging treatments in chronic hepatitis B. ( Hadziyannis, SJ; Papatheodoridis, GV, 2004)
" The conference issued recommendations on the investigation and management of chronic hepatitis B, including the use of lamivudine, adefovir and interferon."4.82The management of chronic viral hepatitis: a Canadian consensus conference 2004. ( Bain, V; Cooper, C; Lowe, C; Martin, S; Myers, RP; Sherman, M; Villeneuve, JP, 2004)
" Adefovir dipivoxil is indicated for the treatment of chronic hepatitis B in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (alanine [ALT] or aspartate [AST]) or histologically active disease."4.82Adefovir dipivoxil: focus on its use in the treatment of chronic hepatitis B. ( Baker, DE, 2005)
"Two agents are currently approved for the treatment of chronic hepatitis B: interferon alfa and lamivudine."4.81Advances in therapy for chronic hepatitis B. ( Marcellin, P, 2002)
"There are two licensed drugs for chronic hepatitis B virus (HBV), interferon alfa and lamivudine, with similar efficacy rates."4.81How will we use the new antiviral agents for hepatitis B? ( Perrillo, RP, 2002)
"This retrospective study included 289 chronic hepatitis B (CHB) patients without cirrhosis who received entecavir (n = 93), TDF (n = 103), or TAF (n = 86) retreatment for at least 12 months after entecavir or TDF cessation."4.31Retreatment Efficacy and Renal Safety of Tenofovir Alafenamide, Entecavir, and Tenofovir Disoproxil Fumarate After Entecavir or Tenofovir Cessation. ( Chang, KC; Chen, CH; Chiu, SM; Hu, TH; Hung, CH; Lu, SN; Wang, JH, 2023)
"As tenofovir disoproxil fumarate (TDF) requires long-term use, a reduction in bone density should be considered a possibility when treating patients with chronic hepatitis B (CHB) with aging and systemic diseases."4.31Tenofovir disoproxil fumarate versus tenofovir alafenamide on risk of osteoporotic fracture in patients with chronic hepatitis B: A nationwide claims study in South Korea. ( Chang, JI; Cho, YY; Jang, ES; Kim, E; Kim, HJ; Kim, SS; Lee, HW; Seo, GH; Yoon, E, 2023)
"Switching to a tenofovir alafenamide (TAF)-containing regimen has been reported to be associated with body weight gain in human immunodeficiency virus-infected subjects."4.12Body weight changes in treated hepatitis B patients switching to tenofovir alafenamide ( Chuang, WL; Dai, CY; Hsieh, MY; Huang, CF; Huang, CI; Huang, JF; Liang, PC; Nguyen, MH; Trinh, S; Yeh, ML; Yu, ML, 2022)
"Data on long-term tenofovir alafenamide (TAF) therapy for pregnant women with active chronic hepatitis B (CHB) (immune clearance and reactivation phases, currently and previously diagnosed) and their infants are lacking."4.12Tenofovir Alafenamide for Pregnant Chinese Women With Active Chronic Hepatitis B: A Multicenter Prospective Study. ( Chen, ZM; Cui, GL; Feng, YH; Huang, S; Li, GM; Li, GT; Li, J; Li, W; Li, WZ; Li, ZQ; Liang, HX; Lin, WB; Liu, N; Liu, YM; Lv, J; Pan, YJ; Song, N; Sun, CY; Wang, FS; Wang, M; Xu, GH; Xu, JH; Yu, ZJ; Zeng, QL; Zeng, YL; Zhang, DW; Zhang, GF; Zhang, GQ; Zhang, HX; Zhang, JY; Zhou, YH, 2022)
"We aimed to investigate the long-term effects of tenofovir disoproxil fumarate and entecavir treatment on bone mineral density and evaluated the fracture risk assessment tool score in patients with chronic hepatitis B."4.12Effects of Long-Term Tenofovir and Entecavir Treatment on Bone Mineral Density in Patients with Chronic Hepatitis B. ( Çalhan, T; Doğanay, L; Kahraman, R; Kanat, E; Özdil, K; Öztürk, O; Şahin, A; Sayar, S, 2022)
"HBV DNA was extracted from blood samples of two patients with HBeAg-positive chronic HBV infection and persistent viremia despite tenofovir treatment, and subsequently amplified by PCR before full-length HBV genomes were assembled by deep sequencing."4.12Novel hepatitis B virus reverse transcriptase mutations in patients with sustained viremia despite long-term tenofovir treatment. ( Bajpai, PS; Bukh, J; Dalegaard, MI; Fahnøe, U; Lundh, A; Ryom, L; Weis, N; Winckelmann, A, 2022)
"Antenatal antiviral therapy (AVT) is effective in preventing mother-to-child transmission (MTCT) in chronic hepatitis B (CHB); tenofovir disoproxil fumarate (TDF) is the preferred agent."4.12Plasma and breast milk pharmacokinetics of tenofovir alafenamide in mothers with chronic hepatitis B infection. ( Cottrell, M; Crane, H; Di Girolamo, J; Dumond, J; Gane, E; Kashuba, A; Kayes, T; Levy, MT; Lim, TH; Manandhar, S; Symonds, A, 2022)
"Tenofovir alafenamide (TAF) may be preferable to other nucleos(t)ide analogues (NA) regarding outcomes against chronic hepatitis B virus (HBV) infection."4.12Switching to tenofovir alafenamide for nucleos(t)ide analogue-experienced patients with chronic hepatitis B: week 144 results from a real-world, multi-centre cohort study. ( Amagase, H; Azuma, K; Dohmen, K; Furusyo, N; Hayashi, J; Ichiki, Y; Kajiwara, E; Kato, M; Kawano, A; Koyanagi, T; Kuniyoshi, M; Morita, C; Nakamuta, M; Nomura, H; Ogawa, E; Ooho, A; Satoh, T; Shimoda, S; Sugimoto, R; Takahashi, K; Yamashita, N, 2022)
"Non-inferior antiviral efficacy and better renal safety have been reported in chronic hepatitis B patients with tenofovir alafenamide (TAF) treatment."4.12One-year efficacy of tenofovir alafenamide in patients with chronic hepatitis B: An observational study. ( Chen, YC; Chien, RN; Hsu, CW; Tai, DI, 2022)
"Tenofovir is a nucleotidic analog inhibitor used in monotherapy as first line treatment of chronic Hepatitis B virus (HBV) infection."4.12Treatment of chronic hepatitis B: virological and pharmacological aspects ( Foucault, T; Gaudy-Graffin, C; Handala, L; Marlet, J; Paintaud, G, 2022)
"Although tenofovir alafenamide (TAF) and besifovir dipivoxil maleate (BSV) are potent antiviral agents in the treatment of chronic hepatitis B (CHB) infection, their renal safety profiles have not been previously compared."4.12Similar risk of kidney function decline between tenofovir alafenamide and besifovir dipivoxil maleate in chronic hepatitis B. ( Ahn, SH; Jung, CY; Kim, BS; Kim, HW; Kim, SU; Lee, HW; Lee, JI, 2022)
"Entecavir (ETV) or adefovir dipivoxil (ADV) are not recommended during pregnancy because of embryotoxicity or teratogenicity found in animal studies; however, information on the safety of ETV or ADV in humans is limited."4.12Pregnancy outcomes for pregnant women with chronic hepatitis B exposing to entecavir or adefovir dipivoxil therapy before or in early pregnancy. ( Cai, H; Duan, X; Fu, D; Gao, X; Hu, Y; Kang, K; Liu, M; Yi, W; Zhou, M, 2022)
" This study aimed to compare the efficacy of entecavir (ETV) and tenofovir disoproxil fumarate (TDF) in relation to the adverse clinical outcomes among chronic hepatitis B (CHB) patients stratified according to adherence to medication and MVR."4.02Comparable Incidence of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated with Entecavir or Tenofovir. ( Jeong, J; Jung, SW; Kim, MJ; Lee, SB; Park, BR; Park, EJ; Park, NH; Shin, JW, 2021)
"Adefovir plus entecavir (ADV+ETV) rescue therapy in ETV-resistant patients with chronic hepatitis B virus (HBV) infection is suboptimal in some patients."4.02Multiple drug-resistant HBV mutation may contribute to poor response of adefovir + entecavir in entecavir-resistant patients. ( Chen, R; Li, J; Li, L; Li, X; Liu, LM; Liu, Y; Shao, J; Xu, D; Zhao, L; Zhou, Y, 2021)
"Tenofovir alafenamide (TAF) has been newly approved for the treatment of chronic hepatitis B (CHB)."3.96Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B. ( Azuma, K; Dohmen, K; Furusyo, N; Hayashi, J; Kajiwara, E; Kato, M; Kawano, A; Koyanagi, T; Nakamuta, M; Nomura, H; Ogawa, E; Ooho, A; Satoh, T; Shimoda, S; Takahashi, K, 2020)
"We amplified a full-length hepatitis B virus (HBV) genome from the serum of a chronic hepatitis B patient who experienced virological breakthrough with high HBV DNA titer following adefovir (ADV) therapy."3.96An antiviral drug-resistant mutant of hepatitis B virus with high replication capacity in association with a large in-frame deletion in the preS1 region of viral surface gene. ( Li, X; Qin, Y; Tong, S; Wang, T; Zhang, J; Zhao, W, 2020)
"Renal toxicity is a concern in patients with chronic hepatitis B taking nucleotide analogues, such as adefovir (ADV) and tenofovir disoproxil fumarate (TDF)."3.96Long-term Nucleotide Analogue Treatment Has Higher Levels of Renal Toxicities than Does Entecavir in Patients with Chronic Hepatitis B. ( Chang, Y; Cho, EJ; Cho, H; Cho, YY; Kim, YJ; Lee, JH; Nam, JY; Yoon, JH; Yu, SJ, 2020)
"Tenofovir alafenamide (TAF) is the latest agent approved for chronic hepatitis B virus (HBV) treatment."3.96Potential Benefits of Switching Liver Transplant Recipients to Tenofovir Alafenamide Prophylaxis. ( Kim, WR; Kwo, PY; Mannalithara, A; Sripongpun, P, 2020)
" A 68-year-old woman, who underwent long-term treatment with lamivudine and adefovir for chronic hepatitis B, developed proximal muscle weakness in the four extremities."3.91Toxic myopathy with multiple deletions in mitochondrial DNA associated with long-term use of oral anti-viral drugs for hepatitis B: A case study. ( Fujii, T; Honda, H; Iwaki, T; Kawamura, N; Kira, JI; Takase, KI; Uchiumi, T; Urata, M; Yamasaki, R, 2019)
" He had been receiving adefovir dipivoxil (ADV) for the treatment of entecavir (ETV)-resistant chronic hepatitis B (CHB) for four years in his 8-year treatment of hepatocellular carcinoma (HCC), but was referred to our hospital after increased levels of bone pain in his ribs, knees, and ankles."3.91[Adefovir Dipivoxil-induced Fanconi's Syndrome and Osteomalacia Following Multiple Bone Fractures in a Patient with Chronic Hepatitis B]. ( Ikeda, A; Ikeda, F; Kanzaki, H; Kitamura, Y; Makita, T; Murakawa, K; Nishihara, S; Okada, H; Onishi, H; Sendo, T; Shiraha, H; Takaki, A; Takeuchi, Y; Tanaka, Y; Wada, N; Yasunaka, T, 2019)
" The patient had been treated with lamivudine (LAM) in 2005, LAM+adefovir (ADV) in 2009, and ADV+entecavir in 2015 for chronic hepatitis B (CH-B)."3.91[Marked improvement in renal tubular markers after switching from adefovir to tenofovir alafenamide in a case of Fanconi syndrome diagnosed through high ALP levels]. ( Hiraoka, A; Izumoto, H; Kitahata, S; Kondoh, K; Michitaka, K; Ninomiya, T; Tsubouchi, E; Ueki, H; Yamago, H, 2019)
" 61 HBeAg-positive chronic hepatitis B (CHB) patients treated with pegylated interferon alfa-2a alone or in combination with adefovir (10 mg/day) for 48 weeks were included in this retrospective analysis."3.91Serum hepatitis B virus RNA levels as a predictor of HBeAg seroconversion during treatment with peginterferon alfa-2a. ( Chen, PD; Fan, QQ; Jia, W; Qi, X; Wang, T; Wen, X; Zhang, JM; Zhang, WH; Zhu, MQ, 2019)
"Adefovir dipivoxil (ADV) is one of the most important nucleostide analogues currently in use for the treatment of chronic hepatitis B virus (HBV) infection."3.91Low-dose adefovir dipivoxil-induced hypophosphatemia osteomalacia in five chronic hepatitis B virus-infected patients. Is low-dose adefovir dipivoxil-induced nephrotoxicity completely reversible? ( Dai, ZJ; Jin, J; Pan, YJ; Qian, YY; Ruan, LY; Shi, MT; Wu, CM; Zhu, YX, 2019)
"Renal toxicity of adefovir disoproxil (ADV) and tenofovir disoproxil fumarate (TDF) is a significant concern in chronic hepatitis B (CHB) patients."3.91In Vitro and In Vivo Renoprotective Effects of Telbivudine in Chronic Hepatitis B Patients Receiving Nucleotide Analogue. ( Chan, TM; Fung, J; Lai, CL; Liu, SH; Mak, LY; Seto, WK; Wong, DK; Yap, DY; Yuen, MF, 2019)
" Drugs currently used against HBV include IFN-α that decreases viremia, inflammation and the growth of liver fibrosis, and adefovir that decreases the viral load."3.88Chronic hepatitis B virus and liver fibrosis: A mathematical model. ( Friedman, A; Siewe, N, 2018)
"Adefovir dipivoxil (ADV)-induced renal tubular dysfunction and hypophosphatemic osteomalacia (HO) have been given great consideration in the past few years."3.88Adefovir dipivoxil induced hypophosphatemic osteomalacia in chronic hepatitis B: a comparative study of Chinese and foreign case series. ( Chen, N; Li, LY; Liu, LW; Peng, T; Tang, KX; Yu, F; Yu, X; Zhang, JB; Zhang, Q; Zhao, YP, 2018)
"Few studies have addressed the impact of adefovir dipivoxil (ADV)-based combination therapy on the renal function of patients with chronic hepatitis B (CHB)."3.88Telbivudine and adefovir dipivoxil combination therapy improves renal function in patients with chronic hepatitis B: A STROBE-compliant article. ( Nie, ZW; Xu, Y, 2018)
"None of the patients developed lactic acidosis during follow-up [median: 58 (6-155) months]."3.85Lactate serum concentrations during treatment with nucleos(t)ide analogues in hepatitis B with or without cirrhosis. ( Aggeletopoulou, I; Anastassiou, ED; Assimakopoulos, S; Gogos, C; Kalafateli, M; Labropoulou-Karatza, C; Mandellou, M; Taprantzi, D; Thomopoulos, K; Triantos, C; Tselekouni, P; Tsiaoussis, G; Vourli, G, 2017)
"Although high potent nucleos(t)ide analogues are strongly recommended as first-line therapy for chronic hepatitis B (CHB) in China, some patients are still being treated with adefovir disoproxil (ADV), especially those low-income patients whose health insurance could not reimburse the drug cost."3.85Efficacy and safety of three adefovir-based combination therapies in HBeAg-positive chronic hepatitis B patients with suboptimal response to adefovir monotherapy. ( Chen, EQ; Du, LY; Lei, BJ; Lei, XZ; Liao, J; Lu, JJ; Tang, H; Wang, ML; Yan, LB; Zhang, DM; Zhou, TY, 2017)
"We investigated the durability of virological response after lamivudine (LAM) discontinuation in LAM-resistant chronic hepatitis B (CHB) patients with complete virological response after LAM-adefovir (ADV) combination therapy."3.85Durability of the virological response after lamivudine discontinuation in lamivudine-resistant patients with a complete virological response after lamivudine and adefovir combination therapy. ( Ahn, SH; Han, KH; Kim, BK; Kim, DY; Kim, MN; Kim, SU; Park, JY, 2017)
"Tenofovir disoproxil fumarate (TDF) is recommended as first-line monotherapy for nucleos(t)ide (NA)-naïve chronic hepatitis B (CHB) patients and as a second-line rescue therapy for NA-experienced patients with a previous treatment failure."3.85Long-term efficacy and safety of switching from lamivudine+adefovir to tenofovir disoproxil fumarate in virologically suppressed patients. ( Angarano, G; Fasano, M; Fiore, JR; Leone, A; Maggi, P; Santantonio, TA; Volpe, A, 2017)
"This study compared virologic response to entecavir monotherapy and de novo lamivudine plus adefovir (LAM + ADV) combination therapy in patients with chronic hepatitis B (CHB) with high viral load (HVL)."3.83Comparison of entecavir monotherapy and de novo lamivudine and adefovir combination therapy in HBeAg-positive chronic hepatitis B with high viral load: 48-week result. ( Cai, S; Jiang, Y; Lv, F; Peng, J; Yu, T; Zhang, Y, 2016)
"We investigated the long-term efficacy of adefovir add-on lamivudine rescue therapy in lamivudine-resistant chronic hepatitis B and the optimal cutoff hepatitis B virus (HBV) DNA level that predicts complete virological response (CVR) among patients without CVR after 1 year of treatment."3.83Outcome of adefovir add-on lamivudine rescue therapy of up to 5 years in patients with lamivudine-resistant chronic hepatitis B. ( Ahn, SH; Han, KH; Kim, BK; Kim, DY; Kim, SB; Kim, SU; Park, JY, 2016)
"Lamivudine, telbivudine, and entecavir are the first-line drugs covered by the Taiwan National Health Insurance as 3-year treatments for patients with chronic hepatitis B virus (HBV), but the optimal treatment duration of each remains unclear."3.83Off-treatment efficacy of 3-year nucleos(t)ide analogues in chronic hepatitis B patients. ( Bair, MJ; Chang, CW; Chen, CJ; Chen, MJ; Chu, CH; Hu, KC; Lee, KH; Lin, CC; Lin, SC; Liou, TC; Liu, CY; Shih, SC; Wang, HY; Wang, TE, 2016)
"Lamivudine (LAM) plus adefovir (ADV) combination therapy is clinically efficacious for treating chronic hepatitis B (CHB) patients in China, but no pharmacoeconomic evaluations of this strategy are available."3.83Cost-effectiveness comparison of lamivudine plus adefovir combination treatment and nucleos(t)ide analog monotherapies in Chinese chronic hepatitis B patients. ( Gao, Y; Ke, W; Liu, L; Yang, Y; Yao, Z; Ye, X; Zhang, C; Zhou, S, 2016)
"Entecavir-resistance mutations are commonly induced by entecavir treatment in chronic hepatitis B patients."3.83De novo entecavir+adefovir dipivoxil+lamivudine triple-resistance mutations resulting from sequential therapy with adefovir dipivoxil, and lamivudine. ( Cheng, J; Liu, S; Wang, Q; Wang, X; Xing, H; Yang, S, 2016)
" We aimed to establish if IP-10 expression in liver tissue and in plasma of chronic hepatitis B (CHB) patients correlated with each other and further to investigate if IP-10 levels before and during therapy with peginterferon and adefovir could predict treatment outcome in CHB patients."3.83Intrahepatic IP-10 mRNA and plasma IP-10 levels as response marker for HBeAg-positive chronic hepatitis B patients treated with peginterferon and adefovir. ( de Niet, A; Jansen, L; Kootstra, NA; Reesink, HW; Sinnige, MJ; Takkenberg, RB; Verheij, J; Willemse, SB, 2016)
" He had been receiving low-dose adefovir dipivoxil (ADV, 10 mg/day) for the treatment of chronic hepatitis B virus infection for 7 years and he subsequently developed severe hypophosphatemia and proximal renal tubule dysfunction."3.83Pathologic Femoral Neck Fracture Due to Fanconi Syndrome Induced by Adefovir Dipivoxil Therapy for Hepatitis B. ( Dan, J; Kim, BK; Lee, HJ; Lee, YS, 2016)
"Tenofovir disoproxil fumarate (TDF) is newly available for treatment of chronic hepatitis B patients in China."3.83Cost-effectiveness analysis of tenofovir disoproxil fumarate for treatment of chronic hepatitis B in China. ( Gao, Y; Ke, W; Liu, L; Yang, Y; Yao, Z; Ye, X; Zhang, C; Zhou, S, 2016)
"Adefovir dipivoxil (ADV) is effective for hepatitis B virus (HBV) infection; however, ADV may provoke renal injury resulting in osteomalacia, and this side effect is seldom recognized until bone fractures emerge."3.83Urinary β-2 Microglobulin Levels Sensitively Altered in an Osteomalacia Patient Receiving Add-on Adefovir Dipivoxil Therapy for Hepatitis B Virus Infection. ( Hirase, S; Ito, K; Ito, T; Morishima, T; Morita, H; Ohashi, T; Otake, K; Takagi, J; Yoneda, M, 2016)
"Before tenofovir (TDF) become available in South Korea, combination therapy with entecavir (ETV) and adefovir (ADV) was the most potent regimen for chronic hepatitis B (CHB) patients who fail to respond to rescue therapy for drug resistance."3.83The efficacy of tenofovir-based therapy in patients showing suboptimal response to entecavir-adefovir combination therapy. ( Ahn, SH; Choe, WH; Kim, JH; Kim, KH; Ko, SY; Kwon, SY, 2016)
"Entecavir (ETV) is a potent viral replication inhibitor for chronic hepatitis B (CHB) patients."3.83A five years study of antiviral effect of entecavir in Chinese chronic hepatitis B patients. ( Bao, R; Bao, S; Chen, R; Guo, Q; Liu, K; Liu, Y; Wang, H; Xiang, X; Xie, J; Xie, Q, 2016)
"To analyze the effects of preexisting lamivudine (LAM) resistance and applying antiviral treatment (adefovir [ADV] add-on LAM combination treatment) on long-term treatment outcomes, and comparing the clinical outcomes of antiviral-naïve chronic hepatitis B patients receiving entecavir (ETV) monotherapy."3.83Comparison of the clinical outcomes between antiviral-naïve patients treated with entecavir and lamivudine-resistant patients receiving adefovir add-on lamivudine combination treatment. ( Cho, YK; Choi, KY; Jeon, WK; Jung, YS; Kim, BI; Kim, HJ; Park, DI; Park, JH; Park, SK; Sohn, CI; Yang, HJ, 2016)
"The aim of this study was to evaluate serum kidney injury molecule-1 (KIM-1) as a new diagnostic marker of renal dysfunction in chronic hepatitis B (CHB) patients receiving long-term adefovir dipivoxil (ADV) treatment."3.83Circulating kidney injury molecule-1 is a novel diagnostic biomarker for renal dysfunction during long-term adefovir therapy in chronic hepatitis B. ( Li, Z; Liu, Z; Shen, C; Wang, W; Wang, Y; Zhao, C; Zhao, Q, 2016)
"Tenofovir disoproxil fumarate (TDF) is an established nucleotide analogue in the treatment of chronic hepatitis B."3.81Assessment of bone mineral density in tenofovir-treated patients with chronic hepatitis B: can the fracture risk assessment tool identify those at greatest risk? ( Al-Shamma, S; Barr, DA; Burke, K; Foster, GR; Gill, US; Kallis, YN; Kennedy, PT; Kooner, P; Marley, RT; McPhail, MJ; Zissimopoulos, A, 2015)
"Suboptimal viral suppression with adefovir (ADV) poses a challenge in managing chronic hepatitis B."3.81Safety and efficacy of entecavir in adefovir-experienced patients. ( Do, ST; Garcia, RT; Lutchman, GA; Nguyen, HA; Nguyen, KK; Nguyen, MH; Nguyen, NH; Nguyen, TT; Tran, P; Trinh, HN, 2015)
"The risk of hepatocellular carcinoma (HCC) in Caucasian patients with chronic hepatitis B (CHB), treated with entecavir (ETV) or tenofovir (TDF), is unclear."3.81Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir. ( Arends, P; Buti, M; Colombo, M; Dalekos, GN; Esteban, R; Galanis, K; Gatselis, N; Goulis, J; Hansen, BE; Idilman, R; Janssen, HL; Keskın, O; Lampertico, P; Mangia, G; Manolakopoulos, S; Papaioannou, C; Papatheodoridis, GV; Savvidou, S; Sypsa, V; Yurdaydin, C, 2015)
"Increased risk of defective urinary phosphate reabsorption and osteoporosis has been reported in HIV and chronic hepatitis B (CHB) patients treated with tenofovir disoproxil fumarate (TDF)."3.81Long-term treatment with tenofovir in Asian-American chronic hepatitis B patients is associated with abnormal renal phosphate handling. ( Bae, HS; Chan, LS; Chang, M; Fong, TL; Huh, B; Lee, S; Lim, C; Shinada, S; Tien, C; Xu, JJ, 2015)
"To investigate the association between the baseline profiles and dynamics of hepatitis B virus (HBV) DNA polymerase gene mutations and the long-term virological response of lamivudine (LAM)-adefovir (ADV) combination therapy in patients with LAM-resistant chronic hepatitis B."3.81Long-term outcomes and dynamics of mutants associated with lamivudine-adefovir rescue therapy in patients with lamivudine-resistant chronic hepatitis B. ( Choi, K; Jang, JY; Jeong, SW; Kim, BS; Kim, HS; Kim, J; Kim, SG; Kim, YS; Lee, SH, 2015)
"Tenofovir disoproxil fumarate (TDF) monotherapy is a therapeutic option for chronic hepatitis B (CHB) patients infected with hepatitis B virus (HBV) variants resistant to lamivudine (LAM)."3.81Tenofovir monotherapy versus tenofovir plus lamivudine or telbivudine combination therapy in treatment of lamivudine-resistant chronic hepatitis B. ( Ahn, H; Cho, EJ; Cho, H; Cho, Y; Cho, YY; Choi, WM; Jung, EU; Kim, BH; Kim, CM; Kim, CY; Kim, YJ; Lee, DH; Lee, HS; Lee, JH; Lee, M; Lee, YB; Lee, YJ; Park, JW; Park, SJ; Yoo, JJ; Yoon, JH; Yu, SJ, 2015)
"Chronic hepatitis B pregnant women with normal levels of ALT and high levels of HBV DNA were treated with Telbivudine during the third trimester of their pregnancy."3.81Effect of Peg-interferon α-2a combined with Adefovir in HBV postpartum women with normal levels of ALT and high levels of HBV DNA. ( Chen, X; Chen, Y; Du, X; Liu, Y; Lu, J; Ma, L; Ren, S; Shen, C; Zhang, H; Zhang, S, 2015)
"Entecavir (ETV) plus adefovir (ADV) combination therapy is one of the useful treatment option for the patients with chronic hepatitis B (CHB) who had failed on prior nucleos(t) ide analogue (NA) treatments."3.81Comparison of the efficacies of entecavir 0.5 and 1.0 mg combined with adefovir in patients with chronic hepatitis B who had failed on prior nucleos(t)ide analogue treatments. ( Cho, Y; Kim, YJ; Lee, HS; Lee, JH; Yoon, JH; Yu, SJ, 2015)
"To investigate the predictors of proximal kidney tubular dysfunction (PKTD) induced by adefovir dipivoxil (ADV) treatment for chronic hepatitis B."3.81Predictors of kidney tubular dysfunction induced by adefovir treatment for chronic hepatitis B. ( Furusyo, N; Harada, Y; Hayashi, J; Hayashi, T; Ihara, T; Ikezaki, H; Murata, M; Ogawa, E; Shimizu, M; Toyoda, K, 2015)
" These pregnant females developed lamivudine (LAM)- or telbivudine (LdT)-resistant chronic hepatitis B and received tenofovir (TDF) therapy (300 mg/d), and its curative effect, maternal and perinatal adverse events, fetal growth and development, and neonatal prognosis were evaluated."3.81Tenofovir rescue therapy in pregnant females with chronic hepatitis B. ( Cai, HD; Cao, YJ; Hu, YH; Liu, M; Yi, W, 2015)
"Patients with chronic hepatitis B (HBV DNA load, >17 000 IU/mL) were treated with pegylated interferon alfa-2a and adefovir for 48 weeks."3.81Natural Killer Cell Characteristics in Patients With Chronic Hepatitis B Virus (HBV) Infection Are Associated With HBV Surface Antigen Clearance After Combination Treatment With Pegylated Interferon Alfa-2a and Adefovir. ( de Niet, A; Jansen, L; Kootstra, NA; Reesink, HW; Stelma, F; Takkenberg, RB; Tempelmans Plat-Sinnige, MJ; van Leeuwen, EM, 2015)
"Tenofovir disoproxil fumarate has been used in chronic hepatitis B patients with suboptimal virologic response to nucleos(t)ide analogues."3.81Efficacy of tenofovir switch therapy for nucleos(t)ide-experienced patients with chronic hepatitis B. ( Chan, HL; Chan, HY; Lo, AO; Tse, YK; Wong, GL; Wong, VW, 2015)
"To evaluate urine β2-microglobulin (β2-M), retinol-binding protein (RBP) excretion, and renal impairment with adefovir dipivoxil (ADV) for chronic hepatitis B."3.81Early kidney injury during long-term adefovir dipivoxil therapy for chronic hepatitis B. ( Cai, H; Chen, JY; Ding, F; Hu, JH; Jia, HY; Li, LJ; Lian, JS; Lu, YF; Xiang, DR; Yang, YD; Yu, GD; Yu, L; Zeng, LY; Zhang, YM; Zheng, L, 2015)
"We evaluated the efficacy of tenofovir (TDF)-based rescue therapy and compared the outcomes of TDF monotherapy and TDF-based nucleoside analog (NA) combination therapy in patients with suboptimal response (SOR) to adefovir (ADV) with or without NAs in lamivudine (LAM)-resistant chronic hepatitis B."3.81Tenofovir-based rescue therapy in chronic hepatitis B patients with suboptimal responses to adefovir with prior lamivudine resistance. ( Cheong, JY; Cho, HJ; Cho, SW; Kim, SS; Shin, SJ; Yoo, BM, 2015)
"In chronic hepatitis B patients, lamivudine (LAM) and adefovir (ADV) combination therapy is commonly used as a rescue therapy for LAM resistance, but it often results in incomplete viral suppression."3.81Efficacy of Tenofovir-based Rescue Therapy in Lamivudine-resistant Chronic Hepatitis B Patients With Failure of Lamivudine and Adefovir Combination. ( Bang, SJ; Jeong, ID; Jung, SW; Kim, BG; Kim, CJ; Kim, MH; Lee, BU; Park, BR; Park, JH; Park, NH; Shin, JW, 2015)
"In the past decade, many chronic hepatitis B (CHB) patients have undergone sequential treatment with lamivudine (LAM), adefovir (ADV), and entecavir (ETV) to manage antiviral resistance or insufficient suppression of HBV-DNA."3.81Tenofovir-based rescue therapy for chronic hepatitis B patients who had failed treatment with lamivudine, adefovir, and entecavir. ( Bang, SJ; Jeong, ID; Jung, SW; Kim, BG; Kim, CJ; Kim, EH; Kim, JH; Kim, MH; Lee, BU; Park, BR; Park, JH; Park, NH; Shin, JW; Sung, SJ, 2015)
"To compare the efficacy of telbivudine monotherapy and telbivudine combination therapy with adefovir in patients with nucleos(t)ide-naive chronic hepatitis B, high-level hepatitis B virus (HBV) load and hepatitis B e antigen (HBeAg)-positivity, and to explore the relationship between treatment regimen adherence and treatment outcomes."3.81[Efficacy and safety of telbivudine alone and combined with adefovir for the treatment of nucleos(t)ide-naive chronic hepatitis B in patients with high-level hepatitis B virus load]. ( Dang, B; Kang, W; Liu, Q; Sun, Y; Wang, C; Yao, N; Yu, Z; Zhao, K, 2015)
"To investigate the effects of adefovir dipivoxil (ADV) on blood phosphorus metabolism in patients with chronic hepatitis B (CHB)."3.81[Adefovir dipivoxil effects on and related factors of blood phosphorus metabolism in patients with chronic hepatitis B]. ( Ding, G; Kang, Y; Li, K; Li, W; Mao, Z; Ning, H; Shang, J; Xiao, E, 2015)
"To evaluate the long-term efficacy adefovir (ADV)-based combination therapies in entecavir (ETV)-resistant chronic hepatitis B (CHB) patients."3.81Management of entecavir-resistant chronic hepatitis B with adefovir-based combination therapies. ( Hwang, SG; Jang, MK; Jeong, SH; Jung, YK; Kim, BH; Kim, HS; Kim, IH; Kim, JH; Kim, JW; Kim, SG; Kim, TY; Kim, YS; Lee, JI; Lee, JW; Lee, SH; Park, H; Park, JW; Park, SJ; Seo, YS; Suh, SJ; Yim, HJ, 2015)
"We compared the efficacies of entecavir (ETV) plus tenofovir (TDF) and ETV plus adefovir (ADV) in chronic hepatitis B (CHB) patients with genotypic resistance to lamivudine (LAM) who showed a suboptimal response to LAM and ADV combination therapy."3.81Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy. ( Park, JG; Park, SY, 2015)
"To observe the clinical efficacy of combination therapy with peg-IFNalpha and adefovir (CPIA) in women who were hepatfis B virus (HBV) carriers and had just given birth and received telbivudine (LdT) during pregnancy for prevention of mother-to-child transmission."3.81[Efficacy of combination antiviral therapy following childbirth in pregnant HBV carriers receiving telbivudine for prevention of mother-to-child transmission]. ( Cao, ZH; Chen, XY; He, ZM; Jin, Y; Liu, YL; Lu, JF; Ma, LN; Zhang, SB, 2015)
"Renal dysfunction and Fanconi's syndrome associated with hypophosphatemia caused by long-term administration of low-dose adefovir dipivoxil (ADV) has been reported in recent years."3.80Renal dysfunction and hypophosphatemia during long-term lamivudine plus adefovir dipivoxil therapy in patients with chronic hepatitis B. ( Akuta, N; Arase, Y; Hara, T; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Saitoh, S; Seko, Y; Sezaki, H; Suzuki, F; Suzuki, Y; Tanaka, M, 2014)
"Few studies have investigated the emergence of multidrug resistance to adefovir dipivoxil (ADV) plus lamivudine (LAM) combination therapy for patients with LAM-refractory chronic hepatitis B (CHB)."3.80Long-term efficacy and emergence of multidrug resistance in patients with lamivudine-refractory chronic hepatitis B treated by combination therapy with adefovir plus lamivudine. ( Akuta, N; Arase, Y; Hara, T; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Mineta, R; Saitoh, S; Sezaki, H; Suzuki, F; Suzuki, Y; Watahiki, S, 2014)
"We investigated the long-term efficacy of entecavir (ETV) + adefovir (ADV) combination therapy versus ETV monotherapy in lamivudine (LAM)-resistant chronic hepatitis B (CHB) patients who failed to respond to ADV rescue therapy."3.80Long-term efficacy of entecavir plus adefovir combination therapy versus entecavir monotherapy in adefovir refractory chronic hepatitis B patients with prior lamivudine resistance. ( Kim, DG; Kim, IH; Kim, SH; Kim, SW; Lee, S; Lee, SO; Lee, ST; Seo, SY; Sohn, JY, 2014)
"Previous studies have demonstrated that the treatment of chronic hepatitis B (CHB) infection with adefovir (ADV) can impair renal function."3.80Telbivudine protects renal function in patients with chronic hepatitis B infection in conjunction with adefovir-based combination therapy. ( Kim, HY; Kim, YJ; Lee, HJ; Lee, HS; Lee, JH; Lee, M; Oh, S; Yeum, TS; Yoon, JH; Yu, SJ, 2014)
"Entecavir (ETV) plus adefovir (ADV) combination therapy may be a promising option for chronic hepatitis B (CHB) patients who have failed on prior nucleos(t)ide analog (NA) treatment."3.80Efficacy of 2years of entecavir plus adefovir therapy in patients with chronic hepatitis B who had failed on prior nucleos(t)ide analog treatment. ( Wang, X; Wang, Y; Xiong, Y; Zhang, C; Zhu, Y, 2014)
"Entecavir (ETV) and tenofovir disoproxil fumarate (TDF) are the two first-line anti-viral therapies for chronic hepatitis B (CHB); however, there are limited studies directly comparing their effectiveness."3.80Tenofovir is superior to entecavir for achieving complete viral suppression in HBeAg-positive chronic hepatitis B patients with high HBV DNA. ( Gao, L; Li, J; Nguyen, MH; Trinh, HN, 2014)
"We investigated the efficacy and safety of tenofovir disoproxil fumarate (TDF)-based treatment in chronic hepatitis B (CHB) patients who failed previous antiviral therapies."3.80Efficacy and safety of tenofovir-based rescue therapy for chronic hepatitis B patients with previous nucleo(s/t)ide treatment failure. ( Byun, KS; Choe, WH; Kim, JH; Kim, YS; Kwon, SY; Lee, CH; Lee, CI; Yeon, JE; Yoon, EL, 2014)
"Tenofovir (TDF) has similar antiviral efficacy in both treatment-naive and lamivudine-resistant chronic hepatitis B (CHB) patients."3.80Efficacy of tenofovir in adefovir-experienced patients compared with treatment-naive patients with chronic hepatitis B. ( Akyüz, F; Badur, S; Baran, B; Bozdayi, AM; Idilman, R; Kabaçam, G; Karatayli, E; Karatayli, S; Kaymakoglu, S; Keskin, O; Onel, D; Ormeci, AC; Tüzün, A; Yurdaydin, C, 2014)
" The first choice of therapy in chronic hepatitis B infection can be pegylated interferon for 48 weeks or continuous entecavir or tenofovir therapy."3.80[Diagnosis and treatment of chronic hepatitis B and D. Hungarian national consensus guideline]. ( Gervain, J; Horváth, G; Hunyady, B; Lengyel, G; Makara, M; Pár, A; Szalay, F; Telegdy, L; Tornai, I, 2014)
"Only lamivudine has been included for patients with chronic hepatitis B (CHB) in the National List of Essential Drugs (NLED), a pharmaceutical reimbursement list in Thailand."3.80A cost-utility analysis of drug treatments in patients with HBeAg-positive chronic hepatitis B in Thailand. ( Chaikledkaew, U; Tantai, N; Tanwandee, T; Teerawattananon, Y; Werayingyong, P, 2014)
"The role of quantitative hepatitis B surface antigen (HBsAg) levels in patients receiving highly potent oral antiviral therapy is controversial, and here, we determined the HBsAg response in 121 chronic hepatitis B patients treated with tenofovir 300 mg daily."3.80Relevance of hepatitis B surface antigen levels in patients with chronic hepatitis B during 5 year of tenofovir treatment. ( Gupta, E; Hissar, SS; Sarin, SK; Sharma, MK; Singh, AK, 2014)
"The aim of the present study was to assess the long-term impact of entecavir (ETV) on T, B and natural killer (NK) cell immunity in patients with suboptimal responses to adefovir (SRA) chronic hepatitis B (CHB)."3.80Effects of entecavir on peripheral blood lymphocyte profiles in chronic hepatitis B patients with suboptimal responses to adefovir. ( Hu, X; Jiang, Y; Wang, Q; Zhang, L; Zhao, P, 2014)
"In chronic hepatitis B patients treated with peginterferon and adefovir, we identified strong associations of SLC16A9 gene variation and carnitine levels with HBsAg loss."3.80HBsAg loss in patients treated with peginterferon alfa-2a and adefovir is associated with SLC16A9 gene variation and lower plasma carnitine levels. ( Chin, DJ; de Niet, A; Jansen, L; Kootstra, NA; Lopatin, U; Plat-Sinnige, MJ; Reesink, HW; Stelma, F; Takkenberg, RB; van Dort, KA; van Iperen, EP; Zwinderman, AH, 2014)
"Tenofovir disoproxil fumarate (TDF) is recommended as treatment for chronic hepatitis B patients harboring lamivudine-associated resistance mutations (LAM-R, rtM204V/I ± rtL180M)."3.80Evaluation of HBV DNA decay kinetics in patients containing both rtM204V/I mutant and wild-type HBV subpopulations during tenofovir DF (TDF) monotherapy or combination therapy with emtricitabine (FTC)/TDF. ( Dinh, P; Flaherty, JF; Fung, S; Gane, EJ; Kitrinos, KM; Liu, Y; Miller, MD; Svarovskaia, ES, 2014)
" Fifteen HBeAg-positive chronic hepatitis B (CHB) patients were treated with adefovir dipivoxil."3.80Decline in intrahepatic cccDNA and increase in immune cell reactivity after 12 weeks of antiviral treatment were associated with HBeAg loss. ( Chen, J; Chen, LH; Dong, J; Gao, LY; Jiang, JJ; Liu, YR; You, J; Zeng, DW; Zheng, Q; Zhu, YY, 2014)
"Knowledge on Hepatitis B surface antigen (HBsAg) kinetics in chronic hepatitis B (CHB) patients with long-term adefovir dipivoxil (ADV) treatment is limited."3.80Kinetics of serum HBsAg in Chinese patients with chronic HBV infection with long-term adefovir dipivoxil treatment. ( Hou, F; Huo, N; Li, F; Li, M; Wang, Q; Xi, H; Xu, X; Zhang, X, 2014)
"Since the licensing of lamivudine in 1999, the treatment of chronic hepatitis B has been revolutionized by the introduction of oral nucleoside and nucleotide analogues (NAs), which act as inhibitors of the HBV polymerase."3.80Antiviral therapy of chronic hepatitis B. ( Berg, T; van Bömmel, F, 2014)
"A 64-year-old woman was prescribed lamivudine and adefovir (ADV) for chronic hepatitis B."3.80[A case of chronic hepatitis B managed with continued adefovir despite treatment-related Fanconi syndrome and osteomalacia]. ( Asahina, Y; Iizuka, K; Iizuka, Y; Ito, E; Kobayashi, K; Mochizuki, N; Sakai, H; Watanabe, M, 2014)
"In chronic hepatitis B patients with kidney transplantation, sequential monotherapy with antiviral agents with low barriers to resistance should be avoided, and initial therapy with entecavir is a better option."3.80Efficacy and safety of tenofovir in a kidney transplant patient with chronic hepatitis B and nucleos(t)ide multidrug resistance: a case report. ( Shan, C; Wu, P; Yin, GQ, 2014)
"To evaluate the efficacy and safety of tenofovir disoproxil fumarate (TDF) in patients with chronic hepatitis B (CHB) after failure of nucleoside-analogues (NAs)."3.80[Efficacy of 48-week tenofovir disoproxil fumarate therapy in patients who were unresponsive to nucleoside-analogue treatments]. ( Ao, Y; Chong, Y; Huang, M; Jie, Y; Li, X; Lin, G; Pang, Y; Shi, H; Tao, L; Wu, Y; Yang, F; Zhang, M, 2014)
"To investigate the treatment efficacy of adefovir dipivoxil combined with a corticosteroid on hepatitis B virus-associated glomerulonephritis (HBV-GN)."3.80Efficacy of adefovir dipivoxil combined with a corticosteroid in 38 cases of nephrotic syndrome induced by hepatitis B virus-associated glomerulonephritis. ( Li, H; Qiu, L; Xiao, P; Yuan, X; Zhou, Q, 2014)
"This study investigated the antiviral efficacy of adefovir (ADV) rescue therapy and the feasibility of lamivudine (LAM) discontinuation in LAM-resistant chronic hepatitis B (CH-B) patients who had attained a virological response (VR) with LAM + ADV combination therapy."3.80The feasibility of discontinuing lamivudine in lamivudine-resistant chronic hepatitis B patients on lamivudine and adefovir combination therapy. ( Byoun, YS; Chung, SM; Jang, ES; Jeong, SH; Kim, HS; Kim, JW, 2014)
"Adefovir (ADV) resistance is more frequent in lamivudine (LMV)-resistant chronic hepatitis B (CHB) patients than in nucleos(t)ide analogue-naïve patients."3.80Different mechanism of selection of adefovir-resistant mutant viruses during adefovir monotherapy in patients with lamivudine-resistant chronic hepatitis B. ( Cho, YK; Cui, XJ; Jeong, SU; Song, BC, 2014)
"This study assessed the antiviral efficacy and safety of tenofovir disoproxil fumarate (TDF) for up to 12 months in Korean treatment-naïve chronic hepatitis B (CHB) patients."3.80Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide-naïve chronic hepatitis B patients in Korea: data from the clinical practice setting in a single-center cohort. ( Ahn, SH; Ahn, SS; Chon, YE; Han, KH; Kim, BK; Kim, DY; Kim, SU; Park, JY, 2014)
"Adefovir (ADV) and lamivudine (LAM) combination therapy (ADV+LAM) has been a useful option for patients with LAM-resistant (LAM-r) chronic hepatitis B (CHB)."3.80Long-term outcomes of two rescue therapies in lamivudine-refractory patients with chronic hepatitis B: combined lamivudine and adefovir, and 1-mg entecavir. ( Ahn, DG; Baek, EK; Cho, HJ; Chung, HW; Kim, HJ; Kwon, JC; Lee, H; Lee, JJ; Ze, E, 2014)
" Here, we describe two additional patients with chronic hepatitis B (CHB) who developed a TDF-induced Fanconi syndrome that reverted after TDF withdrawal and had viral replication fully suppressed upon switching to entecavir (ETV)."3.80Tenofovir-induced Fanconi syndrome in chronic hepatitis B monoinfected patients that reverted after tenofovir withdrawal. ( Brocchieri, A; Castelli, F; Colombo, M; Facchetti, F; Fugazza, A; Lampertico, P; Mangia, G; Spinetti, A; Viganò, M; Zaltron, S, 2014)
"Tenofovir (300 mg/d) is an effective and safe rescue therapy in chronic hepatitis B patients who failed initial treatment with LAM and secondary treatment of LAM plus ADV."3.80[Tenofovir rescue therapy for chronic hepatitis B patients after suboptimal response to treatment with lamivudine plus adefovir dipivoxil]. ( Fan, H; Fan, Y; Ge, Y; Li, D; Liu, X; Liu, Z; Lyu, W; Yang, H; Zhou, B, 2014)
"There is very limited experience in the management of telbivudine (LdT)-associated virological breakthrough (VBT) and resistance in the treatment of chronic hepatitis B (CHB) patients, and the guideline recommendations are primitively based on the general principles of rescue therapy to nucleos(t)ide analog resistance."3.79Telbivudine plus adefovir therapy for chronic hepatitis B patients with virological breakthrough or genotypic resistance to telbivudine. ( Bai, XF; Huang, CX; Li, Y; Lian, JQ; Wang, JP; Zhang, Y, 2013)
"Chronic hepatitis B patients (CHB) treated with adefovir were followed up to evaluate nephrotoxicity and its outcome."3.79Resolution of adefovir-related nephrotoxicity by adefovir dose-reduction in patients with chronic hepatitis B. ( Aung, MO; Chiu, LL; Dan, YY; Gowans, M; Hartono, JL; Khoo, MJ; Koay, E; Lee, GH; Lee, YM; Lim, K; Lim, SG; Low, HC; Soon, C; Tan, PS; Thwin, MA, 2013)
"A 55-year-old male patient with chronic hepatitis B was started on tenofovir."3.79Geographic tongue and tenofovir. ( Costa, JB; Ferreira, AO; Marinho, RT; Velosa, J, 2013)
"In patients with lamivudine (LAM)-resistant chronic hepatitis B (CHB) receiving adefovir (ADV) add-on LAM therapy, insufficient viral suppression or the appearance of additional ADV resistance has remained unresolved."3.79Partial virological response to adefovir add-on lamivudine rescue therapy in patients with lamivudine-resistant chronic hepatitis B. ( Ahn, SH; Choi, A; Chon, CY; Chon, YE; Han, KH; Kim, DY; Kim, SU; Park, JY, 2013)
"To evaluate the efficacy and safety of Entecavir (ETV) plus adefovir (ADV) for chronic hepatitis B (CHB) patients after multiple nucleos(t)ide analogue (NAs) failure treatment."3.79Entecavir plus adefovir rescue therapy for chronic hepatitis B patients after multiple treatment failures in real-life practice. ( Deng, JY; He, FQ; Li, GL; Li, JY; Li, Q; Pan, QR; Qin, Y; Xu, XH, 2013)
"Tenofovir disoproxil fumarate (TDF) is increasingly used in patients with chronic hepatitis B (CHB) infection."3.79Tenofovir-associated Fanconi syndrome in patients with chronic hepatitis B monoinfection. ( Gracey, DM; McKenzie, P; Snelling, P; Strasser, SI, 2013)
" A total of 71 subjects under follow-up for chronic hepatitis B and receiving lamivudine (LVD) therapy for one year or longer at the Hacettepe University Faculty of Medicine, Department of Internal Medicine, Gastroenterology Unit were included in the study with informed consent."3.79[Detection of resistance mutations in chronic hepatitis B patients receiving antiviral therapy for over one year]. ( Alp, A; Aydoğan, S; Balaban, Y; Ergünay, K; Hasçelik, G; Simşek, H; Tatar, G; Us, D, 2013)
"The aim of this study was to compare the effect of combination lamivudine (LAM) and adefovir dipivoxil (ADV) versus entecavir (ETV) monotherapy for naïve HBeAg-positive chronic hepatitis B (CHB) patients."3.79Combination lamivudine and adefovir versus entecavir for the treatment of naïve chronic hepatitis B patients: a pilot study. ( Cai, FJ; Ding, JG; Du, QW; Fu, RQ; Hong, L; Sun, QF; Wu, YH; Zhou, QQ, 2013)
"The aim of our study was to validate the roadmap concept in the treatment of chronic hepatitis B, and to investigate the virologic efficacy and kinetics of quantitative hepatitis B surface antigen (qHBsAg) during telbivudine therapy in a real-world setting."3.79Real-world application of the roadmap model in chronic hepatitis B patients with telbivudine therapy. ( Hsu, PI; Lai, KH; Lin, KH; Tsai, TJ; Tsay, FW; Wang, HM; Yu, HC, 2013)
"Patients with chronic hepatitis B treated with tenofovir or entecavir were included in this retrospective study."3.79Comparison of tenofovir and entecavir in patients with chronic HBV infection. ( Akkoyunlu, Y; Ceylan, B; Eren, G; Fincanci, M; Muderrisoglu, C; Tozalgan, U; Yardimci, C, 2013)
"Treatment strategies for entecavir (ETV)-resistant chronic hepatitis B (CHB) patients are not yet well established."3.79Efficacy of adefovir-based combination therapy for patients with Lamivudine- and entecavir-resistant chronic hepatitis B virus infection. ( Cho, Y; Cho, YY; Choi, WM; Kim, CY; Kim, YJ; Lee, DH; Lee, HS; Lee, JH; Lee, M; Lee, YB; Yoo, JJ; Yoon, JH; Yu, SJ, 2013)
"Lamivudine (LAM) plus adefovir (ADV) combination therapy has been accepted as one of the best treatments for LAM-resistant chronic hepatitis B (CHB)."3.79Lamivudine plus adefovir combination therapy for lamivudine resistance in hepatitis-B-related hepatocellular carcinoma patients. ( Choe, WH; Kim, JH; Ko, SY; Kwon, SY; Lee, CH, 2013)
"In the current study we aimed to show the common YMDD motif mutations in viral polymerase gene in chronic hepatitis B patients during lamivudine and adefovir therapy."3.79Prevelance of common YMDD motif mutations in long term treated chronic HBV infections in a Turkish population. ( Alagozlu, H; Coskun, M; Koksal, B; Ozdemir, O; Yilmaz, A, 2013)
" Adefovir, entecavir, tenofovir and lamivudine (with rescue therapy in cases of viral resistance) were compared for treating adult patients with chronic hepatitis B undergoing treatment for the first time, with high levels of alanine aminotransferase, no evidence of cirrhosis and without HIV co-infection."3.79Incorporated antivirals for chronic hepatitis B in Brazil: a cost-effectiveness analysis. ( Acurcio, Fde A; Almeida, AM; Andrade, EI; Brandão, CM; Cherchiglia, ML; Oliveira, GL; Silva, AL, 2013)
"To investigate the efficacy and safety ofTelbivudine +Tenofovir combination therapy in chronic hepatitis B patients, over a period of 52 weeks, in real life clinical settings."3.79Telbivudine plus tenofovir in combination therapy in patients with chronic hepatitis B infection--an Indian experience. ( Panda, C, 2013)
" We investigated the long-term safety and efficacy of these antiviral drugs in patients with chronic hepatitis B virus (HBV) infection, with compensated or decompensated cirrhosis, and compared results with those from lamivudine."3.79Long-term efficacy and safety of lamivudine, entecavir, and tenofovir for treatment of hepatitis B virus-related cirrhosis. ( Akbal, E; Akin, E; Alkan, E; Ataseven, H; Aygün, C; Başar, O; Baykal, O; Coban, S; Demir, M; Gülşen, MT; Ibiş, M; Koçkar, MC; Köklü, S; Köksal, AŞ; Küçükazman, M; Nadir, I; Ozdil, K; Pürnak, T; Tuna, Y; Yildirim, B; Yüksel, I; Yüksel, O, 2013)
"The efficacy of adefovir (ADV) plus entecavir (ETV) combination in patients with chronic hepatitis B (CHB) who developed multidrug refractoriness had not been fully evaluated."3.79The efficacy of adefovir plus entecavir combination therapy in patients with chronic hepatitis B refractory to both lamivudine and adefovir. ( Cho, EJ; Cho, Y; Chung, KH; Jeong, SH; Jin, E; Kim, CY; Kim, JW; Kim, YJ; Lee, DH; Lee, HS; Lee, JH; Yoon, JH; Yu, SJ, 2013)
"Fifty-three patients with confirmed genotypic lamivudine-resistant chronic hepatitis B were treated with entecavir."3.79The short-term efficacy of entecavir in lamivudine-resistant chronic hepatitis B: influence of sequential adefovir-refractoriness. ( Choi, DJ; Jung, YK; Kim, JH; Kim, YS; Ku, YS; Kwon, OS, 2013)
"To compare the efficacy of rescue therapies in lamivudine (LAM)-resistant chronic hepatitis B (CHB) infections including: (1) adefovir dipivoxil (ADV) monotherapy, (2) ADV plus LAM combination therapy and (3) entecavir (ETV) 1."3.79Treatment of lamivudine-resistant chronic hepatitis B infection: a multicenter retrospective study. ( Ahn, SH; Hong, SP; Hwang, SG; Kim, BH; Kim, HS; Kim, IH; Kim, JH; Lee, JI; Lee, JM; Lee, JW; Lee, SH; Lee, SJ; Park, SJ; Park, YM; Seo, YS; Yim, HJ; Yoon, EL, 2013)
"We studied the cost-effectiveness of tenofovir and entecavir in e antigen positive (CHBe+) and negative (CHBe-) chronic hepatitis B."3.79Should chronic hepatitis B be treated as early as possible? ( Colle, I; Gamil, M; Horsmans, Y; Hulstaert, F; Nevens, F; Schwierz, C; Thiry, N; Van de Sande, S, 2013)
"We evaluated the efficacy of tenofovir disoproxil fumarate (TDF) in patients with lamivudine failure (LAM-F) in comparison with that in nucleoside/nucleotide analogue (NA)-naïve patients with chronic hepatitis B (CHB)."3.79Efficacy of tenofovir in patients with Lamivudine failure is not different from that in nucleoside/nucleotide analogue-naive patients with chronic hepatitis B. ( Akyuz, F; Badur, S; Baran, B; Besisik, F; Bozbey, HU; Demir, K; Evirgen, S; Gokturk, S; Gulluoglu, M; Karaca, C; Kaymakoglu, S; Onel, D; Ormeci, AC; Soyer, OM, 2013)
"The availability of entecavir is economically attractive as part of early treatment for patients with chronic hepatitis B without HIV co-infection."3.78[Cost-effectiveness of nucleoside/nucleotide analogues in chronic hepatitis B]. ( Acurcio, Fde A; Almeida, AM; Andrade, EI; Araújo de Oliveira, GL; Brandão, CM; Carmo, RA; Cherchiglia, ML; Silva, AL, 2012)
"To understand the genotype characteristics and its evolution of patients with poor response to initial combined treatment of Lamivudine and Adefovir dipivoxil for chronic hepatitis B."3.78[Genotypes and evolution characteristics of three patients with poor response to initial treatment of Lamivudine and Adefovir dipivoxil for hepatitis]. ( Huang, XX; Lou, GQ; Shi, JP; Wang, J; Wu, J; Zhu, MF, 2012)
"We intended to investigate the effects of pre-existing mutations at reverse transcriptase region of hepatitis B virus (HBV) on the occurrence of virological breakthrough (VB) to adefovir dipivoxil (ADV) in patients with lamivudine (LAM)-resistant chronic hepatitis B (CHB)."3.78rtL180M mutation of hepatitis B virus is closely associated with frequent virological resistance to adefovir dipivoxil therapy. ( Chung, YH; Jin, YJ; Kim, JA; Kim, KM; Kim, SE; Lee, D; Lee, HC; Lee, YS; Lim, YS; Park, WH; Shim, JH; Suh, DJ, 2012)
"Before tenofovir approval for chronic hepatitis B therapy, the clinical management of patients with suboptimal response or virological breakthrough during combination treatment with lamivudine and adefovir dipivoxil was a difficult clinical challenge."3.78High dose lamivudine in HBV-related cirrhotic patients with unsatisfactory response after adefovir add-on. ( Aldini, R; Azzaroli, F; Buonfiglioli, F; Galli, S; Giandinoto, M; Lisotti, A; Mazzella, G; Montagnani, M; Turco, L, 2012)
"The impact of adefovir dipivoxil (ADV) treatment on the immune system in patients with chronic hepatitis B (CHB) is unknown."3.78Adefovir dipivoxil modulates cytokine expression in Th1/Th2 cells in patients with chronic hepatitis B. ( Liu, YY; Ma, ZH; Niu, JQ; Piao, RL; Tian, D; Zhang, M; Zhao, C, 2012)
"A male 36 years old patient diagnosed with anti HBe-positive chronic hepatitis B (CHB) had received lamivudine treatment for 7 years following an initial unsuccessfull interferon treatment."3.78Molecular characterization of a novel entecavir mutation pattern isolated from a multi-drug refractory patient with chronic hepatitis B infection. ( Bozdayi, AM; Cinar, K; Gokahmetoglu, S; Güven, K; Idilman, R; Karatayli, E; Karatayli, SC; Yurdaydin, C, 2012)
"Adefovir is usually applied for therapy of chronic hepatitis B (CHB), but its effectiveness after cessation is still unknown."3.78A prospective clinical study in hepatitis B e antigen-negative chronic hepatitis B patients with stringent cessation criteria for adefovir. ( Diao, S; Ha, M; Huang, C; Huang, Z; Kuan, C; Lin, M; She, H; Shen, L; Shen, W; Sun, L; Zhang, G, 2012)
"The optimal treatment of patients with chronic hepatitis B (CHB) who develop resistance to both lamivudine (LMV) and entecavir (ETV) after sequential monotherapy of LMV and ETV remains little known."3.78Efficacy of entecavir and adefovir combination therapy for patients with lamivudine- and entecavir-resistant chronic hepatitis B. ( Cha, JM; Jeon, JW; Joo, KR; Kim, S; Lee, JI; Lim, JU; Lim, K; Park, JJ; Shin, HP, 2012)
"A total of 559 chronic hepatitis B (CHB) patients who had been treated for at least 12 months with adefovir add-on therapy due to resistance to lamivudine were retrospectively included."3.78Viral response at 6 months is associated with treatment outcome of adefovir add-on therapy for lamivudine-resistance. ( Choi, MS; Gwak, GY; Kim, YJ; Koh, KC; Lee, JH; Paik, SW; Sinn, DH; Yoo, BC, 2012)
"We investigated serum viral kinetics and peripheral blood lymphocyte dynamics in chronic hepatitis B patients during the first year of tenofovir therapy."3.78Peripheral blood lymphocyte dynamics and viral kinetics in patients with chronic active hepatitis B virus infection treated by tenofovir. ( Arasli, M; Buyukuysal, C; Delikanli, B; Harmandar, F; Ustundag, Y, 2012)
"The combination of entecavir, a nucleoside analogue, and adefovir, a nucleotide analogue, would be a promising salvage treatment for chronic hepatitis B (CHB) patients who fail nucleoside/nucleotide analogue (NA) regimens."3.78Entecavir plus adefovir combination treatment for chronic hepatitis B patients after failure of nucleoside/nucleotide analogues. ( Heo, NY; Lee, HC; Lee, TH; Lim, YS; Shim, JH; Suh, DJ, 2012)
"Among 141 HIV-HBV-coinfected patients treated with tenofovir in our centre, 87% were good-responders to therapy."3.78Quasispecies analysis and in vitro susceptibility of HBV strains isolated from HIV-HBV-coinfected patients with delayed response to tenofovir. ( Branger, M; Collin, G; Fraqueiro, G; Gervais, A; Lada, O; Leclerc, L; Marcellin, P; Martinot-Peignoux, M; Matheron, S; Moucari, R; Peytavin, G; Roquebert, B, 2012)
"The aim of this study was to investigate the relationship between HBV DNA levels at baseline and on-treatment and the virological response at 96 weeks after adefovir add-on therapy in chronic hepatitis B (CHB) patients with lamivudine resistance."3.78HBV DNA level at 24 weeks is the best predictor of virological response to adefovir add-on therapy in patients with lamivudine resistance. ( Bang, SJ; Du Jeong, I; Eum, JB; Jung, SW; Kim, BG; Kim, CJ; Park, BR; Park, NH; Shin, JW, 2012)
" entecavir (ETV) monotherapy in HBeAg-positive hepatitis B patients who fail to respond to sequential treatment with LAM and ADV."3.78Lamivudine plus adefovir vs. entecavir in HBeAg-positive hepatitis B with sequential treatment failure of lamivudine and adefovir. ( Ahn, SH; Chon, CY; Han, KH; Kim, DY; Lee, JM; Lee, MH; Park, JY; Ryu, HJ; Son, CY, 2012)
"Adefovir and tenofovir are nucleotide analogues used as long-term therapy of chronic hepatitis B."3.78Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B. ( Chong, WH; Collins, MT; Gara, N; Ghany, MG; Hoofnagle, JH; Jake Liang, T; Kleiner, DE; Zhao, X, 2012)
"Tenofovir is a nucleotide reverse-transcriptase inhibitor approved for treatment of human immunodeficiency virus infection, as well as chronic hepatitis B (CHB)."3.78Similar risk of renal events among patients treated with tenofovir or entecavir for chronic hepatitis B. ( Baqai, S; Clark, MD; Gish, RG; Kane, SD; Mangahas, MF; Shaw, RE, 2012)
"To evaluate the changes in the renal function of patients with chronic hepatitis B (CHB) receiving adefovir dipivoxil (ADV) or telbivudine (L-DT) monotherapy."3.78[Influence of adefovir dipivoxil or telbivudine monotherapy on renal function of patients with chronic hepatitis B]. ( Fan, R; Guo, Y; Hou, J; Li, X; Peng, J; Sun, J; Yang, S; Zhong, C, 2012)
"In the first year of treatment for chronic hepatitis B, virologic response and tolerability did not differ significantly between tenofovir and entecavir."3.78Comparison of the efficacy of tenofovir and entecavir for the treatment of nucleos(t)ide-naive patients with chronic hepatitis B. ( Akin, MS; Doğan, ÜB; Gümürdülü, Y; Kara, B; Soylu, A, 2012)
"We present a case of a 62-year-old man who underwent total hip arthroplasty for treatment of pathologic femoral neck fracture associated with adefovir dipivoxil-induced osteomalacia."3.78Pathological femoral fractures due to osteomalacia associated with adefovir dipivoxil treatment for hepatitis B: a case report. ( Arishima, Y; Hirotsu, M; Ishidou, Y; Kakoi, H; Kamizono, J; Komiya, S; Nagano, S; Nakamura, S; Saitoh, Y; Setoguchi, T; Tanaka, M; Yokouchi, M, 2012)
"There is a paucity of data on the long-term efficacy of combination lamivudine and adefovir therapy in patients with lamivudine-resistant chronic hepatitis B."3.78Outcome of lamivudine-resistant chronic hepatitis B after up to 5 years of combination therapy with adefovir. ( Fung, J; Hung, IF; Lai, CL; Liu, K; Seto, WK; Wong, DK; Yuen, JC; Yuen, MF, 2012)
"Lamivudine (LAM) resistance now poses a major problem in the management of patients with chronic hepatitis B virus (HBV) infection."3.78Comparison of rescue strategies in lamivudine-resistant patients with chronic hepatitis B. ( Huang, L; Li, T; Wang, C; Xu, D; Zhao, P, 2012)
"The patient cohort included four adult chronic hepatitis B patients who had undergone sequential monotherapy, first with lamivudine (LMV) and then, after developing viral breakthrough, with adefovir (ADV) therapy."3.78Clonal evolution of hepatitis B virus polymerase gene mutations during lamivudine-adefovir combination treatment. ( Choe, WH; Kim, BK; Kim, JH; Kim, KH; Ko, SY; Kwon, SY; Lee, CH, 2012)
" To evaluate the resistance to adefovir (ADV) therapy in patients with chronic hepatitis B infection, a study was conducted on 70 patients (63 males and 7 females), who had received in first line lamivudine and second line adefovir."3.78Use of ALLGIO probe assays for detection of HBV resistance to adefovir in patients with chronic hepatitis B, Kerman, Iran. ( Afshar, RM; Mollaie, HR, 2012)
"To investigate retrospectively the long-term efficacy of various treatment strategies using adefovir dipivoxil (adefovir) in patients with lamivudine-resistant chronic hepatitis B."3.78Treatment strategies using adefovir dipivoxil for individuals with lamivudine-resistant chronic hepatitis B. ( An, H; Chun, HJ; Jeen, YT; Jung, JY; Keum, B; Kim, CD; Kim, CH; Kim, JD; Kim, YS; Lee, HS; Ryu, HS; Seo, YS; Um, SH; Yim, HJ; Yun, TJ, 2012)
"To investigate the efficacy of long-term lamivudine (3TC) and adefovir dipivoxil (ADV) combination therapy in 3TC-resistant chronic hepatitis B virus (HBV) infected patients, we analysed 28 3TC-resistant patients treated with the combination therapy during 47 months (range, 9-75)."3.77Four-year study of lamivudine and adefovir combination therapy in lamivudine-resistant hepatitis B patients: influence of hepatitis B virus genotype and resistance mutation pattern. ( Fukushima, K; Inoue, J; Iwasaki, T; Kakazu, E; Kondo, Y; Niitsuma, H; Obara, N; Shiina, M; Shimosegawa, T; Tamai, K; Ueno, Y; Wakui, Y; Yamagiwa, Y, 2011)
"Although adefovir dipivoxil (ADV) has been used for antiviral treatment of lamivudine (LAM)-resistant chronic hepatitis B (CHB) patients, the long-term efficacy of this treatment is not well understood."3.77Initial virological response and viral mutation with adefovir dipivoxil added to ongoing Lamivudine therapy in Lamivudine-resistant chronic hepatitis B. ( Arai, M; Fukai, K; Imazeki, F; Kanda, T; Wu, S; Yokosuka, O; Yonemitsu, Y, 2011)
"Tenofovir disoproxil fumarate (TDF), a nucleotide analogue and potent inhibitor of hepatitis B virus (HBV) polymerase, showed superior efficacy to adefovir dipivoxil in treatment of chronic hepatitis B through 48 weeks."3.77Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. ( Anderson, J; Borroto-Esoda, K; Buggisch, P; Buti, M; De Man, RA; Flisiak, R; Gane, E; Germanidis, G; Gurel, S; Heathcote, EJ; Kaita, K; Kotzev, I; Krastev, Z; Kurdas, OO; Lee, SS; Manns, M; Marcellin, P; Mondou, E; Rousseau, F; Shiffman, ML; Snow-Lampart, A; Sorbel, J; Tchernev, K; Trinh, H; Weilert, F, 2011)
"The study evaluated whether a liquid suspension of adefovir dipivoxil (ADV) is effective and safe when dose adjusted based on varying degrees of renal impairment in patients with chronic hepatitis B."3.77Efficacy and pharmacokinetics of adefovir dipivoxil liquid suspension in patients with chronic hepatitis B and renal impairment. ( Frederick, D; Pol, S; Rostaing, L; Rousseau, F; Schiff, E; Shiffman, ML; Thabut, D; Zeuzem, S; Zong, J, 2011)
"We investigated the 4-year incidence and predictors of adefovir resistance in chronic hepatitis B patients with or without lamivudine (LAM)-resistance treated with adefovir dipivoxil with or without short-term LAM overlapping."3.77Characteristics of adefovir resistance in patients with or without lamivudine-resistant hepatitis B virus treated with adefovir: a 4-year experience. ( Chang, MH; Changchien, CS; Chen, CH; Hu, TH; Hung, CH; Lee, CM; Lu, SN; Wang, JH, 2011)
"The aim of this study was to determine the optimal time and HBV DNA levels during the treatment period for prediction of virological breakthrough (VBT) 3 years after adefovir monotherapy in chronic hepatitis B (CHB) patients with lamivudine resistance."3.77The level of HBV DNA at month 12 is an important predictor of virological breakthrough during adefovir monotherapy in chronic hepatitis B patients with lamivudine resistance. ( Jung, SW; Kim, MC; Park, NH; Shin, JW, 2011)
" We analyzed the frequency and effect of Tregs on cellular immune responses against HBV in 35 chronic hepatitis B eAg-ve and eAg+ve patients treated with tenofovir 300 mg/day."3.77Circulating Tregs correlate with viral load reduction in chronic HBV-treated patients with tenofovir disoproxil fumarate. ( Hissar, SS; Khanam, A; Kotillil, S; Mishra, SK; Sarin, SK; Shrivastava, S; Sukriti, S; TrehanPati, N, 2011)
"Amino acid (AA) changes in specific hepatitis B core antigen (HBcAg) regions were assessed in patients infected with chronic hepatitis B (CHB) after a 12-month untreated period and after receiving antiviral therapy (interferon, lamivudine or adefovir dipivoxil), and in inactive hepatitis B surface antigen-positive carriers."3.77HBV core region variability: effect of antiviral treatments on main epitopic regions. ( Buti, M; Esteban, R; Fernandez-Fernandez, P; Homs, M; Jardi, R; Quer, J; Rodriguez-Frias, F; Schaper, M; Tabernero, D, 2011)
"This study included 82 patients with HBeAg-negative chronic hepatitis B (CHB) who received adefovir dipivoxil therapy."3.77[Virological response to adefovir dipivoxil predicts the long-term development of resistance in previously untreated patients with HBeAg-negative chronic hepatitis B]. ( Andrade, RJ; Chueca, N; Figueruela, B; Fraga, E; García, F; Gila, A; Martín, JM; Muñoz Rueda, P; Nogales, C; Puche, B; Romero-Gómez, M; Salmerón, J; Suárez, E, 2011)
"Combination emtricitabine (FTC) or lamivudine (LAM) with tenofovir disoproxil (TDF) is the recommended first-line regime for treatment in chronic hepatitis B virus (HBV)/HIV co-infection."3.77Managing hepatitis B/HIV co-infected: adding entecavir to truvada (tenofovir disoproxil/emtricitabine) experienced patients. ( Beadsworth, MB; Pennell, A; Phillips, M; Ratcliffe, L; Vilar, FJ, 2011)
"An increasing number of patients with chronic hepatitis B infection are being treated with the newly licensed drug, adefovir."3.77Adefovir-induced Stevens-Johnson syndrome and toxic epidermal necrolysis overlap syndrome. ( Chattopadhyay, P; Sarma, N, 2011)
"To assess the long-term effectiveness and safety of adefovir (ADV) plus lamivudine (LMV) in LMV-resistant (R) kidney transplants with chronic hepatitis B, 11 such patients were treated with add-on ADV."3.77Long-term add-on therapy with adefovir in lamivudine-resistant kidney graft recipients with chronic hepatitis B. ( Aroldi, A; Colombo, M; Facchetti, F; Invernizzi, F; Lampertico, P; Lunghi, G; Messa, PG; Viganò, M, 2011)
"The aims of this study were to assess the long-term efficacy of lamivudine (LAM) plus adefovir dipivoxil (ADV) combination therapy in patients with chronic hepatitis B resistant to LAM, to identify predictive factors of complete viral response (HBV-DNA <2."3.77Clinical course and predictive factors of virological response in long-term lamivudine plus adefovir dipivoxil combination therapy for lamivudine-resistant chronic hepatitis B patients. ( Aizawa, M; Fujise, K; Hoshina, S; Kono, M; Tajiri, H; Tatsuzawa, K; Tsubota, A, 2011)
" A 46-year-old female patient with chronic hepatitis B had persistent detectable HBV DNA and positive serum hepatitis B e antigen (HBeAg), even while on long-term lamivudine and adefovir therapy."3.77Development of immunity against hepatitis B virus after donor lymphocyte infusion in a peripheral blood stem cell transplantation recipient with chronic hepatitis B. ( Chen, CH; Chiang, LT; Ko, BS; Yao, M, 2011)
"To assess the peripheral T lymphocyte subsets in chronic hepatitis B virus (HBV) infection, and their dynamics in response to adefovir dipivoxil monotherapy."3.77Parallel decline of CD8+CD38+ lymphocytes and viremia in treated hepatitis B patients. ( Cao, W; Li, TS; Qiu, ZF, 2011)
"Chronic hepatitis B patients who were treated with anti-viral agents (lamivudine, adefovir, entecavir) and have stopped the treatment were recruited."3.77Predictors of relapse in chronic hepatitis B after discontinuation of anti-viral therapy. ( Chan, HL; Ge, S; Guo, W; Hu, J; Huang, X; Jiang, J; Jiang, Z; Liang, Y; Liu, Z; Su, M; Wong, VW; Xie, R; Zhu, M, 2011)
"We report a case of an immunocompromised patient affected by chronic hepatitis B virus (HBV) with high basal HBV viremia (>8 log(10) IU/ml) who failed an entecavir regimen, despite the absence of primary or secondary drug resistance mutations."3.77Successful switch to tenofovir after suboptimal response to entecavir in an immunocompromised patient with chronic hepatitis B and without genotypic hepatitis B virus resistance. ( Andreoni, M; Bertoli, A; Ceccarelli, L; Perno, CF; Salpini, R; Sarrecchia, C; Sordillo, P; Svicher, V; Volpi, A, 2011)
"Primary or secondary failure of adefovir dipivoxil (ADV) therapy of chronic hepatitis B is not infrequent."3.77Adefovir serum levels do not differ between responders and nonresponders. ( Buti, M; Deterding, K; Guerrero, A; Janssen, H; Kirschner, J; Naesens, L; Neyts, J; Reijnders, J; Wedemeyer, H; Zoulim, F, 2011)
"Therapy of chronic hepatitis B with HBV-polymerase inhibitors, in particular tenofovir or adefovir, may affect renal function."3.77Effect of HBV polymerase inhibitors on renal function in patients with chronic hepatitis B. ( Athmann, C; Berger, F; Filmann, N; Hegener, P; Henke, J; Herrmann, E; Hueppe, D; Mauss, S; Schmutz, G, 2011)
"An increasing number of patients with chronic hepatitis B (CHB) have experienced treatment failure to adefovir (ADV) and their management poses a growing challenge."3.77The efficacy of entecavir therapy in chronic hepatitis B patients with suboptimal response to adevofir. ( Do, ST; Garcia, RT; Nguyen, HA; Nguyen, KK; Nguyen, MH; Nguyen, TT; Sheen, E; Tran, P; Trinh, HN, 2011)
"In chronic hepatitis B (CHB) patients, adefovir is commonly used as a rescue therapy for lamivudine resistance, but often results in incomplete virological suppression."3.77Management options for lamivudine-resistant chronic hepatitis B patients with suboptimal virological suppression by adefovir. ( Chan, HL; Chan, HY; Ong, A; Tse, CH; Wong, GL; Wong, VW, 2011)
"This study aimed to evaluate the long-term efficacy of entecavir (ETV) in adefovir (ADV)-refractory chronic hepatitis B (CHB) patients with prior lamivudine (LMV) resistance."3.77Long-term efficacy of entecavir in adefovir-refractory chronic hepatitis B patients with prior lamivudine resistance. ( Jang, JS; Jang, MK; Kim, DJ; Kim, HS; Kim, HY; Kim, KH; Lee, JH; Lee, MS; Park, CK; Park, JW; Seo, DD; Shin, WG, 2011)
"To evaluate virological response to adefovir (ADV) monotherapy and emergence of ADV-resistant mutations in lamivudine (LAM)-resistant chronic hepatitis B patients."3.77Virological response to adefovir monotherapy and the risk of adefovir resistance. ( Choi, MS; Gwak, GY; Koh, KC; Lee, HIe; Lee, JH; Paik, SW; Sinn, DH; Yoo, BC, 2011)
"To study the factors influencing the long-term usage of lamivudine (LAM) in chronic hepatitis B (CHB) patients and the management after drug-resistance."3.77[Lamivudine-resistant analysis and management for chronic hepatitis B patients with initial lamivudine therapy]. ( Chen, Y; He, LL; Lei, BJ; Lei, XZ; Xu, H, 2011)
"Previous research has demonstrated that tenofovir disoproxil fumarate (DF) is the most cost-effective nucleos(t)ide treatment for chronic hepatitis B (CHB) in the UK, Spain, Italy and France."3.77Cost effectiveness of tenofovir disoproxil fumarate for the treatment of chronic hepatitis B from a Canadian public payer perspective. ( Bentley, A; Dakin, H; Fidler, C; Fung, S; Sherman, M, 2011)
"Adefovir dipivoxil is commonly used for treatment of chronic hepatitis B."3.77[Adefovir dipivoxil-induced Fanconi syndrome and hypophosphatemic osteomalacia associated with muscular weakness in a patient with chronic hepatitis B]. ( Dong, GF; Li, L; Xie, YS; Zhang, X, 2011)
"We investigated the durability of the biochemical and virologic responses after adefovir (ADV) discontinuation in lamivudine-resistant (LMV-R) chronic hepatitis B (CHB) patients, and the outcomes of ADV discontinuation compared to that of ADV maintenance."3.77Virologic response is not durable after adefovir discontinuation in lamivudine-resistant chronic hepatitis B patients. ( Byun, KS; Jung, ES; Jung, YK; Kim, JH; Lee, KG; Ryu, HS; Seo, YS; Um, SH; Yeon, JE; Yim, HJ, 2011)
" The use of lamivudine and tenofovir resulted in arrest of proteinuria and stabilisation of renal function."3.77Hepatitis B virus related membranous glomerulonephritis and proteinuria treated with lamivudine and tenofovir. ( Das, P; Ford, M; Holt, S; Kingdon, E; Vivek, V, 2011)
"The aims of this study were to evaluate therapy with lamivudine (LAM) and adefovir dipivoxil (ADV) monotherapy in chronic hepatitis B virus (HBV)-infected patients with frequent measurements of DNA levels, to characterize HBV genotypes, and to determine the emergence of nucleos(t)ide analogue mutants before and during the therapy by direct-sequencing the reverse transcriptase region and by INNO-LiPA HBV DR v3."3.76Monitoring of therapy in patients with chronic hepatitis B virus. ( Arrese, E; Basaras, M; Blanco, S; Cisterna, R; Ruiz, P, 2010)
" The purpose of this study was to evaluate the effect of a new therapeutic strategy combining Lamivudine (LAM) and ADV in patients with HBeAg-positive chronic hepatitis B (CHB) and poor response to ADV monotherapy."3.76Combination of Lamivudine and adefovir therapy in HBeAg-positive chronic hepatitis B patients with poor response to adefovir monotherapy. ( Cao, J; Chen, EQ; Lei, BJ; Liu, L; Tang, H; Wang, JR; Wang, LC, 2010)
"Long-term lamivudine (LAM) and adefovir (ADV) treatment has been found to induce the emergence of drug-resistant hepatitis B virus (HBV) in a significant number of patients with chronic hepatitis B (CHB) infection."3.76Lamivudine and adefovir resistance in children and young adults with chronic hepatitis B. ( Akman, SA; Halicioglu, O; Kose, S, 2010)
"Recently, we reported on three patients with chronic hepatitis B virus (HBV) infection for whom adefovir (ADF) therapy virologically failed, most likely due to a preexisting rtI233V HBV polymerase mutation."3.76Selection and counterselection of the rtI233V adefovir resistance mutation during antiviral therapy. ( Funk, A; Helm, M; Olotu, C; Rockstroh, JK; Schildgen, O; Sirma, H; Zöllner, B, 2010)
" In adefovir (ADV) treated chronic hepatitis B patients carrying rtA181T/rtA181V mutations, overlap with surface gene mutations such as sW172stop/sL173F has been reported."3.76Hepatitis B viral surface mutations in patients with adefovir resistant chronic hepatitis B with A181T/V polymerase mutations. ( Bak, YT; Byun, KS; Joo, MK; Jung, YK; Kim, JH; Kim, JS; Park, JJ; Yeon, JE; Yim, HJ, 2010)
"The aim of this study was to determine the evolution of full-length hepatitis B virus (HBV) sequences in chronic hepatitis B (CHB) patients with sequential lamivudine (LAM) and adefovir (ADV) resistance."3.76Evolution of full-length HBV sequences in chronic hepatitis B patients with sequential lamivudine and adefovir dipivoxil resistance. ( Changchien, CS; Chen, CH; Hu, TH; Hung, CH; Lee, CM; Lu, SN; Tung, WC; Wang, JC; Wang, JH, 2010)
" The aim of this study was to clarify the effect of molecular characteristics on the antiviral response to adefovir in patients with lamivudine-resistant chronic hepatitis B (CHB)."3.76Response to adefovir depends on mutation patterns in precore region, basal core promoter and reverse transcriptase, and on-treatment responses in Lamivudine-resistant chronic hepatitis B patients. ( Cho, YK; Choi, EK; Cui, XJ; Hyun, S; Jeong, SU; Kim, HU; Park, NH; Shin, JW; Song, BC; Song, HJ, 2010)
"There have been no reports comparing the therapeutic results of adefovir (ADV) and entecavir (ETV) rescue therapy for patients with lamivudine (LAM)-resistant chronic hepatitis B (CHB)."3.76Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy. ( Cho, YK; Jeon, WK; Kim, BI; Kim, HJ; Park, DI; Park, JH; Sohn, CI, 2010)
"Adefovir dipivoxil, an acyclic nucleoside analogue, has been approved for the treatment of patients with chronic hepatitis B."3.76[A case of osteomalacia related to adefovir in a patient with chronic hepatitis B]. ( Ahn, SY; Choe, WH; Choi, YH; Jang, YM; Kim, BK; Ko, SY; Kwon, SY; Lee, CH, 2010)
"The aim of this study was to assess the cost-effectiveness of tenofovir disoproxil fumarate (TDF) in the treatment of chronic hepatitis B (CHB) versus alternative nucleos(t)ides from a UK National Health Service (NHS) perspective."3.76Cost-utility analysis of tenofovir disoproxil fumarate in the treatment of chronic hepatitis B. ( Bentley, A; Dakin, H; Dusheiko, G, 2010)
"Adefovir dipivoxil treatment has significantly improved the outcome of chronic hepatitis B virus (HBV) infection."3.76Th1 and Th2 immune response in chronic hepatitis B patients during a long-term treatment with adefovir dipivoxil. ( Hao, C; Jiang, Y; Li, W; Ma, Z; Niu, J; Xin, G; Xu, H; Yan, H; Zhao, P, 2010)
"Data on the efficacy of adefovir dipivoxil (ADV) in elderly and cirrhotic patients with lamivudine-resistant (LAM-R) chronic hepatitis B are scarce."3.75Adefovir dipivoxil is effective for the treatment of cirrhotic patients with lamivudine failure. ( Bailly, F; Beaugrand, M; Benhamou, Y; Marcellin, P; Maynard, M; Monchecourt, F; Parvaz, P; Trepo, C; Trylesinski, A; Zarski, JP; Zoulim, F, 2009)
" The aim was to evaluate the long-term outcome of lamivudine monoprophylaxis with adefovir salvage for liver transplantation in chronic hepatitis B."3.75Lamivudine monoprophylaxis and adefovir salvage for liver transplantation in chronic hepatitis B: a seven-year follow-up study. ( Chan, HL; Chan, HY; Kwan, KY; Lai, PB; Limquiaco, JL; Tse, CH; Wong, GL; Wong, J; Wong, VW, 2009)
"Patients with chronic hepatitis B (CHB) who will and those who will not respond to adefovir (ADV) monotherapy need to be identified at an early stage in order to adjust treatment and prevent future development of antiviral resistance."3.75On-treatment monitoring of adefovir therapy in chronic hepatitis B: virologic response can be assessed at 24 weeks. ( de Man, RA; Hansen, BE; Janssen, HL; Leemans, WF; Pas, SD; Reijnders, JG; Schutten, M, 2009)
"The purpose of this study was to evaluate the renal side-effects of adefovir therapy in kidney-transplant (KT) recipients with chronic hepatitis B virus (HBV) infection, who have become resistant to lamivudine therapy."3.75Renal side effects of adefovir in hepatitis B virus-(HBV) positive kidney allograft recipients. ( Alric, L; Huart, A; Izopet, J; Kamar, N; Rostaing, L; Tack, I, 2009)
"The aims of the study were to investigate the efficacy of rescue therapy with lamivudine (LAM) and adefovir (ADV) combination for 6 months followed by ADV monotherapy in lamivudine-resistant chronic hepatitis B (LAM-R CHB) patients, and to analyze the frequency of ADV resistance mutant development in such patients."3.75A short course of add-on adefovir dipivoxil treatment in lamivudine-resistant chronic hepatitis B patients. ( Ahishali, E; Badur, S; Bektas, M; Bozkaya, H; Cakaloglu, Y; Cinar, K; Idilman, R; Karayalcin, S; Kaymakoglu, S; Mithat Bozdayi, A; Oguz Onder, F; Okten, A; Pinarbasi, B; Yurdaydin, C, 2009)
"Fourteen chronic hepatitis B patients (57% lamivudine-experienced) with a viral load above 5log(10)copies/mL after 12months of adefovir therapy and thereafter were treated with entecavir 1mg daily."3.75Entecavir shows limited efficacy in HBeAg-positive hepatitis B patients with a partial virologic response to adefovir therapy. ( de Man, RA; Janssen, HL; Pas, SD; Reijnders, JG; Schutten, M, 2009)
"It has been shown that adefovir dipivoxil is an effective antiviral agent in the treatment of chronic hepatitis B (CHB), not only in wild-type hepatitis B virus (HBV) infection, but also in lamivudine-resistant (LAMV-R) cases."3.75[Virologic response to adefovir dipivoxil monotherapy is not durable in HBeAg-positive, lamivudine-resistant chronic hepatitis B patients]. ( Choi, MS; Jung, HW; Kim, KH; Koh, KC; Lee, JH; Paik, SW; Park, SH; Yeon, KK; Yoo, BC, 2009)
"The antiviral effect of adefovir dipivoxil (ADV) added to ongoing lamivudine (LAM) treatment for LAM-resistant chronic hepatitis B (CHB) differs among patients."3.75Factors contributing to antiviral effect of adefovir dipivoxil therapy added to ongoing lamivudine treatment in patients with lamivudine-resistant chronic hepatitis B. ( Doi, Y; Hagiwara, H; Hayashi, E; Hayashi, N; Hiramatsu, N; Imai, Y; Kanto, T; Kasahara, A; Kashihara, T; Kato, M; Kiso, S; Kurashige, N; Mita, E; Nagase, T; Ohkawa, K; Oshita, M; Takehara, T; Yakushijin, T; Yamada, A; Yoshihara, H, 2009)
"The aim of this study was to elucidate the antiviral efficacy of lamivudine (LMV)-adefovir (ADV) combination therapy in chronic hepatitis B patients who showed resistance to LMV and ADV consecutively."3.75[Antiviral efficacy of lamivudine/adefovir combination therapy in chronic hepatitis b patients with resistance to lamivudine and adefovir consecutively]. ( Gwak, GY; Koh, KC; Lee, HIe; Lee, JH; Paik, SW; Park, MK; Suh, HJ; Yoo, BC, 2009)
"The aim of the study was to estimate the effect of viral factors (HBV genotype, viral load and kinetics) to treatment response in chronic hepatitis B (CHB) and first-line therapy with adefovir dipivoxil (ADV)."3.75Rapid HBV DNA decrease (week 12) is an important prognostic factor for first-line treatment with adefovir dipivoxil for chronic hepatitis B. ( Bock, T; Hass, HG; Kaiser, S; Nehls, O, 2009)
"Data concerning the outcome of lamivudine-resistant (LAM-R) chronic hepatitis B (CHB) patients with compensated cirrhosis under adefovir (ADV) treatment are limited."3.75Clinical outcome of lamivudine-resistant chronic hepatitis B patients with compensated cirrhosis under adefovir salvage treatment. Importance of HCC surveillance. ( Buti, M; Elefsiniotis, I; Esteban, R; Jardi, R; Vezali, E, 2009)
"Clinical data of 233 chronic hepatitis B patients treated with lamivudine 100mg daily (91 patients were switched to Adefovir 10mg daily or Adefovir 10mg in combination with lamivudine 100mg daily) were retrospective."3.75[Factors associated with response to lamivudine: retrospective study of 233 patients with chronic hepatitis B]. ( Fu, J; Li, SG; Tan, B; Wen, FY; Wu, JL; Yang, XY; Zhou, HJ, 2009)
"To explore the mechanism for adefovir dipivoxil (ADV) resistance occurred in chronic hepatitis B patients of a series of phase III clinical trails."3.75[Dissection of mechanism for the adefovir dipivoxil resistance in chronic hepatitis B patients]. ( Cai, SF; Deng, H; Deng, XH; Guo, JJ; Huang, AL; Li, QL; Lu, P; Xin, XJ; Yang, C; Zeng, AZ, 2009)
"The efficacy of entecavir (ETV) monotherapy in treatment-experienced patients with chronic hepatitis B (CHB) is debatable."3.75Evolution of hepatitis B virus mutation during entecavir rescue therapy in patients with antiviral resistance to lamivudine and adefovir. ( Byun, KS; Choe, WH; Hong, SP; Ji, SI; Jung, YK; Kim, BK; Kim, JH; Kim, KH; Kim, SO; Ko, SY; Kwon, SY; Lee, CH; Yeon, JE, 2009)
"To study the predictive value of ALT, HBeAg and HBV DNA levels at baseline and HBV DNA levels at week 12 adefovir dipivoxil (ADV) treatment to the efficacy of it at week 52 in patients with HBeAg-positive chronic hepatitis B (CHB)."3.74[The predictive value of ALT, HBeAg and HBV DNA levels at baseline and the degree of HBV suppression at week 12 adefovir dipivoxil treatment to the efficacy of it at week 52 in patients with HBeAg-positive chronic hepatitis B]. ( Chen, YM; Gao, ZL; Li, JG; Lin, BL; Lu, WL; Xie, DY; Xu, QH, 2008)
"A 43-year-old man was treated with lamivudine for hepatitis B e antigen-positive chronic hepatitis B."3.74Selection of an entecavir-resistant mutant despite prolonged hepatitis B virus DNA suppression, in a chronic hepatitis B patient with preexistent lamivudine resistance: successful rescue therapy with tenofovir. ( de Man, RA; Janssen, HL; Leemans, WF; Niesters, HG; Schalm, SW; van der Eijk, AA, 2008)
"This longitudinal study included 41 patients with chronic hepatitis B virus (HBV) infection receiving ADV monotherapy or ADV plus lamivudine (3TC)."3.74Adefovir for chronic hepatitis B treatment: identification of virological markers linked to therapy response. ( Buti, M; Esteban, R; Ferrer-Costa, C; Homs, M; Jardi, R; Rodriguez-Frias, F; Schaper, M; Tabernero, D, 2008)
"The long-term efficacy of adefovir dipivoxil in combination with lamivudine to chronic hepatitis B virus (HBV) infection is still unclear."3.74Virological response and hepatocarcinogenesis in lamivudine-resistant hepatitis B virus genotype C patients treated with lamivudine plus adefovir dipivoxil. ( Akuta, N; Arase, Y; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Sezaki, H; Suzuki, F; Suzuki, Y; Yatsuji, H, 2008)
"To study the resistant rate of hepatitis B virus (HBV) to ADV and the dynamic evolution of HBV in lamivudine (Lam)-resistant chronic hepatitis B (CHB) patients."3.74[The rate of hepatitis B virus resistance to adefovir dipivoxil (ADV) and the evolution of hepatitis B virus in lamivudine-resistant chronic hepatitis B patients with ADV monotherapy]. ( Huang, YX; Mao, RC; Qin, YL; Weng, XH; Wu, XH; Yin, YK; Zhang, JM; Zhang, QB; Zhang, WQ, 2007)
"To determine the factors affecting the virological response to adefovir dipivoxil (ADV) among patients with lamivudine resistant chronic hepatitis B."3.74Early virological suppression is associated with good maintained response to adefovir dipivoxil in lamivudine resistant chronic hepatitis B. ( Chan, HL; Chan, HY; Chim, AM; Sung, JJ; Tse, CH; Wong, GL; Wong, VW, 2007)
"To determine the factors associated with virological response (VR), HBeAg loss or the emergence of adefovir (ADV)-related mutations in ADV-treated chronic hepatitis B (CHB) patients with lamivudine (LAM) resistance."3.74Viral genotype and baseline load predict the response to adefovir treatment in lamivudine-resistant chronic hepatitis B patients. ( Bonovas, S; Buti, M; Elefsiniotis, I; Esteban, R; Jardi, R; Rodriguez-Frias, F; Schapper, M; Vargas, V, 2007)
"The outcomes of lamivudine-resistant chronic hepatitis B patients treated with long-term adefovir dipivoxil have not been well described."3.74Combination adefovir-lamivudine prevents emergence of adefovir resistance in lamivudine-resistant hepatitis B. ( Khoo, TL; Lee, AU; McCaughan, GW; Ngu, MC; Prakoso, E; Strasser, SI; van der Poorten, D, 2007)
"This study was conducted to clarify the resistance profile of a novel mutation pattern emerging during lamivudine (3TC) therapy and showing cross-resistance to adefovir dipivoxil (ADV) in a patient with chronic hepatitis B."3.74A novel mutation pattern emerging during lamivudine treatment shows cross-resistance to adefovir dipivoxil treatment. ( Bozdayi, AM; Karaaslan, H; Karatayli, E; Karayalçin, S; Kayhan, H; Sahin, F; Türkyilmaz, AR; Yurdaydin, C, 2007)
"Adefovir dipivoxil (ADV) resistance in patients with lamivudine-resistant chronic hepatitis B is not well understood."3.74[Effect of initial virologic response to adefovir on the development of resistance to adefovir in lamivudine-resistant chronic hepatitis B]. ( Kim, DG; Kim, HC; Kim, IH; Kim, SH; Kim, SW; Lee, SO; Lee, ST; Shin, KD, 2007)
"The efficacy of long-term adefovir dipivoxil monotherapy or combination of adefovir and lamivudine in hepatitis B e antigen (HBe-Ag)-negative lamivudine-resistant chronic hepatitis B (CHB) patients is still under investigation."3.74Long-term therapy with adefovir dipivoxil in hepatitis B e antigen-negative patients developing resistance to lamivudine. ( Bethanis, S; Christias, E; Christidou, A; Goulis, J; Karamanolis, D; Koutsounas, S; Manolakopoulos, S; Papatheodoridis, G; Pavlidis, C; Saveriadis, A; Triantos, C; Tzourmakliotis, D; Vlachogiannakos, J, 2008)
"We summarize the clinical history and laboratory results following the introduction of tenofovir among 6 patients coinfected with human immunodeficiency virus (HIV) and hepatitis B virus (HBV) who presented with severe liver disease while receiving lamivudine-based highly active antiretroviral therapy."3.74Tenofovir-based rescue therapy for advanced liver disease in 6 patients coinfected with HIV and hepatitis B virus and receiving lamivudine. ( Guillemi, S; Gutiérrez, S; Harrigan, PR; Jahnke, N; Montaner, JS; Montessori, V, 2008)
" In our department, tenofovir was prescribed in addition to lamivudine for the treatment of lamivudine resistant chronic hepatitis B."3.74Switching patients with lamivudine resistant chronic hepatitis B virus from tenofovir to adefovir results in less potent HBV-DNA suppression. ( de Man, RA; Janssen, HL; Leemans, WF; Niesters, HG, 2008)
"The aims of the present study were to assess initial virological response (IVR) to adefovir (ADV) treatment for chronic hepatitis B, to identify patients with suboptimal response and to determine the incidence of ADV-resistant mutants."3.74Evaluation of initial virological response to adefovir and development of adefovir-resistant mutations in patients with chronic hepatitis B. ( Enrĺquez, J; Gallego, A; García-Samaniego, J; Hornillos, P; Margall, N; Romero, M; Sheldon, J; Soriano, V, 2008)
"In lamivudine-resistant patients with chronic hepatitis B (CHB), we compared efficacy, predictive response factors and changes in viral mutants in two antiviral approaches with adefovir."3.74Lamivudine-resistant chronic hepatitis B: an observational study on adefovir in monotherapy or in combination with lamivudine. ( Alessandria, C; Barbon, V; Carenzi, S; Gaia, S; Lagget, M; Marzano, A; Olivero, A; Rizzetto, M; Smedile, A, 2008)
"The aim of this study was to assess the therapeutic effectiveness of adefovir dipivoxil (ADV), administered in combination with lamivudine (LAM) or as monotherapy, and the rate of resistance to ADV, in hepatitis B e antigen (HBeAg)-negative adult patients with chronic hepatitis B virus (HBV) infection and clinical or virologic resistance to LAM."3.74Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study. ( Armignacco, O; Barbarini, G; Barbaro, G; Barlattani, A; Camporiondo, MP; Ferri, F; Francavilla, R; Mazzoni, E; Mecenate, F; Nauri, L; Nosotti, L; Paffetti, A; Pellicelli, AM; Romano, M; Soccorsi, F; Struglia, C; Villani, R, 2008)
"One hundred and thirty-one post-liver transplantation patients with chronic hepatitis B and failing lamivudine therapy with detectable serum hepatitis B virus (HBV) deoxyribonucleic acid by hybridization assays or > or =1 x 10(6) copies/mL by polymerase chain reaction, and elevated alanine transaminase levels despite continuous lamivudine, were enrolled in an open-label study of adefovir dipivoxil."3.73Activity of adefovir dipivoxil against all patterns of lamivudine-resistant hepatitis B viruses in patients. ( Brosgart, CL; Delaney, WE; Fry, J; Gibbs, CS; Lama, N; Miller, MD; Schiff, ER; Westland, CE; Wulfsohn, M; Xiong, S; Yang, H, 2005)
"We describe the case of a patient with chronic hepatitis B who became resistant to lamivudine and was treated successfully with adefovir dipivoxil in addition to lamivudine."3.73Sustained HBs seroconversion during lamivudine and adefovir dipivoxil combination therapy for lamivudine failure. ( Chevallier, M; Chevallier, P; Durantel, S; Lot, M; Maynard, M; Parvaz, P; Trepo, C; Zoulim, F, 2005)
"Long-term treatment with lamivudine is required to control viral replication in patients with hepatitis B e antigen-negative chronic hepatitis B, but is associated with a high rate of viral resistance."3.73Adefovir dipivoxil added to ongoing lamivudine therapy in patients with lamivudine-resistant hepatitis B e antigen-negative chronic hepatitis B. ( Eugenidis, N; Giouleme, O; Gkisakis, D; Grammatikos, N; Katsinelos, P; Nikolaidis, N; Orfanou-Koumerkeridou, E; Patsiaoura, K; Theodoropoulos, K; Tziomalos, K; Vassiliadis, T; Zezos, P, 2005)
"We determined the clinical outcome of hepatitis e antigen (HBeAg)-negative chronic hepatitis B patients treated with long-term nucleos(t)ide analog therapy starting with lamivudine."3.73Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine. ( Dimakopoulos, K; Dimou, E; Hadziyannis, SJ; Kitis, G; Manesis, E; Manolakopoulos, S; Papatheodoridis, GV; Rapti, I; Tzourmakliotis, D, 2005)
"Although a recent study did not show any differences in the reduction of HBV DNA comparing monotherapy with adefovir dipivoxil to adefovir-lamivudine combination therapy in patients with lamivudine-resistant chronic hepatitis B, mathematical analysis of early viral kinetics suggests an additional effect of lamivudine on the infected cell loss during adefovir-lamivudine combination therapy."3.73Viral kinetics in patients with lamivudine-resistant hepatitis B during adefovir-lamivudine combination therapy. ( Faust, D; Gärtner, BC; Herrmann, E; Hofmann, WP; Mihm, U; Sarrazin, C; Zeuzem, S, 2005)
"Fifty chronic hepatitis B (CHB) patients with lamivudine resistant HBV mutants who had received lamivudine for more than 12 months were included in the study."3.73[Clinical outcomes after discontinuation of Lamivudine in chronic hepatitis B patients with Lamivudine resistant HBV mutant]. ( Cho, HJ; Choi, HY; Hong, SP; Hwang, SG; Kim, JK; Kim, NK; Ko, KH; Park, H; Park, PW; Rim, KS, 2005)
"To evaluate the efficacy and safety of adefovir dipivoxil in treatment of decompensated liver cirrhosis patients with YMDD motif mutation during lamivudine therapy."3.73[Adefovir dipivoxil in treatment of decompensated liver cirrhosis patients with YMDD mutation]. ( Su, GG; Ying, MF; Zhao, NF; Zhou, Y, 2005)
"Seven antiretroviral-naive HIV-infected individuals with chronic hepatitis B treated with adefovir for longer than 6 months were assessed."3.73Risk of selecting K65R in antiretroviral-naive HIV-infected individuals with chronic hepatitis B treated with adefovir. ( Berger, F; Corral, A; Mauss, S; Rockstroh, J; Rodés, B; Schwarze-Zander, C; Sheldon, JA; Soriano, V, 2005)
"We studied the impact of tenofovir disoproxil fumarate, given as an antiretroviral medication, on patients with chronic hepatitis B virus (HBV) co-infection."3.73Impact of tenofovir-containing antiretroviral therapy on chronic hepatitis B in a cohort co-infected with human immunodeficiency virus. ( Berger, A; Bickel, M; Carlebach, A; Klauke, S; Lutz, T; Staszewski, S; Stephan, C; Stuermer, M, 2005)
"Currently, adefovir is an effective rescue therapy that broadens the existing range of options for patients with lamivudine-resistant chronic hepatitis B infection, particularly those with decompensated cirrhosis awaiting a liver graft, and those with recurrent posttransplantation HBV."3.73Clinical and virological effects during two years of ongoing adefovir dipivoxil in the treatment of lamivudine-resistant chronic hepatitis B infection. ( Baliellas, C; Cañas, C; Casanovas, A; Casanovas, T; Chahri, N; Figueras, J; Gil-Vernet, S; Gornals, JB; Sabidó, M; Serrano, T; Verdura, B, 2005)
"To estimate the cost-effectiveness over a 4-year duration of lamivudine and adefovir dipivoxil for patients with hepatitis B 'e' antigen-negative chronic hepatitis B."3.73Cost-effectiveness analysis of lamivudine and adefovir dipivoxil in the treatment of patients with HBeAg-negative chronic hepatitis B. ( Aguilar, J; Buti, M; Calleja, JL; Casado, MA; Esteban, R; Rueda, M; Salmerón, J, 2006)
"We have studied a 49-year-old patient with a HBeAg-negative chronic hepatitis B in whom, after 34 months of treatment with lamivudine and associated with an increase in the serum hepatitis B virus (HBV) DNA, the lamivudine resistance mutations M204I and L180V were detected."3.73[Lamivudine and adefovir resistance in a patient with HBeAg negative chronic hepatitis B]. ( Mateos, ML; Moreira, V; Tato, M, 2006)
"A 56-year-old male patient received adefovir dipivoxil (10 mg/day) for chronic hepatitis B resistant to lamivudine."3.73Adefovir dipivoxil-associated thrombocytopenia in a patient with chronic hepatitis B. ( Amato, A; Gaeta, GB; Stornaiuolo, G, 2006)
"One patient with chronic hepatitis B virus (HBV) infection developed resistance to lamivudine after 15 months of treatment."3.73Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. ( Lai, V; Mirza, D; Mutimer, D; Zhang, WX, 2006)
"Although adefovir dipivoxil (ADV) has a unique profile of delayed and infrequent resistance in treatment-naïve chronic hepatitis B patients, the association of ADV resistance with previous lamivudine (LAM) resistance is not well understood."3.73Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. ( Chung, YH; Jung, SW; Kim, KM; Kim, SO; Lee, HC; Lee, YS; Lim, YS; Suh, DJ; Yoo, W, 2006)
"The nucleotide analog adefovir dipivoxil (ADV) is an effective antiviral treatment for chronic hepatitis B virus (HBV) infection, with resistance to ADV estimated to occur less frequently than resistance to lamivudine treatment."3.73Detection of rtN236T and rtA181V/T mutations associated with resistance to adefovir dipivoxil in samples from patients with chronic hepatitis B virus infection by the INNO-LiPA HBV DR line probe assay (version 2). ( Borlang, J; Giles, E; Heathcote, EJ; Osiowy, C; Villeneuve, JP, 2006)
"Continuation of lamivudine therapy is controversial for patients with chronic hepatitis B when viral breakthrough occurs."3.73[Comparison of clinical outcome between patients continuing and discontinuing lamivudine therapy in acute exacerbation after viral breakthrough during lamivudine therapy in chronic hepatitis B]. ( Eun, JR, 2006)
"Lamivudine is widely used for the treatment of chronic hepatitis B infection because of it's remarkable antiviral efficacy and safety."3.73[A case of severe skin eruption caused by lamivudine in a patient with chronic hepatitis B]. ( Baik, du S; Kim, BH; Kim, HJ; Kim, SB; Seo, PJ; Shin, JE; Song, IH; Yun, SY, 2006)
"Adefovir dipivoxil effectively inhibits both hepatitis B virus (HBV) replication and disease activity in patients with chronic hepatitis B."3.72Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. ( Angus, P; Ayres, A; Bartholomeusz, A; Brosgart, C; Colledge, D; Delaney, W; Edwards, R; Gibbs, C; Locarnini, S; Vaughan, R; Xiong, S; Yang, H, 2003)
"3%) patients developed hepatitis B virus DNA breakthrough 47 and 53 months, respectively, after transplantation, but they remained well after treatment with adefovir."3.72Live-donor liver transplantation for acute-on-chronic hepatitis B liver failure. ( Fan, ST; Lai, CL; Liu, CL; Lo, CM; Wei, WI; Wong, J; Yong, BH, 2003)
"Three-hundred and twenty-four patients were enrolled in an open-label, multicenter, international study in which pre- and post-liver transplantation (LT) patients with recurrent chronic hepatitis B (CHB) and evidence of lamivudine-resistant HBV were treated with adefovir dipivoxil 10 mg once daily."3.72Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. ( Brosgart, CL; Choy, GS; Colombo, M; Fry, J; Hadziyannis, S; James, C; Lai, CL; Lama, N; Lilly, L; Namini, H; Neuhaus, P; Rendina, M; Samuel, D; Schiff, ER; Terrault, N; Tillmann, HL; Van Doren, S; Villeneuve, JP; Westland, C; Wulfsohn, MS; Xiong, S; Zeuzem, S, 2003)
" This article reviews recently published clinical data on the two currently available antivirals for the treatment of chronic hepatitis B infection, lamivudine and adefovir dipivoxil."3.72Antivirals for the treatment of chronic hepatitis B: current and future options. ( Dixon, JS; Humphries, JC, 2003)
"Lamivudine is a treatment option for the therapy of chronic hepatitis B with an excellent safety profile."3.72Severe exacerbation of chronic hepatitis B after emergence of lamivudine resistance in a cirrhotic patient: immediate switch to adefovir dipivoxil appears to be indicated. ( Flemming, P; Klempnauer, J; Manns, MP; Nashan, B; Niemann, P; Rohde, P; Tillmann, HL; Tischendorf, JJ; Trautwein, C; Wiegand, J, 2004)
"Lamivudine resistance occurs in patients with chronic hepatitis B at rates of 16%-32% after 1 year and 49% after 3 years."3.72Tenofovir disoproxil fumarate for the treatment of lamivudine-resistant hepatitis B. ( Chung, RT; Dienstag, JL; Kuo, A, 2004)
" Ninety-eight liver biopsy samples from patients in the major phases of the natural history of chronic hepatitis B and 32 pairs of samples from patients receiving adefovir dipivoxil (ADV) therapy were assessed."3.72Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. ( Bowden, S; Brosgart, CL; Chen, SS; Delaney, WE; Gibbs, CS; Goodman, Z; Lau, G; Locarnini, S; Marcellin, P; Petersen, J; Trepo, C; Werle-Lapostolle, B; Wursthorn, K; Xiong, S; Zoulim, F, 2004)
"Resistant hepatitis B virus (HBV) strains develop in 30% of liver transplant recipients treated with lamivudine within 2 years from the time of transplantation."3.72Tenofovir therapy for lamivudine resistance following liver transplantation. ( Duncan, R; Lau, DT; Madariaga, JR; Montalbano, M; Muslu, H; Neff, GW; Nery, C; Nery, J; O'Brien, CB; Ruiz, P; Safdar, K; Schiff, ER; Shire, NJ; Tzakis, AG, 2004)
"Adefovir dipivoxil (Hepsera), a first-line therapy for chronic hepatitis B, is an esterase-activated prodrug of PMEA."3.72Remofovir mesylate: a prodrug of PMEA with improved liver-targeting and safety in rats and monkeys. ( Erion, MD; Hong, Z; Lin, CC; Vitarella, D; Yeh, LT, 2004)
"Lamivudine has been shown to be an effective therapy for chronic hepatitis B, but resistance to this nucleoside agent is common after prolonged use."3.70Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. ( Gutfreund, K; Hirsch, K; Lamy, P; Murray, A; Perrillo, R; Schiff, E; Statler, A; Wright, T; Yoshida, E, 2000)
"Among 3656 highly viremic mothers treated with TDF, hepatitis B virus DNA suppression to the levels <200,000 IU/mL at delivery was achieved in 34% to 100% of mothers."3.01The Use of Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide for Preventing Vertical Transmission of Hepatitis B. ( Deng, Y; Pan, CQ; Park, J; Zhu, L, 2023)
" However, greater adverse effects on renal function were observed for TDF than ETV at 60 months compared to 12 months."3.01Renal and bone side effects of long-term use of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide fumarate in patients with Hepatitis B: a network meta-analysis. ( Liu, S; Liu, Z; Ma, X; Xin, Y; Zhao, Z, 2023)
" The treatment using NAs was well-tolerated and there was no serious drug-related adverse event reported."3.01Short-term and long-term safety and efficacy of tenofovir alafenamide, tenofovir disoproxil fumarate and entecavir treatment of acute-on-chronic liver failure associated with hepatitis B. ( Chen, T; Chen, Y; Fu, M; Fu, S; Gao, Z; He, Y; Hu, C; Li, J; Liu, J; Yan, T; Yang, Y; Zhang, R; Zhao, Y; Zhou, M, 2021)
"Pradefovir is a liver targeted novel prodrug of adefovir (PMEA) developed to provide higher antiviral activity with reduced systemic toxicities."2.94Safety, efficacy, and pharmacokinetics of pradefovir for the treatment of chronic hepatitis B infection. ( Chen, H; Ding, Y; Jin, W; Li, C; Li, X; Liu, C; Liu, J; Niu, J; Wu, M; Zhang, D; Zhang, H; Zhu, X, 2020)
"Functional cure is the major goal of chronic hepatitis B (CHB) therapy though few biomarkers predict this outcome."2.90Predicting HBsAg clearance in genotype A chronic hepatitis B using HBsAg epitope profiling: A biomarker for functional cure. ( Cloherty, G; Deerain, J; Gaggar, A; Hammond, R; Kitrinos, K; Leary, T; Locarnini, S; O'Donnell, T; Subramanian, M; Walsh, R; Wong, D; Yuen, L, 2019)
"A total of 95 patients with chronic hepatitis B being treated with NUCs were enrolled."2.87Combinational use of hepatitis B viral antigens predicts responses to nucleos(t)ide analogue/peg-interferon sequential therapy. ( Chayama, K; Enomoto, H; Enomoto, M; Hino, K; Hiramatsu, N; Ikeda, F; Kagawa, T; Kanda, T; Kang, JH; Kurosaki, M; Matsumoto, A; Mine, T; Miyase, S; Morihara, D; Murata, K; Nagaoka, S; Nishiguchi, S; Okuse, C; Saito, S; Sakisaka, S; Shinkai, N; Suzuki, Y; Takaguchi, K; Tanaka, E; Tanaka, Y; Tsuge, M; Yatsuhashi, H; Yokosuka, O, 2018)
"Current treatments for chronic hepatitis B (CHB) include pegylated interferon alpha (PEG-IFN-α) which is an immune modulator, and nucleos(t)ide analogs (NAs) which directly inhibit HBV DNA polymerase."2.84Addition of nucleoside analogues to peg-IFNα-2a enhances virological response in chronic hepatitis B patients without early response to peg-IFNα-2a: a randomized controlled trial. ( Guo, H; Jiao, J; Liu, Z; Qi, W; Wang, J; Wang, X; Xu, Y; Yu, F; Zhao, P; Zhou, C, 2017)
"Treatment of patients with chronic hepatitis B (CHB) with nucleos(t)ide analogues (NAs) suppresses hepatitis B virus (HBV) DNA production but does not affect the synthesis of the RNA pregenome or HBV messenger RNA."2.82Hepatitis B Virus Pregenomic RNA Is Present in Virions in Plasma and Is Associated With a Response to Pegylated Interferon Alfa-2a and Nucleos(t)ide Analogues. ( Jansen, L; Kootstra, NA; Reesink, HW; Takkenberg, RB; van Dort, KA; Zaaijer, HL, 2016)
"In lamivudine-treated patients with suboptimal virological response at week 24, promptly adding on ADV is necessary to prevent resistance development."2.80Randomized, three-arm study to optimize lamivudine efficacy in hepatitis B e antigen-positive chronic hepatitis B patients. ( Chen, C; Chen, S; Chen, X; Cheng, J; Dou, X; Hou, J; Jia, J; Jiang, J; Li, T; Liang, X; Long, H; Ma, H; Ning, Q; Niu, J; Ren, H; Sheng, J; Shi, G; Shi, J; Sun, J; Sun, Y; Tan, D; Tang, H; Wan, M; Wang, H; Xie, Q; Yu, Y; Zhuang, H, 2015)
" During the open-label phase, grade 3/4 drug-related adverse events were uncommon (1."2.80Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection. ( Aguilar Schall, R; Buti, M; Charuworn, P; Flaherty, JF; Flisiak, R; Gane, E; Gurel, S; Kitrinos, KM; Krastev, Z; Marcellin, P; Martins, EB; Petersen, J; Subramanian, GM; Tsai, N, 2015)
"Adefovir + telbivudine treatment resulted in a significant reduction in HBV DNA levels."2.79Telbivudine and adefovir combination therapy for patients with chronic lamivudine-resistant hepatitis B virus infections. ( Chang, KC; Chiu, KW; Chou, YP; Hsu, YC; Hu, TH; Lin, MT; Tsai, MC; Tseng, PL; Yen, YH; Yu, HC, 2014)
"One major challenge in the treatment of chronic hepatitis B is to maintain long-term viral suppression without promoting the selection of drug-resistant mutations."2.79No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B. ( Borroto-Esoda, K; Corsa, A; Flaherty, J; Kitrinos, KM; Liu, Y; Marcellin, P; Miller, MD; Snow-Lampart, A, 2014)
" Most adverse events were mild in severity and considered unrelated to study drug."2.79Efficacy and safety of tenofovir disoproxil fumarate in Asian-Americans with chronic hepatitis B in community settings. ( Bae, H; Chan, S; Lou, L; Pan, CQ; Trinh, H; Yao, A, 2014)
"Current treatment options for chronic hepatitis B (CHB) are nucleoside or nucleotide analogues and pegylated interferons."2.79First-line monotherapies of tenofovir and entecavir have comparable efficacies in hepatitis B treatment. ( Cagatay, A; Ceylan, B; Erdem, L; Gokturk, K; Gunduz, A; Karaosmanoglu, H; Kocak, F; Mete, B; Ozaras, R; Ozgunes, N; Senates, E; Tabak, F, 2014)
"Sixty-one HBeAg-positive chronic hepatitis B patients were randomized to receive Peg-IFN alpha-2b alone (1."2.79Combination therapy with pegylated interferon alpha-2b and adefovir dipivoxil in HBeAg-positive chronic hepatitis B versus interferon alone: a prospective, randomized study. ( Dai, YR; Liu, YH; Sun, N; Wang, GL; Wu, T; Yuan, JZ; Zhou, XH, 2014)
"No patient experienced HBV recurrence through 72 weeks of the study while he or she was receiving the randomized treatment."2.78Randomized trial of emtricitabine/tenofovir disoproxil fumarate after hepatitis B immunoglobulin withdrawal after liver transplantation. ( Bzowej, N; Dinh, P; Flaherty, J; Martin, P; Poordad, F; Pungpapong, S; Rossi, S; Schiano, T; Spivey, J; Subramanian, GM; Teperman, LW, 2013)
"Patients with chronic hepatitis B and incomplete response to ADV were randomized in a double-blind trial of TDF vs."2.78Similar evolution of hepatitis B virus quasispecies in patients with incomplete adefovir response receiving tenofovir/emtricitabine combination or tenofovir monotherapy. ( Al Hawajri, N; Borroto-Esoda, K; Dény, P; Kitrinos, K; Lavocat, F; Pichoud, C; Zoulim, F, 2013)
" Tenofovir gel, when used intermittently, was safe to use in women with HBV infection."2.78Safety of coitally administered tenofovir 1% gel, a vaginal microbicide, in chronic hepatitis B virus carriers: results from the CAPRISA 004 trial. ( Abdool Karim, Q; Abdool Karim, SS; Baxter, C; Tshabalala, P; Yende-Zuma, N, 2013)
"There is no standard management of chronic hepatitis B (CHB) patients with suboptimal response to nucleoside/nucleotide analogues (NAs)."2.77Lamivudine plus adefovir or telbivudine plus adefovir for chronic hepatitis B patients with suboptimal response to adefovir. ( Bai, L; Chen, EQ; Liang, LB; Tang, H; Wang, JR; Yan, LB; Zhou, TY, 2012)
"Spontaneous reactivation of chronic hepatitis B (CHB) is an important cause of acute-on-chronic liver failure (ACLF)."2.76Tenofovir improves the outcome in patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure. ( Garg, H; Garg, V; Kumar, A; Kumar, M; Sarin, SK; Sharma, BC, 2011)
"Patients with chronic hepatitis B (HBeAg+ and HBeAg-) randomized in two trials of adefovir (ADV) vs placebo, with available paired liver biopsies and FT-AT at baseline and after 48 weeks of treatment were included."2.74Impact of adefovir dipivoxil on liver fibrosis and activity assessed with biochemical markers (FibroTest-ActiTest) in patients infected by hepatitis B virus. ( Benhamou, Y; Hadziyannis, S; Marcellin, P; Ngo, Y; Poynard, T; Ratziu, V, 2009)
"Treatment of chronic hepatitis B with generic ADV was effective and well tolerated, but relapse may develop when treatment was discontinued."2.74[Efficacy and durability of generic adefovir dipivoxil in patients with HBeAg positive chronic hepatitis]. ( Chen, XY; Ding, HG; Dong, PL; Min, J; Wang, DM; Zhang, B; Zhang, XM, 2009)
"Adefovir dipivoxil (ADV) has demonstrated activity against wild-type and lamivudine-resistant hepatitis B virus (HBV)."2.73Suboptimal response to adefovir dipivoxil therapy for chronic hepatitis B in nucleoside-naive patients is not due to pre-existing drug-resistant mutants. ( Carrouée-Durantel, S; Durantel, D; Naesens, L; Neyts, J; Pichoud, C; Trépo, C; Werle-Lapostolle, B; Zoulim, F, 2008)
"Treatment with adefovir dipivoxil (ADV) increases the rate of HBV e antigen (HBeAg) loss; however, the immune mechanisms associated with this treatment response are not understood."2.73Hepatitis B virus e antigen loss during adefovir dipivoxil therapy is associated with enhanced virus-specific CD4+ T-cell reactivity. ( Andreone, P; Brosgart, CL; Chokshi, S; Cooksley, H; Frederick, D; Gilson, R; Maayan, Y; Naoumov, NV; Neumann, AU; Paganin, S; Warnes, T; Wedemeyer, H; Zoulim, F, 2008)
"Adefovir dipivoxil (ADV) is a licensed treatment for chronic hepatitis B in adults."2.73The pharmacokinetics and safety of adefovir dipivoxil in children and adolescents with chronic hepatitis B virus infection. ( Dhawan, A; Frederick, D; Kelly, D; Mizerski, J; Sokal, EM; Wirth, S, 2008)
"Adefovir/lamivudine treatment resulted in greater viraemia reduction than adefovir monotherapy."2.73Dynamics of lamivudine-resistant hepatitis B virus during adefovir monotherapy versus lamivudine plus adefovir combination therapy. ( Arnold, C; Dervisevic, S; Ijaz, S; Mechurova, J; Naoumov, NV; Tatman, N; Tedder, RS, 2008)
"Lamivudine was combined for or=6 months in 12 (group III)."2.72Overlap lamivudine treatment in patients with chronic hepatitis B receiving adefovir for lamivudine-resistant viral mutants. ( Chen, DS; Chen, PJ; Chen, TC; Kao, JH; Lai, MY; Lin, FY; Liu, CJ, 2006)
"To investigate the efficacy, safety, and the tolerability of two dosing regimens of ADV (10 mg daily or 30 mg daily), two double-blind, placebo-controlled studies were performed in patients with chronic hepatitis B and compensated liver disease who were not undergoing current treatment and who had evidence of hepatitis B virus (HBV) replication."2.71Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double-blind, randomized, placebo-controlled studies. ( Arterbrun, S; Brosgart, CL; Currie, G; Deray, G; Hadziyannis, SJ; Hulot, JS; Izzedine, H; Launay-Vacher, V; Marcellini, P; Westland, C, 2004)
"Adefovir dipivoxil was recently approved for the treatment of wild-type and lamivudine-resistant hepatitis B virus (HBV) infection."2.71Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. ( Berg, T; Bergk, A; Mauss, S; Reinke, P; Schürmann, D; van Bömmel, F; Wiedenmann, B; Wünsche, T, 2004)
"Adefovir dipivoxil (ADV) has demonstrated clinical activity against wild-type and lamivudine-resistant HBV, but it is unclear whether resistance mutations will emerge after long-term therapy with this drug."2.70Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks. ( Brosgart, C; Delaney, WE; Fry, J; Gibbs, CS; Heathcote, EJ; Ho, V; Miller, MD; Westland, CE; Xiong, S; Yang, H, 2002)
"Treatment for chronic hepatitis B as a once-daily oral dose was well tolerated and associated with significant and sustained reductions in serum HBV DNA levels during treatment."2.69A placebo-controlled phase I/II study of adefovir dipivoxil in patients with chronic hepatitis B virus infection. ( Chopra, KB; Gilson, RJ; Jaffe, HS; Murray-Lyon, IM; Nelson, MR; Newell, AM; Rice, SJ; Tedder, RS; Toole, J; Weller, IV, 1999)
" However, less attention has been put on their adverse events."2.61Bayesian Network Meta-Analysis for Assessing Adverse Effects of Anti-hepatitis B Drugs. ( Ji, J; Jia, Y; Shen, Y; Xun, P; Zhou, J, 2019)
"Long-term treatment of chronic hepatitis B (CHB) with nucleos(t)ide analogues is often necessary to achieve durable viral suppression."2.58Long-term safety and efficacy of nucleo(t)side analogue therapy in hepatitis B. ( Buti, M; Esteban, R; Riveiro-Barciela, M, 2018)
"The primary goal of therapy for chronic hepatitis B (CHB) is to prevent liver disease progression."2.55Management of Antiviral Resistance in Chronic Hepatitis B. ( Lim, YS, 2017)
"Current agents for the treatment of chronic hepatitis B (CHB) can be classified into interferon-α (standard or pegylated) (IFN) and nucleos(t)ide analogues (NAs)."2.52Optimal therapy of chronic hepatitis B: how do I treat HBeAg-positive patients? ( Papatheodoridis, GV; Vlachogiannakos, J, 2015)
"HBeAg negative chronic hepatitis B (CHB) is a frequent, progressive and difficult-to-cure phase of CHB."2.52Optimal therapy of chronic hepatitis B: how do I treat my HBeAg-negative patients? ( Invernizzi, F; Lampertico, P; Viganò, M, 2015)
"For chronic HBV carrier liver cirrhosis patients, a successful vaccine response can only be achieved in selected patients, such as those treated with experimentally reduced immunosuppression protocols."2.52Molecular Mechanisms to Control Post-Transplantation Hepatitis B Recurrence. ( Takaki, A; Yagi, T; Yasunaka, T, 2015)
" Long-term use of NUCs with maintained viral suppression results in a decrease in liver-related complications."2.52Monotherapy for hepatitis B infection: a review of treatment options. ( Demirhan, YE; Gultekin, G; Isal, B; Khodor, H; Ozaras, R; Unal, UK; Yetim, N, 2015)
"Increased risk of lactic acidosis has also been described for those with impaired liver and renal function taking entecavir."2.50Extrahepatic effects of nucleoside and nucleotide analogues in chronic hepatitis B treatment. ( Fung, J; Lai, CL; Seto, WK; Yuen, MF, 2014)
"NAs are used in most HBeAg-positive chronic hepatitis B patients for several reasons."2.50HBeAg-positive chronic hepatitis B: why do i treat my patients with Nucleos(t)ide analogs? ( Buti, M, 2014)
" Long-term administration of ETV or TDF suppresses HBV replication in >95% of patients after 5 years of treatment with high rates of biochemical normalization, regression of fibrosis and cirrhosis at histology as well as preventing clinical decompensation but not HCC, in compensated cirrhosis and improving survival."2.50HBeAg-negative chronic hepatitis B: why do I treat my patients with nucleos(t)ide analogues? ( Lampertico, P; Mangia, G; Viganò, M, 2014)
"Although a rather benign course of chronic hepatitis B virus (HBV) infection during childhood has been described, 3-5% and 0."2.50Management of chronic hepatitis B in children: an unresolved issue. ( Cainelli, F; Comparcola, D; Della Corte, C; Nobili, V; Vento, S, 2014)
"Should treatment of chronic hepatitis B virus infection be necessary during pregnancy, tenofovir, listed by the FDA as pregnancy category B drug, is to be preferred."2.49[Interdisciplinary aspects of and new drugs for chronic hepatitis B]. ( Horváth, G, 2013)
"We expect future eradication of chronic hepatitis B virus infection by proper prevention and optimal management of antiviral resistance."2.49Options for the management of antiviral resistance during hepatitis B therapy: reflections on battles over a decade. ( Hwang, SG; Yim, HJ, 2013)
"In children, the natural history of chronic hepatitis B and C is different from that in adults."2.49[Treatment of viral hepatitis in children]. ( Kekez, AJ, 2013)
"Specialized treatment of CHB in pregnancy, coinfection, decompensated cirrhosis, and posttransplant is safe and effective."2.48New advances in chronic hepatitis B. ( Lee, WM; Tujios, SR, 2012)
"There are five approved drugs for the treatment of chronic hepatitis B(lamivudine, adefovir dipivoxil [ADV], entecavir [ETV], as well as pegylated and standard interferon) in Japan."2.48[New drugs of treatment of patients with chronic hepatitis B]. ( Suzuki, F, 2012)
"The specific drugs available for chronic hepatitis B infection include standard and pegylated IFN-α, and nucleoside/nucleotide analogs that directly inhibit the reverse transcriptase."2.48Tenofovir disoproxil fumarate in the treatment of chronic hepatitis B. ( Buti, M; Homs, M, 2012)
"Treatment of chronic hepatitis B (CHB) with nucleos(t)ide analogs is often required over a prolonged period to achieve durable virologic suppression."2.48Considerations for the long-term treatment of chronic hepatitis B with nucleos(t)ide analogs. ( Buti, M; Petersen, J, 2012)
" However, drug resistance caused by their long-term use becomes a practical problem, which influences the long-term outcomes in patients."2.48Diagnostic and therapeutic progress of multi-drug resistance with anti-HBV nucleos(t)ide analogues. ( Cui, YJ; Song, ZL; Teng, DH; Zheng, H; Zheng, WP, 2012)
"In the natural history of chronic hepatitis B infection, HBeAg marks the first two of the four phases, namely the immune tolerant phase and the immune clearance phase, and is associated with highly replicative activity of the hepatitis B virus (HBV)."2.47Treatment of HBeAg-positive chronic hepatitis B with nucleos(t)ide analogues. ( Leung, N, 2011)
"Major progress in the treatment of chronic hepatitis B (CHB) has been made during the last decade with the development of antivirals that inhibit viral polymerase activity."2.47Hepatitis B virus resistance to antiviral drugs: where are we going? ( Zoulim, F, 2011)
"Treatment of chronic hepatitis B is still challenging."2.47[Interferon-based versus direct antiviral therapy in patients with chronic hepatitis B]. ( Tornai, I, 2011)
" In most patients, NUC need to be administered on a long-term basis, thus increasing the risk of adverse effects."2.47Drug safety evaluation of adefovir in HBV infection. ( Colombo, M; Lampertico, P; Viganò, M, 2011)
"Antiviral therapy is aimed to persistently suppress hepatitis B virus (HBV) to prevent liver complications and improve survival and long-term administration of nucleos(t)ide analogues represents an attractive treatment strategy."2.45HBeAg-negative chronic hepatitis B: why do I treat my patients with nucleos(t)ide analogues. ( Colombo, M; Lampertico, P, 2009)
"The main goal for treatment of chronic hepatitis B is to prevent complications such as liver cirrhosis or hepatocellular carcinoma."2.44Treatment of chronic hepatitis B infection: an update of Swedish recommendations. ( Bläckberg, J; Duberg, AS; Fischler, B; Friman, S; Karlström, O; Lindh, M; Norkrans, G; Reichard, O; Sangfeldt, P; Söderström, A; Sönnerborg, A; Uhnoo, I; Weiland, O; Wejstål, R; Wiström, J, 2008)
"Chronic hepatitis B is still a major public health problem, aggravated by the growing phenomenon of immigration from areas with a high prevalence of infection with this virus."2.44[Clinical management of patients with chronic hepatitis B virus infection]. ( González-Diéguez, ML; Rodríguez, M, 2008)
"adefovir/pegIFN-alpha) were not available."2.44Comparative cost-effectiveness of antiviral therapies in patients with chronic hepatitis B: a systematic review of economic evidence. ( Jiang, XH; Li, YP; Qin, WX; Sun, X, 2007)
"However, recurrence rates are high after cessation of treatment."2.43[Management of chronic hepatitis B]. ( von Weizsäcker, F, 2005)
"Appropriate management of chronic hepatitis B must rely not only on the standard serologic markers but also on tests that quantify viral load and on the study of viral genome variability according to clinical situation."2.43[New virologic tests and their application in management of chronic hepatitis B]. ( Zoulim, F, 2006)
"Regardless of prophylaxis, the risk of recurrence is associated with pre-graft viral load."2.43[Liver transplantation for complications of hepatitis B]. ( Roche, B; Samuel, D, 2006)
"To address the clinical management of chronic hepatitis B virus (HBV) infection."2.43Management of chronic hepatitis B virus infection: current perspectives for the nurse practitioner. ( Perrillo, R, 2006)
"Registered treatment for chronic hepatitis B currently consists of (pegylated) interferon, lamivudine and adefovir, while entecavir is expected to be licensed in the short term."2.43Antiviral treatment for chronic hepatitis B virus infection--immune modulation or viral suppression? ( Buster, EH; Janssen, HL, 2006)
" Physicochemical properties, cellular permeation, renal toxicity, and bioavailability all had to be addressed during the development of these compounds."2.43Perspectives on the development of acyclic nucleotide analogs as antiviral drugs. ( Lee, WA; Martin, JC, 2006)
"In patients with liver cirrhosis (Child B and C) only nucleos(t)ides should be used."2.43[Therapy of hepatitis B virus infection]. ( Trautwein, C, 2006)
"About 350 million people worldwide have chronic hepatitis B virus (HBV) infection."2.42Slowing the progression of chronic hepatitis B. Early antiviral therapy can help minimize complications. ( Jacobson, IM; Purow, DB, 2003)
"Adefovir dipivoxil (Hepsera) is an oral prodrug of the nucleotide analogue adefovir."2.42Adefovir dipivoxil: a review of its use in chronic hepatitis B. ( Dando, T; Plosker, G, 2003)
"Furthermore, chronic hepatitis B was historically a controversial indication for liver transplantation because of a low post-transplant survival, with graft infection being the major contributor to adverse outcomes."2.42Nucleoside analogues and other antivirals for treatment of hepatitis B in the peritransplant period. ( Keeffe, EB; Yu, AS, 2003)
"Adefovir dipivoxil is an oral prodrug of adefovir, a nucleotide analogue of adenosine monophosphate."2.42[Application and efficacy of adefovir dipivoxil in hepatitis B virus-associated chronic liver diseases]. ( Cho, YK; Kim, BI, 2003)
"Adefovir dipivoxil is an acyclic nucleotide analogue that was developed in part to improve on the limitations of earlier therapies."2.42Adefovir dipivoxil: a new antiviral agent for the treatment of hepatitis B virus infection. ( Mattes, KA; Qaqish, RB; Ritchie, DJ, 2003)
"The treatment plan for chronic hepatitis B needs to be individualized based on the stage of both viral infections and the available options."2.42Management of chronic hepatitis B in the HIV-infected patient. ( Thio, CL, 2004)
"Treatment with Adefovir dipivoxil is a long term treatment (48 weeks), it is well tolerated, and side effects are moderate and reversible."2.42[Adefovir dipivoxil is a new drug for treatment of chronic hepatitis B]. ( Stránský, J, 2004)
"Currently approved treatments for chronic hepatitis B are limited by low rates of sustained response, side effects, or drug resistance."2.42New treatment of chronic hepatitis B. ( Lok, AS, 2004)
"The prevalence of chronic hepatitis B infection varies greatly in different regions of the world."2.42Antiviral therapy for treatment-naïve hepatitis B virus patients. ( Lau, DT; Membreno, FE, 2004)
"The treatment of the patient with chronic hepatitis B virus infection (HBV) must be carried out with the knowledge that the percentage of patients infected with the B virus that develop chronic hepatitis remains between 5-10%."2.42[Treatment of chronic hepatitis B virus infection]. ( Carreño, N; Moreno, D; Sangro, B, 2004)
"Treatment of chronic hepatitis B needs to consider two aspects."2.42[Management of hepatitis B]. ( de Gottardi, A; Negro, F, 2004)
"For HBeAG-positive chronic hepatitis B and HBeAG-negative chronic hepatitis B, the duration of interferon therapy is 4-6 months and 12 months, respectively."2.42Treatment of chronic hepatitis B: who to treat, what to use, and for how long? ( Fung, SK; Lok, AS, 2004)
"In hepatitis B e antigen-negative chronic hepatitis B, adefovir dipivoxil was recently found to maintain its efficacy even after 3 years of therapy."2.42Adefovir dipivoxil in the treatment of chronic hepatitis B virus infection. ( Hadziyannis, SJ; Papatheodoridis, GV, 2004)
"Chronic hepatitis B virus infection is common and may cause significant disease morbidity, including chronic hepatitis, cirrhosis, and hepatocellular carcinoma."2.41Update on the management of chronic hepatitis B. ( Davis, GL, 2002)
"In IFN-naive patients with chronic hepatitis B (and compensated liver disease) alpha-interferon is still the first-line therapy."2.41[New developments in therapy of chronic hepatitis B. When are nucleoside analogs indicated?]. ( Erhardt, A; Häussinger, D; Heintges, T; Petry, W, 2000)
"Lamivudine has been demonstrated to have consistent efficacy and safety in large-scale, phase III clinical trials."2.41Nucleoside analogues in the treatment of chronic hepatitis B. ( Leung, N, 2000)
"Lamivudine has been introduced as an alternative to IFN, showing at least similar efficacy, but with a wider spectrum of indications and without the adverse effects."2.41Drug therapy for hepatitis B. ( Regev, A; Schiff, ER, 2001)
" The aim was to investigate the expression of IL-1β in CHB patients treated with Peg-IFN-α combination with TDF and TDF/Peg-IFN-α monotherapy."1.91The expression of interleukin-1β in patients with chronic hepatitis B treated with pegylated-interferon-alpha combined with tenofovir disoproxil fumarate and monotherapy. ( Hu, X; Li, Y; Luo, H; Qin, B; Tan, G, 2023)
"We retrospectively enrolled 70 unresectable HCC patients who were seropositive for HBsAg and accepted tenofovir alafenamide fumarate (TAF) therapy before anti-PD-1 in combination with an antiangiogenic treatment."1.72Interaction between baseline HBV loads and the prognosis of patients with HCC receiving anti-PD-1 in combination with antiangiogenic therapy undergoing concurrent TAF prophylaxis. ( Chen, J; Hu, X; Li, Q; Li, R; Yuan, G; Zang, M, 2022)
" TAF was well tolerated and only 4 patients discontinued therapy due to adverse event during a median duration of TAF dosing of 74 weeks."1.72Safety and Effectiveness of Tenofovir Alafenamide in Usual Clinical Practice Confirms Results of Clinical Trials: TARGET-HBV. ( Bernstein, DE; Fried, MW; Lok, AS; Mospan, AR; Schiff, ER; Smith, CI; Trinh, HN; Zink, RC, 2022)
"The prediction of hepatocellular carcinoma (HCC) development during nucleotide/nucleoside analog (NA) therapy is clinically important in patients with chronic hepatitis B."1.56Validation of hepatocellular carcinoma risk scores in Japanese chronic hepatitis B cohort receiving nucleot(s)ide analog. ( Hayakawa, Y; Higuchi, M; Inada, K; Itakura, J; Izumi, N; Kaneko, S; Kirino, S; Kurosaki, M; Maeyashiki, C; Nakanishi, H; Okada, M; Osawa, L; Sekiguchi, S; Shimizu, T; Takahashi, Y; Takaura, K; Tamaki, N; Tsuchiya, K; Wang, W; Watakabe, K; Yamashita, K; Yasui, Y, 2020)
"Fanconi syndrome with osteomalacia can develop in patients with chronic hepatitis B infection being treated with adefovir at a conventional low dosage of 10 mg/day."1.56Osteomalacia and renal failure due to Fanconi syndrome caused by long-term low-dose Adefovir Dipivoxil: a case report. ( Cen, X; Cui, Y; Liu, Z; Mu, G; Xiang, Q; Xie, Q; Yu, Y; Zhang, H; Zhang, J, 2020)
" Secondary assessments included maternal HBV DNA reduction at delivery, and maternal or infant adverse events during follow up."1.56Efficacy and safety of tenofovir alafenamide fumarate for preventing mother-to-child transmission of hepatitis B virus: a national cohort study. ( Cao, L; Chen, B; Chen, R; Ding, Y; Fan, J; Gan, W; Huang, Y; Lin, C; Liu, Y; Pan, CQ; Sheng, Q; Wang, S; Wang, Y; Zhu, L, 2020)
"A 68-year-old man with type 2 diabetes mellitus and chronic hepatitis B infection was referred to the nephrology department before planned surgery for hepatocellular carcinoma."1.51Hypophosphatemic Osteomalacia Associated with Adefovir-induced Fanconi Syndrome Initially Diagnosed as Diabetic Kidney Disease and Vitamin D Deficiency. ( Iino, N; Koda, R; Narita, I; Tsuchida, M, 2019)
"The optimal management of chronic hepatitis B (CHB) patients with partial virologic response (PVR) to tenofovir disoproxil fumarate (TDF) remains unclear."1.51Efficacy of long-term tenofovir disoproxil fumarate therapy in chronic hepatitis B patients with partial virologic response in real practice. ( Kim, BS; Lee, CH; Song, JE, 2019)
"Acquired Fanconi syndrome has been associated with the long-term ingestion of several nucleoside analogs used to treat chronic hepatitis B virus infection."1.51A case of entecavir-induced Fanconi syndrome. ( Fujii, T; Kawasoe, K; Nitta, K; Ohta, A, 2019)
"In areas where chronic hepatitis B virus infection is prevalent, acute hepatitis E virus superinfection on chronic hepatitis B virus infection occurs sporadically."1.48Seroclearance of hepatitis B surface antigen following hepatitis E exacerbation on chronic hepatitis E and B dual infection in a renal transplant recipient: a case report. ( Chiang, YJ; Chu, YD; Yeh, CS; Yeh, CT, 2018)
"Fanconi syndrome is a rare adverse effect of tenofovir disoproxil fumarate (TDF)."1.46Short Communication: Resolution of Tenofovir Disoproxil Fumarate Induced Fanconi Syndrome with Switch to Tenofovir Alafenamide Fumarate in a HIV-1 and Hepatitis B Coinfected Patient. ( Karris, MY, 2017)
"A major hurdle in the long-term treatment of chronic hepatitis B (CHB) patients is to maintain viral suppression in the absence of drug resistance."1.46No detectable resistance to tenofovir disoproxil fumarate in HBeAg+ and HBeAg- patients with chronic hepatitis B after 8 years of treatment. ( Buti, M; Cathcart, AL; Corsa, AC; Flaherty, JF; Gane, EJ; Kitrinos, KM; Liu, Y; Marcellin, P; Miller, MD, 2017)
"Long-term TDF treatment appears to be safe and effective in patients with prior failure of LAM and a suboptimal response to ADV therapy."1.46Five-year efficacy and safety of tenofovir-based salvage therapy for patients with chronic hepatitis B who previously failed LAM/ADV therapy. ( Angus, P; Bowden, S; Desmond, P; George, J; Lee, A; Lim, L; Locarnini, S; Marion, K; Nicoll, A; Patterson, S; Roberts, S; Sievert, W; Strasser, S; Thompson, A, 2017)
"Mortality and complications including hepatocellular carcinoma are associated primarily with cirrhosis and age, but not with HBeAg status or viral load probably because modern therapies considerably reduce viral replication in almost all patients."1.43Long-term follow-up of HBsAg-positive patients in Germany. ( Amani, A; Niederau, C; Thiel, A, 2016)
"Multidrug resistance protein 4 is a critical protein associated with the antiviral efficacy of NAs, and combination therapy of NA and MRP inhibitors could reduce the dosage for long-term NA use."1.43Multidrug resistance protein 4 is a critical protein associated with the antiviral efficacy of nucleos(t)ide analogues. ( Chen, Q; Liu, W; Liu, Y; Lu, M; Song, H; Wang, B; Xu, C; Xu, D; Yang, D; Zhang, W; Zheng, X, 2016)
"Eighty-one chronic hepatitis B patients with a viral load above 4 log 10 copies/ml and high levels of serum alanine aminotransferase were treated with ETV 0."1.43Profile of HBV polymerase gene mutations during entecavir treatment in patients with chronic hepatitis B. ( Song, J; Sun, M; Tan, G; Wang, J; Wu, X, 2016)
"The cumulative probability of HBV recurrence at 1, 3, 5, and 7 years was 1%, 3%, 3%, and 4%, respectively."1.43The long-term efficacy of combining nucleos(t)ide analog and low-dose hepatitis B immunoglobulin on post-transplant hepatitis B virus recurrence. ( Akyildiz, M; Balci, D; Cinar, K; Dayangac, M; Gungor, G; Hazinedaroglu, S; Idilman, R; Kalkan, C; Keskin, O; Tokat, Y; Yilmaz, TU, 2016)
"Reduction of viraemia in patients with chronic hepatitis B virus (HBV) infection using nucleoside/nucleotide analogues reduces fatal liver disease-related events, but development of resistance in virus presents serious clinical challenge."1.43Comparative evaluation of long-term monotherapies & combination therapies in patients with chronic hepatitis B: A pilot study. ( Dixit, VK; Jain, AK; Nath, G; Singh, N; Srivastava, M, 2016)
"The treatments for chronic hepatitis B (CHB) are interferon and nucleoside analogues reverse transcriptase (RT) inhibitors."1.42Discovering novel direct acting antiviral agents for HBV using in silico screening. ( Enomoto, M; Hayakawa, M; Iwadate, M; Kawada, N; Murakami, Y; Tamori, A; Tanahashi, T; Umeyama, H; Yano, Y, 2015)
"This case indicates that Fanconi's syndrome with osteomalacia can be acquired by a chronic hepatitis B patient taking ADV at a conventional dosage of 10 mg/day."1.42Osteomalacia and Fanconi's syndrome caused by long-term low-dose adefovir dipivoxil. ( Chen, YS; Sun, FR; Wang, BF; Wang, BY; Wang, Y; Zhang, D, 2015)
"Charts were reviewed for LAM-resistant chronic hepatitis B (CHB) patients who visited the Zhejiang Province People's Hospital and The First Affiliated Hospital, College of Medicine, Zhejiang University, from June 2009 to May 2013."1.42Tenofovir disoproxil fumarate is superior to lamivudine plus adefovir in lamivudine-resistant chronic hepatitis B patients. ( Huang, HJ; Li, MW; Pan, HY; Xie, YJ; Yang, DH; Zhao, NF, 2015)
"Splenomegaly is a common finding in chronic hepatitis B infection."1.42Remission of splenic marginal zone lymphoma in a patient treated for hepatitis B: a case of HBV-associated lymphoma. ( Huits, RM; Koot, AW; Visscher, AP, 2015)
"Viral genotype shift in chronic hepatitis B (CHB) patients during antiviral therapy has been reported, but the underlying mechanism remains elusive."1.42Deep sequencing analysis of HBV genotype shift and correlation with antiviral efficiency during adefovir dipivoxil therapy. ( Chen, J; Gong, X; Huang, A; Huang, W; Liang, Z; Shan, X; Shan, Y; Wang, Y; Xu, G; Zen, A; Zhang, D; Zhang, X; Zhao, Y; Zhou, X, 2015)
"Lamivudine resistance was common in all populations, especially in Hans with prevalence of 42."1.42Epidemiology study of HBV genotypes and antiviral drug resistance in multi-ethnic regions from Western China. ( Cai, B; Chen, J; Liao, Y; Lu, X; Su, Z; Tao, C; Wang, L; Ying, B; Zhang, Q, 2015)
" No significant adverse event was observed due to TDF administration; renal function pre- and post-LT were also acceptably preserved."1.40One year of hepatitis B immunoglobulin plus tenofovir therapy is safe and effective in preventing recurrent hepatitis B post-liver transplantation. ( Lilly, LB; Renner, EL; Selzner, N; Tanaka, T; Therapondos, G, 2014)
"Chronic hepatitis B is an important health problem worldwide."1.40Lamivudine and Adefovir Motif Variants Detected in chronic Hepatıtıs B patients. ( Atmaca, S; Mese, S; Ozbek, E; Ozekinci, T, 2014)
"Adefovir has a good inhibitory effect against the latent or hidden HBV in neutrophils."1.40[Detection and analysis of HBV in polymorphonuclear neutrophils of patients with hepatitis B]. ( Han, Z; Wang, J, 2014)
" Antiviral treatments were withdrawn in patients who met all of the following 7 criteria: (i) no clinical and histologic evidence of cirrhosis, (ii) normal liver biochemistry, (iii) negative for both HBV DNA and hepatitis B envelope antigen (HBeAg), (iv) no resistance to antiviral agent, (v) antiviral therapy > 9 months, (vi) maintenance dosage of immunosuppressant for > 3 months, and (vii) no history of acute rejection during recent 6 months."1.40Successful withdrawal of antiviral treatment in kidney transplant recipients with chronic hepatitis B viral infection. ( Cho, JH; Choi, JY; Huh, S; Kang, YJ; Kim, CD; Kim, HK; Kim, JS; Kim, YL; Kwon, O; Lim, JH; Park, GY; Park, SH, 2014)
"Twenty chronic hepatitis B (CHB) patients who had been receiving ETV for more than 6 months and developed virologic breakthrough due to ETV resistance were consecutively enrolled."1.40Adefovir and lamivudine combination therapy in patients with entecavir-resistant chronic hepatitis B: antiviral responses and evolution of mutations. ( Baik, SK; Chae, HB; Hong, SP; Kim, CW; Kim, JH; Kim, MY; Kim, YS; Lee, CD; Lee, HJ; Lee, JI; Lee, JW; Lee, MS; Park, CK; Park, SH; Seo, YS; Suh, SJ; Um, SH; Yim, HJ, 2014)
"The treatment of HBeAg-negative chronic hepatitis B (CHB) is considered to be open-ended, with no guidelines for treatment cessation."1.40Treatment cessation in noncirrhotic, e-antigen negative chronic hepatitis B is safe and effective following prolonged anti-viral suppression with nucleosides/nucleotides. ( Afdhal, NH; Bonder, A; Lau, D; Patwardhan, VR; Sengupta, N, 2014)
"The prevalence of chronic hepatitis B in Bangladesh is reported to be 7."1.40Efficacy of adefovir dipivoxil therapy in patients with chronic hepatitis B viral infection. ( Chowdhury, MS; Khan, MR; Mahmuduzzaman, M; Miah, AR; Rahman, KM; Raihan, MA; Roknuzzaman, SM; Roy, PK; Saha, M, 2014)
"Hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHB) is the most frequent and difficult-to-treat viral hepatitis worldwide."1.39Individualized treatment of HBeAg-negative chronic hepatitis B using pegylated interferon-α2a as first-line and week-12 HBV DNA/HBsAg stopping rule: a cost-effectiveness analysis. ( Bonino, F; Brunetto, MR; Caputo, A; Coco, B; Espinos, B; Iannazzo, S; Latour, A; Rossetti, F, 2013)
"HIV worsens the natural history of chronic hepatitis B virus (HBV) infection."1.39Influence of HIV infection on response to tenofovir in patients with chronic hepatitis B. ( Aguilera, A; Barreiro, P; del Romero, J; Mena, A; Pedreira, J; Plaza, Z; Poveda, E; Rodriguez, C; Sierra-Enguita, R; Soriano, V; Tomé, S; Vispo, E, 2013)
"Combined prophylaxis with TDF/ETV nucleoside plus nucleotide analogs and cessation of immunoglobulin after liver transplantation in chronic hepatitis B is safe and effective."1.39Nucleoside plus nucleotide analogs and cessation of hepatitis B immunoglobulin after liver transplantation in chronic hepatitis B is safe and effective. ( Braat, AE; Claas, EC; Coenraad, MJ; Knoester, M; van Hoek, B; Vossen, AC; Wesdorp, DJ, 2013)
"Treated with adefovir dipivoxil antiviral therapy, and mesured the setologic indicators after 12 weeks, 24 weeks,36 weeks and 48 weeks."1.39[The clinical significance of hepatitis B virus large surface protein in the diagnosis and treatment of patients with hepatitis B]. ( Chen, W; Sun, Q; Xie, FY, 2013)
"Some patients with chronic hepatitis B virus (HBV) infection progress to hepatocellular carcinoma (HCC)."1.39Effect of nucleos(t)ide analogue therapy on hepatocarcinogenesis in chronic hepatitis B patients: a propensity score analysis. ( Andou, Y; Hisanaga, Y; Kanamori, A; Kiriyama, S; Kumada, T; Niinomi, T; Tada, T; Tanaka, J; Tanikawa, M; Toyoda, H; Yamamoto, K; Yasuda, S, 2013)
"Patients with chronic hepatitis B receiving different schedules of nucleoside/nucleotide analogues were followed for a median duration of 102 months, i."1.39Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy: finite treatment duration unlikely. ( Bahrami, S; Chevaliez, S; Grare, M; Hézode, C; Pawlotsky, JM, 2013)
"In patients affected by chronic hepatitis because of HBV infection, long-term suppressive therapy with nucleos(t)ides analogues in the HBeAg- patients has shown low effects on HBsAg titre (qHBsAg) decrease, and HBsAg loss is difficult to achieve."1.39Kinetics and prediction of HBsAg loss during therapy with analogues in patients affected by chronic hepatitis B HBeAg negative and genotype D. ( Baietto, L; Boglione, L; Burdino, E; Cariti, G; Cusato, J; D'Avolio, A; De Rosa, FG; Di Perri, G; Ghisetti, V; Gregori, G, 2013)
"TDF/emtricitabine was less likely to be associated with detectable HBV than other regimens, including TDF monotherapy (odds ratio, 2."1.39Patterns and causes of suboptimal response to tenofovir-based therapy in individuals coinfected with HIV and hepatitis B virus. ( Avihingsanon, A; Bowden, S; Dore, GJ; Finlayson, R; Hoy, JF; Lewin, SR; Littlejohn, M; Locarnini, S; Matthews, GV; Revill, PA; Ruxrungtham, K; Sasadeusz, J; Saulynas, M; Seaberg, EC; Thio, CL, 2013)
"Patients with HBV recurrence were divided into four groups according to their treatment: group L (lamivudine-based therapy n = 21) and group N [new nucleos(t)ide analogue (NA)-based therapy, n = 38]."1.39Outcome of various treatments for posttransplant hepatitis B virus recurrence. ( Han, SS; Hong, G; Kong, SY; Lee, KB; Lee, KW; Park, KU; Park, SJ; Suh, KS; Yi, NJ, 2013)
"To investigate 3-year antiviral efficacy and side effect of adefovir dipivoxil (ADV) on the old patients with hepatitis B chronic infection."1.38[Three-year efficacy and side effect of adefovir dipivoxil for the treatment of the old patients with chronic hepatitis B virus infection]. ( Lou, GQ; Lu, L; Qian, JC; Shi, JP; Yan, FL; Zhu, MF, 2012)
"Adefovir dipivoxil (ADV) is an oral bioavailable prodrug of adefovir that possesses potent in vitro activity against hepadnaviruses, retroviruses and herpes viruses."1.38Nephrotoxicity, including acquired Fanconi's syndrome, caused by adefovir dipivoxil - is there a safe dose? ( Ho, YY; Law, ST; Li, KK, 2012)
" Modification of the dosing interval or discontinuation of ADV was required in seven and three patients, respectively, and none of them showed a further decline in the eGFR."1.38Frequency and risk factors of renal impairment during long-term adefovir dipivoxil treatment in chronic hepatitis B patients. ( Cho, HC; Choi, MS; Gwak, GY; Kim, YJ; Koh, KC; Lee, JH; Paik, SW; Sinn, DH; Yoo, BC, 2012)
"This retrospective study enrolled 38 chronic hepatitis B patients treated with IFN-α plus a nucleos(t)ide analog who achieved HBsAg seroconversion during the period from June 2001 to May 2009."1.38Potent hepatitis B surface antigen response to treatment of hepatitis-B-e-antigen-positive chronic hepatitis B with α-interferon plus a nucleos(t)ide analog. ( Cao, Z; Chen, X; Jin, Y; Liu, Y; Ma, B; Ma, L; Wu, H; Yu, H; Zhang, H; Zhang, Y; Zheng, Y, 2012)
" Several studies suggest that NAs long-term administration have been associated with low rates of serious adverse events (AEs), including lactic acidosis, renal function impairment, osteopenia and osteoporosis."1.38Safety of long-term nucleos(t)ide treatment in chronic hepatitis B. ( Ridruejo, E; Silva, MO, 2012)
"The effectiveness of antiviral treatments of chronic hepatitis B has been poorly studied in Brazil."1.38Antiviral therapy against chronic hepatitis B in Brazil: high rates of lamivudine resistance mutations and correlation with HBV genotypes. ( Fernandes, CA; Gomes, Sde A; Mello, FC, 2012)
"In patients with chronic hepatitis B virus (HBV) infection, persistent exposure to high concentrations of antigen can disrupt T-cell functions."1.38Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues. ( Alfieri, A; Boni, C; Brancaccio, G; Colombo, M; Ferrari, C; Gaeta, GB; Giuberti, T; Laccabue, D; Lampertico, P; Missale, G; Pesci, M; Schivazappa, S; Viganò, M, 2012)
"We report on how adefovir-induced membranous nephropathy related to hepatitis B was caused by lamivudine-resistant virus after a liver transplant due to Byler's disease."1.38A case of adefovir-induced membranous nephropathy related to hepatitis B caused by lamivudine-resistant virus after liver transplant due to Byler's disease. ( Ebata, S; Hashimoto, S; Ishikawa, Y; Ito, M; Koike, T; Maoka, T; Mochizuki, T; Suzuki, A, 2012)
"New insights into the treatment of chronic hepatitis B with relevance for clinical practice have been adopted in these concise, revised guidelines."1.38The 2012 revised Dutch national guidelines for the treatment of chronic hepatitis B virus infection. ( Baak, BC; Bakker, CM; Beuers, UH; Brouwer, JT; Buster, EH; Drenth, JP; Honkoop, P; Janssen, HL; Kerbert-Dreteler, MJ; Koek, GH; Tan, AC; van der Spek, BW; van Erpecum, KJ; van Hoek, B; van Nieuwkerk, KM; van Soest, H; Vrolijk, JM, 2012)
"Lamivudine treatment improves renal outcome in patients with hepatitis B virus-associated MN (HBV-MN), but prolonged use leads to the emergence of lamivudine-resistant variants."1.38Experience of anti-viral therapy in hepatitis B-associated membranous nephropathy, including Lamivudine-resistant strains. ( Choi, BS; Choi, SR; Chung, BH; Hong, YA; Kim, YS; Park, CW; Park, HS; Sun, IO; Yang, CW, 2012)
"Current agents used in the treatment of chronic hepatitis B (CHB) can be classified into interferons-α (IFN-α: standard or pegylated) and nucleos(t)ide analogues (NUCs)."1.37Treatment of HBeAg-negative chronic hepatitis B patients with nucleos(t)ide analogues. ( Papatheodoridis, GV, 2011)
"Lamivudine (LAM) has been extensively used to treat hepatitis B, but high incidence of drug resistance has required rescue studies."1.37Add-on adefovir is superior to a switch to entecavir as rescue therapy for Lamivudine-resistant chronic hepatitis B. ( Chung, GE; Hwang, SY; Jeong, JB; Jung, YJ; Kim, BG; Kim, D; Kim, HY; Kim, W; Kim, YJ; Lee, HS; Lee, JH; Lee, KL; Yoon, JH, 2011)
"Forty-five HBeAg-positive chronic hepatitis B patients with a virologic response [negative PCR (<12 IU/ml)] who had discontinued therapy were analyzed retrospectively for VR, HBeAg reversion and biochemical flare."1.37Defining virologic relapse in chronic hepatitis B. ( Cho, HC; Choi, MS; Gwak, GY; Kim, KH; Koh, KC; Lee, JH; Lee, YY; Paik, SW; Sinn, DH; Yoo, BC; Yun, WK, 2011)
" IFN therapy requires dosage reduction and close monitoring in patients with a GFR <50 ml/min/1."1.37Does the antiviral therapy of patients with chronic hepatitis exert nephrotoxic effects? ( Bob, F; Bozdog, G; Cioca, D; Curescu, M; Gadalean, F; Gluhovschi, C; Gluhovschi, G; Kaycsa, A; Petrica, L; Sporea, I; Velciov, S; Vernic, C, 2011)
"The effect of chronic hepatitis B (CHB) treatment on hepatocyte apoptosis has not been evaluated."1.37Changes of serum levels of keratin-18 fragments in hepatitis B e antigen-negative chronic hepatitis B patients under oral antiviral therapy. ( Georgiou, A; Giannousis, IP; Hadziyannis, E; Manolakopoulos, SG; Papatheodoridis, GV, 2011)
"Treatment with adefovir dipivoxil reduced the frequency of CD4(+)CXCR5(+) TFH, PD-1(+)CD4(+)CXCR5(+) TFH cells and the concentrations of HBsAg and HBeAg, but increased the concentrations of HBsAb, HBeAb, IL-2 and IFN-γ in IA patients."1.37High frequency of CD4+ CXCR5+ TFH cells in patients with immune-active chronic hepatitis B. ( Feng, J; Hua, C; Jiang, Y; Li, W; Lu, L; Qin, L; Shi, X; Wang, J; Wang, Y; Zhao, P, 2011)
"In total, 33 patients with chronic hepatitis B virus (HBV) infection with evidence of active viral replication (HBV DNA levels ≥ 10(5) copies/mL) or a history of treatment failure to lamivudine/adefovir sequential therapy between April 2007 and July 2009 were treated with entecavir (1."1.37Long-term efficacy of entecavir therapy in chronic hepatitis B patients with antiviral resistance to lamivudine and adefovir. ( Cho, YS; Choi, JW; Kim, KA; Kwak, MS; Lee, CK; Lee, JS; Park, BK; Suh, JH; Won, SY, 2011)
"Adefovir Dipivoxil (ADV) is an important agent to suppress hepatitis B virus (HBV) replication with suboptimal effect on virological and serological response."1.37Optimization of adefovir therapy in chronic hepatitis B according to baseline predictors and on-treatment HBV DNA: a 5-year prospective study. ( Geng, da Y; Lu, B; Lu, H; Ma, LX; Shen, F; Zhang, JY, 2011)
"Forty adefovir-refractory chronic hepatitis B patients with prior lamivudine resistance who had received entecavir for > or = 6 months were included and monitored for virologic response and entecavir resistance."1.36Low efficacy of entecavir therapy in adefovir-refractory hepatitis B patients with prior lamivudine resistance. ( Cheong, JY; Cho, SW; Hong, SP; Kim, SO; Koh, KH; Lee, MH; Yoo, WD, 2010)
"A total of 44 chronic hepatitis B (CHB) patients (mean age: 42 +/- 13."1.36[Genotype distribution of chronic hepatitis B and hepatitis C patients and investigation of the resistance patterns in hepatitis B cases]. ( Akcan, Y; Altindiş, M; Demirdal, T; Demirtürk, N; Gülamber, G; Kalayci, R, 2010)
"With lamivudine as initial treatment, 62% of patients developed drug resistance after 4 years."1.36Long-term outcome of renal transplant recipients with chronic hepatitis B infection-impact of antiviral treatments. ( Chan, TM; Choy, BY; Tang, CS; Yap, DY; Yuen, MF; Yung, S, 2010)
"In treatment-naive patients with chronic hepatitis B the first line therapy should be PeglFN-alpha2a monotherapy, and the first-line should be entecavir or tenofovir (highest potential for HBV replication suppression and high genetic barrier to resistance)."1.36[Antiviral treatment of chronic B hepatitis; 2010 - therapeutic recommendations]. ( Boroń-Kaczmarska, A; Cianciara, J; Flisiak, R; Gładysz, A; Halota, W; Juszczyk, J; Kryczka, W; Malkowski, P; Pawlowska, M; Simon, K, 2010)
"Data on liver fibrosis evolution in HIV-HBV-coinfected patients treated with tenofovir disoproxil fumarate (TDF) are scarce."1.36Liver fibrosis changes in HIV-HBV-coinfected patients: clinical, biochemical and histological effect of long-term tenofovir disoproxil fumarate use. ( Bonnard, P; Boyd, A; Girard, PM; Lacombe, K; Lascoux-Combe, C; Lasnier, E; Meynard, JL; Miailhes, P; Molina, JM; Wendum, D, 2010)
"Overall, 63 (13%) patients had chronic hepatitis B (HBsAg-positive), 115 (23%) had never been exposed to HBV (HBsAg-negative, anti-HBc-negative and anti-HBs-negative), 108 (22%) had signs of cured infection (anti-HBc-positive and anti-HBs-positive) and 209 (42%) had isolated anti-HBc (HBsAg-negative, anti-HBc-positive and anti-HBs-negative)."1.36Occult HBV infection in untreated HIV-infected adults in Côte d'Ivoire. ( Anglaret, X; Attia, A; Chenal, H; Danel, C; Eholié, S; Gabillard, D; Messou, E; N'Dri-Yoman, T; Polneau, S; Seyler, C; Toni, T; Wakasugi, N, 2010)
"Serum samples of 199 chronic hepatitis B patients undergoing NA treatment from five hospitals in four northern cities of China were obtained between January 2007 and July 2009."1.36Profile of HBV antiviral resistance mutations with distinct evolutionary pathways against nucleoside/nucleotide analogue treatment among Chinese chronic hepatitis B patients. ( Abuduheilili, X; Dong, JP; Hou, CS; Jiao, XJ; Li, T; Li, XG; Liu, BM; Sun, XW; Wang, YH; Xu, J; Yan, CH; Yan, L; Yang, JX; Zhuang, H, 2010)
"HBV genotypes from 177 HBeAg-positive chronic hepatitis B (CHB) patients were identified and the patients were treated with ADV 10 mg per day for 48 weeks."1.35[Comparison of antiviral responses to adefovir dipivoxil therapy of genotype B and genotype C HBV infected patients]. ( Deng, H; Guo, JJ; Hao, MJ; Huang, AL; Huang, WX; Li, QL; Peng, FY; Xin, XJ; Yang, C; Yuan, Z; Zeng, AZ; Zhang, ZZ, 2008)
"Lamivudine has a high rate of antiviral resistance."1.35Rapid re-emergence of YMDD mutation of hepatitis B virus with hepatic decompensation after lamivudine retreatment. ( Byun, KS; Choe, WH; Kwon, SY; Lee, CH; Yeon, JE, 2008)
"Lamivudine resistance is a result of mutations in YMDD motif in which rt203-206th codons (Y: tyrosine; M: methionin; D: aspartic acid; D: aspartic acid) of reverse trancriptase; the catalytic part of hepatitis B polymerase enzyme, takes place."1.35[YMDD motif variants detected by Inno-Lipa HBV DR assay in chronic hepatitis B patients during lamivudine therapy]. ( Arslan, U; Findik, D; Ural, O, 2008)
"Adefovir dipivoxil (ADV) is a nucleotide analogue that inhibits wild-type hepatitis B virus (HBV) and lamivudine (LMV)-resistant HBV mutants."1.35[The efficacy of adefovir dipivoxil monotherapy and the incidence of genotypic resistance to adefovir dipivoxil in patients with lamivudine-resistant chronic hepatitis B infection]. ( Bae, JH; Cho, M; Heo, J; Kang, DH; Kim, GH; Moon, JH; Song, GA; Yoon, KT, 2008)
"Adefovir has a potent antiviral activity as a rescue treatment against lamivudine-resistant strains."1.35Association of lamivudine-resistant mutational patterns with the antiviral effect of adefovir in patients with chronic hepatitis B. ( Cha, CK; Cheong, JY; Cho, SW; Hong, SP; Kim, SO; Kwon, HC; Yoo, WD, 2009)
"A total of 97 chronic hepatitis B (CHB) patients with YMDD mutants who had been treated with ADV for >12 months were analysed."1.35Hepatitis B virus with the rtL80V/I mutation is associated with a poor response to adefovir dipivoxil therapy. ( Chung, YH; Kim, JA; Kim, KM; Kim, SE; Lee, HC; Lee, YS; Lim, YS; Park, NH; Shin, JW; Suh, DJ, 2009)
"Lamivudine was started at the same time as the TNF antagonist in the other 2 patients, whose viral loads remained undetectable."1.35Spondyloarthropathy and chronic B hepatitis. Effect of anti-TNF therapy. ( Di Martino, V; Herbein, G; Prati, C; Toussirot, E; Wendling, D, 2009)
"Long-term management of some chronic hepatitis B patients might require combination therapy using drugs with distinct resistance profiles to sustain viral suppression and to reduce the resistance-associated failure."1.35Anti-hepatitis B virus activity in vitro of combinations of tenofovir with nucleoside/nucleotide analogues. ( Borroto-Esoda, K; Curtis, M; Miller, MD; Qi, X; Zhu, Y, 2009)
"Diagnosis and treatment of chronic hepatitis B (CHB) have improved in recent years with introduction of new oral antiviral drugs."1.35Current trends in chronic hepatitis B management: results of a questionnaire. ( Buti, M; Córdoba, J; Esteban, R; García-Martínez, R; Les, I; Quintana, M, 2009)
"We performed a cohort study of 290 chronic hepatitis B patients: 145 patients treated with 10 mg ADV and 145 patients unexposed to ADV at two community clinics, who were matched for age (+/-10 years), sex, and baseline eGFR."1.35Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil. ( Garcia, RT; Ha, NB; Levitt, BS; Nguyen, HA; Nguyen, KK; Nguyen, MH; Trinh, HN; Vu, AA, 2009)
"A 36 year old man with chronic hepatitis B and cirrhosis was admitted in our Department for the onset of jaundice, ascites and ALT flare (x 35 u."1.35Salvage therapy with tenofovir followed by adefovir maintenance in a cirrhotic patient with a lamivudine resistant HBV flare. ( Brancaccio, G; Gaeta, GB; Nardiello, S; Precone, V; Sgrò, G; Stornaiuolo, G, 2009)
"In lamivudine-treated samples, wild-type strains (57."1.35Dynamic changes of HBV quasispecies and deletion patterns in a chronic hepatitis B patient. ( Ding, H; Ji, F; Li, F; Ma, S; Zeng, C; Zhou, L, 2009)
"A total of 170 naïve HBeAg-positive chronic hepatitis B patients were treated with a nucleoside/nucleotide analogues (NA), either lamivudine, adefovir, entecavir, or telbivudine, for at least 2 years and followed up for 1 more year."1.35Different models of HBeAg seroconversion predicated by on-treatment ALT and HBV DNA profiles. ( Cong, M; Jia, J; Li, H; Liu, T; Ma, H; Ou, X; Ren, J; Wang, B; Wang, P; Wang, X; You, H, 2009)
"Chronic hepatitis B affects 5-10% of HIV patients in Western countries."1.35Hepatitis B in HIV patients: what is the current treatment and what are the challenges? ( Barreiro, P; Fernández, JV; Labarga, P; Medrano, J; Soriano, V; Tuma, P; Vispo, E, 2009)
"Individuals with chronic hepatitis B infection carry a significantly increased risk of life-threatening liver sequelae including cirrhosis, hepatic decompensation and hepatocellular carcinoma."1.35Tenofovir disoproxil fumarate for the treatment of hepatitis B infection. ( Adusumilli, S, 2009)
"Success in antiviral therapy for chronic hepatitis B is supported by highly sensitive PCR-based assays for hepatitis B virus (HBV) DNA."1.34COBAS AmpliPrep-COBAS TaqMan hepatitis B virus (HBV) test: a novel automated real-time PCR assay for quantification of HBV DNA in plasma. ( Allice, T; Cerutti, F; Colucci, G; Franchello, A; Gabella, S; Ghisetti, V; Marzano, A; Pittaluga, F; Varetto, S, 2007)
"Adefovir dipivoxil is a nucleotide prodrug indicated for the treatment of patients with hepatitis B e antigen positive or hepatitis B e antigen negative chronic hepatitis B, lamivudine-resistant HBV infection, HBV infection pre- or post-liver transplantation, or HlV co-infection."1.34Progress in the treatment of chronic hepatitis B: long-term experience with adefovir dipivoxil. ( Delaney, WE, 2007)
"Adefovir dipivoxil (ADV) has demonstrated clinical activity against both wild-type and lamivudine-resistant hepatitis B virus (HBV)."1.34Evolution of viral load and changes of polymerase and precore/core promoter sequences in lamivudine-resistant hepatitis B virus during adefovir therapy. ( Bae, SH; Chang, UI; Choi, JY; Jang, JW; Lee, YC; Sun, HS; Wie, SH; Yang, JM; Yoon, SK, 2007)
"Adefovir dipivoxil is an analogue nucleotide recently approved for the treatment of chronic hepatitis HBV-related."1.34[Recent advances in the treatment of the hepatitis HBV-related. Effectiveness and tolerability of adefovir dipivoxil]. ( Palumbo, E, 2007)
"In this report, a chronic hepatitis B case who had never received adefovir dipivoxil but had primary adefovir resistance, was presented."1.34[A case of chronic hepatitis B with primary adefovir resistance]. ( Erensoy, S; Pullukçu, H; Sertöz, R; Taşbakan, M; Ulusoy, S; Yamazhan, T, 2007)
"Forty-four patients with chronic hepatitis B (CHB) were included."1.34Antiviral efficacy of adefovir dipivoxil versus lamivudine in patients with chronic hepatitis B sequentially treated with lamivudine and adefovir due to lamivudine resistance. ( Bak, YT; Byun, KS; Kim, JH; Kim, JS; Lee, CH; Park, JJ; Seo, YS; Yeon, JE, 2007)
"Treatment with lamivudine for 1-year is highly cost-effective compared with no treatment of CHB but has limited effect on reducing the rate of disease progression."1.34The cost-effectiveness of long-term antiviral therapy in the management of HBeAg-positive and HBeAg-negative chronic hepatitis B in Singapore. ( Gane, E; Lacey, LF, 2007)
"Adefovir dipivoxil is a acyclic nucleotide phosphate analogue and known to have potent anti-HBV effect."1.33[Therapeutic effect of adefovir dipivoxil on recurrent or de novo infection of hepatitis B virus after liver transplantation: a preliminary report]. ( Ahn, CS; Ha, TY; Hwang, S; Kim, KH; Kim, KK; Lee, SG; Moon, DB, 2005)
"Treatment options for chronic hepatitis B virus (HBV) infection have disparate risks and benefits."1.33Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis. ( Dulai, GS; Farid, M; Gralnek, IM; Kanwal, F; Martin, P; Spiegel, BM, 2005)
"Adefovir dipivoxil is an oral prodrug of adefovir."1.33Chronic hepatitis B--treatment with nucleoside analogues. ( Leung, N, 2005)
"Treatment with adefovir dipivoxil for 144 weeks was well tolerated and resulted in significant and sustained reductions in HBV DNA and ALT in HIV/HBV co-infected patients."1.33Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1. ( Benhamou, Y; Biao, L; Brosgart, C; Calvez, V; Chang, CG; Currie, G; Fievet, MH; Marcelin, AG; Poynard, T; Thibault, V; Vig, P; Xiong, S, 2006)
"Lamivudine treatment was initially effective in all patients; three patients during the second year of treatment developed lamivudine resistance-associated mutations (rt-L180M, rt-M204V) with severe disease reactivation, remitted after switch to adefovir treatment."1.33Heart transplantation in patients with chronic hepatitis B: clinical evolution, molecular analysis, and effect of treatment. ( Cirillo, G; Costagliola, L; Karayiannis, P; Marrone, A; Ragone, E; Ruggiero, G; Utili, R; Zampino, R, 2005)
"Adefovir dipivoxil (ADV) is a potent nucleotide analogue against both the wild-type and lamivudine (LMV) resistant hepatitis B virus (HBV)."1.33Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil. ( Byun, KS; Chang, YJ; Chung, HJ; Hong, SP; Kim, JH; Kim, SO; Lee, CH; Moon, MS; Seo, YS; Yeon, JE; Yoo, W; Yu, SK, 2006)
"Treatment of chronic hepatitis B (CHB) involves a number of complex and controversial issues."1.33Chronic hepatitis B: a critical appraisal of current approaches to therapy. ( Alberti, A; Buti, M; Cooksley, WG; Fried, MW; Gish, RG; Hadziyannis, SJ; Keeffe, EB; Liaw, YF; Naoumov, NV; Perrillo, RP; Peters, M; Schalm, S; Schiff, ER; Thio, CL; Tsai, N, 2006)
"In patients with chronic hepatitis B virus (HBV), 2 predominant precursor dendritic cell (DC) subtypes, the myeloid dendritic cell (mDC) and the plasmacytoid dendritic cell (pDC), were recently found to be functionally impaired."1.33Favorable effect of adefovir on the number and functionality of myeloid dendritic cells of patients with chronic HBV. ( Biesta, PJ; Janssen, HL; Kusters, JG; Sprengers, D; van der Molen, RG, 2006)
"Patients with chronic hepatitis B virus (HBV) infection were tested for HBeAg, anti-HBe, liver profile and HBV-DNA by a branched DNA (bDNA) assay."1.32Precore and core promoter mutations of hepatitis B virus and hepatitis B e antigen-negative chronic hepatitis B in Korea. ( Cha, YJ; Kim, HJ; Lee, DH; Park, JW; Park, SM; Yoo, BC, 2003)
"Hepatitis B e antigen (HBeAg) negative chronic hepatitis B (CHB) is frequently caused by a mutation (G1896A) in the hepatitis B virus (HBV) precore (PC) reading frame that creates a stop codon, causing premature termination of the PC protein."1.32Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro. ( Bowden, S; Chen, RY; Colledge, D; Delaney, WE; Desmond, P; Edwards, R; Isom, H; Locarnini, SA; Shaw, T, 2003)
"Adefovir is a potent nucleotide analog inhibitor of hepatitis B virus (HBV) DNA polymerase."1.32Comparative effects of adefovir and selected nucleoside inhibitors of hepatitis B virus DNA polymerase on mitochondrial DNA in liver and skeletal muscle cells. ( Birkus, G; Cihlar, T; Gibbs, CS, 2003)
"Current therapies for the treatment of chronic hepatitis B virus (HBV) infection do not eliminate viral replication once therapy is stopped, resulting in a rapid rebound of viremia in a majority of patients."1.32Use of adefovir in the treatment of the chronic hepatitis B virus infection with resistance to lamivudine. ( Barcena Marugan, R; Cid Gomez, L; Lopez Serrano, P, 2003)
"Lamivudine was then reintroduced together with ADV, and serum HBV DNA became undetectable by polymerase chain reaction."1.32Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. ( Brosgart, CL; Durantel, D; Durantel, S; Gibbs, CS; Parvaz, P; Trépo, C; Villeneuve, JP; Werle, B; Westland, C; Xiong, S; Zoulim, F, 2003)
"The management of chronic hepatitis B poses specific problems in the presence of human immunodeficiency virus (HIV) coinfection, because therapeutic approaches have to address both hepatitis B virus (HBV) and HIV infections."1.32Treatment of chronic hepatitis B in the human immunodeficiency virus-infected patient: present and future. ( Camino, N; Núñez, M; Puoti, M; Soriano, V, 2003)
"Our study shows that ADV dosed at 10 mg/day for the treatment of LAM-resistant chronic hepatitis B in patients co-infected with HIV is not associated with renal tubular dysfunction or a significant change in renal function."1.32The renal tolerance of low-dose adefovir dipivoxil by lamivudine-resistant individuals co-infected with hepatitis B and HIV. ( Bagnis, CI; Beaufils, H; Benhamou, Y; Brosgart, C; Deray, G; Hannon, H; Izzedine, H; Poynard, T; Sullivan, M, 2004)
"Adefovir dipivoxil is a clinically approved drug that can block the action of an anthrax toxin."1.32Selective inhibition of anthrax edema factor by adefovir, a drug for chronic hepatitis B virus infection. ( Bergson, P; Gibbs, CS; Shen, Y; Soelaiman, S; Tang, WJ; Wang, CR; Zhukovskaya, NL; Zimmer, MI, 2004)
"Lamivudine was administered in 2 patients, lamivudine+hepatitis B immunoglobulin (HBIG) in 63, and adefovir+HBIG in 3."1.32Prevention of hepatitis B virus reinfection after orthotopic liver transplantation. ( Chen, XS; Ding, GS; Fu, H; Fu, ZR; Guo, WY; Shi, XM; Wang, ZX; Zhang, JJ, 2004)
"Worldwide, hepatocellular carcinoma (HCC) is more prevalent in men than in women, suggesting that sex hormones and/or X-chromosome-linked genes may be involved in hepatocarcinogenesis."1.31Androgen-receptor gene CAG repeats, plasma testosterone levels, and risk of hepatitis B-related hepatocellular carcinoma. ( Chang, HC; Chen, CJ; Chen, PJ; Cheng, SW; Hsiao, TJ; Lee, SD; Liaw, YF; Lin, MW; Lin, SM; Liu, CJ; Yang, SY; Yu, MW, 2000)
"Adefovir dipivoxil has recently been reported to be a potent and highly effective inhibitor of HBV replication in both wild-type and lamivudine resistant HBV infection."1.31Successful treatment with adefovir dipivoxil in a patient with fibrosing cholestatic hepatitis and lamivudine resistant hepatitis B virus. ( Alexander, GJ; Bloor, S; Lamy, P; Walsh, KM; Wight, DG; Woodall, T, 2001)

Research

Studies (1,207)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's3 (0.25)18.2507
2000's428 (35.46)29.6817
2010's702 (58.16)24.3611
2020's74 (6.13)2.80

Authors

AuthorsStudies
Gao, Y7
Kong, F2
Song, X1
Shang, J2
Yao, L3
Xia, J2
Peng, Y1
Liu, W6
Gong, H1
Mu, M1
Cui, H1
Han, T4
Chen, W6
Wu, X8
Yang, Y11
Yan, X4
Jin, Z1
Wang, P4
Zhu, Q1
Chen, L10
Zhao, C3
Zhang, D6
Jin, W2
Wang, D2
Wen, X2
Liu, C4
Jia, J8
Mao, Q3
Ding, Y3
Jin, X2
Zhang, Z4
Li, G7
Niu, J9
Yeh, ML2
Liang, PC1
Trinh, S1
Huang, CI1
Huang, CF2
Hsieh, MY3
Huang, JF3
Dai, CY4
Chuang, WL8
Nguyen, MH15
Yu, ML3
Zeng, QL1
Zhang, HX1
Zhang, JY2
Huang, S1
Li, WZ1
Li, GM1
Pan, YJ2
Feng, YH1
Li, ZQ2
Zhang, GF1
Xu, JH1
Lin, WB1
Xu, GH1
Liu, N1
Zhang, GQ1
Li, GT1
Li, W9
Zeng, YL1
Song, N1
Wang, M5
Zhang, DW1
Chen, ZM1
Cui, GL1
Li, J29
Lv, J4
Liu, YM1
Liang, HX1
Sun, CY1
Zhou, YH2
Yu, ZJ2
Wang, FS1
Jeong, J2
Shin, JW9
Jung, SW8
Park, EJ2
Park, NH10
Kahraman, R1
Şahin, A1
Öztürk, O2
Çalhan, T1
Sayar, S1
Kanat, E1
Doğanay, L2
Özdil, K2
Han, N1
Yan, LL1
Tang, H13
Kumada, T5
Toyoda, H5
Yasuda, S3
Ito, T2
Tanaka, J4
Ogawa, E7
Nakamuta, M3
Koyanagi, T3
Ooho, A3
Furusyo, N6
Kajiwara, E3
Dohmen, K3
Kawano, A3
Satoh, T3
Takahashi, K3
Azuma, K3
Yamashita, N4
Sugimoto, R2
Amagase, H2
Kuniyoshi, M2
Ichiki, Y2
Morita, C2
Kato, M5
Shimoda, S3
Nomura, H3
Hayashi, J5
Liu, JK1
Vutien, P1
Huang, DQ1
Ishigami, M1
Landis, CS1
Dilokthornsakul, P1
Sawangjit, R1
Tangkijvanich, P2
Chayanupatkul, M1
Tanwandee, T4
Sukeepaisarnjaroen, W2
Sriuttha, P1
Permsuwan, U1
Lim, YS18
Seto, WK9
Kurosaki, M3
Fung, S8
Kao, JH5
Hou, J7
Gordon, SC4
Flaherty, JF17
Yee, LJ3
Zhao, Y10
Agarwal, K5
Lampertico, P20
Lin, HY1
Tseng, TC2
Innocenti, I1
Reda, G1
Visentin, A1
Coscia, M1
Motta, M1
Murru, R1
Moia, R1
Gentile, M1
Pennese, E1
Quaglia, FM1
Albano, F1
Cassin, R1
Deodato, M1
Ielo, C1
Frustaci, AM1
Piciocchi, A1
Rughini, A1
Arena, V1
Di Sevo, D1
Tomasso, A1
Autore, F1
Del Poeta, G1
Scarfò, L1
Mauro, FR1
Tedeschi, A1
Trentin, L1
Pompili, M1
Foà, R1
Ghia, P1
Cuneo, A1
Laurenti, L1
Lim, J1
Choi, WM4
Shim, JH6
Lee, D5
Kim, KM5
Lee, HC10
Choi, J3
Kudose, S1
Lunenfeld, E1
Markowitz, GS1
Winckelmann, A1
Fahnøe, U1
Bajpai, PS1
Dalegaard, MI1
Lundh, A1
Ryom, L1
Bukh, J1
Weis, N1
Kayes, T1
Crane, H1
Symonds, A1
Dumond, J1
Cottrell, M1
Di Girolamo, J1
Manandhar, S1
Lim, TH1
Gane, E14
Kashuba, A2
Levy, MT3
Papatheodoridis, GV14
Mimidis, K1
Manolakopoulos, S5
Gatselis, N2
Goulis, J3
Kapatais, A1
Manesis, E2
Vasiliadis, T2
Triantos, C3
Samonakis, D1
Sevastianos, V2
Karatapanis, S1
Elefsiniotis, I4
Deutsch, M1
Mylopoulou, T1
Papatheodoridi, M1
Kranidioti, H1
Agorastou, P1
Karaoulani, T1
Kyriazidou, A1
Zisimopoulos, K1
Dalekos, GN2
Chen, YC1
Hsu, CW3
Chien, RN6
Tai, DI1
Foucault, T1
Handala, L1
Paintaud, G1
Gaudy-Graffin, C1
Marlet, J1
Kumar, M2
Lee, MH7
Hu, X5
Li, R1
Li, Q6
Zang, M1
Yuan, G3
Chen, J9
Tseng, TN1
Chen, CH6
Jung, CY1
Kim, HW1
Lee, JI7
Lee, HW4
Ahn, SH23
Kim, SU9
Kim, BS4
Chiu, SM1
Chang, KC3
Hu, TH7
Hung, CH4
Wang, JH6
Lu, SN5
Wang, ML3
Chen, EQ8
Yim, HJ12
Kim, JH26
Cho, YK6
Kweon, YO3
Cho, HC3
Hwang, JS2
Lee, C2
Koh, MS1
Baek, YH1
Park, YM2
Lee, JH25
Kang, MK1
Lee, JS4
Chon, YE4
Cheon, GJ1
Chae, HB5
Sohn, JH1
Sato, K4
Inoue, J4
Akahane, T2
Kobayashi, T3
Sato, S1
Kisara, N1
Ninomiya, M2
Iwata, T2
Sano, A2
Tsuruoka, M2
Onuki, M2
Masamune, A2
Takai, S1
Nakamura, T1
Sato, T3
Kimura, O1
Sawahashi, S1
Niitsuma, H2
Chen, JW1
Cao, XY1
Qi, X4
Zhang, JM6
Suda, G1
Baba, M2
Yamamoto, Y1
Sho, T1
Ogawa, K1
Kimura, M3
Hosoda, S1
Yoshida, S1
Kubo, A1
Fu, Q1
Yang, Z5
Tokuchi, Y1
Kitagataya, T1
Maehara, O1
Ohnishi, S1
Yamada, R1
Ohara, M1
Kawagishi, N1
Natsuizaka, M1
Nakai, M1
Morikawa, K1
Furuya, K1
Suzuki, K1
Izumi, T1
Meguro, T1
Terashita, K1
Ito, J1
Tsunematsu, I1
Sakamoto, N1
Zhu, L3
Park, J1
Deng, Y2
Pan, CQ6
Byun, KS10
Yoo, BC11
Cheng, CH1
Hung, HC1
Lee, JC1
Wang, YC1
Wu, TH1
Lee, CF1
Wu, TJ1
Chou, HS1
Chan, KM1
Lee, WC1
Hwang, EG1
Jung, EA1
Yoo, JJ5
Kim, SG3
Kim, YS12
Luo, H1
Tan, G2
Li, Y19
Qin, B1
Kim, E1
Kim, SS4
Yoon, E1
Jang, ES3
Chang, JI1
Cho, YY5
Seo, GH1
Kim, HJ10
Liu, Z11
Zhao, Z3
Ma, X3
Liu, S5
Xin, Y1
Duan, YQ1
Hu, P6
Murata, K3
Tsukuda, S1
Suizu, F1
Kimura, A1
Sugiyama, M2
Watashi, K1
Noguchi, M1
Mizokami, M4
Blackard, JT1
Kwara, A1
Sherman, KE2
Kim, KH12
Deng, HH1
Xu, M4
Lou, Y1
Gao, HB1
Uchida, Y1
Nakao, M1
Tsuji, S1
Uemura, H1
Kouyama, JI1
Naiki, K1
Motoya, D1
Sugawara, K1
Nakayama, N1
Imai, Y2
Tomiya, T1
Mochida, S1
Zhang, H9
Wu, M1
Zhu, X5
Li, C6
Li, X23
Chen, H3
Liu, J10
Zheng, Z1
Liao, W1
Liu, L11
Cai, S3
Zhu, H2
Yin, S1
Li, XK1
Zhang, MX1
Shao, FZ1
Zhou, DQ1
Xue, JD1
Liu, TJ1
Chi, XL1
Lu, BJ1
Wang, XB1
Mao, DW2
Yang, HS1
Yang, HZ1
Zhao, WX1
Zhang, GL1
Zhao, YM1
Zou, JD1
Liu, MY2
Zhang, KK1
Yang, XZ1
Gan, DN1
Zhang, P1
Li, ZG1
Li, S3
Ye, YA1
Kirino, S1
Tamaki, N1
Kaneko, S2
Inada, K1
Yamashita, K1
Osawa, L1
Hayakawa, Y1
Sekiguchi, S1
Watakabe, K1
Okada, M1
Wang, W8
Shimizu, T1
Higuchi, M1
Takaura, K1
Maeyashiki, C1
Yasui, Y1
Nakanishi, H1
Tsuchiya, K1
Itakura, J1
Takahashi, Y1
Izumi, N2
Gao, X1
Duan, X1
Cai, H2
Hu, Y4
Liu, M5
Kang, K1
Zhou, M3
Fu, D1
Yi, W2
Madeddu, G2
Fiore, V1
Melis, M2
Ortu, S2
Mannu, F1
Muredda, AA2
Garrucciu, G2
Bandiera, F2
Zaru, S1
Bagella, P1
Calvisi, DF1
Babudieri, S2
Mak, LY2
Buti, M37
Tak, WY3
Ramji, A1
Chen, CY3
Tam, E1
Bae, H2
Gaggar, A8
Lau, A1
Liu, Y35
Wu, G3
Suri, V1
Tan, SK1
Subramanian, GM11
Trinh, H9
Yoon, SK5
Chan, HLY2
Halim, AA1
Alsayed, B1
Embarak, S1
Yaseen, T1
Dabbous, S1
Fontaine, O1
Dueluzeau, R1
Raibaud, P1
Chabanet, C1
Popoff, MR1
Badoual, J1
Gabilan, JC1
Andremont, A1
Gómez, L1
Andrés, S1
Sánchez, J1
Alonso, JM1
Rey, J1
López, F1
Jiménez, A1
Yan, Z1
Zhou, L3
Wang, J24
Huang, L4
Hu, K1
Liu, H6
Wang, H14
Guo, Z1
Song, Y1
Huang, H7
Yang, R1
Owen, TW1
Al-Kaysi, RO1
Bardeen, CJ1
Cheng, Q1
Wu, S2
Cheng, T1
Zhou, X6
Wang, B8
Zhang, Q9
Yao, Y3
Ochiai, T1
Ishiguro, H2
Nakano, R2
Kubota, Y2
Hara, M1
Sunada, K1
Hashimoto, K1
Kajioka, J1
Fujishima, A1
Jiao, J5
Gai, QY3
Zang, YP2
Niu, LL2
Fu, YJ3
Wang, X14
Yao, LP2
Qin, QP1
Wang, ZY2
Aleksic Sabo, V1
Knezevic, P1
Borges-Argáez, R1
Chan-Balan, R1
Cetina-Montejo, L1
Ayora-Talavera, G1
Sansores-Peraza, P1
Gómez-Carballo, J1
Cáceres-Farfán, M1
Jang, J1
Akin, D1
Bashir, R1
Yu, Z3
Zhu, J2
Jiang, H1
He, C2
Xiao, Z1
Xu, J7
Sun, Q2
Han, D1
Lei, H1
Zhao, K3
Fu, H3
Wilson, BK1
Step, DL1
Maxwell, CL1
Gifford, CA1
Richards, CJ1
Krehbiel, CR1
Warner, JM1
Doerr, AJ1
Erickson, GE1
Guretzky, JA1
Rasby, RJ1
Watson, AK1
Klopfenstein, TJ1
Sun, Y7
Pham, TD1
Lee, BK1
Yang, FC1
Wu, KH1
Lin, WP1
Hu, MK1
Lin, L6
Shao, J3
Sun, M2
Xu, G3
Zhang, X12
Xu, N1
Wang, R1
He, H1
Dong, X3
Yang, M3
Yang, Q2
Duan, S1
Yu, Y5
Han, J2
Zhang, C11
Yang, X2
Wang, T4
Campbell, DA1
Gao, K1
Zager, RA1
Johnson, ACM1
Guillem, A1
Keyser, J1
Singh, B1
Steubl, D1
Schneider, MP1
Meiselbach, H1
Nadal, J1
Schmid, MC1
Saritas, T1
Krane, V1
Sommerer, C1
Baid-Agrawal, S1
Voelkl, J1
Kotsis, F1
Köttgen, A1
Eckardt, KU1
Scherberich, JE1
Li, H8
Sun, L5
Zhu, Z1
Naren, N1
Zhang, XX7
Gentile, GL1
Rupert, AS1
Carrasco, LI1
Garcia, EM1
Kumar, NG1
Walsh, SW1
Jefferson, KK1
Guest, RL1
Samé Guerra, D1
Wissler, M1
Grimm, J1
Silhavy, TJ1
Yoo, JS1
Kim, Y1
Kim, JS5
Lee, EJ1
Roe, JH1
Delorme, M1
Bouchard, PA1
Simon, M1
Simard, S1
Lellouche, F1
D'Urzo, KA1
Mok, F1
D'Urzo, AD1
Koneru, B1
Lopez, G1
Farooqi, A1
Conkrite, KL1
Nguyen, TH1
Macha, SJ1
Modi, A1
Rokita, JL1
Urias, E1
Hindle, A1
Davidson, H1
Mccoy, K1
Nance, J1
Yazdani, V1
Irwin, MS1
Yang, S6
Wheeler, DA1
Maris, JM1
Diskin, SJ1
Reynolds, CP1
Abhilash, L1
Kalliyil, A1
Sheeba, V1
Hartley, AM2
Meunier, B2
Pinotsis, N1
Maréchal, A2
Xu, JY1
Genko, N1
Haraux, F1
Rich, PR1
Kamalanathan, M1
Doyle, SM1
Xu, C2
Achberger, AM1
Wade, TL1
Schwehr, K1
Santschi, PH1
Sylvan, JB1
Quigg, A1
Leong, W1
Xu, W2
Gao, S1
Zhai, X1
Wang, C8
Gilson, E1
Ye, J1
Lu, Y1
Yan, R1
Zhang, Y16
Hu, Z2
You, Q1
Cai, Q1
Yang, D5
Gu, S1
Dai, H1
Zhao, X4
Gui, C1
Gui, J1
Wu, PK1
Hong, SK1
Starenki, D1
Oshima, K1
Shao, H1
Gestwicki, JE1
Tsai, S1
Park, JI1
Wang, Y24
Zhao, R1
Gu, Z1
Dong, C2
Guo, G1
Li, L11
Barrett, HE1
Meester, EJ1
van Gaalen, K1
van der Heiden, K1
Krenning, BJ1
Beekman, FJ1
de Blois, E1
de Swart, J1
Verhagen, HJ1
Maina, T1
Nock, BA1
Norenberg, JP1
de Jong, M1
Gijsen, FJH1
Bernsen, MR1
Martínez-Milla, J1
Galán-Arriola, C1
Carnero, M1
Cobiella, J1
Pérez-Camargo, D1
Bautista-Hernández, V1
Rigol, M1
Solanes, N1
Villena-Gutierrez, R1
Lobo, M1
Mateo, J1
Vilchez-Tschischke, JP1
Salinas, B1
Cussó, L1
López, GJ1
Fuster, V1
Desco, M1
Sanchez-González, J1
Ibanez, B1
van den Berg, P1
Schweitzer, DH1
van Haard, PMM1
Geusens, PP1
van den Bergh, JP1
Huang, X3
Xu, H6
Yang, G3
Lin, Z2
Salem, HF1
Nafady, MM1
Kharshoum, RM1
Abd El-Ghafar, OA1
Farouk, HO1
Domiciano, D1
Nery, FC1
de Carvalho, PA1
Prudente, DO1
de Souza, LB1
Chalfun-Júnior, A1
Paiva, R1
Marchiori, PER1
Lu, M3
An, Z1
Jiang, J5
Du, S1
Zhou, H1
Cui, J1
Wu, W2
Song, J2
Lian, Q1
Uddin Ahmad, Z1
Gang, DD1
Konggidinata, MI1
Gallo, AA1
Zappi, ME1
Yang, TWW1
Johari, Y1
Burton, PR1
Earnest, A1
Shaw, K1
Hare, JL1
Brown, WA1
Kim, GA1
Han, S1
Choi, GH1
Gallo, A1
Cancelli, C1
Ceron, E1
Covino, M1
Capoluongo, E1
Pocino, K1
Ianiro, G1
Cammarota, G1
Gasbarrini, A1
Montalto, M1
Somasundar, Y1
Lu, IC1
Mills, MR1
Qian, LY1
Olivares, X1
Ryabov, AD1
Collins, TJ1
Zhao, L3
Doddipatla, S1
Thomas, AM1
Nikolayev, AA1
Galimova, GR1
Azyazov, VN1
Mebel, AM1
Kaiser, RI1
Guo, S1
Yang, P1
Yu, X3
Wu, Y5
Yu, B2
Han, B1
George, MW1
Moor, MB1
Bonny, O1
Langenberg, E1
Paik, H1
Smith, EH1
Nair, HP1
Hanke, I1
Ganschow, S1
Catalan, G1
Domingo, N1
Schlom, DG1
Assefa, MK1
Hayton, TW1
Becker, B1
Enikeev, D1
Netsch, C1
Gross, AJ1
Laukhtina, E1
Glybochko, P1
Rapoport, L1
Herrmann, TRW1
Taratkin, M1
Dai, W1
Shi, J4
Carreno, J1
Kloner, RA1
Pickersgill, NA1
Vetter, JM1
Kim, EH2
Cope, SJ1
Du, K1
Venkatesh, R1
Giardina, JD1
Saad, NES1
Bhayani, SB1
Figenshau, RS1
Eriksson, J1
Landfeldt, E1
Ireland, S1
Jackson, C1
Wyatt, E1
Gaudig, M1
Stancill, JS1
Happ, JT1
Broniowska, KA1
Hogg, N1
Corbett, JA1
Tang, LF1
Bi, YL1
Fan, Y3
Sun, YB1
Wang, AL1
Xiao, BH1
Wang, LF2
Qiu, SW1
Guo, SW1
Wáng, YXJ1
Sun, J9
Chu, S1
Pan, Q1
Li, D4
Zheng, S3
Ma, L4
Wang, L11
Hu, T1
Wang, F3
Han, Z2
Yin, Z1
Ge, X1
Xie, K1
Lei, P1
Dias-Santagata, D1
Lennerz, JK1
Sadow, PM1
Frazier, RP1
Govinda Raju, S1
Henry, D1
Chung, T1
Kherani, J1
Rothenberg, SM1
Wirth, LJ1
Marti, CN1
Choi, NG1
Bae, SJ1
Ni, L1
Luo, X1
Dai, T1
Lee, R1
Fleischer, AS1
Wemhoff, AP1
Ford, CR1
Kleppinger, EL1
Helms, K1
Bush, AA1
Luna-Abanto, J1
García Ruiz, L1
Laura Martinez, J1
Álvarez Larraondo, M1
Villoslada Terrones, V1
Dukic, L1
Maric, N1
Simundic, AM1
Chogtu, B1
Ommurugan, B1
Thomson, SR1
Kalthur, SG1
Benidir, M1
El Massoudi, S1
El Ghadraoui, L1
Lazraq, A1
Benjelloun, M1
Errachidi, F1
Cassar, M1
Law, AD1
Chow, ES1
Giebultowicz, JM1
Kretzschmar, D1
Salonurmi, T1
Nabil, H1
Ronkainen, J1
Hyötyläinen, T1
Hautajärvi, H1
Savolainen, MJ1
Tolonen, A1
Orešič, M1
Känsäkoski, P1
Rysä, J1
Hakkola, J1
Hukkanen, J1
Zhu, N1
Du, Q1
Hao, P1
Cao, X1
Li, CX1
Zhao, S2
Luo, XM1
Feng, JX1
Gonzalez-Cotto, M1
Guo, L1
Karwan, M1
Sen, SK1
Barb, J1
Collado, CJ1
Elloumi, F1
Palmieri, EM1
Boelte, K1
Kolodgie, FD1
Finn, AV1
Biesecker, LG1
McVicar, DW1
Qu, F1
Deng, Z2
Xie, Y2
Tang, J3
Chen, Z4
Luo, W1
Xiong, D1
Zhao, D1
Fang, J1
Zhou, Z4
Niu, PP1
Song, B1
Xu, YM1
Qiu, N1
Yin, J1
Zhang, J9
Guo, W2
Liu, T6
Chen, D6
Luo, K1
He, Z3
Zheng, G1
Xu, F2
Sun, W1
Yin, F1
van Hest, JCM1
Du, L2
Shi, X2
Kang, S1
Duan, W2
Zhang, S4
Feng, J4
Qi, N1
Shen, G1
Ren, H10
Shang, Q1
Zhao, W4
Jiang, X3
Alame, M1
Cornillot, E1
Cacheux, V1
Tosato, G1
Four, M1
De Oliveira, L1
Gofflot, S1
Delvenne, P1
Turtoi, E1
Cabello-Aguilar, S1
Nishiyama, M1
Turtoi, A1
Costes-Martineau, V1
Colinge, J1
Guo, Q2
Quan, M1
Dong, J3
Bai, J1
Han, R1
Cai, Y2
Lv, YQ1
Chen, Q3
Lyu, HD1
Deng, L1
Zhou, D1
Xiao, X2
De Langhe, S1
Billadeau, DD1
Lou, Z1
Zhang, JS1
Xue, Z1
Shen, XD1
Gao, F1
Busuttil, RW1
Kupiec-Weglinski, JW1
Ji, H2
Otano, I1
Alvarez, M1
Minute, L1
Ochoa, MC1
Migueliz, I1
Molina, C1
Azpilikueta, A1
de Andrea, CE1
Etxeberria, I1
Sanmamed, MF1
Teijeira, Á1
Berraondo, P1
Melero, I1
Zhong, Z1
Xie, X1
Yu, Q1
Zhou, C3
Yin, Y1
Li, CW1
Hsu, JL1
Zhou, Q2
Hu, B1
Fu, P1
Atyah, M1
Ma, Q2
Xu, Y4
Dong, Q1
Hung, MC1
Ren, N1
Huang, P1
Liao, R1
Chen, X12
Cao, Q1
Yuan, X2
Nie, W1
Yang, J6
Shao, B1
Bi, Z1
Liang, X2
Tie, Y1
Mo, F1
Xie, D1
Wei, Y1
Wei, X2
Dokla, EME1
Fang, CS1
Chu, PC1
Chang, CS1
Abouzid, KAM1
Chen, CS1
Blaszczyk, R1
Brzezinska, J1
Dymek, B1
Stanczak, PS1
Mazurkiewicz, M1
Olczak, J1
Nowicka, J1
Dzwonek, K1
Zagozdzon, A1
Golab, J1
Golebiowski, A1
Xin, Z1
Himmelbauer, MK1
Jones, JH1
Enyedy, I1
Gilfillan, R1
Hesson, T1
King, K1
Marcotte, DJ1
Murugan, P1
Santoro, JC1
Gonzalez-Lopez de Turiso, F1
Pedron, J1
Boudot, C1
Brossas, JY1
Pinault, E1
Bourgeade-Delmas, S1
Sournia-Saquet, A1
Boutet-Robinet, E1
Destere, A1
Tronnet, A1
Bergé, J1
Bonduelle, C1
Deraeve, C1
Pratviel, G1
Stigliani, JL1
Paris, L1
Mazier, D1
Corvaisier, S1
Since, M1
Malzert-Fréon, A1
Wyllie, S1
Milne, R1
Fairlamb, AH1
Valentin, A1
Courtioux, B1
Verhaeghe, P1
Fang, X1
Gao, M1
Gao, H2
Bi, W1
Cui, Y2
Zhang, L8
Fan, H2
Yu, H2
Mathison, CJN1
Chianelli, D1
Rucker, PV1
Nelson, J1
Roland, J1
Huang, Z4
Xie, YF1
Epple, R1
Bursulaya, B1
Gao, MY1
Shaffer, J1
Briones, S1
Sarkisova, Y1
Galkin, A1
Li, N2
Hua, S1
Kasibhatla, S1
Kinyamu-Akunda, J1
Kikkawa, R1
Molteni, V1
Tellew, JE1
Pang, B1
Liu, Q3
Liu, X5
Huang, Y7
Josephine Fauci, A1
Ma, Y1
Soo Lee, M1
Yuan, W1
Gao, R1
Qi, H1
Zheng, W1
Yang, F5
Chua, H1
Wang, K4
Ou, Y1
Huang, M4
Zhu, Y8
Yu, J2
Tian, J1
Zhao, M1
Hu, J5
Yao, C1
Zhang, B2
Usawachintachit, M1
Tzou, DT1
Washington, SL1
Hu, W1
Chi, T1
Sorensen, MD1
Bailey, MR1
Hsi, RS1
Cunitz, BW1
Simon, J1
Wang, YN1
Dunmire, BL1
Paun, M1
Starr, F1
Lu, W3
Evan, AP1
Harper, JD1
Han, G1
Rodrigues, AE1
Fouladvand, F1
Falahi, E1
Asbaghi, O1
Abbasnezhad, A1
Anigboro, AA1
Avwioroko, OJ1
Cholu, CO1
Sonei, A1
Fazelipour, S1
Kanaani, L1
Jahromy, MH1
Jo, K1
Hong, KB1
Suh, HJ2
Park, JH7
Shin, E1
Park, E1
Kouakou-Kouamé, CA1
N'guessan, FK1
Montet, D1
Djè, MK1
Kim, GD1
González-Fernández, D1
Pons, EDC1
Rueda, D1
Sinisterra, OT1
Murillo, E1
Scott, ME1
Koski, KG1
Shete, PB1
Gonzales, R1
Ackerman, S1
Cattamanchi, A1
Handley, MA1
Li, XX1
Xiao, SZ1
Gu, FF1
He, WP2
Ni, YX1
Han, LZ1
Heffernan, JK1
Valgepea, K1
de Souza Pinto Lemgruber, R1
Casini, I1
Plan, M1
Tappel, R1
Simpson, SD1
Köpke, M1
Nielsen, LK1
Marcellin, E1
Cen, YK1
Lin, JG1
Wang, YL1
Wang, JY1
Liu, ZQ1
Zheng, YG1
Spirk, D1
Noll, S1
Burnier, M1
Rimoldi, S1
Noll, G1
Sudano, I1
Penzhorn, BL1
Oosthuizen, MC1
Kobos, LM1
Alqatani, S1
Ferreira, CR1
Aryal, UK1
Hedrick, V1
Sobreira, TJP1
Shannahan, JH1
Gale, P1
Singhroy, DN1
MacLean, E1
Kohli, M1
Lessem, E1
Branigan, D1
England, K1
Suleiman, K1
Drain, PK1
Ruhwald, M1
Schumacher, S1
Denkinger, CM1
Waning, B1
Van Gemert, W1
Pai, M1
Myers, RK1
Bonsu, JM1
Carey, ME1
Yerys, BE1
Mollen, CJ1
Curry, AE1
Douglas, TA1
Alinezhadbalalami, N1
Balani, N1
Schmelz, EM1
Davalos, RV1
Kamaldinov, T1
Erndt-Marino, J1
Levin, M1
Kaplan, DL1
Hahn, MS1
Heidarimoghadam, R1
Farmany, A1
Lee, JJ2
Kang, J2
Park, S3
Cho, JH3
Oh, S2
Park, DJ1
Perez-Maldonado, R1
Cho, JY2
Park, IH1
Kim, HB1
Song, M1
Mfarrej, B1
Jofra, T1
Morsiani, C1
Gagliani, N1
Fousteri, G1
Battaglia, M1
Giuliano, C1
Levinger, I1
Vogrin, S1
Neil, CJ1
Allen, JD1
Lv, Y2
Yuan, R1
Cai, B2
Bahrami, B1
Chowdhury, AH1
Yang, C5
Qiao, Q1
Liu, SF1
Zhang, WH3
Kolano, L1
Knappe, D1
Volke, D1
Sträter, N1
Hoffmann, R1
Coussens, M1
Calders, P1
Lapauw, B1
Celie, B1
Banica, T1
De Wandele, I1
Pacey, V1
Malfait, F1
Rombaut, L1
Vieira, D1
Angel, S1
Honjol, Y1
Gruenheid, S1
Gbureck, U1
Harvey, E1
Merle, G1
Seo, G1
Lee, G1
Kim, MJ4
Baek, SH1
Choi, M1
Ku, KB1
Lee, CS1
Jun, S1
Park, D1
Kim, HG1
Kim, SJ2
Lee, JO1
Kim, BT1
Park, EC1
Kim, SI1
Ende, M1
Kirkkala, T1
Loitzenbauer, M1
Talla, D1
Wildner, M1
Miletich, R1
Criado, A1
Lavela, P1
Tirado, JL1
Pérez-Vicente, C1
Kang, D1
Feng, D2
Fang, Z1
Wei, F3
De Clercq, E1
Pannecouque, C1
Zhan, P1
Guo, Y4
Shen, Y3
Wang, Q7
Kawazoe, Y1
Jena, P1
Sun, Z1
Li, Z5
Liang, H1
Xu, X3
Ma, G1
Huo, X1
Church, JS1
Chace-Donahue, F1
Blum, JL1
Ratner, JR1
Zelikoff, JT1
Schwartzer, JJ1
Fiseha, T1
Tamir, Z1
Yao, W1
Mi, K1
Cheng, J6
Gu, C1
Huang, J3
Sun, HB1
Xing, WQ1
Liu, XB1
Zheng, Y3
Yang, SJ1
Wang, ZF1
Liu, SL1
Ba, YF1
Zhang, RX1
Liu, BX1
Fan, CC1
Chen, PN1
Liang, GH1
Yu, YK1
Wang, HR1
Li, HM1
Li, ZX1
Lalani, SS1
Anasir, MI1
Poh, CL1
Khan, IT1
Nadeem, M1
Imran, M1
Khalique, A1
Raspini, B1
Porri, D1
De Giuseppe, R1
Chieppa, M1
Liso, M1
Cerbo, RM1
Civardi, E1
Garofoli, F1
Monti, MC1
Vacca, M1
De Angelis, M1
Cena, H1
Kong, D1
Han, X1
Zhou, Y10
Xue, H1
Zhang, W4
Ruan, Z1
Noer, PR1
Kjaer-Sorensen, K1
Juhl, AK1
Goldstein, A1
Ke, C1
Oxvig, C1
Duan, C2
Lin, S1
Wang, Z4
Bhattacharya, R1
Mazumder, D1
Ma, C1
Tang, Y1
Kong, X1
Lu, J2
Zhang, M5
Vital-Jacome, M1
Cazares-Granillo, M1
Carrillo-Reyes, J1
Buitron, G1
Jacob, SI1
Douair, I1
Maron, L1
Ménard, G1
Rusjan, P1
Sabioni, P1
Di Ciano, P1
Mansouri, E1
Boileau, I1
Laveillé, A1
Capet, M1
Duvauchelle, T1
Schwartz, JC1
Robert, P1
Le Foll, B1
Xia, Y1
Chen, S4
Luo, M1
Wu, J6
He, Y3
Garbacz, P1
Misiak, M1
Jackowski, K1
Yuan, Q1
Sherrell, PC1
Bi, X1
Nutho, B1
Mahalapbutr, P1
Hengphasatporn, K1
Pattaranggoon, NC1
Simanon, N1
Shigeta, Y1
Hannongbua, S1
Rungrotmongkol, T1
Caffrey, PJ1
Kher, R1
Bian, K1
Delaney, S1
Xue, J1
Wu, P2
Xu, L4
Yuan, Y1
Luo, J1
Ye, S1
Ustriyana, P1
Wei, B1
Raee, E1
Wesdemiotis, C1
Sahai, N1
Kaur, A1
Nigam, K1
Srivastava, S1
Tyagi, A1
Dang, S1
Millar, JE1
Bartnikowski, N1
Passmore, MR1
Obonyo, NG1
Malfertheiner, MV1
von Bahr, V1
Redd, MA1
See Hoe, L1
Ki, KK1
Pedersen, S1
Boyle, AJ1
Baillie, JK1
Shekar, K1
Palpant, N1
Suen, JY1
Matthay, MA1
McAuley, DF1
Fraser, JF1
Settles, JA1
Gerety, GF1
Spaepen, E1
Suico, JG1
Child, CJ1
Oh, BL1
Lee, EY1
Lee, HY1
Yu, HG1
Leslie, I1
Boos, LA1
Larkin, J1
Pickering, L1
Lima, HK1
Vogel, K1
Hampel, D1
Wagner-Gillespie, M1
Fogleman, AD1
Ferraz, SL1
O'Connor, M1
Mazzucchelli, TG1
Kajiyama, H1
Suzuki, S1
Shimbo, A1
Utsumi, F1
Yoshikawa, N1
Kikkawa, F1
Javvaji, PK1
Dhali, A1
Francis, JR1
Kolte, AP1
Roy, SC1
Selvaraju, S1
Mech, A1
Sejian, V1
DeSilva, S1
Vaidya, SS1
Mao, C1
Akhatayeva, Z1
Cheng, H1
Zhang, G3
Jiang, F1
Meng, X1
Elnour, IE1
Lan, X1
Song, E1
Rohde, S1
Antonides, CFJ1
Muslem, R1
de Woestijne, PCV1
der Meulen, MHV1
Kraemer, US1
Dalinghaus, M1
Bogers, AJJC1
Pourmand, A1
Ghassemi, M1
Sumon, K1
Amini, SB1
Hood, C1
Sikka, N1
Duan, H1
Chen, WP1
Fan, M1
Wang, WP1
Yu, L5
Tan, SJ1
Xin, S6
Wan, LJ1
Guo, YG1
Tanda, S1
Gingl, K1
Ličbinský, R1
Hegrová, J1
Goessler, W1
Li, ZL1
Zhou, YL3
Yan, W1
Luo, L1
Su, ZZ1
Fan, MZ1
Wang, SR1
Zhao, WG1
Xu, D17
Hassan, HM1
Jiang, Z2
Bachmann, KF1
Haenggi, M1
Jakob, SM1
Takala, J1
Gattinoni, L1
Berger, D1
Bentley, RF1
Vecchiarelli, E1
Banks, L1
Gonçalves, PEO1
Thomas, SG1
Goodman, JM1
Mather, K1
Boachie, R1
Anini, Y1
Panahi, S1
Anderson, GH1
Luhovyy, BL1
Nafie, MS1
Arafa, K1
Sedky, NK1
Alakhdar, AA1
Arafa, RK1
Fan, S1
Hu, H3
Liang, J2
Hu, BC1
Wen, Z1
Hu, D1
Liu, YY2
Chu, Q1
Wu, MC3
Lu, X2
Hu, M1
Shen, H1
Yao, M2
Dahlgren, RA1
Vysloužil, J1
Kulich, P1
Zeman, T1
Vaculovič, T1
Tvrdoňová, M1
Mikuška, P1
Večeřa, Z1
Stráská, J1
Moravec, P1
Balcar, VJ1
Šerý, O1
Qiao, L1
Xiong, X1
Peng, X1
Zheng, J1
Duan, J1
Xiao, W2
Zhou, HY1
Sui, ZY1
Zhao, FL1
Sun, YN1
Wang, HY2
Han, BH1
Jintao, X1
Shasha, Y1
Jincai, W1
Chunyan, L1
Mengya, Y1
Yongli, S1
Rasoanirina, BNV1
Lassoued, MA1
Miladi, K1
Razafindrakoto, Z1
Chaâbane-Banaoues, R1
Ramanitrahasimbola, D1
Cornet, M1
Sfar, S1
Liang, C1
Xing, Q1
Yi, JL1
Zhang, YQ1
Li, CY1
Tang, SJ1
Gao, C1
Sun, X2
Peng, M1
Sun, XF1
Zhang, T1
Shi, JH1
Liao, CX1
Gao, WJ1
Sun, LL1
Cao, WH1
Lyu, J1
Yu, CQ1
Wang, SF1
Pang, ZC1
Cong, LM1
Dong, Z1
Wu, F1
Wu, XP1
Jiang, GH1
Wang, XJ1
Wang, BY2
Li, LM1
Pan, L1
Wan, SP1
Yi, HWL1
He, HJ1
Yong, ZP1
Shan, GL1
Weng, TT1
Yan, SQ1
Gao, GP1
Wei, C1
Tao, FB1
Shao, ZH1
Yao, T1
Dong, S1
Shi, S1
Feng, YL1
Zhang, YW1
Wang, SP1
Shi, AX1
Operario, D1
Zhang, ZH1
Zhu, XF1
Zaller, N1
Gao, P1
Sun, YH1
Zhang, HB2
Woo, HY2
Park, JY13
Bae, SH5
Kim, CW4
Jang, JY2
Kim, DJ2
Kim, IH7
Heo, J4
Xiang, Q1
Xie, Q9
Mu, G1
Cen, X1
Lee, SB1
Park, BR5
Chen, R8
Luo, D1
Si, L2
Huang, B1
Cheng, F2
Jang, BK2
Qin, Y3
Tong, S2
Cao, L1
Lin, C2
Sheng, Q1
Wang, S2
Fan, J3
Gan, W2
Chen, B3
Yip, TC1
Wong, GL8
Song, K1
Yan, Q1
Lv, M1
Chen, Y7
Dai, Y2
Gao, Z4
Li, ZB1
Niu, XX1
Chen, SH1
Fu, YM1
Wang, CY1
Shao, Q1
Chen, G2
Ji, D4
Liu, LM1
Tian, Y1
Yao, Z4
Liao, H3
Zhao, J3
Bernstein, DE1
Trinh, HN9
Schiff, ER8
Smith, CI1
Mospan, AR1
Zink, RC1
Fried, MW2
Lok, AS12
Hu, C2
Zhang, R2
Fu, S1
Fu, M1
Yan, T1
Chen, T1
Marcos-Fosch, C1
Esteban, R16
Zhang, MY1
Zhu, GQ1
Zheng, JN1
Cheng, Z2
Van Poucke, S1
Shi, KQ1
Huang, HH1
Chen, FY1
Zheng, MH1
Vincenti, D2
Piselli, P1
Solmone, M1
D'Offizi, G1
Capobianchi, MR1
Menzo, S1
He, L2
Jiang, Y8
Karris, MY1
Chan, HL17
Hui, AJ3
Janssen, HL25
Chowdhury, A1
Tsang, TY1
Mehta, R2
Massetto, B4
Kitrinos, KM12
McHutchison, JG8
Acharya, SK2
Stepanova, T1
Cathcart, AL3
Kim, K1
Brunetto, M2
Marcellin, P42
Abdul Basit, S1
Dawood, A1
Ryan, J1
Gish, R2
Scott, LJ1
Su, TH1
Liu, CJ3
Zhou, F1
Zhang, YY1
de Niet, A8
Jansen, L11
Stelma, F4
Willemse, SB2
Kuiken, SD1
Weijer, S1
van Nieuwkerk, CMJ1
Zaaijer, HL9
Molenkamp, R3
Takkenberg, RB10
Koot, M3
Verheij, J2
Beuers, U1
Reesink, HW13
van der Ree, MH2
Peters, MW1
Janssen, HLA1
Matsumoto, A2
Nishiguchi, S1
Enomoto, H1
Kang, JH1
Tanaka, Y4
Shinkai, N1
Enomoto, M2
Kanda, T2
Yokosuka, O2
Yatsuhashi, H1
Nagaoka, S1
Okuse, C1
Kagawa, T1
Mine, T1
Takaguchi, K2
Saito, S1
Hino, K1
Ikeda, F4
Sakisaka, S1
Morihara, D1
Miyase, S1
Tsuge, M2
Chayama, K2
Hiramatsu, N2
Suzuki, Y8
Tanaka, E3
Gong, GZ3
Xu, DZ1
Guo, LM1
Pan, C3
Geng, S1
Mi, H1
Zhao, G1
Yu, W2
Wen, YM1
Wang, XY2
Kalafateli, M1
Aggeletopoulou, I1
Mandellou, M1
Assimakopoulos, S1
Tselekouni, P1
Taprantzi, D1
Tsiaoussis, G1
Vourli, G1
Anastassiou, ED1
Gogos, C1
Labropoulou-Karatza, C1
Thomopoulos, K1
Welkers, MRA2
van Dort, KA4
Lopatin, U4
de Jong, MD1
Kootstra, NA7
Qi, W1
Yu, F2
Guo, H1
Zhao, P8
Wu, K1
Shen, F4
Qiu, L2
Chang, S1
Shaheen, AA1
Al-Mattooq, M1
Yazdanfar, S1
Burak, KW2
Swain, MG1
Congly, SE1
Borman, MA1
Lee, SS7
Myers, RP5
Coffin, CS3
Huang, R1
Wu, C1
Hsu, YC2
Wei, MT1
Tartaglia, A2
Ferrara, SM1
Sica, S1
Santantonio, T5
Zhang, DM1
Du, LY1
Yan, LB2
Zhou, TY3
Lei, XZ2
Lei, BJ4
Lu, JJ2
Liao, J2
Kong, Y2
Ma, H5
You, H4
Ou, X3
Rodríguez, M2
Pascasio, JM1
Fraga, E2
Fuentes, J1
Prieto, M3
Sánchez-Antolín, G1
Calleja, JL5
Molina, E1
García-Buey, ML1
Blanco, MÁ1
Salmerón, J3
Bonet, ML1
Pons, JA1
González, JM1
Casado, MÁ4
Jorquera, F1
Kim, DH4
Kang, HS2
Hur, SS1
Sim, S1
Park, YK3
Park, ES3
Lee, AR2
Kwon, SY12
Lee, HJ5
Park, SY3
Chung, WJ1
Lee, CH15
Suh, JI1
Viganò, M10
Loglio, A2
Grossi, G1
Wong, D4
Littlejohn, M2
Edwards, R3
Jackson, K2
Revill, P1
Kitrinos, K5
Subramanian, M2
Buti-Ferret, M1
Janssen, H2
Locarnini, S11
Thompson, A2
Riveiro-Barciela, M1
Su, WW1
Lee, CM7
Peng, CY3
Chu, HC1
Huang, YH1
Liaw, YF11
Yeh, CT2
Yeh, CS1
Chu, YD1
Chiang, YJ1
Ayoub, MM1
Elantouny, NG1
El-Nahas, HM1
Ghazy, FES1
Cheng, Y1
Su, H2
Friedman, A1
Siewe, N1
Guo, X3
Ouyang, Y1
Liu, K6
Lin, CL1
Chen, N1
Zhang, JB1
Zhao, YP3
Li, LY1
Liu, LW1
Peng, T1
Tang, KX1
Huang, C3
Yang, XH1
Yang, YL1
Huang, AL5
Shi, XF2
Xu, WX1
Lin, CS1
Chen, YM2
Deng, H4
Mei, YY1
Zhao, ZX1
Xie, DY4
Gao, ZL4
Xie, C1
Peng, L1
Bao, L1
Yang, L1
Li, WT2
Zhao, ZH1
Caviglia, GP1
Olivero, A2
Ngatchou, D1
Saracco, GM1
Smedile, A3
Feenstra, KA1
Su, Q1
Watanabe, K1
Hashimoto, S2
Maoka, T2
Yamamoto, R1
Okamoto, N1
Koike, T2
Koda, R1
Tsuchida, M1
Iino, N1
Narita, I1
Yan, JY1
Kan, QC1
Udompap, P1
Kim, D2
Ahmed, A2
Kim, WR2
Min, IS1
Shin, IS1
Lee, NE1
Son, HS1
Kim, SB3
Seo, SY2
Kim, SH3
Kim, SW3
Lee, SO3
Lee, ST3
Deng, R1
Tao, CM1
Nie, ZW1
Chen, K1
Liang, L1
Cai, X1
Huang, A2
Tang, N1
Fong, TL2
Lee, BT1
Tien, A1
Chang, M2
Lim, C2
Ahn, A1
Bae, HS2
Wu, CS1
Zhao, Q2
Wang, JW1
Qian, Y1
Fan, YC2
Liang, S1
Liang, D1
Zeng, C2
Xia, Z1
Shen, J2
Peng, W1
Wen, T1
Fujii, T2
Takase, KI1
Honda, H1
Kawamura, N1
Yamasaki, R1
Urata, M1
Uchiumi, T1
Iwaki, T1
Kira, JI1
Makita, T1
Kanzaki, H1
Onishi, H1
Ikeda, A1
Takaki, A3
Wada, N1
Takeuchi, Y2
Yasunaka, T3
Shiraha, H1
Nishihara, S1
Murakawa, K1
Kitamura, Y1
Okada, H1
Sendo, T1
Song, JE1
Kondoh, K1
Michitaka, K1
Hiraoka, A2
Izumoto, H1
Ueki, H1
Kitahata, S1
Yamago, H1
Tsubouchi, E1
Ninomiya, T1
He, F1
Xiang, C1
Feng, X2
Bai, X2
Takeda, S1
Qing, Y1
Chang, Y2
Nam, JY1
Cho, H3
Cho, EJ6
Yu, SJ9
Yoon, JH11
Kim, YJ16
Jia, W1
Zhu, MQ1
Chen, PD1
Fan, QQ1
Sutherland, N1
Li Wai Suen, CFD1
Mills, C1
Lokan, J1
Sinclair, M1
Tada, T4
Miyake, N1
Kurisu, A1
Ohisa, M1
Akita, T1
Qian, YY1
Dai, ZJ1
Ruan, LY1
Jin, J1
Shi, MT1
Zhu, YX1
Wu, CM1
Wong, DK6
Sievert, W9
Buggisch, P6
Petersen, J11
Flisiak, R9
Manns, M4
Kaita, K3
Krastev, Z7
Crans, G1
Op den Brouw, M1
Jump, B1
Flaherty, J3
Kawasoe, K1
Ohta, A1
Nitta, K1
Hagiwara, S1
Nishida, N2
Ida, H1
Ueshima, K1
Minami, Y1
Takita, M1
Komeda, Y1
Kudo, M1
Jia, Y1
Zhou, J2
Ji, J1
Xun, P1
Sripongpun, P1
Mannalithara, A1
Kwo, PY1
Liu, SH1
Yap, DY2
Fung, J8
Chan, TM2
Lai, CL16
Yuen, MF14
Walsh, R1
Hammond, R1
Yuen, L1
Deerain, J1
O'Donnell, T1
Leary, T1
Cloherty, G1
Sheng, HP1
Zhang, XY1
Wang, GN1
Shi, WB1
Zhao, F1
Lian, JQ2
Wang, JP3
Huang, CX1
Bai, XF2
Hartono, JL1
Aung, MO2
Dan, YY2
Gowans, M1
Lim, K2
Lee, YM2
Lee, GH2
Low, HC2
Tan, PS1
Thwin, MA1
Soon, C1
Chiu, LL1
Khoo, MJ1
Koay, E1
Lim, SG9
Childs, K1
Joshi, D1
Byrne, R1
Bruce, M1
Carey, I1
Taylor, C1
Teperman, LW1
Poordad, F2
Bzowej, N2
Martin, P4
Pungpapong, S1
Schiano, T1
Dinh, P9
Rossi, S2
Spivey, J1
Ma, YJ1
Iannazzo, S1
Coco, B1
Brunetto, MR3
Rossetti, F1
Caputo, A1
Latour, A1
Espinos, B1
Bonino, F1
Almeida, AM2
Silva, AL2
Brandão, CM2
Cherchiglia, ML2
Andrade, EI2
Araújo de Oliveira, GL1
Carmo, RA1
Acurcio, Fde A2
Rodriguez, C4
Chevaliez, S4
Bensadoun, P1
Pawlotsky, JM5
Amarapurkar, DN1
Patel, N1
Tujios, SR2
Lee, WM3
Tanaka, M2
Suzuki, F10
Seko, Y1
Hara, T2
Kawamura, Y6
Sezaki, H6
Hosaka, T7
Akuta, N6
Kobayashi, M13
Saitoh, S5
Arase, Y6
Ikeda, K6
Kumada, H7
Ji, YY2
Yao, GB2
Ma, XY3
Pang, HY1
Wu, SM3
Chen, CW3
Xu, XW2
Gu, EL2
Zhu, MF3
Qian, JC1
Lu, L2
Yan, FL1
Shi, JP2
Lou, GQ2
Arama, V2
Leblebicioglu, H2
Zarski, JP6
Zeuzem, S8
Mauss, S6
Sieklucki, J2
Acalovschi, M1
Usluer, G1
Klauck, I2
Morais, E2
Bjork, S2
Lescrauwaet, B3
Kamar, D2
Simon, K4
Ichchou, L1
Rist, S1
Lespessailles, E1
Prié, D1
Benhamou, CL1
Salpini, R3
Alteri, C2
Cento, V1
Pollicita, M1
Micheli, V2
Gubertini, G2
De Sanctis, GM2
Visca, M2
Romano, S2
Sarrecchia, C2
Andreoni, M2
Angelico, M3
Parruti, G2
Svicher, V3
Perno, CF3
Park, MS1
Kim, BK11
Kim, KS1
Kim, JK3
Kim, DY12
Baartarkhuu, O1
Han, KH14
Chon, CY8
Ferreira, AO1
Marinho, RT1
Velosa, J1
Costa, JB1
Cao, ZH3
Ma, LN4
Zhang, HW1
Liu, YL3
Chen, XY8
Huang, XX1
Gunsar, F2
Chan, SC2
Cheung, C1
Chok, KS1
Sharr, W1
Chan, AC1
Cheung, TT1
Fan, ST3
Lo, CM3
Weegink, CJ3
Terpstra, V3
Dijkgraaf, MG1
Jansen, PL2
Rijckborst, V2
Beld, MG2
Lee, JY2
Lee, YS13
Suh, DJ8
Plaza, Z1
Aguilera, A1
Mena, A1
Vispo, E3
Sierra-Enguita, R1
Tomé, S1
Pedreira, J1
Barreiro, P4
del Romero, J1
Soriano, V12
Poveda, E2
Choi, A1
Wang, JC3
He, LL2
Xu, XH1
Li, GL1
He, FQ1
Li, JY1
Pan, QR1
Deng, JY1
Singal, AK2
Salameh, H1
Kuo, YF1
Fontana, RJ3
Terrault, N2
Lavocat, F5
Dény, P1
Pichoud, C3
Al Hawajri, N1
Borroto-Esoda, K11
Zoulim, F34
Wong, VW11
Chan, FK2
Huang, FY2
Hung, IF2
Baxter, C1
Yende-Zuma, N1
Tshabalala, P1
Abdool Karim, Q1
Abdool Karim, SS1
Gracey, DM1
Snelling, P1
McKenzie, P1
Strasser, SI5
Goel, V1
Bose, PD1
Sarma, MP1
Hazam, RK1
Das, BC2
Gondal, R2
Kar, P3
Horváth, G3
Lin, MT2
Chou, YP1
Yu, HC2
Tsai, MC3
Tseng, PL3
Yen, YH2
Chiu, KW1
Wesdorp, DJ1
Knoester, M1
Braat, AE1
Coenraad, MJ1
Vossen, AC1
Claas, EC1
van Hoek, B2
Asselah, T5
Rodriguez-Frias, F5
Frias, FR1
Tabernero, D4
Šperl, J3
Pradat, P2
Le Pogam, MA1
Okon, JB1
Trolliet, P1
Miailhes, P5
Brochier, C1
Maynard, M3
Bailly, F3
Cotte, L1
Watahiki, S3
Mineta, R2
Corsa, A3
Snow-Lampart, A6
Miller, MD11
Yue, W1
Yuan, H1
Mao, XR1
Deng, YD1
Tian, JH2
He, YQ1
Li, RH1
Zhang, SF1
Wan, G1
Cai, HD2
Aydoğan, S1
Ergünay, K1
Balaban, Y2
Alp, A1
Simşek, H2
Tatar, G2
Hasçelik, G1
Us, D1
Sayan, M2
Buğdacı, MS1
Sohn, JY1
Lee, S4
Kim, DG2
Srivastava, M2
Rungta, S1
Dixit, VK2
Shukla, SK1
Singh, TB1
Jain, AK2
Du, QW1
Ding, JG2
Sun, QF2
Hong, L2
Cai, FJ1
Zhou, QQ1
Wu, YH2
Fu, RQ2
Lin, KH1
Hsu, PI1
Tsay, FW1
Wang, HM1
Tsai, TJ1
Lai, KH1
Jin, Y3
He, ZM2
Lu, JF2
Zhang, YH2
Sun, H3
Tu, Z2
Yan, H4
Pan, Y2
Lian, Z1
Chi, X2
Ceylan, B2
Yardimci, C1
Fincanci, M1
Eren, G1
Tozalgan, U1
Muderrisoglu, C1
Akkoyunlu, Y1
González-Artacho, C1
Rodríguez Sicilia, MJ1
Alegría-Motte, C1
Gómez García, M1
Lee, YB3
Lee, M5
Lee, DH6
Cho, Y6
Kim, CY6
Lee, HS11
Peng, H1
Yin, W2
Hwang, SG5
Ko, SY7
Choe, WH10
Ding, XC1
Liu, XY1
Xu, CQ1
Liu, SW1
Alagozlu, H1
Ozdemir, O1
Koksal, B1
Yilmaz, A1
Coskun, M1
Ouzan, D1
Pénaranda, G1
Joly, H1
Khiri, H1
Pironti, A1
Halfon, P1
Yuan, L1
Qiao, B1
Tanaka, T1
Renner, EL1
Selzner, N1
Therapondos, G1
Lilly, LB1
Huang, ZB1
Zhao, SS2
Dai, XH2
Zhou, RR2
Yi, PP1
Chen, RC2
Zhang, BX1
Fan, XG2
Klause, U1
Takkenberg, B2
Chu, T1
Petric, R1
Berg, T8
Moeller, B1
Chan, S5
Pipili, C1
Cholongitas, E4
Papatheodoridis, G2
Kim, MN2
Lee, CK3
Kim, HS9
Niederau, C2
Habersetzer, F2
Vermehren, J1
Bludzin, W1
Jinga, M1
Ulusoy, S2
Oliveira, GL1
Yeum, TS1
Kim, HY4
Kwan, P2
Fabri, M1
Horban, A5
Pelemis, M1
Hann, HW4
Gurel, S4
Caruntu, FA1
Husa, P2
Li, M5
Mangia, G4
Triolo, M1
Della Corte, C2
Colombo, M12
Pérez-Cameo, C1
Pons, M1
Tan, D2
Ning, Q3
Fan, R2
Shi, G2
Wan, M2
Sheng, J2
Dou, X2
Chen, C2
Li, B1
Park, H3
Chan, CK1
Chang, TT12
Mathurin, P1
Lau, G2
Gane, EJ4
Xiong, Y1
Gao, L3
Jia, S1
Li, F5
Chang, K1
Zhang, K5
Jiang, W1
Shang, Y1
Deng, S1
Chen, M1
Eguchi, H1
Tsuruta, M1
Tani, J1
Kuwahara, R1
Hiromatsu, Y1
Kim, HN1
Rodriguez, CV1
Van Rompaey, S1
Eron, JJ1
Thio, CL6
Crane, HM1
Overton, ET1
Saag, MS1
Martin, J1
Geng, E1
Mugavero, M1
Rodriguez, B1
Mathews, WC1
Boswell, S1
Moore, R1
Kitahata, MM1
Lee, CI1
Yoon, EL3
Yeon, JE8
Keskin, O3
Ormeci, AC2
Baran, B2
Kabaçam, G2
Tüzün, A1
Karatayli, E4
Akyüz, F2
Karatayli, S1
Bozdayi, AM4
Onel, D2
Badur, S3
Idilman, R6
Kaymakoglu, S3
Yurdaydin, C6
Hamnvik, OP1
Vaidya, A1
Becker, C1
Cai, SH1
Lv, FF1
Jiang, YG1
Peng, J5
Price, J1
Stalke, P1
Rybicka, M1
Wróblewska, A1
Dreczewski, M1
Stracewska, E1
Smiatacz, T1
Bielawski, KP1
Xie, FY1
Zeng, Y1
Su, M2
Lin, J1
Jiang, L1
Yang, B1
Ou, Q1
Ozekinci, T1
Mese, S1
Ozbek, E1
Atmaca, S1
Yao, A1
Lou, L2
Boyd, A5
Maylin, S4
Gozlan, J5
Delaugerre, C5
Simon, F2
Girard, PM7
Lacombe, K8
Seo, YB1
Im, SJ1
Song, MJ1
You, CR1
Jang, JW3
Yang, SH1
Suh, YS1
Song, JS1
Kim, BM1
Jeong, SH5
Sung, YC1
Lim, JH1
Park, GY1
Kang, YJ1
Kwon, O1
Choi, JY4
Park, SH4
Kim, YL1
Kim, HK1
Huh, S1
Kim, CD2
Maklad, S1
Doss, W1
El Din, SS1
Hassan, K1
Zeid, AA1
Hunyady, B2
Gervain, J2
Lengyel, G1
Makara, M2
Pár, A2
Szalay, F2
Telegdy, L2
Tornai, I3
Zhou, P1
Li, XJ2
Nguyen, V1
Tan, PK1
Greenup, AJ1
Glass, A1
Davison, S1
Samarasinghe, D1
Holdaway, S1
Chatterjee, U1
Locarnini, SA3
Liu, F2
Bradshaw, D1
Danta, M2
Xu, Z4
Tantai, N1
Chaikledkaew, U1
Werayingyong, P1
Teerawattananon, Y1
Błudzin, W1
Dziambor, A1
Goryszewski, D1
Postawa-Kłosińska, B1
Kolasa, K1
Singh, AK1
Sharma, MK1
Hissar, SS2
Gupta, E1
Sarin, SK5
Peytavin, G4
Geipel, A2
Glebe, D2
Will, H2
Gerlich, WH6
Lee, AJ1
Jeon, CH1
Sadler, MD1
Peng, D1
Du, Y2
Jia, T1
Chang, L1
van Iperen, EP1
Plat-Sinnige, MJ1
Chin, DJ1
Zwinderman, AH1
Chang, HY1
Yang, SY2
Svarovskaia, ES3
Nobili, V1
Comparcola, D1
Cainelli, F1
Vento, S1
Tang, CM1
Yau, TO1
Maynard-Muet, M1
Lebossé, F1
Carrat, F2
Bouix, C1
Lascoux-Combe, C3
Sogni, P1
Rey, D2
Barthe, Y1
Pol, S7
Cacoub, P2
Piroth, L2
Galati, G1
De Vincentis, A1
Vespasiani-Gentilucci, U1
Gallo, P1
Solmone, MC1
Dell'Unto, C1
Picardi, A1
Zheng, Q1
Zhu, YY1
Liu, YR1
You, J1
Zeng, DW1
Gao, LY1
Chen, LH1
Jiang, JJ1
Xi, H2
Hou, F1
Huo, N2
Ozaras, R2
Mete, B1
Ozgunes, N1
Gunduz, A1
Karaosmanoglu, H1
Cagatay, A1
Gokturk, K1
Erdem, L1
Kocak, F1
Senates, E1
Tabak, F1
Ke, W3
Ye, X4
Zhou, S3
Li, MR1
Xi, HL1
Wang, QH1
Hou, FQ1
Xu, XY2
Goulis, I2
Antoniadis, N2
Fouzas, I2
Imvrios, G2
Papanikolaou, V2
Akriviadis, E2
Lo, GH2
Corsa, AC3
Mitchell, B1
Fung, SK5
Zeng, T1
Liu, JY2
Lei, Y1
Zhong, S2
Ridruejo, E2
Panda, C1
Kekez, AJ1
Suh, SJ3
Seo, YS9
Lee, CD2
Lee, MS3
Park, CK3
Kim, MY2
Baik, SK2
Lee, JW5
Hong, SP15
Um, SH4
Ruhi, Ç1
Süleymanlar, İ1
Koçak, H1
Dinçkan, A1
Ersoy, F1
Süleymanlar, G1
Xiong, H3
Cheng, YC1
van Bömmel, F3
Warner, N2
Gürtler, LG1
Neumann-Fraune, M1
Beggel, B2
Kaiser, R3
Obermeier, M1
de Man, RA11
Dusheiko, GM1
Heathcote, EJ14
Huang, G2
Lau, WY2
Wang, ZG1
Pan, ZY2
Yuan, SX1
Zhou, WP2
Sirma, H4
Schildgen, O6
Iizuka, Y1
Sakai, H1
Kobayashi, K1
Iizuka, K1
Ito, E1
Mochizuki, N1
Asahina, Y1
Watanabe, M1
Patwardhan, VR1
Sengupta, N1
Bonder, A1
Lau, D1
Afdhal, NH1
Liu, YH1
Wu, T1
Sun, N1
Wang, GL2
Yuan, JZ1
Dai, YR1
Zhou, XH1
Shan, C1
Yin, GQ1
Ahn, H2
Gill, US1
Zissimopoulos, A1
Al-Shamma, S1
Burke, K1
McPhail, MJ1
Barr, DA1
Kallis, YN1
Marley, RT1
Kooner, P1
Foster, GR2
Kennedy, PT1
Nguyen, NH1
Nguyen, TT3
Do, ST2
Tran, P2
Nguyen, HA5
Nguyen, KK4
Garcia, RT4
Lutchman, GA1
Tao, L1
Jie, Y2
Shi, H2
Lin, G2
Ao, Y2
Pang, Y1
Chong, Y3
Tsai, NC2
Washington, MK3
Charuworn, P2
Arends, P1
Sypsa, V1
Savvidou, S1
Hansen, BE6
Papaioannou, C1
Galanis, K1
Mweemba, A1
Zanolini, A1
Mulenga, L1
Emge, D1
Chi, BH1
Wandeler, G1
Vinikoor, MJ1
Tien, C1
Xu, JJ1
Chan, LS1
Huh, B1
Shinada, S1
Hou, JL6
Sheng, JF3
Tan, DM1
Niu, JQ2
Chen, SJ3
Mao, YM1
Jia, JD2
Ji, Y1
Xiao, P1
Chung, SM1
Byoun, YS1
Kim, JW5
Samarkos, M1
Theofanis, V1
Eliadi, I1
Vlachogiannakos, J3
Polyzos, A1
Jacobson, IM5
Martins, EB3
Dusheiko, G4
Rustgi, VK2
Kim, J1
Lee, SH4
Choi, K1
Jeong, SW1
Grizzi, F1
Desmet, VJ1
Cui, XJ2
Jeong, SU2
Song, BC3
Rezaeeaval, M1
Pang, JX1
Alcantara, L1
Klein, P1
Ahn, SS1
Ze, E1
Baek, EK1
Chung, HW1
Ahn, DG1
Cho, HJ3
Kwon, JC1
Lee, H1
Moon, HW1
Li, T4
Long, H2
Zhuang, H4
Jung, EU1
Kim, BH5
Park, SJ5
Park, JW4
Lee, YJ1
Kim, CM1
Du, X1
Ren, S1
Shen, C3
Murakami, Y1
Hayakawa, M1
Yano, Y1
Tanahashi, T1
Tamori, A1
Kawada, N1
Iwadate, M1
Umeyama, H1
Cheng, W1
Sicard, E1
Ryder, SD1
Lawson, E1
Brocchieri, A1
Spinetti, A2
Zaltron, S2
Facchetti, F4
Fugazza, A1
Castelli, F2
Khan, MR1
Chowdhury, MS1
Saha, M1
Roknuzzaman, SM1
Mahmuduzzaman, M1
Miah, AR1
Roy, PK1
Raihan, MA1
Rahman, KM1
Jiang, SW2
Hu, AR2
Hu, YR2
Chen, SX1
Xiong, T1
Gao, GS1
Liang, XY2
Ding, SX2
Weng, PJ1
Ge, Y1
Yang, H7
Lyu, W1
Zhou, B2
Maggi, P2
Montinaro, V1
Leone, A2
Fasano, M3
Volpe, A2
Bellacosa, C1
Grattagliano, V1
Coladonato, L1
Lapadula, G1
Angarano, G3
Invernizzi, F3
Tsai, N4
Aguilar Schall, R2
Makowska, Z1
Dill, MT1
Bart Takkenberg, R1
Heim, MH1
Cui, S1
Gong, Y1
Lin, Q3
Pan, F1
Hong, F1
Wongcharatrawee, S1
Llamoso, C2
Lee, KS2
Gwak, GY7
Paik, YH2
Choi, MS7
Koh, KC8
Paik, SW8
Yu, YQ1
Wang, JL1
Pan, HY2
Wang, YE1
Gomes-Gouvêa, MS2
Ferreira, AC1
Teixeira, R1
Andrade, JR1
Ferreira, AS1
Barros, LM1
Rezende, RE1
Nastri, AC1
Leite, AG2
Piccoli, LZ1
Galvan, J1
Conde, SR1
Soares, MC1
Kliemann, DA1
Bertolini, DA1
Kunyoshi, AS1
Lyra, AC1
Oikawa, MK1
de Araújo, LV1
Carrilho, FJ2
Mendes-Corrêa, MC2
Pinho, JR2
Nie, CY1
Ha, FS1
Shimizu, M3
Ikezaki, H1
Hayashi, T1
Ihara, T1
Harada, Y1
Toyoda, K1
Murata, M2
Wang, BF1
Sun, FR1
Chen, YS1
Hu, YH1
Cao, YJ1
De Francesco, MA1
Gargiulo, F1
Giagulli, C1
Caccuri, F1
Caruso, A1
Ouyang, R1
Yang, DH1
Xie, YJ1
Zhao, NF2
Li, MW1
Huang, HJ1
Ho, EY1
Yau, T1
Rousseau, F12
Lau, GK6
Tempelmans Plat-Sinnige, MJ1
van Leeuwen, EM1
An, J1
Xu, LJ1
Liao, RX1
Mao, JF1
Chi, Y1
Wang, O1
Liu, XQ1
Liu, ZY1
Xing, XP1
Xia, WB1
Lo, AO1
Tse, YK1
Chan, HY5
Zhao, N1
Pan, H1
Jia, HY1
Ding, F1
Chen, JY1
Lian, JS1
Zhang, YM1
Zeng, LY1
Xiang, DR2
Hu, JH1
Yu, GD1
Lu, YF1
Zheng, L1
Li, LJ1
Yang, YD1
Chen, HL1
Lee, CN1
Chang, CH1
Ni, YH1
Shyu, MK1
Chen, SM1
Hu, JJ1
Lin, HH1
Zhao, LL1
Mu, SC1
Lai, MW1
Lee, CL1
Lin, HM1
Tsai, MS1
Hsu, JJ1
Chen, DS2
Chan, KA1
Chang, MH2
Jin, B1
Kim, S2
Kim, ND1
Nam, CM1
Choi, SH2
Mao, R1
Zhao, PW1
Ji, HF1
Feng, JY1
Jiang, YF3
Doğan, ÜB2
Öztürk, AB1
Akın, MS2
Yalaki, S1
Singla, B1
Bhattacharyya, R1
Chakraborti, A1
Sharma, BK1
Kapil, S1
Chawla, YK1
Arora, SK1
Das, A1
Dhiman, RK1
Duseja, A1
Li, XY1
You, X1
Jie, YS2
Lin, GL1
Wu, YK1
Huang, MX1
Li, ZY1
Chong, YT1
Shin, SJ1
Yoo, BM1
Cho, SW9
Cheong, JY9
Kim, MH2
Kim, CJ4
Lee, BU2
Jeong, ID3
Kim, BG4
Bang, SJ4
Kim, V1
Abreu, RM1
Nakagawa, DM1
Baldassare, RM1
Ono, SK2
Sung, SJ1
Koot, AW1
Visscher, AP1
Huits, RM1
Lu, F1
Duan, Z1
Su, F1
Dai, J2
Cui, X1
Ning, H2
Wang, G1
Qiu, P2
Zhou, SF2
Wen, P2
Wen, J1
Primignani, M1
Jovani, M1
Iavarone, M1
Fraquelli, M1
Casazza, G1
de Franchis, R1
Jiang, D1
Shan, X1
Liang, Z1
Shan, Y1
Huang, W2
Zen, A1
Gong, X1
Lai, J1
Yang, N1
Yao, N1
Kang, W1
Dang, B1
Yu, T1
Lv, F1
Yagi, T1
Shin, GC1
Rhee, JK1
Yang, SI1
Khodor, H1
Yetim, N1
Unal, UK1
Demirhan, YE1
Gultekin, G1
Isal, B1
Gu, J1
Sun, R2
Shen, S1
Amani, A1
Thiel, A1
Li, K1
Ding, G1
Xiao, E1
Mao, Z1
Kang, Y1
Jang, MK2
Kim, TY1
Jung, YK6
Park, JG1
Lian, J1
Xiang, H1
Lyu, H1
Liao, Y1
Su, Z1
Ying, B1
Tao, C1
Thu, AM1
Poovorawan, K1
Kittitrakul, C1
Nontprasert, A1
Sriboonvorakul, N1
Phumratanaprapin, W1
Leowattana, W1
Wilairatana, P1
Kim, SK1
Kim, SR1
Imoto, S1
Tohyama, M1
Otono, Y1
Tamura, T1
Zhang, SB1
Lin, CC3
Bair, MJ1
Chen, CJ2
Lee, KH1
Chen, MJ1
Liu, CY1
Chang, CW1
Hu, KC1
Liou, TC1
Lin, SC1
Chu, CH1
Shih, SC1
Wang, TE1
Bai, L2
Feng, Y1
Yuan, Z2
Song, H1
Zheng, X1
Jiang, B1
Li, XM1
Su, R1
Cao, Y1
Hou, W1
Xu, LF1
Wen, JB1
Xiao, XZ1
Chi, J1
Song, S1
Tsai, HW2
Lin, YJ1
Wu, HC1
Wu, IC3
Cheng, PN2
Yen, CJ1
Chan, SH1
Su, IJ1
Xing, H1
Sinnige, MJ1
Goyal, A1
Murray, JM1
Garcia, M1
Le Moal, G1
Godet, C1
Beraud, G1
Chagneau-Derrode, C1
Roblot, F1
Dan, J1
Defresne, F1
Sokal, E3
Tsuji, K1
Takagi, J1
Morita, H1
Ito, K1
Ohashi, T1
Hirase, S1
Morishima, T1
Otake, K1
Yoneda, M1
Xiang, X1
Bao, R1
Xie, J1
Bao, S1
Duan, SH1
Bao, ZY1
Yuan, XD1
Liu, MS1
Akyildiz, M2
Gungor, G1
Yilmaz, TU1
Kalkan, C1
Dayangac, M1
Cinar, K3
Balci, D1
Hazinedaroglu, S1
Tokat, Y1
Giakoustidis, D1
Giouleme, O3
Wei, W1
Cheng, KL1
Xu, MM1
Qiu, Q1
Yang, LK1
Duan, XW1
Duan, ZP1
Cao, H3
Shu, X5
Xu, Q1
Cho, EY1
Lee, JM6
Ip, P1
Kopaniszen, M1
Lee, B1
Cullaro, G1
Chong, CK1
Wu, R1
Cheng, C1
Yuen, J1
Ngai, V1
Pereira-Gómez, M1
Bou, JV1
Andreu, I1
Sanjuán, R1
Park, SK1
Yang, HJ3
Jung, YS1
Park, DI2
Sohn, CI2
Jeon, WK2
Kim, BI3
Choi, KY1
Santana, LC1
Mantovani, NP1
Ferreira, MC1
Arnold, R1
Duro, RL1
Ferreira, PR1
Hunter, JR1
Leal, É1
Diaz, RS1
Komninakis, SV1
Asano, M1
Inoue, T1
Sakamoto, M1
Enomoto, N1
Shirasaki, T1
Honda, M1
Gatanaga, H1
Oka, S1
Kawamura, YI1
Dohi, T1
Shuno, Y1
Yano, H1
You, S1
Naftel, J1
Khakoo, SI1
Buchanan, R1
Wu, CK1
Wang, LP1
Han, FZ1
Yan, XB2
Lim, L1
Patterson, S1
George, J2
Strasser, S1
Lee, A1
Nicoll, A1
Desmond, P2
Roberts, S1
Marion, K1
Bowden, S9
Angus, P2
Maida, I1
Mura, MS1
Luo, Q1
Zeng, W1
Ruggiero, G2
Marrone, A2
Rainone, I1
Boemio, A1
Adinolfi, LE1
Pasquale, G1
Rinaldi, L1
Guerrera, B1
Andreana, L1
Zampino, R2
Singh, N1
Nath, G1
Ying, H1
Wei, L3
Hong, LJ1
Fiore, JR1
Santantonio, TA1
Chung, GE2
Lin, BL1
Xu, QH7
Lu, WL1
Li, JG1
Jaroszewicz, J1
Lu, YP1
Guo, T1
Wang, BJ1
Dong, JH1
Zhu, JF1
Lu, MJ1
Yang, DL1
Carrouée-Durantel, S1
Durantel, D2
Werle-Lapostolle, B2
Naesens, L2
Neyts, J3
Trépo, C9
Zeng, AZ3
Peng, FY1
Xin, XJ3
Li, QL3
Guo, JJ3
Zhang, ZZ1
Hao, MJ1
Huang, WX1
Lindh, M1
Uhnoo, I1
Bläckberg, J1
Duberg, AS1
Friman, S1
Fischler, B1
Karlström, O1
Norkrans, G1
Reichard, O1
Sangfeldt, P1
Söderström, A1
Sönnerborg, A1
Weiland, O1
Wejstål, R1
Wiström, J1
Leemans, WF4
Niesters, HG4
van der Eijk, AA2
Schalm, SW4
Shorbagi, A1
Fournier, C1
Bronowicki, JP1
Nani, A1
Barraud, H1
Cadranel, JF2
Menne, S2
Butler, SD2
George, AL2
Tochkov, IA2
Xiong, S16
Gerin, JL2
Cote, PJ2
Tennant, BC2
Tong, M3
Arterburn, S4
Frederick, D9
Parvaz, P3
Beaugrand, M1
Benhamou, Y12
Trylesinski, A2
Monchecourt, F1
Lui, YY2
Deterding, K4
Manns, MP2
Wedemeyer, H6
Choi, JW2
Kim, TN1
Eun, JR2
Arslan, U1
Ural, O1
Findik, D1
Keeffe, EB8
Shiffman, ML5
Tong, MJ3
Mondou, E7
Sorbel, J8
Dieterich, DT3
Han, SH1
Tobias, H1
Ahmed, CS1
Lu, P2
Katsounas, A1
Jochum, C1
Canbay, A1
Schlaak, J1
Gerken, G2
Germanidis, G3
Kotzev, I2
Tchernev, K2
Weilert, F2
Kurdas, OO2
Anderson, J3
Quinn, J1
Leung, N6
Sollano, J1
Lao-Tan, J1
Lesmana, L1
Jeffers, L4
Sherman, M7
Min, A1
Mencarini, K1
Diva, U1
Cross, A1
Wilber, R1
Lopez-Talavera, J1
Pallier, C1
Brillet, R2
Nordmann, P1
Hézode, C3
Koh, KH2
Kang, CJ2
Choi, YW1
Lunghi, G2
Amini-Bavil-Olyaee, S3
Sheldon, J5
Lutz, T4
Trautwein, C5
Tacke, F3
García Buey, L1
González Mateos, F1
Moreno Otero, R1
Peñas, B2
Sarmento E Castro, R1
González-Diéguez, ML1
Limquiaco, JL1
Wong, J2
Tse, CH4
Kwan, KY1
Lai, PB1
Moon, JH1
Cho, M2
Yoon, KT1
Bae, JH1
Kim, GH3
Kang, DH1
Song, GA1
Rebers, SP1
Menting, S1
Schinkel, J1
Cha, CK1
Kwon, HC1
Kim, SO10
Yoo, WD3
Izzedine, H4
Kheder-Elfekih, R1
Housset, P1
Sarkozy, C1
Brocheriou, I1
Deray, G3
Scott, JD1
McMahon, B1
Poynard, T7
Ngo, Y1
Hadziyannis, S4
Ratziu, V4
Reijnders, JG5
Pas, SD3
Schutten, M3
Buster, EH3
Hwang, YJ1
Kwon, OS2
Choi, DJ2
Jardi, R6
Schaper, M3
Ferrer-Costa, C1
Homs, M3
Kamar, N2
Huart, A1
Tack, I1
Alric, L2
Izopet, J2
Rostaing, L3
Oguz Onder, F1
Ahishali, E1
Bektas, M1
Pinarbasi, B1
Karayalcin, S2
Cakaloglu, Y1
Mithat Bozdayi, A1
Bozkaya, H1
Okten, A1
Yatsuji, H3
Valencia, ME1
Moreno, V1
Ohkawa, K2
Takehara, T2
Kanada, A1
Deguchi, M1
Kagita, M1
Hikita, H1
Sasakawa, A1
Kohga, K1
Uemura, A1
Sakamori, R1
Yamaguchi, S1
Miyagi, T1
Ishida, H1
Tatsumi, T1
Hayashi, N2
Chung, YH6
Kim, JA2
Kim, SE2
Saab, S1
Ham, MY1
Stone, MA1
Holt, C1
Qiu, YW1
Jiang, XH2
Huang, LH2
Ding, H2
Jiang, YM1
Dai, YX1
Wendling, D1
Di Martino, V1
Prati, C1
Toussirot, E1
Herbein, G1
Choi, HM1
Koo, HW1
Jung, HW1
Yeon, KK1
Curtis, M5
Kurashige, N1
Yakushijin, T1
Kiso, S1
Kanto, T1
Kasahara, A1
Doi, Y1
Yamada, A1
Oshita, M1
Mita, E1
Hagiwara, H1
Nagase, T1
Yoshihara, H1
Hayashi, E1
Kashihara, T1
Les, I1
García-Martínez, R1
Córdoba, J1
Quintana, M1
Buffet, C1
Park, MK1
Lee, HIe2
Hass, HG1
Bock, T1
Nehls, O1
Kaiser, S1
Han, Y1
Liu, CM1
Lin, ZM1
Kong, XF1
Yu, DM1
Zhang, DH1
Jin, GD1
Lu, ZM2
Gong, QM1
Ha, NB4
Vu, AA1
Levitt, BS2
Arrese, E1
Basaras, M1
Blanco, S1
Ruiz, P2
Cisterna, R1
Brosa, M1
Rueda, M3
Durantel, S4
Barraud, L1
Heichen, M1
Guastadisegni, A1
Pastore, G2
Herbers, U2
Mohebbi, SR1
Sabahi, F1
Zali, MR1
Luedde, T2
Stornaiuolo, G2
Brancaccio, G2
Precone, V1
Sgrò, G1
Nardiello, S1
Gaeta, GB4
Jones, J4
Shepherd, J4
Baxter, L1
Gospodarevskaya, E1
Hartwell, D1
Harris, P2
Price, A3
Ji, F1
Ma, S1
Cong, M2
Ren, J1
Wang, LC2
Cao, J1
Wang, JR2
Akman, SA1
Kose, S1
Halicioglu, O1
Nguyen, T2
Vezali, E1
McMahon, BJ2
Zhou, HJ1
Li, SG1
Wen, FY1
Yang, XY1
Wu, JL1
Tan, B1
Fu, J1
Wang, CM1
Liang, ZL1
Zhong, YW1
Ren, XQ1
Xu, ZH1
Xu, DP1
Tuma, P1
Labarga, P1
Fernández, JV1
Medrano, J1
Vassiliadis, TG1
Koumerkeridis, G1
Koumaras, H1
Tziomalos, K2
Patsiaoura, K2
Grammatikos, N2
Mpoumponaris, A1
Gkisakis, D2
Theodoropoulos, K2
Panderi, A1
Katsinelos, P2
Eugenidis, N2
Wu, MS1
Chen, WL2
Xiao, L1
Zhao, LZ1
Wei, SJ1
Jenh, AM2
Pham, PA2
Lei, J1
Perry, CM1
Simpson, D1
Zhang, DZ6
Cai, SF1
Deng, XH1
Gong, ZJ1
Hu, DF1
Ji, SI1
Adusumilli, S1
Llop, E1
de la Revilla, J1
Pons, F2
Martínez, JL1
Abreu, L1
Olotu, C2
Funk, A3
Zöllner, B2
Helm, M2
Rockstroh, JK2
Jain, P1
Zhu, M2
Fan, X1
Fang, D1
Bin, D1
Xueyong, L1
Jun, C1
Hongshan, W1
Piccolo, P1
Lenci, I1
Demelia, L1
Piras, MR1
Antonucci, G1
Nosotti, L2
Mari, T1
De Santis, A1
Ponti, ML1
Sorbello, O1
Iacomi, F1
Joo, MK1
Park, JJ3
Bak, YT2
Wu, XF1
Wei, N1
Wong, T1
Girgis, CM1
Ngu, MC2
Emmett, L1
Archer, KA1
Seibel, MJ1
Sung, J1
Piratvisuth, T3
Perrillo, RP5
Tung, WC1
Changchien, CS4
Zhao, WF2
Shao, YL1
Chen, LY1
Wu, JH1
Zhu, YL1
Gan, JH2
Scotto, G3
Fazio, V3
Song, HJ1
Hyun, S1
Choi, EK1
Kim, HU1
Muñoz Bertrán, E1
Pérez Ceballos, E1
Gómez Espín, R1
Ortega González, I1
Ueno, Y2
Wakui, Y1
Fukushima, K1
Yamagiwa, Y1
Shiina, M1
Kondo, Y1
Kakazu, E1
Tamai, K1
Obara, N1
Iwasaki, T1
Shimosegawa, T2
Tsoi, KK1
Teo, EK1
Mohamed, R1
Mihm, U2
Thibault, V5
Valantin, MA2
Schneider, L1
Cuestas, ML1
Rivero, CW1
Minassian, ML1
Castillo, AI1
Gentile, EA1
Trinks, J1
León, L1
Daleoso, G1
Frider, B1
Lezama, C1
Galoppo, M1
Giacove, G1
Mathet, VL1
Oubiña, JR1
Wörmann, T1
Prüfer-Krämer, L1
Krämer, A1
Moucari, R2
Boyer, N2
Ripault, MP2
Castelnau, C2
Mackiewicz, V1
Dauvergne, A1
Valla, D1
Vidaud, M1
Chanoine, MH1
Mitsui, F1
Kimura, T1
Kitamura, S1
Abe, H1
Saneto, H1
Kawaoka, T1
Miki, D1
Hatakeyama, T1
Hiraga, N1
Imamura, M1
Kawakami, Y1
Aikata, H1
Takahashi, S1
Hayes, CN1
Igarashi, H1
Morimoto, K1
Colquitt, J1
Cooper, K1
Zeng, WQ1
Kalayci, R1
Altindiş, M1
Gülamber, G1
Demirtürk, N1
Akcan, Y1
Demirdal, T1
Aizawa, M2
Tsubota, A2
Fujise, K2
Takamatsu, M1
Namiki, Y1
Ohkusa, T1
Tajiri, H2
Wu, B1
Tang, CS1
Yung, S1
Choy, BY1
Liu, LJ1
Du, SC1
Yang, RF1
Moller, B1
Suarez, E2
Oldach, D1
Woo, G1
Tomlinson, G1
Nishikawa, Y1
Kowgier, M1
Pham, B1
Ungar, WJ1
Einarson, TR1
Krahn, M1
Gori, C1
Marcuccilli, F1
Bertoli, A2
Longo, R1
Bernassola, M1
Gallinaro, V1
Ursitti, A1
Feasi, M1
Cassola, G1
Ceccherini-Silberstein, F1
Cappiello, G1
Spanò, A1
Schildgen, V1
Ziegler, S1
Tillmann, RL1
Heo, NY2
Dunn, SR1
Ahn, M1
Xu, QJ1
Liang, ZG1
He, ZK1
Dong, PL1
Wang, DM1
Zhang, XM1
Ding, HG1
Min, J1
Cho, YJ1
Jeon, SJ1
Lee, YC2
Ahn, SY1
Jang, YM1
Choi, YH2
Rami, A1
Loustau-Ratti, V1
Morlat, P1
Goderel, I1
Sene, D1
Rosenthal, E1
de Vries-Sluijs, TE1
Prins, JM1
Hoepelman, AI1
Richter, C1
Mulder, JW1
van der Ende, ME1
Dakin, H3
Bentley, A2
Fidler, C2
Harper, C1
Rago, A1
Lichtner, M1
Mecarocci, S1
Marocco, R1
Cenfra, N1
Belvisi, V1
Del Borgo, C1
Cimino, G1
Mastroianni, CM1
Avihingsanon, A2
Lewin, SR2
Kerr, S1
Chang, JJ1
Piyawat, K1
Napissanant, N1
Matthews, GV2
Dore, GJ3
Lange, J1
Ruxrungtham, K3
Hirakawa, M1
Juszczyk, J2
Boroń-Kaczmarska, A2
Cianciara, J1
Gładysz, A1
Halota, W1
Kryczka, W1
Malkowski, P1
Pawlowska, M2
Chen, LB3
Yang, XA3
Einecke, D1
Ryu, HJ2
Rhee, SY1
Margeridon-Thermet, S1
Liu, TF1
Kagan, RM1
Verheyen, J1
Shafer, RW1
Chotiyaputta, W1
Peterson, C1
Ditah, FA1
Goodwin, D1
Jonas, MM3
Block, JM1
Haber, BA1
Karpen, SJ1
London, WT1
Murray, KF2
Narkewicz, MR1
Rosenthal, P2
Schwarz, KB1
Xin, G2
Sun, P1
Fukai, K1
Imazeki, F1
Arai, M1
Yonemitsu, Y1
Fontanges, T1
Blin, P1
Bregman, B1
Schmidely, N1
Roudot-Thoraval, F2
Bonacini, M2
Schiff, E3
Thabut, D2
Zong, J1
Patterson, SJ1
Lee, AU2
Nicoll, AJ1
Desmond, PV1
Roberts, SK1
Angus, PW1
Lasnier, E1
Molina, JM1
Bonnard, P1
Wendum, D1
Meynard, JL1
N'Dri-Yoman, T1
Anglaret, X1
Messou, E1
Attia, A1
Polneau, S1
Toni, T1
Chenal, H1
Seyler, C1
Gabillard, D1
Wakasugi, N1
Eholié, S1
Danel, C1
Kahloun, A1
Bourlière, M2
Pais, R1
Ma, Z1
Hao, C1
Yang, JX1
Liu, BM1
Li, XG1
Yan, CH1
Sun, XW1
Wang, YH1
Jiao, XJ1
Yan, L2
Dong, JP1
Hou, CS1
Abuduheilili, X1
Zhong, Y3
Hilgendorf, I1
Loebermann, M1
Borchert, K1
Junghanss, C1
Freund, M1
Schmitt, M1
Xie, QF1
Bai, HL1
Luo, HT1
Ye, YN1
Zhong, RX1
Sonneveld, MJ3
Shamliyan, TA1
Johnson, JR1
MacDonald, R1
Shaukat, A1
Yuan, JM1
Kane, RL1
Wilt, TJ1
Tu, XL1
Cheng, QH1
Mutimer, D3
Kim, MC1
Durval, A1
Zamidei, L1
Bettocchi, D1
Luzzio, MG1
Consales, G1
Kim, W1
Lee, KL1
Hwang, SY2
Jung, YJ1
Jeong, JB1
Sheen, IS1
Akarca, US2
Suet-Hing Wong, F1
Peschell, K1
Carosi, G2
Rizzetto, M8
Alberti, A4
Cariti, G2
Craxì, A2
Filice, G2
Levrero, M1
Mazzotta, F1
Piccinino, F1
Prati, D1
Raimondo, G1
Sagnelli, E1
Toti, M1
Bruno, R3
Di Marco, V3
Ferrari, C2
Marzano, A5
Pollicino, T1
Puoti, M4
Wang, XC2
Wu, YT2
Tan, YF2
Tang, JM2
Pan, JQ2
Garg, H1
Garg, V1
Sharma, BC1
Kumar, A1
TrehanPati, N2
Kotillil, S1
Shrivastava, S1
Khanam, A1
Sukriti, S1
Mishra, SK1
Kobashi, H2
Yamamoto, K3
Ozeki, I2
Arakawa, T2
Nakajima, T2
Kuwata, Y2
Akaike, J1
Ohmura, T2
Karino, Y2
Toyota, J2
Fernandez-Fernandez, P1
Quer, J1
Shin, SK1
Hahn, JS1
Sinn, DH5
Yun, WK1
Lee, YY1
Gluhovschi, C1
Gadalean, F1
Kaycsa, A1
Curescu, M1
Sporea, I1
Gluhovschi, G1
Petrica, L1
Velciov, S1
Bozdog, G1
Bob, F1
Vernic, C1
Cioca, D1
Pradeep Kumar, S1
Medhi, S2
Asim, M1
Daudé, M1
Sauné, K1
Lavayssière, L1
Basse, G1
Esposito, L1
Guitard, J1
Chaung, KT1
Liu, WC1
Young, KC1
Gila, A1
Figueruela, B1
Chueca, N1
Muñoz Rueda, P1
Puche, B1
García, F1
Martín, JM1
Andrade, RJ1
Nogales, C1
Romero-Gómez, M1
Guan, Q1
Ratcliffe, L1
Beadsworth, MB1
Pennell, A1
Phillips, M1
Vilar, FJ1
Chattopadhyay, P1
Sarma, N1
Chappell, B1
Myrick, F1
Schawalder, J1
Heathcote, J1
Tang, LH1
Chen, LZ1
Ren, X1
Choi, PC1
Chan, AW1
Chim, AM2
Yiu, KK1
Chu, SH1
Sung, JJ4
Stitou, H1
Desire, N1
Tubiana, R1
Katlama, C2
Aroldi, A1
Messa, PG1
Tatsuzawa, K1
Kono, M1
Hoshina, S1
Raptopoulou-Gigi, M1
Cheinquer, H2
Brown, RS1
Bialkowska, J1
Tang, S1
Beebe, S1
Cooney, E1
Chiang, LT1
Ko, BS1
Zaaijer, H1
Weegink, C1
Dijkgraaf, M1
Jansen, P1
Beld, M1
Reesink, H1
Manesis, EK1
Petraki, K1
Tiniakos, D1
Hadziyannis, SJ16
Minami, M4
Okanoue, T5
Cao, W1
Qiu, ZF1
Li, TS1
Ciancio, A1
Liang, Y1
Xie, R1
Ge, S1
Volpi, A1
Ceccarelli, L1
Sordillo, P1
Giannousis, IP1
Manolakopoulos, SG1
Hadziyannis, E2
Georgiou, A1
Wang, ZH1
Guo, YB1
Li, XH1
Wang, YM2
Lai, JY2
Wang, JF1
Li, MK1
Jiang, M1
Popescu, M1
Kirschner, J1
Guerrero, A1
Reijnders, J1
Mirandola, S2
Campagnolo, D2
Bortoletto, G1
Franceschini, L1
Marcolongo, M1
Cassino, L1
Benetti, S1
Fay, F1
Tanno, H1
Quarleri, J1
Berger, F3
Filmann, N1
Hueppe, D1
Henke, J1
Hegener, P1
Athmann, C1
Schmutz, G2
Herrmann, E2
Law, ST1
Li, KK1
Ho, YY1
Kwak, MS2
Zoutendijk, R2
van Vuuren, AJ1
Boucher, CA1
Yuen, LK1
Hua, C1
Qin, L1
Si-Ahmed, SN1
Mallet, V1
Cruiziat, C1
Dumortier, J1
Jin, YJ1
Park, WH1
Yu, JH1
Fan, WB1
Xie, SS1
Li, WW1
Sheen, E1
Wu, XL1
Zeng, WZ1
Qin, JP2
Jiang, MD2
Giles, M1
Visvanathan, K1
Sasadeusz, J2
Sheng, YJ1
Tong, SW1
Hu, HD1
Sun, HX1
Montagnani, M1
Giandinoto, M1
Lisotti, A1
Galli, S1
Azzaroli, F1
Buonfiglioli, F1
Turco, L1
Aldini, R1
Mazzella, G1
Ong, A1
Kim, KA1
Suh, JH1
Cho, YS1
Won, SY1
Park, BK1
Seo, DD1
Jang, JS1
Shin, WG1
Mak, B1
Sutedja, D1
Fernandes, M1
Lai, V2
da Silva, AC1
Guastini, CF1
Martins, LG1
Silva, MH1
Gianini, RJ1
Uip, DE1
Lu, H1
Geng, da Y1
Lu, B2
Ma, LX1
Razonable, RR1
Zhou, PP1
Hao, JG1
Li, SK1
Hou, XC1
Yang, ZX1
Gu, XB1
Piao, RL1
Tian, D1
Ma, ZH1
Brown, A1
Schollmeyer, J1
Sterneck, M1
Sarrazin, C2
Lutgehetmann, M2
Wang, QY1
Dou, YQ1
Zhang, LR1
Zhao, LF1
Karatayli, SC2
Gokahmetoglu, S1
Güven, K1
Ha, M2
Diao, S2
Lin, M2
She, H2
Kuan, C1
Shen, L2
Shen, W2
Miyajima, I1
Sata, M1
Ebinuma, H1
Saito, H1
Zhu, JY1
Minde, Z1
Yimin, M1
Guangbi, Y1
JinLin, H1
Hao, W1
Hong, R1
Yuming, W1
Xiaqiu, Z1
Daozhen, X1
Yagang, C1
Junqi, N1
Youming, C1
Yaozong, W1
Dixon, J1
Barker, K1
D'Addiego, G1
Giammario, A1
Campanale, F1
Cao, Z1
Ma, B1
Wu, H1
Dong, GF1
Xie, YS1
Jeon, JW1
Shin, HP1
Joo, KR1
Cha, JM1
Lim, JU1
Xing, X1
Fan, XH1
Geng, JZ1
Zheng, YY1
Lu, HY1
Si, QT1
Zhang, MH1
Zhang, YG1
Ji, SW1
Guo, HH1
Zhou, CY1
Wang, JB1
Zhong, JH1
Li, le Q1
Wu, LC1
Arasli, M1
Ustundag, Y1
Delikanli, B1
Harmandar, F1
Buyukuysal, C1
Cox, N1
Tillmann, H1
Ju, T1
Segovia, MC1
Chacra, W1
Benayed, R1
Riley-Gillis, B1
Sone, Y1
Fujimori, M1
Lee, TH1
Lada, O1
Gervais, A1
Branger, M1
Roquebert, B1
Collin, G1
Fraqueiro, G1
Leclerc, L1
Martinot-Peignoux, M2
Matheron, S1
Zhang, WL1
Xie, SL1
Hu, JL1
Cai, XF1
Lai, GQ1
Eum, JB1
Du Jeong, I1
Hsiao, CC1
Chang, J1
Wu, JY1
Liu, WH1
Han, SY1
Chen, PJ3
Yeh, SH1
Ayana, DA1
Lee, KG1
Jung, ES1
Ryu, HS2
Hu, KQ2
Yu, AS2
Bunchorntavakul, C1
Reddy, KR1
Lassel, L1
Liang, JY1
Krygier, R1
Bacia, V1
Baka-Cwierz, B1
Bluszcz-Roznowska, A1
Brzostek, T1
Deroń, Z1
Durlik, M1
Janczewska-Kazek, E1
Kalinowska, A1
Mach, T1
Olszok, I1
Pisula, A1
Wawrzynowicz-Syczewska, M1
Silva, MO1
Xing, J1
Xiao, SX1
Wang, YD1
Zhao, CY1
Lu, HZ1
Yu, WY1
Zhou, JY1
Yan, WZ1
Ghany, MG2
Feld, JJ1
Heller, T1
Doo, E1
Rotman, Y1
Nagabhyru, P1
Koh, C1
Kleiner, DE2
Wright, EC1
Liang, TJ1
Hoofnagle, JH3
Son, CY1
Ma, XJ1
Chen, XP1
Chen, XF1
Luo, XD1
Ma, HY1
Kelly, D3
Pollack, H2
Mizerski, J4
Dai, WW1
Li, DK1
Gara, N1
Collins, MT1
Chong, WH1
Jake Liang, T1
Gish, RG5
Clark, MD1
Kane, SD1
Shaw, RE1
Mangahas, MF1
Baqai, S1
Mello, FC1
Fernandes, CA1
Gomes, Sde A1
Seo, EG1
Han, JH1
Yoon, SM1
Park, SM2
Youn, SJ1
Szenborn, L1
Wysocki, J1
McHutchison, J1
Pang, PS1
Luminos, LM1
Qiu, H1
Wei, AL1
Kuang, X1
Fan, K1
Deng, G1
Gadano, A1
Lovegren, M1
Cohen, D1
Rapti, I3
Vassilopoulos, D2
Das, P1
Vivek, V1
Ford, M1
Kingdon, E1
Holt, S1
Chu, M1
Cho, SM1
Choe, BH1
Cho, MH1
Kwon, S1
Lee, WK1
Zhong, C1
Stroffolini, T1
Spadaro, A1
Scifo, G1
Russello, M1
Montalto, G1
Bertino, G1
Surace, L1
Caroleo, B1
Foti, G1
Portelli, V1
Madonia, S1
Sapienza, M1
Cosco, L1
Frugiuele, P1
Galdieri, A1
Brandolino, N1
Siciliano, R1
Bruno, S1
Almasio, PL1
Liang, LB1
Zhang, WJ1
Cai, SP1
Fan, ZP1
Ji, YJ1
Tuaillon, E1
Lozano, C1
Kuster, N1
Poinso, A1
Kania, D1
Nagot, N1
Mondain, AM1
Pageaux, GP1
Ducos, J1
Van de Perre, P1
Reynes, J1
Boni, C1
Laccabue, D1
Giuberti, T1
Schivazappa, S1
Alfieri, A1
Pesci, M1
Missale, G1
Kara, B1
Gümürdülü, Y1
Soylu, A1
Mikulska, M1
Taramasso, L1
Giacobbe, DR1
Caligiuri, P1
Bruzzone, B1
Di Biagio, A1
Viscoli, C1
Cevik, E1
Yakut, M1
Seven, G1
Setoguchi, T1
Ishidou, Y1
Arishima, Y1
Hirotsu, M1
Saitoh, Y1
Nakamura, S1
Kakoi, H1
Nagano, S1
Yokouchi, M1
Kamizono, J1
Komiya, S1
Ebata, S1
Suzuki, A1
Ito, M1
Ishikawa, Y1
Mochizuki, T1
Baba, N1
Kubota, J1
Miyoshi, K1
Fujioka, S1
Moritou, Y1
Miyake, Y1
Iwasaki, Y1
Lai, HW1
Chang, CC1
Chen, TH1
Chen, TY1
Yuen, JC2
Ma, J4
He, B2
Li, NP2
Tang, W1
Yip, B1
Chaung, K1
Wong, CR1
Cheung, R1
Sebastiani, G1
Rossi, C1
Velo, E1
Erne, EM1
Vario, A1
Tempesta, D1
Romualdi, C1
Li, MY1
Yuan, XL1
Köklü, S1
Tuna, Y1
Gülşen, MT1
Demir, M1
Köksal, AŞ1
Koçkar, MC1
Aygün, C1
Coban, S1
Ataseven, H2
Akin, E1
Pürnak, T1
Yüksel, I1
Ibiş, M1
Yildirim, B1
Nadir, I1
Küçükazman, M1
Akbal, E1
Yüksel, O1
Başar, O1
Alkan, E1
Baykal, O1
Baak, BC1
Bakker, CM1
Beuers, UH1
Brouwer, JT1
Drenth, JP1
van Erpecum, KJ1
Honkoop, P1
Kerbert-Dreteler, MJ1
Koek, GH1
van Nieuwkerk, KM1
van Soest, H1
van der Spek, BW1
Tan, AC1
Vrolijk, JM1
Cai, M1
Striki, A1
Cheng, D1
Wei, H2
Tian, Z2
Kiriyama, S1
Tanikawa, M1
Hisanaga, Y1
Kanamori, A1
Niinomi, T1
Andou, Y1
Chung, KH1
Jin, E1
Ku, YS1
Lee, SJ1
Bahrami, S1
Grare, M1
Zhao, KK1
Miao, QL1
Wang, YX1
Zheng, SM1
Lin, H1
Liu, XC1
Shen, CF1
Afdhal, N1
Bornstein, JD1
Tana, MM1
Fu, SY1
Ma, MM1
Sherman, AC1
Daucher, M1
Davey, RT1
Masur, H1
Kottilil, S1
Kohli, A1
Shimohata, H1
Sakai, S1
Ogawa, Y1
Hirayama, K1
Sun, IO1
Hong, YA1
Park, HS1
Choi, SR1
Chung, BH1
Park, CW1
Yang, CW1
Choi, BS1
Tuncer, I1
Katrinli, S1
Enc, FY1
Colak, Y1
Ulasoglu, C1
Dinler, G1
Hulstaert, F1
Schwierz, C1
Nevens, F1
Thiry, N1
Gamil, M1
Colle, I1
Van de Sande, S1
Horsmans, Y1
Hige, S1
Jin, Q1
Boglione, L1
D'Avolio, A1
Gregori, G1
Burdino, E1
Baietto, L1
Cusato, J1
Ghisetti, V3
De Rosa, FG1
Di Perri, G1
Seaberg, EC1
Revill, PA1
Hoy, JF1
Finlayson, R1
Saulynas, M1
Afshar, RM1
Mollaie, HR1
Yun, TJ1
Jung, JY1
Kim, CH1
An, H1
Kim, JD1
Keum, B1
Jeen, YT1
Chun, HJ1
Song, ZL1
Cui, YJ1
Zheng, WP1
Teng, DH1
Zheng, H1
Oyagüez, I1
Lozano, V1
Yi, NJ1
Lee, KW1
Kong, SY1
Park, KU1
Lee, KB1
Hong, G1
Han, SS1
Suh, KS1
Maratea, D1
Fadda, V1
Trippoli, S1
Messori, A1
Bagnard, G1
Lapalus, M1
Soyer, OM1
Gokturk, S1
Evirgen, S1
Bozbey, HU1
Karaca, C1
Demir, K1
Besisik, F1
Gulluoglu, M1
Komolmit, P1
Pessôa, MG1
Fassio, E1
Bessone, F1
Daruich, J1
Pathan, R1
Dong, Y1
Chen, ZT1
Wu, JC1
Chen, JJ1
Luo, EP1
Westland, CE3
Delaney, WE8
Ho, V1
Fry, J7
Brosgart, C7
Gibbs, CS8
Davis, GL1
McClellan, MB1
Núñez, M3
Pérez-Olmeda, M1
Díaz, B1
Ríos, P1
González-Lahoz, J2
Ristig, MB1
Crippin, J2
Aberg, JA1
Powderly, WG1
Lisker-Melman, M2
Kessels, L1
Tebas, P2
Nelson, M2
Portsmouth, S1
Stebbing, J1
Atkins, M1
Barr, A1
Matthews, G1
Pillay, D1
Fisher, M1
Bower, M1
Gazzard, B1
Cha, YJ1
Chen, RY1
Shaw, T2
Colledge, D2
Isom, H1
Fisher, DA1
Huffam, SE1
Birkus, G1
Cihlar, T1
Goodman, Z5
Wulfsohn, MS3
Brosgart, CL16
Tassopoulos, NC3
Kitis, G4
Mailliard, ME1
Gollan, JL1
Bernard-Chabert, B1
Sacchi, P1
Zocchetti, C1
Ciappina, V1
Iino, S1
Mukherjee, S1
Wulfsohn, M2
Westland, C5
Delaney, W2
Chen, SS2
Gibbs, C2
Miller, M1
Purow, DB1
Vaughan, R1
Ayres, A1
Bartholomeusz, A1
Ortleb, J1
Barcena Marugan, R1
Cid Gomez, L1
Lopez Serrano, P1
Dando, T1
Plosker, G1
Maier, KP2
Lagget, M2
Liu, CL2
Wei, WI1
Yong, BH1
Ristig, M1
Drechsler, H1
Villeneuve, JP5
Werle, B2
Hochman, JA1
Balistreri, WF1
Neuhaus, P1
Tillmann, HL3
Samuel, D4
Lilly, L1
Rendina, M1
Lama, N3
James, C1
Namini, H1
Choy, GS1
Van Doren, S1
Aloman, C1
Wands, JR1
Humphries, JC1
Dixon, JS1
Camino, N2
Perrillo, R3
Willems, B1
Moorat, A1
Gardner, S1
Woessner, M1
Bourne, E1
Peters, MG2
Hann Hw, Hw1
Rubin, R1
Kowdley, K1
Gray Df, Df1
Sullivan, M2
Kleber, K1
Ebrahimi, R1
Taéron, C1
Daftary, MN1
Hannon, H1
Bagnis, CI1
Beaufils, H1
Qaqish, RB1
Mattes, KA1
Ritchie, DJ1
Beckebaum, S1
Malagó, M1
Dirsch, O1
Cicinnati, VR1
Trippler, M1
Treichel, U1
Broelsch, CE1
Zhukovskaya, NL1
Zimmer, MI1
Soelaiman, S1
Bergson, P1
Wang, CR1
Tang, WJ1
Rivkin, AM1
Wiegand, J1
Tischendorf, JJ1
Nashan, B1
Klempnauer, J1
Flemming, P1
Niemann, P1
Rohde, P1
Kuo, A1
Dienstag, JL2
Chung, RT1
Cooper, DA1
Pozniak, AL1
DeJesus, E1
Zhong, L1
Cheng, AK1
Ala, A1
Stránský, J1
Sagir, A1
Avci, A1
Erhardt, A2
Lörke, J1
Heintges, T2
Häussinger, D2
Sumida, Y1
Kanemasa, K1
Tachibana, S1
Maekawa, K1
Mori, K1
Wursthorn, K3
Tu, SS1
Cooksley, WG2
Stephan, C2
Brodt, HR1
Berger, A3
Mösch, M1
Lennemann, TS1
Stürmer, M1
Staszewski, S2
Wang, ZX1
Ding, GS1
Zhang, JJ1
Chen, XS1
Guo, WY1
Shi, XM1
Fu, ZR1
Woolley, IJ1
Veitch, AJ1
Harangozo, CS1
Moyle, M1
Korman, TM1
Lau, DT2
Membreno, FE1
Bonyhay, L1
Lai, CJ1
Terrault, NA1
Hulot, JS1
Launay-Vacher, V1
Marcellini, P1
Currie, G5
Arterbrun, S1
Carreño, N1
Moreno, D1
Sangro, B1
Kolyvanos Naumann, U1
Käser, L1
Vetter, W1
de Gottardi, A1
Negro, F1
Karayiannis, P2
Zhang, DF1
Neff, GW1
Nery, J1
O'Brien, CB1
Duncan, R1
Shire, NJ1
Nery, C1
Montalbano, M1
Muslu, H1
Safdar, K1
Tzakis, AG1
Madariaga, JR1
Wünsche, T1
Reinke, P1
Bergk, A1
Schürmann, D2
Wiedenmann, B1
Ferenci, P1
Bain, V1
Cooper, C1
Martin, S1
Lowe, C1
Vilde, JL1
Dandri, M2
Burda, MR1
Zuckerman, DM1
Matschl, U1
Pollok, JM1
Rogiers, X1
Gocht, A1
Köck, J1
Blum, HE2
von Weizsäcker, F2
Yeh, LT1
Vitarella, D1
Hong, Z1
Erion, MD1
Chevallier, M1
Chevallier, P1
Lot, M1
Brook, G1
Cargnel, A1
Rockstroh, J3
Thio, C1
Vassiliadis, T1
Nikolaidis, N1
Zezos, P1
Orfanou-Koumerkeridou, E1
Kim, KK1
Hwang, S1
Ahn, CS1
Moon, DB1
Ha, TY1
Lee, SG1
Mazzaferro, V1
Carenzi, S2
Romito, R1
Pulvirenti, A1
Franchello, A3
Salizzoni, M1
Del Poggio, P1
Jamoletti, C1
Zaccanelli, M1
Kanwal, F1
Gralnek, IM1
Dulai, GS1
Farid, M1
Spiegel, BM1
Owens, DK1
Black, M1
Boelle, PY1
Serfaty, L1
Valleron, AJ1
Dimou, E2
Dimakopoulos, K1
Tzourmakliotis, D2
Gärtner, BC1
Faust, D2
Hofmann, WP1
Ng, IO1
Baker, DE1
Korba, BE1
Orito, E2
van de Ende, M1
Tung, HD1
Li, HQ1
Li, JH1
Dong, JQ1
Gao, JR1
Gou, CY1
Choi, HY1
Ko, KH1
Park, PW1
Kim, NK1
Rim, KS1
Su, GG1
Ying, MF1
Palumbo, E2
Saracino, A1
Sheldon, JA1
Corral, A1
Rodés, B1
Schwarze-Zander, C2
Carlebach, A2
Bickel, M1
Klauke, S1
Stuermer, M2
Vig, P1
Calvez, V2
Marcelin, AG2
Fievet, MH1
Chang, CG1
Biao, L1
Fontaine, H1
Vallet-Pichard, A1
Chaix, ML2
Serpaggi, J1
Verkarre, V2
Varaut, A1
Morales, E1
Nalpas, B1
Weitzman, G1
Jacobson, I1
Ragone, E1
Costagliola, L1
Cirillo, G1
Utili, R1
Conjeevaram, H1
Marrero, J1
Oberhelman, K2
Hussain, M2
Gornals, JB1
Casanovas, T2
Sabidó, M1
Baliellas, C1
Casanovas, A1
Cañas, C1
Serrano, T1
Verdura, B1
Chahri, N1
Gil-Vernet, S1
Figueras, J1
Aguilar, J1
Mateos, ML1
Tato, M1
Moreira, V1
Yoo, W2
Chang, YJ1
Yu, SK1
Chung, HJ1
Moon, MS1
Amato, A1
Peters, M1
Naoumov, NV4
Schalm, S1
Chun, S1
Zucker, SD1
Zhang, WX1
Mirza, D1
Hartmann, H2
Roche, B1
Libbrecht, E2
Sablon, E2
Cursaro, C1
Andreone, P2
Laoi, BN2
Herra, C2
Norris, S2
Crowley, B2
Osborn, MK1
Butt, AA1
Wend, UC1
Willems, WR1
Montazeri, G1
Mohamadnejad, M1
Takagi, H1
Kakizaki, S1
Sohara, N1
Mori, M1
Lu, JX1
Feng, B1
Zeng, GB1
Osiowy, C1
Giles, E1
Borlang, J1
Zeng, M1
Mao, Y1
Yao, G1
Ji, BN1
Chang, CN1
Barker, KF1
Lee, WA1
Martin, JC1
Chen, TC1
Lin, FY1
Lai, MY1
Takeda, A2
Davidson, P2
Müller, C1
Volz, T1
Longerich, T1
Schirmacher, P1
Metzler, F1
Zankel, M1
Fischer, C1
von Boemmel, F1
Hoffmann, C1
Stoehr, A1
Wolf, E1
Jaeger, H1
Thimme, R1
Ramos, B1
Díaz-Pollán, B1
Martín-Carbonero, L1
van der Molen, RG2
Sprengers, D1
Biesta, PJ1
Kusters, JG2
Villet, S2
Andersen, J1
Lynch, P1
Alston-Smith, B1
Jacobson, JM1
Johnson, VA1
Pollard, RB1
Rooney, JF2
Swindells, S1
Polsky, B1
Seo, PJ1
Baik, du S1
Yun, SY1
Shin, JE1
Song, IH1
Ollivet, A1
Tran, N1
Chuck, SL1
Santos, SA1
Uriel, AJ1
Park, JS2
Lucas, J1
Carriero, D1
Jaffe, D1
Chen, YK1
Yin, YK2
Yu, YS1
Wei, LJ1
Kreter, B1
Stoop, JN1
Kuipers, EJ1
Lin, XH1
Si, CW4
Yu, YY1
Ren, XM1
Liu, P1
Zhang, SL1
Kang, XP1
Polipalli, SK1
Chattopadhyay, S1
Hussain, Z1
Malik, A1
Husain, SA1
Begum, N1
Allice, T2
Cerutti, F2
Pittaluga, F2
Varetto, S2
Gabella, S2
Colucci, G1
Ryu, SH1
Qin, YL1
Huang, YX1
Mao, RC1
Zhang, WQ1
Zhang, QB1
Wu, XH1
Weng, XH1
Mitsoula, P1
Sasadeusz, JJ1
Locarnini, SL1
Macdonald, G1
Bouvier-Alias, M1
Zafrani, ES1
Dhumeaux, D1
Trojan, J1
Teuber, G1
Brunelle, MN1
Lucifora, J1
Holy, A1
Lee, LP1
Hou, NJ1
Lin, ZY1
Chen, SC1
Wang, LY1
Tsai, JF1
Chang, WY1
Takamura, M1
Ichida, T1
Ohkoshi, S1
Tsubata, S1
Osaki, A1
Aoyagi, T1
Nomoto, M1
Uehara, K1
Terada, H1
Aoyagi, Y1
Ersoz, G1
Karasu, Z1
Ilter, T1
Batur, Y1
Akarca, U1
Widjaja, D1
Yarlagadda, S1
Singu, BS1
Loganathan, RS1
Blum, S1
Bloom, A1
Remy, P1
Lim, CY1
Kowdley, KV3
Shah, U1
Memon, I1
Cheema, HA1
Ali, S1
Thobani, S1
Mirza, R1
Mallet, VO1
Dhalluin-Venier, V1
Correas, JM1
Viard, JP1
Chang, UI1
Wie, SH1
Yang, JM2
Sun, HS1
Ling, N1
Vargas, V1
Schapper, M1
Bonovas, S1
Gerlich, W1
Garcia-Gasco, P1
Larry, L1
Lu, XZ1
Alison, T1
Arora, G1
Kim, MS1
Lee, SY1
Cha, SB1
Zhao, H3
Zhang, YX3
Tang, XP3
Yamazhan, T1
Sertöz, R1
Pullukçu, H1
Taşbakan, M1
Erensoy, S1
Gaglio, PJ1
Sterling, R1
Daniels, E1
Tedaldi, E1
van der Poorten, D1
Prakoso, E1
Khoo, TL1
McCaughan, GW2
Cooksley, H2
Ribeiro, RM1
Powers, KA1
Shudo, E1
Hui, CK2
Lewin, S1
Perelson, AS1
Locornini, S1
Karaaslan, H1
Kayhan, H1
Türkyilmaz, AR1
Sahin, F1
Qin, WX1
Li, YP1
Gimferrer, M1
Kim, HC1
Shin, KD1
Moon, YM1
Chao, YC1
Minuk, GY1
Harb, G1
Qiao, XJ1
Brown, NA1
Doutreloigne, J1
Van De Velde, H1
Shapiro, F1
Shiryu, H1
Lacey, LF1
Veenstra, DL2
Sullivan, SD1
Clarke, L1
Iloeje, UH1
Tafesse, E1
Di Bisceglie, A2
Lei, CL2
Castelló Miralles, I1
Del Val Antoñana, A1
Muñoz Vicente, M1
Moreno-Osset, E1
Tassopoulos, N1
Chokshi, S1
Maayan, Y1
Gilson, R1
Warnes, T1
Paganin, S1
Neumann, AU1
Bethanis, S1
Koutsounas, S1
Christias, E1
Saveriadis, A1
Pavlidis, C1
Christidou, A1
Karamanolis, D1
Rodríguez Frías, F1
Crespo, J1
Enríquez, J1
Carnicer, F1
Romero, M2
García Bengoechea, M1
García Samaniego, J1
Miras, M1
Pérez Roldán, F1
Ter Borg, MJ1
Nüesch, R1
Ananworanich, J1
Srasuebkul, P1
Chetchotisakd, P1
Prasithsirikul, W1
Klinbuayam, W1
Mahanontharit, A1
Jupimai, T1
Hirschel, B1
Gutiérrez, S1
Guillemi, S1
Jahnke, N1
Montessori, V1
Harrigan, PR1
Montaner, JS1
Dalmi, L1
Ibrányi, E1
Tan, J1
Degertekin, B1
Wong, SN1
Husain, M1
Zhang, HY1
Luk, JM1
Leung, KW1
Yueng, YH1
Wong, A1
Yuen, KY1
Naoumov, NN1
Gallego, A1
García-Samaniego, J1
Margall, N1
Hornillos, P1
Enrĺquez, J1
Sokal, EM1
Wirth, S1
Dhawan, A1
Gaia, S1
Barbon, V1
Alessandria, C1
Chow, WC1
Woessner, MA1
Scott, SA1
Gray, DF1
Gardner, SD1
Sánchez-Tapias, JM1
Pellicelli, AM1
Barbaro, G1
Francavilla, R1
Romano, M1
Barbarini, G1
Mazzoni, E1
Mecenate, F1
Paffetti, A1
Barlattani, A1
Struglia, C1
Villani, R1
Nauri, L1
Armignacco, O1
Ferri, F1
Camporiondo, MP1
Soccorsi, F1
Nam, SW1
Lee, SW1
Kang, SB1
Cho, SH1
Han, JY1
Kato, N1
Goto, T1
Omata, M1
Kang, JK1
Lim, NK1
Spackman, DE1
Bisceglie, A1
Lacey, L1
Pwu, RF1
Iwasaki, S1
Ijaz, S1
Arnold, C1
Dervisevic, S1
Mechurova, J1
Tatman, N1
Tedder, RS2
Ayoub, WS1
Tsiang, M1
Toole, JJ1
Gilson, RJ1
Chopra, KB1
Newell, AM1
Murray-Lyon, IM1
Nelson, MR1
Rice, SJ1
Toole, J1
Jaffe, HS1
Weller, IV1
Petry, W1
Freiman, JS1
Yoshida, E1
Statler, A1
Hirsch, K1
Wright, T1
Gutfreund, K1
Lamy, P2
Murray, A1
Yu, MW1
Cheng, SW1
Lin, MW1
Chang, HC1
Hsiao, TJ1
Lin, SM1
Lee, SD1
Regev, A1
Suárez García, E1
Romero Gómez, M1
Grande Santamaría, L1
Walsh, KM1
Woodall, T1
Wight, DG1
Bloor, S1
Alexander, GJ1
Wolters, LM1
Bombled, T1
Bochet, MV1

Clinical Trials (79)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Dose-Ranging Study of Pradefovir in Patients With Compensated Hepatitis B[NCT00230503]Phase 2220 participants Interventional2004-06-30Completed
A Prospective Cohort Study of Tenofovir Alafenamide Switch Therapy in Chronic Hepatitis B Patients Who Are Unsatisfied to Entecavir Therapy[NCT05583006]60 participants (Anticipated)Observational2023-11-06Recruiting
A Prospective Cohort Study of Tenofovir Alafenamide Switching Therapy in Kidney or Liver Transplant Recipients With Chronic Hepatitis B Virus Infection[NCT05410496]Phase 450 participants (Anticipated)Interventional2021-06-22Recruiting
A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Switching From Tenofovir Disoproxil Fumarate (TDF) 300 mg QD to Tenofovir Alafenamide (TAF) 25 mg QD in Subjects With Chronic Hepatitis B Who Are Virologically Suppressed[NCT02979613]Phase 3490 participants (Actual)Interventional2016-12-29Completed
Real World Study on the Effect of HBV-DNA High-precision Detection Based Anti-viral Regimen Adjustment on Achieving Complete Virologic Response in Patients With Chronic Hepatitis B.(REACH)[NCT04724785]10,000 participants (Anticipated)Observational2020-12-01Recruiting
To Evaluate the Efficacy and Safety of Tenofovir Amibufenamide in Chronic Hepatitis B (CHB) Patients With Low-level Viraemia (LLV) After Entecavir Treatment[NCT05755776]204 participants (Anticipated)Observational2023-03-01Recruiting
A Randomized, Multicenter, Prospective Study to Compare Antiviral Efficacy and Safety of Switching to ETV Plus TDF Versus Maintaining LAM/LDT Plus ADF Combination in CHC With PVR to LAM/LDF Plus ADF Combination Rescue Therapy for YMDD Mutation[NCT01597934]Phase 4104 participants (Anticipated)Interventional2012-08-31Active, not recruiting
A Two-year, Open-label, Virological Response Adaptive Design, Multicenter Study to Evaluate Efficacy of Telbivudine in HBeAg Negative Adult CHB Patients With Roadmap Strategy[NCT01521975]Phase 4360 participants (Actual)Interventional2011-01-01Completed
An Observational Study of Patients With Chronic Hepatitis B (CHB) Infection[NCT03692897]5,000 participants (Anticipated)Observational2018-10-11Recruiting
A Multicenter Controlled Open-label Trial of Evaluating Tenofovir Alafenamide, Tenofovir Disoproxil Fumarate and Entecavir in Acute-on-chronic Liver Failure of Chronic Hepatitis B Patients[NCT03640728]200 participants (Anticipated)Observational2019-01-25Recruiting
Regression of Liver Fibrosis by Tenofovir Alafenamide (TAF) in Treatment-Naive CHB Related Fibrosis/Cirrhosis: a 96w Open-label Multicenter Study[NCT04939441]Phase 4100 participants (Anticipated)Interventional2021-04-20Active, not recruiting
Switching From Tenofovir Disoproxil Fumarate(TDF) to Tenofovir AlaFenamide(TAF) vs. Maintaining TDF Monotherapy in Chronic Hepatitis B Patients With Genotypic Resistance to Adefovir or Entecavir[NCT03241641]Phase 4174 participants (Actual)Interventional2017-10-26Completed
Chronic HBV Infection in Pregnant Women Taking TAF to Prevent Mother-to-child Transmission in the Third Trimester: a Multicenter, Prospective Study[NCT04237376]600 participants (Anticipated)Observational2019-04-09Recruiting
Safety and Efficacy of Tenofovir Alafenamide for Chronic Hepatitis B Patients With Decompensated Liver Disease[NCT04683341]Phase 4100 participants (Anticipated)Interventional2020-09-01Recruiting
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD Versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg-Positive, Chronic Hepatitis B[NCT01940471]Phase 3875 participants (Actual)Interventional2013-09-11Completed
Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (Genvoya) as Maintenance Treatment of HIV-1/Hepatitis B Virus (HBV)-Coinfected Patients: an Observational Study[NCT03425994]275 participants (Actual)Observational [Patient Registry]2018-02-06Active, not recruiting
Tenofovir Alafenamide Versus Entecavir for the Treatment of Chronic Hepatitis B: An Open Label, Randomized Controlled Trial[NCT03933384]Phase 4420 participants (Anticipated)Interventional2019-08-19Recruiting
Efficacy and Safety of Tenofovir Alafenamide in Chronic Hepatitis B Patients With Suboptimal Response Following Nucleos(t)Ide Therapy[NCT04201808]Phase 4100 participants (Anticipated)Interventional2021-05-01Recruiting
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD Versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg-Negative, Chronic Hepatitis B[NCT01940341]Phase 3426 participants (Actual)Interventional2013-09-12Completed
A Randomized Prospective Open-label Trial for Comparing Combination Therapy Peg-Interferon Alfa-2a/Adefovir Dipivoxil and Peg-Interferon Alfa-2a/Tenofovir Disoproxil Fumarate Versus no Treatment in HBeAg Negative Chronic Hepatitis B Patients With Low Vira[NCT00973219]151 participants (Actual)Interventional2009-09-30Completed
Randomized Trial of Tenofovir Versus Lamivudine Plus Adefovir in Lamivudine Plus Adefovir Treated Lamivudine-resistant Chronic Hepatitis B Patients With Undetectable Hepatitis B Virus DNA.[NCT01732367]Phase 4171 participants (Actual)Interventional2012-11-30Completed
Clinical Investigation About Therapeutic Effects and Long-term Follow-up After Ending Anti-hepatitis B Virus Therapy With Nucleos(t)Ide Analogs in Patients With Chronic Hepatitis b[NCT02883647]100 participants (Anticipated)Observational2014-01-31Recruiting
"Analysis of Proximal Renal Tubular Function of Real World Chronic Hepatitis B (CHB) Patients Who Are Suppressed on TDF and Switched to TAF"[NCT02957994]Phase 482 participants (Actual)Interventional2016-12-22Active, not recruiting
The Effects of Vitamin D and Calcium Supplementation to Parathyroid Hormone in CHB Patients Treated With Tenofovir Disoproxil Fumarate[NCT05313477]Phase 464 participants (Anticipated)Interventional2022-05-01Recruiting
A Randomized, Double-Blind, Controlled Evaluation of Tenofovir DF Versus Adefovir Dipivoxil for the Treatment of Presumed Pre-Core Mutant Chronic Hepatitis B[NCT00117676]Phase 3382 participants (Actual)Interventional2005-02-28Completed
A Randomized, Double-Blind, Controlled Evaluation of Tenofovir DF Versus Adefovir Dipivoxil for the Treatment of HBeAg Positive Chronic Hepatitis B[NCT00116805]Phase 3266 participants (Actual)Interventional2005-06-30Completed
The Effect of Telbivudine on Renal Function in Chronic Hepatitis B Patients With Mild to Moderate Renal Impairment[NCT03778567]Phase 431 participants (Actual)Interventional2013-08-01Completed
Continuation of Lamivudine Plus Adefovir Versus Switching to Entecavir Plus Adefovir in Adults With Chronic Hepatitis B Who Have Resistant Mutants to Lamivudine and Show Suboptimal Response to Combination of Lamivudine Plus Adefovir[NCT01023217]Phase 490 participants (Actual)Interventional2009-11-30Completed
Mechanisms Associated With Favorable Response to Peginterferon-Alpha Add-on Therapy Following Long-term Nucleos(t)Ide Analogue Treatment in Patients With Chronic Hepatitis B[NCT02364336]Phase 214 participants (Actual)Interventional2015-02-14Completed
A Prospective, Randomized, Controlled Clinical Trial to Evaluate the Role of Peg-IFN Alfa-2a in Reducing RelapSe Rate in Patients With Hepatitis B e Antigen(HBeAg)-nEgative Chronic Hepatitis B After Discontinuation of NUC Therapy[NCT02594293]Phase 4180 participants (Actual)Interventional2015-10-31Completed
A Phase 3b, Randomized, Double-Blind, Double-Dummy Study Evaluating the Antiviral Efficacy, Safety, and Tolerability of Tenofovir Disoproxil Fumarate (DF) Monotherapy Versus Emtricitabine Plus Tenofovir DF Fixed-Dose Combination Therapy in Subjects With C[NCT00737568]Phase 3280 participants (Actual)Interventional2008-09-30Completed
Antiviral Efficacy of Continuing Lamivudine Plus Adefovir or Switching to Telbivudine Plus Adefovir in HBeAg-positive Lamivudine-refractory Chronic Hepatitis B Patients Who Have Suboptimal Response to Lamivudine Plus Adefovir for at Least 12 Months[NCT01270165]Phase 3110 participants (Anticipated)Interventional2010-06-30Recruiting
Exploratory Study on Antiviral Therapy for Patients With Chronic Hepatitis B Virus Infection (Immune Tolerance Period)[NCT05382351]Phase 2238 participants (Anticipated)Interventional2022-05-10Recruiting
A Phase IV Study to Evaluate the Efficacy, Safety and Tolerability of Tenofovir DF in Asian-American Adults With Chronic Hepatitis B Infection[NCT00736190]Phase 490 participants (Actual)Interventional2008-08-31Completed
Comparative Study of the Effect of Entecavir Versus Tenofovir on the Presence of HBV DNA in the Peripheral Blood Mononuclear Cells in Chronic Hepatitis B Patients[NCT05168293]100 participants (Anticipated)Observational2022-02-01Not yet recruiting
Prevention of Mother-to-child Transmission of Hepatitis B Virus: a One Arm, Open Label Intervention Study to Estimate the Optimal Timing of Tenofovir (TDF) in Pregnancy[NCT02995005]Phase 1/Phase 298 participants (Actual)Interventional2018-05-24Completed
Multi-center Study Evaluating Persistence of Hepatitis B Virus Replication, Long-term Prognostic Indicators and Their Clinical Relevance in Patients Co-infected With the Human Immunodeficiency Virus and Chronic Hepatitis B[NCT02889094]152 participants (Actual)Observational2016-10-31Active, not recruiting
HBV Viral Suppression by Entecavir in Adefovir Partial Responders[NCT00704106]60 participants (Actual)Observational2008-05-31Completed
Combination Treatment of Nucleoside (Acid)Analogue (NAs) and Pegylated Interferon α-2b for NAs Treated, Hepatitis B Related, Compensatory Cirrhosis Patients With Low Level Hepatitis b Virus Surface Antigen (HBsAg)[NCT03969017]Phase 284 participants (Anticipated)Interventional2019-06-17Recruiting
A Multi-centre, Double Blind, Double Dummy, Randomised, Controlled Study to Evaluate the Efficacy and Safety of TDF 300mg Once Daily (QD) Versus Adefovir Dipivoxil (ADV) 10mg QD in Chinese Subjects With CHB[NCT01300234]Phase 3512 participants (Actual)Interventional2011-03-30Completed
A Multinational, Multicenter, Open-label, Randomized Controlled Trial to Investigate the Effectiveness of Tenofovir Alafenamide in Reducing Clinical Events in Chronic Hepatitis B Patients Beyond Treatment Indications by Current Guidelines[NCT03753074]Phase 4780 participants (Anticipated)Interventional2019-02-18Recruiting
A Multicenter Randomized Controlled Open-label Trial of Tenofovir Plus Entecavir Combination vs. Tenofovir Monotherapy in Chronic Hepatitis B Patients With Genotypic Resistance to Adefovir and Partial Virologic Response to Ongoing Treatment[NCT01639066]Phase 4102 participants (Actual)Interventional2012-09-25Completed
Predictive Value of HBV pgRNA on Long-term Outcomes in Hepatitis B Patients Treated With Antiviral Therapy[NCT05965388]5,000 participants (Anticipated)Observational2023-12-01Not yet recruiting
Clinical Efficacy and Safety of Tenofovir Disoproxil Fumarate and Entcavir in Treatment of Chronic Hepatitis B Patients in Upper Egypt[NCT05874440]100 participants (Anticipated)Observational2023-04-15Recruiting
A Multinational, Multi-center, Open, Comparative, Paralleled, Roll-over Study to Assess the Safety and Antiviral Activity of LB80380 Tablet Compared to Entecavir 0.5 mg After Additional 48 Weeks of Treatment in Chronic Hepatitis B Patients Who Have Comple[NCT01242787]Phase 2115 participants (Anticipated)Interventional2010-08-31Active, not recruiting
A Phase IIb, Open, Multinational, Multi-center, Randomised, Comparative, Parallel Study to Assess the Safety and Antiviral Activity of LB80380 Compared to Entecavir 0.5 mg in Chronic Hepatitis B Patients for 48 Weeks With a Planned Analysis of Efficacy an[NCT01026610]Phase 2115 participants (Actual)Interventional2009-08-31Completed
Antiretroviral Treatment Outcomes in HIV-HBV Co-infected Patients in Southern Africa: a Collaborative Multi-country Prospective Cohort Analysis for International Epidemiologic Databases to Evaluate AIDS- Southern Africa (HIV/HBV-coinfection in IeDEA-SA)[NCT02060162]897 participants (Actual)Observational2013-10-31Completed
A Randomized, Open-label, Multi-center Clinical Trial to Evaluate Addition of Peginterferon Alfa-2a to CHB Patients Treated With NAs and Achieved HBV DNA<15 IU/ml、HBeAg<100 PEIU/ml、HBsAg Positive and HBsAg<1500 IU/ml.[NCT02894918]Phase 4114 participants (Anticipated)Interventional2016-09-30Active, not recruiting
A Phase 2, Randomized, Double-Blind Study Exploring the Efficacy, Safety and Tolerability of Tenofovir Disoproxil Fumarate (DF) Monotherapy Versus Emtricitabine Plus Tenofovir DF Fixed-Dose Combination Therapy in Subjects Currently Being Treated With Adef[NCT00307489]Phase 2106 participants (Actual)Interventional2006-03-31Completed
Randomized, Open-Label, Comparative Study to Evaluate Early Viral Load Reductions and Exploratory Viral Kinetics Following Administration of Entecavir or Adefovir in Nucleoside-Naive Adults With Chronic Hepatitis B Infection[NCT00096785]Phase 369 participants (Actual)Interventional2004-12-31Completed
Efficacy of HBV Therapeutic Vaccine in Consolidation of Nucleos(t)Ide Analogues Therapy: a Pilot Study[NCT02505009]Phase 4116 participants (Actual)Interventional2015-05-01Completed
[NCT01918631]36 participants (Actual)Interventional2013-08-31Completed
The Natural History of Liver Disease in a Cohort of Participants With Hepatitis B and/or Hepatitis C With or Without HIV Infection[NCT01350648]569 participants (Actual)Observational2011-08-23Completed
A Phase 1b/2a Randomized, Open-label Clinical Trial of Daily Myrcludex B Versus Entecavir in Patients With HBeAg Negative Chronic Hepatitis B[NCT02881008]Phase 1/Phase 248 participants (Actual)Interventional2012-11-14Completed
Efficacy of Adefovir and Lamivudine Combination Therapy in Patients With Entecavir Resistance[NCT01546116]Phase 420 participants (Actual)Interventional2010-02-28Completed
[NCT02019966]1,020 participants (Actual)Observational2014-05-12Completed
Maâthermes a Randomised Controlled Trial of Spa Treatment of Overweight and Obesity[NCT01258114]Phase 3400 participants (Actual)Interventional2007-03-31Completed
A Phase 2, Double-Blind, Multi-center, Randomized Study Comparing Tenofovir Disoproxil Fumarate, Emtricitabine Plus Tenofovir Disoproxil Fumarate, and Entecavir in the Treatment of Chronic Hepatitis B Subjects With Decompensated Liver Disease and in the P[NCT00298363]Phase 2112 participants (Actual)Interventional2006-04-30Completed
Tenofovir Reduces Morbidity and Mortality in Patients With Spontaneous Reactivation of Hepatitis B Presenting as Acute-on-chronic Liver Failure (ACLF): A Randomized Placebo Controlled Trial[NCT01074645]Phase 427 participants (Actual)Interventional2007-11-30Completed
An Open-label Trial of 48-week Peginterferon Alfa-2a (PEGASYS) to Assess the Sustained Response of Chronic Hepatitis B Patients With HBeAg Seroconversion on Nucleot(s)Ide Analogue Therapy[NCT02068365]Phase 441 participants (Actual)Interventional2013-06-30Completed
Combination of Lamivudine and Adefovir Dipivoxil for Treatment of Chronic Hepatitis B[NCT00023309]Phase 241 participants (Actual)Interventional2001-08-31Completed
Open Label Study of Nucleus(t)Ide Treated Patients Randomised to Tenofovir, or Tenofovir + Telbivudine[NCT02774837]Phase 4146 participants (Actual)Interventional2016-04-30Active, not recruiting
A Randomized, Double-Blind Evaluation of the Antiviral Efficacy, Safety, and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Adolescents With Chronic Hepatitis B Infection[NCT00734162]Phase 3106 participants (Actual)Interventional2008-12-31Completed
A Comparative Study of Chronic Hepatitis B Subjects Treated With Entecavir Plus Tenofovir Combination Therapy vs. Entecavir Monotherapy in Adults Who Are Treatment-Naive to Nucleosides and Nucleotides: The BE-LOW Study[NCT00410072]Phase 3669 participants (Actual)Interventional2007-04-30Completed
Changes in Dynamic Liver Function Tests in Patients With Chronic Viral Hepatitis Undergoing Antiviral Therapy[NCT02782247]52 participants (Actual)Observational2016-05-31Completed
Prognostic Relevance of Fatty Liver Disease for Patients With Chronic Hepatitis B[NCT05317260]408 participants (Actual)Observational2002-01-01Completed
Liver Fibrosis in Zambian HIV-HBV Co-infected Patients: a Long-term Prospective Cohort Study[NCT02344680]303 participants (Actual)Observational2015-10-31Active, not recruiting
A Single-arm, Multinational, Two Year Study Evaluating the Efficacy and Safety of lead-in Telbivudine for 24 Weeks With or Without Tenofovir Treatment Intensification in Adult Patients With HBeAg-positive Chronic Hepatitis B.[NCT00651209]Phase 4105 participants (Actual)Interventional2008-02-29Completed
A Multi-Center Phase 3, Open-Label, Parallel-Group Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Adefovir Dipivoxil Liquid Suspension in Patients With Chronic Hepatitis B and Varying Degrees of Renal Impairment[NCT00071201]Phase 348 participants Interventional2003-06-30Completed
Treatment With Peginterferon Alfa-2a (40 KD) (PEGASYS®) of Chronic Hepatitis B Patients, Who Have Failed Anti-viral Treatment. A Pilot Study.[NCT00226382]Phase 450 participants (Actual)Interventional2005-01-31Completed
A Prospective, Randomized, Multicenter, Open-label Study Evaluating HBeAg Seroconversion in HBeAg Positive CHB Patients on Treatment With NA Switched to Combined Therapy With Peginterferon Alfa-2a and NA for 48 Weeks[NCT02474316]Phase 4366 participants (Anticipated)Interventional2014-08-31Recruiting
Tenofovir Disoproxil Fumarate Alone Versus Its Combination With Emtricitabine for Treatment of Chronic Hepatitis B[NCT00524173]Phase 235 participants (Actual)Interventional2007-08-29Terminated
Prospective Randomized Study for the Comparison of Adding Adefovir Dipivoxil and Switching to Entecavir in Patients With Lamivudine-resistant Chronic Hepatitis B[NCT00531167]Phase 4219 participants (Actual)Interventional2007-04-30Completed
Entecavir for Patients With Decompensated HBV-Related Cirrhosis:a Prospective Randomized Controlled Trial[NCT00663182]Phase 4200 participants (Anticipated)Interventional2008-01-31Enrolling by invitation
Entecavir Intensification for Persistent Hepatitis B Virus (HBV) Viremia in HIV-HBV Infection[NCT00662545]Phase 410 participants (Actual)Interventional2008-04-30Completed
A Randomized, Phase II, Controlled Trial Comparing the Efficacy of Adefovir Dipivoxil and Tenofovir Disoproxil Fumarate for the Treatment of Lamivudine-Resistant Hepatitis B Virus in Subjects Who Are Co-Infected With HIV[NCT00033163]Phase 290 participants InterventionalCompleted
A Randomized, Open-Label Trial of Telbivudine Versus Adefovir Dipivoxil in Adults With HBegAg-Positive, Compensated Chronic Hepatitis B[NCT00115245]Phase 30 participants Interventional2004-11-30Completed
A Study on the Viral Kinetics of Different Regimens of Pegylated Interferon and Lamivudine Combination Therapy in HBeAg Positive Chronic Hepatitis B[NCT00226447]Phase 230 participants Interventional2002-12-31Completed
A Phase 3b, Open-Label Program of Adefovir Dipivoxil in the Treatment of Patients With Lamivudine-Resistant Chronic Hepatitis B Who Have Limited Treatment Options[NCT00042393]0 participants Expanded AccessApproved for marketing
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change From Baseline in eGFR-CG at Week 96

"Cockcroft-Gault formula is as follows:~For men: Glomerular filtration rate (GFR) = (140 - age in years) * body weight in kg / 72 * serum creatinine (mg/dL)~For women: GFR = 0.85 * (140 - age in years) * body weight in kg / 72 * serum creatinine (mg/dL).~Change from baseline was calculated as the value at Week 96 minus the value at Baseline." (NCT02979613)
Timeframe: Baseline; Week 96

InterventionmL/min (Median)
TAF 25 mg1.626
TDF 300 mg0.544

Change From Baseline in Estimated Glomerular Filtration Rate Calculated Using the Cockcroft-Gault Equation (eGFR-CG) at Week 48

"Cockcroft-Gault formula is as follows:~For men: Glomerular filtration rate (GFR) = (140 - age in years) * body weight in kg / 72 * serum creatinine (mg/dL)~For women: GFR = 0.85 * (140 - age in years) * body weight in kg / 72 * serum creatinine (mg/dL).~Change from baseline was calculated as the value at Week 48 minus the value at Baseline." (NCT02979613)
Timeframe: Baseline; Week 48

InterventionmL/min (Median)
TAF 25 mg2.240
TDF 300 mg-1.722

Change From Baseline in FibroTest® Score at Week 48

The FibroTest score is used to assess liver fibrosis. Scores range from 0.00 to 1.00, with higher scores indicating a greater degree of fibrosis. Change from baseline was calculated as the value at Week 48 minus the value at Baseline. (NCT02979613)
Timeframe: Baseline; Week 48

Interventionscores on a scale (Mean)
TAF 25 mg-0.02
TDF 300 mg-0.01

Change From Baseline in FibroTest® Score at Week 96

The FibroTest score is used to assess liver fibrosis. Scores range from 0.00 to 1.00, with higher scores indicating a greater degree of fibrosis. Change from baseline was calculated as the value at Week 96 minus the value at Baseline. (NCT02979613)
Timeframe: Baseline; Week 96

Interventionscores on a scale (Mean)
TAF 25 mg-0.03
TDF 300 mg-0.03

Percent Change From Baseline in Hip BMD at Week 96

Percent Change = Change from baseline at a postbaseline visit/baseline * 100%. (NCT02979613)
Timeframe: Baseline; Week 96

Interventionpercent change (Mean)
TAF 25 mg1.157
TDF 300 mg0.180

Percent Change From Baseline in Hip Bone Mineral Density (BMD) at Week 48

Percent Change = Change from baseline at a postbaseline visit/baseline * 100%. (NCT02979613)
Timeframe: Baseline; Week 48

Interventionpercent change (Mean)
TAF 25 mg0.659
TDF 300 mg-0.507

Percent Change From Baseline in Spine BMD at Week 48

Percent Change = Change from baseline at a postbaseline visit/baseline * 100%. (NCT02979613)
Timeframe: Baseline; Week 48

Interventionpercent change (Mean)
TAF 25 mg1.743
TDF 300 mg-0.138

Percent Change From Baseline in Spine BMD at Week 96

Percent Change = Change from baseline at a postbaseline visit/baseline * 100%. (NCT02979613)
Timeframe: Baseline; Week 96

Interventionpercent change (Mean)
TAF 25 mg2.330
TDF 300 mg1.726

Percentage of Participants With HBeAg Loss at Week 96

HBeAg loss was defined as HBeAg changing from positive at baseline to negative at a postbaseline visit with baseline HBeAb negative or missing. The M = F approach was used for this analysis. (NCT02979613)
Timeframe: Week 96

Interventionpercentage of participants (Number)
TAF 25 mg17.9
TDF 300 mg9.0

Percentage of Participants With HBeAg Seroconversion at Week 48

HBeAg seroconversion was defined as HBeAg loss and HBeAb changing from negative/missing at baseline to positive at a postbaseline visit. The M = F approach was used for this analysis. (NCT02979613)
Timeframe: Week 48

Interventionpercentage of participants (Number)
TAF 25 mg2.6
TDF 300 mg0.0

Percentage of Participants With HBeAg Seroconversion at Week 96

HBeAg seroconversion was defined as HBeAg loss and HBeAb changing from negative/missing at baseline to positive at a postbaseline visit. The M = F approach was used for this analysis. (NCT02979613)
Timeframe: Week 96

Interventionpercentage of participants (Number)
TAF 25 mg5.1
TDF 300 mg2.6

Percentage of Participants With HBsAg Loss at Week 96

HBsAg loss was defined as HBsAg changing from positive at baseline to negative at a postbaseline visit with baseline HBsAb negative or missing. The M = F approach was used for this analysis. (NCT02979613)
Timeframe: Week 96

Interventionpercentage of participants (Number)
TAF 25 mg1.6
TDF 300 mg2.4

Percentage of Participants With HBsAg Seroconversion at Week 48

HBsAg seroconversion was defined as HBsAg loss and HBsAb changes from negative/missing at baseline to positive at a postbaseline visit. The M = F approach was used for this analysis. (NCT02979613)
Timeframe: Week 48

Interventionpercentage of participants (Number)
TAF 25 mg0.0
TDF 300 mg0.0

Percentage of Participants With HBsAg Seroconversion at Week 96

HBsAg seroconversion was defined as HBsAg loss and HBsAb changes from negative/missing at baseline to positive at a postbaseline visit. The M = F approach was used for this analysis. (NCT02979613)
Timeframe: Week 96

Interventionpercentage of participants (Number)
TAF 25 mg0.8
TDF 300 mg0.4

Percentage of Participants With HBV DNA Levels < 20 IU/mL at Week 48

The percentage of participants with HBV DNA < 20 IU/mL at Week 48 was analyzed, which included participants who have the last available on-treatment HBV DNA, 20 IU/mL in the Week 48 analysis window. Missing=Failure (M = F) approach was used for analysis. (NCT02979613)
Timeframe: Weeks 48

Interventionpercentage of participants (Number)
TAF 25 mg96.3
TDF 300 mg96.3

Percentage of Participants With HBV DNA Levels < 20 IU/mL at Week 96

The percentage of participants with HBV DNA < 20 IU/mL at Week 96 was analyzed, which included participants who have the last available on-treatment HBV DNA, 20 IU/mL in the Week 96 analysis window. M = F approach was used for analysis. (NCT02979613)
Timeframe: Week 96

Interventionpercentage of participants (Number)
TAF 25 mg94.7
TDF 300 mg93.9

Percentage of Participants With HBV DNA Levels ≥ 20 IU/mL at Week 96, as Determined by the Modified US FDA-Defined Snapshot Algorithm

"The percentage of participants with HBV DNA ≥ 20 IU/mL at Week 96 was analyzed using the modified US FDA-defined snapshot algorithm, which included participants who:~Had the last available on-treatment HBV DNA ≥ 20 IU/mL in the Week 96 analysis window (from Day 589 to Day 840, inclusive), or~Did not have on-treatment HBV DNA data available in the Week 96 analysis window and~Discontinued study drug prior to or in the Week 96 analysis window due to lack of efficacy, or~Discontinued study drug prior to or in the Week 96 analysis window due to reason other than lack of efficacy and had the last available on-treatment HBV DNA ≥ 20 IU/mL" (NCT02979613)
Timeframe: Week 96

Interventionpercentage of participants (Number)
TAF 25 mg0.4
TDF 300 mg0.4

Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss at Week 48

HBeAg loss was defined as HBeAg changing from positive at baseline to negative at a postbaseline visit with baseline HBeAb negative or missing. The M = F approach was used for this analysis. (NCT02979613)
Timeframe: Week 48

Interventionpercentage of participants (Number)
TAF 25 mg7.7
TDF 300 mg6.4

Percentage of Participants With Hepatitis B Surface Antigen (HBsAg) Loss at Week 48

HBsAg loss was defined as HBsAg changing from positive at baseline to negative at a postbaseline visit with baseline HBsAb negative or missing. The M = F approach was used for this analysis. (NCT02979613)
Timeframe: Week 48

Interventionpercentage of participants (Number)
TAF 25 mg0.0
TDF 300 mg2.0

Percentage of Participants With Hepatitis B Virus (HBV) DNA Levels ≥ 20 IU/mL at Week 48, as Determined by the Modified United States Food and Drug Administration (US FDA)-Defined Snapshot Algorithm

"The percentage of participants with HBV DNA ≥ 20 IU/mL at Week 48 was analyzed using the modified US FDA-defined snapshot algorithm, which included participants who:~Had the last available on-treatment HBV DNA ≥ 20 IU/mL in the Week 48 analysis window (from Day 295 to Day 378, inclusive), or~Did not have on-treatment HBV DNA data available in the Week 48 analysis window and~Discontinued study drug prior to or in the Week 48 analysis window due to lack of efficacy, or~Discontinued study drug prior to or in the Week 48 analysis window due to reason other than lack of efficacy and had the last available on-treatment HBV DNA ≥ 20 IU/mL" (NCT02979613)
Timeframe: Week 48

Interventionpercentage of participants (Number)
TAF 25 mg0.4
TDF 300 mg0.4

Percentage of Participants With HBV DNA Levels < 20 IU/mL (Target Detected/Not Detected) at Week 48

The percentage of participants with HBV DNA < 20 IU/mL at Week 48 was analyzed, which included participants who have the last available on-treatment HBV DNA, 20 IU/mL in the Week 48 analysis window. The method of determining percentage of participants with HBV DNA levels <20 IU/mL (target detected/not detected i.e., lower limit of detection) at Week 48, was handled by M = F, and Missing=Excluded (M = E) approaches. (NCT02979613)
Timeframe: Week 48

,
Interventionpercentage of participants (Number)
M = F Approach: < 20 IU/mL Target Not DetectedM = F Approach: < 20 IU/mL Target DetectedM = E Approach: < 20 IU/mL Target Not DetectedM = E Approach: < 20 IU/mL Target Detected
TAF 25 mg63.432.965.534.0
TDF 300 mg62.034.364.135.4

Percentage of Participants With HBV DNA Levels < 20 IU/mL (Target Detected/Not Detected) at Week 96

The percentage of participants with HBV DNA < 20 IU/mL at Week 96 was analyzed, which included participants who have the last available on-treatment HBV DNA, 20 IU/mL in the Week 96 analysis window. The method of determining percentage of participants with HBV DNA levels <20 IU/mL (target detected/not detected i.e., lower limit of detection) at Week 96, was handled by Missing=Failure (M = F), and Missing=Excluded (M = E) approaches. (NCT02979613)
Timeframe: Week 96

,
Interventionpercentage of participants (Number)
M = F Approach: < 20 IU/mL Target Not DetectedM = F Approach: < 20 IU/mL Target DetectedM = E Approach: < 20 IU/mL Target Not DetectedM = E Approach: < 20 IU/mL Target Detected
TAF 25 mg65.828.869.330.3
TDF 300 mg66.127.870.129.4

Percentage of Participants With Normal Alanine Aminotransferase (ALT) at Week 48 (by Central Laboratory and the American Association for the Study of Liver Diseases [AASLD] Criteria)

Central laboratory ULN for ALT were as follows: ≤ 43 U/L for males aged 18 to < 69 years and ≤ 35 U/L for males aged ≥ 69 years; ≤ 34 U/L for females aged 18 to < 69 years and ≤ 32 U/L for females aged ≥ 69 years. The ULN for ALT using the 2018 AASLD normal range was 25 U/L for females and 35 U/L for males. M = F approach was used for analysis. (NCT02979613)
Timeframe: Week 48

,
Interventionpercentage of participants (Number)
Central Laboratory CriteriaAASLD Criteria
TAF 25 mg89.379.0
TDF 300 mg84.975.1

Percentage of Participants With Normal ALT at Week 96 (by Central Laboratory and the AASLD Criteria)

Central laboratory ULN for ALT were as follows: ≤ 43 U/L for males aged 18 to < 69 years and ≤ 35 U/L for males aged ≥ 69 years; ≤ 34 U/L for females aged 18 to < 69 years and ≤ 32 U/L for females aged ≥ 69 years. The ULN for ALT using the 2018 AASLD normal range was 25 U/L for females and 35 U/L for males. M = F approach was used for analysis. (NCT02979613)
Timeframe: Week 96

,
Interventionpercentage of participants (Number)
Central Laboratory CriteriaAASLD Criteria
TAF 25 mg88.580.7
TDF 300 mg91.486.5

Percentage of Participants With Normalized ALT at Week 48 (by Central Laboratory and AASLD Criteria)

ALT normalization was defined as an ALT value that changed from above the normal range at baseline to within the normal range at the given postbaseline visit. Central laboratory ULN for ALT were as follows: ≤ 43 U/L for males aged 18 to < 69 years and ≤ 35 U/L for males aged ≥ 69 years; ≤ 34 U/L for females aged 18 to < 69 years and ≤ 32 U/L for females aged ≥ 69 years. The ULN for ALT using the 2018 AASLD normal range was 25 U/L for females and 35 U/L for males. M = F approach was used for analysis. (NCT02979613)
Timeframe: Week 48

,
Interventionpercentage of participants (Number)
Central Laboratory CriteriaAASLD Criteria
TAF 25 mg50.050.0
TDF 300 mg36.826.4

Percentage of Participants With Normalized ALT at Week 96 (by Central Laboratory and AASLD Criteria)

ALT normalization was defined as an ALT value that changed from above the normal range at baseline to within the normal range at the given postbaseline visit. Central laboratory ULN for ALT were as follows: ≤ 43 U/L for males aged 18 to < 69 years and ≤ 35 U/L for males aged ≥ 69 years; ≤ 34 U/L for females aged 18 to < 69 years and ≤ 32 U/L for females aged ≥ 69 years. The ULN for ALT using the 2018 AASLD normal range was 25 U/L for females and 35 U/L for males. M = F approach was used for analysis. (NCT02979613)
Timeframe: Week 96

,
Interventionpercentage of participants (Number)
Central Laboratory CriteriaAASLD Criteria
TAF 25 mg56.355.8
TDF 300 mg78.973.6

Change From Baseline at Week 48 in Serum Creatinine

(NCT01940471)
Timeframe: Baseline, Week 48

Interventionmg/dL (Mean)
TAF 25 mg0.009
TDF 300 mg0.026

Percent Change From Baseline in Hip Bone Mineral Density (BMD) at Week 48

(NCT01940471)
Timeframe: Baseline, Week 48

Interventionpercentage change (Mean)
TAF 25 mg-0.100
TDF 300 mg-1.715

Percent Change From Baseline in Spine BMD at Week 48

(NCT01940471)
Timeframe: Baseline, Week 48

Interventionpercentage change (Mean)
TAF 25 mg-0.417
TDF 300 mg-2.294

Percentage of Participants With Hepatitis B e Antigen (HBeAg) Seroconversion to Antibody Against Hepatitis B e Antigen (Anti-HBe) at Week 48

(NCT01940471)
Timeframe: Week 48

Interventionpercentage of participants (Number)
TAF 25 mg10.3
TDF 300 mg8.1

Percentage of Participants With Hepatitis B Virus (HBV) DNA < 29 IU/mL at Week 48

(NCT01940471)
Timeframe: Week 48

Interventionpercentage of participants (Number)
TAF 25 mg63.9
TDF 300 mg66.8

Percentage of Participants With Treatment-emergent Proteinuria by Urinalysis (Dipstick) Through Week 48

Grades 1 (mild), 2 (moderate), and 3 (severe) were the highest treatment-emergent postbaseline grades for urine protein using the dipstick method. (NCT01940471)
Timeframe: Up to 48 weeks

,
Interventionpercentage of participants (Number)
Grade 1Grade 2Grade 3
TAF 25 mg23.93.50
TDF 300 mg17.84.50.3

Change From Baseline in Serum Creatinine at Week 48

(NCT01940341)
Timeframe: Baseline, Week 48

Interventionmg/dL (Mean)
TAF 25 mg0.01
TDF 300 mg0.02

Percent Change From Baseline in Hip Bone Mineral Density (BMD) at Week 48

(NCT01940341)
Timeframe: Baseline, Week 48

Interventionpercentage change (Mean)
TAF 25 mg-0.288
TDF 300 mg-2.156

Percent Change From Baseline in Spine BMD at Week 48

(NCT01940341)
Timeframe: Baseline, Week 48

Interventionpercentage change (Mean)
TAF 25 mg-0.876
TDF 300 mg-2.514

Percentage of Participants With Hepatitis B Virus (HBV) DNA < 29 IU/mL

The primary efficacy endpoint was determined by the achievement of HBV DNA < 29 IU/mL at Week 48. (NCT01940341)
Timeframe: Week 48

InterventionPercentage of participants (Number)
TAF 25 mg94.0
TDF 300 mg92.9

Percentage of Participants With Treatment-emergent Proteinuria by Urinalysis (Dipstick) Through Week 48

Grades 1 (mild), 2 (moderate), and 3 (severe) were the highest treatment-emergent postbaseline grades for urine protein using the dipstick method. (NCT01940341)
Timeframe: Up to 48 weeks

,
Interventionpercentage of participants (Number)
Grade 1Grade 2Grade 3
TAF 25 mg18.11.10
TDF 300 mg16.42.10

Percentage of Participants With ALT Normalization at Week 48

ALT normalization was defined as ALT > upper limit of normal (ULN) at baseline and within the normal range at the end of blinded treatment. The ULN was 43 U/L for males and 34 U/L for females aged 18 to < 69, and 35 U/L for males and 32 U/L for females aged ≥ 69. (NCT00117676)
Timeframe: Baseline; Week 48

Interventionpercentage of participants (Number)
TDF-TDF76.3
ADV-TDF77.1

Percentage of Participants With ALT Normalization at Weeks 96

ALT normalization was defined as ALT > ULN at baseline and within the normal range at Week 96. The ULN was 43 U/L for males and 34 U/L for females aged 18 to < 69, and 35 U/L for males and 32 U/L for females aged ≥ 69. (NCT00117676)
Timeframe: Baseline; Week 96

Interventionpercentage of participants (Number)
TDF-TDF72.4
ADV-TDF68.5

Percentage of Participants With HBV DNA < 400 Copies/mL at Week 48

(NCT00117676)
Timeframe: Week 48

Interventionpercentage of participants (Number)
TDF-TDF93.2
ADV-TDF63.2

Percentage of Participants With HBV DNA < 400 Copies/mL at Weeks 96

(NCT00117676)
Timeframe: Week 96

Interventionpercentage of participants (Number)
TDF-TDF90.6
ADV-TDF89.3

Change From Baseline in ALT at Weeks 48, 96, 144, 192, 240, 288, 336, 384, 432, and 480

(NCT00117676)
Timeframe: Baseline; Weeks 48, 96, 144, 192, 240, 288, 336, 384, 432, and 480

,
Interventionunits per liter (Mean)
Week 48Week 96Week 144Week 192Week 240Week 288Week 336Week 384Week 432Week 480
ADV-TDF-124.4-138.5-140.0-140.3-139.5-134.7-143.1-132.6-131.9-129.2
TDF-TDF-95.0-93.7-99.1-99.6-97.7-98.9-98.9-96.1-97.0-94.9

Change From Baseline in HBV DNA at Weeks 48, 96, 144, 192, 240, 288, 336, 384, 432, and 480

(NCT00117676)
Timeframe: Baseline; Weeks 48, 96, 144, 192, 240, 288, 336, 384, 432, and 480

,
Interventionlog10 copies/mL (Mean)
Week 48Week 96Week 144Week 192Week 240Week 288Week 336Week 384Week 432Week 480
ADV-TDF-4.07-4.74-4.77-4.75-4.77-4.81-4.81-4.79-4.69-4.75
TDF-TDF-4.57-4.54-4.61-4.56-4.59-4.61-4.61-4.56-4.60-4.57

Change From Baseline in Knodell and Ishak Necroinflammatory Scores at Week 240

The Knodell necroinflammatory score is the combined score for necrosis and inflammation domains of the Knodell scoring system, and ranges from 0 (best) to 14 (worst). The Ishak score measures the degree of liver fibrosis (scarring) caused by chronic necroinflammation (inflammation leading to cell death) and ranges from 0 (best) to 6 (worst). (NCT00117676)
Timeframe: Baseline; Week 240

,
Interventionunits on a scale (Mean)
Knodell ScoreIshak Score
ADV-TDF-4.9-4.2
TDF-TDF-4.6-4.0

Change From Baseline in Knodell and Ishak Necroinflammatory Scores at Week 48

The Knodell necroinflammatory score is the combined score for necrosis and inflammation domains of the Knodell scoring system, and ranges from 0 (best) to 14 (worst). The Ishak score measures the degree of liver fibrosis (scarring) caused by chronic necroinflammation (inflammation leading to cell death) and ranges from 0 (best) to 6 (worst). (NCT00117676)
Timeframe: Baseline; Week 48

,
Interventionunits on a scale (Mean)
Knodell Necroinflammatory ScoreIshak Necroinflammatory Score
ADV-TDF-3.4-2.6
TDF-TDF-3.5-2.6

Change From Week 48 in ALT at Weeks 96, 144, 192, 240, 288, 336, 384, 432, and 480

(NCT00117676)
Timeframe: Week 48; Weeks 96, 144, 192, 240, 288, 336, 384, 432, and 480

,
Interventionunits per liter (Mean)
Week 96Week 144Week 192Week 240Week 288Week 336Week 384Week 432Week 480
ADV-TDF-0.6-0.3-3.6-3.9-4.1-2.0-3.9-8.9-5.9
TDF-TDF2.4-0.60.7-2.5-3.9-2.6-2.9-4.6-2.8

Change From Week 48 in HBV DNA at Weeks 96, 144, 192, 240, 288, 336, 384, 432, and 480

(NCT00117676)
Timeframe: Week 48; Weeks 96, 144, 192, 240, 288, 336, 384, 432, and 480

,
Interventionlog10 copies/mL (Mean)
Week 96Week 144Week 192Week 240Week 288Week 336Week 384Week 432Week 480
ADV-TDF-0.60-0.63-0.61-0.61-0.64-0.65-0.66-0.67-0.72
TDF-TDF0.02-0.030.01-0.04-0.04-0.05-0.02-0.04-0.05

Number of Participants With HBV Genotypic Changes From Baseline at Week 144 (Resistance Surveillance)

Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL at Week 144 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 96 with HBV DNA ≥ 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen after Week 96 and had HBV DNA ≥ 400 copies/mL at the time of the addition. (NCT00117676)
Timeframe: Baseline; Weeks 97 to 144

,,
Interventionparticipants (Number)
Participants evaluatedChanges at conserved sites within HBV polymeraseChanges at polymorphic sites in HBV polymeraseNo genotypic changes (wild-type virus)Unable to genotype
ADV-TDF00000
TDF-TDF40121
TDF-TDF With Addition of FTC00000

Number of Participants With HBV Genotypic Changes From Baseline at Week 192 (Resistance Surveillance)

Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL at Week 192 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 144 with HBV DNA ≥ 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen after Week 144 and had HBV DNA ≥ 400 copies/mL at the time of the addition. (NCT00117676)
Timeframe: Baseline; Weeks 145 to 192

,,
Interventionparticipants (Number)
Participants evaluatedChanges at conserved sites within HBV polymeraseChanges at polymorphic sites in HBV polymeraseNo genotypic changes (wild-type virus)Unable to genotype
ADV-TDF00000
TDF-TDF30111
TDF-TDF With Addition of FTC10010

Number of Participants With HBV Genotypic Changes From Baseline at Week 240 (Resistance Surveillance)

Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL at Week 240 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 192 with HBV DNA ≥ 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen after Week 192 and had HBV DNA ≥ 400 copies/mL at the time of the addition. (NCT00117676)
Timeframe: Baseline; Weeks 193 to 240

,,
Interventionparticipants (Number)
Participants evaluatedChanges at conserved sites within HBV polymeraseChanges at polymorphic sites in HBV polymeraseNo genotypic changes (wild-type virus)Unable to genotype
ADV-TDF20002
TDF-TDF11000
TDF-TDF With Addition of FTC20200

Number of Participants With HBV Genotypic Changes From Baseline at Week 288 (Resistance Surveillance)

Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL at Week 288 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 240 with HBV DNA ≥ 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen after Week 240 and had HBV DNA ≥ 400 copies/mL at the time of the addition. (NCT00117676)
Timeframe: Baseline; Weeks 241 to 288

,,
Interventionparticipants (Number)
Participants evaluatedChanges at conserved sites within HBV polymeraseChanges at polymorphic sites in HBV polymeraseNo genotypic changes (wild-type virus)Unable to genotype
ADV-TDF10100
TDF-TDF30210
TDF-TDF With Addition of FTC10100

Number of Participants With HBV Genotypic Changes From Baseline at Week 336 (Resistance Surveillance)

Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL at Week 336 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 288 with HBV DNA ≥ 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen after Week 288 and had HBV DNA ≥ 400 copies/mL at the time of the addition. (NCT00117676)
Timeframe: Baseline; Weeks 289 to 336

,,
Interventionparticipants (Number)
Participants evaluatedChanges at conserved sites within HBV polymeraseChanges at polymorphic sites in HBV polymeraseNo genotypic changes (wild-type virus)Unable to genotype
ADV-TDF10001
TDF-TDF00000
TDF-TDF With Addition of FTC10010

Number of Participants With HBV Genotypic Changes From Baseline at Week 384 (Resistance Surveillance)

Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL at Week 384 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 336 with HBV DNA ≥ 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen after Week 336 and had HBV DNA ≥ 400 copies/mL at the time of the addition. (NCT00117676)
Timeframe: Baseline; Weeks 337 to 384

,,
Interventionparticipants (Number)
Participants evaluatedChanges at conserved sites within HBV polymeraseChanges at polymorphic sites in HBV polymeraseNo genotypic changes (wild-type virus)Unable to genotype
ADV-TDF00000
TDF-TDF10001
TDF-TDF With Addition of FTC00000

Number of Participants With HBV Genotypic Changes From Baseline at Week 432 (Resistance Surveillance)

Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL at Week 432 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 384 with HBV DNA ≥ 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen after Week 384 and had HBV DNA ≥ 400 copies/mL at the time of the addition. (NCT00117676)
Timeframe: Baseline; Weeks 385 to 432

,,
Interventionparticipants (Number)
Participants evaluatedChanges at conserved sites within HBV polymeraseChanges at polymorphic sites in HBV polymeraseNo genotypic changes (wild-type virus)Unable to genotype
ADV-TDF10100
TDF-TDF20020
TDF-TDF With Addition of FTC00000

Number of Participants With HBV Genotypic Changes From Baseline at Week 48 (Resistance Surveillance)

Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL at Week 48, those with viral breakthrough, and those who discontinued after Week 24 with HBV DNA ≥ 400 copies/mL. (NCT00117676)
Timeframe: Baseline; Week 48

,
Interventionparticipants (Number)
Participants evaluatedChanges at conserved sites in HBV polymeraseChanges at polymorphic sites in HBV polymeraseNo genotypic changes (wild-type virus)Unable to be genotyped
ADV-TDF42714201
TDF-TDF80341

Number of Participants With HBV Genotypic Changes From Baseline at Week 480 (Resistance Surveillance)

Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL at Week 480 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 432 with HBV DNA ≥ 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen after Week 432 and had HBV DNA ≥ 400 copies/mL at the time of the addition. (NCT00117676)
Timeframe: Baseline; Weeks 433 to 480

,,
Interventionparticipants (Number)
Participants evaluatedChanges at conserved sites within HBV polymeraseChanges at polymorphic sites in HBV polymeraseNo genotypic changes (wild-type virus)Unable to genotype
ADV-TDF00000
TDF-TDF00000
TDF-TDF With Addition of FTC00000

Number of Participants With HBV Genotypic Changes From Baseline at Week 96 (Resistance Surveillance)

Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL at Week 96 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 48 with HBV DNA ≥ 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen and had HBV DNA ≥ 400 copies/mL at the time of the addition. (NCT00117676)
Timeframe: Baseline; Weeks 49 to 96

,,
Interventionparticipants (Number)
Participants evaluatedChanges at conserved sites within HBV polymeraseChanges at polymorphic sites in HBV polymeraseNo genotypic changes (wild-type virus)Unable to be genotyped
ADV-TDF00000
TDF-TDF60240
TDF-TDF With Addition of FTC10100

Percentage of Participants With ALT Normalization at Weeks 144, 192, 240, 288, 336, and 384

ALT normalization was defined as ALT > ULN at baseline and within the normal range at the subsequent time point. The ULN was 43 U/L for males and 34 U/L for females aged 18 to < 69, and 35 U/L for males and 32 U/L for females aged ≥ 69. (NCT00117676)
Timeframe: Baseline; Weeks 144, 192, 240, 288, 336, and 384

,
Interventionpercentage of participants (Number)
Week 144Week 192Week 240Week 288Week 336Week 384
ADV-TDF70.076.475.772.965.469.2
TDF-TDF74.368.270.369.965.965.3

Percentage of Participants With ALT Normalization at Weeks 432 and 480

ALT normalization was defined as ALT > ULN at baseline and within the normal range at the subsequent time point. The ULN was 43 U/L for males and 34 U/L for females aged 18 to < 69, and 35 U/L for males and 32 U/L for females aged ≥ 69. (NCT00117676)
Timeframe: Baseline; Weeks 432 and 480

,
Interventionpercentage of participants (Number)
Week 432Week 480
ADV-TDF87.288.9
TDF-TDF86.580.0

Percentage of Participants With HBsAg Loss and/or Seroconversion to Anti-HBs at Week 96

HBsAg loss was defined as HBsAg positive at baseline and HBsAg negative at Week 96. Seroconversion to anti-HBs was defined as change of detectable antibody to HBsAg from negative at baseline to positive at Week 96. (NCT00117676)
Timeframe: Baseline; Week 96

,
Interventionpercentage of participants (Number)
HBsAg LossAnti-HBs Seroconversion
ADV-TDF00
TDF-TDF00

Percentage of Participants With HBsAg Loss and/or Seroconversion to Anti-HBs at Weeks 144, 192, 240, 288, 336, 384, 432, and 480

HBsAg loss was defined as HBsAg positive at baseline and HBsAg negative at the subsequent time point. Seroconversion to anti-HBs was defined as change of detectable antibody to HBsAg from negative at baseline to positive at the subsequent time point. (NCT00117676)
Timeframe: Baseline; Weeks 144, 192, 240, 288, 336, 384, 432, and 480

,
Interventionpercentage of participants (Number)
HBsAg Loss - Week 144Anti-HBs Seroconversion - Week 144HBsAg Loss - Week 192Anti-HBs Seroconversion - Week 192HBsAg Loss - Week 240Anti-HBs Seroconversion - Week 240HBsAg Loss - Week 288Anti-HBs Seroconversion - Week 288HBsAg Loss - Week 336Anti-HBs Seroconversion - Week 336HBsAg Loss - Week 384Anti-HBs Seroconversion - Week 384HBsAg Loss - Week 432Anti-HBs Seroconversion - Week 432HBsAg Loss - Week 480Anti-HBs Seroconversion - Week 480
ADV-TDF00000.800.80.80.80.80.80.81.60.82.40.8
TDF-TDF00000000000.80.41.20.41.20.8

Percentage of Participants With HBV DNA < 400 Copies/mL and Histological Improvement (2-point Reduction in Knodell Necroinflammatory Score Without Worsening in Knodell Fibrosis Score) at Week 48

"Complete response was a composite endpoint defined as histological response and HBV DNA < 400 copies/mL. Histological response was based on the Knodell numerical scoring of liver biopsy specimens and defined as at least a 2-point reduction in Knodell necroinflammatory score without worsening in Knodell fibrosis score. The Knodell necroinflammatory score is the combined necrosis and inflammation domain scores and ranges from 0 to 14; the Knodell fibrosis domain score ranges from 0 to 4.~A participant was a nonresponder for the primary endpoint if either biopsy (baseline or end-of-treatment) was missing or if there was not an HBV DNA value available at or beyond Week 40." (NCT00117676)
Timeframe: Baseline; Week 48

,
Interventionpercentage of participants (Number)
YesNo
ADV-TDF48.851.2
TDF-TDF70.829.2

Percentage of Participants With HBV DNA < 400 Copies/mL at Weeks 144, 192, 240, 288, 336, and 384

(NCT00117676)
Timeframe: Weeks 144, 192, 240, 288, 336, and 384

,
Interventionpercentage of participants (Number)
Week 144Week 192Week 240Week 288Week 336Week 384
ADV-TDF88.486.883.982.978.076.3
TDF-TDF86.784.082.880.577.074.3

Percentage of Participants With HBV DNA < 400 Copies/mL at Weeks 432 and 480

(NCT00117676)
Timeframe: Weeks 432 and 480

,
Interventionpercentage of participants (Number)
Week 432Week 480
ADV-TDF97.7100.0
TDF-TDF97.6100.0

Percentage of Participants With Hepatitis B S-Antigen (HBsAg) Loss or Seroconversion Antibody to HBs (Anti-HBs) at Week 48

HBsAg loss was defined as HBsAg positive at baseline and HBsAg negative at Week 48. Seroconversion to anti-HBs was defined as change of detectable antibody to HBsAg from negative at baseline to positive at Week 48. (NCT00117676)
Timeframe: Baseline; Week 48

,
Interventionpercentage of participants (Number)
HBsAg LossSeroconversion to anti-HBs
ADV-TDF00
TDF-TDF00

Percentage of Participants With Histological Response at Week 240

Histological response was based on the Knodell numerical scoring of liver biopsy specimens and defined as at least a 2-point reduction in Knodell necroinflammatory score without worsening in Knodell fibrosis score. The Knodell necroinflammatory score is the combined necrosis and inflammation domain scores and ranges from 0 to 14; the Knodell fibrosis domain score ranges from 0 to 4. (NCT00117676)
Timeframe: Baseline; Week 240

,
Interventionpercentage of participants (Number)
YesNo
ADV-TDF85.114.9
TDF-TDF87.312.7

Percentage of Participants With Histological Response at Week 48

Histological response was based on the Knodell numerical scoring of liver biopsy specimens and defined as at least a 2-point reduction in Knodell necroinflammatory score without worsening in Knodell fibrosis score. The Knodell necroinflammatory score is the combined necrosis and inflammation domain scores and ranges from 0 to 14; the Knodell fibrosis domain score ranges from 0 to 4. (NCT00117676)
Timeframe: Baseline; Week 48

,
Interventionpercentage of participants (Number)
YesNo
ADV-TDF68.831.2
TDF-TDF72.427.6

Ranked Assessment of Necroinflammation and Fibrosis at Week 240

Participants were ranked as having improvement, no change, worsening, or missing data (compared to Baseline) based on the Knodell scoring system, and results are presented as the percentage of participants in each category. The Knodell necroinflammatory score is the combined score for necrosis and inflammation domains of the Knodell scoring system, which ranges from 0 (best) to 14 (worst). The Knodell fibrosis domain score ranges from 0 (best) to 4 (worst). A decrease of 1 point or more indicated improvement, and an increase of 1 point or more indicated worsening. (NCT00117676)
Timeframe: Baseline; Week 240

,
Interventionpercentage of participants (Number)
Improvement - NecroinflammationNo Change - NecroinflammationWorsening - NecroinflammationImprovement - FibrosisNo Change - FibrosisWorsening - Fibrosis
ADV-TDF94.61.44.159.533.86.8
TDF-TDF96.72.70.762.034.04.0

Ranked Assessment of Necroinflammation and Fibrosis at Week 48

Participants were ranked as having improvement, no change, worsening, or missing data (compared to Baseline) based on the Knodell scoring system, and results are presented as the percentage of participants in each category. The Knodell necroinflammatory score is the combined score for necrosis and inflammation domains of the Knodell scoring system, which ranges from 0 (best) to 14 (worst). The Knodell fibrosis domain score ranges from 0 (best) to 4 (worst). A decrease of 1 point or more indicated improvement, and an increase of 1 point or more indicated worsening. (NCT00117676)
Timeframe: Baseline; Week 48

,
Interventionpercentage of participants (Number)
Improvement - NecroinflammationNo Change - NecroinflammationWorsening - NecroinflammationMissing Data - NecroinflammationImprovement - FibrosisNo Change - FibrosisWorsening - FibrosisMissing Data - Fibrosis
ADV-TDF81.68.00.89.625.654.410.49.6
TDF-TDF82.06.84.86.422.063.28.46.4

Percentage of Participants With Alanine Aminotransferase (ALT) Normalization at Week 48

ALT normalization was defined as ALT > upper limit of normal (ULN) at baseline and within the normal range at the end of blinded treatment. The ULN was 43 U/L for males and 34 U/L for females aged 18 to < 69, and 35 U/L for males and 32 U/L for females aged ≥ 69. (NCT00116805)
Timeframe: Baseline; Week 48

Interventionpercentage of participants (Number)
TDF-TDF68.0
ADV-TDF54.4

Percentage of Participants With ALT Normalization at Week 96

ALT normalization was defined as ALT > ULN at baseline and within the normal range at Week 96. The ULN was 43 U/L for males and 34 U/L for females aged 18 to < 69, and 35 U/L for males and 32 U/L for females aged ≥ 69. (NCT00116805)
Timeframe: Baseline; Week 96

Interventionpercentage of participants (Number)
TDF-TDF65.2
ADV-TDF74.4

Percentage of Participants With HBV DNA < 400 Copies/mL and Histological Improvement (2-point Reduction in Knodell Necroinflammatory Score Without Worsening in Knodell Fibrosis Score) at Week 48

"Complete response was a composite endpoint defined as histological response and HBV DNA < 400 copies/mL. Histological response was based on the Knodell numerical scoring of liver biopsy specimens and defined as at least a 2-point reduction in Knodell necroinflammatory score without worsening in Knodell fibrosis score. The Knodell necroinflammatory score is the combined necrosis and inflammation domain scores and ranges from 0 to 14; the Knodell fibrosis domain score ranges from 0 to 4.~A participant was a nonresponder for the primary endpoint if either biopsy (baseline or end-of-treatment) was missing or if there was not an HBV DNA value available at or beyond Week 40." (NCT00116805)
Timeframe: Baseline; Week 48

Interventionpercentage of participants (Number)
TDF-TDF66.5
ADV 10 mg12.2

Percentage of Participants With HBV DNA < 400 Copies/mL at Week 48

(NCT00116805)
Timeframe: Week 48

Interventionpercentage of participants (Number)
TDF-TDF76.1
ADV-TDF13.3

Percentage of Participants With HBV DNA < 400 Copies/mL at Week 96

(NCT00116805)
Timeframe: Week 96

Interventionpercentage of participants (Number)
TDF-TDF77.6
ADV-TDF77.9

Change From Baseline in ALT at Weeks 48, 96, 144, 192, 240, 288, 336, 384, 432, and 480

(NCT00116805)
Timeframe: Baseline; Weeks 48, 96, 144, 192, 240, 288, 336, 384, 432, and 480

,
InterventionU/L (Mean)
Week 48Week 96Week 144Week 192Week 240Week 288Week 336Week 384Week 432Week 480
ADV-TDF-106.1-120.4-126.2-139.6-134.8-130.9-132.3-133.7-162.1-157.5
TDF-TDF-107.2-107.8-100.7-101.4-95.9-102.3-101.9-108.1-105.0-92.3

Change From Baseline in HBV DNA at Weeks 48, 96, 144, 192, 240, 288, 336, 384, 432, and 480

(NCT00116805)
Timeframe: Baseline; Weeks 48, 96, 144, 192, 240, 288, 336, 384, 432, and 480

,
Interventionlog10 IU/mL (Mean)
Week 48Week 96Week 144Week 192Week 240Week 288Week 336Week 384Week 432Week 480
ADV-TDF-3.93-6.38-6.31-6.49-6.45-6.49-6.46-6.28-6.45-6.37
TDF-TDF-6.17-6.26-6.32-6.30-6.22-6.27-6.35-6.38-6.13-6.18

Change From Baseline in Knodell and Ishak Necroinflammatory Scores at Week 240

The Knodell necroinflammatory score is the combined score for necrosis and inflammation domains of the Knodell scoring system, and ranges from 0 (best) to 14 (worst). The Ishak score measures the degree of liver fibrosis (scarring) caused by chronic necroinflammation (inflammation leading to cell death) and ranges from 0 (best) to 6 (worst). (NCT00116805)
Timeframe: Baseline; Week 240

,
Interventionunits on a scale (Mean)
Knodell Necroinflammatory ScoreIshak Necroinflammatory Score
ADV-TDF-5.1-4.5
TDF-TDF-4.8-4.1

Change From Baseline in Knodell and Ishak Necroinflammatory Scores at Week 48

The Knodell necroinflammatory score is the combined score for necrosis and inflammation domains of the Knodell scoring system, and ranges from 0 (best) to 14 (worst). The Ishak score measures the degree of liver fibrosis (scarring) caused by chronic necroinflammation (inflammation leading to cell death) and ranges from 0 (best) to 6 (worst). (NCT00116805)
Timeframe: Baseline; Week 48

,
Interventionunits on a scale (Mean)
Knodell Necroinflammatory ScoreIshak Necroinflammatory Score
ADV-TDF-3.2-2.6
TDF-TDF-3.6-2.7

Change From Week 48 in ALT at Weeks 96, 144, 192, 240, 288, 336, 384, 432, and 480

(NCT00116805)
Timeframe: Week 48; Weeks 96, 144, 192, 240, 288, 336, 384, 432, and 480

,
InterventionU/L (Mean)
Week 96Week 144Week 192Week 240Week 288Week 336Week 384Week 432Week 480
ADV-TDF-6.9-0.7-7.8-8.1-10.3-9.3-6.9-11.6-7.1
TDF-TDF-2.0-0.4-1.33.7-1.6-1.2-4.4-4.3-5.5

Change From Week 48 in HBV DNA at Weeks 96, 144, 192, 240, 288, 336, 384, 432, and 480

(NCT00116805)
Timeframe: Week 48; Weeks 96, 144, 192, 240, 288, 336, 384, 432, and 480

,
Interventionlog10 IU/mL (Mean)
Week 96Week 144Week 192Week 240Week 288Week 336Week 384Week 432Week 480
ADV-TDF-2.43-2.27-2.41-2.49-2.62-2.59-2.34-2.32-2.16
TDF-TDF-0.10-0.19-0.20-0.14-0.18-0.25-0.29-0.13-0.24

Number of Participants With HBV Genotypic Changes From Baseline at Week 144 (Resistance Surveillance)

Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL at Week 144 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 96 with HBV DNA ≥ 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen after Week 96 and had HBV DNA ≥ 400 copies/mL at the time of the addition. (NCT00116805)
Timeframe: Baseline; Weeks 97 to 144

,,,
Interventionparticipants (Number)
Participants evaluatedChanges at conserved sites in HBV polymeraseChanges at polymorphic sites in HBV polymeraseNo genotypic changes (wild-type virus)Unable to be genotyped
ADV-TDF52300
ADV-TDF With Addition of FTC50031
TDF-TDF21010
TDF-TDF With Addition of FTC72320

Number of Participants With HBV Genotypic Changes From Baseline at Week 192 (Resistance Surveillance)

Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL at Week 192 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 144 with HBV DNA ≥ 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen after Week 144 and had HBV DNA ≥ 400 copies/mL at the time of the addition. (NCT00116805)
Timeframe: Baseline; Weeks 145 to 192

,,,
Interventionparticipants (Number)
Participants evaluatedChanges at conserved sites in HBV polymeraseChanges at polymorphic sites in HBV polymeraseNo genotypic changes (wild-type virus)Unable to be genotyped
ADV-TDF10100
ADV-TDF With Addition of FTC10100
TDF-TDF20101
TDF-TDF With Addition of FTC50013

Number of Participants With HBV Genotypic Changes From Baseline at Week 240 (Resistance Surveillance)

Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL at Week 240 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 192 with HBV DNA ≥ 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen after Week 192 and had HBV DNA ≥ 400 copies/mL at the time of the addition. (NCT00116805)
Timeframe: Baseline; Weeks 193 to 240

,,,
Interventionparticipants (Number)
Participants evaluatedChanges at conserved sites in HBV polymeraseChanges at polymorphic sites in HBV polymeraseNo genotypic changes (wild-type virus)Unable to be genotyped
ADV-TDF00000
ADV-TDF With Addition of FTC11000
TDF-TDF30210
TDF-TDF With Addition of FTC30021

Number of Participants With HBV Genotypic Changes From Baseline at Week 288 (Resistance Surveillance)

Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL at Week 288 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 240 with HBV DNA ≥ 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen after Week 240 and had HBV DNA ≥ 400 copies/mL at the time of the addition. (NCT00116805)
Timeframe: Baseline; Weeks 241 to 288

,,,
Interventionparticipants (Number)
Participants evaluatedChanges at conserved sites in HBV polymeraseChanges at polymorphic sites in HBV polymeraseNo genotypic changes (wild-type virus)Unable to be genotyped
ADV-TDF00000
ADV-TDF With Addition of FTC00000
TDF-TDF30021
TDF-TDF With Addition of FTC00000

Number of Participants With HBV Genotypic Changes From Baseline at Week 336 (Resistance Surveillance)

Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL at Week 336 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 288 with HBV DNA ≥ 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen after Week 288 and had HBV DNA ≥ 400 copies/mL at the time of the addition. (NCT00116805)
Timeframe: Baseline; Weeks 289 to 336

,,,
Interventionparticipants (Number)
Participants evaluatedChanges at conserved sites in HBV polymeraseChanges at polymorphic sites in HBV polymeraseNo genotypic changes (wild-type virus)Unable to be genotyped
ADV-TDF10010
ADV-TDF With Addition of FTC00000
TDF-TDF10001
TDF-TDF With Addition of FTC00000

Number of Participants With HBV Genotypic Changes From Baseline at Week 384 (Resistance Surveillance)

Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL at Week 384 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 336 with HBV DNA ≥ 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen after Week 336 and had HBV DNA ≥ 400 copies/mL at the time of the addition. (NCT00116805)
Timeframe: Baseline; Weeks 337 to 384

,,,
Interventionparticipants (Number)
Participants evaluatedChanges at conserved sites in HBV polymeraseChanges at polymorphic sites in HBV polymeraseNo genotypic changes (wild-type virus)Unable to be genotyped
ADV-TDF21100
ADV-TDF With Addition of FTC20110
TDF-TDF10001
TDF-TDF With Addition of FTC00000

Number of Participants With HBV Genotypic Changes From Baseline at Week 432 (Resistance Surveillance)

Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL at Week 432 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 384 with HBV DNA ≥ 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen after Week 384 and had HBV DNA ≥ 400 copies/mL at the time of the addition. (NCT00116805)
Timeframe: Baseline; Weeks 385 to 432

,,,
Interventionparticipants (Number)
Participants evaluatedChanges at conserved sites in HBV polymeraseChanges at polymorphic sites in HBV polymeraseNo genotypic changes (wild-type virus)Unable to be genotyped
ADV-TDF00000
ADV-TDF With Addition of FTC10010
TDF-TDF10100
TDF-TDF With Addition of FTC30030

Number of Participants With HBV Genotypic Changes From Baseline at Week 48 (Resistance Surveillance)

Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL, those with viral breakthrough, and those who discontinued after Week 24 with HBV DNA ≥ 400 copies/mL. (NCT00116805)
Timeframe: Baseline; Week 48

,
Interventionparticipants (Number)
Participants evaluatedChanges at conserved sites in HBV polymeraseChanges at polymorphic sites in HBV polymeraseNo genotypic changes (wild-type virus)Unable to be genotyped
ADV-TDF75817437
TDF-TDF3121379

Number of Participants With HBV Genotypic Changes From Baseline at Week 480 (Resistance Surveillance)

Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL at Week 480 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 432 with HBV DNA ≥ 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen after Week 432 and had HBV DNA ≥ 400 copies/mL at the time of the addition. (NCT00116805)
Timeframe: Baseline; Weeks 433 to 480

,,,
Interventionparticipants (Number)
Participants evaluatedChanges at conserved sites in HBV polymeraseChanges at polymorphic sites in HBV polymeraseNo genotypic changes (wild-type virus)Unable to be genotyped
ADV-TDF10010
ADV-TDF With Addition of FTC00000
TDF-TDF00000
TDF-TDF With Addition of FTC30120

Number of Participants With HBV Genotypic Changes From Baseline at Week 96 (Resistance Surveillance)

Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL at Week 96 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 48 with HBV DNA ≥ 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen and had HBV DNA ≥ 400 copies/mL at the time of the addition. (NCT00116805)
Timeframe: Baseline; Weeks 49 to 96

,,,
Interventionparticipants (Number)
Participants evaluatedChanges at conserved sites in HBV polymeraseChanges at polymorphic sites in HBV polymeraseNo genotypic changes (wild-type virus)Unable to be genotyped
ADV-TDF1621121
ADV-TDF With Addition of FTC103232
TDF-TDF1823103
TDF-TDF With Addition of FTC130157

Percentage of Participants With ALT Normalization at Weeks 144, 192, 240, 288, 336, and 384

ALT normalization was defined as ALT > ULN at baseline and within the normal range at the subsequent time point. The ULN was 43 U/L for males and 34 U/L for females aged 18 to < 69, and 35 U/L for males and 32 U/L for females aged ≥ 69. (NCT00116805)
Timeframe: Baseline; Weeks 144, 192, 240, 288, 336, and 384

,
Interventionpercentage of participants (Number)
Week 144Week 192Week 240Week 288Week 336Week 384
ADV-TDF67.869.465.970.167.967.1
TDF-TDF60.259.650.051.346.252.6

Percentage of Participants With ALT Normalization at Weeks 432 and 480

ALT normalization was defined as ALT > ULN at baseline and within the normal range at the subsequent time point. The ULN was 43 U/L for males and 34 U/L for females aged 18 to < 69, and 35 U/L for males and 32 U/L for females aged ≥ 69. (NCT00116805)
Timeframe: Baseline; Weeks 432 and 480

,
Interventionpercentage of participants (Number)
Week 432Week 480
ADV-TDF78.682.8
TDF-TDF79.675.0

Percentage of Participants With HBeAg Loss or Seroconversion to Anti-HBe at Week 96

HBeAg loss was defined as HBeAg positive at baseline and HBeAg negative at Week 96. Seroconversion to anti-HBe was defined as change of detectable antibody to HBeAg from negative at baseline to positive at Week 96. (NCT00116805)
Timeframe: Baseline; Week 96

,
Interventionpercentage of participants (Number)
HBeAg LossSeroconversion to Anti-HBe
ADV-TDF25.622.0
TDF-TDF25.922.8

Percentage of Participants With HBsAg Loss or Seroconversion to Anti-HBs at Week 96

HBsAg loss was defined as HBsAg positive at baseline and HBsAg negative at the subsequent time point. Seroconversion to anti-HBs was defined as change of detectable antibody to HBsAg from negative at baseline to positive at the subsequent time point. (NCT00116805)
Timeframe: Baseline; Week 96

,
Interventionpercentage of participants (Number)
HBsAg LossAnti-HBs Seroconversion
ADV-TDF5.84.7
TDF-TDF5.34.1

Percentage of Participants With HBsAg Loss or Seroconversion to Anti-HBs at Weeks 144, 192, 240, 288, 336, 384, 432, and 480

HBsAg loss was defined as HBsAg positive at baseline and HBsAg negative at the subsequent time point. Seroconversion to anti-HBs was defined as change of detectable antibody to HBsAg from negative at baseline to positive at the subsequent time point. (NCT00116805)
Timeframe: Baseline; Weeks 144, 192, 240, 288, 336, 384, 432, and 480

,
Interventionpercentage of participants (Number)
HBsAg Loss - Week 144Anti-HBs Seroconversion - Week 144HBsAg Loss - Week 192Anti-HBs Seroconversion - Week 192HBsAg Loss - Week 240Anti-HBs Seroconversion - Week 240HBsAg Loss - Week 288Anti-HBs Seroconversion - Week 288HBsAg Loss - Week 336Anti-HBs Seroconversion - Week 336HBsAg Loss - Week 384Anti-HBs Seroconversion - Week 384HBsAg Loss - Week 432Anti-HBs Seroconversion - Week 432HBsAg Loss - Week 480Anti-HBs Seroconversion - Week 480
ADV-TDF8.06.87.96.78.08.08.08.07.97.99.07.910.28.010.17.9
TDF-TDF7.55.29.46.49.26.39.26.410.37.511.08.110.97.610.98.0

Percentage of Participants With HBV DNA < 400 Copies/mL at Weeks 144, 192, 240, 288, 336, and 384

(NCT00116805)
Timeframe: Weeks 144, 192, 240, 288, 336, and 384

,
Interventionpercentage of participants (Number)
Week 144Week 192Week 240Week 288Week 336Week 384
ADV-TDF70.571.666.364.862.160.5
TDF-TDF71.767.963.461.359.456.1

Percentage of Participants With HBV DNA < 400 Copies/mL at Weeks 432 and 480

(NCT00116805)
Timeframe: Weeks 432 and 480

,
Interventionpercentage of participants (Number)
Week 432Week 480
ADV-TDF100.096.6
TDF-TDF93.098.0

Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss/Seroconversion at Week 48

HBeAg loss was defined as HBeAg positive at baseline and HBeAg negative at Week 48. Seroconversion to anti-HBe was defined as change of detectable antibody to HBeAg from negative at baseline to positive at Week 48. (NCT00116805)
Timeframe: Baseline; Week 48

,
Interventionpercentage of participants (Number)
HBeAg LossHBeAg Seroconversion
ADV-TDF17.517.5
TDF-TDF22.220.9

Percentage of Participants With Hepatitis B S-Antigen (HBsAg) Loss or Seroconversion at Week 48

HBsAg loss was defined as HBsAg positive at baseline and HBsAg negative at Week 48. Seroconversion to anti-HBs was defined as change of detectable antibody to HBsAg from negative at baseline to positive at Week 48. (NCT00116805)
Timeframe: Baseline; Week 48

,
Interventionpercentage of participants (Number)
HBsAg LossHBsAg Seroconversion
ADV-TDF00
TDF-TDF3.21.3

Percentage of Participants With Histological Response at Week 240

Histological response was based on the Knodell numerical scoring of liver biopsy specimens and defined as at least a 2-point reduction in Knodell necroinflammatory score without worsening in Knodell fibrosis score. The Knodell necroinflammatory score is the combined necrosis and inflammation domain scores and ranges from 0 to 14; the Knodell fibrosis domain score ranges from 0 to 4. (NCT00116805)
Timeframe: Baseline; Week 240

,
Interventionpercentage of participants (Number)
YesNo
ADV-TDF89.610.4
TDF-TDF88.211.8

Percentage of Participants With Histological Response at Week 48

Histological response was based on the Knodell numerical scoring of liver biopsy specimens and defined as at least a 2-point reduction in Knodell necroinflammatory score without worsening in Knodell fibrosis score. The Knodell necroinflammatory score is the combined necrosis and inflammation domain scores and ranges from 0 to 14; the Knodell fibrosis domain score ranges from 0 to 4. (NCT00116805)
Timeframe: Baseline; Week 48

,
Interventionpercentage of participants (Number)
YesNo
ADV-TDF67.832.2
TDF-TDF74.425.6

Ranked Assessment of Necroinflammation and Fibrosis at Week 240

Participants were ranked as having improvement, no change, worsening, or missing data (compared to Baseline) based on the Knodell scoring system, and results are presented as the percentage of participants in each category. The Knodell necroinflammatory score is the combined score for necrosis and inflammation domains of the Knodell scoring system, which ranges from 0 (best) to 14 (worst). The Knodell fibrosis domain score ranges from 0 (best) to 4 (worst). A decrease of 1 point or more indicated improvement, and an increase of 1 point or more indicated worsening. (NCT00116805)
Timeframe: Baseline; Week 240

,
Interventionpercentage of participants (Number)
Improvement - NecroinflammationNo Change - NecroinflammationWorsening - NecroinflammationImprovement - FibrosisNo Change - FibrosisWorsening - Fibrosis
ADV-TDF97.92.1058.339.62.1
TDF-TDF96.13.9056.639.53.9

Ranked Assessment of Necroinflammation and Fibrosis at Week 48

Participants were ranked as having improvement, no change, worsening, or missing data (compared to Baseline) based on the Knodell scoring system, and results are presented as the percentage of participants in each category. The Knodell necroinflammatory score is the combined score for necrosis and inflammation domains of the Knodell scoring system, which ranges from 0 (best) to 14 (worst). The Knodell fibrosis domain score ranges from 0 (best) to 4 (worst). A decrease of 1 point or more indicated improvement, and an increase of 1 point or more indicated worsening. (NCT00116805)
Timeframe: Baseline; Week 48

,
Interventionpercentage of participants (Number)
Improvement - NecroinflammationNo Change - NecroinflammationWorsening - NecroinflammationMissing Data - NecroinflammationImprovement - FibrosisNo Change - FibrosisWorsening - FibrosisMissing Data - Fibrosis
ADV-TDF78.93.35.612.220.061.16.712.2
TDF-TDF81.34.53.410.819.963.65.111.4

Complete Virologic Response (CVR, Serum HBV DNA Undetectable by PCR or Less Than 60 IU/mL)

(NCT01023217)
Timeframe: at week 52 from randomization

Interventionparticipants (Number)
Adefovir Plus Entecavir13
Adefovir Plus Lamivudine2

Change in Interferon-stimulated-gene (ISG) Expression

Change in level of ISG expression before and after 1st peginterferon injection (NCT02364336)
Timeframe: 6 hours after first injection of peginterferon

Interventionlog 2 fold change (Mean)
PPP1R3GALAS1INHBBMMRN1LYVE1SLC8A1PPARGC1ANOTUMIGFBP3LTBP1STARD5RTN4RL1ZPR1
HBeAg Negative-2.7161.670-2.20-1.597-1.184-1.382-1.5730.870-0.723-0.5481.7981.808-0.972

Change in Natural Killer (NK) Cell Degranulation

NK cell degranulation is calculated as 100*(degranulated NK cells)/(NK cells). Changes are calculated by subtracting baseline from 6 hours after first peginterferon injection. (NCT02364336)
Timeframe: 6 hours after first injection of peginterferon and baseline

Intervention% of NK cells (Mean)
Blood baselineBlood 6 hoursBlood change
HBeAg Positive0.080.06-0.02

Change in Natural Killer (NK) Cell Degranulation

NK cell degranulation is calculated as 100*(degranulated NK cells)/(NK cells). Changes are calculated by subtracting baseline from 6 hours after first peginterferon injection. (NCT02364336)
Timeframe: 6 hours after first injection of peginterferon and baseline

Intervention% of NK cells (Mean)
Blood baselineBlood 6 hoursBlood changeLiver baselineLiver 6 hoursLiver change
HBeAg Negative0.640.52-0.123.374.871.51

Change in Natural Killer (NK) Cell Frequency

NK cell frequency is calculated as 100*(NK cells)/(mononuclear cells). Changes are calculated by subtracting baseline from 6 hours after first peginterferon injection. (NCT02364336)
Timeframe: 6 hours after first injection of peginterferon and baseline

Interventionpercentage of mononuclear cells (Mean)
Blood baselineBlood 6 hoursBlood change
HBeAg Positive15.6010.30-5.3

Change in Natural Killer (NK) Cell Frequency

NK cell frequency is calculated as 100*(NK cells)/(mononuclear cells). Changes are calculated by subtracting baseline from 6 hours after first peginterferon injection. (NCT02364336)
Timeframe: 6 hours after first injection of peginterferon and baseline

Interventionpercentage of mononuclear cells (Mean)
Blood baselineBlood 6 hoursBlood changeLiver baselineLiver 6 hoursLiver change
HBeAg Negative11.8213.741.9224.6924.780.09

Hepatitis B e Antigen (HBeAg) Loss

Proportion of HBeAg positive patients showing eAg loss at end of treatment, and 24 and 48 weeks off peginterferon treatment. (NCT02364336)
Timeframe: End of treatment, 24 weeks, and 48 weeks

InterventionParticipants (Count of Participants)
End of treatmentWeek 24 post treatmentWeek 48 post treatment
HBeAg Positive000

Hepatitis B s Antigen (HBsAg) Loss

Proportion of HBsAg positive patients showing sAG loss at end of treatment and 24 and 48 weeks off peginterferon treatment (NCT02364336)
Timeframe: End of treatment, 24 weeks, and 48 weeks

,
InterventionParticipants (Count of Participants)
End of treatmentWeek 24 post treatmentWeek 48 post treatment
HBeAg Negative100
HBeAg Positive000

Percentage of Participants With HBV DNA < 400 Copies/mL at Week 96

(NCT00737568)
Timeframe: Week 96

Interventionpercentage of participants (Number)
Tenofovir DF89.4
FTC/Tenofovir DF86.3

Development of Drug-resistant Mutations (DRMs)

The development of DRMs was summarized, either as development of new DRMs or enrichment of existing DRMs. (NCT00737568)
Timeframe: Baseline to Week 240

,
Interventionparticipants (Number)
New tenofovir DF DRMsEnrichment of tenofovir DF DRMsNew FTC DRMsEnrichment of FTC DRMs
FTC/Tenofovir DF0001
Tenofovir DF0000

HBV DNA Level at Weeks 48, 96, 144, 192, and 240

(NCT00737568)
Timeframe: Weeks 48, 96, 144, 192, and 240

,
Interventionlog10 copies/mL (Mean)
Week 48 (TDF: n=130; FTC/TDF: n=133)Week 96 (TDF: n=132; FTC/TDF: n=127)Week 144 (TDF: n=128; FTC/TDF: n=123)Week 192 (TDF: n=126; FTC/TDF: n=119)Week 240 (TDF: n=118; FTC/TDF: n=116)
FTC/Tenofovir DF2.482.282.292.232.26
Tenofovir DF2.422.292.262.252.23

Percent Change From Baseline in BMD of the Hip at Weeks 24, 48, 72, 96, 144, 192, and 240

BMD is calculated as g/cm^2; the mean (SD) percentage change is presented. (NCT00737568)
Timeframe: Baseline; Weeks 24, 48, 72, 96, 144, 192, and 240

,
Interventionpercentage change (Mean)
% Change at Week 24 (TDF: n=130; FTC/TDF: n=127)% Change at Week 48 (TDF: n=126; FTC/TDF: n=118)% Change at Week 72 (TDF: n=121; FTC/TDF: n=115)% Change at Week 96 (TDF: n=125; FTC/TDF: n=112)% Change at Week 144 (TDF: n=120; FTC/TDF: n=107)% Change at Week 192 (TDF: n=116; FTC/TDF: n=105)% Change at Week 240 (TDF: n=111; FTC/TDF: n=100)
FTC/Tenofovir DF-0.59-1.00-1.61-1.77-1.91-2.41-2.63
Tenofovir DF-0.71-1.15-1.59-1.70-2.02-2.33-2.46

Percent Change From Baseline in Bone Mineral Density (BMD) of the Spine at Weeks 24, 48, 72, 96, 144, 192, and 240

BMD is calculated as grams per cubic centimeter (g/cm^2); the mean (SD) percentage change is presented. (NCT00737568)
Timeframe: Baseline; Weeks 24, 48, 72, 96, 144, 192, and 240

,
Interventionpercentage change (Mean)
% Change at Week 24 (TDF: n=132; FTC/TDF: n=127)% Change at Week 48 (TDF: n=126; FTC/TDF: n=121)% Change at Week 72 (TDF: n=123; FTC/TDF: n=119)% Change at Week 96 (TDF: n=126; FTC/TDF: n=114)% Change at Week 144 (TDF: n=123; FTC/TDF: n=110)% Change at Week 192 (TDF: n=120; FTC/TDF: n=106)% Change at Week 240 (TDF: n=115; FTC/TDF: n=102)
FTC/Tenofovir DF-1.83-1.73-1.95-1.72-1.63-1.60-1.15
Tenofovir DF-1.74-1.68-1.35-1.24-1.36-1.32-0.83

Percentage of Participants With HBeAg Loss at Weeks 48, 96, 144, 192, and 240

The percentage of participants who were HBeAg positive at baseline and who had HBeAg Loss at the given time point was summarized. Loss of HBeAg was defined as change of detectable HBeAg from positive to negative. (NCT00737568)
Timeframe: Baseline; Weeks 48, 96, 144, 192, and 240

,
Interventionpercentage of participants (Number)
Week 48Week 96Week 144Week 192Week 240
FTC/Tenofovir DF5.913.217.614.719.1
Tenofovir DF9.215.423.121.524.6

Percentage of Participants With HBV DNA < 169 Copies/mL at Weeks 48, 96, 144, 192, and 240

(NCT00737568)
Timeframe: Weeks 48, 96, 144, 192, and 240

,
Interventionpercentage of participants (Number)
Week 48Week 96Week 144Week 192Week 240
FTC/Tenofovir DF77.783.584.984.282.0
Tenofovir DF76.685.886.585.181.6

Percentage of Participants With HBV DNA < 400 Copies/mL at Weeks 48, 144, 192, and 240

(NCT00737568)
Timeframe: Weeks 48, 144, 192, and 240

,
Interventionpercentage of participants (Number)
Week 48Week 144Week 192Week 240
FTC/Tenofovir DF84.284.985.682.7
Tenofovir DF81.687.286.583.0

Percentage of Participants With HBV Surface Antigen (HBsAg) Loss at Weeks 48, 96, 144, 192, and 240

The percentage of participants with HBsAg Loss at the given time point was summarized. Loss of HBsAg was defined as change of detectable HBsAg from positive to negative. (NCT00737568)
Timeframe: Baseline; Weeks 48, 96, 144, 192, and 240

,
Interventionpercentage of participants (Number)
Week 48Week 96Week 144Week 192Week 240
FTC/Tenofovir DF0.70.71.42.92.9
Tenofovir DF0.00.00.70.71.4

Percentage of Participants With Normal ALT at Weeks 48, 96, 144, 192, and 240

Normal ALT was defined as having a value less than or equal to the ULN. The ULN was 43 U/L for males and 34 U/L for females aged 18 to < 69, and 35 U/L for males and 32 U/L for females aged ≥ 69. (NCT00737568)
Timeframe: Weeks 48, 96, 144, 192, and 240

,
Interventionpercentage of participants (Number)
Week 48Week 96Week 144Week 192Week 240
FTC/Tenofovir DF69.869.875.576.371.9
Tenofovir DF67.470.270.275.971.6

Percentage of Participants With Seroconversion to Antibody Against HBeAg (Anti-HBe) at Weeks 48, 96, 144, 192, and 240

The percentage of participants who were HBeAg positive at baseline and who had seroconversion to anti-HBe at the given time point was summarized. Seroconversion to anti-HBe was defined as change of detectable antibody to HBeAg from negative to positive. (NCT00737568)
Timeframe: Baseline; Weeks 48, 96, 144, 192, and 240

,
Interventionpercentage of participants (Number)
Week 48Week 96Week 144Week 192Week 240
FTC/Tenofovir DF4.410.311.810.310.3
Tenofovir DF6.210.812.310.812.3

Percentage of Participants With Seroconversion to Antibody Against HBV Surface Antigen (Anti-HBs) at Weeks 48, 96, 144, 192, and 240

The percentage of participants with seroconversion to anti-HBs at the given time point was summarized. Seroconversion to anti-HBs was defined as change of detectable antibody to HBsAg from negative to positive. (NCT00737568)
Timeframe: Baseline; Weeks 48, 96, 144, 192, and 240

,
Interventionpercentage of participants (Number)
Week 48Week 96Week 144Week 192Week 240
FTC/Tenofovir DF0.00.00.70.70.7
Tenofovir DF0.00.00.00.00.0

Percentage of Participants With Virologic Breakthrough at Weeks 48, 96, 144, 192, and 240

The percentage of participants with virologic breakthrough at the given time point was summarized. Virologic breakthrough was defined as having two consecutive 1.0 log10 or greater increases in serum HBV DNA from on-treatment nadir, or two consecutive HBV DNA values ≥ 400 copies/mL after being < 400 copies/mL. (NCT00737568)
Timeframe: Baseline; Weeks 48, 96, 144, 192, and 240

,
Interventionpercentage of participants (Number)
Week 48 (TDF: n=130; FTC/TDF: n=133)Week 96 (TDF: n=132; FTC/TDF: n=127)Week 144 (TDF: n=128; FTC/TDF: n=123)Week 192 (TDF: n=126; FTC/TDF: n=119)Week 240 (TDF: n=118; FTC/TDF: n=116)
FTC/Tenofovir DF0.80.00.80.00.0
Tenofovir DF0.00.00.80.80.0

Change From Baseline in FibroTest Value

The FibroTest score is used to assess liver fibrosis and is calculated based on a formula including the participant's age and sex and 5 laboratory parameters: alpha 2 macroglobulin, haptoglobin, gamma-glutamyl transferase (GGT), bilirubin, and apolipoprotein A1. Scores can range from 0.00 to 1.00, with higher scores indicating a greater degree of fibrosis. (NCT00736190)
Timeframe: Baseline and Week 48

InterventionScores on a scale (Mean)
Tenofovir DF-0.006

Number of Participants With Alanine Aminotransferase (ALT) Normal at Week 48

Number of participants with normal ALT (at or below the upper limit of normal [ULN] for the central laboratory [34 U/L])at Week 48 (NCT00736190)
Timeframe: Week 48

InterventionParticipants (Number)
Tenofovir DF59

Number of Participants With ALT Normalized (Baseline Values > ULN [34 U/L] and <= ULN at a Subsequent Visit) at Week 48

A normal value at Week 48 after having elevated ALT at baseline; normal ALT is defined as being at or below the ULN for the central laboratory (34 U/L) (NCT00736190)
Timeframe: Week 48

Interventionparticipants (Number)
Tenofovir DF40

Number of Participants With Composite Endpoint of Hepatitis B Virus (HBV) DNA <400 Copies/mL (<69 IU/mL) and Normal ALT at Week 48

Blood samples were collected for evaluating serum chemistry, including determination of ALT, and for measuring HBV DNA via PCR method. Composite endpoints proposed in the protocol included the percentage of participants with HBV DNA < 400 copies/mL (<69 IU/mL) and normal ALT (ALT <= ULN [34 U/L]); and with HBV DNA < 400 copies/mL, normal ALT, and HBeAg loss/seroconversion. Because so few participants lost hepatitis B e antigen (HBeAg) or developed antibody to hepatitis B e antigen (anti-HBe), only the composite endpoint of HBV DNA < 400 copies/mL and normal ALT was analyzed. (NCT00736190)
Timeframe: Week 48

InterventionParticipants (Number)
Tenofovir DF55

Number of Participants With HBV DNA < 169 Copies/mL (<29 IU/mL) at Week 48

Blood samples from study participants were collected for measuring HBV DNA via PCR method. (NCT00736190)
Timeframe: Week 48

InterventionParticipants (Number)
Tenofovir DF73

Number of Participants With Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) <400 Copies/mL (<69 IU/mL)

Blood samples were collected from study participants for measuring HBV DNA via polymerase chain reaction (PCR) method. (NCT00736190)
Timeframe: Week 48

InterventionParticipants (Number)
Tenofovir DF74

Number of Participants With HBeAg/Hepatitis B Surface Antigen (HBsAg) Loss and Seroconversion

HBeAg/HBsAg loss is defined for an individual participant as HBeAg+/HBsAg+ at baseline and HBeAg-/HBsAg- at Week 48. HBeAg/HBsAg serocoversion is defined for an individual participant as HBeAg+/HBsAg+ at baseline and HBeAg-/HBsAg- and anti-HBe+/antibody to hepatitis B surface antigen+ (anti-HBs+) at Week 48. (NCT00736190)
Timeframe: Week 48

InterventionParticipants (Number)
HBsAg+ at baselineHBsAg- at baselineHBsAg+ at Week 48HBsAg data missing at Week 48HBeAg+ at baselineHBeAg- at baselineHBeAg loss by Week 48Anti-HBe+ seroconversion by Week 48
Tenofovir DF900882533766

Summary of Resistance Surveillance for Participants Who Discontinued the Study Early

Serum was collected for HBV resistance surveillance, and sequence analysis of the HBV polymerase was assessed through di-deoxy sequencing of baseline and postbaseline samples. (NCT00736190)
Timeframe: Week 48

InterventionParticipants (Number)
No changes in HBV pol/RTChanges at polymorphic sitesChanges at conserved sitesUnable to genotype
Tenofovir DF1001

Summary of Resistance Surveillance for Participants With Virologic Breakthrough

Serum was collected for HBV resistance surveillance, and sequence analysis of the HBV polymerase was assessed through di-deoxy sequencing of baseline and postbaseline samples. (NCT00736190)
Timeframe: Week 48

InterventionParticipants (Number)
No changes in HBV pol/RTChanges at polymorphic sitesChanges at conserved sitesUnable to genotype
Tenofovir DF2000

Summary of Resistance Surveillance for Participants Without Virologic Breakthrough

Serum was collected for HBV resistance surveillance, and sequence analysis of the HBV polymerase was assessed through di-deoxy sequencing of baseline and postbaseline samples. (NCT00736190)
Timeframe: Week 48

InterventionParticipants (Number)
No changes in HBV pol/RTChanges at polymorphic sitesChanges at conserved sitesUnable to genotype
Tenofovir DF6121

Change From Baseline of Log 10 Copies/mL HBV DNA at Weeks 48, 96, 144, 192 and 240

"Change from Baseline of log 10 copies/mL HBV DNA at Weeks 48, 96, 144, 192 and 240 in the HBeAg-positive and HBeAg-negative population was assessed. HBeAg is a viral protein that is secreted by hepatitis B-infected cells. It is associated with chronic hepatitis B infections and is used as a marker of active viral disease and a participant's degree of infectiousness. A positive result indicates that the participant has high levels of virus in the blood and greater infectiousness. Usually a negative result indicates that the participant has lower levels of virus in the blood and less infectious. Values at Day 0 were considered as Baseline values. Change from Baseline was calculated as post Baseline values minus Baseline values. A non-completers equal failures approach is used for the analysis in ITT population. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed." (NCT01300234)
Timeframe: Baseline, Weeks 48, 96, 144, 192 and 240

,
Interventionlog10 copies/mL (Mean)
Week 48,HBeAg-positive, n=102, 97Week 48,HBeAg-negative, n=151, 148Week 96, HBeAg-positive, n=101, 97Week 96, HBeAg-negative, n=147,148Week 144, HBeAg-postive, n=100, 96Week 144, HBeAg-negative, n=145, 146Week 192, HBeAg-positive, n=97,93Week 192, HBeAg-negative, n=145,145Week 240, HBeAg-positive, n=91,90Week 240, HBeAg-negative, n=138,138
ADV-TDF-4.4-4.3-6.5-4.8-6.5-4.9-6.6-4.8-6.5-4.9
TDF-TDF-6.4-4.9-6.5-4.9-6.6-4.9-6.6-4.9-6.6-4.9

Number of HBeAg-negative Participants Achieving HBsAg Loss and HBsAg Seroconversion at Weeks 24, 48, 96, 144, 192, 240

HBsAg loss is defined as a negative HBsAg result for those participants with who were HBsAg positive at Baseline. Seroconversion to anti-HBs is defined as HBsAg loss and a positive anti-HBs result. This report includes data up to and including Week 240. (NCT01300234)
Timeframe: Weeks 24, 48, 96, 144, 192 and 240

,
InterventionParticipants (Number)
Week 24, HBsAg lossWeek 24, HBsAg seroconversionWeek 48, HBsAg lossWeek 48, HBsAg seroconversionWeek 96, HBsAg lossWeek 96, HBsAg seroconversionWeek 144, HBsAg lossWeek 144, HBsAg seroconversionWeek 192, HBsAg lossWeek 192, HBsAg seroconversionWeek 240, HBsAg lossWeek 240, HBsAg seroconversion
ADV-TDF000000110000
TDF-TDF000000000000

Number of HBeAg-positive Participants Achieving HBeAg Loss and HBeAg Seroconversion at Weeks 24, 48, 96, 144, 192 and 240.

HBeAg loss is defined as a negative HBeAg result for those participants who were HBeAg positive at Baseline. Seroconversion to anti-HBe is defined as HBeAg loss and a positive anti-HBe result. This report includes data up to and including Weeks 24, 48, 96, 144, 192 and 240. (NCT01300234)
Timeframe: Weeks 24, 48, 96, 144, 192 and 240

,
InterventionParticipants (Number)
Week 24, HBeAg lossWeek 24, HBeAg seroconversionWeek 48, HBeAg lossWeek 48, HBeAg seroconversionWeek 96, HBeAg lossWeek 96, HBeAg seroconversionWeek 144, HBeAg lossWeek 144, HBeAg seroconversionWeek 192, HBeAg lossWeek 192, HBeAg seroconversionWeek 240, HBeAg lossWeek 240, HBeAg seroconversion
ADV-TDF441092118242031243628
TDF-TDF151418163732373343334333

Number of HBeAg-positive Participants Achieving Hepatitis B Surface Antigen (HBsAg) Loss and HBsAg Seroconversion at Weeks 24, 48, 96, 144, 192 and 240

HBsAg loss is defined as negative HBsAg results for those participants with who were HBsAg positive at Baseline. Seroconversion to anti-HBs is defined as HBsAg loss and a positive anti-HBs result. This report includes data up to and including Week 240. (NCT01300234)
Timeframe: Weeks 24, 48, 96, 144, 192 and 240

,
InterventionParticipants (Number)
Week 24, HBsAg lossWeek 24, HBsAg seroconversionWeek 48, HBsAg lossWeek 48, HBsAg seroconversionWeek 96, HBsAg lossWeek 96, HBsAg seroconversionWeek 144, HBsAg lossWeek 144, HBaAg seroconversionWeek 192, HBsAg, lossWeek 192, HBsAg, seroconversionWeek 240, HBsAg lossWeek 240 HBsAg seroconversion
ADV-TDF000000000000
TDF-TDF000000101010

Number of Participants Achieving Durable HBsAg Loss From Weeks 24 to Week 48

"Durable HBsAg loss is defined as the loss of HBsAg and no detectable HBV DNA and ALT normalization at any three consecutive visits at least 12 Weeks apart. This report includes data up to and including Week 48. A non-completers equal failures approach was used for the analysis in ITT population." (NCT01300234)
Timeframe: Week 24 to Week 48

,
InterventionParticipants (Number)
HBeAg-positive, n =100, 97HBeAg-negative, n=150, 147
ADV 10 mg00
TDF 300 mg00

Number of Participants Achieving Durable HBsAg Loss From Weeks 96 to Week 240

"Durable HBsAg loss is defined as the loss of HBsAg and no detectable HBV DNA and ALT normalization at any three consecutive visits at least 12 Weeks apart from Week 96 to 240. This report includes data up to and including Week 240. A non-completers equal failures approach was used for the analysis in ITT population." (NCT01300234)
Timeframe: Week 96 to Week 240

,
InterventionParticipants (Number)
HBeAg-positive, n= 88, 90HBeAg-negative, n = 132, 137
ADV-TDF01
TDF-TDF10

Number of Participants in the Indicated Category for Renal Laboratory Abnormalities

"The Gilead Grading Scale for Severity of Adverse Events and Laboratory Abnormalities, version 21, September 2011 was used for grading. Confirmed is defined as two consecutive visits. mg=milligrams. dL=deciliter, G= Grade." (NCT01300234)
Timeframe: Up to Week 240

,
InterventionParticipants (Number)
Creatinine increase of 0.5 mg/dL above BaselineConfirmed creatinine >=2.0 mg/dLConfirmed clearance <50 milliliters/minuteConfirmed phosphorus G 3/4 abnormality, <2.0 mg/dL
ADV-TDF0000
TDF-TDF1003

Number of Participants With Alanine Aminotransferase (ALT) Normalization at Weeks 48, 96, 144, 192 and 240 in Participants Who Had Abnormal ALT at Baseline

"Participants who had abnormal ALT at Baseline and had normalized ALT at Weeks 48, 96, 144, 192 and 240 were assessed. This report includes data up to and including Weeks 48, 96, 144, 192 and 240. An increased level of ALT is referred to as abnormal ALT (the normal range is 0 to 48 units per liter [U/L]). Values at Day 0 were considered as Baseline values. A non-completers equal failures approach is used for the analysis in ITT population. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed." (NCT01300234)
Timeframe: Baseline; Weeks 48, 96, 144, 192 and 240

,
InterventionParticipants (Number)
Week 48, HBeAg-positive, n=102, 97Week 48, HBeAg-negative, n=136, 132Week 96, HBeAg-positive, n=102, 97Week 96, HBeAg-negative, n=136,132Week 144, HBeAg-positive, n=102, 97Week 144, HBeAg-negative, n=136, 132Week 192, HBeAg-positive, n=102, 97Week 192, HBeAg-negative, n=136,132Week 240, HBeAg-positive, n=102, 97Week 240, HBeAg-negative, n=136,132
ADV-TDF8311688118871197911880111
TDF-TDF8812093126921238912582119

Number of Participants With Any Serious Adverse Event (SAE) and Any Non-serious Adverse Event (AE)

An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, or is Grade 4 (life threatening or disabling). Participants with any non-serious AEs and SAEs has been reported. (NCT01300234)
Timeframe: Up to Week 240 treatment period and 24 weeks follow-up visit off treatment

,
InterventionParticipants (Number)
Non-serious AESAE
ADV-TDF12120
TDF-TDF14012

Number of Participants With Histological Improvement at Weeks 48 and 240 Who Had a Baseline Knodell Necroinflammatory Score (KNS) >=2.

Histological improvement is defined as a reduction of >=2 points in the KNS with no increase in fibrosis at Week 48 and Week 240 in participants with Baseline KNS >=2 which was derived from the American Association for the Study of Liver Diseases Practice Guidelines for Management of Chronic Hepatitis B (2009) and the European Association for the Study of the Liver Clinical Practice Guidelines Management of chronic hepatitis B virus infection (2012). The Knodell scale consists of 5 domains: periportal +/- bridging necrosis (scored from best to worst: 0, 1, 3, 4, 5, 6, or 10); intralobular degeneration and focal necrosis (0 to 4); portal inflammation (0 to 4); and fibrosis (0 to 4). The necroinflammatory score (ranging from 0 [best] to 14 [worst]) is the combined score for necrosis (0 to 10) plus inflammation (0 to 4; the participant is scored for only one inflammatory condition). Liver biopsy slides within 6 months prior to randomization could be accepted as Baseline evaluation. (NCT01300234)
Timeframe: Baseline; Week 48 and Week 240

,
InterventionParticipants (Number)
Week 48, HBeAg-positive, n=38, 49Week 48, HBeAg-negative, n=45, 50Week 240, HBeAg-positive, n=38, 49Week 240, HBeAg-negative, n=45, 50
ADV-TDF393424
TDF-TDF313258

Number of Participants With the Indicated Grade 3 and Grade 4 Treatment-emergent (TE) Laboratory Abnormalities (LAs)

TE grade 3 or grade 4 LAs are defined as values that increase by >=1 grade from Baseline (Day 0) to Grade 3 (severe) or 4 (potentially life threatening) at any post-Baseline value. The Gilead Grading Scale for Severity of Adverse Events and Laboratory Abnormalities, version 21, September 2011 was referred for grading. Laboratory parameters assessed included Sodium for hyponatremia and hypernatremia; Potassium for hypokalemia and hyperkalemia; glucose for hypoglycemia and hyperglycemia non-fasting; Phosphate for hypophosphatemia; alanine aminotransferase/aspartate aminotransferase, bilirubin, creatinine kinase, hemoglobin, platelets, neutrophils, lymphocytes, prothrombin time and amylase. (NCT01300234)
Timeframe: Up to Week 240

,
Interventionparticipants (Number)
SodiumPhosphateAlanine aminotransferaseAspartate aminotransferaseBilirubinCreatine kinaseHemoglobinPlateletsNeutrophilsProthrombin timePotassiumGlucoseLymphocytesAmylase
ADV-TDF0314614534170232
TDF-TDF22191016446101121

Number of Participants With the Indicated Treatment-emergent Laboratory Abnormalities for Serum Creatinine and Serum Phosphorus

The Gilead Grading Scale for Severity of Adverse Events and Laboratory Abnormalities, version 21, September 2011 was referred for grading. Serum creatinine: Grade 1, > 133 to 177 micromoles per Liter (µmoles/Liter), Grade 2, >177 to 265 µmoles/Liter, Grade 3, >265 to 530 µmoles/Liter, Grade 4, >530 µmoles/Liter. Serum phosphorus: Grade 2, 0.63 to <0.80 millimoles per Liter (mmoles/L), Grade 3, 0.31 to <0.63 mmoles/L, Grade 4, <0.31 mmoles/L. The normal range for serum phosphorus was 0.8 to 1.45 mmoles/L; the upper limit for a Grade 2 abnormality is 0.80 mmoles/L. Therefore, no Grade 1 abnormalities could be attributed, as values were contained within the normal range. NA indicates the value was not available for the indicated time point. (NCT01300234)
Timeframe: Up to Week 240

,
InterventionParticipants (Number)
Serum creatinine, Grade 1Serum creatinine, Grade 2Serum creatinine, Grade 3Serum creatinine, Grade 4Serum phosphorus, Grade 1Serum phosphorus, Grade 2Serum phosphorus, Grade 3Serum phosphorus, Grade 4
ADV-TDF1000NA5530
TDF-TDF0000NA4220

Number of Participants With Virological Breakthrough at Weeks 48, 96, 144, 192 and 240

"The number of HBeAg-positive and HBeAg-negative participants who had virological breakthrough at Weeks 48, 96, 144, 192 and 240 were assessed. Virological breakthrough is defined by >= one log increase in HBV DNA from NADIR (as determined by two sequential HBV DNA measurements at least one month apart or last on treatment measurement). A non-completers equal failures approach was used for the analysis in ITT population." (NCT01300234)
Timeframe: Weeks 48, 96, 144, 192 and 240

,
InterventionParticipants (Number)
Week 48,HBeAg-Positive, n=103, 99Week 48, HBeAg-Negative, n=154, 153Week 96, HBeAg-positive, n=103, 99Week 96, HBeAg-negative, n=154, 153Week 144, HBeAg-positive, n=103, 99Week 144, HBeAg-negative, n=154, 153Week 192, HBeAg-positive, n=103, 99Week 192, HBeAg-negative, n=154, 153Week 240, HBeAg-positive, n=103, 99Week 240, HBeAg-negative, n=154, 153
ADV-TDF42437475118
TDF-TDF0002030343

Participants With HBV DNA <400 Copies/mL at Weeks 96, 144, 192, and 240

"The number of participants with HBV DNA <400 copies/mL in the hepatitis B e antigen (HBeAg)-positive and HBeAg-negative population was assessed. HBeAg is a viral protein that is secreted by hepatitis B-infected cells. It is associated with chronic hepatitis B infections and is used as a marker of active viral disease and a participant's degree of infectiousness. A positive result indicates that the participant has high levels of virus in the blood and greater infectiousness. Usually, a negative result indicates that the participant has lower levels of virus in the blood and is less infectious. Week 96, 144, 192, and 240 data are not yet available, as this report includes data up to and including Week 48. A non-completers equal failures approach is used for the analysis in ITT population. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed." (NCT01300234)
Timeframe: Weeks 96, 144, 192, and 240

,
InterventionParticipants (Number)
Week 96, HBeAg-positive, n=103, 99Week 96, HBeAg-negative, n=154, 153Week 144, HBeAg-positive, n=103, 99Week 144, HBeAg-negative, n=154,153Week 192, HBeAg-positive, n=103,99Week 192,HBeAg-negative, n=154,153Week 240, HBeAg-positive, n=103,99Week 240, HBeAg-negative, n=154,153
ADV-TDF92143951459314187137
TDF-TDF95144971449414487138

Participants With Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) <400 Copies/Milliliter (mL) at Week 48

"The number of participants with Hepatitis B Virus (HBV) deoxyribonucleic acid (DNA) <400 copies/milliliter (mL) at Week 48 in the hepatitis B e antigen (HBeAg)-positive and HBeAg-negative population was assessed. HBeAg is a viral protein that is secreted by hepatitis B-infected cells. It is associated with chronic hepatitis B infections and is used as a marker of active viral disease and a participant's degree of infectiousness. A positive result indicates that the participant has high levels of virus in the blood and greater infectiousness. Usually, a negative result indicates that the participant has lower levels of virus in the blood and is less infectious. A non-completers equal failures approach is used for the analysis in ITT population. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed." (NCT01300234)
Timeframe: Week 48

,
InterventionParticipants (Number)
HBeAg-positive, n=103, 99HBeAg-negative, n=154, 153
ADV 10 mg18109
TDF 300 mg79149

Change From Baseline in Alanine Aminotransferase (ALT) Levels at Week 168

(NCT00307489)
Timeframe: 168 weeks

InterventionU/mL (Mean)
Tenofovir DF-26.8
Emtricitibine/Tenofovir DF-54.5

Change From Baseline in Alanine Aminotransferase (ALT) Levels at Week 48

(NCT00307489)
Timeframe: 48 Weeks

InterventionU/mL (Mean)
Tenofovir DF-21.6
Emtricitibine/Tenofovir DF-41.4

Change From Baseline in log10 Plasma HBV DNA Levels at Week 168

(NCT00307489)
Timeframe: 168 weeks

Interventionlog10 copies/mL (Mean)
Tenofovir DF-3.79
Emtricitibine/Tenofovir DF-3.48

Change From Baseline in log10 Plasma HBV DNA Levels at Week 48

(NCT00307489)
Timeframe: 48 Weeks

Interventionlog10 copies/mL (Mean)
Tenofovir DF-3.58
Emtricitibine/Tenofovir DF-3.34

HBeAg Seroconversion at Week 48

Defined as having negative serum HBeAg and positive serum antibody to HBeAg [anti-HBe] for subjects with positive serum HBeAg at baseline. (NCT00307489)
Timeframe: 48 Weeks

Interventionparticipants (Number)
Tenofovir DF2
Emtricitibine/Tenofovir DF3

HBsAg Loss at Week 168

Defined as having negative serum HBsAg for subjects with positive HBsAg at baseline. (NCT00307489)
Timeframe: 168 weeks

InterventionParticipants (Number)
Tenofovir DF1
Emtricitibine/Tenofovir DF0

HBsAg Loss at Week 48

Defined as having negative serum HBsAg for subjects with positive HBsAg at baseline. (NCT00307489)
Timeframe: 48 Weeks

Interventionparticipants (Number)
Tenofovir DF1
Emtricitibine/Tenofovir DF0

Hepatitis B Early Antigen (HBeAg) Loss at Week 168

Defined as having negative serum HBeAg for subjecst with positive HBeAg at baseline. (NCT00307489)
Timeframe: 168 weeks

InterventionPercent of Participants (Number)
Tenofovir DF21.6
Emtricitibine/Tenofovir DF24.3

Hepatitis B Early Antigen (HBeAg) Loss at Week 48

Defined as having negative serum HBeAg for subjects with positive HBeAg at baseline. (NCT00307489)
Timeframe: 48 Weeks

Interventionparticipants (Number)
Tenofovir DF3
Emtricitibine/Tenofovir DF3

Hepatitis B Surface Antigen (HBsAg) Seroconversion at Week 168

Defined as having negative serum BHsAg and positive serum antibody to HBsAg (anti-HBs) for subject with positive serum BHsAg at baseline. (NCT00307489)
Timeframe: 168 weeks

InterventionParticipants (Number)
Tenofovir DF1
Emtricitibine/Tenofovir DF0

Hepatitis B Surface Antigen (HBsAg) Seroconversion at Week 48

Defined as having negative serum HBsAg and positive serum antibody to HBsAg [anti-HBs] for subject with positive serum HBsAg at baseline. (NCT00307489)
Timeframe: 48 Weeks

Interventionparticipants (Number)
Tenofovir DF1
Emtricitibine/Tenofovir DF0

Percentage of Participants With Normal ALT at Week 168

ULN for males = 43 U/L; ULN for females = 34 U/L (NCT00307489)
Timeframe: 168 weeks

InterventionPercent of Participants (Number)
Tenofovir DF74.0
Emtricitibine/Tenofovir DF74.0

Percentage of Participants With Normal ALT at Week 48

ULN for males = 43 U/L; 34 U/L for females (NCT00307489)
Timeframe: 48 Weeks

Interventionpercentage of participants (Number)
Tenofovir DF66.7
Emtricitibine/Tenofovir DF73.1

Percentage of Participants With Normalized ALT at Week 168

Subjects with elevated ALT at baseline that return to normal by Week 48. (NCT00307489)
Timeframe: 168 weeks

InterventionPercent of Participants (Number)
Tenofovir DF68.0
Emtricitibine/Tenofovir DF70.8

Percentage of Participants With Normalized ALT at Week 48

Subjects with elevated ALT at baseline that return to normal by Week 48. (NCT00307489)
Timeframe: 48 Weeks

Interventionpercentage of participants (Number)
Tenofovir DF40.7
Emtricitibine/Tenofovir DF61.5

Percentage of Participants With Plasma HBV DNA < 169 Copies/mL at Week 168

P-values were from a Cochran-Mantel-Haenszel test, controlling for baseline HBeAg status and prior lamivudine use. (NCT00307489)
Timeframe: 168 weeks

InterventionPercent of Participants (Number)
Tenofovir DF80.4
Emtricitibine/Tenofovir DF78.0

Percentage of Participants With Plasma HBV DNA < 169 Copies/mL at Week 48

(NCT00307489)
Timeframe: 48 weeks

Interventionpercentage of participants (Number)
Tenofovir DF75.5
Emtricitibine/Tenofovir DF69.2

Percentage of Participants With Plasma HBV DNA < 400 Copies/mL at Week 168

(NCT00307489)
Timeframe: 168 weeks

InterventionPercent of Participants (Number)
Tenofovir DF82.4
Emtricitibine/Tenofovir DF84.0

Percentage of Participants With Plasma HBV DNA < 400 Copies/mL at Week 48

(NCT00307489)
Timeframe: 48 Weeks

Interventionpercentage of participants (Number)
Tenofovir DF81.1
Emtricitibine/Tenofovir DF80.8

Alanine Aminotransferase (ALT) Normalization

Number of participants with ALT ≤ 1 x upper limit of normal (ULN) (NCT00096785)
Timeframe: Week 48

Interventionparticipants (Number)
Entecavir25
Adefovir20

Change From Baseline in HBV DNA by PCR Assay at Week 48

Antiviral efficacy, as measured by the mean reduction in serum HBV DNA levels by PCR (log10 copies/mL) at Week 48, adjusted for baseline (Week 48 - Baseline). A negative value = improvement. (NCT00096785)
Timeframe: Baseline, Week 48

Interventionlog10 c/mL (Mean)
Entecavir-7.28
Adefovir-5.08

Change From Baseline in Hepatitis B Virus DNA (HBV DNA) by Polymerase Chain Reaction (PCR) Assay at Week 12

Antiviral efficacy, as measured by the mean reduction in serum HBV DNA levels by PCR (log10 copies/mL) at Week 12, adjusted for baseline (Week 12 - baseline). A negative value = improvement. (NCT00096785)
Timeframe: Baseline, Week 12

Interventionlog10 copies/mL (Mean)
Entecavir-6.23
Adefovir-4.52

HBV DNA Viral Kinetics Estimates of Exponential Decay Model - Half-Life of Free Virus

The biphasic decline of HBV DNA is characterized via a 4-parameter exponential decay model previously published for HBV compounds. An important derived parameter is the half-life of free virus (ie, the average amount of time for HBV particles in plasma to be reduced to half the initial level), calculated as 24*ln(2)/c. The model parameters reflect the biphasic pattern that is typically observed after initiation of antiviral therapy. Parameters were estimated for each subject separately and then averaged within each treatment group. (NCT00096785)
Timeframe: Week 12

Interventionhours (Number)
Entecavir14.52
Adefovir32.46

Viral Load Undetectable (HBV DNA <300 Copies/mL)

Number of Subjects with HBV DNA <300 copies/mL by Roche COBAS® Amplicor (limit of quantitation 300 copies/mL) (NCT00096785)
Timeframe: Week 48

InterventionParticipants (Number)
Entecavir19
Adefovir6

HBV DNA Viral Kinetics - Spline Model

This analysis uses a 3-parameter piece-wise linear model and describes the biphasic decline in HBV DNA (measured by PCR assay) through Week 12. The 3 parameters are the values for the 2 slopes, describing the first and second phase declines, respectively, and the estimated HBV DNA at the knot (at day 10; the time point where the 2 phases join). The biphasic viral decay kinetics for each treatment were obtained using a spline fitting procedure to estimate the 3 parameters for each subject; these estimates were then averaged within each treatment group. (NCT00096785)
Timeframe: Week 12

,
Interventionlog10 copies/mL (Number)
First slope (first phase of viral decay)Second slope (second phase of viral decay)
Adefovir-0.329-0.024
Entecavir-0.391-0.034

HBV DNA Viral Kinetics Estimates of Exponential Decay Model - Efficacy in Blocking Virus Production and de Novo Infections

The biphasic decline of HBV DNA is characterized via a 4-parameter exponential decay model previously published for HBV compounds. The model parameters of interest are the effectiveness of the drug in blocking virus production from infected cells (efficacy, ε) and effectiveness of the study treatment in blocking de novo infection of susceptible cells (η). The model parameters reflect the biphasic pattern that is typically observed after initiation of antiviral therapy. Parameters were estimated for each subject separately and then averaged within each treatment group. (NCT00096785)
Timeframe: Week 12

,
Interventionpercent effective (Number)
Efficacy in blocking virus production - εEffectiveness in blocking de novo infections - η
Adefovir99.465.87
Entecavir99.876.07

HBV DNA Viral Kinetics Estimates of Exponential Decay Model - Viral Clearance Rate and Infected Cell Death Rate

The biphasic decline of HBV DNA is characterized via a 4-parameter exponential decay model previously published for HBV compounds. The model parameters of interest are the clearance rate of the free virus (c), the death rate of productively infected cells (δ), The model parameters reflect the biphasic pattern that is typically observed after initiation of antiviral therapy. Parameters were estimated for each subject separately and then averaged within each treatment group. (NCT00096785)
Timeframe: Week 12

,
Interventionper day (Number)
Viral Clearance - cInfected cell death - δ
Adefovir0.910.04
Entecavir1.700.08

Summary of Safety - Laboratory Abnormalities Reported as Clinical AEs

Laboratory abnormalities reported as clinical AEs (NCT00096785)
Timeframe: Week 48

,
InterventionParticipants (Number)
ALT increasedLipase increasedBlood phosphorus decreasedLiver function test abnormalPlatelet count decreasedProtein urine present
Adefovir221111
Entecavir110000

Summary of Safety - Most Frequent (> 10%) Adverse Events (AEs), Serious Adverse Events (SAEs), Discontinuations Due to AEs, and Deaths

AE=new untoward medical occurrence or worsening of pre-existing medical condition regardless of causal relationship to treatment. SAE=untoward medical occurrence that is life-threatening, a congenital anomaly/birth defect, or an important medical event, or results in death, inpatient hospitalization/prolongation of hospitalization, or persistent/significant disability. AE grades: mild (1), moderate (2), severe (3), life-threatening (4), death (5). ALT flare= >2x baseline & >10x ULN up to end of therapy + 5 days. Hepatic SAE=SAEs consistent with worsening of hepatitis or hepatic decompensation. (NCT00096785)
Timeframe: cumulative through the end of on-treatment observation as available at the time of the Week 48 dataset

,
InterventionParticipants (Number)
DeathSerious AEDiscontinuation due to AEMalignant neoplasmOn Treatment: Any AEOn Treatment: HeadacheOn Treatment: Upper Respiratory InfectionOn Treatment: InfluenzaOn Treatment: NasopharyngitisOn Treatment: PyrexiaOn Treatment: Back PainOn Treatment: Grade 3-4 AEsALT FlareHepatic SAE
Adefovir031027684665512
Entecavir010028986440201

Proportion of Patients With Biochemical Response at 12 Weeks of Therapy

Biochemical response is defined as normalization of ALT level at week 12 compared to baseline. (NCT02881008)
Timeframe: 12 weeks

InterventionParticipants (Count of Participants)
Arm A3
Arm B4
Arm C4
Arm D4
Arm E2
Arm F4

Proportion of Patients With Biochemical Response at 24 Weeks of Therapy

Biochemical response is defined as normalization of ALT level at week 24 compared to baseline. (NCT02881008)
Timeframe: 24 weeks

InterventionParticipants (Count of Participants)
Arm D5
Arm F3

Proportion of Patients With cccDNA Response at 24 Week of Therapy

Virological cccDNA response is defined as reduction of intrahepatic cccDNA by 0.5 logs in comparison to baseline at week 24. (NCT02881008)
Timeframe: 24 weeks

InterventionParticipants (Count of Participants)
Arm F0

Proportion of Patients With HBsAg Response at 12 Week of Therapy

HBsAg response is defined as serum HBsAg decline of at least 0.5 logs IU/ml (or HBsAg negativation) at week 12 compared to baseline. (NCT02881008)
Timeframe: 12 week

InterventionParticipants (Count of Participants)
Arm A0
Arm B0
Arm C1
Arm D0
Arm E0
Arm F0

Proportion of Patients With HBsAg Response at 24 Week of Therapy

HBsAg response is defined as serum HBsAg decline of at least 0.5 logs IU/ml (or HBsAg negativation) at week 24 compared to baseline. (NCT02881008)
Timeframe: 24 weeks

InterventionParticipants (Count of Participants)
Arm D0
Arm F0

Proportion of Patients With HBV DNA Response at Week 12 of Therapy

HBV DNA response is defined as persistent reduction of HBV DNA by >1 log IU/ml or negativation at week 12 compared to baseline. (NCT02881008)
Timeframe: 12 weeks

InterventionParticipants (Count of Participants)
Arm A2
Arm B0
Arm C2
Arm D8
Arm E1
Arm F6

Proportion of Patients With HBV DNA Response at Week 24 of Therapy

HBV DNA response is defined as persistent reduction of HBV DNA by >1 log IU/ml or negativation at week 24 compared to baseline. (NCT02881008)
Timeframe: 24 weeks

InterventionParticipants (Count of Participants)
Arm D7
Arm F6

In the Subset of Participants Undergoing Liver Transplantation, Time to Recurrence of Hepatitis B, Defined as 2 Consecutive Plasma HBV DNA Concentrations ≥ 400 Copies/mL or 2 Consecutive HBsAg(+) Results

(NCT00298363)
Timeframe: Baseline to Week 168

InterventionDays (Number)
Tenofovir DFNA
FTC/TDFNA
EntecavirNA
OverallNA

Median Change in MELD Score From Baseline at Week 144

MELD scores, used to assess prognosis and suitability for transplant, are calculated based on laboratory values only and can range from 6 to 40, with higher scores indicating greater disease severity. (NCT00298363)
Timeframe: Baseline to Week 144

Interventionunits on a scale (Median)
Tenofovir DF-2.0
FTC/TDF-1.5
Entecavir-2.0
Overall-2.0

Median Change in MELD Score From Baseline at Week 168

MELD scores, used to assess prognosis and suitability for transplant, are calculated based on laboratory values only and can range from 6 to 40, with higher scores indicating greater disease severity. (NCT00298363)
Timeframe: Baseline to Week 168

Interventionunits on a scale (Median)
Tenofovir DF-2.0
FTC/TDF-2.0
Entecavir-2.0
Overall-2.0

Median Change in MELD Score From Baseline at Week 96

MELD scores, used to assess prognosis and suitability for transplant, are calculated based on laboratory values only and can range from 6 to 40, with higher scores indicating greater disease severity. (NCT00298363)
Timeframe: Baseline to Week 96

Interventionunits on a scale (Median)
Tenofovir DF-2.0
FTC/TDF-3.0
Entecavir-3.0
Overall-2.0

Median Change in Model for End-Stage Liver Disease (MELD) Score From Baseline at Week 48

MELD scores, used to assess prognosis and suitability for transplant, are calculated based on laboratory values only and can range from 6 to 40, with higher scores indicating greater disease severity. (NCT00298363)
Timeframe: Baseline to Week 48

Interventionunits on a scale (Median)
Tenofovir DF-2.0
FTC/TDF-2.0
Entecavir-2.0
Overall-2.0

Median DAVG in Plasma HBV DNA Levels at 144 Weeks Relative to Baseline

Change from baseline was evaluated by subtracting baseline HBV DNA log_10 copies/mL from Week 144 HBV DNA log_10 copies/mL. DAVG is defined as the area of the trapezoid under the response-time curve divided by time to the last available evaluation of the patient minus the baseline value. (NCT00298363)
Timeframe: Baseline to 144 weeks

Interventionlog _10 copies/mL (Median)
Tenofovir DF-3.07
FTC/TDF-3.82
Entecavir-3.76
Overall-3.49

Median DAVG in Plasma HBV DNA Levels at 168 Weeks Relative to Baseline

Change from baseline was evaluated by subtracting baseline HBV DNA log_10 copies/mL from Week 168 HBV DNA log_10 copies/mL. DAVG is defined as the area of the trapezoid under the response-time curve divided by time to the last available evaluation of the patient minus the baseline value. (NCT00298363)
Timeframe: Baseline to 168 weeks

Interventionlog_10 copies/mL (Median)
Tenofovir DF-3.16
FTC/TDF-4.06
Entecavir-3.77
Overall-3.66

Median DAVG in Plasma HBV DNA Levels at 96 Weeks Relative to Baseline

Change from baseline was evaluated by subtracting baseline HBV DNA log_10 copies/mL from Week 96 HBV DNA log_10 copies/mL. DAVG is defined as the area of the trapezoid under the response-time curve divided by time to the last available evaluation of the patient minus the baseline value. (NCT00298363)
Timeframe: Baseline to 96 weeks

Interventionlog_10 copies/mL (Median)
Tenofovir DF-3.06
FTC/TDF-4.06
Entecavir-3.32
Overall-3.40

Median Time-averaged Change (DAVG) in Plasma Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Levels at 48 Weeks Relative to Baseline

Change from baseline was evaluated by subtracting baseline HBV DNA log_10 copies/mL from Week 48 HBV DNA log_10 copies/mL. DAVG is defined as the area of the trapezoid under the response-time curve divided by time to the last available evaluation of the patient minus the baseline value. (NCT00298363)
Timeframe: Baseline to 48 weeks

Interventionlog_10 copies/mL (Median)
Tenofovir DF-2.93
FTC/TDF-3.45
Entecavir-3.61
Overall-3.19

Percent Probability of a Confirmed Increase in Serum Creatinine of ≥ 0.5 mg/dL From Baseline or a Confirmed Serum Phosphorus Level < 2.0 mg/dL

Results are expressed as proportions of participants who experience a confirmed increase in serum creatinine of ≥ 0.5 mg/dL from baseline or a confirmed serum phosphorus level < 2.0 mg/dL using the KM method of estimation. (NCT00298363)
Timeframe: Baseline to Week 168

Interventionpercent probability (KM estimate) (Number)
Tenofovir DF15
FTC/TDF14
TDF or FTC/TDF14
Entecavir10

Percent Probability of Tolerability Failure

Tolerability failure was defined as permanent discontinuation of study drug due to a treatment-emergent adverse event (AE), including any subject who temporarily discontinued study drug due to an AE and did not restart. Results are expressed as proportions of participants who experience tolerability failure using the Kaplan-Meier (KM) method of estimation. (NCT00298363)
Timeframe: Baseline to Week 168

Interventionpercent probability (KM estimate) (Number)
Tenofovir DF18
FTC/TDF4
TDF or FTC/TDF11
Entecavir14

Percentage of Participants With a Decrease in CPT Score of ≥ 2 Points From Baseline at Week 144

CPT scores, widely used to grade the severity of cirrhosis and to determine the need for liver transplantation, are calculated based on a combination of laboratory values and clinical features. CPT scores can range from 5 to 15, with higher scores indicating a greater severity of disease. (NCT00298363)
Timeframe: Baseline to Week 144

Interventionpercentage of participants (Number)
Tenofovir DF25.9
FTC/TDF51.9
Entecavir45.5
Overall40.0

Percentage of Participants With a Decrease in CPT Score of ≥ 2 Points From Baseline at Week 168

CPT scores, widely used to grade the severity of cirrhosis and to determine the need for liver transplantation, are calculated based on a combination of laboratory values and clinical features. CPT scores can range from 5 to 15, with higher scores indicating a greater severity of disease. (NCT00298363)
Timeframe: Baseline to Week 168

Interventionpercentage of participants (Number)
Tenofovir DF24.0
FTC/TDF45.8
Entecavir45.5
Overall36.7

Percentage of Participants With a Decrease in CPT Score of ≥ 2 Points From Baseline at Week 48

CPT scores, widely used to grade the severity of cirrhosis and to determine the need for liver transplantation, are calculated based on a combination of laboratory values and clinical features. CPT scores can range from 5 to 15, with higher scores indicating a greater severity of disease. (NCT00298363)
Timeframe: Baseline to Week 48

Interventionpercentage of participants (Number)
Tenofovir DF25.9
FTC/TDF48.0
Entecavir41.7
Overall37.5

Percentage of Participants With a Decrease in CPT Score of ≥ 2 Points From Baseline at Week 96

CPT scores, widely used to grade the severity of cirrhosis and to determine the need for liver transplantation, are calculated based on a combination of laboratory values and clinical features. CPT scores can range from 5 to 15, with higher scores indicating a greater severity of disease. (NCT00298363)
Timeframe: Baseline to Week 96

Interventionpercentage of participants (Number)
Tenofovir DF23.1
FTC/TDF52.0
Entecavir50.0
Overall39.3

Percentage of Participants With an Increase in Child-Pugh Turcotte (CPT) Score of ≥ 2 Points at Weeks 48

CPT scores, widely used to grade the severity of cirrhosis and to determine the need for liver transplantation, are calculated based on a combination of laboratory values and clinical features. CPT scores can range from 5 to 15, with higher scores indicating a greater severity of disease. (NCT00298363)
Timeframe: Baseline to Week 48

Interventionpercentage of participants (Number)
Tenofovir DF0.0
FTC/TDF2.6
Entecavir0.0
Overall1.0

Percentage of Participants With an Increase in CPT Score of ≥ 2 Points at Week 144

CPT scores, widely used to grade the severity of cirrhosis and to determine the need for liver transplantation, are calculated based on a combination of laboratory values and clinical features. CPT scores can range from 5 to 15, with higher scores indicating a greater severity of disease. (NCT00298363)
Timeframe: Baseline to Week 144

Interventionpercentage of participants (Number)
Tenofovir DF0.0
FTC/TDF2.5
Entecavir0.0
Overall1.0

Percentage of Participants With an Increase in CPT Score of ≥ 2 Points at Week 168

CPT scores, widely used to grade the severity of cirrhosis and to determine the need for liver transplantation, are calculated based on a combination of laboratory values and clinical features. CPT scores can range from 5 to 15, with higher scores indicating a greater severity of disease. (NCT00298363)
Timeframe: Baseline to Week 168

Interventionpercentage of participants (Number)
Tenofovir DF2.4
FTC/TDF0.0
Entecavir0.0
Overall1.0

Percentage of Participants With an Increase in CPT Score of ≥ 2 Points at Week 96

CPT scores, widely used to grade the severity of cirrhosis and to determine the need for liver transplantation, are calculated based on a combination of laboratory values and clinical features. CPT scores can range from 5 to 15, with higher scores indicating a greater severity of disease. (NCT00298363)
Timeframe: Baseline to Week 96

Interventionpercentage of participants (Number)
Tenofovir DF0.0
FTC/TDF0.0
Entecavir0.0
Overall0.0

Percentage of Participants With Baseline ADV-R + LAM-R Mutations Achieving HBV DNA < 400 Copies/mL by 168 Weeks

ADV resistance mutation + LAM resistance mutations are defined as the presence of the rtA181T/V HBV gene mutation and/or the rtN236T HBV gene mutation, and the rtM204V/I HBV gene mutation with or without the rtL180M HBV gene mutation. (NCT00298363)
Timeframe: Baseline to Week 168

Interventionpercentage of participants (Number)
Tenofovir DF50

Percentage of Participants With Normalized Alanine Aminotransferase (ALT) (for Subjects With Elevated ALT at Baseline) at Week 48

Normalized ALT is defined as having a baseline ALT value > the upper limit of the normal range (ULN), and a decrease in ALT value to ≤ ULN at the given time point. (NCT00298363)
Timeframe: Baseline to Week 48

Interventionpercentage of participants (Number)
Tenofovir DF46.2
FTC/TDF64.0
Entecavir41.2
Overall51.5

Percentage of Participants With Normalized ALT (for Subjects With Elevated ALT at Baseline) at Week 144

Normalized ALT is defined as having a baseline ALT value > ULN, and a decrease in ALT value to ≤ ULN at the given time point. (NCT00298363)
Timeframe: Baseline to Week 144

Interventionpercentage of participants (Number)
Tenofovir DF34.6
FTC/TDF64.0
Entecavir37.5
Overall46.3

Percentage of Participants With Normalized ALT (for Subjects With Elevated ALT at Baseline) at Week 168

Normalized ALT is defined as having a baseline ALT value > ULN, and a decrease in ALT value to ≤ ULN at the given time point. (NCT00298363)
Timeframe: Baseline to Week 168

Interventionpercentage of participants (Number)
Tenofovir DF29.2
FTC/TDF60.0
Entecavir37.5
Overall43.1

Percentage of Participants With Normalized ALT (for Subjects With Elevated ALT at Baseline) at Week 96

Normalized ALT is defined as having a baseline ALT value > ULN, and a decrease in ALT value to ≤ ULN at the given time point. (NCT00298363)
Timeframe: Baseline to Week 96

Interventionpercentage of participants (Number)
Tenofovir DF50.0
FTC/TDF58.3
Entecavir31.3
Overall48.5

Percentage of Participants With Only Baseline Adefovir Dipivoxil Resistance (ADV-R) Mutations Achieving HBV DNA < 400 Copies/mL by 168 Weeks

ADV resistance mutations are defined as the presence of the rtA181T/V HBV gene mutation and/or the rtN236T HBV gene mutation. (NCT00298363)
Timeframe: Baseline to Week 168

Interventionpercentage of participants (Number)
Tenofovir DF100
FTC/TDF100

Percentage of Participants With Only Baseline Lamivudine-resistance (LAM-R) Mutations Achieving HBV DNA < 400 Copies/mL by 168 Weeks

LAM resistance mutations are defined as the presence of the rtM204V/I HBV gene mutation with or without the rtL180M HBV gene mutation. (NCT00298363)
Timeframe: Baseline to Week 168

Interventionpercentage of participants (Number)
Tenofovir DF100
FTC/TDF100
Entecavir100

Percentage of Participants With Plasma HBV DNA < 400 Copies/mL at Week 144

The percentage of participants with plasma HBV DNA < 400 copies/mL at Week 144 was summarized. (NCT00298363)
Timeframe: Week 144

Interventionpercentage of participants (Number)
Tenofovir DF50.0
FTC/TDF77.5
Entecavir52.4
Overall61.0

Percentage of Participants With Plasma HBV DNA < 400 Copies/mL at Week 168

The percentage of participants with plasma HBV DNA < 400 copies/mL at Week 168 was summarized. (NCT00298363)
Timeframe: Week 168

Interventionpercentage of participants (Number)
Tenofovir DF50.0
FTC/TDF75.7
Entecavir52.4
Overall60.0

Percentage of Participants With Plasma HBV DNA < 400 Copies/mL at Week 48

The percentage of participants with plasma HBV DNA < 400 copies/mL at Week 48 was summarized. (NCT00298363)
Timeframe: Week 48

Interventionpercentage of participants (Number)
Tenofovir DF70.5
FTC/TDF87.8
Entecavir72.7
Overall77.6

Percentage of Participants With Plasma HBV DNA < 400 Copies/mL at Week 96

The percentage of participants with plasma HBV DNA < 400 copies/mL at Week 96 was summarized. (NCT00298363)
Timeframe: Week 96

Interventionpercentage of participants (Number)
Tenofovir DF59.1
FTC/TDF79.5
Entecavir57.1
Overall66.3

Percentage of Participants With HBeAg Loss and HBeAg Seroconversion at Week 144 (for Participants Who Were HBeAg Positive at Baseline)

Loss of HBeAg was defined as change of detectable HBeAg from positive to negative. HBeAg seroconversion was defined as change of detectable antibody to HBeAg from negative to positive. (NCT00298363)
Timeframe: Baseline to Week 144

,,,
Interventionpercentage of participants (Number)
HBeAg LossHBeAg Seroconversion
Entecavir16.70.0
FTC/TDF33.313.3
Overall22.911.4
Tenofovir DF14.314.3

Percentage of Participants With HBeAg Loss and HBeAg Seroconversion at Week 168 (for Participants Who Were HBeAg Positive at Baseline)

Loss of HBeAg was defined as change of detectable HBeAg from positive to negative. HBeAg seroconversion was defined as change of detectable antibody to HBeAg from negative to positive. (NCT00298363)
Timeframe: Baseline to Week 168

,,,
Interventionpercentage of participants (Number)
HBeAg LossHBeAg Seroconversion
Entecavir16.70.0
FTC/TDF35.721.4
Overall27.318.2
Tenofovir DF23.123.1

Percentage of Participants With HBeAg Loss and HBeAg Seroconversion at Week 96 (for Participants Who Were HBeAg Positive at Baseline)

Loss of HBeAg was defined as change of detectable HBeAg from positive to negative. HBeAg seroconversion was defined as change of detectable antibody to HBeAg from negative to positive. (NCT00298363)
Timeframe: Baseline to Week 96

,,,
Interventionpercentage of participants (Number)
HBeAg LossHBeAg Seroconversion
Entecavir0.00.0
FTC/TDF33.313.3
Overall20.011.4
Tenofovir DF14.314.3

Percentage of Participants With HBsAg Loss and HBsAg Seroconversion at Week 144

Loss of HBsAg was defined as change of detectable HBsAg from positive to negative. HBsAg seroconversion was defined as change of detectable antibody to HBsAg from negative to positive. (NCT00298363)
Timeframe: Baseline to Week 144

,,,
Interventionpercentage of participants (Number)
HBsAg LossHBsAg Seroconversion
Entecavir0.00.0
FTC/TDF0.00.0
Overall0.00.0
Tenofovir DF0.00.0

Percentage of Participants With HBsAg Loss and HBsAg Seroconversion at Week 168

Loss of HBsAg was defined as change of detectable HBsAg from positive to negative. HBsAg seroconversion was defined as change of detectable antibody to HBsAg from negative to positive. (NCT00298363)
Timeframe: Baseline to Week 168

,,,
Interventionpercentage of participants (Number)
HBsAg LossHBsAg Seroconversion
Entecavir0.00.0
FTC/TDF0.00.0
Overall0.00.0
Tenofovir DF0.00.0

Percentage of Participants With HBsAg Loss and HBsAg Seroconversion at Week 96

Loss of HBsAg was defined as change of detectable HBsAg from positive to negative. HBsAg seroconversion was defined as change of detectable antibody to HBsAg from negative to positive. (NCT00298363)
Timeframe: Baseline to Week 96

,,,
Interventionpercentage of participants (Number)
HBsAg LossHBsAg Seroconversion
Entecavir0.00.0
FTC/TDF0.00.0
Overall0.00.0
Tenofovir DF0.00.0

Percentage of Participants With Hepatitis B Early Antigen (HBeAg) Loss and HBeAg Seroconversion at Week 48 (for Participants Who Were HBeAg Positive at Baseline)

Loss of HBeAg was defined as change of detectable HBeAg from positive to negative. HBeAg seroconversion was defined as change of detectable antibody to HBeAg from negative to positive. (NCT00298363)
Timeframe: Baseline to Week 48

,,,
Interventionpercentage of participants (Number)
HBeAg LossHBeAg Seroconversion
Entecavir0.00.0
FTC/TDF26.713.3
Overall19.413.9
Tenofovir DF21.421.4

Percentage of Participants With Hepatitis B Surface Antigen (HBsAg) Loss and HBsAg Seroconversion at Week 48

Loss of HBsAg was defined as change of detectable HBsAg from positive to negative. HBsAg seroconversion was defined as change of detectable antibody to HBsAg from negative to positive. (NCT00298363)
Timeframe: Baseline to Week 48

,,,
Interventionpercentage of participants (Number)
HBsAg LossHBsAg Seroconversion
Entecavir0.00.0
FTC/TDF0.00.0
Overall0.00.0
Tenofovir DF0.00.0

Biological Response

A biochemical response was defined as a decrease in serum ALT levels into the normal range (<41 U/L). (NCT00023309)
Timeframe: week 196 from randomization

,
Interventionparticipants (Number)
YesNo
Adefovir127
Lamivudine and Adefovir211

HBeAg Loss at Week 196

Loss of hepatitis B surface antigen (HBsAg) at week 196 (NCT00023309)
Timeframe: Week 196 from randomization

,
Interventionparticipants (Number)
YesNo
Adefovir59
Lamivudine and Adefovir134

Histological Response

A histological response was defined as a decrease in the HAI score by at least three points with no worsening of the Ishak fibrosis score. (NCT00023309)
Timeframe: week 196 from randomization

,
Interventionparticipants (Number)
YesNo
Adefovir55
Lamivudine and Adefovir153

Maintained Combined Response (Virological, Biochemical and Histological Response).

A maintained combined response was defined as a combination of a virological, biochemical and histological responses at weeks 48 and 192. A virological response was defined as a decrease in HBV DNA levels to undetectable by the Amplicor assay (<500 copies/mL). A biochemical response was defined as a decrease in serum ALT levels into the normal range (<41 U/L). A histological response was defined as a decrease in the HAI score by at least three points with no worsening of the Ishak fibrosis score. (NCT00023309)
Timeframe: 196 weeks from randomization

,
Interventionparticipants (Number)
YesNo
Adefovir613
Lamivudine and Adefovir157

Virological Response

A virological response was defined as a decrease in HBV DNA levels to undetectable by the Amplicor assay (<500 copies/mL). (NCT00023309)
Timeframe: Week 196 from randomization

,
Interventionparticipants (Number)
YesNo
Adefovir613
Lamivudine and Adefovir175

Change From Baseline in Z-score for Spine BMD at Week 144

Data were summarized by treatment and age group (grouped by baseline age for analysis). (NCT00734162)
Timeframe: Baseline; Week 144

Interventionz-score (Mean)
TDF 12-14 Years-0.20
TDF 15-17 Years-0.05
Placebo 12-14 Years-0.16
Placebo 15-17 Years-0.04
Total TDF 12-17 Years-0.08
Total Placebo 12-17 Years-0.06

Change From Baseline in Z-score for Spine BMD at Week 192

Data were summarized by treatment and age group (grouped by baseline age for analysis). (NCT00734162)
Timeframe: Baseline; Week 192

Interventionz-score (Mean)
TDF 12-14 Years-0.24
TDF 15-17 Years0.08
Placebo 12-14 Years-0.26
Placebo 15-17 Years-0.05
Total TDF 12-17 Years0.02
Total Placebo 12-17 Years-0.10

Change From Baseline in Z-score for Spine BMD at Week 48

To assess any effect of treatment on growth, Z-scores were used to express the deviation from a reference population for lumbar spine BMD. A Z-score of 0 indicated that a subject was typical of the population for their age, ethnicity, and gender. A negative Z-score indicated that the subject's recorded value was lower than typical for their age, ethnicity, and gender. A positive Z-score indicates that the subject's recorded value was higher than typical for their age, ethnicity, and gender. Data were summarized by treatment and age group (grouped by baseline age for analysis). (NCT00734162)
Timeframe: Baseline; Week 48

Interventionz-score (Mean)
TDF 12-14 Years0.02
TDF 15-17 Years-0.10
Placebo 12-14 Years0.04
Placebo 15-17 Years0.05
Total TDF 12-17 Years-0.08
Total Placebo 12-17 Years0.05

Change From Baseline in Z-score for Spine BMD at Week 72

Data were summarized by treatment and age group (grouped by baseline age for analysis). (NCT00734162)
Timeframe: Baseline; Week 72

Interventionz-score (Mean)
TDF 12-14 Years-0.10
TDF 15-17 Years-0.05
Placebo 12-14 Years0.09
Placebo 15-17 Years0.10
Total TDF 12-17 Years-0.06
Total Placebo 12-17 Years0.10

Change From Baseline in Z-score for Spine BMD at Week 96

Data were summarized by treatment and age group (grouped by baseline age for analysis). (NCT00734162)
Timeframe: Baseline; Week 96

Interventionz-score (Mean)
TDF 12-14 Years-0.19
TDF 15-17 Years-0.07
Placebo 12-14 Years-0.02
Placebo 15-17 Years-0.13
Total TDF 12-17 Years-0.10
Total Placebo 12-17 Years-0.11

Change From Baseline in Z-score for Whole Body BMD at Week 144

Data were summarized by treatment and age group (grouped by baseline age for analysis). (NCT00734162)
Timeframe: Baseline; Week 144

Interventionz-score (Mean)
TDF 12-14 Years-0.27
TDF 15-17 Years-0.21
Placebo 12-14 Years-0.06
Placebo 15-17 Years-0.16
Total TDF 12-17 Years-0.22
Total Placebo 12-17 Years-0.14

Change From Baseline in Z-score for Whole Body BMD at Week 192

Data were summarized by treatment and age group (grouped by baseline age for analysis). (NCT00734162)
Timeframe: Baseline; Week 192

Interventionz-score (Mean)
TDF 12-14 Years-0.34
TDF 15-17 Years-0.11
Placebo 12-14 Years-0.21
Placebo 15-17 Years-0.19
Total TDF 12-17 Years-0.16
Total Placebo 12-17 Years-0.19

Change From Baseline in Z-score for Whole Body BMD at Week 48

Data were summarized by treatment and age group (grouped by baseline age for analysis). (NCT00734162)
Timeframe: Baseline; Week 48

Interventionz-score (Mean)
TDF 12-14 Years0.02
TDF 15-17 Years-0.15
Placebo 12-14 Years0.10
Placebo 15-17 Years0.04
Total TDF 12-17 Years-0.12
Total Placebo 12-17 Years0.05

Change From Baseline in Z-score for Whole Body BMD at Week 72

Data were summarized by treatment and age group (grouped by baseline age for analysis). (NCT00734162)
Timeframe: Baseline; Week 72

Interventionz-score (Mean)
TDF 12-14 Years0.02
TDF 15-17 Years-0.19
Placebo 12-14 Years0.20
Placebo 15-17 Years0.06
Total TDF 12-17 Years-0.16
Total Placebo 12-17 Years0.09

Change From Baseline in Z-score for Whole Body BMD at Week 96

Data were summarized by treatment and age group (grouped by baseline age for analysis). (NCT00734162)
Timeframe: Baseline; Week 96

Interventionz-score (Mean)
TDF 12-14 Years-0.12
TDF 15-17 Years-0.19
Placebo 12-14 Years0.09
Placebo 15-17 Years-0.06
Total TDF 12-17 Years-0.18
Total Placebo 12-17 Years-0.03

Percent Change From Baseline in Spine BMD at Week 144

Data were summarized by treatment and age group (grouped by baseline age for analysis). (NCT00734162)
Timeframe: Baseline; Week 144

Interventionpercentage change (Mean)
TDF 12-14 Years19.224
TDF 15-17 Years5.289
Placebo 12-14 Years21.346
Placebo 15-17 Years6.144
Total TDF 12-17 Years8.133
Total Placebo 12-17 Years9.311

Percent Change From Baseline in Spine BMD at Week 192

Data were summarized by treatment and age group (grouped by baseline age for analysis). (NCT00734162)
Timeframe: Baseline; Week 192

Interventionpercentage change (Mean)
TDF 12-14 Years23.933
TDF 15-17 Years6.673
Placebo 12-14 Years25.036
Placebo 15-17 Years6.867
Total TDF 12-17 Years10.050
Total Placebo 12-17 Years11.212

Percent Change From Baseline in Spine BMD at Week 72

Data were summarized by treatment and age group (grouped by baseline age for analysis). (NCT00734162)
Timeframe: Baseline; Week 72

Interventionpercentage change (Mean)
TDF 12-14 Years11.516
TDF 15-17 Years3.589
Placebo 12-14 Years14.131
Placebo 15-17 Years6.117
Total TDF 12-17 Years5.144
Total Placebo 12-17 Years8.080

Percent Change From Baseline in Spine BMD at Week 96

Data were summarized by treatment and age group (grouped by baseline age for analysis). (NCT00734162)
Timeframe: Baseline; Week 96

Interventionpercentage change (Mean)
TDF 12-14 Years13.811
TDF 15-17 Years4.196
Placebo 12-14 Years16.687
Placebo 15-17 Years4.272
Total TDF 12-17 Years6.119
Total Placebo 12-17 Years7.003

Percent Change From Baseline in Spine Bone Mineral Density (BMD) at Week 48

Data were summarized by treatment and age group (grouped by baseline age for analysis). (NCT00734162)
Timeframe: Baseline; Week 48

Interventionpercentage change (Mean)
TDF 12-14 Years9.234
TDF 15-17 Years2.114
Placebo 12-14 Years9.038
Placebo 15-17 Years4.435
Total TDF 12-17 Years3.510
Total Placebo 12-17 Years5.562

Percent Change From Baseline in Whole Body BMD at Week 144

Data were summarized by treatment and age group (grouped by baseline age for analysis). (NCT00734162)
Timeframe: Baseline; Week 144

Interventionpercentage change (Mean)
TDF 12-14 Years10.940
TDF 15-17 Years3.529
Placebo 12-14 Years12.638
Placebo 15-17 Years4.730
Total TDF 12-17 Years4.949
Total Placebo 12-17 Years6.505

Percent Change From Baseline in Whole Body BMD at Week 192

Data were summarized by treatment and age group (grouped by baseline age for analysis). (NCT00734162)
Timeframe: Baseline; Week 192

Interventionpercentage change (Mean)
TDF 12-14 Years13.923
TDF 15-17 Years4.295
Placebo 12-14 Years14.797
Placebo 15-17 Years4.549
Total TDF 12-17 Years6.086
Total Placebo 12-17 Years7.223

Percent Change From Baseline in Whole Body BMD at Week 48

Data were summarized by treatment and age group (grouped by baseline age for analysis). (NCT00734162)
Timeframe: Baseline; Week 48

Interventionpercentage change (Mean)
TDF 12-14 Years5.123
TDF 15-17 Years1.339
Placebo 12-14 Years5.470
Placebo 15-17 Years3.236
Total TDF 12-17 Years2.048
Total Placebo 12-17 Years3.817

Percent Change From Baseline in Whole Body BMD at Week 72

Data were summarized by treatment and age group (grouped by baseline age for analysis). (NCT00734162)
Timeframe: Baseline; Week 72

Interventionpercentage change (Mean)
TDF 12-14 Years7.282
TDF 15-17 Years2.141
Placebo 12-14 Years8.480
Placebo 15-17 Years4.335
Total TDF 12-17 Years3.067
Total Placebo 12-17 Years5.391

Percent Change From Baseline in Whole Body BMD at Week 96

Data were summarized by treatment and age group (grouped by baseline age for analysis). (NCT00734162)
Timeframe: Baseline; Week 96

Interventionpercentage change (Mean)
TDF 12-14 Years8.034
TDF 15-17 Years3.023
Placebo 12-14 Years10.056
Placebo 15-17 Years4.291
Total TDF 12-17 Years3.943
Total Placebo 12-17 Years5.675

Percentage of Participants With at Least a 6% Decrease From Baseline in Bone Mineral Density (BMD) of the Spine at Week 72

"Data were summarized by treatment and age group (grouped by baseline age for analysis).~In contrast with what was previously reported in the interim results posting, 1 participant met the primary safety endpoint of at least a 6% decrease from baseline in spine BMD at Week 72, based on the final BMD data analysis. The apparent discrepancy was due to the correction factor applied to the subject-specific BMD calculations performed at the time of the Interim Week 72 clinical study report that could not take into account the actual Week 72 phantom data (ie, calibration test used in longitudinal clinical trials to monitor and adjust for shifts in the dual-energy x-ray absorptiometry (DXA) scanner calibration over time), which were not provided by the site at that time. The correction factor applied to the final analysis has been properly based on all phantom data through the end of Week 72, as well as through the end of Week 192." (NCT00734162)
Timeframe: Baseline to Week 72

Interventionpercentage of participants (Number)
TDF 12-14 Years0
TDF 15-17 Years2.4
Placebo 12-14 Years0
Placebo 15-17 Years0
Total TDF 12-17 Years1.9
Total Placebo 12-17 Years0

Percentage of Participants With HBV DNA < 400 Copies/mL at Week 72

"The percentage of participants with HBV DNA < 400 copies/mL at Week 72 was summarized by treatment and age group (grouped by baseline age for analysis), using the missing = failure (M = F) analysis with the double-blind efficacy evaluation (DBEE) algorithm.~In the M = F analysis method, all missing data were considered as failure to meet the outcome measure threshold. This method was combined with the DBEE algorithm, which included all available data for the double-blind period, and any data for the open-label period were not included; data generated during treatment-free follow-up from subjects who achieved HBsAg loss and entered treatment-free follow-up during double-blind treatment period were included." (NCT00734162)
Timeframe: Week 72

Interventionpercentage of participants (Number)
TDF 12-14 Years90.0
TDF 15-17 Years88.1
Placebo 12-14 Years0
Placebo 15-17 Years0
Total TDF 12-17 Years88.5
Total Placebo 12-17 Years0

Number of Participants With Changes in Drug-Resistant Mutations During the Study

The number of participants with changes in drug-resistant mutations during the study was summarized. (NCT00734162)
Timeframe: Baseline through Week 192

,
Interventionparticipants (Number)
New TDF Drug-Resistant MutationsEnrichment of TDF Drug-Resistant Mutations
Total Placebo 12-17 Years00
Total TDF 12-17 Years00

Percentage of Participants Who Were HBeAg-Positive at Baseline and Who Had HBeAg Loss at Weeks 48, 72, 96, 144, and 192

Data were summarized by treatment and age group (grouped by baseline age for analysis) using the missing = failure method. (NCT00734162)
Timeframe: Baseline; Weeks 48, 72, 96, 144, and 192

,,,,,
Interventionpercentage of participants (Number)
Week 48Week 72Week 96Week 144Week 192
Placebo 12-14 Years7.723.138.553.853.8
Placebo 15-17 Years8.611.428.634.337.1
TDF 12-14 Years11.111.144.444.433.3
TDF 15-17 Years17.923.130.838.543.6
Total Placebo 12-17 Years8.314.631.339.641.7
Total TDF 12-17 Years16.720.833.339.641.7

Percentage of Participants Who Were HBeAg-Positive at Baseline and Who Had HBeAg Seroconversion at Weeks 48, 72, 96, 144, and 192

Data were summarized by treatment and age group (grouped by baseline age for analysis) using the missing = failure method. (NCT00734162)
Timeframe: Baseline; Weeks 48, 72, 96, 144, and 192

,,,,,
Interventionpercentage of participants (Number)
Week 48Week 72Week 96Week 144Week 192
Placebo 12-14 Years7.723.138.553.853.8
Placebo 15-17 Years8.611.425.734.337.1
TDF 12-14 Years11.111.144.433.333.3
TDF 15-17 Years15.423.130.838.538.5
Total Placebo 12-17 Years8.314.629.239.641.7
Total TDF 12-17 Years14.620.833.337.537.5

Percentage of Participants Who Were HBeAg-Positive at Baseline Who Had HBV DNA < 400 Copies/mL, Normal ALT, and HBeAg Loss/Seroconversion at Weeks 48, 72, 96, 144, and 192

Data were summarized by treatment and age group (grouped by baseline age for analysis) using the missing = failure method. (NCT00734162)
Timeframe: Baseline; Weeks 48, 72, 96, 144, and 192

,,,,,
Interventionpercentage of participants (Number)
Week 48Week 72Week 96Week 144Week 192
Placebo 12-14 Years0030.846.246.2
Placebo 15-17 Years0022.925.725.7
TDF 12-14 Years11.111.144.422.233.3
TDF 15-17 Years12.815.428.230.828.2
Total Placebo 12-17 Years0025.031.331.3
Total TDF 12-17 Years12.514.631.329.229.2

Percentage of Participants Who Were HBeAg-Positive With Abnormal ALT at Baseline Who Had HBV DNA < 400 Copies/mL, Normalized ALT, and HBeAg Loss/Seroconversion at Weeks 48, 72, 96, 144, and 192

Data were summarized by treatment and age group (grouped by baseline age for analysis) using the missing = failure method. (NCT00734162)
Timeframe: Baseline; Weeks 48, 72, 96, 144, and 192

,,,,,
Interventionpercentage of participants (Number)
Week 48Week 72Week 96Week 144Week 192
Placebo 12-14 Years0033.355.655.6
Placebo 15-17 Years0024.227.327.3
TDF 12-14 Years16.716.750.033.350.0
TDF 15-17 Years18.522.233.329.629.6
Total Placebo 12-17 Years0026.233.333.3
Total TDF 12-17 Years18.221.236.430.333.3

Percentage of Participants With Abnormal ALT at Baseline Who Had HBV DNA < 400 Copies/mL and Normalized ALT at Weeks 48, 72, 96, 144, and 192

Data were summarized by treatment and age group (grouped by baseline age for analysis) using the missing = failure method. (NCT00734162)
Timeframe: Baseline; Weeks 48, 72, 96, 144, and 192

,,,,,
Interventionpercentage of participants (Number)
Week 48Week 72Week 96Week 144Week 192
Placebo 12-14 Years0055.666.777.8
Placebo 15-17 Years0054.569.757.6
TDF 12-14 Years85.785.785.757.185.7
TDF 15-17 Years71.471.478.671.467.9
Total Placebo 12-17 Years0054.869.061.9
Total TDF 12-17 Years74.374.380.068.671.4

Percentage of Participants With Abnormal ALT at Baseline Who Had Normalized ALT at Weeks 48, 72, 96, 144, and 192

Data were summarized by treatment and age group (grouped by baseline age for analysis) using the missing = failure method. (NCT00734162)
Timeframe: Baseline; Weeks 48, 72, 96, 144, and 192

,,,,,
Interventionpercentage of participants (Number)
Week 48Week 72Week 96Week 144Week 192
Placebo 12-14 Years11.122.266.766.777.8
Placebo 15-17 Years21.233.363.672.769.7
TDF 12-14 Years85.785.785.757.185.7
TDF 15-17 Years71.471.478.671.475.0
Total Placebo 12-17 Years19.031.064.371.471.4
Total TDF 12-17 Years74.374.380.068.677.1

Percentage of Participants With at Least a 6% Decrease From Baseline in Spine BMD at Weeks 48, 96, 144, and 192

The percentage of participants reported is the cumulative incidence from baseline to the respective time point. Data were summarized by treatment and age group (grouped by baseline age for analysis). (NCT00734162)
Timeframe: Baseline; Weeks 48, 96, 144, and 192

,,,,,
Interventionpercentage of participants (Number)
Week 48Week 96Week 144Week 192
Placebo 12-14 Years0000
Placebo 15-17 Years0004.9
TDF 12-14 Years0000
TDF 15-17 Years02.42.44.8
Total Placebo 12-17 Years0003.7
Total TDF 12-17 Years01.91.93.8

Percentage of Participants With at Least a 6% Decrease From Baseline in Whole Body BMD at Weeks 48, 72, 96, 144, and 192

The percentage of participants reported is the cumulative incidence from baseline to the respective time point. Data were summarized by treatment and age group (grouped by baseline age for analysis). (NCT00734162)
Timeframe: Baseline; Weeks 48, 72, 96, 144, and 192

,,,,,
Interventionpercentage of participants (Number)
Week 48Week 72Week 96Week 144Week 192
Placebo 12-14 Years00000
Placebo 15-17 Years0002.42.4
TDF 12-14 Years00000
TDF 15-17 Years00000
Total Placebo 12-17 Years0001.91.9
Total TDF 12-17 Years00000

Percentage of Participants With HBsAg Seroconversion at Weeks 48, 72, 96, 144, and 192

HBsAg seroconversion was defined as change of detectable antibody to HBsAg from negative to positive. Data were summarized by treatment and age group (grouped by baseline age for analysis), using the M = F. (NCT00734162)
Timeframe: Baseline; Weeks 48, 72, 96, 144, and 192

,,,,,
Interventionpercentage of participants (Number)
Week 48Week 72Week 96Week 144Week 192
Placebo 12-14 Years00000
Placebo 15-17 Years00000
TDF 12-14 Years00000
TDF 15-17 Years02.42.42.40
Total Placebo 12-17 Years00000
Total TDF 12-17 Years01.91.91.90

Percentage of Participants With HBV DNA < 169 Copies/mL at Weeks 48, 72, 96, 144, and 192

Data were summarized by treatment and age group (grouped by baseline age for analysis) using the missing = failure method. (NCT00734162)
Timeframe: Weeks 48, 72, 96, 144, and 192

,,,,,
Interventionpercentage of participants (Number)
Week 48Week 72Week 96Week 144Week 192
Placebo 12-14 Years0053.869.276.9
Placebo 15-17 Years0063.482.973.2
TDF 12-14 Years80.090.090.090.090.0
TDF 15-17 Years81.083.388.188.183.3
Total Placebo 12-17 Years0061.179.674.1
Total TDF 12-17 Years80.884.688.588.584.6

Percentage of Participants With HBV DNA < 400 Copies/mL and Normal ALT at Weeks 48, 72, 96, 144, and 192

Data were summarized by treatment and age group (grouped by baseline age for analysis) using the missing = failure method. (NCT00734162)
Timeframe: Weeks 48, 72, 96, 144, and 192

,,,,,
Interventionpercentage of participants (Number)
Week 48Week 72Week 96Week 144Week 192
Placebo 12-14 Years0046.253.869.2
Placebo 15-17 Years0051.268.363.4
TDF 12-14 Years70.080.080.060.080.0
TDF 15-17 Years69.069.073.869.064.3
Total Placebo 12-17 Years0050.064.864.8
Total TDF 12-17 Years69.271.275.067.367.3

Percentage of Participants With HBV DNA < 400 Copies/mL at Weeks 48, 96, 144, and 192

Data were summarized by treatment and age group (grouped by baseline age for analysis) using the missing = failure method. (NCT00734162)
Timeframe: Weeks 48, 96, 144, and 192

,,,,,
Interventionpercentage of participants (Number)
Week 48Week 96Week 144Week 192
Placebo 12-14 Years053.869.276.9
Placebo 15-17 Years068.385.473.2
TDF 12-14 Years90.090.0100.090.0
TDF 15-17 Years85.788.190.585.7
Total Placebo 12-17 Years064.881.574.1
Total TDF 12-17 Years86.588.592.386.5

Percentage of Participants With Hepatitis B Surface Antigen (HBsAg) Loss at Weeks 48, 72, 96, 144, and 192

Data were summarized by treatment and age group (grouped by baseline age for analysis), using the M = F. (NCT00734162)
Timeframe: Baseline; Weeks 48, 72, 96, 144, and 192

,,,,,
Interventionpercentage of participants (Number)
Week 48Week 72Week 96Week 144Week 192
Placebo 12-14 Years00000
Placebo 15-17 Years00000
TDF 12-14 Years00000
TDF 15-17 Years02.42.42.42.4
Total Placebo 12-17 Years00000
Total TDF 12-17 Years01.91.91.91.9

Percentage of Participants With Normal Alanine Aminotransferase (ALT) at Weeks 48, 72, 96, 144, and 192

Data were summarized by treatment and age group (grouped by baseline age for analysis) using the missing = failure method. (NCT00734162)
Timeframe: Weeks 48, 72, 96, 144, and 192

,,,,,
Interventionpercentage of participants (Number)
Week 48Week 72Week 96Week 144Week 192
Placebo 12-14 Years30.830.869.269.284.6
Placebo 15-17 Years26.841.565.975.675.6
TDF 12-14 Years70.080.080.060.080.0
TDF 15-17 Years76.276.276.271.471.4
Total Placebo 12-17 Years27.838.966.774.177.8
Total TDF 12-17 Years75.076.976.969.273.1

Percentage of Participants Who Achieved Hepatitis B Virus DNA (HBV DNA) Levels <50 IU/mL by Polymerase Chain Reaction (PCR) at Week 96

HBV DNA levels <50 IU/mL=approximately 300 copies/mL. Analyses of binary efficacy endpoint during on-treatment period focused on participants who received treatment and used the analysis of noncompleter=failure (NC=F). All participants who received treatment were included in the denominator, and participants with missing measurements were counted as nonresponders for the specific endpoints. (NCT00410072)
Timeframe: At Week 96

InterventionPercentage of participants (Number)
ETV 0.5 mg76.4
ETV 0.5 mg +TDF 300 mg83.2

Mean Log 10 HBV DNA at Weeks 48 and 96

HBV DNA was analyzed by PCR, using the Roche COBAS®TaqMan - HPS assay. Reduction in Log 10 HBV count=reduced viral load. (NCT00410072)
Timeframe: Baseline, Weeks 48 and 96

,
Interventionlog10 copies/mL (Mean)
Baseline (n=182, 197)Overall at Week 48 (n=176, 180)Overall at Week 96 (n=165, 170)
ETV 0.5 mg7.481.881.68
ETV 0.5 mg +TDF 300 mg7.531.561.51

Number of Participants With Adverse Events, Serious Adverse Events, and Discontinuations From Study Drug Due to Adverse Events or Laboratory Abnormalities

AE: any new untoward medical occurrence/worsening of pre-existing medical condition, whether or not related to study drug. SAE: any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was an overdose. Participants who discontinued the study due to any AEs were recorded. (NCT00410072)
Timeframe: From enrollment through Week 100 + 24-week follow-up

,
InterventionParticipants (Number)
DeathsSAEsAdverse eventsDiscontinuations due to AEsRelated AEs
ETV 0.5 mg012132239
ETV 0.5 mg +TDF 300 mg314131549

Number of Participants With HBV DNA in Relevant Categories at Weeks 48 and 96

Using the Roche COBAS TaqMan - HPS assay. Lower limit of Quantitation (LOQ) is the level above which quantitative results may be obtained with a specified degree of confidence. The LOQ is mathematically defined as equal to 10 times the standard deviation of the results for a series of replicates used to determine a justifiable limit of detection. Limits of quantitation are matrix-, method-, and analyte-specific. (NCT00410072)
Timeframe: At Weeks 48 and 96

,
InterventionPercentage of participants (Number)
< LOQ (29 IU/mL) at Week 48LOQ - <50 IU/mL at Week 4850 - <172 IU/mL at Week 48172 - <1720 IU/mL at Week 481720 - <17,200 IU/mL at Week 4817,200 - <172,000 IU/mL at Week 48≥172,000 IU/mL at Week 48Missing at Week 48< LOQ (29 IU/mL) at Week 96LOQ - <50 IU/mL at Week 9650 - <172 IU/mL at Week 96172 - <1720 IU/mL at Week 961720 - <17,200 IU/mL at Week 9617,200 - <172,000 IU/mL at Week 96≥172,000 IU/mL at Week 96Missing at Week 96
ETV 0.5 mg67.62.77.17.79.31.60.53.374.71.63.35.54.90.509.3
ETV 0.5 mg +TDF 300 mg74.65.66.64.10.5008.681.71.51.01.5000.513.7

Number of Participants With HBV Resistance at Week 96

ETVr=entecavir resistance; TFDr=tenofovir resistance. HBV polymerase using the Trugene® HBV Genotyping Kit. HBV resistance: genotyping of HBV polymerase will be performed on stored viral samples at any timepoint when considered appropriate based on virologic response, including any specimen with detectable HBV DNA. When appropriate, phenotyping will also be used. (NCT00410072)
Timeframe: Week 96

,
InterventionParticipants (Number)
ETVrTDFr
ETV 0.5 mg00
ETV 0.5 mg +TDF 300 mg00

Number of Participants With HBV Resistance Through Week 48

ETVr=entecavir resistance; TDFr=tenofovir resistance. HBV polymerase using the Trugene® HBV Genotyping Kit. HBV resistance: genotyping of HBV polymerase will be performed on stored viral samples at any timepoint when considered appropriate based on virologic response, including any specimen with detectable HBV DNA. When appropriate, phenotyping will also be used. (NCT00410072)
Timeframe: Week 48

,
InterventionParticipants (Number)
ETVrTDFr
ETV 0.5 mg00
ETV 0.5 mg +TDF 300 mg00

Number of Participants With Virologic Breakthrough at Week 48

ETVr=entecavir resistance; TFDr=tenofovir resistance. Virologic breakthrough= confirmed >= 1 log10 increase in HBV DNA from the on-treatment nadir (NCT00410072)
Timeframe: Week 48

,
InterventionParticipants (Number)
ETVrTDFr
ETV 0.5 mg00
ETV 0.5 mg +TDF 300 mg00

Number of Participants With Virologic Breakthrough at Week 96

ETVr=entecavir resistance; TFDr=tenofovir resistance. Virologic breakthrough=confirmed >=1 log10 increase in HBV DNA from moving nadir (NCT00410072)
Timeframe: Week 96

,
InterventionParticipants (Number)
ETVrTDFr
ETV 0.5 mg00
ETV 0.5 mg +TDF 300 mg00

Percentage of Participants Who Achieved HBV DNA Levels <50 IU/mL by PCR at Week 48 and Week 96 by Hepatitis B e Antigen (HBeAg) Status

HBV DNA levels <50 IU/mL=approximately 300 copies/mL. Analyses of binary efficacy endpoint during on-treatment period focused on participants who received treatment and used the analysis of noncompleter=failure (NC=F). All participants who received treatment were included in the denominator, and participants with missing measurements were counted as nonresponders for the specific endpoints. (NCT00410072)
Timeframe: At Weeks 48 and 96

,
InterventionPercentage of participants (Number)
HBeAg+ at Week 48 (n=126, n=138)HBeAg- at Week 48 (n=56, n=59)HBeAg+ at Week 96 (n=126, n=138)HBeAg- at Week 96 (n=56, n=59)
ETV 0.5 mg61.191.169.891.1
ETV 0.5 mg +TDF 300 mg74.693.280.489.8

Percentage of Participants Who Achieved HBV DNA Levels

LOD=Lower limit of detection. LOD) LOD=10 IU/mL, or approximately 58 copies/mL. LOD is the lowest concentration level that can be determined to be statistically different from a blank (99% confidence). The LOD is typically determined to be in the region where the signal to noise ratio is greater than 5. Limits of detection are matrix-, method-, and analyte-specific.Analyses of binary efficacy endpoint during on-treatment period focused on participants who received treatment and used the analysis of noncompleter=failure (NC=F). All participants who received treatment were included in the denominator, and participants with missing measurements were counted as nonresponders for the specific endpoints. (NCT00410072)
Timeframe: At Weeks 48 and 96

,
InterventionPercentage of participants (Number)
Overall at Week 48Overall at Week 96
ETV 0.5 mg58.268.1
ETV 0.5 mg +TDF 300 mg66.076.6

Percentage of Participants Who Achieved HBV DNA Levels

LOQ=lower limit of quantitation. LOQ=29 IU/mL, or approximately 169 copies/mL. LOQ is the level above which quantitative results may be obtained with a specified degree of confidence. The LOQ is mathematically defined as equal to 10 times the standard deviation of the results for a series of replicates used to determine a justifiable limit of detection. Limits of quantitation are matrix-, method-, and analyte-specific.Analyses of binary efficacy endpoint during on-treatment period focused on participants who received treatment and used the analysis of noncompleter=failure (NC=F). All participants who received treatment were included in the denominator, and participants with missing measurements were counted as nonresponders for the specific endpoints. (NCT00410072)
Timeframe: At Weeks 48 and 96

,
InterventionPercentage of participants (Number)
Overall at Week 48Overall at Week 96
ETV 0.5 mg67.674.7
ETV 0.5 mg +TDF 300 mg74.681.7

Percentage of Participants With Alanine Aminotransferase (ALT) Normalization at Weeks 48 and 96

ALT normalization= ≤1*upper limit of normal (ULN). Analyses of binary efficacy endpoint during on-treatment period focused on participants who received treatment and used the analysis of noncompleter=failure (NC=F). All participants who received treatment were included in the denominator, and participants with missing measurements were counted as nonresponders for the specific endpoints. (NCT00410072)
Timeframe: At Weeks 48 and 96

,
InterventionPercentage of participants (Number)
Overall at Week 48Overall at Week 96
ETV 0.5 mg83.081.9
ETV 0.5 mg +TDF 300 mg72.668.0

Percentage of Participants With HBeAg Seroconversion [( at Weeks 48 and 96

HBeAg seroconversion=HBeAg loss and presence of hepatitis B e antibody (HBeAb). HBeAg is a hepatitis B viral protein and is an indicator of active viral replication. (NCT00410072)
Timeframe: At Weeks 48 and 96

,
InterventionPercentage of participants (Number)
Week 48Week 96
ETV 0.5 mg22.232.5
ETV 0.5 mg +TDF 300 mg18.121.7

Percentage of Participants With HBsAg Seroconversion at Weeks 48 and 96

HBsAg = a part of the hepatitis B virus that, when in the blood, is an early marker of infection. (NCT00410072)
Timeframe: At Weeks 48 and 96

,
InterventionPercentage of participants (Number)
Week 48Week 96
ETV 0.5 mg0.81.6
ETV 0.5 mg +TDF 300 mg0.72.9

Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss at Weeks 48 and 96

HBeAg is a hepatitis B viral protein and is an indicator of active viral replication. Analyses of binary efficacy endpoint during on-treatment period focused on participants who received treatment and used the analysis of noncompleter=failure (NC=F). All participants who received treatment were included in the denominator, and participants with missing measurements were counted as nonresponders for the specific endpoints. (NCT00410072)
Timeframe: At Weeks 48 and 96

,
InterventionPercentage of participants (Number)
Week 48Week 96
ETV 0.5 mg25.43.97
ETV 0.5 mg +TDF 300 mg19.629.7

Percentage of Participants With Hepatitis B Surface Antigen (HBsAg) Loss at Weeks 48 and 96

HBsAg = A part of the hepatitis B virus. When found in the blood, HBsAg is an early marker of infection. Analyses of binary efficacy endpoint during on-treatment period focused on participants who received treatment and used the analysis of noncompleter=failure (NC=F). All participants who received treatment were included in the denominator, and participants with missing measurements were counted as nonresponders for the specific endpoints. (NCT00410072)
Timeframe: At Weeks 48 and 96

,
InterventionPercent of participants (Number)
Week 48Week 96
ETV 0.5 mg3.24.0
ETV 0.5 mg +TDF 300 mg1.45.1

Number of Participants With HBV DNA <1000 IU/ml at Week 192

Number of participants whose serum HBV DNA level was <1000 IU/ml at Week 192 (NCT00524173)
Timeframe: At Week 192

InterventionParticipants (Count of Participants)
Tenofovir Only12
Tenofovir & Emtricitabine12

Number of Participants With Loss of HBsAg

The number of participants whose serum hepatitis B surface antigen was no longer detectable. (NCT00524173)
Timeframe: 192 weeks

InterventionParticipants (Count of Participants)
Tenofovir Only1
Tenofovir & Emtricitabine0

Number of Participants With Normalized Alanine Aminotransferase (ALT)

Number of participants whose serum ALT levels were measured within normal limits. (NCT00524173)
Timeframe: 192 weeks

InterventionParticipants (Count of Participants)
Tenofovir Only8
Tenofovir & Emtricitabine13

Number of Subjects With Hepatitis b Virus (HBV) DNA <1000 IU/ml at Week 48

Number of subjects whose serum HBV DNA level was <1000 IU/ml at Week 48 (NCT00524173)
Timeframe: At Week 48

InterventionParticipants (Count of Participants)
Tenofovir Only11
Tenofovir & Emtricitabine13

Hepatitis B Virus (HBV) DNA

"HBV DNA carries the genetic blueprint of the virus. How many HBV DNA particles or copies are found in the blood indicates how rapidly the virus is reproducing in the liver." (NCT00662545)
Timeframe: week 24

Interventionlog 10 IU/ml (Median)
Entecavir Intensification2.4
Standard of Care0.8

HIV RNA < 75 Copies/ml

(NCT00662545)
Timeframe: entry, week 12, and week 24

Interventionparticipants (Number)
Entecavir Intensification5
Standard of Care5

Incidence of ALT Flares

ALT flare: sudden increase in blood level of alanine transaminase (ALT) (NCT00662545)
Timeframe: every 4 weeks for 24 weeks

Interventionparticipants (Number)
Entecavir Intensification0
Standard of Care0

Incidence of New Hepatic Decompensation( Ascites, Variceal Hemorrhage, Encephalopathy)

(NCT00662545)
Timeframe: every 4 weeks for 24 weeks

Interventionparticipants (Number)
Entecavir Intensification0
Standard of Care0

Incidence of Permanent Discontinuation Due to Toxicity

(NCT00662545)
Timeframe: 24 weeks

Interventionparticipants (Number)
Entecavir Intensification0
Standard of Care0

Reviews

226 reviews available for adenine and Hepatitis B, Chronic

ArticleYear
Economic Evaluation of Oral Nucleos(t)ide Analogues for Patients with Chronic Hepatitis B in Thailand.
    Applied health economics and health policy, 2022, Volume: 20, Issue:4

    Topics: Adenine; Antiviral Agents; Cost-Benefit Analysis; Hepatitis B, Chronic; Humans; Organophosphonates;

2022
Review article: switching patients with chronic hepatitis B to tenofovir alafenamide-a review of current data.
    Alimentary pharmacology & therapeutics, 2022, Volume: 55, Issue:8

    Topics: Adenine; Aged; Alanine; Antiviral Agents; Hepatitis B, Chronic; Humans; Tenofovir

2022
The Use of Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide for Preventing Vertical Transmission of Hepatitis B.
    Journal of clinical gastroenterology, 2023, 02-01, Volume: 57, Issue:2

    Topics: Adenine; Antiviral Agents; Female; Hepatitis B; Hepatitis B, Chronic; Humans; Infant; Infectious Dis

2023
Risk of dyslipidemia in chronic hepatitis B patients taking tenofovir alafenamide: a systematic review and meta-analysis.
    Hepatology international, 2023, Volume: 17, Issue:4

    Topics: Adenine; Alanine; Cholesterol; Cholesterol, LDL; Dyslipidemias; Hepatitis B; Hepatitis B, Chronic; H

2023
Renal and bone side effects of long-term use of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide fumarate in patients with Hepatitis B: a network meta-analysis.
    BMC gastroenterology, 2023, Nov-10, Volume: 23, Issue:1

    Topics: Adenine; Alanine; Antiviral Agents; Bone and Bones; Creatinine; Fumarates; Hepatitis B; Hepatitis B,

2023
[Research progress on the effect of tenofovir disoproxil fumarate on blood lipid profile].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2023, Oct-20, Volume: 31, Issue:10

    Topics: Adenine; Antiviral Agents; DNA, Viral; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; Humans;

2023
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
Fanconi syndrome induced by adefovir dipivoxil: a case report and clinical review.
    The Journal of international medical research, 2020, Volume: 48, Issue:10

    Topics: Adenine; Antiviral Agents; Fanconi Syndrome; Hepatitis B virus; Hepatitis B, Chronic; Humans; Organo

2020
Nucleos(t)ide analogues for preventing HBV reactivation in immunosuppressed patients with hematological malignancies: a network meta-analysis.
    Expert review of anti-infective therapy, 2017, Volume: 15, Issue:5

    Topics: Adenine; Antiviral Agents; Controlled Clinical Trials as Topic; Guanine; Hematologic Neoplasms; Hepa

2017
Efficacy of Nucleot(s)ide Analogs Therapy in Patients with Unresectable HBV-Related Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.
    Disease markers, 2017, Volume: 2017

    Topics: Adenine; Antiviral Agents; Arabinofuranosyluracil; Carcinoma, Hepatocellular; Guanine; Hepatitis B v

2017
Tenofovir alafenamide for the treatment of chronic hepatitis B virus infection.
    Expert review of clinical pharmacology, 2017, Volume: 10, Issue:7

    Topics: Adenine; Alanine; Animals; Antiviral Agents; Bone Density; Creatinine; DNA, Viral; Hepatitis B e Ant

2017
Tenofovir Alafenamide: A Review in Chronic Hepatitis B.
    Drugs, 2017, Volume: 77, Issue:9

    Topics: Adenine; Adolescent; Adult; Alanine; Antiviral Agents; Female; Hepatitis B e Antigens; Hepatitis B,

2017
Combination Therapy for Chronic Hepatitis B: Current Updates and Perspectives.
    Gut and liver, 2017, Sep-15, Volume: 11, Issue:5

    Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Hepatitis B, Chronic; Humans; Interferon-alpha

2017
Tenofovir alafenamide as compared to tenofovir disoproxil fumarate in the management of chronic hepatitis B with recent trends in patient demographics.
    Expert review of gastroenterology & hepatology, 2017, Volume: 11, Issue:11

    Topics: Adenine; Age Factors; Alanine; Antiviral Agents; Bone Density; Clinical Decision-Making; Female; Glo

2017
Tenofovir alafenamide in the treatment of chronic hepatitis B: design, development, and place in therapy.
    Drug design, development and therapy, 2017, Volume: 11

    Topics: Adenine; Alanine; Antiviral Agents; Clinical Trials as Topic; Hepatitis B, Chronic; Humans; Molecula

2017
Tenofovir alafenamide (TAF) treatment of HBV, what are the unanswered questions?
    Expert review of anti-infective therapy, 2018, Volume: 16, Issue:2

    Topics: Adenine; Alanine; Antiviral Agents; Bone Density; Dose-Response Relationship, Drug; Hepatitis B, Chr

2018
Long-term safety and efficacy of nucleo(t)side analogue therapy in hepatitis B.
    Liver international : official journal of the International Association for the Study of the Liver, 2018, Volume: 38 Suppl 1

    Topics: Adenine; Administration, Oral; Alanine; Antiviral Agents; Drug-Related Side Effects and Adverse Reac

2018
Bayesian Network Meta-Analysis for Assessing Adverse Effects of Anti-hepatitis B Drugs.
    Clinical drug investigation, 2019, Volume: 39, Issue:9

    Topics: Adenine; Antiviral Agents; Bayes Theorem; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Network

2019
Drugs in the Pipeline for HBV.
    Clinics in liver disease, 2019, Volume: 23, Issue:3

    Topics: Adenine; Antiviral Agents; DNA, Viral; Female; Forecasting; Hepatitis B Surface Antigens; Hepatitis

2019
Update in the management of chronic hepatitis B.
    Current opinion in gastroenterology, 2013, Volume: 29, Issue:3

    Topics: Adenine; Antiviral Agents; Drug Monitoring; Guanine; Hepatitis B Surface Antigens; Hepatitis B, Chro

2013
Treatment of delta hepatitis.
    Expert review of anti-infective therapy, 2013, Volume: 11, Issue:5

    Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Farnesyl-Diphosphate Farnesyltransferase; Hepa

2013
Meta-analysis: the impact of oral anti-viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B.
    Alimentary pharmacology & therapeutics, 2013, Volume: 38, Issue:2

    Topics: Adenine; Administration, Oral; Age Factors; Antiviral Agents; Carcinoma, Hepatocellular; Guanine; He

2013
[Interdisciplinary aspects of and new drugs for chronic hepatitis B].
    Orvosi hetilap, 2013, Jul-21, Volume: 154, Issue:29

    Topics: Adenine; Antiviral Agents; Comorbidity; Drug Interactions; Drug Therapy, Combination; Female; Gastro

2013
Long-term results of treatment with nucleoside and nucleotide analogues (entecavir and tenofovir) for chronic hepatitis B.
    Clinics in liver disease, 2013, Volume: 17, Issue:3

    Topics: Adenine; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Guanine; Hepati

2013
Hepatitis B in HIV-infected patients.
    Clinics in liver disease, 2013, Volume: 17, Issue:3

    Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Coinfection; Drug Resistance, Viral; Hepatitis B Vaccine

2013
[Reactivation of chronic hepatitis B].
    Vnitrni lekarstvi, 2013, Volume: 59, Issue:7

    Topics: Adenine; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antiviral Agents; Biomarkers

2013
Efficacy of lamivudine combined with adefovir dipivoxil versus entecavir monotherapy in patients with hepatitis B-associated decompensated cirrhosis: A meta-analysis.
    Journal of clinical pharmacology, 2014, Volume: 54, Issue:2

    Topics: Adenine; Alanine Transaminase; Antiviral Agents; Creatinine; DNA, Viral; Drug Therapy, Combination;

2014
Options for the management of antiviral resistance during hepatitis B therapy: reflections on battles over a decade.
    Clinical and molecular hepatology, 2013, Volume: 19, Issue:3

    Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B virus; Hep

2013
Comparison of the efficacy of Lamivudine plus adefovir versus entecavir in the treatment of Lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis.
    Clinical therapeutics, 2013, Volume: 35, Issue:12

    Topics: Adenine; Antiviral Agents; Clinical Trials as Topic; Drug Resistance, Viral; Drug Therapy, Combinati

2013
Review article: nucleos(t)ide analogues in patients with chronic hepatitis B virus infection and chronic kidney disease.
    Alimentary pharmacology & therapeutics, 2014, Volume: 39, Issue:1

    Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Nucleosides; Organopho

2014
Extrahepatic effects of nucleoside and nucleotide analogues in chronic hepatitis B treatment.
    Journal of gastroenterology and hepatology, 2014, Volume: 29, Issue:3

    Topics: Acidosis, Lactic; Adenine; Administration, Oral; Antiviral Agents; Arabinofuranosyluracil; Dose-Resp

2014
HBeAg-positive chronic hepatitis B: why do i treat my patients with Nucleos(t)ide analogs?
    Liver international : official journal of the International Association for the Study of the Liver, 2014, Volume: 34 Suppl 1

    Topics: Adenine; Age Factors; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Guanine; Hepatitis B

2014
HBeAg-negative chronic hepatitis B: why do I treat my patients with nucleos(t)ide analogues?
    Liver international : official journal of the International Association for the Study of the Liver, 2014, Volume: 34 Suppl 1

    Topics: Adenine; Age Factors; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Guanine; Hepatitis B

2014
Impact of HBV therapy on the incidence of hepatocellular carcinoma.
    Liver international : official journal of the International Association for the Study of the Liver, 2014, Volume: 34 Suppl 1

    Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Guanine; Hepatitis

2014
New therapeutic perspectives in HBV: when to stop NAs.
    Liver international : official journal of the International Association for the Study of the Liver, 2014, Volume: 34 Suppl 1

    Topics: Adenine; Algorithms; Antiviral Agents; Biomarkers; DNA, Viral; Drug Therapy, Combination; Guanine; H

2014
Clinical utility of entecavir for chronic hepatitis B in Chinese patients.
    Drug design, development and therapy, 2013, Dec-12, Volume: 8

    Topics: Adenine; Antiviral Agents; China; Cost-Benefit Analysis; Drug Resistance, Viral; Hepatitis B, Chroni

2013
Peginterferon alpha versus other antiviral regimes for Chinese HBeAg-positive chronic hepatitis B patients.
    Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences, 2013, Volume: 38, Issue:12

    Topics: Adenine; Antiviral Agents; China; Drug Therapy, Combination; Guanine; Hepatitis B e Antigens; Hepati

2013
Hypophosphatemic osteomalacia due to drug-induced Fanconi's syndrome associated with adefovir dipivoxil treatment for hepatitis B.
    Internal medicine (Tokyo, Japan), 2014, Volume: 53, Issue:3

    Topics: Adenine; Bone Diseases, Metabolic; Fanconi Syndrome; Hepatitis B, Chronic; Humans; Hypophosphatemia;

2014
An update on hepatitis B, D, and E viruses.
    Topics in antiviral medicine, 2014, Volume: 21, Issue:5

    Topics: Adenine; Drug Therapy, Combination; Guanine; Hepatitis B, Chronic; Hepatitis D, Chronic; Hepatitis E

2014
Managing hepatitis B to prevent liver cancer: recent advances.
    Expert review of gastroenterology & hepatology, 2014, Volume: 8, Issue:4

    Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Liver N

2014
Efficacy and resistance in de novo combination lamivudine and adefovir dipivoxil therapy versus entecavir monotherapy for the treatment-naive patients with chronic hepatitis B: a meta-analysis.
    Virology journal, 2014, Mar-28, Volume: 11

    Topics: Adenine; Drug Resistance, Viral; Drug Therapy, Combination; Guanine; Hepatitis B Surface Antigens; H

2014
Management of chronic hepatitis B in children: an unresolved issue.
    Journal of gastroenterology and hepatology, 2014, Volume: 29, Issue:5

    Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Carrier State; Child; Databases, Bibliographic

2014
Management of chronic hepatitis B infection: current treatment guidelines, challenges, and new developments.
    World journal of gastroenterology, 2014, May-28, Volume: 20, Issue:20

    Topics: Adenine; Antiviral Agents; Disease Management; DNA, Viral; Drug Delivery Systems; Drug Resistance, V

2014
Comparison of efficacy and safety of tenofovir and entecavir in chronic hepatitis B virus infection: a systematic review and meta-analysis.
    PloS one, 2014, Volume: 9, Issue:6

    Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Safety; Tenofo

2014
Molecular diagnosis and treatment of drug-resistant hepatitis B virus.
    World journal of gastroenterology, 2014, May-21, Volume: 20, Issue:19

    Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Guanine; Hepatitis B virus; Hepatitis B, Chronic;

2014
Entecavir plus adefovir combination therapy versus lamivudine add-on adefovir for lamivudine-resistant chronic hepatitis B: A meta-analysis.
    Journal of clinical pharmacology, 2014, Volume: 54, Issue:9

    Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Guanine; H

2014
Treatment of chronic hepatitis B in clinical practice with entecavir or tenofovir.
    World journal of gastroenterology, 2014, Jun-21, Volume: 20, Issue:23

    Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Organophosphona

2014
[Treatment of viral hepatitis in children].
    Acta medica Croatica : casopis Hravatske akademije medicinskih znanosti, 2013, Volume: 67, Issue:4

    Topics: Adenine; Adolescent; Antiviral Agents; Child; Child Welfare; Drug Therapy, Combination; Female; Hepa

2013
Treating Immune-tolerant Hepatitis B.
    Journal of viral hepatitis, 2015, Volume: 22, Issue:2

    Topics: Adenine; Antiviral Agents; Drug Therapy; Hepatitis B, Chronic; Humans; Interferons; Nucleotides; Org

2015
Optimal therapy of chronic hepatitis B: how do I treat HBeAg-positive patients?
    Liver international : official journal of the International Association for the Study of the Liver, 2015, Volume: 35 Suppl 1

    Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Guanine; Hepatitis B e Antigens; Hepatitis B,

2015
Optimal therapy of chronic hepatitis B: how do I treat my HBeAg-negative patients?
    Liver international : official journal of the International Association for the Study of the Liver, 2015, Volume: 35 Suppl 1

    Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Guanine; Hepatitis B e Antigens; Hepatitis B,

2015
Pegylated interferon alfa for chronic hepatitis B: systematic review and meta-analysis.
    Journal of viral hepatitis, 2016, Volume: 23, Issue:3

    Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Hepatitis B e Antigens; Hepatitis B, Chronic;

2016
Molecular Mechanisms to Control Post-Transplantation Hepatitis B Recurrence.
    International journal of molecular sciences, 2015, Jul-30, Volume: 16, Issue:8

    Topics: Adenine; Antiviral Agents; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis B, Chronic; Humans; Im

2015
Monotherapy for hepatitis B infection: a review of treatment options.
    Expert review of anti-infective therapy, 2015, Volume: 13, Issue:12

    Topics: Adenine; Animals; Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans

2015
[Hepatitis B Virus Infection: Current Trends and Issues].
    Rinsho byori. The Japanese journal of clinical pathology, 2015, Volume: 63, Issue:6

    Topics: Adenine; Animals; Antiviral Agents; Carcinoma, Hepatocellular; Hepatitis B virus; Hepatitis B, Chron

2015
HBsAg seroclearance or seroconversion induced by peg-interferon alpha and lamivudine or adefovir combination therapy in chronic hepatitis B treatment: a meta-analysis and systematic review.
    Revista espanola de enfermedades digestivas, 2016, Volume: 108, Issue:5

    Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Hepatitis B Surface Antigens; Hepatitis B, Chr

2016
Chronic hepatitis B in children: Therapeutic challenges and perspectives.
    Journal of gastroenterology and hepatology, 2017, Volume: 32, Issue:2

    Topics: Adenine; Alanine Transaminase; Antigens, Viral; Antiviral Agents; Child; Guanine; Hepatitis B virus;

2017
A Meta-Analysis of the Efficacy of Interferon Monotherapy or Combined with Different Nucleos(t)ide Analogues for Chronic Hepatitis B.
    International journal of environmental research and public health, 2016, 07-21, Volume: 13, Issue:5

    Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Guanine; Hepatitis B virus; Hepati

2016
Relationship between nephrotoxicity and long-term adefovir dipivoxil therapy for chronic hepatitis B: A meta-analysis.
    Medicine, 2016, Volume: 95, Issue:50

    Topics: Adenine; Creatinine; Glomerular Filtration Rate; Hepatitis B, Chronic; Humans; Kidney; Kidney Diseas

2016
Management of Antiviral Resistance in Chronic Hepatitis B.
    Gut and liver, 2017, Mar-15, Volume: 11, Issue:2

    Topics: Adenine; Antiviral Agents; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Guanine; Hep

2017
[Treatment recommendations of chronic hepatitis B. Did the world escape us?].
    Przeglad epidemiologiczny, 2008, Volume: 62, Issue:1

    Topics: Adenine; Antiviral Agents; Disease Management; Drug Therapy, Combination; Guanine; Health Planning G

2008
Treatment of chronic hepatitis B infection: an update of Swedish recommendations.
    Scandinavian journal of infectious diseases, 2008, Volume: 40, Issue:6-7

    Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Deoxycytidine; Drug Therapy, Combination; Emtr

2008
[Management of chronic hepatitis B in treatment-naive patients].
    The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 2008, Volume: 51, Issue:6

    Topics: Adenine; Antiviral Agents; Arabinofuranosyluracil; Guanine; Hepatitis B, Chronic; Humans; Interferon

2008
[Management of antiviral-resistant chronic hepatitis B virus infection].
    The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 2008, Volume: 51, Issue:6

    Topics: Adenine; Antiviral Agents; Arabinofuranosyluracil; Drug Resistance, Multiple, Viral; Guanine; Hepati

2008
[Combination therapy in chronic hepatitis B].
    Gastroenterologie clinique et biologique, 2008, Volume: 32, Issue:1 Pt 2

    Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B, Chronic;

2008
[Is it possible to stop nucleos(t)ide analogue based therapy in chronic hepatitis B?].
    Gastroenterologie clinique et biologique, 2008, Volume: 32, Issue:1 Pt 2

    Topics: Adenine; Antiviral Agents; DNA, Viral; Hepatitis B Antigens; Hepatitis B virus; Hepatitis B, Chronic

2008
A review of telbivudine for the management of chronic hepatitis B virus infection.
    Expert opinion on drug metabolism & toxicology, 2008, Volume: 4, Issue:10

    Topics: Adenine; Antiviral Agents; Clinical Trials as Topic; Drug Evaluation, Preclinical; Drug Resistance,

2008
LB80380: a promising new drug for the treatment of chronic hepatitis B.
    Expert opinion on investigational drugs, 2008, Volume: 17, Issue:10

    Topics: Adenine; Alanine Transaminase; Antiviral Agents; DNA, Viral; Guanine; Hepatitis B e Antigens; Hepati

2008
LB80380: a promising new drug for the treatment of chronic hepatitis B.
    Expert opinion on investigational drugs, 2008, Volume: 17, Issue:10

    Topics: Adenine; Alanine Transaminase; Antiviral Agents; DNA, Viral; Guanine; Hepatitis B e Antigens; Hepati

2008
LB80380: a promising new drug for the treatment of chronic hepatitis B.
    Expert opinion on investigational drugs, 2008, Volume: 17, Issue:10

    Topics: Adenine; Alanine Transaminase; Antiviral Agents; DNA, Viral; Guanine; Hepatitis B e Antigens; Hepati

2008
LB80380: a promising new drug for the treatment of chronic hepatitis B.
    Expert opinion on investigational drugs, 2008, Volume: 17, Issue:10

    Topics: Adenine; Alanine Transaminase; Antiviral Agents; DNA, Viral; Guanine; Hepatitis B e Antigens; Hepati

2008
A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2008, Volume: 6, Issue:12

    Topics: Adenine; Antiviral Agents; Case Management; DNA, Viral; Guanine; Hepatitis B, Chronic; Humans; Inter

2008
[Interferon in hepatitis B].
    Enfermedades infecciosas y microbiologia clinica, 2008, Volume: 26 Suppl 7

    Topics: Adenine; Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Genotype; Guanine; H

2008
[Nucleoside and nucleotide analogs in the treatment of chronic hepatitis B].
    Enfermedades infecciosas y microbiologia clinica, 2008, Volume: 26 Suppl 7

    Topics: Adenine; Antiviral Agents; Clinical Trials as Topic; Deoxycytidine; Drug Resistance, Viral; Drug The

2008
[Entecavir].
    Enfermedades infecciosas y microbiologia clinica, 2008, Volume: 26 Suppl 7

    Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Clinical Trials as Topic; Drug Resistance, Viral; Drug T

2008
[Resistance in hepatitis B virus].
    Enfermedades infecciosas y microbiologia clinica, 2008, Volume: 26 Suppl 7

    Topics: Adenine; Antiviral Agents; Drug Resistance, Multiple, Viral; Drug Resistance, Viral; Drug Therapy, C

2008
[Clinical management of patients with chronic hepatitis B virus infection].
    Enfermedades infecciosas y microbiologia clinica, 2008, Volume: 26 Suppl 7

    Topics: Adenine; Antiviral Agents; Biopsy; Combined Modality Therapy; Deoxycytidine; Drug Resistance, Viral;

2008
Role of combination therapy in chronic hepatitis B.
    Current gastroenterology reports, 2009, Volume: 11, Issue:1

    Topics: Adenine; Antiviral Agents; Deoxycytidine; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combinat

2009
Nucleos(t)ide analogues for hepatitis B virus: strategies for long-term success.
    Best practice & research. Clinical gastroenterology, 2008, Volume: 22, Issue:6

    Topics: Adenine; Adenine Nucleotides; Alanine Transaminase; Carcinoma, Hepatocellular; DNA, Viral; Drug Admi

2008
Peginterferon for the treatment of chronic hepatitis B in the era of nucleos(t)ide analogues.
    Best practice & research. Clinical gastroenterology, 2008, Volume: 22, Issue:6

    Topics: Adenine; Antiviral Agents; DNA, Viral; Guanine; Hepatitis B e Antigens; Hepatitis B Surface Antigens

2008
HBeAg-negative chronic hepatitis B: why do I treat my patients with nucleos(t)ide analogues.
    Liver international : official journal of the International Association for the Study of the Liver, 2009, Volume: 29 Suppl 1

    Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Guanine; Hepatitis B e Antigens; Hepatitis B, Chr

2009
Chronic hepatitis B: early viral suppression and long-term outcomes of therapy with oral nucleos(t)ides.
    Journal of viral hepatitis, 2009, Volume: 16, Issue:3

    Topics: Adenine; Administration, Oral; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Hepatitis B vir

2009
On-treatment outcome prediction and adjustment during chronic hepatitis B therapy: now and future.
    Antiviral therapy, 2009, Volume: 14, Issue:1

    Topics: Adenine; Antiviral Agents; Cost-Benefit Analysis; DNA, Viral; Drug Resistance, Multiple, Viral; Hepa

2009
[Chronic hepatitis B: current therapy].
    Bulletin de l'Academie nationale de medecine, 2008, Volume: 192, Issue:8

    Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; Guanine; Hepatitis B Vacc

2008
Adefovir dipivoxil and pegylated interferon alpha for the treatment of chronic hepatitis B: an updated systematic review and economic evaluation.
    Health technology assessment (Winchester, England), 2009, Volume: 13, Issue:35

    Topics: Adenine; Adult; Aged; Antiviral Agents; Female; Hepatitis B, Chronic; Humans; Interferon-alpha; Male

2009
Tenofovir for the treatment of hepatitis B virus.
    Pharmacotherapy, 2009, Volume: 29, Issue:10

    Topics: Adenine; Antiviral Agents; Drug Approval; Drug Interactions; Hepatitis B virus; Hepatitis B, Chronic

2009
Meta-analysis: adefovir dipivoxil in combination with lamivudine in patients with lamivudine-resistant hepatitis B virus.
    Virology journal, 2009, Oct-09, Volume: 6

    Topics: Adenine; Antiviral Agents; Clinical Trials as Topic; Drug Resistance, Viral; Hepatitis B virus; Hepa

2009
Tenofovir disoproxil fumarate: in chronic hepatitis B.
    Drugs, 2009, Nov-12, Volume: 69, Issue:16

    Topics: Adenine; Administration, Oral; Adult; Hepatitis B, Chronic; Humans; Organophosphonates; Prodrugs; Ra

2009
Lenalidomide-induced acute liver failure.
    Blood transfusion = Trasfusione del sangue, 2009, Volume: 7, Issue:4

    Topics: Adenine; Aged, 80 and over; Antineoplastic Agents; Antiviral Agents; Hepatitis B, Chronic; Humans; L

2009
Current treatments for patients with HBeAg-positive chronic hepatitis B virus infection: a comparison focusing on HBeAg seroconversion.
    Liver international : official journal of the International Association for the Study of the Liver, 2010, Volume: 30, Issue:4

    Topics: Adenine; Adjuvants, Immunologic; Antiviral Agents; Dose-Response Relationship, Drug; Drug Administra

2010
Avoiding and managing lamivudine resistance in chronic hepatitis B: current approaches and potential strategies including pegylated interferon.
    Liver international : official journal of the International Association for the Study of the Liver, 2010, Volume: 30, Issue:5

    Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Guanine; Hepatitis B,

2010
Effect of newer oral antiviral agents on future therapy of chronic hepatitis B.
    Antiviral therapy, 2010, Volume: 15, Issue:1

    Topics: Adenine; Administration, Oral; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination;

2010
[Hepatitis B reactivation in an HbsAg-negative/anti-HBc-positive patient with B-cell non-Hodgkin lymphoma receiving chemotherapy with rituximab].
    Gastroenterologia y hepatologia, 2010, Volume: 33, Issue:5

    Topics: Adenine; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antibody

2010
Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B infection.
    Health technology assessment (Winchester, England), 2010, Volume: 14 Suppl 1

    Topics: Adenine; Alanine Transaminase; Antiviral Agents; Cost-Benefit Analysis; Disease Progression; Hepatit

2010
On-treatment monitoring of chronic hepatitis B virus infection: an Asian-Pacific perspective.
    Journal of gastroenterology and hepatology, 2010, Volume: 25, Issue:5

    Topics: Adenine; Antiviral Agents; Asia; Biomarkers; DNA, Viral; Drug Monitoring; Drug Resistance, Viral; Gu

2010
Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses.
    Gastroenterology, 2010, Volume: 139, Issue:4

    Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Guanine; Hepatitis B e Antigens; Hepatitis B,

2010
Mixed treatment comparison meta-analysis evaluating the relative efficacy of nucleos(t)ides for treatment of nucleos(t)ide-naive patients with chronic hepatitis B.
    Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 2010, Volume: 13, Issue:8

    Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Guanine; Hepatitis B, Chronic; Humans; Lamivud

2010
Tenofovir disoproxil fumarate in the treatment of chronic hepatitis B.
    Expert review of anti-infective therapy, 2010, Volume: 8, Issue:10

    Topics: Adenine; Antiviral Agents; Clinical Trials, Phase III as Topic; Double-Blind Method; Hepatitis B vir

2010
Review article: chronic hepatitis B - anti-viral or immunomodulatory therapy?
    Alimentary pharmacology & therapeutics, 2011, Volume: 33, Issue:5

    Topics: Adenine; Antiviral Agents; Decision Making; Guanine; Hepatitis B, Chronic; Humans; Immunomodulation;

2011
Systematic review of the literature on comparative effectiveness of antiviral treatments for chronic hepatitis B infection.
    Journal of general internal medicine, 2011, Volume: 26, Issue:3

    Topics: Adenine; Animals; Antiviral Agents; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alp

2011
Chronic hepatitis B: peginterferon or nucleos(t)ide analogues?
    Liver international : official journal of the International Association for the Study of the Liver, 2011, Volume: 31 Suppl 1

    Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alph

2011
Treatment of HBeAg-positive chronic hepatitis B with nucleos(t)ide analogues.
    Liver international : official journal of the International Association for the Study of the Liver, 2011, Volume: 31 Suppl 1

    Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic;

2011
Hepatitis B virus resistance to antiviral drugs: where are we going?
    Liver international : official journal of the International Association for the Study of the Liver, 2011, Volume: 31 Suppl 1

    Topics: Adenine; Antiviral Agents; Capsid; Clinical Protocols; Drug Resistance, Viral; Guanine; Hepatitis B

2011
Treatment of chronic hepatitis B: update of the recommendations from the 2007 Italian Workshop.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2011, Volume: 43, Issue:4

    Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Hepatitis B virus; Hepatitis B, Chronic; Human

2011
[Treatment of patients with lamivudine-resistant chronic hepatitis B].
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2011, Volume: 108, Issue:2

    Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Guanine; Hepatitis B, Chronic; Humans; Lamivudine

2011
Comparison of the 48-week efficacy between entecavir and adefovir in HBeAg-positive nucleos(t)ide-naïve Asian patients with chronic hepatitis B: a meta-analysis.
    Virology journal, 2011, Feb-22, Volume: 8

    Topics: Adenine; Antiviral Agents; Asia; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Orga

2011
Comparison of the efficacy of tenofovir and adefovir in the treatment of chronic hepatitis B: a systematic review.
    Virology journal, 2011, Mar-09, Volume: 8

    Topics: Adenine; Antiviral Agents; Controlled Clinical Trials as Topic; Hepatitis B virus; Hepatitis B, Chro

2011
[Interferon-based versus direct antiviral therapy in patients with chronic hepatitis B].
    Orvosi hetilap, 2011, May-29, Volume: 152, Issue:22

    Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Guanine; Hepatitis B virus; Hepati

2011
[Progress and perspectives in treatment of chronic hepatitis B].
    Nihon rinsho. Japanese journal of clinical medicine, 2011, Volume: 69, Issue:4

    Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Interferons; Lami

2011
Drug safety evaluation of adefovir in HBV infection.
    Expert opinion on drug safety, 2011, Volume: 10, Issue:5

    Topics: Adenine; Antiviral Agents; Clinical Trials, Phase III as Topic; Hepatitis B, Chronic; Humans; Organo

2011
Antiviral therapy for hepatitis B infection during pregnancy and breastfeeding.
    Antiviral therapy, 2011, Volume: 16, Issue:5

    Topics: Adenine; Antiviral Agents; Breast Feeding; Female; Guanine; Hepatitis B; Hepatitis B virus; Hepatiti

2011
Lamivudine plus adefovir combination therapy versus entecavir monotherapy for lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis.
    Virology journal, 2011, Aug-08, Volume: 8

    Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Guanine; Hepatitis B,

2011
Antiviral drugs for viruses other than human immunodeficiency virus.
    Mayo Clinic proceedings, 2011, Volume: 86, Issue:10

    Topics: Acyclovir; Adenine; Amantadine; Antiviral Agents; Comorbidity; Drug Therapy, Combination; Foscarnet;

2011
[The past, present and future treatment for chronic hepatitis B].
    Nihon rinsho. Japanese journal of clinical medicine, 2011, Volume: 69 Suppl 4

    Topics: Adenine; Adult; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Interferons; Lamivudine; Or

2011
[Lamivudine, adefovir dipivoxil].
    Nihon rinsho. Japanese journal of clinical medicine, 2011, Volume: 69 Suppl 4

    Topics: Adenine; Antiviral Agents; Hepatitis B, Chronic; Humans; Lamivudine; Organophosphonates

2011
[Prevention for the development of hepatitis B virus-related hepatocellular carcinoma by anti-viral treatment].
    Nihon rinsho. Japanese journal of clinical medicine, 2011, Volume: 69 Suppl 4

    Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Hepatitis B, Chronic; Humans; Interferons; Lam

2011
Lamivudine with or without adefovir dipivoxil for postoperative hepatocellular carcinoma.
    The Cochrane database of systematic reviews, 2011, Dec-07, Issue:12

    Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Hepatitis B, Chroni

2011
Quantification of serum hepatitis B surface antigen: is it useful for the management of chronic hepatitis B?
    Gut, 2012, Volume: 61, Issue:5

    Topics: Adenine; Antiviral Agents; Biomarkers; Guanine; Hepatitis B e Antigens; Hepatitis B Surface Antigens

2012
Emerging pipeline drugs for hepatitis B infection.
    Expert opinion on emerging drugs, 2011, Volume: 16, Issue:4

    Topics: Adenine; Antiviral Agents; Clinical Trials as Topic; Drug Design; Drugs, Investigational; Guanine; H

2011
Comparative meta-analysis of adefovir dipivoxil monotherapy and combination therapy of adefovir dipivoxil and lamivudine for lamivudine-resistant chronic hepatitis B.
    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2012, Volume: 16, Issue:3

    Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis

2012
Adefovir dipivoxil in chronic hepatitis B: history and current uses.
    Expert opinion on pharmacotherapy, 2012, Volume: 13, Issue:2

    Topics: Adenine; Antiviral Agents; Hepatitis B, Chronic; Humans; Nucleic Acid Synthesis Inhibitors; Organoph

2012
Meta-analysis: oral anti-viral agents in adults with decompensated hepatitis B virus cirrhosis.
    Alimentary pharmacology & therapeutics, 2012, Volume: 35, Issue:6

    Topics: Adenine; Administration, Oral; Adult; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combin

2012
New advances in chronic hepatitis B.
    Current opinion in gastroenterology, 2012, Volume: 28, Issue:3

    Topics: Adenine; Antiviral Agents; Coinfection; Disease Progression; Drug Resistance, Viral; Female; Guanine

2012
New perspectives in the therapy of chronic hepatitis B.
    Gut, 2012, Volume: 61 Suppl 1

    Topics: Adenine; Antiviral Agents; Drug Monitoring; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; H

2012
[New drugs of treatment of patients with chronic hepatitis B].
    Nihon rinsho. Japanese journal of clinical medicine, 2012, Volume: 70, Issue:4

    Topics: Adenine; Antiviral Agents; Arabinofuranosyluracil; Deoxycytidine; Emtricitabine; Hepatitis B, Chroni

2012
First-line treatment of chronic hepatitis B with entecavir or tenofovir in 'real-life' settings: from clinical trials to clinical practice.
    Journal of viral hepatitis, 2012, Volume: 19, Issue:6

    Topics: Adenine; Antiviral Agents; Clinical Trials as Topic; Guanine; Hepatitis B, Chronic; Humans; Nucleosi

2012
Tenofovir disoproxil fumarate in the treatment of chronic hepatitis B.
    Expert review of gastroenterology & hepatology, 2012, Volume: 6, Issue:4

    Topics: Adenine; Drug Resistance, Viral; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Organophospho

2012
[Comparison of peg-interferon monotherapy to peg-interferon and nucleoside analogue combination therapy for hepatitis B: a meta-analysis of randomized controlled trials].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2012, Volume: 20, Issue:6

    Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Hepatitis B, Chronic; Humans; Interferons; Lam

2012
Long-term therapy with nucleoside/nucleotide analogues for chronic hepatitis B in Asian patients.
    Antiviral therapy, 2013, Volume: 18, Issue:7

    Topics: Adenine; Antiviral Agents; Asian People; Carcinoma, Hepatocellular; Disease Progression; Drug Resist

2013
Considerations for the long-term treatment of chronic hepatitis B with nucleos(t)ide analogs.
    Expert review of gastroenterology & hepatology, 2012, Volume: 6, Issue:6

    Topics: Adenine; Age Factors; Antiviral Agents; Comorbidity; DNA, Viral; Drug Resistance, Viral; Guanine; He

2012
Diagnostic and therapeutic progress of multi-drug resistance with anti-HBV nucleos(t)ide analogues.
    World journal of gastroenterology, 2012, Dec-28, Volume: 18, Issue:48

    Topics: Adenine; Antiviral Agents; Drug Resistance, Multiple; Guanine; Hepatitis B e Antigens; Hepatitis B v

2012
Cost effectiveness of first-line oral antiviral therapies for chronic hepatitis B : a systematic review.
    PharmacoEconomics, 2013, Volume: 31, Issue:1

    Topics: Adenine; Antiviral Agents; Cost-Benefit Analysis; Guanine; Health Care Costs; Hepatitis B, Chronic;

2013
Letter: First-line monotherapies for chronic hepatitis B - indirect comparison between entecavir and tenofovir.
    Alimentary pharmacology & therapeutics, 2013, Volume: 37, Issue:5

    Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Randomized Con

2013
Update on the management of chronic hepatitis B.
    Reviews in gastroenterological disorders, 2002,Summer, Volume: 2, Issue:3

    Topics: Adenine; Antiviral Agents; Hepatitis B, Chronic; Humans; Interferons; Lamivudine; Organophosphonates

2002
Advances in therapy for chronic hepatitis B.
    Seminars in liver disease, 2002, Volume: 22 Suppl 1

    Topics: Adenine; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Organo

2002
Management of chronic hepatitis B virus infection in remote-dwelling Aboriginals and Torres Strait Islanders: an update for primary healthcare providers.
    The Medical journal of Australia, 2003, Jan-20, Volume: 178, Issue:2

    Topics: Adenine; Adolescent; Adult; Algorithms; Antiviral Agents; Australia; Carcinoma, Hepatocellular; Chil

2003
Treatment of HBeAg-negative chronic hepatitis B.
    Seminars in liver disease, 2003, Volume: 23, Issue:1

    Topics: Adenine; Antiviral Agents; Endpoint Determination; Hepatitis B e Antigens; Hepatitis B, Chronic; Hum

2003
Adefovir dipivoxil.
    Drugs of today (Barcelona, Spain : 1998), 2003, Volume: 39, Issue:2

    Topics: Adenine; Antiviral Agents; Clinical Trials as Topic; Drug Interactions; Hepatitis B, Chronic; Humans

2003
[Antiviral therapy for chronic viral hepatitis B and C].
    Nihon rinsho. Japanese journal of clinical medicine, 2003, Volume: 61 Suppl 2

    Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon a

2003
Slowing the progression of chronic hepatitis B. Early antiviral therapy can help minimize complications.
    Postgraduate medicine, 2003, Volume: 114, Issue:1

    Topics: Adenine; Administration, Oral; Adult; Alanine Transaminase; Antiviral Agents; Biomarkers; Child; Dis

2003
Adefovir dipivoxil: a review of its use in chronic hepatitis B.
    Drugs, 2003, Volume: 63, Issue:20

    Topics: Adenine; Antiviral Agents; Clinical Trials as Topic; Drug Administration Schedule; Drug Resistance,

2003
[Hepatitis: associated diseases. Risk groups -- prevention -- treatment].
    Praxis, 2003, Aug-13, Volume: 92, Issue:33

    Topics: Adenine; Adult; Antiviral Agents; Child; DNA, Viral; Female; Hepacivirus; Hepatitis B; Hepatitis B S

2003
Nucleoside analogues and other antivirals for treatment of hepatitis B in the peritransplant period.
    Clinics in liver disease, 2003, Volume: 7, Issue:3

    Topics: Adenine; Antiviral Agents; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunoglobulins; Lamivud

2003
Current pharmacotherapy for the treatment of chronic hepatitis B.
    Expert opinion on pharmacotherapy, 2003, Volume: 4, Issue:10

    Topics: 2-Aminopurine; Adenine; Antiviral Agents; Clinical Trials as Topic; Famciclovir; Hepatitis B e Antig

2003
Chronic viral hepatitis: always be current!
    Pediatrics in review, 2003, Volume: 24, Issue:12

    Topics: Adenine; Adolescent; Adult; Antiviral Agents; Child; Female; Hepacivirus; Hepatitis B; Hepatitis B v

2003
[Application and efficacy of adefovir dipivoxil in hepatitis B virus-associated chronic liver diseases].
    The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 2003, Volume: 42, Issue:5

    Topics: Adenine; Antiviral Agents; Hepatitis B, Chronic; Humans; Liver Diseases; Organophosphonates

2003
Viral hepatitis B.
    Lancet (London, England), 2003, Dec-20, Volume: 362, Issue:9401

    Topics: Adenine; Antiviral Agents; Comorbidity; Drug Therapy, Combination; Genotype; Hepatitis B; Hepatitis

2003
Rescue therapy for drug resistant hepatitis B: another argument for combination chemotherapy?
    Gastroenterology, 2004, Volume: 126, Issue:1

    Topics: Adenine; Antiviral Agents; Drug Resistance, Microbial; Drug Therapy, Combination; Hepatitis B virus;

2004
Adefovir (Hepsera) for chronic hepatitis B infection.
    American family physician, 2003, Dec-15, Volume: 68, Issue:12

    Topics: Adenine; Antiviral Agents; Hepatitis B, Chronic; Humans; Organophosphonates

2003
Adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B: a review of the major clinical studies.
    Journal of hepatology, 2003, Volume: 39 Suppl 1

    Topics: Adenine; Antiviral Agents; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; He

2003
Combination therapy for chronic hepatitis B.
    Journal of hepatology, 2003, Volume: 39 Suppl 1

    Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Hepatitis B Antibodies; Hepatitis B e Antigens

2003
Treatment of HBeAg negative chronic hepatitis B with new drugs (adefovir and others).
    Journal of hepatology, 2003, Volume: 39 Suppl 1

    Topics: Adenine; Antiviral Agents; Arabinofuranosyluracil; Deoxycytidine; Emtricitabine; Guanine; Hepatitis

2003
Treatment of chronic hepatitis B virus infection in patients co-infected with human immunodeficiency virus.
    Journal of hepatology, 2003, Volume: 39 Suppl 1

    Topics: Acquired Immunodeficiency Syndrome; Adenine; Antiretroviral Therapy, Highly Active; Antiviral Agents

2003
Adefovir dipivoxil: a new antiviral agent for the treatment of hepatitis B virus infection.
    Clinical therapeutics, 2003, Volume: 25, Issue:12

    Topics: Adenine; Animals; Antiviral Agents; Clinical Trials as Topic; Drug Administration Schedule; Drug Res

2003
Adefovir dipivoxil in the treatment of chronic hepatitis B.
    The Annals of pharmacotherapy, 2004, Volume: 38, Issue:4

    Topics: Adenine; Antiviral Agents; Drug Interactions; Drug Resistance, Viral; Drug Therapy, Combination; Hep

2004
Management of chronic hepatitis B in the HIV-infected patient.
    The AIDS reader, 2004, Volume: 14, Issue:3

    Topics: Adenine; Algorithms; Antiviral Agents; Clinical Trials as Topic; Decision Trees; Drug Therapy, Combi

2004
Editorial comment: HIV and HBV coinfection--a coming-of-age in treatment strategies.
    The AIDS reader, 2004, Volume: 14, Issue:3

    Topics: Adenine; Antiviral Agents; Comorbidity; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Guanin

2004
[Adefovir dipivoxil is a new drug for treatment of chronic hepatitis B].
    Vnitrni lekarstvi, 2004, Volume: 50, Issue:3

    Topics: Adenine; Antiviral Agents; Hepatitis B, Chronic; Humans; Organophosphonates

2004
[New approaches in the treatment of hepatitis B].
    Deutsche medizinische Wochenschrift (1946), 2004, May-21, Volume: 129, Issue:21

    Topics: 2-Aminopurine; Adenine; Antiviral Agents; Arabinofuranosyluracil; Carcinoma, Hepatocellular; Contrai

2004
Overview of treatment of hepatitis B: key approaches and clinical challenges.
    Seminars in liver disease, 2004, Volume: 24 Suppl 1

    Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Genotype;

2004
Treatment of patients with chronic hepatitis B with adefovir dipivoxil.
    Seminars in liver disease, 2004, Volume: 24 Suppl 1

    Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Hepatitis B e Antigens; Hepatitis B v

2004
Management of hepatitis B in liver transplantation patients.
    Seminars in liver disease, 2004, Volume: 24 Suppl 1

    Topics: Adenine; Antiviral Agents; Hepatitis B, Chronic; Humans; Immunization, Passive; Immunoglobulins; Lam

2004
Treatment with interferons (including pegylated interferons) in patients with hepatitis B.
    Seminars in liver disease, 2004, Volume: 24 Suppl 1

    Topics: Adenine; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Hepatitis B

2004
New treatment of chronic hepatitis B.
    Seminars in liver disease, 2004, Volume: 24 Suppl 1

    Topics: Adenine; Animals; Antiviral Agents; Arabinofuranosyluracil; Deoxycytidine; Drug Resistance, Viral; E

2004
Antiviral therapy for treatment-naïve hepatitis B virus patients.
    Gastroenterology clinics of North America, 2004, Volume: 33, Issue:3

    Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Hepatitis B, Chronic; Humans; Interferon-alpha

2004
Treatment of hepatitis B virus infection in patients coinfected with HIV.
    Gastroenterology clinics of North America, 2004, Volume: 33, Issue:3

    Topics: Adenine; Antiviral Agents; Hepatitis B, Chronic; HIV Infections; Humans; Interferon-alpha; Lamivudin

2004
Antiviral therapy in patients with chronic hepatitis B and cirrhosis.
    Gastroenterology clinics of North America, 2004, Volume: 33, Issue:3

    Topics: Adenine; Antiviral Agents; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Liver Cirrhos

2004
[Treatment of chronic hepatitis B virus infection].
    Anales del sistema sanitario de Navarra, 2004, Volume: 27 Suppl 2

    Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Hepatitis B e Antigens; Hepatitis B, Chronic;

2004
[Hepatitis B (acute and chronic)].
    Praxis, 2004, Jul-28, Volume: 93, Issue:31-32

    Topics: Acute Disease; Adenine; Adolescent; Adult; Antiviral Agents; Child; Diagnosis, Differential; Drug Th

2004
[Antiviral treatment of chronic hepatitis B with adefovir dipivoxil].
    Nihon rinsho. Japanese journal of clinical medicine, 2004, Volume: 62 Suppl 8

    Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans;

2004
[Management of hepatitis B].
    Therapeutische Umschau. Revue therapeutique, 2004, Volume: 61, Issue:8

    Topics: Adenine; Adult; Antiviral Agents; Child; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B

2004
Treatment of chronic hepatitis B: who to treat, what to use, and for how long?
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2004, Volume: 2, Issue:10

    Topics: Adenine; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis B, Chr

2004
Adefovir dipivoxil in the treatment of chronic hepatitis B virus infection.
    Expert review of anti-infective therapy, 2004, Volume: 2, Issue:4

    Topics: Adenine; Antiviral Agents; Clinical Trials as Topic; Drug Approval; Drug Resistance, Viral; Hepatiti

2004
Current therapies for chronic hepatitis B virus infection.
    Expert review of anti-infective therapy, 2004, Volume: 2, Issue:5

    Topics: Adenine; Antiviral Agents; Drug Resistance; Drug Resistance, Viral; Drug Therapy, Combination; Hepat

2004
Adefovir dipivoxil in chronic hepatitis B infection.
    Expert opinion on pharmacotherapy, 2004, Volume: 5, Issue:11

    Topics: Adenine; Animals; Antiviral Agents; Clinical Trials as Topic; Drug Resistance, Viral; Hepatitis B e

2004
Adefovir dipivoxil: review of a novel acyclic nucleoside analogue.
    International journal of clinical practice, 2004, Volume: 58, Issue:9

    Topics: Adenine; AIDS-Related Opportunistic Infections; Antiviral Agents; Drug Resistance, Viral; Hepatitis

2004
Emerging treatments in chronic hepatitis B.
    Expert opinion on emerging drugs, 2004, Volume: 9, Issue:2

    Topics: Adenine; Antiviral Agents; Clinical Trials as Topic; Drug Combinations; Drug Resistance, Viral; Drug

2004
Treatment of chronic viral hepatitis.
    Best practice & research. Clinical gastroenterology, 2004, Volume: 18 Suppl

    Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Hepatitis B, Chronic; Hepatitis C, Chronic; He

2004
The management of chronic viral hepatitis: a Canadian consensus conference 2004.
    Canadian journal of gastroenterology = Journal canadien de gastroenterologie, 2004, Volume: 18, Issue:12

    Topics: Adenine; Adult; Antiviral Agents; Canada; Child; Child, Preschool; Drug Therapy, Combination; Enzyme

2004
[Subjective literature review: adefovir-dipivoxil].
    Medecine et maladies infectieuses, 2004, Volume: 34, Issue:4

    Topics: Adenine; Antiviral Agents; Clinical Trials as Topic; Hepatitis B, Chronic; Humans; Organophosphonate

2004
Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel.
    AIDS (London, England), 2005, Feb-18, Volume: 19, Issue:3

    Topics: Adenine; Antiviral Agents; Comorbidity; Deoxycytidine; Disease Progression; Drug Monitoring; Emtrici

2005
[Chronic hepatitis B: which patients should be treated and how?].
    Gastroenterologie clinique et biologique, 2005, Volume: 29, Issue:4

    Topics: Adenine; Antiviral Agents; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamiv

2005
[Management of chronic hepatitis B].
    Praxis, 2005, Apr-20, Volume: 94, Issue:16

    Topics: Adenine; Adolescent; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Hepatitis B virus;

2005
Adefovir dipivoxil: focus on its use in the treatment of chronic hepatitis B.
    Reviews in gastroenterological disorders, 2005,Spring, Volume: 5, Issue:2

    Topics: Adenine; Antiviral Agents; Clinical Trials as Topic; Drug Monitoring; Hepatitis B, Chronic; Humans;

2005
[Clinical and virologic characteristics and treatment for chronic hepatitis B: relation with HBV genotypes].
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2005, Volume: 102, Issue:6

    Topics: Adenine; Antiviral Agents; Genotype; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic

2005
[Drug therapy in chronic liver disease].
    Praxis, 2005, Nov-30, Volume: 94, Issue:48

    Topics: Adenine; Administration, Oral; Anti-HIV Agents; Antiviral Agents; Azathioprine; Cholangitis, Scleros

2005
Therapeutic options for chronic hepatitis B: considerations and controversies.
    The American journal of gastroenterology, 2006, Volume: 101 Suppl 1

    Topics: Adenine; Antiviral Agents; Decision Making; DNA, Viral; Hepatitis B Antigens; Hepatitis B virus; Hep

2006
[New virologic tests and their application in management of chronic hepatitis B].
    Presse medicale (Paris, France : 1983), 2006, Volume: 35, Issue:2 Pt 2

    Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Genetic Variation; Genotype; Hepatiti

2006
[Treatment of chronic hepatitis B].
    Presse medicale (Paris, France : 1983), 2006, Volume: 35, Issue:2 Pt 2

    Topics: Adenine; Administration, Oral; Antiviral Agents; Biopsy; DNA, Viral; Drug Resistance, Viral; Drug Th

2006
[Liver transplantation for complications of hepatitis B].
    Presse medicale (Paris, France : 1983), 2006, Volume: 35, Issue:2 Pt 2

    Topics: Adenine; Antiviral Agents; Clinical Trials as Topic; Drug Resistance, Viral; Drug Therapy, Combinati

2006
Medical therapy of patients affected by HBeAg-negative chronic hepatitis B.
    Minerva gastroenterologica e dietologica, 2006, Volume: 52, Issue:1

    Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferon

2006
Personal view: the management of chronic hepatitis B infection.
    Alimentary pharmacology & therapeutics, 2006, Apr-01, Volume: 23, Issue:7

    Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Guanine; H

2006
Current treatment of chronic hepatitis B.
    Archives of Iranian medicine, 2006, Volume: 9, Issue:1

    Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Forecasting; Hepatitis B e Antigens; Hepatitis

2006
Management of chronic hepatitis B virus infection: current perspectives for the nurse practitioner.
    Journal of the American Academy of Nurse Practitioners, 2006, Volume: 18, Issue:5

    Topics: Acute Disease; Adenine; Algorithms; Antiviral Agents; Carcinoma, Hepatocellular; Carrier State; Dise

2006
Antiviral treatment for chronic hepatitis B virus infection--immune modulation or viral suppression?
    The Netherlands journal of medicine, 2006, Volume: 64, Issue:6

    Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Fibrosis; Genotype; Hepatitis B e Antigens; He

2006
Perspectives on the development of acyclic nucleotide analogs as antiviral drugs.
    Antiviral research, 2006, Volume: 71, Issue:2-3

    Topics: Adenine; Animals; Antiviral Agents; Dogs; Drug Design; Hepatitis B virus; Hepatitis B, Chronic; HIV

2006
Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Health technology assessment (Winchester, England), 2006, Volume: 10, Issue:28

    Topics: Adenine; Antiviral Agents; Cost-Benefit Analysis; Drug Carriers; Drug Therapy, Combination; Health S

2006
New developments in the treatment of chronic hepatitis B.
    Expert opinion on biological therapy, 2006, Volume: 6, Issue:9

    Topics: Adenine; Animals; Antiviral Agents; Clinical Trials as Topic; DNA, Viral; Drug Resistance, Viral; Dr

2006
Chronic Hepatitis B and C--current treatment and future therapeutic prospects.
    Wiener medizinische Wochenschrift (1946), 2006, Volume: 156, Issue:13-14

    Topics: Adenine; Antiviral Agents; DNA-Directed RNA Polymerases; Hepatitis B e Antigens; Hepatitis B, Chroni

2006
[Therapy of hepatitis B].
    Praxis, 2006, Sep-06, Volume: 95, Issue:36

    Topics: Adenine; Administration, Oral; Antiviral Agents; Diagnosis, Differential; Hepatitis B, Chronic; Huma

2006
[Therapy of hepatitis B virus infection].
    Praxis, 2006, Sep-06, Volume: 95, Issue:36

    Topics: Adenine; Antiviral Agents; Drug Antagonism; Drug Resistance, Viral; Drug Synergism; Drug Therapy, Co

2006
[Managing resistance to analogue antiviral drugs in a decompensated cirrhosis patient].
    Gastroenterologie clinique et biologique, 2006, Volume: 30, Issue:10 Pt 2

    Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B virus; Hep

2006
[Treating chronic lamivudine-resistant hepatitis B in HIV co-infected patients].
    Gastroenterologie clinique et biologique, 2006, Volume: 30, Issue:10 Pt 2

    Topics: Adenine; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiviral Agents; Drug Resistance,

2006
[Managing lamivudine resistance in liver transplantation for hepatitis B liver disease].
    Gastroenterologie clinique et biologique, 2006, Volume: 30, Issue:10 Pt 2

    Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B; Hepatitis

2006
Why adefovir is not yet available in Canada.
    Canadian journal of gastroenterology = Journal canadien de gastroenterologie, 2006, Volume: 20, Issue:11

    Topics: Adenine; Antiviral Agents; Canada; Drug Utilization; Hepatitis B, Chronic; Humans; Immunosuppressive

2006
Cross-study analysis of the relative efficacies of oral antiviral therapies for chronic hepatitis B infection in nucleoside-naive patients.
    Clinical drug investigation, 2007, Volume: 27, Issue:1

    Topics: Adenine; Administration, Oral; Algorithms; Antiviral Agents; Clinical Trials, Phase II as Topic; Cli

2007
[Resistance to adefovir in patients with chronic hepatitis B].
    The Korean journal of hepatology, 2006, Volume: 12, Issue:4

    Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans;

2006
A systematic review and economic evaluation of adefovir dipivoxil and pegylated interferon-alpha-2a for the treatment of chronic hepatitis B.
    Journal of viral hepatitis, 2007, Volume: 14, Issue:2

    Topics: Adenine; Antiviral Agents; Cost-Benefit Analysis; England; Hepatitis B e Antigens; Hepatitis B, Chro

2007
Improving outcomes for patients with chronic hepatitis B.
    Current gastroenterology reports, 2007, Volume: 9, Issue:1

    Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Guanine; Hepatitis B Vaccines; Hepatitis B, Chron

2007
Treatment paradigms on hepatitis B e antigen-negative chronic hepatitis B patients.
    Expert opinion on investigational drugs, 2007, Volume: 16, Issue:6

    Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Guanine; Hepatitis B e Antigens; Hepatitis B, Chr

2007
Treatment of chronic hepatitis B in HIV-infected patients in 2007.
    Journal of HIV therapy, 2007, Volume: 12, Issue:1

    Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; HIV Infections; Humans; Interferon-alpha;

2007
Chronic hepatitis B with advanced fibrosis or cirrhosis: impact of antiviral therapy.
    Reviews in gastroenterological disorders, 2007,Spring, Volume: 7, Issue:2

    Topics: Adenine; Antiviral Agents; Disease Progression; DNA, Viral; Drug Resistance, Viral; Guanine; Hepatit

2007
Comparative cost-effectiveness of antiviral therapies in patients with chronic hepatitis B: a systematic review of economic evidence.
    Journal of gastroenterology and hepatology, 2007, Volume: 22, Issue:9

    Topics: Adenine; Antiviral Agents; China; Cost-Benefit Analysis; Databases, Factual; Hepatitis B, Chronic; H

2007
[Indications for antiviral therapy for chronic hepatitis B].
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2007, Volume: 104, Issue:10

    Topics: Adenine; Antiviral Agents; Biomarkers; Carrier State; Consensus Development Conferences as Topic; DN

2007
[Therapy for chronic hepatitis B: relationship between HBV genotype and efficacy or resistance of anti-viral therapy].
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2007, Volume: 104, Issue:10

    Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Genotype; Guanine; Hepatitis B virus; Hepatitis B

2007
Review article: Success and failure of nucleoside and nucleotide analogues in chronic hepatitis B.
    Alimentary pharmacology & therapeutics, 2007, Volume: 26 Suppl 2

    Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Guanine; Hepatitis B, Chronic; Humans; Lamivudine

2007
[Pharmacological agents for the treatment of chronic hepatitis B].
    Gastroenterologia y hepatologia, 2008, Volume: 31, Issue:3

    Topics: Adenine; Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Follow-Up Studies; G

2008
Evaluating anti-viral drug selection and treatment duration in HBeAg-negative chronic hepatitis B: a cost-effectiveness analysis.
    Alimentary pharmacology & therapeutics, 2008, Volume: 27, Issue:12

    Topics: Adenine; Antiviral Agents; Cost-Benefit Analysis; Epidemiologic Methods; Guanine; Hepatitis B e Anti

2008
Clinical implications of resistance patterns against HBV-polymerase inhibitors for the treatment of chronic hepatitis B.
    Journal of HIV therapy, 2007, Volume: 12, Issue:4

    Topics: Adenine; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B, Chronic; Humans; Lamivudine

2007
Review article: current antiviral therapy of chronic hepatitis B.
    Alimentary pharmacology & therapeutics, 2008, Volume: 28, Issue:2

    Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Deoxycytidine; Drug Resistance, Viral; Emtrici

2008
[New developments in therapy of chronic hepatitis B. When are nucleoside analogs indicated?].
    Zeitschrift fur Gastroenterologie, 2000, Volume: 38, Issue:1

    Topics: Adenine; Antiviral Agents; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Liver Transpl

2000
Current limitations to nucleoside analogue therapy for chronic hepatitis B virus infection in the liver transplant and non-transplant settings.
    Journal of gastroenterology and hepatology, 2000, Volume: 15, Issue:3

    Topics: 2-Aminopurine; Adenine; Antiviral Agents; DNA, Viral; Famciclovir; Hepatitis B e Antigens; Hepatitis

2000
Nucleoside analogues in the treatment of chronic hepatitis B.
    Journal of gastroenterology and hepatology, 2000, Volume: 15 Suppl

    Topics: 2-Aminopurine; Adenine; Antiviral Agents; Deoxycytidine; Emtricitabine; Famciclovir; Hepatitis B e A

2000
Drug therapy for hepatitis B.
    Advances in internal medicine, 2001, Volume: 46

    Topics: Adenine; Antiviral Agents; Disease Progression; Female; Hepatitis B, Chronic; Humans; Interferons; L

2001
Hepatitis B infection in China.
    Clinics in liver disease, 2001, Volume: 5, Issue:2

    Topics: 2-Aminopurine; Adenine; Antiviral Agents; China; Deoxycytidine; DNA, Viral; Drug Therapy, Combinatio

2001
[Current knowledge on chronic hepatitis B therapy].
    Gastroenterologie clinique et biologique, 2001, Volume: 25, Issue:4 Suppl

    Topics: Adenine; Antiviral Agents; Drug Resistance, Microbial; Hepatitis B, Chronic; Humans; Interferon-alph

2001
Nucleoside analogues for chronic hepatitis B.
    European journal of gastroenterology & hepatology, 2001, Volume: 13, Issue:12

    Topics: 2-Aminopurine; Adenine; Antiviral Agents; Famciclovir; Ganciclovir; Guanine; Hepatitis B virus; Hepa

2001
How will we use the new antiviral agents for hepatitis B?
    Current gastroenterology reports, 2002, Volume: 4, Issue:1

    Topics: 2-Aminopurine; Adenine; Alanine Transaminase; Antiviral Agents; Drug Resistance; Drug Therapy, Combi

2002
Adefovir dipivoxil. Bis-POM PMEA, GS 0840, GS 840, Piv2PMEA.
    Drugs in R&D, 2002, Volume: 3, Issue:3

    Topics: Adenine; Animals; Clinical Trials as Topic; Drug Industry; Hepatitis B, Chronic; HIV Infections; Hum

2002

Trials

228 trials available for adenine and Hepatitis B, Chronic

ArticleYear
Pradefovir Treatment in Patients With Chronic Hepatitis B: Week 24 Results From a Multicenter, Double-Blind, Randomized, Noninferiority, Phase 2 Trial.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2022, 06-10, Volume: 74, Issue:11

    Topics: Adenine; Antiviral Agents; DNA, Viral; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chron

2022
Non-Inferior Efficacy of Tenofovir Disoproxil to Tenofovir Disoproxil Fumarate in Virologically Suppressed Chronic Hepatitis B Patients.
    Drug design, development and therapy, 2022, Volume: 16

    Topics: Adenine; Antiviral Agents; Creatinine; DNA, Viral; Fumarates; Hepatitis B e Antigens; Hepatitis B vi

2022
Switching to tenofovir alafenamide versus continued therapy in chronic hepatitis B patients who were treated with entecavir: A prospective, multicenter, randomized controlled study.
    Medicine, 2022, Sep-30, Volume: 101, Issue:39

    Topics: Adenine; Alanine; Antiviral Agents; DNA, Viral; Female; Fumarates; Guanine; Hepatitis B Surface Anti

2022
Safety, efficacy, and pharmacokinetics of pradefovir for the treatment of chronic hepatitis B infection.
    Antiviral research, 2020, Volume: 174

    Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Hepatitis B virus;

2020
Adefovir Dipivoxil plus Chinese Medicine in HBeAg-Positive Chronic Hepatitis B Patients: A Randomized Controlled 48-Week Trial.
    Chinese journal of integrative medicine, 2020, Volume: 26, Issue:5

    Topics: Adenine; Adult; Antiviral Agents; Double-Blind Method; Drug Therapy, Combination; Drugs, Chinese Her

2020
Mitochondrial toxicity and body shape changes during nucleos(t)ide analogues administration in patients with chronic hepatitis B.
    Scientific reports, 2020, 02-06, Volume: 10, Issue:1

    Topics: Adenine; Adiposity; Antiviral Agents; Cross-Sectional Studies; DNA, Mitochondrial; DNA, Viral; Drug

2020
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study.
    The lancet. Gastroenterology & hepatology, 2020, Volume: 5, Issue:5

    Topics: Adenine; Alanine; Antiviral Agents; Bone Density; Creatinine; DNA, Viral; Double-Blind Method; Drug

2020
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study.
    The lancet. Gastroenterology & hepatology, 2020, Volume: 5, Issue:5

    Topics: Adenine; Alanine; Antiviral Agents; Bone Density; Creatinine; DNA, Viral; Double-Blind Method; Drug

2020
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study.
    The lancet. Gastroenterology & hepatology, 2020, Volume: 5, Issue:5

    Topics: Adenine; Alanine; Antiviral Agents; Bone Density; Creatinine; DNA, Viral; Double-Blind Method; Drug

2020
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study.
    The lancet. Gastroenterology & hepatology, 2020, Volume: 5, Issue:5

    Topics: Adenine; Alanine; Antiviral Agents; Bone Density; Creatinine; DNA, Viral; Double-Blind Method; Drug

2020
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
Entecavir+tenofovir vs. lamivudine/telbivudine+adefovir in chronic hepatitis B patients with prior suboptimal response.
    Clinical and molecular hepatology, 2020, Volume: 26, Issue:3

    Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Administration Schedule; Drug Resistance, Viral;

2020
Efficacy of 104-week Telbivudine-based optimization strategy in patients with HBeAg-negative chronic hepatitis B virus infections.
    BMC infectious diseases, 2020, Dec-07, Volume: 20, Issue:1

    Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; China; Creatinine; DNA, Viral; Drug Therapy,

2020
Short-term and long-term safety and efficacy of tenofovir alafenamide, tenofovir disoproxil fumarate and entecavir treatment of acute-on-chronic liver failure associated with hepatitis B.
    BMC infectious diseases, 2021, Jun-14, Volume: 21, Issue:1

    Topics: Acute-On-Chronic Liver Failure; Adenine; Adult; Alanine; Antiviral Agents; Guanine; Hepatitis B viru

2021
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-B

2016
Peg-interferon plus nucleotide analogue treatment versus no treatment in patients with chronic hepatitis B with a low viral load: a randomised controlled, open-label trial.
    The lancet. Gastroenterology & hepatology, 2017, Volume: 2, Issue:8

    Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; Female; Hepatitis B Antibo

2017
Combinational use of hepatitis B viral antigens predicts responses to nucleos(t)ide analogue/peg-interferon sequential therapy.
    Journal of gastroenterology, 2018, Volume: 53, Issue:2

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Antiviral Agents; Biomarkers; Drug Administration Schedule;

2018
Addition of nucleoside analogues to peg-IFNα-2a enhances virological response in chronic hepatitis B patients without early response to peg-IFNα-2a: a randomized controlled trial.
    BMC gastroenterology, 2017, Aug-30, Volume: 17, Issue:1

    Topics: Adenine; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Guanine; Hepatitis B e Antigens

2017
Effects of the combined administration of entecavir and adefovir dipivoxil to improve hepatic fibrosis in hepatitis B patients with interferon resistance.
    Minerva medica, 2017, Volume: 108, Issue:6

    Topics: Adenine; Aged; Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Bilirubin; Creat

2017
Tenofovir
    World journal of gastroenterology, 2017, 11-07, Volume: 23, Issue:41

    Topics: Adenine; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Dr

2017
Evaluating the efficacy of switching from lamivudine plus adefovir to tenofovir disoproxil fumarate monotherapy in lamivudine-resistant stable hepatitis B patients.
    PloS one, 2018, Volume: 13, Issue:1

    Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Fem

2018
ALT flares during nucleotide analogue therapy are associated with HBsAg loss in genotype A HBeAg-positive chronic hepatitis B.
    Liver international : official journal of the International Association for the Study of the Liver, 2018, Volume: 38, Issue:10

    Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind Method; Female; Hep

2018
Phase IV randomized clinical study: Peginterferon alfa-2a with adefovir or entecavir pre-therapy for HBeAg-positive chronic hepatitis B.
    Journal of the Formosan Medical Association = Taiwan yi zhi, 2018, Volume: 117, Issue:7

    Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind Method; Drug Admini

2018
Combined effect of pegylated interferon α with adefovir on renal function in Chinese patients with chronic hepatitis B.
    Medicine, 2018, Volume: 97, Issue:34

    Topics: Adenine; Adult; Antiviral Agents; China; Drug Therapy, Combination; Female; Glomerular Filtration Ra

2018
Ten-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B virus infection.
    Liver international : official journal of the International Association for the Study of the Liver, 2019, Volume: 39, Issue:10

    Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Biomarkers; DNA, Viral; Double-Blind Method; Dru

2019
Ten-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B virus infection.
    Liver international : official journal of the International Association for the Study of the Liver, 2019, Volume: 39, Issue:10

    Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Biomarkers; DNA, Viral; Double-Blind Method; Dru

2019
Ten-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B virus infection.
    Liver international : official journal of the International Association for the Study of the Liver, 2019, Volume: 39, Issue:10

    Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Biomarkers; DNA, Viral; Double-Blind Method; Dru

2019
Ten-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B virus infection.
    Liver international : official journal of the International Association for the Study of the Liver, 2019, Volume: 39, Issue:10

    Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Biomarkers; DNA, Viral; Double-Blind Method; Dru

2019
Switching from entecavir to tenofovir alafenamide versus maintaining entecavir for chronic hepatitis B.
    Journal of medical virology, 2019, Volume: 91, Issue:10

    Topics: Adenine; Adult; Aged; Alanine; Antiviral Agents; Female; Guanine; Hepatitis B Surface Antigens; Hepa

2019
Switching from entecavir to tenofovir alafenamide versus maintaining entecavir for chronic hepatitis B.
    Journal of medical virology, 2019, Volume: 91, Issue:10

    Topics: Adenine; Adult; Aged; Alanine; Antiviral Agents; Female; Guanine; Hepatitis B Surface Antigens; Hepa

2019
Switching from entecavir to tenofovir alafenamide versus maintaining entecavir for chronic hepatitis B.
    Journal of medical virology, 2019, Volume: 91, Issue:10

    Topics: Adenine; Adult; Aged; Alanine; Antiviral Agents; Female; Guanine; Hepatitis B Surface Antigens; Hepa

2019
Switching from entecavir to tenofovir alafenamide versus maintaining entecavir for chronic hepatitis B.
    Journal of medical virology, 2019, Volume: 91, Issue:10

    Topics: Adenine; Adult; Aged; Alanine; Antiviral Agents; Female; Guanine; Hepatitis B Surface Antigens; Hepa

2019
Predicting HBsAg clearance in genotype A chronic hepatitis B using HBsAg epitope profiling: A biomarker for functional cure.
    Liver international : official journal of the International Association for the Study of the Liver, 2019, Volume: 39, Issue:11

    Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; Biomarkers; DNA, Viral; Double-Blind Method;

2019
Randomized trial of emtricitabine/tenofovir disoproxil fumarate after hepatitis B immunoglobulin withdrawal after liver transplantation.
    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2013, Volume: 19, Issue:6

    Topics: Adenine; Adult; Aged; Antiviral Agents; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Fem

2013
Efficacy and safety of telbivudine plus adefovir dipivoxil combination therapy and entecavir monotherapy for HBeAg-positive chronic hepatitis B patients with resistance to adefovir dipivoxil.
    Journal of viral hepatitis, 2013, Volume: 20 Suppl 1

    Topics: Adenine; Adult; Antiviral Agents; China; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combinati

2013
Efficacy of telbivudine treatment for hepatitis B e antigen-positive chronic hepatitis B patients with poor response to adefovir dipivoxil.
    Journal of viral hepatitis, 2013, Volume: 20 Suppl 1

    Topics: Adenine; Adult; Antiviral Agents; China; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B e A

2013
Two years efficiency of lamivudine and adefovir dipivoxil combined therapy in chronic hepatitis B patients.
    European review for medical and pharmacological sciences, 2013, Volume: 17, Issue:5

    Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Hepatitis B, Chroni

2013
Antiviral efficacies of currently available rescue therapies for multidrug-resistant chronic hepatitis B.
    Clinical and molecular hepatology, 2013, Volume: 19, Issue:1

    Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combinatio

2013
Extended treatment with peginterferon α-2a in combination with lamivudine or adefovir for 96 weeks yields high rates of HBeAg and HBsAg seroconversion.
    Journal of digestive diseases, 2013, Volume: 14, Issue:8

    Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Administration Schedule; Drug Therapy, Combinatio

2013
Baseline hepatitis B surface antigen (HBsAg) as predictor of sustained HBsAg loss in chronic hepatitis B patients treated with pegylated interferon-α2a and adefovir.
    Antiviral therapy, 2013, Volume: 18, Issue:7

    Topics: Adenine; Adult; Aged; Antiviral Agents; Biopsy; Drug Therapy, Combination; Female; Follow-Up Studies

2013
Randomized trial of the virologic response during up to two years of entecavir-adefovir combination therapy in multiple-drug-refractory chronic hepatitis B virus patients.
    Antimicrobial agents and chemotherapy, 2013, Volume: 57, Issue:7

    Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy

2013
Similar evolution of hepatitis B virus quasispecies in patients with incomplete adefovir response receiving tenofovir/emtricitabine combination or tenofovir monotherapy.
    Journal of hepatology, 2013, Volume: 59, Issue:4

    Topics: Adenine; Adult; Antiviral Agents; Deoxycytidine; DNA, Viral; Double-Blind Method; Drug Resistance, V

2013
Safety of coitally administered tenofovir 1% gel, a vaginal microbicide, in chronic hepatitis B virus carriers: results from the CAPRISA 004 trial.
    Antiviral research, 2013, Volume: 99, Issue:3

    Topics: Adenine; Adult; Anti-Infective Agents, Local; Antiviral Agents; Carrier State; Female; Hepatitis B v

2013
Telbivudine and adefovir combination therapy for patients with chronic lamivudine-resistant hepatitis B virus infections.
    Archives of virology, 2014, Volume: 159, Issue:1

    Topics: Adenine; Adult; Aged; Antibodies, Viral; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Com

2014
No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B.
    Hepatology (Baltimore, Md.), 2014, Volume: 59, Issue:2

    Topics: Adenine; Antiviral Agents; DNA, Viral; Double-Blind Method; Drug Resistance, Viral; Genotype; Hepati

2014
No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B.
    Hepatology (Baltimore, Md.), 2014, Volume: 59, Issue:2

    Topics: Adenine; Antiviral Agents; DNA, Viral; Double-Blind Method; Drug Resistance, Viral; Genotype; Hepati

2014
No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B.
    Hepatology (Baltimore, Md.), 2014, Volume: 59, Issue:2

    Topics: Adenine; Antiviral Agents; DNA, Viral; Double-Blind Method; Drug Resistance, Viral; Genotype; Hepati

2014
No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B.
    Hepatology (Baltimore, Md.), 2014, Volume: 59, Issue:2

    Topics: Adenine; Antiviral Agents; DNA, Viral; Double-Blind Method; Drug Resistance, Viral; Genotype; Hepati

2014
[Clinical efficacy of various antiviral-based strategies to treat chronic hepatitis patients with positivity for hepatitis B e antigen and rtN236T mutation].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2013, Volume: 21, Issue:3

    Topics: Adenine; Adult; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis B e Antigens; H

2013
[Efficacy and safety of peginterferon alfa-2a (40 kd) plus adefovir for 96 weeks in HBeAg-negative chronic hepatitis B patients].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2013, Volume: 21, Issue:7

    Topics: Adenine; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis B e Antigens; Hepatit

2013
Antiviral treatment improves disrupted peripheral B lymphocyte homeostasis in chronic hepatitis B virus-infected patients.
    Experimental biology and medicine (Maywood, N.J.), 2013, Nov-01, Volume: 238, Issue:11

    Topics: Adenine; Adult; Antiviral Agents; B-Lymphocytes; Female; Flow Cytometry; Hepatitis B, Chronic; Homeo

2013
De novo combination therapy adefovir plus lamivudine as a treatment for women of child-bearing age with HBeAg-positive chronic hepatitis B before pregnancy.
    Journal of medical virology, 2014, Volume: 86, Issue:3

    Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Antiviral Agents; Disease Transmission, Infectious

2014
Add-on peg-interferon leads to loss of HBsAg in patients with HBeAg-negative chronic hepatitis and HBV DNA fully suppressed by long-term nucleotide analogs.
    Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2013, Volume: 58, Issue:4

    Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Female; Guanine; Hepatitis B e Antigens; Hepatit

2013
Add-on peg-interferon leads to loss of HBsAg in patients with HBeAg-negative chronic hepatitis and HBV DNA fully suppressed by long-term nucleotide analogs.
    Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2013, Volume: 58, Issue:4

    Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Female; Guanine; Hepatitis B e Antigens; Hepatit

2013
Add-on peg-interferon leads to loss of HBsAg in patients with HBeAg-negative chronic hepatitis and HBV DNA fully suppressed by long-term nucleotide analogs.
    Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2013, Volume: 58, Issue:4

    Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Female; Guanine; Hepatitis B e Antigens; Hepatit

2013
Add-on peg-interferon leads to loss of HBsAg in patients with HBeAg-negative chronic hepatitis and HBV DNA fully suppressed by long-term nucleotide analogs.
    Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2013, Volume: 58, Issue:4

    Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Female; Guanine; Hepatitis B e Antigens; Hepatit

2013
Experimental HBsAg/anti-HBs complex assay for prediction of HBeAg loss in chronic hepatitis B patients treated with pegylated interferon and adefovir.
    Antiviral therapy, 2014, Volume: 19, Issue:3

    Topics: Adenine; Adult; Antigen-Antibody Complex; Antiviral Agents; Area Under Curve; DNA, Viral; Female; He

2014
Long-term efficacy and safety of emtricitabine plus tenofovir DF vs. tenofovir DF monotherapy in adefovir-experienced chronic hepatitis B patients.
    Journal of hepatology, 2014, Volume: 60, Issue:4

    Topics: Adenine; Antiviral Agents; Deoxycytidine; DNA, Viral; Double-Blind Method; Drug Resistance, Viral; D

2014
Maintaining remission in lamivudine-resistant patients with a virological response to adefovir add-on lamivudine after stopping lamivudine therapy.
    Liver international : official journal of the International Association for the Study of the Liver, 2014, Volume: 34, Issue:10

    Topics: Adenine; Alanine Transaminase; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination;

2014
Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B.
    Gastroenterology, 2014, Volume: 146, Issue:4

    Topics: Adenine; Adult; Antiviral Agents; Biomarkers; Deoxycytidine; DNA, Viral; Double-Blind Method; Drug C

2014
[Therapeutic effect of antiviral regimens for chronic hepatitis B refractory to lamivudine plus adefovir].
    Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2013, Volume: 33, Issue:12

    Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Guanine; Hepatitis B v

2013
The 104-week efficacy and safety of telbivudine-based optimization strategy in chronic hepatitis B patients: a randomized, controlled study.
    Hepatology (Baltimore, Md.), 2014, Volume: 59, Issue:4

    Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Antiviral Agents; China; Dose-Response Relationshi

2014
Efficacy of switching to telbivudine plus adefovir in suboptimal responders to lamivudine plus adefovir.
    World journal of gastroenterology, 2013, Volume: 19, Issue:43

    Topics: Adenine; Administration, Oral; Adult; Aged; Antiviral Agents; Biomarkers; DNA, Viral; Drug Administr

2013
Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA.
    Gastroenterology, 2014, Volume: 146, Issue:5

    Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Antiviral Agents; Biomarkers; Deoxycytidine; DNA,

2014
Efficacy and safety of tenofovir disoproxil fumarate in Asian-Americans with chronic hepatitis B in community settings.
    PloS one, 2014, Volume: 9, Issue:3

    Topics: Adenine; Adolescent; Adult; Asian; Creatinine; Drug Resistance, Viral; Female; Hepatitis B, Chronic;

2014
Safety and immunogenicity of therapeutic DNA vaccine with antiviral drug in chronic HBV patients and its immunogenicity in mice.
    Liver international : official journal of the International Association for the Study of the Liver, 2015, Volume: 35, Issue:3

    Topics: Adenine; Adult; Animals; Antibody Formation; Antiviral Agents; DNA, Viral; Female; Hepatitis B e Ant

2015
Entecavir 1mg versus combined lamivudine/adefovir dipivoxil in chronic HBV Egyptian patients resistant to LAM monotherapy, non-randomised controlled study.
    Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology, 2014, Volume: 15, Issue:1

    Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Egy

2014
Non-interventional study AI463-12 of real-world chronic HBV infection management--baseline characteristics and treatment patterns of Polish patients kohort.
    Przeglad epidemiologiczny, 2013, Volume: 67, Issue:4

    Topics: Adenine; Adult; Antiviral Agents; Cohort Studies; Europe; Female; Guanine; Hepatitis B, Chronic; Hum

2013
Persistent viremia in human immunodeficiency virus/hepatitis B coinfected patients undergoing long-term tenofovir: virological and clinical implications.
    Hepatology (Baltimore, Md.), 2014, Volume: 60, Issue:2

    Topics: Adenine; Adult; Coinfection; DNA, Viral; Drug Resistance, Viral; Female; Follow-Up Studies; Genotype

2014
[Long-term efficacy and safety of telbivudine as monotherapy and as combination therapy with adefovir dipivoxil in HBeAg-positive chronic hepatitis B patients].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2014, Volume: 22, Issue:3

    Topics: Adenine; Adolescent; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis B e Antig

2014
Role of a 48-week pegylated interferon therapy in hepatitis B e antigen positive HIV-co-infected patients on cART including tenofovir: EMVIPEG study.
    Journal of hepatology, 2014, Volume: 61, Issue:4

    Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; CD4 Lymphocyte Count; Coinf

2014
First-line monotherapies of tenofovir and entecavir have comparable efficacies in hepatitis B treatment.
    European journal of gastroenterology & hepatology, 2014, Volume: 26, Issue:7

    Topics: Adenine; Adolescent; Adult; Antiviral Agents; Cohort Studies; Drug Resistance, Viral; Female; Follow

2014
Kinetics and prediction of HBsAg loss during long-term therapy with nucleos(t)ide analogues of different potency in patients with chronic hepatitis B.
    PloS one, 2014, Volume: 9, Issue:6

    Topics: Adenine; Adult; Antiviral Agents; Female; Guanine; Hepatitis B Surface Antigens; Hepatitis B, Chroni

2014
No resistance to tenofovir disoproxil fumarate through 96 weeks of treatment in patients with lamivudine-resistant chronic hepatitis B.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2014, Volume: 12, Issue:12

    Topics: Adenine; Antiviral Agents; Deoxycytidine; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combinat

2014
Kinetics of hepatitis B surface antigen loss in patients with HBeAg-positive chronic hepatitis B treated with tenofovir disoproxil fumarate.
    Journal of hepatology, 2014, Volume: 61, Issue:6

    Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Antiviral Agents; Double-Blind Method; Female; Gen

2014
Antiviral therapy improves postoperative survival in patients with hepatocellular carcinoma: a randomized controlled trial.
    Annals of surgery, 2015, Volume: 261, Issue:1

    Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Hepatitis

2015
Combination therapy with pegylated interferon alpha-2b and adefovir dipivoxil in HBeAg-positive chronic hepatitis B versus interferon alone: a prospective, randomized study.
    Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban, 2014, Volume: 34, Issue:4

    Topics: Adenine; Adolescent; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis B e Antig

2014
Viral suppression and cirrhosis regression with tenofovir disoproxil fumarate in Asians with chronic hepatitis B.
    Digestive diseases and sciences, 2015, Volume: 60, Issue:1

    Topics: Adenine; DNA, Viral; Double-Blind Method; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; I

2015
Viral suppression and cirrhosis regression with tenofovir disoproxil fumarate in Asians with chronic hepatitis B.
    Digestive diseases and sciences, 2015, Volume: 60, Issue:1

    Topics: Adenine; DNA, Viral; Double-Blind Method; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; I

2015
Viral suppression and cirrhosis regression with tenofovir disoproxil fumarate in Asians with chronic hepatitis B.
    Digestive diseases and sciences, 2015, Volume: 60, Issue:1

    Topics: Adenine; DNA, Viral; Double-Blind Method; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; I

2015
Viral suppression and cirrhosis regression with tenofovir disoproxil fumarate in Asians with chronic hepatitis B.
    Digestive diseases and sciences, 2015, Volume: 60, Issue:1

    Topics: Adenine; DNA, Viral; Double-Blind Method; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; I

2015
Tenofovir disoproxil fumarate vs adefovir dipivoxil in Chinese patients with chronic hepatitis B after 48 weeks: a randomized controlled trial.
    Journal of viral hepatitis, 2015, Volume: 22, Issue:2

    Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Asian People; China; DNA, Viral; Double-Blind Me

2015
Tenofovir disoproxil fumarate vs adefovir dipivoxil in Chinese patients with chronic hepatitis B after 48 weeks: a randomized controlled trial.
    Journal of viral hepatitis, 2015, Volume: 22, Issue:2

    Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Asian People; China; DNA, Viral; Double-Blind Me

2015
Tenofovir disoproxil fumarate vs adefovir dipivoxil in Chinese patients with chronic hepatitis B after 48 weeks: a randomized controlled trial.
    Journal of viral hepatitis, 2015, Volume: 22, Issue:2

    Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Asian People; China; DNA, Viral; Double-Blind Me

2015
Tenofovir disoproxil fumarate vs adefovir dipivoxil in Chinese patients with chronic hepatitis B after 48 weeks: a randomized controlled trial.
    Journal of viral hepatitis, 2015, Volume: 22, Issue:2

    Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Asian People; China; DNA, Viral; Double-Blind Me

2015
Tenofovir disoproxil fumarate in Asian or Pacific Islander chronic hepatitis B patients with high viral load (≥ 9 log10 copies/ml).
    Liver international : official journal of the International Association for the Study of the Liver, 2015, Volume: 35, Issue:2

    Topics: Adenine; Adult; Asian People; Drug Resistance, Viral; Hepatitis B, Chronic; Humans; Native Hawaiian

2015
Tenofovir disoproxil fumarate in Asian or Pacific Islander chronic hepatitis B patients with high viral load (≥ 9 log10 copies/ml).
    Liver international : official journal of the International Association for the Study of the Liver, 2015, Volume: 35, Issue:2

    Topics: Adenine; Adult; Asian People; Drug Resistance, Viral; Hepatitis B, Chronic; Humans; Native Hawaiian

2015
Tenofovir disoproxil fumarate in Asian or Pacific Islander chronic hepatitis B patients with high viral load (≥ 9 log10 copies/ml).
    Liver international : official journal of the International Association for the Study of the Liver, 2015, Volume: 35, Issue:2

    Topics: Adenine; Adult; Asian People; Drug Resistance, Viral; Hepatitis B, Chronic; Humans; Native Hawaiian

2015
Tenofovir disoproxil fumarate in Asian or Pacific Islander chronic hepatitis B patients with high viral load (≥ 9 log10 copies/ml).
    Liver international : official journal of the International Association for the Study of the Liver, 2015, Volume: 35, Issue:2

    Topics: Adenine; Adult; Asian People; Drug Resistance, Viral; Hepatitis B, Chronic; Humans; Native Hawaiian

2015
Randomized, three-arm study to optimize lamivudine efficacy in hepatitis B e antigen-positive chronic hepatitis B patients.
    Journal of gastroenterology and hepatology, 2015, Volume: 30, Issue:4

    Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Female; H

2015
Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection.
    Journal of hepatology, 2015, Volume: 62, Issue:3

    Topics: Adenine; Adult; Alanine; Antiviral Agents; DNA, Viral; Female; Hepatitis B, Chronic; Humans; Male; M

2015
Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection.
    Digestive diseases and sciences, 2015, Volume: 60, Issue:5

    Topics: Adenine; Antiviral Agents; Biomarkers; DNA, Viral; Drug Administration Schedule; Drug Resistance, Vi

2015
Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection.
    Digestive diseases and sciences, 2015, Volume: 60, Issue:5

    Topics: Adenine; Antiviral Agents; Biomarkers; DNA, Viral; Drug Administration Schedule; Drug Resistance, Vi

2015
Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection.
    Digestive diseases and sciences, 2015, Volume: 60, Issue:5

    Topics: Adenine; Antiviral Agents; Biomarkers; DNA, Viral; Drug Administration Schedule; Drug Resistance, Vi

2015
Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection.
    Digestive diseases and sciences, 2015, Volume: 60, Issue:5

    Topics: Adenine; Antiviral Agents; Biomarkers; DNA, Viral; Drug Administration Schedule; Drug Resistance, Vi

2015
Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection.
    Digestive diseases and sciences, 2015, Volume: 60, Issue:5

    Topics: Adenine; Antiviral Agents; Biomarkers; DNA, Viral; Drug Administration Schedule; Drug Resistance, Vi

2015
Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection.
    Digestive diseases and sciences, 2015, Volume: 60, Issue:5

    Topics: Adenine; Antiviral Agents; Biomarkers; DNA, Viral; Drug Administration Schedule; Drug Resistance, Vi

2015
Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection.
    Digestive diseases and sciences, 2015, Volume: 60, Issue:5

    Topics: Adenine; Antiviral Agents; Biomarkers; DNA, Viral; Drug Administration Schedule; Drug Resistance, Vi

2015
Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection.
    Digestive diseases and sciences, 2015, Volume: 60, Issue:5

    Topics: Adenine; Antiviral Agents; Biomarkers; DNA, Viral; Drug Administration Schedule; Drug Resistance, Vi

2015
Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection.
    Digestive diseases and sciences, 2015, Volume: 60, Issue:5

    Topics: Adenine; Antiviral Agents; Biomarkers; DNA, Viral; Drug Administration Schedule; Drug Resistance, Vi

2015
An intrahepatic transcriptional signature of enhanced immune activity predicts response to peginterferon in chronic hepatitis B.
    Liver international : official journal of the International Association for the Study of the Liver, 2015, Volume: 35, Issue:7

    Topics: Adenine; Adult; Antiviral Agents; Biopsy; Chi-Square Distribution; Drug Therapy, Combination; Female

2015
Entecavir plus adefovir versus adefovir plus lamivudine in hepatitis B virus e antigen-positive, lamivudine-resistant chronic hepatitis B.
    Journal of gastroenterology and hepatology, 2014, Volume: 29, Issue:7

    Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combinatio

2014
Preemptive adefovir versus lamivudine for prevention of hepatitis B reactivation in chronic hepatitis B patients undergoing chemotherapy.
    Hepatology international, 2015, Volume: 9, Issue:2

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Femal

2015
Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial.
    Gut, 2016, Volume: 65, Issue:6

    Topics: Adenine; Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; G

2016
Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial.
    Gut, 2016, Volume: 65, Issue:6

    Topics: Adenine; Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; G

2016
Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial.
    Gut, 2016, Volume: 65, Issue:6

    Topics: Adenine; Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; G

2016
Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial.
    Gut, 2016, Volume: 65, Issue:6

    Topics: Adenine; Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; G

2016
Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial.
    Gut, 2016, Volume: 65, Issue:6

    Topics: Adenine; Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; G

2016
Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial.
    Gut, 2016, Volume: 65, Issue:6

    Topics: Adenine; Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; G

2016
Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial.
    Gut, 2016, Volume: 65, Issue:6

    Topics: Adenine; Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; G

2016
Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial.
    Gut, 2016, Volume: 65, Issue:6

    Topics: Adenine; Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; G

2016
Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial.
    Gut, 2016, Volume: 65, Issue:6

    Topics: Adenine; Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; G

2016
Efficacy of maternal tenofovir disoproxil fumarate in interrupting mother-to-infant transmission of hepatitis B virus.
    Hepatology (Baltimore, Md.), 2015, Volume: 62, Issue:2

    Topics: Adenine; Adult; DNA, Viral; Female; Follow-Up Studies; Gestational Age; Hepatitis B virus; Hepatitis

2015
Delayed Reduction of Hepatitis B Viral Load and Dynamics of Adefovir-Resistant Variants during Adefovir plus Entecavir Combination Rescue Therapy.
    International journal of medical sciences, 2015, Volume: 12, Issue:5

    Topics: Adenine; Adult; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Guanine; Hepati

2015
Cost-effectiveness analysis of lamivudine, telbivudine, and entecavir in treatment of chronic hepatitis B with adefovir dipivoxil resistance.
    Drug design, development and therapy, 2015, Volume: 9

    Topics: Adenine; Adult; Antiviral Agents; Cost-Benefit Analysis; Double-Blind Method; Drug Resistance, Viral

2015
[Treatment options in HBeAg-positive chronic hepatitis B patients with a poor response to 24-week interferon monotherapy].
    Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2015, Volume: 35, Issue:6

    Topics: Adenine; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Guanine; Hep

2015
Hepatitis B Virus Pregenomic RNA Is Present in Virions in Plasma and Is Associated With a Response to Pegylated Interferon Alfa-2a and Nucleos(t)ide Analogues.
    The Journal of infectious diseases, 2016, Jan-15, Volume: 213, Issue:2

    Topics: Adenine; Adult; Amantadine; Antiviral Agents; Biomarkers; DNA, Viral; Drug Therapy, Combination; Fem

2016
The curative effect of adefovir dipivoxil treating HBeAg negative chronic hepatitis B and treating HBeAg positive chronic hepatitis B combining interferon α-2b.
    Pakistan journal of pharmaceutical sciences, 2015, Volume: 28, Issue:4 Suppl

    Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Combinations; Female; Hepat

2015
[A randomized controlled trial on 240-week monotherapy with entecavir or adefovir in patients with chronic hepatitis B and cirrhosis].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2015, Volume: 23, Issue:10

    Topics: Adenine; Aged; Alanine Transaminase; alpha-Fetoproteins; Antiviral Agents; Aspartate Aminotransferas

2015
Cost-effectiveness of Lamivudine, Telbivudine, Adefovir Dipivoxil and Entecavir on decompensated hepatitis B virus-related cirrhosis.
    European review for medical and pharmacological sciences, 2016, Volume: 20, Issue:5

    Topics: Adenine; Adult; Antiviral Agents; Cost-Benefit Analysis; Female; Guanine; Hepatitis B virus; Hepatit

2016
[Efficacy Observation of Yiguanjian Decoction Combined Adefovir Dipivoxil Tablet in Treating HBeAg Negative Chronic Viral Hepatitis B Active Compensated Liver Cirrhosis Patients].
    Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine, 2016, Volume: 36, Issue:5

    Topics: Adenine; Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Bilirubin; DNA, Viral;

2016
CONSORT: Effects of adding adefovirdipivoxil to peginterferon alfa-2a at different time points on HBeAg-positivepatients: A prospective, randomized study.
    Medicine, 2016, Volume: 95, Issue:31

    Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Administration Schedule; Dr

2016
Effect of nucleoside analogues in the treatment of hepatitis B cirrhosis and its effect on Th17 cell.
    European review for medical and pharmacological sciences, 2017, Volume: 21, Issue:2

    Topics: Adenine; Adult; Aged; Antiviral Agents; Female; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; L

2017
Suboptimal response to adefovir dipivoxil therapy for chronic hepatitis B in nucleoside-naive patients is not due to pre-existing drug-resistant mutants.
    Antiviral therapy, 2008, Volume: 13, Issue:3

    Topics: Adenine; Adolescent; Adult; Cell Line, Tumor; DNA, Viral; Dose-Response Relationship, Drug; Drug Res

2008
Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.
    Hepatology (Baltimore, Md.), 2008, Volume: 48, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Dose-Response

2008
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
    The New England journal of medicine, 2008, Dec-04, Volume: 359, Issue:23

    Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind M

2008
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
    The New England journal of medicine, 2008, Dec-04, Volume: 359, Issue:23

    Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind M

2008
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
    The New England journal of medicine, 2008, Dec-04, Volume: 359, Issue:23

    Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind M

2008
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
    The New England journal of medicine, 2008, Dec-04, Volume: 359, Issue:23

    Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind M

2008
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
    The New England journal of medicine, 2008, Dec-04, Volume: 359, Issue:23

    Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind M

2008
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
    The New England journal of medicine, 2008, Dec-04, Volume: 359, Issue:23

    Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind M

2008
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
    The New England journal of medicine, 2008, Dec-04, Volume: 359, Issue:23

    Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind M

2008
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
    The New England journal of medicine, 2008, Dec-04, Volume: 359, Issue:23

    Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind M

2008
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
    The New England journal of medicine, 2008, Dec-04, Volume: 359, Issue:23

    Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind M

2008
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
    The New England journal of medicine, 2008, Dec-04, Volume: 359, Issue:23

    Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind M

2008
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
    The New England journal of medicine, 2008, Dec-04, Volume: 359, Issue:23

    Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind M

2008
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
    The New England journal of medicine, 2008, Dec-04, Volume: 359, Issue:23

    Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind M

2008
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
    The New England journal of medicine, 2008, Dec-04, Volume: 359, Issue:23

    Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind M

2008
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
    The New England journal of medicine, 2008, Dec-04, Volume: 359, Issue:23

    Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind M

2008
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
    The New England journal of medicine, 2008, Dec-04, Volume: 359, Issue:23

    Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind M

2008
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
    The New England journal of medicine, 2008, Dec-04, Volume: 359, Issue:23

    Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind M

2008
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
    The New England journal of medicine, 2008, Dec-04, Volume: 359, Issue:23

    Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind M

2008
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
    The New England journal of medicine, 2008, Dec-04, Volume: 359, Issue:23

    Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind M

2008
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
    The New England journal of medicine, 2008, Dec-04, Volume: 359, Issue:23

    Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind M

2008
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
    The New England journal of medicine, 2008, Dec-04, Volume: 359, Issue:23

    Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind M

2008
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
    The New England journal of medicine, 2008, Dec-04, Volume: 359, Issue:23

    Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind M

2008
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
    The New England journal of medicine, 2008, Dec-04, Volume: 359, Issue:23

    Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind M

2008
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
    The New England journal of medicine, 2008, Dec-04, Volume: 359, Issue:23

    Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind M

2008
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
    The New England journal of medicine, 2008, Dec-04, Volume: 359, Issue:23

    Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind M

2008
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
    The New England journal of medicine, 2008, Dec-04, Volume: 359, Issue:23

    Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind M

2008
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
    The New England journal of medicine, 2008, Dec-04, Volume: 359, Issue:23

    Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind M

2008
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
    The New England journal of medicine, 2008, Dec-04, Volume: 359, Issue:23

    Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind M

2008
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
    The New England journal of medicine, 2008, Dec-04, Volume: 359, Issue:23

    Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind M

2008
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
    The New England journal of medicine, 2008, Dec-04, Volume: 359, Issue:23

    Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind M

2008
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
    The New England journal of medicine, 2008, Dec-04, Volume: 359, Issue:23

    Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind M

2008
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
    The New England journal of medicine, 2008, Dec-04, Volume: 359, Issue:23

    Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind M

2008
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
    The New England journal of medicine, 2008, Dec-04, Volume: 359, Issue:23

    Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind M

2008
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
    The New England journal of medicine, 2008, Dec-04, Volume: 359, Issue:23

    Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind M

2008
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
    The New England journal of medicine, 2008, Dec-04, Volume: 359, Issue:23

    Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind M

2008
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
    The New England journal of medicine, 2008, Dec-04, Volume: 359, Issue:23

    Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind M

2008
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
    The New England journal of medicine, 2008, Dec-04, Volume: 359, Issue:23

    Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind M

2008
Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir.
    Hepatology (Baltimore, Md.), 2009, Volume: 49, Issue:1

    Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Female; Guanine; Hep

2009
Complex dynamics of hepatitis B virus resistance to adefovir.
    Hepatology (Baltimore, Md.), 2009, Volume: 49, Issue:1

    Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B virus; Hep

2009
Failure of adefovir 20 mg to improve suboptimal response in lamivudine-resistant hepatitis B patients treated with adefovir 10 mg and lamivudine.
    Journal of viral hepatitis, 2008, Volume: 15, Issue:12

    Topics: Adenine; Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resi

2008
Impact of adefovir dipivoxil on liver fibrosis and activity assessed with biochemical markers (FibroTest-ActiTest) in patients infected by hepatitis B virus.
    Journal of viral hepatitis, 2009, Volume: 16, Issue:3

    Topics: Adenine; Adult; Antiviral Agents; Biomarkers; Biopsy; Double-Blind Method; Female; Hepatitis B e Ant

2009
Mutations associated with the therapeutic efficacy of adefovir dipivoxil added to lamivudine in patients resistant to lamivudine with type B chronic hepatitis.
    Journal of medical virology, 2009, Volume: 81, Issue:5

    Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combinatio

2009
[A study on the treatment of chronic hepatitis B with YMDD mutation].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2009, Volume: 17, Issue:3

    Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug The

2009
Adefovir dipivoxil resistance patterns in patients with lamivudine-resistant chronic hepatitis B.
    Antiviral therapy, 2009, Volume: 14, Issue:4

    Topics: Adenine; Adult; Aged; Cell Line; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Fema

2009
Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone.
    Hepatology (Baltimore, Md.), 2009, Volume: 50, Issue:4

    Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Dose-Response Relationship, Drug; Drug Resistance, Vir

2009
Rescue monotherapy in lamivudine-resistant hepatitis B e antigen-positive chronic hepatitis B: adefovir versus entecavir.
    Antiviral therapy, 2009, Volume: 14, Issue:5

    Topics: Adenine; Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Female; Guanine; Hepatitis B e Antig

2009
Adefovir plus lamivudine are more effective than adefovir alone in lamivudine-resistant HBeAg- chronic hepatitis B patients: a 4-year study.
    Journal of gastroenterology and hepatology, 2010, Volume: 25, Issue:1

    Topics: Adenine; Adult; Aged; Alanine Transaminase; Antiviral Agents; Biomarkers; DNA, Viral; Drug Resistanc

2010
[A clinical study of adefovir dipivoxil treatment for chronic hepatitis patients with cirrhosis in their decompensation period].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2009, Volume: 17, Issue:7

    Topics: Adenine; Administration, Oral; Adult; Aged; Antiviral Agents; Collagen; DNA, Viral; Drug Resistance,

2009
Full-length hepatitis B virus sequences from naïve patients with fluctuation of viral load during ADV monotherapy.
    Virus genes, 2010, Volume: 40, Issue:2

    Topics: Adenine; Adult; Amino Acid Substitution; Antiviral Agents; China; DNA, Viral; Female; Genome, Viral;

2010
A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B.
    Antiviral therapy, 2009, Volume: 14, Issue:8

    Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; H

2009
[The analyse of effectiveness in HBeAg-positive chronic viral hepatitis B treated by adefovir dipivoxil combined with bicyclol].
    Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology, 2009, Volume: 23, Issue:4

    Topics: Adenine; Adolescent; Adult; Aged; Biphenyl Compounds; Drug Therapy, Combination; Hepatitis B e Antig

2009
[Comparison of efficacy between adefovir dipivoxil and entecavir in patients with chronic hepatitis B].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2010, Volume: 18, Issue:1

    Topics: Adenine; Administration, Oral; Alanine Transaminase; Antiviral Agents; DNA, Viral; Female; Guanine;

2010
Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues.
    Journal of hepatology, 2010, Volume: 52, Issue:4

    Topics: Adenine; Adult; Antiviral Agents; Drug Resistance, Viral; Female; Follow-Up Studies; Guanine; Hepati

2010
Long-term adefovir dipivoxil monotherapy for up to 5 years in lamivudine-resistant chronic hepatitis B.
    Antiviral therapy, 2010, Volume: 15, Issue:2

    Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B e An

2010
Sequential therapy with adefovir dipivoxil and pegylated interferon alfa-2a for HBeAg-negative patients.
    Journal of viral hepatitis, 2011, Volume: 18, Issue:8

    Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Femal

2011
Importance of serum concentration of adefovir for Lamivudine-adefovir combination therapy in patients with lamivudine-resistant chronic hepatitis B.
    Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:8

    Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combinatio

2010
[Comparison of the efficacy of 48 week-Entecavir therapy with that of Adefovir therapy for chronic hepatitis B patients].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2010, Volume: 18, Issue:5

    Topics: Adenine; Adolescent; Adult; Antiviral Agents; DNA, Viral; Female; Guanine; Hepatitis B virus; Hepati

2010
Overlap/switch to adefovir monotherapy for lamivudine-resistant patients who responded to combination therapy: a pilot controlled study.
    Internal medicine (Tokyo, Japan), 2010, Volume: 49, Issue:12

    Topics: Adenine; Adult; Aged; Drug Resistance, Viral; Drug Therapy, Combination; Female; Follow-Up Studies;

2010
Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection.
    Gastroenterology, 2010, Volume: 139, Issue:4

    Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Antiviral Agents; Deoxycytidine; DNA, Viral; Doubl

2010
Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection.
    Gastroenterology, 2010, Volume: 139, Issue:4

    Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Antiviral Agents; Deoxycytidine; DNA, Viral; Doubl

2010
Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection.
    Gastroenterology, 2010, Volume: 139, Issue:4

    Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Antiviral Agents; Deoxycytidine; DNA, Viral; Doubl

2010
Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection.
    Gastroenterology, 2010, Volume: 139, Issue:4

    Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Antiviral Agents; Deoxycytidine; DNA, Viral; Doubl

2010
Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection.
    Gastroenterology, 2010, Volume: 139, Issue:4

    Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Antiviral Agents; Deoxycytidine; DNA, Viral; Doubl

2010
Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection.
    Gastroenterology, 2010, Volume: 139, Issue:4

    Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Antiviral Agents; Deoxycytidine; DNA, Viral; Doubl

2010
Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection.
    Gastroenterology, 2010, Volume: 139, Issue:4

    Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Antiviral Agents; Deoxycytidine; DNA, Viral; Doubl

2010
Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection.
    Gastroenterology, 2010, Volume: 139, Issue:4

    Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Antiviral Agents; Deoxycytidine; DNA, Viral; Doubl

2010
Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection.
    Gastroenterology, 2010, Volume: 139, Issue:4

    Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Antiviral Agents; Deoxycytidine; DNA, Viral; Doubl

2010
Question of ALT flare during switch to adefovir from lamivudine: A single center open-label, randomized, safety study (June 17, 2005 to February 5, 2009).
    Journal of medical virology, 2010, Volume: 82, Issue:9

    Topics: Adenine; Alanine Transaminase; Antiviral Agents; Drug Substitution; Drug Therapy, Combination; Femal

2010
[Effect of adefovir and lamivudine combination therapy on lamivudine resistance chronic hepatitis B patients for 48 weeks].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2010, Volume: 18, Issue:7

    Topics: Adenine; Adolescent; Adult; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Fem

2010
[Efficacy and durability of generic adefovir dipivoxil in patients with HBeAg positive chronic hepatitis].
    Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology, 2009, Volume: 23, Issue:6

    Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Double-Blind Method; Female; Hepatitis B Antibod

2009
[Add on lamivudine to adefovir monotherapy for the treatment of lamivudine-resistant chronic hepatitis B patients].
    The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 2010, Volume: 56, Issue:2

    Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Fem

2010
Long-term therapy with tenofovir is effective for patients co-infected with human immunodeficiency virus and hepatitis B virus.
    Gastroenterology, 2010, Volume: 139, Issue:6

    Topics: Adenine; Adult; Anti-HIV Agents; Antiviral Agents; CD4 Lymphocyte Count; DNA, Viral; Drug Resistance

2010
Efficacy of tenofovir disoproxil fumarate/emtricitabine compared with emtricitabine alone in antiretroviral-naive HIV-HBV coinfection in Thailand.
    Antiviral therapy, 2010, Volume: 15, Issue:6

    Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; CD4 Lymphocyte Count; Deoxy

2010
[Short-term efficacy of adefovir dipivoxil as an add-on therapy in the pegylated IFNalpha-2a treatment for HBeAg positive chronic hepatitis B patients].
    Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology, 2010, Volume: 24, Issue:1

    Topics: Adenine; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis B e Antigens; Hepatit

2010
Efficacy of adefovir add-on lamivudine rescue therapy compared with switching to entecavir monotherapy in patients with lamivudine-resistant chronic hepatitis B.
    Journal of medical virology, 2010, Volume: 82, Issue:11

    Topics: Adenine; Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; G

2010
Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B.
    Gut, 2011, Volume: 60, Issue:2

    Topics: Adenine; Adult; Aged; Aged, 80 and over; DNA, Viral; Drug Resistance, Viral; Epidemiologic Methods;

2011
[Efficacy of the 96-week adefovir dipivoxil therapy in patients with chronic hepatitis B].
    Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology, 2010, Volume: 24, Issue:3

    Topics: Adenine; Adolescent; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Genotype;

2010
[Observation on effect of peg interferon lphaa-2a treating lamivudine resistant chronic hepatitis B].
    Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology, 2010, Volume: 24, Issue:3

    Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B virus; Hep

2010
[Efficacy of adefovir treatment in the lamivudine-resistant chronic hepatitis B patients].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2010, Volume: 18, Issue:12

    Topics: Adenine; Adult; Antiviral Agents; Drug Resistance, Viral; Female; Hepatitis B, Chronic; Humans; Lami

2010
Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease.
    Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:1

    Topics: Adenine; Adolescent; Adult; Aged; Creatinine; Deoxycytidine; DNA, Viral; Drug Combinations; Emtricit

2011
Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease.
    Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:1

    Topics: Adenine; Adolescent; Adult; Aged; Creatinine; Deoxycytidine; DNA, Viral; Drug Combinations; Emtricit

2011
Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease.
    Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:1

    Topics: Adenine; Adolescent; Adult; Aged; Creatinine; Deoxycytidine; DNA, Viral; Drug Combinations; Emtricit

2011
Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease.
    Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:1

    Topics: Adenine; Adolescent; Adult; Aged; Creatinine; Deoxycytidine; DNA, Viral; Drug Combinations; Emtricit

2011
[Influence of adefovir dipivoxil on HBV specific CTL in patients with chronic hepatitis B].
    Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology, 2010, Volume: 24, Issue:5

    Topics: Adenine; Adult; Antiviral Agents; Drug Administration Schedule; Female; Hepatitis B, Chronic; Humans

2010
Tenofovir improves the outcome in patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure.
    Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3

    Topics: Adenine; Adolescent; Adult; Antiviral Agents; DNA, Viral; Female; Hepatitis B virus; Hepatitis B, Ch

2011
Evaluation of adefovir & lamivudine in chronic hepatitis B: correlation with HBV viral kinetic, hepatic-necro inflammation & fibrosis.
    The Indian journal of medical research, 2011, Volume: 133

    Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Drug Resistance, Viral; Female; Hepatitis B

2011
Association of intrahepatic cccDNA reduction with the improvement of liver histology in chronic hepatitis B patients receiving oral antiviral agents.
    Journal of medical virology, 2011, Volume: 83, Issue:4

    Topics: Adenine; Adult; Antiviral Agents; Blood; DNA, Circular; DNA, Viral; Female; Guanine; Hepatitis B vir

2011
No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus.
    Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3

    Topics: Adenine; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Gene Products, pol; Hep G2 Cells; Hep

2011
Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study.
    Hepatology (Baltimore, Md.), 2011, Volume: 54, Issue:1

    Topics: Adenine; Antiviral Agents; DNA, Viral; Dose-Response Relationship, Drug; Drug Resistance, Viral; Fem

2011
Intrahepatic response markers in chronic hepatitis B patients treated with peginterferon alpha-2a and adefovir.
    Journal of gastroenterology and hepatology, 2011, Volume: 26, Issue:10

    Topics: Adenine; Adult; Antiviral Agents; Biomarkers; Biopsy; Chi-Square Distribution; DNA, Circular; DNA, V

2011
[Safety and efficacy of Entecavir combined with Adefovir in patients with chronic hepatitis B who fail to respond to nucleoside analog treatment].
    Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2011, Volume: 31, Issue:6

    Topics: Adenine; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Guanine; Hepatitis B, Chronic;

2011
Randomised clinical trial: efficacy of peginterferon alfa-2a in HBeAg positive chronic hepatitis B patients with lamivudine resistance.
    Alimentary pharmacology & therapeutics, 2011, Volume: 34, Issue:4

    Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; China; Drug Resistance, Viral; Drug Therapy, Com

2011
Simple scoring system predicting genotypic resistance during rescue therapy for Lamivudine-resistant chronic hepatitis B.
    Journal of clinical gastroenterology, 2012, Volume: 46, Issue:3

    Topics: Adenine; Adult; Aged; Antiviral Agents; Cohort Studies; Drug Resistance, Viral; Drug Therapy, Combin

2012
Efficacy and tolerance of a combination of tenofovir disoproxil fumarate plus emtricitabine in patients with chronic hepatitis B: a European multicenter study.
    Antiviral research, 2011, Volume: 92, Issue:1

    Topics: Adenine; Adult; Aged; Antiviral Agents; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Eur

2011
Lamivudine plus adefovir is a good option for chronic hepatitis B patients with viral relapse after cessation of lamivudine treatment.
    Virology journal, 2011, Aug-04, Volume: 8

    Topics: Adenine; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis B, Chronic; Humans; L

2011
[The levels of HBsAg can predict the efficacy of peglated interferon-alpha 2a combined with adefovir dipivoxil, in HBeAg-positive chronic hepatitis B patients].
    Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology, 2011, Volume: 25, Issue:2

    Topics: Adenine; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis B e Antigens; Hepatit

2011
Clinical outcomes of lamivudine-adefovir therapy in chronic hepatitis B cirrhosis.
    Journal of clinical gastroenterology, 2011, Volume: 45, Issue:9

    Topics: Adenine; Aged; Antiviral Agents; Cohort Studies; Disease Progression; Drug Therapy, Combination; Fem

2011
[Relationship between HBeAg seroconversion with genotypes and HBV specific CTL in patients with chronic hepatitis B treated with Adefovir dipivoxil].
    Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology, 2011, Volume: 25, Issue:3

    Topics: Adenine; Adult; Antiviral Agents; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Immu

2011
[Efficacy of two nucleoside analogs to treat resistant HBeAg-negative chronic hepatitis B].
    Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology, 2011, Volume: 25, Issue:4

    Topics: Adenine; Adolescent; Adult; Antiviral Agents; Child; Child, Preschool; Drug Resistance, Viral; Femal

2011
Five years of treatment with adefovir dipivoxil in Chinese patients with HBeAg-positive chronic hepatitis B.
    Liver international : official journal of the International Association for the Study of the Liver, 2012, Volume: 32, Issue:1

    Topics: Adenine; Adolescent; Adult; Antiviral Agents; Asian People; DNA, Viral; Drug Resistance, Viral; Fema

2012
[Clinical antiviral effects of Peg-IFNa-2a in patients with chronic hepatitis B].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2011, Volume: 19, Issue:9

    Topics: Adenine; Adult; Antiviral Agents; Female; Guanine; Hepatitis B, Chronic; Humans; Interferon-alpha; M

2011
Genetic variation in IL28B and treatment outcome in HBeAg-positive and -negative chronic hepatitis B patients treated with Peg interferon alfa-2a and adefovir.
    Scandinavian journal of gastroenterology, 2012, Volume: 47, Issue:4

    Topics: Adenine; Antiviral Agents; Cohort Studies; DNA, Viral; Drug Therapy, Combination; Ethnicity; Follow-

2012
[A clinical study on the efficacy of HBeAg-positive chronic hepatitis B patients treated with adefovir dipivoxil for 4 years].
    Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology, 2011, Volume: 25, Issue:5

    Topics: Adenine; Adult; Antiviral Agents; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Ch

2011
[Polish multicenter study on safety and efficacy of adefovir dipivoxil in the treatment of lamivudine resistant chronic hepatitis B in adults (HEP 2008)].
    Przeglad epidemiologiczny, 2011, Volume: 65, Issue:4

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Com

2011
Randomized trial of entecavir plus adefovir in patients with lamivudine-resistant chronic hepatitis B who show suboptimal response to lamivudine plus adefovir.
    Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:6

    Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Female; Guanine; Hepatit

2012
[Entecavir 1.0mg monotherapy or entecavir plus adefovir dipivoxil for patients with lamivudine-resistant chronic hepatitis B had suboptimal response to lamivudine plus adefovir dipivoxil].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2011, Volume: 19, Issue:11

    Topics: Adenine; Adult; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Guanine

2011
Improved efficacy by individualized combination therapy with Peg IFN-a 2a and ADV in HBeAg positive chronic hepatitis B patients.
    Hepato-gastroenterology, 2012, Volume: 59, Issue:115

    Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; Biomarkers; Chi-Square Distribution; China;

2012
Randomised clinical trial: the benefit of combination therapy with adefovir and lamivudine for chronic hepatitis B.
    Alimentary pharmacology & therapeutics, 2012, Volume: 35, Issue:9

    Topics: Adenine; Adult; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatit

2012
[Efficacy of lamivudine and adefovir de novo combination therapy or after mono-therapy in chronic hepatitis B patients].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2012, Volume: 20, Issue:2

    Topics: Adenine; Adult; Drug Therapy, Combination; Female; Hepatitis B, Chronic; Humans; Lamivudine; Male; M

2012
Efficacy and safety of long-term adefovir dipivoxil therapy in children with chronic hepatitis B infection.
    The Pediatric infectious disease journal, 2012, Volume: 31, Issue:6

    Topics: Adenine; Adolescent; Child; Child, Preschool; DNA, Viral; Double-Blind Method; Drug Resistance, Vira

2012
Randomized, placebo-controlled trial of tenofovir disoproxil fumarate in adolescents with chronic hepatitis B.
    Hepatology (Baltimore, Md.), 2012, Volume: 56, Issue:6

    Topics: Adenine; Adolescent; Alanine Transaminase; Antiviral Agents; Bone Density; Child; DNA, Viral; Double

2012
[Clinical study on Baihua Xianglian detoxification recipe combined with adefovir dipivoxil in treating HBeAg positive chronic hepatitis].
    Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine, 2012, Volume: 32, Issue:2

    Topics: Adenine; Adult; Antiviral Agents; Drugs, Chinese Herbal; Female; Hepatitis B e Antigens; Hepatitis B

2012
Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B.
    Gastroenterology, 2012, Volume: 143, Issue:3

    Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; Biomarkers; DNA, Viral; Drug Resistance, Vir

2012
Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B.
    Gastroenterology, 2012, Volume: 143, Issue:3

    Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; Biomarkers; DNA, Viral; Drug Resistance, Vir

2012
Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B.
    Gastroenterology, 2012, Volume: 143, Issue:3

    Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; Biomarkers; DNA, Viral; Drug Resistance, Vir

2012
Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B.
    Gastroenterology, 2012, Volume: 143, Issue:3

    Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; Biomarkers; DNA, Viral; Drug Resistance, Vir

2012
Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir.
    Gastroenterology, 2012, Volume: 143, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; Biomarkers; Chi-Square Dis

2012
Virologic responses to add-on adefovir dipivoxil treatment versus entecavir monotherapy in children with lamivudine-resistant chronic hepatitis B.
    Journal of pediatric gastroenterology and nutrition, 2012, Volume: 55, Issue:6

    Topics: Adenine; Adolescent; Antiviral Agents; Child; Child, Preschool; DNA, Viral; Drug Resistance, Viral;

2012
[Experimental study on effect of dahuang zhechong wan combined with adefovir dipivoxil in preventing hepatic fibrosis in patients with chronic hepatitis B].
    Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica, 2012, Volume: 37, Issue:6

    Topics: Adenine; Administration, Oral; Adult; Aged; Antiviral Agents; Biomarkers; Drug Therapy, Combination;

2012
Rescue therapy for lamivudine-resistant chronic hepatitis B: adefovir monotherapy, adefovir plus lamivudine or entecavir combination therapy.
    Internal medicine (Tokyo, Japan), 2012, Volume: 51, Issue:12

    Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Fem

2012
Lamivudine plus adefovir or telbivudine plus adefovir for chronic hepatitis B patients with suboptimal response to adefovir.
    Antiviral therapy, 2012, Volume: 17, Issue:6

    Topics: Adenine; Adult; Biomarkers; DNA, Viral; Drug Therapy, Combination; Female; Genotype; Hepatitis B e A

2012
[The clinical efficacy and safety of adefovir dipivoxil in combination with bicyclol for the treatment of senior patients with chronic hepatitis B].
    Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology, 2011, Volume: 25, Issue:6

    Topics: Adenine; Aged; Aged, 80 and over; Antiviral Agents; Biphenyl Compounds; DNA, Viral; Female; Hepatiti

2011
Clonal analysis of the quasispecies of antiviral-resistant HBV genomes in patients with entecavir resistance during rescue treatment and successful treatment of entecavir resistance with tenofovir.
    Antiviral therapy, 2013, Volume: 18, Issue:1

    Topics: Adenine; Adult; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genome,

2013
[The therapeutic effect of Anluohuaxian capsule combined with adefovir dipivoxil on patients with chronic hepatitis B and influence on hepatic histology].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2012, Volume: 20, Issue:5

    Topics: Adenine; Adult; Antiviral Agents; Drugs, Chinese Herbal; Female; Hepatitis B, Chronic; Humans; Liver

2012
Randomized trial of lamivudine, adefovir, and the combination in HBeAg-positive chronic hepatitis B.
    Clinics and research in hepatology and gastroenterology, 2012, Volume: 36, Issue:6

    Topics: Adenine; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis B e Antigens; Hepatit

2012
Comparison of the antiviral effects of entecavir and adefovir dipivoxil in chronic HBV infection: a randomized control trial.
    Acta gastro-enterologica Belgica, 2012, Volume: 75, Issue:3

    Topics: Adenine; Adult; Aged; Alanine Transaminase; Antiviral Agents; Bilirubin; DNA, Viral; Female; Guanine

2012
Sustained efficacy of adefovir add-on therapy in chronic hepatitis B patient with a poor virological response to peginterferon alfa.
    Scandinavian journal of gastroenterology, 2013, Volume: 48, Issue:2

    Topics: Adenine; Adult; Antiviral Agents; Biomarkers; Drug Administration Schedule; Drug Therapy, Combinatio

2013
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.
    Lancet (London, England), 2013, Feb-09, Volume: 381, Issue:9865

    Topics: Adenine; Adult; Biopsy, Needle; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administ

2013
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.
    Lancet (London, England), 2013, Feb-09, Volume: 381, Issue:9865

    Topics: Adenine; Adult; Biopsy, Needle; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administ

2013
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.
    Lancet (London, England), 2013, Feb-09, Volume: 381, Issue:9865

    Topics: Adenine; Adult; Biopsy, Needle; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administ

2013
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.
    Lancet (London, England), 2013, Feb-09, Volume: 381, Issue:9865

    Topics: Adenine; Adult; Biopsy, Needle; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administ

2013
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.
    Lancet (London, England), 2013, Feb-09, Volume: 381, Issue:9865

    Topics: Adenine; Adult; Biopsy, Needle; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administ

2013
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.
    Lancet (London, England), 2013, Feb-09, Volume: 381, Issue:9865

    Topics: Adenine; Adult; Biopsy, Needle; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administ

2013
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.
    Lancet (London, England), 2013, Feb-09, Volume: 381, Issue:9865

    Topics: Adenine; Adult; Biopsy, Needle; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administ

2013
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.
    Lancet (London, England), 2013, Feb-09, Volume: 381, Issue:9865

    Topics: Adenine; Adult; Biopsy, Needle; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administ

2013
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.
    Lancet (London, England), 2013, Feb-09, Volume: 381, Issue:9865

    Topics: Adenine; Adult; Biopsy, Needle; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administ

2013
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.
    Lancet (London, England), 2013, Feb-09, Volume: 381, Issue:9865

    Topics: Adenine; Adult; Biopsy, Needle; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administ

2013
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.
    Lancet (London, England), 2013, Feb-09, Volume: 381, Issue:9865

    Topics: Adenine; Adult; Biopsy, Needle; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administ

2013
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.
    Lancet (London, England), 2013, Feb-09, Volume: 381, Issue:9865

    Topics: Adenine; Adult; Biopsy, Needle; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administ

2013
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.
    Lancet (London, England), 2013, Feb-09, Volume: 381, Issue:9865

    Topics: Adenine; Adult; Biopsy, Needle; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administ

2013
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.
    Lancet (London, England), 2013, Feb-09, Volume: 381, Issue:9865

    Topics: Adenine; Adult; Biopsy, Needle; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administ

2013
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.
    Lancet (London, England), 2013, Feb-09, Volume: 381, Issue:9865

    Topics: Adenine; Adult; Biopsy, Needle; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administ

2013
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.
    Lancet (London, England), 2013, Feb-09, Volume: 381, Issue:9865

    Topics: Adenine; Adult; Biopsy, Needle; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administ

2013
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.
    Lancet (London, England), 2013, Feb-09, Volume: 381, Issue:9865

    Topics: Adenine; Adult; Biopsy, Needle; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administ

2013
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.
    Lancet (London, England), 2013, Feb-09, Volume: 381, Issue:9865

    Topics: Adenine; Adult; Biopsy, Needle; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administ

2013
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.
    Lancet (London, England), 2013, Feb-09, Volume: 381, Issue:9865

    Topics: Adenine; Adult; Biopsy, Needle; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administ

2013
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.
    Lancet (London, England), 2013, Feb-09, Volume: 381, Issue:9865

    Topics: Adenine; Adult; Biopsy, Needle; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administ

2013
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.
    Lancet (London, England), 2013, Feb-09, Volume: 381, Issue:9865

    Topics: Adenine; Adult; Biopsy, Needle; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administ

2013
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.
    Lancet (London, England), 2013, Feb-09, Volume: 381, Issue:9865

    Topics: Adenine; Adult; Biopsy, Needle; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administ

2013
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.
    Lancet (London, England), 2013, Feb-09, Volume: 381, Issue:9865

    Topics: Adenine; Adult; Biopsy, Needle; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administ

2013
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.
    Lancet (London, England), 2013, Feb-09, Volume: 381, Issue:9865

    Topics: Adenine; Adult; Biopsy, Needle; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administ

2013
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.
    Lancet (London, England), 2013, Feb-09, Volume: 381, Issue:9865

    Topics: Adenine; Adult; Biopsy, Needle; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administ

2013
Augmentation of hepatitis B virus-specific cellular immunity with programmed death receptor-1/programmed death receptor-L1 blockade in hepatitis B virus and HIV/hepatitis B virus coinfected patients treated with adefovir.
    AIDS research and human retroviruses, 2013, Volume: 29, Issue:4

    Topics: Adenine; Adult; Antiviral Agents; B7-H1 Antigen; CD8-Positive T-Lymphocytes; Double-Blind Method; He

2013
[Efficacy of combination therapy of lamivudine and adefovir dipivoxyl for patients with hepatitis B-induced decompensated liver cirrhosis].
    Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences, 2012, Volume: 37, Issue:12

    Topics: Adenine; Adult; Antiviral Agents; Drug Therapy, Combination; End Stage Liver Disease; Female; Hepati

2012
Adding adefovir vs. switching to entecavir for lamivudine-resistant chronic hepatitis B (ACE study): a 2-year follow-up randomized controlled trial.
    Liver international : official journal of the International Association for the Study of the Liver, 2013, Volume: 33, Issue:2

    Topics: Adenine; Adult; Analysis of Variance; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female;

2013
Antiviral treatment alters the frequency of activating and inhibitory receptor-expressing natural killer cells in chronic hepatitis B virus infected patients.
    Mediators of inflammation, 2012, Volume: 2012

    Topics: Adenine; Adult; Antiviral Agents; Female; Hepatitis B, Chronic; Humans; Killer Cells, Natural; Male;

2012
Tenofovir rescue therapy for chronic hepatitis B patients after multiple treatment failures.
    World journal of gastroenterology, 2012, Dec-21, Volume: 18, Issue:47

    Topics: Adenine; Adult; Antiviral Agents; Creatinine; Drug Tolerance; Female; Genotype; Hepatitis B, Chronic

2012
Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load.
    Hepatology (Baltimore, Md.), 2013, Volume: 58, Issue:2

    Topics: Adenine; Adult; Antiviral Agents; Deoxycytidine; DNA, Viral; Dose-Response Relationship, Drug; Drug

2013
Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load.
    Hepatology (Baltimore, Md.), 2013, Volume: 58, Issue:2

    Topics: Adenine; Adult; Antiviral Agents; Deoxycytidine; DNA, Viral; Dose-Response Relationship, Drug; Drug

2013
Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load.
    Hepatology (Baltimore, Md.), 2013, Volume: 58, Issue:2

    Topics: Adenine; Adult; Antiviral Agents; Deoxycytidine; DNA, Viral; Dose-Response Relationship, Drug; Drug

2013
Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load.
    Hepatology (Baltimore, Md.), 2013, Volume: 58, Issue:2

    Topics: Adenine; Adult; Antiviral Agents; Deoxycytidine; DNA, Viral; Dose-Response Relationship, Drug; Drug

2013
Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load.
    Hepatology (Baltimore, Md.), 2013, Volume: 58, Issue:2

    Topics: Adenine; Adult; Antiviral Agents; Deoxycytidine; DNA, Viral; Dose-Response Relationship, Drug; Drug

2013
Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load.
    Hepatology (Baltimore, Md.), 2013, Volume: 58, Issue:2

    Topics: Adenine; Adult; Antiviral Agents; Deoxycytidine; DNA, Viral; Dose-Response Relationship, Drug; Drug

2013
Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load.
    Hepatology (Baltimore, Md.), 2013, Volume: 58, Issue:2

    Topics: Adenine; Adult; Antiviral Agents; Deoxycytidine; DNA, Viral; Dose-Response Relationship, Drug; Drug

2013
Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load.
    Hepatology (Baltimore, Md.), 2013, Volume: 58, Issue:2

    Topics: Adenine; Adult; Antiviral Agents; Deoxycytidine; DNA, Viral; Dose-Response Relationship, Drug; Drug

2013
Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load.
    Hepatology (Baltimore, Md.), 2013, Volume: 58, Issue:2

    Topics: Adenine; Adult; Antiviral Agents; Deoxycytidine; DNA, Viral; Dose-Response Relationship, Drug; Drug

2013
52-week efficacy and safety of telbivudine with conditional tenofovir intensification at week 24 in HBeAg-positive chronic hepatitis B.
    PloS one, 2013, Volume: 8, Issue:2

    Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Administration Schedule; Dr

2013
52-week efficacy and safety of telbivudine with conditional tenofovir intensification at week 24 in HBeAg-positive chronic hepatitis B.
    PloS one, 2013, Volume: 8, Issue:2

    Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Administration Schedule; Dr

2013
52-week efficacy and safety of telbivudine with conditional tenofovir intensification at week 24 in HBeAg-positive chronic hepatitis B.
    PloS one, 2013, Volume: 8, Issue:2

    Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Administration Schedule; Dr

2013
52-week efficacy and safety of telbivudine with conditional tenofovir intensification at week 24 in HBeAg-positive chronic hepatitis B.
    PloS one, 2013, Volume: 8, Issue:2

    Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Administration Schedule; Dr

2013
[Efficacy and safety of telbivudine and adefovir dipivoxil for the treatment of chronic hepatitis B patients with high level hepatitis B virus load and hepatitis B e antigen-positivity].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2012, Volume: 20, Issue:11

    Topics: Adenine; Adult; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Mal

2012
Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks.
    Hepatology (Baltimore, Md.), 2002, Volume: 36, Issue:2

    Topics: Adenine; Adult; Antiviral Agents; Base Sequence; Carcinoma, Hepatocellular; Conserved Sequence; DNA-

2002
Activity of tenofovir on hepatitis B virus replication in HIV-co-infected patients failing or partially responding to lamivudine.
    AIDS (London, England), 2002, Nov-22, Volume: 16, Issue:17

    Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Follow-Up Studies; Hep

2002
Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed.
    The Journal of infectious diseases, 2002, Dec-15, Volume: 186, Issue:12

    Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; H

2002
An open-label study of tenofovir in HIV-1 and Hepatitis B virus co-infected individuals.
    AIDS (London, England), 2003, Jan-03, Volume: 17, Issue:1

    Topics: Adenine; Adult; Anti-HIV Agents; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Follow-Up

2003
Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.
    The New England journal of medicine, 2003, Feb-27, Volume: 348, Issue:9

    Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind M

2003
Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.
    The New England journal of medicine, 2003, Feb-27, Volume: 348, Issue:9

    Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind M

2003
Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.
    The New England journal of medicine, 2003, Feb-27, Volume: 348, Issue:9

    Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind M

2003
Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.
    The New England journal of medicine, 2003, Feb-27, Volume: 348, Issue:9

    Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind M

2003
Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.
    The New England journal of medicine, 2003, Feb-27, Volume: 348, Issue:9

    Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind M

2003
Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.
    The New England journal of medicine, 2003, Feb-27, Volume: 348, Issue:9

    Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind M

2003
Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.
    The New England journal of medicine, 2003, Feb-27, Volume: 348, Issue:9

    Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind M

2003
Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.
    The New England journal of medicine, 2003, Feb-27, Volume: 348, Issue:9

    Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind M

2003
Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.
    The New England journal of medicine, 2003, Feb-27, Volume: 348, Issue:9

    Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind M

2003
Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.
    The New England journal of medicine, 2003, Feb-27, Volume: 348, Issue:9

    Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; Biopsy; DNA, Viral; Double

2003
Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.
    The New England journal of medicine, 2003, Feb-27, Volume: 348, Issue:9

    Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; Biopsy; DNA, Viral; Double

2003
Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.
    The New England journal of medicine, 2003, Feb-27, Volume: 348, Issue:9

    Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; Biopsy; DNA, Viral; Double

2003
Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.
    The New England journal of medicine, 2003, Feb-27, Volume: 348, Issue:9

    Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; Biopsy; DNA, Viral; Double

2003
Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B.
    Hepatology (Baltimore, Md.), 2003, Volume: 38, Issue:1

    Topics: Adenine; Adolescent; Adult; Aged; Amino Acid Substitution; Antiviral Agents; Base Sequence; Conserve

2003
Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil1.
    Gastroenterology, 2003, Volume: 125, Issue:1

    Topics: Adenine; Adult; Antiviral Agents; Asia; DNA, Viral; Europe; Female; Genotype; Hepatitis B e Antigens

2003
Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus.
    Gastroenterology, 2004, Volume: 126, Issue:1

    Topics: Adenine; Adult; Aged; Alanine Transaminase; Amino Acid Motifs; Antiviral Agents; DNA, Viral; Drug Th

2004
Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B.
    Gastroenterology, 2004, Volume: 126, Issue:1

    Topics: Adenine; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind Method; Drug

2004
Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus.
    The Journal of infectious diseases, 2004, Apr-01, Volume: 189, Issue:7

    Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Hepatitis B Surface Antigens; He

2004
Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double-blind, randomized, placebo-controlled studies.
    Kidney international, 2004, Volume: 66, Issue:3

    Topics: Adenine; Adult; Antiviral Agents; Creatinine; Double-Blind Method; Female; Glycosuria; Hematuria; He

2004
Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection.
    Hepatology (Baltimore, Md.), 2004, Volume: 40, Issue:6

    Topics: Adenine; Adult; Drug Resistance, Viral; Female; Hepatitis B, Chronic; HIV Infections; Humans; Immuno

2004
Tenofovir in chronic hepatitis B.
    Hepatology (Baltimore, Md.), 2005, Volume: 41, Issue:5

    Topics: Adenine; Adult; Aged; Hepatitis B, Chronic; Humans; Middle Aged; Organophosphonates; Reverse Transcr

2005
Long-term hepatitis B virus dynamics in HIV-hepatitis B virus-co-infected patients treated with tenofovir disoproxil fumarate.
    AIDS (London, England), 2005, Jun-10, Volume: 19, Issue:9

    Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; DNA, Viral; Epidemiologic Me

2005
Liver transplantation for chronic hepatitis B with lamivudine-resistant YMDD mutant using add-on adefovir dipivoxil plus lamivudine.
    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2005, Volume: 11, Issue:7

    Topics: Adenine; Adult; Aged; Antiviral Agents; DNA-Directed DNA Polymerase; DNA, Viral; Drug Resistance, Vi

2005
Viral dynamics during tenofovir therapy in patients infected with lamivudine-resistant hepatitis B virus mutants.
    Journal of viral hepatitis, 2005, Volume: 12, Issue:4

    Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B virus; Hep

2005
Determinants of early mortality and benefits of lamivudine therapy in patients with hepatitis B virus-related decompensated liver cirrhosis.
    Journal of viral hepatitis, 2005, Volume: 12, Issue:4

    Topics: Adenine; Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Female; Hepatic Encephalopathy; Hepa

2005
Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B.
    The New England journal of medicine, 2005, Jun-30, Volume: 352, Issue:26

    Topics: Adenine; Adolescent; Adult; Animals; Antiviral Agents; DNA, Viral; Double-Blind Method; Drug Adminis

2005
Clinical and virological response to adefovir dipovixil for lamivudine-resistant HBeAg-negative hepatitis B.
    The new microbiologica, 2005, Volume: 28, Issue:3

    Topics: Adenine; Administration, Oral; Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Resis

2005
Efficacy and safety of adefovir dipivoxil in kidney recipients, hemodialysis patients, and patients with renal insufficiency.
    Transplantation, 2005, Oct-27, Volume: 80, Issue:8

    Topics: Adenine; Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Female; Hepatitis B virus; Hepatitis

2005
A double-blind randomized trial of adefovir dipivoxil in Chinese subjects with HBeAg-positive chronic hepatitis B.
    Hepatology (Baltimore, Md.), 2006, Volume: 44, Issue:1

    Topics: Adenine; Adolescent; Adult; Antiviral Agents; China; DNA, Viral; Double-Blind Method; Female; Follow

2006
Overlap lamivudine treatment in patients with chronic hepatitis B receiving adefovir for lamivudine-resistant viral mutants.
    Journal of viral hepatitis, 2006, Volume: 13, Issue:6

    Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combinatio

2006
Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection.
    AIDS (London, England), 2006, Oct-03, Volume: 20, Issue:15

    Topics: Adenine; Anti-HIV Agents; Chi-Square Distribution; DNA, Viral; Drug Resistance, Viral; Hepatitis B e

2006
Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127.
    Hepatology (Baltimore, Md.), 2006, Volume: 44, Issue:5

    Topics: Adenine; Adult; Alanine Transaminase; Anti-HIV Agents; Antiviral Agents; DNA, Viral; Double-Blind Me

2006
Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years.
    Gastroenterology, 2006, Volume: 131, Issue:6

    Topics: Adenine; Adult; Aged; Alanine Transaminase; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral;

2006
Effect of switching to tenofovir with emtricitabine in patients with chronic hepatitis B failing to respond to an adefovir-containing regimen.
    European journal of gastroenterology & hepatology, 2006, Volume: 18, Issue:12

    Topics: Adenine; Adult; Antiviral Agents; Deoxycytidine; DNA, Viral; Drug Resistance, Viral; Drug Therapy, C

2006
[A double-blind, randomized, lamivudine-controlled clinical trial of DAIDING (adefovir dipivoxil) for lamivudine-resistant patients with chronic hepatitis B].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2006, Volume: 14, Issue:11

    Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Double-Blind Method; Drug Resistance, Viral; Fem

2006
[A clinical study of adefovir dipivoxil, made in China, for treatment of hepatitis B e antigen-positive patients with chronic hepatitis B].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2006, Volume: 14, Issue:12

    Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Double-Blind Method; Drug Resistance, Viral; Hep

2006
Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B.
    Hepatology (Baltimore, Md.), 2007, Volume: 45, Issue:2

    Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combinatio

2007
Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B.
    Hepatology (Baltimore, Md.), 2007, Volume: 45, Issue:2

    Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combinatio

2007
Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B.
    Hepatology (Baltimore, Md.), 2007, Volume: 45, Issue:2

    Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combinatio

2007
Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B.
    Hepatology (Baltimore, Md.), 2007, Volume: 45, Issue:2

    Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combinatio

2007
Virological response and incidence of adefovir resistance in lamivudine-resistant patients treated with adefovir dipivoxil.
    Antiviral therapy, 2006, Volume: 11, Issue:6

    Topics: Adenine; Adult; Aged; Antiviral Agents; DNA-Directed DNA Polymerase; Drug Resistance, Viral; Drug Th

2006
Efficacy and safety of adefovir dipivoxil 20 mg daily in HBeAg-positive patients with lamivudine-resistant hepatitis B virus and a suboptimal virological response to adefovir dipivoxil 10 mg daily.
    Journal of hepatology, 2007, Volume: 46, Issue:5

    Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Dose-Response

2007
Hepatitis B virus resistance to adefovir in a nucleotide naive patient with chronic hepatitis B virus infection.
    The Journal of antimicrobial chemotherapy, 2007, Volume: 59, Issue:4

    Topics: Adenine; Adult; Antiviral Agents; Drug Resistance, Viral; Female; Genotype; Hepatitis B virus; Hepat

2007
Adefovir dipivoxil treatment of lamivudine-resistant chronic hepatitis B.
    Antiviral research, 2007, Volume: 75, Issue:2

    Topics: Adenine; Adult; Aged; Alanine Transaminase; Antibodies, Viral; Antiviral Agents; Bilirubin; Creatini

2007
Adefovir dipivoxil alone or in combination with lamivudine for three months in patients with lamivudine resistant compensated chronic hepatitis B.
    Digestive diseases and sciences, 2007, Volume: 52, Issue:12

    Topics: Adenine; Adult; Aged; Alanine Transaminase; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combin

2007
[Three year adefovir dipivoxil treatment for hepatitis B e antigen-positive chronic hepatitis B patients].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2007, Volume: 15, Issue:5

    Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; DNA, Viral; Double-Blind Method; Female; Hepatit

2007
[A clinical study of adefovir dipivoxil in treating lamivudine refractory HBeAg-positive chronic hepatitis B].
    Zhonghua nei ke za zhi, 2007, Volume: 46, Issue:4

    Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Hepa

2007
Impact of early viral kinetics on T-cell reactivity during antiviral therapy in chronic hepatitis B.
    Antiviral therapy, 2007, Volume: 12, Issue:5

    Topics: Adenine; Adult; Antiviral Agents; Deoxycytidine; DNA, Viral; Double-Blind Method; Drug Therapy, Comb

2007
Second tenofovir phase III study for the chronic HBV reaches primary endpoint.
    AIDS patient care and STDs, 2007, Volume: 21, Issue:8

    Topics: Adenine; Anti-HIV Agents; Double-Blind Method; Hepatitis B, Chronic; Humans; Organophosphonates; Rev

2007
Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial.
    Annals of internal medicine, 2007, Dec-04, Volume: 147, Issue:11

    Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Biomarkers; DNA, Viral; Drug Therapy, Combinatio

2007
Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial.
    Annals of internal medicine, 2007, Dec-04, Volume: 147, Issue:11

    Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Biomarkers; DNA, Viral; Drug Therapy, Combinatio

2007
Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial.
    Annals of internal medicine, 2007, Dec-04, Volume: 147, Issue:11

    Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Biomarkers; DNA, Viral; Drug Therapy, Combinatio

2007
Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial.
    Annals of internal medicine, 2007, Dec-04, Volume: 147, Issue:11

    Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Biomarkers; DNA, Viral; Drug Therapy, Combinatio

2007
Cost effectiveness of entecavir versus lamivudine with adefovir salvage in HBeAg-positive chronic hepatitis B.
    PharmacoEconomics, 2007, Volume: 25, Issue:11

    Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Cohort Studies; Cost-Benefit Analysis; Disease Progressi

2007
[Diammonium glycyrrhizinate does not affect efficacy of adefovir dipivoxil therapy in patients with HBeAg-positive chronic hepatitis B].
    Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology, 2007, Volume: 21, Issue:3

    Topics: Adenine; Adult; Antiviral Agents; Double-Blind Method; Glycyrrhizic Acid; Hepatitis B e Antigens; He

2007
[Efficacy of adefovir dipivoxil was not related to genotypes B and C of hepatitis B virus: a randomized, double-blind, multicenter clinical study].
    Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology, 2007, Volume: 21, Issue:3

    Topics: Adenine; Adolescent; Adult; Antiviral Agents; DNA, Viral; Double-Blind Method; Female; Genotype; Hep

2007
Clinical trial: effects of adefovir dipivoxil therapy in Asian and Caucasian patients with chronic hepatitis B.
    Alimentary pharmacology & therapeutics, 2007, Nov-15, Volume: 26, Issue:10

    Topics: Adenine; Adult; Antiviral Agents; Asian People; Double-Blind Method; Drug Administration Schedule; F

2007
Hepatitis B virus e antigen loss during adefovir dipivoxil therapy is associated with enhanced virus-specific CD4+ T-cell reactivity.
    Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:1

    Topics: Adenine; Adult; Antiviral Agents; CD4-Positive T-Lymphocytes; DNA, Viral; Female; Hepatitis B e Anti

2008
[Adefovir dipivoxil compassionate use program in Spain: efficacy and resistance analysis].
    Medicina clinica, 2007, Oct-27, Volume: 129, Issue:15

    Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Female; Hepatitis B viru

2007
Interruptions of tenofovir/emtricitabine-based antiretroviral therapy in patients with HIV/hepatitis B virus co-infection.
    AIDS (London, England), 2008, Jan-02, Volume: 22, Issue:1

    Topics: Adenine; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Deoxycytid

2008
Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations.
    Journal of hepatology, 2008, Volume: 48, Issue:3

    Topics: Adenine; Adult; Aged; Antiviral Agents; Deoxycytidine; DNA, Viral; Drug Resistance, Viral; Drug Ther

2008
Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations.
    Journal of hepatology, 2008, Volume: 48, Issue:3

    Topics: Adenine; Adult; Aged; Antiviral Agents; Deoxycytidine; DNA, Viral; Drug Resistance, Viral; Drug Ther

2008
Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations.
    Journal of hepatology, 2008, Volume: 48, Issue:3

    Topics: Adenine; Adult; Aged; Antiviral Agents; Deoxycytidine; DNA, Viral; Drug Resistance, Viral; Drug Ther

2008
Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations.
    Journal of hepatology, 2008, Volume: 48, Issue:3

    Topics: Adenine; Adult; Aged; Antiviral Agents; Deoxycytidine; DNA, Viral; Drug Resistance, Viral; Drug Ther

2008
96 weeks combination of adefovir dipivoxil plus emtricitabine vs. adefovir dipivoxil monotherapy in the treatment of chronic hepatitis B.
    Journal of hepatology, 2008, Volume: 48, Issue:5

    Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; Deoxycytidine; DNA, Viral; Drug Resistance,

2008
The pharmacokinetics and safety of adefovir dipivoxil in children and adolescents with chronic hepatitis B virus infection.
    Journal of clinical pharmacology, 2008, Volume: 48, Issue:4

    Topics: Adenine; Adolescent; Antiviral Agents; Area Under Curve; Child; Child, Preschool; Dose-Response Rela

2008
Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B.
    Journal of hepatology, 2008, Volume: 48, Issue:5

    Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Therapy,

2008
Short-term overlap lamivudine treatment with adefovir dipivoxil in patients with lamivudine-resistant chronic hepatitis B.
    World journal of gastroenterology, 2008, Mar-21, Volume: 14, Issue:11

    Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Administration Schedule; Dr

2008
Safety, efficacy, and pharmacokinetics of adefovir dipivoxil in children and adolescents (age 2 to <18 years) with chronic hepatitis B.
    Hepatology (Baltimore, Md.), 2008, Volume: 47, Issue:6

    Topics: Adenine; Adolescent; Age Factors; Alanine Transaminase; Antiviral Agents; Child; Child, Preschool; D

2008
Dynamics of lamivudine-resistant hepatitis B virus during adefovir monotherapy versus lamivudine plus adefovir combination therapy.
    Journal of medical virology, 2008, Volume: 80, Issue:7

    Topics: Adenine; Adult; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatit

2008
Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy.
    Hepatology (Baltimore, Md.), 1999, Volume: 29, Issue:6

    Topics: Adenine; Antiviral Agents; DNA, Viral; Half-Life; Hepatitis B Surface Antigens; Hepatitis B virus; H

1999
A placebo-controlled phase I/II study of adefovir dipivoxil in patients with chronic hepatitis B virus infection.
    Journal of viral hepatitis, 1999, Volume: 6, Issue:5

    Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind Method; Female; Hep

1999

Other Studies

754 other studies available for adenine and Hepatitis B, Chronic

ArticleYear
Body weight changes in treated hepatitis B patients switching to tenofovir alafenamide
    Journal of the Formosan Medical Association = Taiwan yi zhi, 2022, Volume: 121, Issue:7

    Topics: Adenine; Alanine; Body Weight; Female; Hepatitis B; Hepatitis B, Chronic; Humans; Male; Middle Aged;

2022
Tenofovir Alafenamide for Pregnant Chinese Women With Active Chronic Hepatitis B: A Multicenter Prospective Study.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2022, Volume: 20, Issue:12

    Topics: Adenine; Adult; Antiviral Agents; China; Cleft Lip; Cleft Palate; Female; Hepatitis B; Hepatitis B S

2022
Tenofovir alafenamide treatment may not worsen the lipid profile of chronic hepatitis B patients: A propensity score-matched analysis.
    Clinical and molecular hepatology, 2022, Volume: 28, Issue:2

    Topics: Adenine; Alanine; Cholesterol; Hepatitis B, Chronic; Humans; Propensity Score; Tenofovir

2022
Effects of Long-Term Tenofovir and Entecavir Treatment on Bone Mineral Density in Patients with Chronic Hepatitis B.
    The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, 2022, Volume: 33, Issue:1

    Topics: Adenine; Antiviral Agents; Bone Density; Guanine; Hepatitis B, Chronic; Humans; Prospective Studies;

2022
[Clinical significance and management strategies of low-level viremia during the treatment of chronic hepatitis B].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2021, Dec-20, Volume: 29, Issue:12

    Topics: Adenine; Antiviral Agents; Hepatitis B virus; Hepatitis B, Chronic; Humans; Tenofovir; Treatment Out

2021
Impact of switching to tenofovir alafenamide fumarate in patients with entecavir-treated chronic hepatitis B.
    European journal of gastroenterology & hepatology, 2021, 12-01, Volume: 33, Issue:1S Suppl 1

    Topics: Adenine; Alanine; Antiviral Agents; Fumarates; Guanine; Hepatitis B Surface Antigens; Hepatitis B, C

2021
Sequential HBV treatment with tenofovir alafenamide for patients with chronic hepatitis B: week 96 results from a real-world, multicenter cohort study.
    Hepatology international, 2022, Volume: 16, Issue:2

    Topics: Adenine; Alanine; Antiviral Agents; Cohort Studies; DNA, Viral; Female; Hepatitis B Surface Antigens

2022
Renal Outcomes With Tenofovir Alafenamide in Liver Transplant Recipients.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2023, Volume: 21, Issue:2

    Topics: Adenine; Alanine; Antiviral Agents; Hepatitis B, Chronic; Humans; Kidney; Liver Transplantation; Ten

2023
Dyslipidemia in chronic hepatitis B patients on tenofovir alafenamide: Facts and puzzles.
    Clinical and molecular hepatology, 2022, Volume: 28, Issue:2

    Topics: Adenine; Alanine; Dyslipidemias; Hepatitis B, Chronic; Humans; Tenofovir

2022
Risk of hepatitis B virus reactivation in chronic lymphocytic leukemia patients receiving ibrutinib with or without antiviral prophylaxis. A retrospective multicentric GIMEMA study.
    Haematologica, 2022, 06-01, Volume: 107, Issue:6

    Topics: Adenine; Antiviral Agents; Hepatitis B virus; Hepatitis B, Chronic; Humans; Leukemia, Lymphocytic, C

2022
Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in treatment-naïve chronic hepatitis B.
    Liver international : official journal of the International Association for the Study of the Liver, 2022, Volume: 42, Issue:7

    Topics: Adenine; Alanine; Carcinoma, Hepatocellular; Female; Hepatitis B, Chronic; Humans; Liver Neoplasms;

2022
CKD in a Patient Treated with Adefovir for Chronic Hepatitis B Virus Infection.
    Kidney360, 2021, 01-28, Volume: 2, Issue:1

    Topics: Adenine; Antiviral Agents; Hepatitis B, Chronic; Humans; Organophosphonates; Renal Insufficiency, Ch

2021
Novel hepatitis B virus reverse transcriptase mutations in patients with sustained viremia despite long-term tenofovir treatment.
    Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2022, Volume: 150-151

    Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chron

2022
Plasma and breast milk pharmacokinetics of tenofovir alafenamide in mothers with chronic hepatitis B infection.
    Alimentary pharmacology & therapeutics, 2022, Volume: 56, Issue:3

    Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Female; Hepatitis B; Hepatitis B, Chronic; HIV Infections;

2022
Switching to tenofovir alafenamide for nucleos(t)ide analogue-experienced patients with chronic hepatitis B: week 144 results from a real-world, multi-centre cohort study.
    Alimentary pharmacology & therapeutics, 2022, Volume: 56, Issue:4

    Topics: Adenine; Adult; Alanine; Antiviral Agents; DNA, Viral; Hepatitis B, Chronic; Humans; Renal Insuffici

2022
HERACLIS-TAF: a multi-centre prospective cohort study on 2-year safety and efficacy of tenofovir alafenamide in patients with chronic hepatitis B with renal and/or bone disorders or risks.
    Alimentary pharmacology & therapeutics, 2022, Volume: 56, Issue:4

    Topics: Adenine; Adult; Alanine; Hepatitis B, Chronic; HIV Infections; Humans; Phosphates; Prospective Studi

2022
One-year efficacy of tenofovir alafenamide in patients with chronic hepatitis B: An observational study.
    Medicine, 2022, Jun-24, Volume: 101, Issue:25

    Topics: Adenine; Alanine; Antiviral Agents; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis

2022
Treatment of chronic hepatitis B: virological and pharmacological aspects
    Virologie (Montrouge, France), 2022, 05-01, Volume: 26, Issue:3

    Topics: Adenine; Alanine; Antiviral Agents; Hepatitis B, Chronic; Humans; Tenofovir

2022
Tenofovir Alafenamide use in pregnant women with chronic hepatitis B virus infection: more data needed.
    Hepatology international, 2022, Volume: 16, Issue:4

    Topics: Adenine; Alanine; Antiviral Agents; Female; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; Hu

2022
Plasma and breast milk pharmacokinetics of tenofovir alafenamide of mothers with chronic hepatitis B infection-Authors' reply.
    Alimentary pharmacology & therapeutics, 2022, Volume: 56, Issue:3

    Topics: Adenine; Alanine; Antiviral Agents; Female; Hepatitis B; Hepatitis B, Chronic; Humans; Milk, Human;

2022
Plasma and breast milk pharmacokinetics of tenofovir alafenamide in mothers with chronic hepatitis B infection.
    Alimentary pharmacology & therapeutics, 2022, Volume: 56, Issue:3

    Topics: Adenine; Alanine; Antiviral Agents; Female; Hepatitis B, Chronic; HIV Infections; Humans; Milk, Huma

2022
Interaction between baseline HBV loads and the prognosis of patients with HCC receiving anti-PD-1 in combination with antiangiogenic therapy undergoing concurrent TAF prophylaxis.
    BMC infectious diseases, 2022, Jul-14, Volume: 22, Issue:1

    Topics: Adenine; Alanine; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Hepatitis B virus; Hepati

2022
Editorial: changes in renal function and bone mineral density after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in chronic hepatitis B patients-author's reply.
    Alimentary pharmacology & therapeutics, 2022, Volume: 56, Issue:5

    Topics: Adenine; Alanine; Bone Density; Fumarates; Hepatitis B, Chronic; Humans; Kidney; Tenofovir

2022
Editorial: changes in renal function and bone mineral density after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in patients with chronic hepatitis B.
    Alimentary pharmacology & therapeutics, 2022, Volume: 56, Issue:5

    Topics: Adenine; Alanine; Bone Density; Fumarates; Hepatitis B, Chronic; Humans; Kidney; Tenofovir

2022
Similar risk of kidney function decline between tenofovir alafenamide and besifovir dipivoxil maleate in chronic hepatitis B.
    Liver international : official journal of the International Association for the Study of the Liver, 2022, Volume: 42, Issue:11

    Topics: Adenine; Alanine; Antiviral Agents; Guanine; Hepatitis B; Hepatitis B, Chronic; Humans; Kidney; Long

2022
Retreatment Efficacy and Renal Safety of Tenofovir Alafenamide, Entecavir, and Tenofovir Disoproxil Fumarate After Entecavir or Tenofovir Cessation.
    Digestive diseases and sciences, 2023, Volume: 68, Issue:2

    Topics: Adenine; Alanine; Antiviral Agents; DNA, Viral; Hepatitis B, Chronic; Humans; Recurrence; Retreatmen

2023
Editorial: switching to tenofovir alafenamide monotherapy is effective and safe for other nucleos(t)ide analogues-treated patients with chronic hepatitis B.
    Alimentary pharmacology & therapeutics, 2022, Volume: 56, Issue:6

    Topics: Adenine; Alanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Tenofovir

2022
Editorial: switching to tenofovir alafenamide monotherapy is effective and safe for other nucleos(t)ide analogues-treated patients with chronic hepatitis B - author's reply.
    Alimentary pharmacology & therapeutics, 2022, Volume: 56, Issue:6

    Topics: Adenine; Alanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Tenofovir

2022
Switching to Tenofovir Alafenamide Fumarate in Chronic Hepatitis B Patients Who Had Detectable HBV DNA during Treatment with Entecavir.
    The Tohoku journal of experimental medicine, 2022, Nov-12, Volume: 258, Issue:4

    Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Fumarates; Hepatitis B, Chronic; H

2022
Effect of nucleos(t)ide analogues on blood lipid profiles in patients with chronic hepatitis B: A cross-sectional survey.
    Medicine, 2022, Dec-16, Volume: 101, Issue:50

    Topics: Adenine; Antiviral Agents; Cross-Sectional Studies; Hepatitis B, Chronic; Humans; Hypercholesterolem

2022
Prophylactic tenofovir alafenamide for hepatitis B virus reactivation and reactivation-related hepatitis.
    Journal of medical virology, 2023, Volume: 95, Issue:2

    Topics: Adenine; Alanine; Antiviral Agents; Hepatitis A; Hepatitis B; Hepatitis B virus; Hepatitis B, Chroni

2023
Tenofovir Alafenamide for Multiple Drug-Resistant Chronic Hepatitis B: A 3-Year Clinical Trial.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2023, Volume: 21, Issue:12

    Topics: Adenine; Antiviral Agents; Hepatitis B, Chronic; HIV Infections; Humans; Tenofovir; Treatment Outcom

2023
Converting from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Patients with Hepatitis B Following Liver Transplantation.
    Annals of transplantation, 2023, Apr-21, Volume: 28

    Topics: Adenine; Alanine; Antiviral Agents; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; Humans; Li

2023
The expression of interleukin-1β in patients with chronic hepatitis B treated with pegylated-interferon-alpha combined with tenofovir disoproxil fumarate and monotherapy.
    BMC gastroenterology, 2023, May-19, Volume: 23, Issue:1

    Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; DNA, Viral; Drug Therapy, Comb

2023
Tenofovir disoproxil fumarate versus tenofovir alafenamide on risk of osteoporotic fracture in patients with chronic hepatitis B: A nationwide claims study in South Korea.
    Alimentary pharmacology & therapeutics, 2023, Volume: 58, Issue:11-12

    Topics: Adenine; Adult; Alanine; Female; Hepatitis B, Chronic; Humans; Male; Middle Aged; Osteoporotic Fract

2023
Immunomodulatory Mechanism of Acyclic Nucleoside Phosphates in Treatment of Hepatitis B Virus Infection.
    Hepatology (Baltimore, Md.), 2020, Volume: 71, Issue:5

    Topics: Adenine; Adult; Aged; Antiviral Agents; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Hu

2020
In response to identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients.
    Journal of hepatology, 2019, Volume: 71, Issue:6

    Topics: Adenine; Hepatitis B, Chronic; Humans; Mutation; Organophosphonates; Tenofovir

2019
Reply to: "In response to identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients."
    Journal of hepatology, 2019, Volume: 71, Issue:6

    Topics: Adenine; Hepatitis B, Chronic; Humans; Mutation; Organophosphonates; Tenofovir

2019
[Analysis of resistance mutations in patients with persistent low viral load during antiviral therapy with tebivudine alone or in combination with adefovir dipivoxil].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2019, 10-20, Volume: 27, Issue:10

    Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chron

2019
Significance of switching of the nucleos(t)ide analog used to treat Japanese patients with chronic hepatitis B virus infection from entecavir to tenofovir alafenamide fumarate.
    Journal of medical virology, 2020, Volume: 92, Issue:3

    Topics: Adenine; Aged; Alanine; Antibodies, Viral; Antiviral Agents; Female; Fumarates; Genotype; Guanine; H

2020
Significance of switching of the nucleos(t)ide analog used to treat Japanese patients with chronic hepatitis B virus infection from entecavir to tenofovir alafenamide fumarate.
    Journal of medical virology, 2020, Volume: 92, Issue:3

    Topics: Adenine; Aged; Alanine; Antibodies, Viral; Antiviral Agents; Female; Fumarates; Genotype; Guanine; H

2020
Significance of switching of the nucleos(t)ide analog used to treat Japanese patients with chronic hepatitis B virus infection from entecavir to tenofovir alafenamide fumarate.
    Journal of medical virology, 2020, Volume: 92, Issue:3

    Topics: Adenine; Aged; Alanine; Antibodies, Viral; Antiviral Agents; Female; Fumarates; Genotype; Guanine; H

2020
Significance of switching of the nucleos(t)ide analog used to treat Japanese patients with chronic hepatitis B virus infection from entecavir to tenofovir alafenamide fumarate.
    Journal of medical virology, 2020, Volume: 92, Issue:3

    Topics: Adenine; Aged; Alanine; Antibodies, Viral; Antiviral Agents; Female; Fumarates; Genotype; Guanine; H

2020
Effect of nucleos(t)ide analogue on serum HBsAg level in chronic hepatitis B patients: A 3-years study.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2020, Volume: 122

    Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Female; Guanine; Hepatitis B e Antigens; Hepatitis B S

2020
Validation of hepatocellular carcinoma risk scores in Japanese chronic hepatitis B cohort receiving nucleot(s)ide analog.
    Journal of gastroenterology and hepatology, 2020, Volume: 35, Issue:9

    Topics: Adenine; Adult; Alanine; Antiviral Agents; Asian People; Carcinoma, Hepatocellular; Cohort Studies;

2020
Pregnancy outcomes for pregnant women with chronic hepatitis B exposing to entecavir or adefovir dipivoxil therapy before or in early pregnancy.
    The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians, 2022, Volume: 35, Issue:3

    Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Gu

2022
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide: perhaps not as simple as we thought.
    The lancet. Gastroenterology & hepatology, 2020, Volume: 5, Issue:5

    Topics: Adenine; Alanine; Antiviral Agents; Cholesterol, LDL; Drug Monitoring; Drug Substitution; Glomerular

2020
Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B.
    Liver international : official journal of the International Association for the Study of the Liver, 2020, Volume: 40, Issue:7

    Topics: Adenine; Alanine; Antiviral Agents; Cohort Studies; Guanine; Hepatitis B, Chronic; Humans; Retrospec

2020
Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B.
    Liver international : official journal of the International Association for the Study of the Liver, 2020, Volume: 40, Issue:7

    Topics: Adenine; Alanine; Antiviral Agents; Cohort Studies; Guanine; Hepatitis B, Chronic; Humans; Retrospec

2020
Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B.
    Liver international : official journal of the International Association for the Study of the Liver, 2020, Volume: 40, Issue:7

    Topics: Adenine; Alanine; Antiviral Agents; Cohort Studies; Guanine; Hepatitis B, Chronic; Humans; Retrospec

2020
Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B.
    Liver international : official journal of the International Association for the Study of the Liver, 2020, Volume: 40, Issue:7

    Topics: Adenine; Alanine; Antiviral Agents; Cohort Studies; Guanine; Hepatitis B, Chronic; Humans; Retrospec

2020
Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B.
    Liver international : official journal of the International Association for the Study of the Liver, 2020, Volume: 40, Issue:7

    Topics: Adenine; Alanine; Antiviral Agents; Cohort Studies; Guanine; Hepatitis B, Chronic; Humans; Retrospec

2020
Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B.
    Liver international : official journal of the International Association for the Study of the Liver, 2020, Volume: 40, Issue:7

    Topics: Adenine; Alanine; Antiviral Agents; Cohort Studies; Guanine; Hepatitis B, Chronic; Humans; Retrospec

2020
Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B.
    Liver international : official journal of the International Association for the Study of the Liver, 2020, Volume: 40, Issue:7

    Topics: Adenine; Alanine; Antiviral Agents; Cohort Studies; Guanine; Hepatitis B, Chronic; Humans; Retrospec

2020
Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B.
    Liver international : official journal of the International Association for the Study of the Liver, 2020, Volume: 40, Issue:7

    Topics: Adenine; Alanine; Antiviral Agents; Cohort Studies; Guanine; Hepatitis B, Chronic; Humans; Retrospec

2020
Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B.
    Liver international : official journal of the International Association for the Study of the Liver, 2020, Volume: 40, Issue:7

    Topics: Adenine; Alanine; Antiviral Agents; Cohort Studies; Guanine; Hepatitis B, Chronic; Humans; Retrospec

2020
Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B.
    Liver international : official journal of the International Association for the Study of the Liver, 2020, Volume: 40, Issue:7

    Topics: Adenine; Alanine; Antiviral Agents; Cohort Studies; Guanine; Hepatitis B, Chronic; Humans; Retrospec

2020
Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B.
    Liver international : official journal of the International Association for the Study of the Liver, 2020, Volume: 40, Issue:7

    Topics: Adenine; Alanine; Antiviral Agents; Cohort Studies; Guanine; Hepatitis B, Chronic; Humans; Retrospec

2020
Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B.
    Liver international : official journal of the International Association for the Study of the Liver, 2020, Volume: 40, Issue:7

    Topics: Adenine; Alanine; Antiviral Agents; Cohort Studies; Guanine; Hepatitis B, Chronic; Humans; Retrospec

2020
Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B.
    Liver international : official journal of the International Association for the Study of the Liver, 2020, Volume: 40, Issue:7

    Topics: Adenine; Alanine; Antiviral Agents; Cohort Studies; Guanine; Hepatitis B, Chronic; Humans; Retrospec

2020
Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B.
    Liver international : official journal of the International Association for the Study of the Liver, 2020, Volume: 40, Issue:7

    Topics: Adenine; Alanine; Antiviral Agents; Cohort Studies; Guanine; Hepatitis B, Chronic; Humans; Retrospec

2020
Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B.
    Liver international : official journal of the International Association for the Study of the Liver, 2020, Volume: 40, Issue:7

    Topics: Adenine; Alanine; Antiviral Agents; Cohort Studies; Guanine; Hepatitis B, Chronic; Humans; Retrospec

2020
Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B.
    Liver international : official journal of the International Association for the Study of the Liver, 2020, Volume: 40, Issue:7

    Topics: Adenine; Alanine; Antiviral Agents; Cohort Studies; Guanine; Hepatitis B, Chronic; Humans; Retrospec

2020
Osteomalacia and renal failure due to Fanconi syndrome caused by long-term low-dose Adefovir Dipivoxil: a case report.
    BMC pharmacology & toxicology, 2020, 06-05, Volume: 21, Issue:1

    Topics: Adenine; Antiviral Agents; Fanconi Syndrome; Hepatitis B, Chronic; Humans; Male; Middle Aged; Organo

2020
Comparable Incidence of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated with Entecavir or Tenofovir.
    Digestive diseases and sciences, 2021, Volume: 66, Issue:5

    Topics: Adenine; Adult; Antiviral Agents; Carcinoma, Hepatocellular; Female; Guanine; Hepatitis B, Chronic;

2021
Hepatitis B virus mutation pattern rtA181S+T184I+M204I may contribute to multidrug resistance in clinical practice: Analysis of a large cohort of Chinese patients.
    Antiviral research, 2020, Volume: 180

    Topics: Adenine; Adult; Antiviral Agents; Asian People; Beijing; Cohort Studies; DNA, Viral; Drug Resistance

2020
Is tenofovir and entecavir combination therapy still the optimal treatment for chronic hepatitis B patients with prior suboptimal response?
    Clinical and molecular hepatology, 2020, Volume: 26, Issue:3

    Topics: Adenine; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Organophosphonates; Telbivudine; Tenofov

2020
An antiviral drug-resistant mutant of hepatitis B virus with high replication capacity in association with a large in-frame deletion in the preS1 region of viral surface gene.
    Virus genes, 2020, Volume: 56, Issue:6

    Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Genes, Viral; Genotype; Hepati

2020
Efficacy and safety of tenofovir alafenamide fumarate for preventing mother-to-child transmission of hepatitis B virus: a national cohort study.
    Alimentary pharmacology & therapeutics, 2020, Volume: 52, Issue:8

    Topics: Abnormalities, Drug-Induced; Adenine; Adult; Alanine; Chemoprevention; China; Cohort Studies; DNA, V

2020
HCC risk reduction with oral nucleos(t)ide analogues in patients with chronic hepatitis B: Not perfect, not good enough.
    Journal of gastroenterology and hepatology, 2020, Volume: 35, Issue:10

    Topics: Adenine; Administration, Oral; Alanine; Carcinoma, Hepatocellular; DNA, Viral; Guanine; Hepatitis B

2020
Switching from entecavir to tenofovir alafenamide for chronic hepatitis B patients with low-level viraemia.
    Liver international : official journal of the International Association for the Study of the Liver, 2021, Volume: 41, Issue:6

    Topics: Adenine; Alanine; Antiviral Agents; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Prospe

2021
Switching from entecavir to tenofovir alafenamide for chronic hepatitis B patients with low-level viraemia.
    Liver international : official journal of the International Association for the Study of the Liver, 2021, Volume: 41, Issue:6

    Topics: Adenine; Alanine; Antiviral Agents; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Prospe

2021
Switching from entecavir to tenofovir alafenamide for chronic hepatitis B patients with low-level viraemia.
    Liver international : official journal of the International Association for the Study of the Liver, 2021, Volume: 41, Issue:6

    Topics: Adenine; Alanine; Antiviral Agents; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Prospe

2021
Switching from entecavir to tenofovir alafenamide for chronic hepatitis B patients with low-level viraemia.
    Liver international : official journal of the International Association for the Study of the Liver, 2021, Volume: 41, Issue:6

    Topics: Adenine; Alanine; Antiviral Agents; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Prospe

2021
Multiple drug-resistant HBV mutation may contribute to poor response of adefovir + entecavir in entecavir-resistant patients.
    Journal of infection in developing countries, 2021, 01-31, Volume: 15, Issue:1

    Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combinatio

2021
Severe hypophosphataemic osteomalacia related to low-dose adefovir dipivoxil therapy in a hepatitis B virus patient.
    Endokrynologia Polska, 2021, Volume: 72, Issue:2

    Topics: Adenine; Antiviral Agents; Hepatitis B virus; Hepatitis B, Chronic; Humans; Hypophosphatemia; Organo

2021
Investigation of multidrug-resistance mutations of hepatitis B virus (HBV) in a large cohort of chronic HBV-infected patients with treatment of nucleoside/nucleotide analogs.
    Antiviral research, 2021, Volume: 189

    Topics: Adenine; Adult; Antiviral Agents; Cohort Studies; DNA, Viral; Drug Resistance, Multiple, Viral; Fema

2021
Safety and Effectiveness of Tenofovir Alafenamide in Usual Clinical Practice Confirms Results of Clinical Trials: TARGET-HBV.
    Digestive diseases and sciences, 2022, Volume: 67, Issue:6

    Topics: Adenine; Alanine; Antiviral Agents; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; M

2022
Nucleos(t)ide analogue therapy: The role of tenofovir alafenamide.
    Liver international : official journal of the International Association for the Study of the Liver, 2021, Volume: 41 Suppl 1

    Topics: Adenine; Aged; Alanine; Antiviral Agents; Hepatitis B, Chronic; Humans; Tenofovir; Treatment Outcome

2021
Evolutionary trends of resistance mutational patterns of HBV reverse transcriptase over years (2002-2012) of different treatment regimens: The legacy of lamivudine/adefovir combination treatment.
    Antiviral research, 2017, Volume: 143

    Topics: Adenine; Antiviral Agents; DNA Mutational Analysis; DNA, Viral; Drug Resistance, Viral; Drug Therapy

2017
Short Communication: Resolution of Tenofovir Disoproxil Fumarate Induced Fanconi Syndrome with Switch to Tenofovir Alafenamide Fumarate in a HIV-1 and Hepatitis B Coinfected Patient.
    AIDS research and human retroviruses, 2017, Volume: 33, Issue:7

    Topics: Adenine; Alanine; Anti-HIV Agents; Coinfection; Fanconi Syndrome; Hepatitis B, Chronic; HIV Infectio

2017
A different inhibitor is required for overcoming entecavir resistance: a comparison of four rescue therapies in a retrospective study.
    British journal of clinical pharmacology, 2017, Volume: 83, Issue:10

    Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Fem

2017
HBsAg loss after peginterferon-nucleotide combination treatment in chronic hepatitis B patients: 5 years of follow-up.
    Journal of viral hepatitis, 2017, Volume: 24, Issue:12

    Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Follow-Up Stu

2017
Analysis of immunological mechanisms exerted by HBsAg-HBIG therapeutic vaccine combined with Adefovir in chronic hepatitis B patients.
    Human vaccines & immunotherapeutics, 2017, 09-02, Volume: 13, Issue:9

    Topics: Adenine; Adjuvants, Immunologic; Adult; Antigen-Antibody Complex; Combined Modality Therapy; Female;

2017
Lactate serum concentrations during treatment with nucleos(t)ide analogues in hepatitis B with or without cirrhosis.
    European journal of gastroenterology & hepatology, 2017, Volume: 29, Issue:9

    Topics: Acidosis, Lactic; Adenine; Adult; Aged; Aged, 80 and over; Antiviral Agents; Biomarkers; Drug Therap

2017
Viral minority variants in the core promoter and precore region identified by deep sequencing are associated with response to peginterferon and adefovir in HBeAg negative chronic hepatitis B patients.
    Antiviral research, 2017, Volume: 145

    Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Genetic Variation;

2017
Letter: lipid-lowering effect of tenofovir disoproxil fumarate in chronic hepatitis B-more evidence is needed. Authors' reply.
    Alimentary pharmacology & therapeutics, 2017, Volume: 46, Issue:8

    Topics: Adenine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lipids; Organophosphonates; Tenofovir

2017
Letter: lipid-lowering effect of tenofovir disoproxil fumarate in chronic hepatitis B-more evidence is needed.
    Alimentary pharmacology & therapeutics, 2017, Volume: 46, Issue:8

    Topics: Adenine; Antiviral Agents; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lipids; Organophosp

2017
Successful treatment with tenofovir alafenamide of a HIV/hepatitis B virus coinfected patient with HIV and hepatitis B virus drug resistance, end-stage renal disease on haemodialysis.
    AIDS (London, England), 2017, 10-23, Volume: 31, Issue:16

    Topics: Adenine; Adult; Alanine; Antiviral Agents; Coinfection; Drug Resistance, Viral; Female; Hepatitis B,

2017
Efficacy and safety of three adefovir-based combination therapies in HBeAg-positive chronic hepatitis B patients with suboptimal response to adefovir monotherapy.
    Journal of viral hepatitis, 2017, Volume: 24 Suppl 1

    Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Hepatitis B e Antig

2017
Effective viral suppression is necessary to reduce hepatocellular carcinoma development in cirrhotic patients with chronic hepatitis B: Results of a 10-year follow up.
    Medicine, 2017, Volume: 96, Issue:44

    Topics: Adenine; Adult; Antiviral Agents; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Hepatitis B

2017
Direct Detection of Drug-Resistant Hepatitis B Virus in Serum Using a Dendron-Modified Microarray.
    Gut and liver, 2018, May-15, Volume: 12, Issue:3

    Topics: Adenine; Dendrimers; DNA, Viral; Drug Resistance, Viral; Guanine; Hepatitis B virus; Hepatitis B, Ch

2018
Seroclearance of hepatitis B surface antigen following hepatitis E exacerbation on chronic hepatitis E and B dual infection in a renal transplant recipient: a case report.
    Journal of medical case reports, 2018, Feb-28, Volume: 12, Issue:1

    Topics: Adenine; Coinfection; Disease Progression; DNA, Viral; Female; Graft Rejection; Hepatitis B Surface

2018
Injectable PLGA Adefovir microspheres; the way for long term therapy of chronic hepatitis-B.
    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2018, Jun-15, Volume: 118

    Topics: Adenine; Animals; Antiviral Agents; Drug Delivery Systems; Drug Liberation; Hepatitis B, Chronic; La

2018
Hepatitis B virus rtA181T/sW172non-stop mutation may increase resistance fold to adefovir- and entecavir-resistant mutants compared to rtA181T/sW172* mutation.
    Antiviral research, 2018, Volume: 154

    Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Genotype; Guanine; Hep

2018
Chronic hepatitis B virus and liver fibrosis: A mathematical model.
    PloS one, 2018, Volume: 13, Issue:4

    Topics: Adenine; Computer Simulation; Diffusion; Drug Delivery Systems; Hepatic Stellate Cells; Hepatitis B

2018
Trends in hepatitis B virus resistance to nucleoside/nucleotide analogues in North China from 2009-2016: A retrospective study.
    International journal of antimicrobial agents, 2018, Volume: 52, Issue:2

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Child, Preschool; Chin

2018
Combination therapy for chronic hepatitis B: The future and beyond.
    Journal of the Formosan Medical Association = Taiwan yi zhi, 2018, Volume: 117, Issue:8

    Topics: Adenine; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferon-alpha; Organophos

2018
Adefovir dipivoxil induced hypophosphatemic osteomalacia in chronic hepatitis B: a comparative study of Chinese and foreign case series.
    BMC pharmacology & toxicology, 2018, 05-16, Volume: 19, Issue:1

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Antiviral Agents; Asian People; Female; Hepatitis B, Chroni

2018
Clinical-features analysis on 926 patients with virological breakthrough in chronic hepatitis B receiving nucleos(t)ide analogues.
    European journal of internal medicine, 2018, Volume: 53

    Topics: Adenine; Adult; DNA, Viral; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Comb

2018
48-Week Outcome after Cessation of Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Patient and the Associated Factors with Relapse.
    Canadian journal of gastroenterology & hepatology, 2018, Volume: 2018

    Topics: Adenine; Adult; Antiviral Agents; Female; Follow-Up Studies; Guanine; Hepatitis B e Antigens; Hepati

2018
[Compare the effect of combined therapy between telbivudine plus adefovir dipivoxil and lamivudine plus adefovir dipivoxil corresponding to renal function in patients with hepatitis B virus infection].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2018, Apr-20, Volume: 26, Issue:4

    Topics: Adenine; Antiviral Agents; Creatinine; DNA, Viral; Drug Therapy, Combination; Glomerular Filtration

2018
Long-term results of chronic hepatitis B antiviral treatment with nucleos(t)ide analogues: a single center experience.
    Minerva gastroenterologica e dietologica, 2019, Volume: 65, Issue:1

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Therapy, Combination; Female; Guanin

2019
Deep sequencing identifies hepatitis B virus core protein signatures in chronic hepatitis B patients.
    Antiviral research, 2018, Volume: 158

    Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Hepatitis B e Antig

2018
[A Case of Fanconi's Syndrome Induced by Adefovir in Hepatitis Type B Patient].
    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2016, Volume: 105, Issue:6

    Topics: Adenine; Aged; Antiviral Agents; Fanconi Syndrome; Female; Guanine; Hepatitis B, Chronic; Humans; Or

2016
Hypophosphatemic Osteomalacia Associated with Adefovir-induced Fanconi Syndrome Initially Diagnosed as Diabetic Kidney Disease and Vitamin D Deficiency.
    Internal medicine (Tokyo, Japan), 2019, Mar-15, Volume: 58, Issue:6

    Topics: Adenine; Aged; Antiviral Agents; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diagnostic Error

2019
Management of individuals with chronic hepatitis B virus infection and persistent normal or mildly elevated aminotransferase levels.
    Journal of cellular biochemistry, 2019, Volume: 120, Issue:4

    Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; Biopsy; Disease Management; DNA, Viral; Fema

2019
Longitudinal trends in renal function in chronic hepatitis B patients receiving oral antiviral treatment.
    Alimentary pharmacology & therapeutics, 2018, Volume: 48, Issue:11-12

    Topics: Adenine; Administration, Oral; Adult; Aged; Antiviral Agents; Cohort Studies; Drug Therapy, Combinat

2018
Treatment Outcome and Renal Safety of 3-Year Tenofovir Disoproxil Fumarate Therapy in Chronic Hepatitis B Patients with Preserved Glomerular Filtration Rate.
    Gut and liver, 2019, 01-15, Volume: 13, Issue:1

    Topics: Adenine; Adult; Antiviral Agents; Drug Administration Schedule; Female; Glomerular Filtration Rate;

2019
Performance of serum HBcrAg in chronic hepatitis B patients with 8-year nucleos(t)ide analogs therapy.
    Clinics and research in hepatology and gastroenterology, 2019, Volume: 43, Issue:3

    Topics: Adenine; Adult; Antiviral Agents; Female; Guanine; Hepatitis B Core Antigens; Hepatitis B e Antigens

2019
Telbivudine and adefovir dipivoxil combination therapy improves renal function in patients with chronic hepatitis B: A STROBE-compliant article.
    Medicine, 2018, Volume: 97, Issue:48

    Topics: Adenine; Adult; Antiviral Agents; Creatinine; Drug Therapy, Combination; Female; Glomerular Filtrati

2018
Cisplatin induces autophagy to enhance hepatitis B virus replication via activation of ROS/JNK and inhibition of the Akt/mTOR pathway.
    Free radical biology & medicine, 2019, 02-01, Volume: 131

    Topics: Acetylcysteine; Adenine; Animals; Antineoplastic Agents; Autophagy; Autophagy-Related Protein 5; Chl

2019
Improvement of bone mineral density and markers of proximal renal tubular function in chronic hepatitis B patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide.
    Journal of viral hepatitis, 2019, Volume: 26, Issue:5

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Bone Density; Drug Substitution; Femal

2019
Improvement of bone mineral density and markers of proximal renal tubular function in chronic hepatitis B patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide.
    Journal of viral hepatitis, 2019, Volume: 26, Issue:5

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Bone Density; Drug Substitution; Femal

2019
Improvement of bone mineral density and markers of proximal renal tubular function in chronic hepatitis B patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide.
    Journal of viral hepatitis, 2019, Volume: 26, Issue:5

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Bone Density; Drug Substitution; Femal

2019
Improvement of bone mineral density and markers of proximal renal tubular function in chronic hepatitis B patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide.
    Journal of viral hepatitis, 2019, Volume: 26, Issue:5

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Bone Density; Drug Substitution; Femal

2019
Methylation status of the stimulator of interferon genes promoter in patients with chronic hepatitis B.
    Medicine, 2018, Volume: 97, Issue:52

    Topics: Adenine; Adult; Antiviral Agents; Biomarkers; DNA, Viral; Female; Guanine; Hepatitis B, Chronic; Hum

2018
The clinical and pathological features of adefovir dipivoxil-related renal impairment
.
    Clinical nephrology, 2019, Volume: 91, Issue:3

    Topics: Adenine; Adult; Antiviral Agents; Creatinine; Female; Glycosuria; Hematuria; Hepatitis B, Chronic; H

2019
The different effects of adefovir dipivoxil and telbivudine on the prognosis of hepatitis b virus-related hepatocellular carcinoma patients after curative resection.
    Medicine, 2019, Volume: 98, Issue:6

    Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Female; Hepatitis B e Antigens; He

2019
Toxic myopathy with multiple deletions in mitochondrial DNA associated with long-term use of oral anti-viral drugs for hepatitis B: A case study.
    Neuropathology : official journal of the Japanese Society of Neuropathology, 2019, Volume: 39, Issue:2

    Topics: Adenine; Administration, Oral; Aged; Antiviral Agents; DNA, Mitochondrial; Female; Gene Deletion; He

2019
[Adefovir Dipivoxil-induced Fanconi's Syndrome and Osteomalacia Following Multiple Bone Fractures in a Patient with Chronic Hepatitis B].
    Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 2019, Volume: 139, Issue:4

    Topics: Adenine; Aged; Carcinoma, Hepatocellular; Fanconi Syndrome; Fractures, Bone; Hepatitis B, Chronic; H

2019
Efficacy of long-term tenofovir disoproxil fumarate therapy in chronic hepatitis B patients with partial virologic response in real practice.
    The Korean journal of internal medicine, 2019, Volume: 34, Issue:4

    Topics: Adenine; Adult; Antiviral Agents; Drug Administration Schedule; Female; Hepatitis B virus; Hepatitis

2019
[Marked improvement in renal tubular markers after switching from adefovir to tenofovir alafenamide in a case of Fanconi syndrome diagnosed through high ALP levels].
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2019, Volume: 116, Issue:4

    Topics: Adenine; Alanine; Alkaline Phosphatase; Antiviral Agents; Biomarkers; DNA, Viral; Drug Resistance, V

2019
Brca1 is involved in tolerance to adefovir dipivoxil‑induced DNA damage.
    International journal of molecular medicine, 2019, Volume: 43, Issue:6

    Topics: Adenine; Antiviral Agents; BRCA1 Protein; Cell Line; Chromosome Aberrations; DNA Damage; Gene Deleti

2019
Long-term Nucleotide Analogue Treatment Has Higher Levels of Renal Toxicities than Does Entecavir in Patients with Chronic Hepatitis B.
    Gut and liver, 2020, 03-15, Volume: 14, Issue:2

    Topics: Adenine; Adult; Aged; Antiviral Agents; Chemical and Drug Induced Liver Injury; Female; Glomerular F

2020
Serum hepatitis B virus RNA levels as a predictor of HBeAg seroconversion during treatment with peginterferon alfa-2a.
    Virology journal, 2019, 05-07, Volume: 16, Issue:1

    Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B virus; Hep

2019
Fibrosing Cholestatic Hepatitis-Like Syndrome in an Immunocompetent Patient With an Acute Flare of Chronic Hepatitis B.
    Hepatology (Baltimore, Md.), 2019, Volume: 70, Issue:4

    Topics: Adenine; Biopsy, Needle; Cholestasis; Disease Progression; Follow-Up Studies; Hepatitis B, Chronic;

2019
Long-term prognosis of liver disease in patients with chronic hepatitis B virus infection receiving nucleos(t)ide analogue therapy: an analysis using a Markov chain model.
    European journal of gastroenterology & hepatology, 2019, Volume: 31, Issue:11

    Topics: Adenine; Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Female; Guanine; Hepatitis B Surf

2019
Low-dose adefovir dipivoxil-induced hypophosphatemia osteomalacia in five chronic hepatitis B virus-infected patients. Is low-dose adefovir dipivoxil-induced nephrotoxicity completely reversible?
    Drug design, development and therapy, 2019, Volume: 13

    Topics: Adenine; Aged; Dose-Response Relationship, Drug; Fanconi Syndrome; Female; Hepatitis B, Chronic; Hum

2019
A case of entecavir-induced Fanconi syndrome.
    CEN case reports, 2019, Volume: 8, Issue:4

    Topics: Acidosis; Acute Kidney Injury; Adenine; Aged; Alanine; Antiviral Agents; Fanconi Syndrome; Guanine;

2019
Potential Benefits of Switching Liver Transplant Recipients to Tenofovir Alafenamide Prophylaxis.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2020, Volume: 18, Issue:3

    Topics: Adenine; Alanine; Hepatitis B, Chronic; HIV Infections; Humans; Liver Transplantation; Tenofovir

2020
In Vitro and In Vivo Renoprotective Effects of Telbivudine in Chronic Hepatitis B Patients Receiving Nucleotide Analogue.
    Digestive diseases and sciences, 2019, Volume: 64, Issue:12

    Topics: Activating Transcription Factor 4; Adenine; Antiviral Agents; Apoptosis; Caspase 12; Cell Line; Cell

2019
[Effects of adefovir dipivoxil on liver pathology in patients with chronic hepatitis B].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2012, Volume: 20, Issue:11

    Topics: Adenine; Adolescent; Adult; Female; Hepatitis B, Chronic; Humans; Liver; Male; Middle Aged; Organoph

2012
Telbivudine plus adefovir therapy for chronic hepatitis B patients with virological breakthrough or genotypic resistance to telbivudine.
    European journal of gastroenterology & hepatology, 2013, Volume: 25, Issue:7

    Topics: Adenine; Antiviral Agents; Biomarkers; Chi-Square Distribution; DNA, Viral; Drug Resistance, Viral;

2013
Combination nucleos(t)ide analogue as initial treatment for chronic hepatitis B: have we put this to rest?
    Hepatology (Baltimore, Md.), 2013, Volume: 58, Issue:2

    Topics: Adenine; Antiviral Agents; Female; Hepatitis B, Chronic; Humans; Male; Phosphorous Acids; Viral Load

2013
Resolution of adefovir-related nephrotoxicity by adefovir dose-reduction in patients with chronic hepatitis B.
    Alimentary pharmacology & therapeutics, 2013, Volume: 37, Issue:7

    Topics: Adenine; Adult; Antiviral Agents; Asian People; Creatinine; Dose-Response Relationship, Drug; Female

2013
Tenofovir-based combination therapy for HIV/HBV co-infection: factors associated with a partial HBV virological response in patients with undetectable HIV viraemia.
    AIDS (London, England), 2013, Jun-01, Volume: 27, Issue:9

    Topics: Adenine; Adult; Anti-HIV Agents; Case-Control Studies; Coinfection; Deoxycytidine; DNA, Viral; Drug

2013
A different look at the management of chronic hepatitis B in a resource-constrained country.
    Journal of viral hepatitis, 2013, Volume: 20 Suppl 1

    Topics: Adenine; Antiviral Agents; China; Drug Therapy, Combination; Health Resources; Hepatitis B virus; He

2013
Individualized treatment of HBeAg-negative chronic hepatitis B using pegylated interferon-α2a as first-line and week-12 HBV DNA/HBsAg stopping rule: a cost-effectiveness analysis.
    Antiviral therapy, 2013, Volume: 18, Issue:4

    Topics: Adenine; Adult; Antiviral Agents; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Drug Administrat

2013
[Cost-effectiveness of nucleoside/nucleotide analogues in chronic hepatitis B].
    Revista de saude publica, 2012, Volume: 46, Issue:6

    Topics: Adenine; Antiviral Agents; Cost-Benefit Analysis; Drug Resistance, Viral; Drug Therapy, Combination;

2012
Characterization of the dynamics of hepatitis B virus resistance to adefovir by ultra-deep pyrosequencing.
    Hepatology (Baltimore, Md.), 2013, Volume: 58, Issue:3

    Topics: Adenine; Adolescent; Adult; Amino Acid Substitution; Antiviral Agents; Drug Resistance, Viral; Drug

2013
Increased eGFR with telbivudine in combination therapy of chronic hepatitis B infection.
    Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology, 2014, Volume: 33, Issue:1

    Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Glomerular Filtration Rate; Guanine; Hepatitis

2014
Renal dysfunction and hypophosphatemia during long-term lamivudine plus adefovir dipivoxil therapy in patients with chronic hepatitis B.
    Journal of gastroenterology, 2014, Volume: 49, Issue:3

    Topics: Adenine; Adult; Aged; Antiviral Agents; Creatinine; Drug Therapy, Combination; Female; Glomerular Fi

2014
[Three-year efficacy and side effect of adefovir dipivoxil for the treatment of the old patients with chronic hepatitis B virus infection].
    Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology, 2012, Volume: 26, Issue:5

    Topics: Adenine; Aged; Aged, 80 and over; Antiviral Agents; Female; Hepatitis B, Chronic; Humans; Male; Orga

2012
Chronic hepatitis B treatment initiation and modification patterns in five European countries: a 2-year longitudinal, non-interventional study.
    Antiviral therapy, 2014, Volume: 19, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine Transaminase; Antiviral Agents; Disease

2014
Reversible increase in FGF23 in a hypophosphatemic renal and bone disease linked to antiviral therapy by adefovir.
    Joint bone spine, 2013, Volume: 80, Issue:6

    Topics: Adenine; Aged; Antiviral Agents; Bone Diseases; Female; Fibroblast Growth Factor-23; Fibroblast Grow

2013
Snapshot on drug-resistance rate and profiles in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice.
    Journal of medical virology, 2013, Volume: 85, Issue:6

    Topics: Adenine; Adult; Antiviral Agents; Cohort Studies; DNA, Viral; Drug Resistance, Viral; Female; Guanin

2013
Geographic tongue and tenofovir.
    BMJ case reports, 2013, Apr-17, Volume: 2013

    Topics: Adenine; Glossitis, Benign Migratory; Hepatitis B, Chronic; Humans; Male; Middle Aged; Organophospho

2013
[Genotypes and evolution characteristics of three patients with poor response to initial treatment of Lamivudine and Adefovir dipivoxil for hepatitis].
    Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology, 2012, Volume: 26, Issue:6

    Topics: Adenine; Adult; Antiviral Agents; Drug Resistance, Viral; Evolution, Molecular; Female; Genetic Drif

2012
Oral nucleoside/nucleotide analogs without hepatitis B immune globulin after liver transplantation for hepatitis B.
    The American journal of gastroenterology, 2013, Volume: 108, Issue:6

    Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Follow-Up Stu

2013
Influence of HIV infection on response to tenofovir in patients with chronic hepatitis B.
    AIDS (London, England), 2013, Sep-10, Volume: 27, Issue:14

    Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Female; Hepatitis B Surface Antigens; Hepatitis B viru

2013
Reversal of cirrhosis: an achievable goal of hepatitis B antiviral therapy.
    Journal of hepatology, 2013, Volume: 59, Issue:4

    Topics: Adenine; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Organophosphonates; Reverse

2013
Partial virological response to adefovir add-on lamivudine rescue therapy in patients with lamivudine-resistant chronic hepatitis B.
    Digestion, 2013, Volume: 87, Issue:3

    Topics: Adenine; Adult; Area Under Curve; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Fem

2013
Comparison of re-treatment outcomes of lamivudine plus adefovir or entecavir in chronic hepatitis B patients with viral relapse after cessation of adefovir.
    European review for medical and pharmacological sciences, 2013, Volume: 17, Issue:9

    Topics: Adenine; Adult; Antiviral Agents; Case-Control Studies; DNA, Viral; Drug Resistance, Viral; Drug The

2013
Entecavir plus adefovir rescue therapy for chronic hepatitis B patients after multiple treatment failures in real-life practice.
    Virology journal, 2013, May-25, Volume: 10

    Topics: Adenine; Adult; Antiviral Agents; Creatine Kinase; Creatinine; DNA, Viral; Female; Guanine; Hepatiti

2013
Prophylaxis in HBV-infected liver transplant patients: end of the HBIG era?
    The American journal of gastroenterology, 2013, Volume: 108, Issue:6

    Topics: Adenine; Antiviral Agents; Female; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Liver Transpla

2013
Regression of cirrhosis with long-term tenofovir treatment.
    Gastroenterology, 2013, Volume: 145, Issue:2

    Topics: Adenine; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Organophosphonates; Reverse

2013
Patterns of hepatitis B surface antigen decline and HBV DNA suppression in Asian treatment-experienced chronic hepatitis B patients after three years of tenofovir treatment.
    Journal of hepatology, 2013, Volume: 59, Issue:4

    Topics: Adenine; Adult; Aged; Antiviral Agents; Asian People; DNA, Viral; Female; Follow-Up Studies; Genotyp

2013
Tenofovir-associated Fanconi syndrome in patients with chronic hepatitis B monoinfection.
    Antiviral therapy, 2013, Volume: 18, Issue:7

    Topics: Adenine; Adult; Antiviral Agents; Biopsy; Creatinine; Fanconi Syndrome; Hepatitis B, Chronic; Humans

2013
Chemokine receptor 5 (CCR5) polymorphism in chronic hepatitis B patients treated with three different nucleos(t)ide analogues.
    The Indian journal of medical research, 2013, Volume: 137, Issue:6

    Topics: Adenine; Alanine Transaminase; Genotype; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Homozyg

2013
Nucleoside plus nucleotide analogs and cessation of hepatitis B immunoglobulin after liver transplantation in chronic hepatitis B is safe and effective.
    Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2013, Volume: 58, Issue:1

    Topics: Adenine; Adult; Aged; Antiviral Agents; Chemoprevention; Cohort Studies; Deoxycytidine; Drug Therapy

2013
Study of hepatitis B virus quasispecies by ultra-deep pyrosequencing: Resolving the nitty-gritty.
    Hepatology (Baltimore, Md.), 2014, Volume: 59, Issue:3

    Topics: Adenine; Amino Acid Substitution; Antiviral Agents; Drug Resistance, Viral; Female; Hepatitis B viru

2014
Evolution of glomerular filtration rate in HIV-infected, HIV-HBV-coinfected and HBV-infected patients receiving tenofovir disoproxil fumarate.
    Journal of viral hepatitis, 2013, Volume: 20, Issue:9

    Topics: Adenine; Adult; Antiviral Agents; Coinfection; Female; Glomerular Filtration Rate; Hepatitis B, Chro

2013
Reply: To PMID 23505208.
    Hepatology (Baltimore, Md.), 2014, Volume: 59, Issue:3

    Topics: Adenine; Amino Acid Substitution; Antiviral Agents; Drug Resistance, Viral; Female; Hepatitis B viru

2014
Long-term efficacy and emergence of multidrug resistance in patients with lamivudine-refractory chronic hepatitis B treated by combination therapy with adefovir plus lamivudine.
    Journal of gastroenterology, 2014, Volume: 49, Issue:6

    Topics: Adenine; Adult; Aged; Asian People; DNA, Viral; Drug Resistance, Multiple; Drug Resistance, Viral; D

2014
[The observation of blood serum creatinine and phosphorus during long-term adefovir dipivoxil treatment in chronic hepatitis].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2013, Volume: 21, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Creatinine; Female; Hepatitis B, Chronic; Humans; Male; Middle Age

2013
[Detection of resistance mutations in chronic hepatitis B patients receiving antiviral therapy for over one year].
    Mikrobiyoloji bulteni, 2013, Volume: 47, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Guan

2013
[HBV vaccine escape mutations in a chronic hepatitis B patient treated with nucleos(t)ide analogues].
    Mikrobiyoloji bulteni, 2013, Volume: 47, Issue:3

    Topics: Adenine; Biopsy; Drug Resistance, Multiple, Viral; Female; Genes, pol; Guanine; Hepatitis B Vaccines

2013
Long-term efficacy of entecavir plus adefovir combination therapy versus entecavir monotherapy in adefovir refractory chronic hepatitis B patients with prior lamivudine resistance.
    Intervirology, 2014, Volume: 57, Issue:1

    Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Fem

2014
Predictors of survival in hepatitis B virus related decompensated cirrhosis on tenofovir therapy: an Indian perspective.
    Antiviral research, 2013, Volume: 100, Issue:2

    Topics: Adenine; Adult; Aged; Bilirubin; Creatinine; DNA, Viral; Female; Hepatitis B, Chronic; Humans; India

2013
Combination lamivudine and adefovir versus entecavir for the treatment of naïve chronic hepatitis B patients: a pilot study.
    Medical science monitor : international medical journal of experimental and clinical research, 2013, Sep-09, Volume: 19

    Topics: Adenine; Adult; Alanine Transaminase; Analysis of Variance; Aspartate Aminotransferases; Bilirubin;

2013
Real-world application of the roadmap model in chronic hepatitis B patients with telbivudine therapy.
    Clinical therapeutics, 2013, Volume: 35, Issue:9

    Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Administration Schedule; Drug Resistance, Viral;

2013
Comparison of tenofovir and entecavir in patients with chronic HBV infection.
    European review for medical and pharmacological sciences, 2013, Volume: 17, Issue:18

    Topics: Adenine; Adult; Aged; DNA, Viral; Female; Guanine; Hepatitis B, Chronic; Humans; Male; Middle Aged;

2013
[Outcome of chronic hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive drugs and anti-TNF agents].
    Gastroenterologia y hepatologia, 2014, Volume: 37, Issue:1

    Topics: Adalimumab; Adenine; Adult; Antibodies, Monoclonal, Humanized; Antiviral Agents; Azathioprine; Crohn

2014
Efficacy of adefovir-based combination therapy for patients with Lamivudine- and entecavir-resistant chronic hepatitis B virus infection.
    Antimicrobial agents and chemotherapy, 2013, Volume: 57, Issue:12

    Topics: Adenine; Adult; Aged; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine;

2013
Lamivudine plus adefovir combination therapy for lamivudine resistance in hepatitis-B-related hepatocellular carcinoma patients.
    Clinical and molecular hepatology, 2013, Volume: 19, Issue:3

    Topics: Adenine; Adult; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Drug Administration Schedul

2013
Prevelance of common YMDD motif mutations in long term treated chronic HBV infections in a Turkish population.
    Asian Pacific journal of cancer prevention : APJCP, 2013, Volume: 14, Issue:9

    Topics: Adenine; Adult; Aged; Amino Acid Motifs; Anti-HIV Agents; Antiviral Agents; Aspartic Acid; Case-Cont

2013
Two rescue therapies in lamivudine-resistant patients with chronic hepatitis B in the central China: adefovir monotherapy and adefovir plus lamivudine.
    Virus genes, 2014, Volume: 48, Issue:1

    Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; China; Drug Resistance, Viral; Female; Hepat

2014
One year of hepatitis B immunoglobulin plus tenofovir therapy is safe and effective in preventing recurrent hepatitis B post-liver transplantation.
    Canadian journal of gastroenterology & hepatology, 2014, Volume: 28, Issue:1

    Topics: Adenine; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Hepati

2014
Chronic hepatitis B monitoring and treatment patterns in five European countries with different access and reimbursement policies.
    Antiviral therapy, 2014, Volume: 19, Issue:3

    Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Europe; Female; Guanine; Hepatitis B virus; Hepatitis

2014
Incorporated antivirals for chronic hepatitis B in Brazil: a cost-effectiveness analysis.
    Revista de saude publica, 2013, Volume: 47, Issue:4

    Topics: Adenine; Adult; Analysis of Variance; Antiviral Agents; Brazil; Cost-Benefit Analysis; Disease Progr

2013
Telbivudine protects renal function in patients with chronic hepatitis B infection in conjunction with adefovir-based combination therapy.
    Journal of viral hepatitis, 2014, Volume: 21, Issue:12

    Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Glomerular Fi

2014
Efficacy of 2years of entecavir plus adefovir therapy in patients with chronic hepatitis B who had failed on prior nucleos(t)ide analog treatment.
    Antiviral research, 2014, Volume: 103

    Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; Cohort Studies; DNA, Viral; Drug Therapy, Co

2014
Tenofovir is superior to entecavir for achieving complete viral suppression in HBeAg-positive chronic hepatitis B patients with high HBV DNA.
    Alimentary pharmacology & therapeutics, 2014, Volume: 39, Issue:6

    Topics: Adenine; Adult; Antiviral Agents; California; Cohort Studies; DNA, Viral; Female; Guanine; Hepatitis

2014
Rapid detection of hepatitis B virus variants associated with lamivudine and adefovir resistance by multiplex ligation-dependent probe amplification combined with real-time PCR.
    Journal of clinical microbiology, 2014, Volume: 52, Issue:2

    Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans;

2014
Factors associated with delayed hepatitis B viral suppression on tenofovir among patients coinfected with HBV-HIV in the CNICS cohort.
    Journal of acquired immune deficiency syndromes (1999), 2014, May-01, Volume: 66, Issue:1

    Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; HIV I

2014
Efficacy and safety of tenofovir-based rescue therapy for chronic hepatitis B patients with previous nucleo(s/t)ide treatment failure.
    Gut and liver, 2014, Volume: 8, Issue:1

    Topics: Adenine; Adult; Biomarkers; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; H

2014
Efficacy of tenofovir in adefovir-experienced patients compared with treatment-naive patients with chronic hepatitis B.
    Antiviral therapy, 2014, Volume: 19, Issue:6

    Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B, Chr

2014
Interactive medical case: wasting away.
    The New England journal of medicine, 2014, Feb-13, Volume: 370, Issue:7

    Topics: Adenine; Adult; Bone Density; Electrolytes; Fanconi Syndrome; Female; Hepatitis B, Chronic; Humans;

2014
Dynamic comparison between Daan real-time PCR and Cobas TaqMan for quantification of HBV DNA levels in patients with CHB.
    BMC infectious diseases, 2014, Feb-14, Volume: 14

    Topics: Adenine; Adolescent; Adult; Antiviral Agents; DNA, Viral; Female; Guanine; Hepatitis B virus; Hepati

2014
An initial assessment of correlations between host- and virus-related factors affecting analogues antiviral therapy in HBV chronically infected patients.
    Medical science monitor : international medical journal of experimental and clinical research, 2014, Feb-26, Volume: 20

    Topics: Adenine; Adult; Age Factors; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Fe

2014
[The clinical significance of hepatitis B virus large surface protein in the diagnosis and treatment of patients with hepatitis B].
    Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology, 2013, Volume: 27, Issue:4

    Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Female; Hepatitis B Surface Antigens; Hepatitis

2013
Establishment of real time allele specific locked nucleic acid quantitative PCR for detection of HBV YIDD (ATT) mutation and evaluation of its application.
    PloS one, 2014, Volume: 9, Issue:2

    Topics: Adenine; Adult; Alleles; Antiviral Agents; DNA Primers; DNA, Viral; Drug Resistance, Viral; Early Di

2014
Lamivudine and Adefovir Motif Variants Detected in chronic Hepatıtıs B patients.
    La Clinica terapeutica, 2014, Volume: 165, Issue:1

    Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chron

2014
Use of hepatitis B surface and "e" antigen quantification during extensive treatment with tenofovir in patients co-infected with HIV-HBV.
    Liver international : official journal of the International Association for the Study of the Liver, 2015, Volume: 35, Issue:3

    Topics: Adenine; Adult; Anti-HIV Agents; Coinfection; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis

2015
[Detection and analysis of HBV in polymorphonuclear neutrophils of patients with hepatitis B].
    Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology, 2014, Volume: 30, Issue:3

    Topics: Adenine; Adult; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic;

2014
Successful withdrawal of antiviral treatment in kidney transplant recipients with chronic hepatitis B viral infection.
    Transplant infectious disease : an official journal of the Transplantation Society, 2014, Volume: 16, Issue:2

    Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Female; Follow-Up Studies; Guani

2014
[Diagnosis and treatment of chronic hepatitis B and D. Hungarian national consensus guideline].
    Orvosi hetilap, 2014, Volume: 155 Suppl

    Topics: Adenine; Antiviral Agents; Consensus; Drug Administration Schedule; Drug Therapy, Combination; Evide

2014
[A case of the patient with HBeAg-negative chronic hepatitis B recurrence after retreatment with adefovir occurred HBsAg seroconversion].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2013, Volume: 21, Issue:12

    Topics: Adenine; Adult; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans;

2013
Anti-viral therapy for prevention of perinatal HBV transmission: extending therapy beyond birth does not protect against post-partum flare.
    Alimentary pharmacology & therapeutics, 2014, Volume: 39, Issue:10

    Topics: Adenine; Adult; Antiviral Agents; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B vir

2014
Commentary: tenofovir is superior to entecavir in HBeAg-positive chronic hepatitis B patients.
    Alimentary pharmacology & therapeutics, 2014, Volume: 39, Issue:9

    Topics: Adenine; Antiviral Agents; Female; Guanine; Hepatitis B, Chronic; Humans; Male; Organophosphonates;

2014
Commentary: tenofovir is superior to entecavir in HBeAg-positive chronic hepatitis B patients--authors' reply.
    Alimentary pharmacology & therapeutics, 2014, Volume: 39, Issue:9

    Topics: Adenine; Antiviral Agents; Female; Guanine; Hepatitis B, Chronic; Humans; Male; Organophosphonates;

2014
Screening and identification of a novel adefovir dipivoxil resistance associated mutation, rtN236V, of HBV from a large cohort of HBV-infected patients.
    Antiviral therapy, 2014, Volume: 19, Issue:6

    Topics: Adenine; Adult; Aged; Amino Acid Substitution; Antiviral Agents; Codon; DNA, Viral; Drug Resistance,

2014
A cost-utility analysis of drug treatments in patients with HBeAg-positive chronic hepatitis B in Thailand.
    BMC health services research, 2014, Apr-14, Volume: 14

    Topics: Adenine; Adult; Antiviral Agents; Cost-Benefit Analysis; Drugs, Essential; Female; Health Services R

2014
Relevance of hepatitis B surface antigen levels in patients with chronic hepatitis B during 5 year of tenofovir treatment.
    Journal of viral hepatitis, 2014, Volume: 21, Issue:6

    Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Monitoring; Female; Hepatitis B

2014
Hepatitis B virus rtI233V mutation and resistance to adefovir.
    The New England journal of medicine, 2014, Apr-24, Volume: 370, Issue:17

    Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic;

2014
Effects of entecavir on peripheral blood lymphocyte profiles in chronic hepatitis B patients with suboptimal responses to adefovir.
    Clinical and experimental pharmacology & physiology, 2014, Volume: 41, Issue:7

    Topics: Adenine; Antiviral Agents; B-Lymphocytes; Case-Control Studies; CD4-Positive T-Lymphocytes; DNA, Vir

2014
Analysis of reverse transcriptase gene mutations in the hepatitis B virus at a university hospital in Korea.
    Annals of laboratory medicine, 2014, Volume: 34, Issue:3

    Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Multiple, Viral; Drug Resistance, Viral; Hep

2014
Letter: Treatment of HBeAg+ chronic hepatitis B--is tenofovir truly superior to entecavir?
    Alimentary pharmacology & therapeutics, 2014, Volume: 39, Issue:11

    Topics: Adenine; Antiviral Agents; Female; Guanine; Hepatitis B, Chronic; Humans; Male; Organophosphonates;

2014
Letter: Treatment of HBeAg+ chronic hepatitis B--is tenofovir truly superior to entecavir? Authors' reply.
    Alimentary pharmacology & therapeutics, 2014, Volume: 39, Issue:11

    Topics: Adenine; Antiviral Agents; Female; Guanine; Hepatitis B, Chronic; Humans; Male; Organophosphonates;

2014
HBsAg loss in patients treated with peginterferon alfa-2a and adefovir is associated with SLC16A9 gene variation and lower plasma carnitine levels.
    Journal of hepatology, 2014, Volume: 61, Issue:4

    Topics: Adenine; Adult; Antiviral Agents; Carnitine; CD8-Positive T-Lymphocytes; Drug Therapy, Combination;

2014
Viral evolutionary changes during tenofovir treatment in a chronic hepatitis B patient with sequential nucleos(t)ide therapy.
    Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2014, Volume: 60, Issue:3

    Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Drug Substitution; Hepatitis B virus; Hepatitis B

2014
Evaluation of HBV DNA decay kinetics in patients containing both rtM204V/I mutant and wild-type HBV subpopulations during tenofovir DF (TDF) monotherapy or combination therapy with emtricitabine (FTC)/TDF.
    Journal of medical virology, 2014, Volume: 86, Issue:9

    Topics: Adenine; Antiviral Agents; Deoxycytidine; DNA, Viral; Drug Therapy, Combination; Emtricitabine; Gene

2014
Coexistence of HBsAg and HBsAb in a difficult-to-treat chronic hepatitis B: loss of HBsAg with entecavir plus tenofovir combination.
    BMC gastroenterology, 2014, May-17, Volume: 14

    Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Guanine; Hepatitis B Antibodies; Hepatitis B e

2014
Decline in intrahepatic cccDNA and increase in immune cell reactivity after 12 weeks of antiviral treatment were associated with HBeAg loss.
    Journal of viral hepatitis, 2014, Volume: 21, Issue:12

    Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Enzyme-Linked Immunospot Assay; Female; Hepatitis B An

2014
Kinetics of serum HBsAg in Chinese patients with chronic HBV infection with long-term adefovir dipivoxil treatment.
    Chinese medical journal, 2014, Volume: 127, Issue:11

    Topics: Adenine; Adult; Antiviral Agents; Female; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans

2014
New nucleos(t)ide analogue monoprophylaxis after cessation of hepatitis B immunoglobulin is effective against hepatitis B recurrence.
    Transplant international : official journal of the European Society for Organ Transplantation, 2014, Volume: 27, Issue:10

    Topics: Adenine; Adult; Cohort Studies; Female; Follow-Up Studies; Graft Rejection; Graft Survival; Guanine;

2014
Higher viral load, higher hepatitis B surface antigen clearance?
    Hepatology (Baltimore, Md.), 2014, Volume: 59, Issue:6

    Topics: Adenine; Antiviral Agents; Female; Hepatitis B, Chronic; Humans; Male; Phosphorous Acids; Viral Load

2014
Telbivudine plus tenofovir in combination therapy in patients with chronic hepatitis B infection--an Indian experience.
    The Journal of the Association of Physicians of India, 2013, Volume: 61, Issue:11

    Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Femal

2013
Investigation into drug-resistant mutations of HBV from 845 nucleoside/nucleotide analogue-naive Chinese patients with chronic HBV infection.
    Antiviral therapy, 2015, Volume: 20, Issue:2

    Topics: Adenine; Adult; Antiviral Agents; China; Clone Cells; Drug Resistance, Viral; Female; Gene Expressio

2015
Adefovir and lamivudine combination therapy in patients with entecavir-resistant chronic hepatitis B: antiviral responses and evolution of mutations.
    Intervirology, 2014, Volume: 57, Issue:5

    Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combinatio

2014
Effect of prophylactic versus preemptive lamivudine treatment and tenofovir on HBsAg+ kidney transplant recipients.
    Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation, 2015, Volume: 13, Issue:1

    Topics: Adenine; Adult; Antiviral Agents; Biomarkers; Drug Administration Schedule; Female; Graft Survival;

2015
Impact of the rtI187V polymerase substitution of hepatitis B virus on viral replication and antiviral drug susceptibility.
    The Journal of general virology, 2014, Volume: 95, Issue:Pt 11

    Topics: Adenine; Adolescent; Adult; Aged; Amino Acid Substitution; Antiviral Agents; Child; China; Cohort St

2014
Antiviral therapy of chronic hepatitis B.
    Intervirology, 2014, Volume: 57, Issue:3-4

    Topics: Adenine; Antiviral Agents; Arabinofuranosyluracil; Carcinoma, Hepatocellular; Gene Products, pol; Gu

2014
Reduction of infectivity in chronic hepatitis B virus carriers among healthcare providers and pregnant women by antiviral therapy.
    Intervirology, 2014, Volume: 57, Issue:3-4

    Topics: Adenine; Antiviral Agents; DNA, Viral; Female; Guanine; Health Personnel; Hepatitis B e Antigens; He

2014
Mechanisms of hepatitis B virus resistance development.
    Intervirology, 2014, Volume: 57, Issue:3-4

    Topics: Adenine; Amino Acid Substitution; Antiviral Agents; Deoxycytidine; Drug Resistance, Multiple, Viral;

2014
Effect of antiretroviral HIV therapy on hepatitis B virus replication and pathogenicity.
    Intervirology, 2014, Volume: 57, Issue:3-4

    Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Coinfection; Deoxycytidine; Emtrici

2014
Hepatitis B virus drug resistance tools: one sequence, two predictions.
    Intervirology, 2014, Volume: 57, Issue:3-4

    Topics: Adenine; Antiviral Agents; Base Sequence; Drug Resistance, Multiple, Viral; Genotype; Guanine; Hepat

2014
Virologic breakthrough in a patient with chronic hepatitis B by combination treatment with tenofovir disoproxil fumarate and entecavir.
    Drug design, development and therapy, 2014, Volume: 8

    Topics: Adenine; Amino Acid Substitution; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy

2014
More on hepatitis B virus rtI233V mutation and resistance to adefovir.
    The New England journal of medicine, 2014, 07-31, Volume: 371, Issue:5

    Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic;

2014
More on hepatitis B virus rtI233V mutation and resistance to adefovir.
    The New England journal of medicine, 2014, 07-31, Volume: 371, Issue:5

    Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic;

2014
The Use of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase.
    Gastroenterology, 2014, Volume: 147, Issue:3

    Topics: Adenine; Alanine Transaminase; Antiviral Agents; DNA, Viral; Female; Hepatitis B e Antigens; Hepatit

2014
[A case of chronic hepatitis B managed with continued adefovir despite treatment-related Fanconi syndrome and osteomalacia].
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2014, Volume: 111, Issue:8

    Topics: Adenine; Fanconi Syndrome; Female; Hepatitis B, Chronic; Humans; Middle Aged; Organophosphonates; Os

2014
Treatment cessation in noncirrhotic, e-antigen negative chronic hepatitis B is safe and effective following prolonged anti-viral suppression with nucleosides/nucleotides.
    Alimentary pharmacology & therapeutics, 2014, Volume: 40, Issue:7

    Topics: Adenine; Adult; Antiviral Agents; Female; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Hum

2014
The rtA181S mutation of hepatitis B virus primarily confers resistance to adefovir dipivoxil.
    Journal of viral hepatitis, 2015, Volume: 22, Issue:3

    Topics: Adenine; Adult; Aged; Antiviral Agents; DNA Mutational Analysis; DNA, Viral; Drug Resistance, Viral;

2015
Efficacy and safety of tenofovir in a kidney transplant patient with chronic hepatitis B and nucleos(t)ide multidrug resistance: a case report.
    Journal of medical case reports, 2014, Aug-21, Volume: 8

    Topics: Adenine; Antiviral Agents; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Follow-Up St

2014
Efficacy of entecavir-tenofovir combination therapy for chronic hepatitis B patients with multidrug-resistant strains.
    Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:11

    Topics: Adenine; Adult; Aged; Antiviral Agents; Base Sequence; Cohort Studies; DNA, Viral; Drug Resistance,

2014
Assessment of bone mineral density in tenofovir-treated patients with chronic hepatitis B: can the fracture risk assessment tool identify those at greatest risk?
    The Journal of infectious diseases, 2015, Feb-01, Volume: 211, Issue:3

    Topics: Adenine; Adult; Body Mass Index; Bone Density; Cross-Sectional Studies; Female; Hepatitis B virus; H

2015
Safety and efficacy of entecavir in adefovir-experienced patients.
    Journal of gastroenterology and hepatology, 2015, Volume: 30, Issue:1

    Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; Biomarkers; Drug Substitution; Female; Follo

2015
[Efficacy of 48-week tenofovir disoproxil fumarate therapy in patients who were unresponsive to nucleoside-analogue treatments].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2014, Volume: 22, Issue:4

    Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B, Chronic;

2014
Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir.
    Journal of hepatology, 2015, Volume: 62, Issue:2

    Topics: Adenine; Adult; Antiviral Agents; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Greece; Guan

2015
Chronic hepatitis B virus coinfection is associated with renal impairment among Zambian HIV-infected adults.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2014, Dec-15, Volume: 59, Issue:12

    Topics: Adenine; Adolescent; Adult; Africa; Anti-HIV Agents; Coinfection; Female; Glomerular Filtration Rate

2014
Long-term treatment with tenofovir in Asian-American chronic hepatitis B patients is associated with abnormal renal phosphate handling.
    Digestive diseases and sciences, 2015, Volume: 60, Issue:2

    Topics: Absorptiometry, Photon; Adenine; Adult; Aged; Antiviral Agents; Asian People; Bone Density; Cross-Se

2015
Efficacy of adefovir dipivoxil combined with a corticosteroid in 38 cases of nephrotic syndrome induced by hepatitis B virus-associated glomerulonephritis.
    Renal failure, 2014, Volume: 36, Issue:9

    Topics: Adenine; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Glomerulonephritis; Glucocortic

2014
The feasibility of discontinuing lamivudine in lamivudine-resistant chronic hepatitis B patients on lamivudine and adefovir combination therapy.
    Intervirology, 2014, Volume: 57, Issue:6

    Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Fea

2014
Tenofovir-associated Fanconi syndrome in a patient with chronic hepatitis B.
    Journal of gastrointestinal and liver diseases : JGLD, 2014, Volume: 23, Issue:3

    Topics: Adenine; Aged, 80 and over; Antiviral Agents; Fanconi Syndrome; Fatal Outcome; Hepatitis B, Chronic;

2014
Long-term outcomes and dynamics of mutants associated with lamivudine-adefovir rescue therapy in patients with lamivudine-resistant chronic hepatitis B.
    Gut and liver, 2015, Volume: 9, Issue:1

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Antiviral Agents; DNA-Directed DNA Polymerase; Drug Resista

2015
Liver biopsy interpretation & the regression of hepatitis B virus related cirrhosis.
    The Indian journal of medical research, 2014, Volume: 140, Issue:2

    Topics: Adenine; Alanine Transaminase; Antiviral Agents; Biomarkers; Biopsy; Hepatitis B, Chronic; Humans; I

2014
Different mechanism of selection of adefovir-resistant mutant viruses during adefovir monotherapy in patients with lamivudine-resistant chronic hepatitis B.
    Antiviral research, 2014, Volume: 112

    Topics: Adenine; Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Female; Hepatitis B; Hepatitis B, Ch

2014
The incidence of hepatocellular carcinoma is reduced in patients with chronic hepatitis B on long-term nucleos(t)ide analogue therapy.
    Alimentary pharmacology & therapeutics, 2014, Volume: 40, Issue:11-12

    Topics: Adenine; Adult; Antiviral Agents; Canada; Carcinoma, Hepatocellular; Female; Guanine; Hepatitis B e

2014
Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide-naïve chronic hepatitis B patients in Korea: data from the clinical practice setting in a single-center cohort.
    Clinical and molecular hepatology, 2014, Volume: 20, Issue:3

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Alanine Transaminase; Antiviral Agents; Cohort Studies; DNA

2014
Long-term outcomes of two rescue therapies in lamivudine-refractory patients with chronic hepatitis B: combined lamivudine and adefovir, and 1-mg entecavir.
    Clinical and molecular hepatology, 2014, Volume: 20, Issue:3

    Topics: Adenine; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Dr

2014
Hepatitis B surface antigen levels at 6 months after treatment can predict the efficacy of lamivudine-adefovir combination therapy in patients with lamivudine-resistant chronic hepatitis B.
    Clinical and molecular hepatology, 2014, Volume: 20, Issue:3

    Topics: Adenine; Adult; Antiviral Agents; Area Under Curve; DNA, Viral; Drug Resistance, Viral; Female; Hepa

2014
Tenofovir monotherapy versus tenofovir plus lamivudine or telbivudine combination therapy in treatment of lamivudine-resistant chronic hepatitis B.
    Antimicrobial agents and chemotherapy, 2015, Volume: 59, Issue:2

    Topics: Adenine; Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Female; Hepatitis B, Chronic; Humans

2015
Effect of Peg-interferon α-2a combined with Adefovir in HBV postpartum women with normal levels of ALT and high levels of HBV DNA.
    Liver international : official journal of the International Association for the Study of the Liver, 2015, Volume: 35, Issue:6

    Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Hepatitis B e Antig

2015
Discovering novel direct acting antiviral agents for HBV using in silico screening.
    Biochemical and biophysical research communications, 2015, Jan-02, Volume: 456, Issue:1

    Topics: Adenine; Albumins; Animals; Antiviral Agents; Binding Sites; Cells, Cultured; Chimera; Databases, Pr

2015
Tenofovir-induced Fanconi syndrome in chronic hepatitis B monoinfected patients that reverted after tenofovir withdrawal.
    Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2014, Volume: 61, Issue:4

    Topics: Adenine; Antiviral Agents; Fanconi Syndrome; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Human

2014
Efficacy of adefovir dipivoxil therapy in patients with chronic hepatitis B viral infection.
    Mymensingh medical journal : MMJ, 2014, Volume: 23, Issue:4

    Topics: Adenine; Adult; Antiviral Agents; Bangladesh; Drug Monitoring; Hepatitis B e Antigens; Hepatitis B v

2014
Nucleotide analogue-resistant mutations in hepatitis B viral genomes found in hepatitis B patients.
    The Journal of general virology, 2015, Volume: 96, Issue:Pt 3

    Topics: Adenine; Amino Acid Substitution; Antiviral Agents; DNA, Viral; Genome, Viral; Genotype; Hepatitis B

2015
Resistant mutants induced by adefovir dipivoxil in hepatitis B virus isolates.
    World journal of gastroenterology, 2014, Dec-07, Volume: 20, Issue:45

    Topics: Adenine; Adult; Antiviral Agents; Chi-Square Distribution; Cross-Sectional Studies; Diagnostic Imagi

2014
Do we need more nucleos(t)ide analogs for the treatment of chronic hepatitis B?
    Journal of hepatology, 2015, Volume: 62, Issue:3

    Topics: Adenine; Antiviral Agents; Female; Guanine; Hepatitis B, Chronic; Humans; Male; Organophosphonates

2015
[Tenofovir rescue therapy for chronic hepatitis B patients after suboptimal response to treatment with lamivudine plus adefovir dipivoxil].
    Zhonghua nei ke za zhi, 2014, Volume: 53, Issue:9

    Topics: Adenine; Adult; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Guanine; Hepati

2014
Bone and kidney toxicity induced by nucleotide analogues in patients affected by HBV-related chronic hepatitis: a longitudinal study.
    The Journal of antimicrobial chemotherapy, 2015, Volume: 70, Issue:4

    Topics: Adenine; Adult; Aged; Antiviral Agents; Bone Diseases; Drug-Related Side Effects and Adverse Reactio

2015
[Promotion of HBeAg seroconversion/loss in patients with chronic hepatitis B following the switch from nucleoside drugs to telbivudine and adefovir].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2014, Volume: 22, Issue:10

    Topics: Adenine; Drug Combinations; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Nucleic Acid Synth

2014
[Hypophosphatemic osteomalacia and renal Fanconi syndrome induced by adefovir in a patient with chronic hepatitis B].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2014, Volume: 22, Issue:10

    Topics: Adenine; Fanconi Syndrome; Hepatitis B, Chronic; Humans; Hypophosphatemia; Organophosphonates; Osteo

2014
Is tenofovir disoproxil fumarate an all-powerful weapon in the treatment of chronic hepatitis B?
    The Korean journal of internal medicine, 2015, Volume: 30, Issue:1

    Topics: Adenine; Antiviral Agents; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Phosphorou

2015
Long-term efficacy of tenofovir disoproxil fumarate therapy after multiple nucleos(t)ide analogue failure in chronic hepatitis B patients.
    The Korean journal of internal medicine, 2015, Volume: 30, Issue:1

    Topics: Adenine; Adult; Aged; Alanine Transaminase; Antiviral Agents; Biomarkers; Creatinine; DNA, Viral; Dr

2015
Response-guided treatment of cirrhotic chronic hepatitis B patients: multicenter prospective study.
    World journal of gastroenterology, 2015, Jan-14, Volume: 21, Issue:2

    Topics: Adenine; Adult; Antiviral Agents; Biomarkers; China; DNA, Viral; Drug Resistance, Viral; Drug Therap

2015
HBV carrying drug-resistance mutations in chronically infected treatment-naive patients.
    Antiviral therapy, 2015, Volume: 20, Issue:4

    Topics: Adenine; Antibodies, Viral; Antiviral Agents; Brazil; DNA, Viral; Drug Resistance, Viral; Gene Produ

2015
Comparison of the efficacies of entecavir 0.5 and 1.0 mg combined with adefovir in patients with chronic hepatitis B who had failed on prior nucleos(t)ide analogue treatments.
    Journal of medical virology, 2015, Volume: 87, Issue:6

    Topics: Adenine; Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; G

2015
Tenofovir rescue regimen following prior suboptimal response to entecavir and adefovir combination therapy in chronic hepatitis B patients exposed to multiple treatment failures.
    Journal of medical virology, 2015, Volume: 87, Issue:6

    Topics: Adenine; Aged; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Fema

2015
Predictors of kidney tubular dysfunction induced by adefovir treatment for chronic hepatitis B.
    World journal of gastroenterology, 2015, Feb-21, Volume: 21, Issue:7

    Topics: Adenine; Adult; Age Factors; Aged; Aged, 80 and over; Antiviral Agents; Chi-Square Distribution; Fem

2015
Osteomalacia and Fanconi's syndrome caused by long-term low-dose adefovir dipivoxil.
    Journal of clinical pharmacy and therapeutics, 2015, Volume: 40, Issue:3

    Topics: Adenine; Antiviral Agents; Calcium; Dose-Response Relationship, Drug; Drug Monitoring; Fanconi Syndr

2015
Tenofovir rescue therapy in pregnant females with chronic hepatitis B.
    World journal of gastroenterology, 2015, Feb-28, Volume: 21, Issue:8

    Topics: Adenine; Adult; Antiviral Agents; Apgar Score; Biomarkers; Birth Weight; China; DNA, Viral; Drug Res

2015
Clinical course of chronic hepatitis B patients receiving nucleos(t)ide analogues after virological breakthrough during monotherapy with lamivudine.
    The new microbiologica, 2015, Volume: 38, Issue:1

    Topics: Adenine; Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; G

2015
[Pharmacoeconomic evaluation of treatments based on antiretrovirals for HBeAg-negative chronic hepatitis B].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2015, Volume: 23, Issue:1

    Topics: Adenine; Antiviral Agents; China; Cost-Benefit Analysis; Economics, Pharmaceutical; Guanine; Hepatit

2015
Tenofovir disoproxil fumarate is superior to lamivudine plus adefovir in lamivudine-resistant chronic hepatitis B patients.
    World journal of gastroenterology, 2015, Mar-07, Volume: 21, Issue:9

    Topics: Adenine; Adolescent; Adult; Antiviral Agents; Biomarkers; DNA, Viral; Drug Resistance, Viral; Drug S

2015
Natural Killer Cell Characteristics in Patients With Chronic Hepatitis B Virus (HBV) Infection Are Associated With HBV Surface Antigen Clearance After Combination Treatment With Pegylated Interferon Alfa-2a and Adefovir.
    The Journal of infectious diseases, 2015, Oct-01, Volume: 212, Issue:7

    Topics: Adenine; Adult; Aged; Antigens, Surface; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Fe

2015
Low-dose adefovir dipivoxil may induce Fanconi syndrome: clinical characteristics and long-term follow-up for Chinese patients.
    Antiviral therapy, 2015, Volume: 20, Issue:6

    Topics: Adenine; Adult; Alkaline Phosphatase; Antiviral Agents; Asian People; Bone Density; Creatinine; Drug

2015
Efficacy of tenofovir switch therapy for nucleos(t)ide-experienced patients with chronic hepatitis B.
    Alimentary pharmacology & therapeutics, 2015, Volume: 41, Issue:11

    Topics: Adenine; Adult; Antiviral Agents; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lami

2015
[Tenofovir rescue therapy for chronic hepatitis B patients after multiple treatment failures].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2015, Volume: 23, Issue:1

    Topics: Adenine; Hepatitis B, Chronic; Humans; Organophosphonates; Tenofovir; Treatment Failure

2015
Early kidney injury during long-term adefovir dipivoxil therapy for chronic hepatitis B.
    World journal of gastroenterology, 2015, Mar-28, Volume: 21, Issue:12

    Topics: Acute Kidney Injury; Adenine; Adult; Antiviral Agents; beta 2-Microglobulin; Biomarkers; Case-Contro

2015
Clonal evolution of multidrug resistant hepatitis B virus during entecavir rescue therapy.
    Liver international : official journal of the International Association for the Study of the Liver, 2015, Volume: 35, Issue:11

    Topics: Adenine; Adult; Antiviral Agents; Clonal Evolution; DNA, Viral; Drug Resistance, Viral; Drug Therapy

2015
Impact of nucleos(t)ide analogue combination therapy on the estimated glomerular filtration rate in patients with chronic hepatitis B.
    Medicine, 2015, Volume: 94, Issue:15

    Topics: Adenine; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Glomerular Filtration Rat

2015
The expression of TLR-9, CD86, and CD95 phenotypes in circulating B cells of patients with chronic viral hepatitis B or C before and after antiviral therapy.
    Mediators of inflammation, 2015, Volume: 2015

    Topics: Adenine; Adult; Aged; Antibodies, Monoclonal; Antiviral Agents; B-Lymphocytes; B7-2 Antigen; DNA, Vi

2015
A case of entecavir resistance which is developed after complete viral suppression during entecavir treatment for nucleoside-naive chronic hepatitis B.
    The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, 2014, Volume: 25 Suppl 1

    Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Guanine; Hepatitis B virus; Hepatitis B, Chronic;

2014
Response to potent anti-HBV agents in chronic hepatitis B and combined effect of HBV reverse transcriptase mutations.
    Gene, 2015, Aug-01, Volume: 567, Issue:1

    Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Mutation; Organ

2015
Entecavir Combined With Adefovir Ameliorates Patients With Chronic Hepatitis B Who Fail to Respond to Nucleotide (Acid) Analog Monotherapy.
    American journal of therapeutics, 2017, Volume: 24, Issue:3

    Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Follow-Up Studies;

2017
Tenofovir-based rescue therapy in chronic hepatitis B patients with suboptimal responses to adefovir with prior lamivudine resistance.
    Journal of medical virology, 2015, Volume: 87, Issue:9

    Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis B,

2015
Efficacy of Tenofovir-based Rescue Therapy in Lamivudine-resistant Chronic Hepatitis B Patients With Failure of Lamivudine and Adefovir Combination.
    Clinical therapeutics, 2015, Jul-01, Volume: 37, Issue:7

    Topics: Adenine; Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; H

2015
Tenofovir-based rescue therapy for chronic hepatitis B patients who had failed treatment with lamivudine, adefovir, and entecavir.
    Journal of gastroenterology and hepatology, 2015, Volume: 30, Issue:10

    Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Multiple; Drug Therapy, Combination;

2015
Remission of splenic marginal zone lymphoma in a patient treated for hepatitis B: a case of HBV-associated lymphoma.
    Acta clinica Belgica, 2015, Volume: 70, Issue:4

    Topics: Adenine; Bone Marrow; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunohistochemistry; Lymphom

2015
Prevalence and types of drug-resistant variants in Chinese patients with acute hepatitis B.
    Journal of medical virology, 2015, Volume: 87, Issue:9

    Topics: Adenine; Adult; Antiviral Agents; China; DNA, Viral; Drug Resistance, Viral; Female; Genetic Variati

2015
The long-term benefits of nucleos(t)ide analogs in compensated HBV cirrhotic patients with no or small esophageal varices: A 12-year prospective cohort study.
    Journal of hepatology, 2015, Volume: 63, Issue:5

    Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Dose-Response Relationship, Drug; Elasticity Ima

2015
Initial combination anti-viral therapy with lamivudine and adefovir dipivoxil decreases short-term fatality rate of hepatitis-B-virus-related acute-on-chronic liver failure.
    Virology journal, 2015, Jun-24, Volume: 12

    Topics: Acute-On-Chronic Liver Failure; Adenine; Adolescent; Adult; Aged; Antiviral Agents; Female; Hepatiti

2015
Deep sequencing analysis of HBV genotype shift and correlation with antiviral efficiency during adefovir dipivoxil therapy.
    PloS one, 2015, Volume: 10, Issue:6

    Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Female; Genotype; Hepatitis B e Antigens; Hepatitis B

2015
[Efficacy and safety of telbivudine alone and combined with adefovir for the treatment of nucleos(t)ide-naive chronic hepatitis B in patients with high-level hepatitis B virus load].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2015, Volume: 23, Issue:4

    Topics: Adenine; Alanine Transaminase; Drug Therapy, Combination; Hepatitis B e Antigens; Hepatitis B virus;

2015
Comparison of entecavir monotherapy and de novo lamivudine and adefovir combination therapy in HBeAg-positive chronic hepatitis B with high viral load: 48-week result.
    Clinical and experimental medicine, 2016, Volume: 16, Issue:3

    Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Antiviral Agents; Blood; DNA, Viral; Female; Guani

2016
Outcome of adefovir add-on lamivudine rescue therapy of up to 5 years in patients with lamivudine-resistant chronic hepatitis B.
    Journal of gastroenterology and hepatology, 2016, Volume: 31, Issue:1

    Topics: Adenine; Alanine Transaminase; Antiviral Agents; Biomarkers; DNA, Viral; Drug Resistance, Viral; Dru

2016
Substitution at rt269 in Hepatitis B Virus Polymerase Is a Compensatory Mutation Associated with Multi-Drug Resistance.
    PloS one, 2015, Volume: 10, Issue:8

    Topics: Adenine; Amino Acid Substitution; Antiviral Agents; Arabinofuranosyluracil; Cell Line, Tumor; Drug R

2015
Long-term follow-up of HBsAg-positive patients in Germany.
    European journal of gastroenterology & hepatology, 2016, Volume: 28, Issue:1

    Topics: Adenine; Adult; Age Factors; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Drug Therapy,

2016
[Adefovir dipivoxil effects on and related factors of blood phosphorus metabolism in patients with chronic hepatitis B].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2015, Volume: 23, Issue:8

    Topics: Adenine; Aged; Antiviral Agents; Creatinine; Drug Therapy, Combination; Hepatitis B, Chronic; Humans

2015
Management of entecavir-resistant chronic hepatitis B with adefovir-based combination therapies.
    World journal of gastroenterology, 2015, Oct-14, Volume: 21, Issue:38

    Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combinatio

2015
Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy.
    Clinical and molecular hepatology, 2015, Volume: 21, Issue:3

    Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Fem

2015
Comprehensive analysis of hospital-based prospective cohort reveals the unique effectiveness and safety for nucleos(t)ide analogues in HBV patients.
    Clinics and research in hepatology and gastroenterology, 2016, Volume: 40, Issue:2

    Topics: Adenine; Adult; Antiviral Agents; Female; Guanine; Hepatitis B, Chronic; Hospitalization; Humans; La

2016
Epidemiology study of HBV genotypes and antiviral drug resistance in multi-ethnic regions from Western China.
    Scientific reports, 2015, Nov-27, Volume: 5

    Topics: Adenine; Adult; Antiviral Agents; China; DNA, Viral; Drug Resistance, Viral; Ethnicity; Female; Geno

2015
Nephrotoxicity caused by oral antiviral agents in patients with chronic hepatitis B treated in a hospital for tropical diseases in Thailand.
    BMC pharmacology & toxicology, 2015, Dec-14, Volume: 16

    Topics: Adenine; Adult; Antiviral Agents; Creatinine; Female; Follow-Up Studies; Guanine; Hepatitis B, Chron

2015
Rhabdomyolysis due to lamivudine re-administration in a patient with HBV-related hepatic failure caused by interruption of lamivudine and adefovir.
    Journal of gastrointestinal and liver diseases : JGLD, 2015, Volume: 24, Issue:4

    Topics: Adenine; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis B, Chr

2015
[Efficacy of combination antiviral therapy following childbirth in pregnant HBV carriers receiving telbivudine for prevention of mother-to-child transmission].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2015, Volume: 23, Issue:11

    Topics: Adenine; Alanine Transaminase; Antiviral Agents; Carrier State; DNA, Viral; Drug Therapy, Combinatio

2015
Off-treatment efficacy of 3-year nucleos(t)ide analogues in chronic hepatitis B patients.
    The Kaohsiung journal of medical sciences, 2016, Volume: 32, Issue:1

    Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; Female; Guanine; Hepatitis B, Chronic; Human

2016
In situ analysis of intrahepatic virological events in chronic hepatitis B virus infection.
    The Journal of clinical investigation, 2016, Mar-01, Volume: 126, Issue:3

    Topics: Adenine; Case-Control Studies; DNA Probes; DNA, Viral; Hep G2 Cells; Hepatitis B Core Antigens; Hepa

2016
Multidrug resistance protein 4 is a critical protein associated with the antiviral efficacy of nucleos(t)ide analogues.
    Liver international : official journal of the International Association for the Study of the Liver, 2016, Volume: 36, Issue:9

    Topics: Adenine; Adult; Antiviral Agents; Cell Line, Tumor; Drug Resistance, Viral; Female; Guanine; Hepatit

2016
[Drug-resistant mutations in hepatitis B virus found in chronic HBV carriers using PCR sequencing technology].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2016, Volume: 24, Issue:1

    Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Genotype; Guanine; Hepatitis B virus;

2016
Profile of HBV polymerase gene mutations during entecavir treatment in patients with chronic hepatitis B.
    Clinics and research in hepatology and gastroenterology, 2016, Volume: 40, Issue:5

    Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Antiviral Agents; Drug Resistance, Viral; Female;

2016
Resistance of ground glass hepatocytes to oral antivirals in chronic hepatitis B patients and implication for the development of hepatocellular carcinoma.
    Oncotarget, 2016, May-10, Volume: 7, Issue:19

    Topics: Adenine; Administration, Oral; Adolescent; Adult; Amino Acid Sequence; Antiviral Agents; Biopsy; Car

2016
Cost-effectiveness comparison of lamivudine plus adefovir combination treatment and nucleos(t)ide analog monotherapies in Chinese chronic hepatitis B patients.
    Drug design, development and therapy, 2016, Volume: 10

    Topics: Adenine; Adult; Cost-Benefit Analysis; Drug Therapy, Combination; Hepatitis B, Chronic; Humans; Lami

2016
De novo entecavir+adefovir dipivoxil+lamivudine triple-resistance mutations resulting from sequential therapy with adefovir dipivoxil, and lamivudine.
    Annals of clinical microbiology and antimicrobials, 2016, Apr-14, Volume: 15

    Topics: Adenine; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Guanine; Hepatitis B virus; Hep

2016
Intrahepatic IP-10 mRNA and plasma IP-10 levels as response marker for HBeAg-positive chronic hepatitis B patients treated with peginterferon and adefovir.
    Antiviral research, 2016, Volume: 131

    Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; Biomarkers; Biopsy; Chemokine CXCL10; DNA, V

2016
Cost-Effectiveness of Peg-Interferon, Interferon and Oral Nucleoside Analogues in the Treatment of Chronic Hepatitis B and D Infections in China.
    Clinical drug investigation, 2016, Volume: 36, Issue:8

    Topics: Adenine; Adult; Age Factors; Aged; Antiviral Agents; China; Cohort Studies; Cost of Illness; Cost-Be

2016
First case report of renal improvement on tenofovir alafenamide in an HIV/hepatitis B virus-coinfected patient with adefovir-induced Fanconi's syndrome.
    AIDS (London, England), 2016, 06-01, Volume: 30, Issue:9

    Topics: Absorptiometry, Photon; Adenine; Alanine; Coinfection; Dose-Response Relationship, Drug; Fanconi Syn

2016
Pathologic Femoral Neck Fracture Due to Fanconi Syndrome Induced by Adefovir Dipivoxil Therapy for Hepatitis B.
    Clinics in orthopedic surgery, 2016, Volume: 8, Issue:2

    Topics: Adenine; Adult; Antiviral Agents; Fanconi Syndrome; Femoral Neck Fractures; Fractures, Spontaneous;

2016
Cost-effectiveness analysis of tenofovir disoproxil fumarate for treatment of chronic hepatitis B in China.
    Hepatology international, 2016, Volume: 10, Issue:6

    Topics: Adenine; Antiviral Agents; Cost-Benefit Analysis; Female; Guanine; Hepatitis B, Chronic; Humans; Lam

2016
Impact of FIB-4 index on hepatocellular carcinoma incidence during nucleos(t)ide analogue therapy in patients with chronic hepatitis B: An analysis using time-dependent receiver operating characteristic.
    Journal of gastroenterology and hepatology, 2017, Volume: 32, Issue:2

    Topics: Adenine; Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Biomarkers; Carcinoma,

2017
Urinary β-2 Microglobulin Levels Sensitively Altered in an Osteomalacia Patient Receiving Add-on Adefovir Dipivoxil Therapy for Hepatitis B Virus Infection.
    Internal medicine (Tokyo, Japan), 2016, Volume: 55, Issue:12

    Topics: Adenine; Aged; Antiviral Agents; beta 2-Microglobulin; Female; Hepatitis B, Chronic; Humans; Japan;

2016
The efficacy of tenofovir-based therapy in patients showing suboptimal response to entecavir-adefovir combination therapy.
    Clinical and molecular hepatology, 2016, Volume: 22, Issue:2

    Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combinatio

2016
Durability of the virological response after lamivudine discontinuation in lamivudine-resistant patients with a complete virological response after lamivudine and adefovir combination therapy.
    Journal of medical virology, 2017, Volume: 89, Issue:1

    Topics: Adenine; Adult; Aged; Anti-HIV Agents; DNA, Viral; Drug Therapy, Combination; Female; Hepatitis B vi

2017
A five years study of antiviral effect of entecavir in Chinese chronic hepatitis B patients.
    Scientific reports, 2016, 07-01, Volume: 6

    Topics: Adenine; Adult; Antiviral Agents; Asian People; China; Drug Resistance, Viral; Drug Therapy, Combina

2016
Is the tenofovir based therapy almighty for previous treatment failure in chronic hepatitis B?
    Clinical and molecular hepatology, 2016, Volume: 22, Issue:2

    Topics: Adenine; Antiviral Agents; DNA, Viral; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chron

2016
The long-term efficacy of combining nucleos(t)ide analog and low-dose hepatitis B immunoglobulin on post-transplant hepatitis B virus recurrence.
    Clinical transplantation, 2016, Volume: 30, Issue:10

    Topics: Adenine; Administration, Oral; Adult; Aged; Antiviral Agents; Drug Administration Schedule; Drug The

2016
Nucleos(t)ide analog(s) prophylaxis after hepatitis B immunoglobulin withdrawal against hepatitis B and D recurrence after liver transplantation.
    Transplant infectious disease : an official journal of the Transplantation Society, 2016, Volume: 18, Issue:5

    Topics: Adenine; Adult; Antiviral Agents; Coinfection; DNA, Viral; Drug Therapy, Combination; Female; Guanin

2016
[HBsAg clearance rate in patients with HBeAg-positive chronic hepatitis B: a comparative effect analysis based on the real world].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2016, May-20, Volume: 24, Issue:5

    Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis

2016
Management of Clevudine-Resistant Chronic Hepatitis B: A Multicenter Cohort Study.
    Gut and liver, 2017, Jan-15, Volume: 11, Issue:1

    Topics: Adenine; Adult; Aged; Antiviral Agents; Arabinofuranosyluracil; Cohort Studies; Disease Management;

2017
Pre-existing mutations related to tenofovir in chronic hepatitis B patients with long-term nucleos(t)ide analogue drugs treatment by ultra-deep pyrosequencing.
    Oncotarget, 2016, Oct-25, Volume: 7, Issue:43

    Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Multiple; Female; Hepatitis B, Chroni

2016
Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B.
    Journal of hepatology, 2017, Volume: 66, Issue:2

    Topics: Adenine; Antiviral Agents; Biopsy; DNA, Circular; DNA, Viral; Female; Hepatitis B virus; Hepatitis B

2017
Lamivudine/Adefovir Treatment Increases the Rate of Spontaneous Mutation of Hepatitis B Virus in Patients.
    PloS one, 2016, Volume: 11, Issue:9

    Topics: Adenine; Drug Resistance, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunosupp

2016
No detectable resistance to tenofovir disoproxil fumarate in HBeAg+ and HBeAg- patients with chronic hepatitis B after 8 years of treatment.
    Journal of viral hepatitis, 2017, Volume: 24, Issue:1

    Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Hepatitis B e Antigens; Hepatitis B v

2017
No detectable resistance to tenofovir disoproxil fumarate in HBeAg+ and HBeAg- patients with chronic hepatitis B after 8 years of treatment.
    Journal of viral hepatitis, 2017, Volume: 24, Issue:1

    Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Hepatitis B e Antigens; Hepatitis B v

2017
No detectable resistance to tenofovir disoproxil fumarate in HBeAg+ and HBeAg- patients with chronic hepatitis B after 8 years of treatment.
    Journal of viral hepatitis, 2017, Volume: 24, Issue:1

    Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Hepatitis B e Antigens; Hepatitis B v

2017
No detectable resistance to tenofovir disoproxil fumarate in HBeAg+ and HBeAg- patients with chronic hepatitis B after 8 years of treatment.
    Journal of viral hepatitis, 2017, Volume: 24, Issue:1

    Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Hepatitis B e Antigens; Hepatitis B v

2017
No detectable resistance to tenofovir disoproxil fumarate in HBeAg+ and HBeAg- patients with chronic hepatitis B after 8 years of treatment.
    Journal of viral hepatitis, 2017, Volume: 24, Issue:1

    Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Hepatitis B e Antigens; Hepatitis B v

2017
No detectable resistance to tenofovir disoproxil fumarate in HBeAg+ and HBeAg- patients with chronic hepatitis B after 8 years of treatment.
    Journal of viral hepatitis, 2017, Volume: 24, Issue:1

    Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Hepatitis B e Antigens; Hepatitis B v

2017
No detectable resistance to tenofovir disoproxil fumarate in HBeAg+ and HBeAg- patients with chronic hepatitis B after 8 years of treatment.
    Journal of viral hepatitis, 2017, Volume: 24, Issue:1

    Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Hepatitis B e Antigens; Hepatitis B v

2017
No detectable resistance to tenofovir disoproxil fumarate in HBeAg+ and HBeAg- patients with chronic hepatitis B after 8 years of treatment.
    Journal of viral hepatitis, 2017, Volume: 24, Issue:1

    Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Hepatitis B e Antigens; Hepatitis B v

2017
No detectable resistance to tenofovir disoproxil fumarate in HBeAg+ and HBeAg- patients with chronic hepatitis B after 8 years of treatment.
    Journal of viral hepatitis, 2017, Volume: 24, Issue:1

    Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Hepatitis B e Antigens; Hepatitis B v

2017
Comparison of the clinical outcomes between antiviral-naïve patients treated with entecavir and lamivudine-resistant patients receiving adefovir add-on lamivudine combination treatment.
    Clinical and molecular hepatology, 2016, Volume: 22, Issue:3

    Topics: Adenine; Adult; Alanine Transaminase; Antibodies, Viral; Antiviral Agents; Disease Progression; DNA,

2016
Identification of a new hepatitis B virus recombinant D2/D3 in the city of São Paulo, Brazil.
    Archives of virology, 2017, Volume: 162, Issue:2

    Topics: Adenine; Adult; Aged; Antiviral Agents; Brazil; Drug Resistance, Viral; Female; Genotype; Hepatitis

2017
Induction of IFN-λ3 as an additional effect of nucleotide, not nucleoside, analogues: a new potential target for HBV infection.
    Gut, 2018, Volume: 67, Issue:2

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Antiviral Agents; Asymptomatic Infections; Carcinoma, Hepat

2018
Comparison of Detection Rate and Mutational Pattern of Drug-Resistant Mutations Between a Large Cohort of Genotype B and Genotype C Hepatitis B Virus-Infected Patients in North China.
    Microbial drug resistance (Larchmont, N.Y.), 2017, Volume: 23, Issue:4

    Topics: Adenine; Adult; Antiviral Agents; China; Cohort Studies; Drug Resistance, Multiple, Viral; Female; G

2017
Treatment outcomes in treatment experienced and treatment naïve patients on Tenofovir disoproxil fumarate for chronic hepatitis B.
    The Journal of infection, 2017, Volume: 74, Issue:1

    Topics: Adenine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Tenofovir; Treatment Outcome

2017
Comparison of the Efficacies and Safety of Combined Therapy between Telbivudine Plus Adefovir and Lamivudine Plus Adefovir in Patients with Hepatitis B Virus Infection in Real-World Practice.
    PloS one, 2016, Volume: 11, Issue:11

    Topics: Adenine; Adult; Biomarkers; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Hepatitis

2016
Circulating kidney injury molecule-1 is a novel diagnostic biomarker for renal dysfunction during long-term adefovir therapy in chronic hepatitis B.
    Medicine, 2016, Volume: 95, Issue:44

    Topics: Adenine; Adult; Antiviral Agents; Biomarkers; Cohort Studies; Female; Hepatitis A Virus Cellular Rec

2016
Relationship between hepatitis B virus reverse transcriptase 181 mutation and S gene mutation in hepatitis B virus chronically infected patients.
    Cellular and molecular biology (Noisy-le-Grand, France), 2016, Oct-31, Volume: 62, Issue:12

    Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Geno

2016
Five-year efficacy and safety of tenofovir-based salvage therapy for patients with chronic hepatitis B who previously failed LAM/ADV therapy.
    Liver international : official journal of the International Association for the Study of the Liver, 2017, Volume: 37, Issue:6

    Topics: Adenine; Adult; Antiviral Agents; Australia; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B

2017
DNMT1 modulation in chronic hepatitis B patients and hypothetic influence on mitochondrial DNA methylation status during long-term nucleo(t)side analogs therapy.
    Journal of medical virology, 2017, Volume: 89, Issue:7

    Topics: Adenine; Aged; Antiviral Agents; Cross-Sectional Studies; Cytosine; DNA (Cytosine-5-)-Methyltransfer

2017
Tenofovir disoproxil fumarate monotherapy maintains HBV suppression achieved by a "de novo" combination of lamivudine-adefovir: a pilot study.
    Le infezioni in medicina, 2016, 12-01, Volume: 24, Issue:4

    Topics: Adenine; Adolescent; Adult; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Fem

2016
Switch to tenofovir-based therapy or to continue adefovir-based therapy in CHB patients with suboptimal response to adefovir-based combination?
    Clinical and molecular hepatology, 2016, Volume: 22, Issue:4

    Topics: Adenine; Antiviral Agents; Hepatitis B, Chronic; Humans; Lamivudine; Organophosphonates; Tenofovir

2016
Comparative evaluation of long-term monotherapies & combination therapies in patients with chronic hepatitis B: A pilot study.
    The Indian journal of medical research, 2016, Volume: 144, Issue:3

    Topics: Adenine; Adult; Drug Combinations; Drug Resistance, Viral; Female; Guanine; Hepatitis B virus; Hepat

2016
Long-term efficacy and safety of switching from lamivudine+adefovir to tenofovir disoproxil fumarate in virologically suppressed patients.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2017, Volume: 49, Issue:5

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug

2017
Tenofovir has inferior efficacy in adefovir-experienced chronic hepatitis B patients compared to nucleos(t)ide-naïve patients.
    Clinical and molecular hepatology, 2017, Volume: 23, Issue:1

    Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Administration Schedule; Drug Resistance, Viral;

2017
[The predictive value of ALT, HBeAg and HBV DNA levels at baseline and the degree of HBV suppression at week 12 adefovir dipivoxil treatment to the efficacy of it at week 52 in patients with HBeAg-positive chronic hepatitis B].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2008, Volume: 16, Issue:5

    Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B, Chronic;

2008
Replication of clinical hepatitis B virus isolate and its application for selecting antiviral agents for chronic hepatitis B patients.
    World journal of gastroenterology, 2008, Jun-14, Volume: 14, Issue:22

    Topics: Adenine; Antiviral Agents; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Vira

2008
[Chronic hepatitis B. Tenofovir--the right choice from the beginning].
    MMW Fortschritte der Medizin, 2008, May-22, Volume: 150, Issue:21

    Topics: Adenine; Antiviral Agents; Drug Approval; Europe; Hepatitis B, Chronic; Humans; Organophosphonates;

2008
[Drug approval studies of Viread. As effective in HBeAg positive as also in HBeAg negative patients].
    MMW Fortschritte der Medizin, 2008, May-22, Volume: 150, Issue:21

    Topics: Adenine; Antiviral Agents; Drug Approval; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Mult

2008
[Comparison of antiviral responses to adefovir dipivoxil therapy of genotype B and genotype C HBV infected patients].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2008, Volume: 16, Issue:6

    Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; DNA, Viral; Female; Genotype; Hepatitis B virus;

2008
Selection of an entecavir-resistant mutant despite prolonged hepatitis B virus DNA suppression, in a chronic hepatitis B patient with preexistent lamivudine resistance: successful rescue therapy with tenofovir.
    European journal of gastroenterology & hepatology, 2008, Volume: 20, Issue:8

    Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Multiple, Viral; Guanine; Hepatitis B

2008
What is the optimum dose of adefovir in the treatment of chronic hepatitis B infection?
    Journal of hepatology, 2008, Volume: 49, Issue:3

    Topics: Adenine; Adult; Antiviral Agents; Dose-Response Relationship, Drug; Hepatitis B e Antigens; Hepatiti

2008
Rapid re-emergence of YMDD mutation of hepatitis B virus with hepatic decompensation after lamivudine retreatment.
    World journal of gastroenterology, 2008, Jul-21, Volume: 14, Issue:27

    Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic;

2008
Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection.
    Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:10

    Topics: Adenine; Animals; Antigens, Viral; Antiviral Agents; Deoxycytidine; Disease Models, Animal; DNA, Vir

2008
Adefovir dipivoxil is effective for the treatment of cirrhotic patients with lamivudine failure.
    Liver international : official journal of the International Association for the Study of the Liver, 2009, Volume: 29, Issue:3

    Topics: Adenine; Adult; Aged; Alanine Transaminase; Cohort Studies; Drug Resistance; Female; Genotype; Hepat

2009
Does the presence of adefovir-resistant variants lead to failure of tenofovir monotherapy?
    Journal of hepatology, 2008, Volume: 49, Issue:5

    Topics: Adenine; Adult; Antiviral Agents; Drug Resistance, Viral; Genetic Variation; Hepatitis B virus; Hepa

2008
[A case of severe hypophosphatemia related to adefovir dipivoxil treatment in a patient with liver cirrhosis related to hepatitis B virus].
    The Korean journal of hepatology, 2008, Volume: 14, Issue:3

    Topics: Absorptiometry, Photon; Adenine; Adult; Antiviral Agents; Bone Density; DNA, Viral; Drug Resistance,

2008
[YMDD motif variants detected by Inno-Lipa HBV DR assay in chronic hepatitis B patients during lamivudine therapy].
    Mikrobiyoloji bulteni, 2008, Volume: 42, Issue:3

    Topics: Adenine; Amino Acid Motifs; Anti-HIV Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combi

2008
Are hepatitis B e antigen (HBeAg)-positive chronic hepatitis B and HBeAg-negative chronic hepatitis B distinct diseases?
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2008, Nov-15, Volume: 47, Issue:10

    Topics: Adenine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Organophosphonates

2008
Sustained hepatitis B e antigen seroconversion in patients with chronic hepatitis B after adefovir dipivoxil treatment: analysis of precore and basal core promoter mutants.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2008, Nov-15, Volume: 47, Issue:10

    Topics: Adenine; Adult; Alanine Transaminase; Asian People; DNA Mutational Analysis; DNA, Viral; Female; Hep

2008
Serum HBsAg changes in HBeAg positive chronic hepatitis B patients with continuous viral load reductions during treatment with adefovir or peg-interferon-alpha-2a.
    Antiviral research, 2009, Volume: 81, Issue:1

    Topics: Adenine; Adult; Antiviral Agents; Female; Hepatitis B Antigens; Hepatitis B virus; Hepatitis B, Chro

2009
Hepatitis B virus genotype-associated variability in antiviral response to adefovir dipivoxil therapy in Chinese Han population.
    The Tohoku journal of experimental medicine, 2008, Volume: 216, Issue:3

    Topics: Adenine; Adult; Alanine Transaminase; Antibodies, Viral; Antiviral Agents; Asian People; DNA, Viral;

2008
Core promoter mutant HBV non-responding to adefovir after viral breakthrough on lamivudine: rapid virologic response to tenofovir plus lamivudine in a cirrhotic patient.
    European journal of medical research, 2008, Oct-27, Volume: 13, Issue:10

    Topics: Adenine; DNA, Viral; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Hepatitis B virus;

2008
Two-year data released on Viread for chronic hepatitis B.
    AIDS patient care and STDs, 2008, Volume: 22, Issue:11

    Topics: Adenine; Adult; Antiviral Agents; Clinical Trials, Phase III as Topic; Hepatitis B, Chronic; Humans;

2008
[Protocol for the antiviral therapy of chronic hepatitis B].
    Orvosi hetilap, 2008, Dec-07, Volume: 149, Issue:49

    Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alp

2008
Chronic hepatitis B--new goals, new treatment.
    The New England journal of medicine, 2008, Dec-04, Volume: 359, Issue:23

    Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis

2008
[Development of clevudine resistance after switching from lamivudine in a patient with chronic hepatitis B].
    The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 2008, Volume: 52, Issue:5

    Topics: Adenine; Adult; Amino Acid Substitution; Antiviral Agents; Arabinofuranosyluracil; Base Sequence; DN

2008
Molecular analysis of an HBsAg-negative hepatitis B virus mutant selected in a tenofovir-treated HIV-hepatitis B virus co-infected patient.
    AIDS (London, England), 2009, Jan-14, Volume: 23, Issue:2

    Topics: Adenine; Adult; Antiviral Agents; Drug Resistance, Viral; Gene Products, pol; Hepatitis B Surface An

2009
Lamivudine monoprophylaxis and adefovir salvage for liver transplantation in chronic hepatitis B: a seven-year follow-up study.
    Journal of medical virology, 2009, Volume: 81, Issue:2

    Topics: Adenine; Adult; Carcinoma, Hepatocellular; DNA, Viral; Drug Resistance, Viral; Female; Follow-Up Stu

2009
[The efficacy of adefovir dipivoxil monotherapy and the incidence of genotypic resistance to adefovir dipivoxil in patients with lamivudine-resistant chronic hepatitis B infection].
    The Korean journal of hepatology, 2008, Volume: 14, Issue:4

    Topics: Adenine; Adult; Amino Acid Substitution; Antiviral Agents; DNA-Directed DNA Polymerase; DNA, Viral;

2008
Susceptibility of hepatitis B virus to lamivudine restored by resistance to adefovir.
    Journal of medical virology, 2009, Volume: 81, Issue:3

    Topics: Adenine; Adult; Amino Acid Substitution; Antiviral Agents; DNA Mutational Analysis; DNA, Viral; Drug

2009
Association of lamivudine-resistant mutational patterns with the antiviral effect of adefovir in patients with chronic hepatitis B.
    Journal of medical virology, 2009, Volume: 81, Issue:3

    Topics: Adenine; Adult; Antiviral Agents; DNA Mutational Analysis; DNA, Viral; Drug Resistance, Viral; Femal

2009
Adefovir dipivoxil-induced acute tubular necrosis and Fanconi syndrome in a renal transplant patient.
    AIDS (London, England), 2009, Feb-20, Volume: 23, Issue:4

    Topics: Acute Kidney Injury; Adenine; Antiviral Agents; Fanconi Syndrome; Hepatitis B, Chronic; Humans; Kidn

2009
On-treatment monitoring of adefovir therapy in chronic hepatitis B: virologic response can be assessed at 24 weeks.
    Journal of viral hepatitis, 2009, Volume: 16, Issue:2

    Topics: Adenine; Adult; Antiviral Agents; Cohort Studies; DNA, Viral; Drug Resistance, Viral; Female; Follow

2009
Early development of clevudine resistance during clevudine therapy in a patient with chronic hepatitis B who received prior lamivudine therapy.
    Liver international : official journal of the International Association for the Study of the Liver, 2009, Volume: 29, Issue:6

    Topics: Adenine; Antiviral Agents; Arabinofuranosyluracil; Drug Resistance, Viral; Hepatitis B virus; Hepati

2009
Adefovir for chronic hepatitis B treatment: identification of virological markers linked to therapy response.
    Antiviral therapy, 2008, Volume: 13, Issue:8

    Topics: Adenine; Antiviral Agents; Biomarkers; Genotype; Hepatitis B e Antigens; Hepatitis B virus; Hepatiti

2008
Renal side effects of adefovir in hepatitis B virus-(HBV) positive kidney allograft recipients.
    Clinical nephrology, 2009, Volume: 71, Issue:1

    Topics: Acid-Base Equilibrium; Adenine; Aged; Antiviral Agents; Cohort Studies; Dose-Response Relationship,

2009
A short course of add-on adefovir dipivoxil treatment in lamivudine-resistant chronic hepatitis B patients.
    Journal of viral hepatitis, 2009, Volume: 16, Issue:4

    Topics: Adenine; Adult; Amino Acid Substitution; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Femal

2009
Virological response and hepatocarcinogenesis in lamivudine-resistant hepatitis B virus genotype C patients treated with lamivudine plus adefovir dipivoxil.
    Intervirology, 2008, Volume: 51, Issue:6

    Topics: Adenine; Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Drug Resistance, Vira

2008
Entecavir shows limited efficacy in HBeAg-positive hepatitis B patients with a partial virologic response to adefovir therapy.
    Journal of hepatology, 2009, Volume: 50, Issue:4

    Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Female; Genotype; Guanine; Hepatitis B e Antigen

2009
Partial virological response to nucleos(t)ide analogues in naïve patients with chronic hepatitis B: From guidelines to field practice.
    Journal of hepatology, 2009, Volume: 50, Issue:4

    Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Nucleosides; Nu

2009
[New molecules in the treatment of chronic hepatitis B].
    Presse medicale (Paris, France : 1983), 2009, Volume: 38, Issue:5

    Topics: Adenine; Antiviral Agents; Arabinofuranosyluracil; Hepatitis B Vaccines; Hepatitis B, Chronic; Human

2009
[Atazanavir-induced nephrolithiasis].
    Enfermedades infecciosas y microbiologia clinica, 2009, Volume: 27, Issue:2

    Topics: Adenine; Adult; Alkynes; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Cy

2009
Hepatitis B virus with the rtL80V/I mutation is associated with a poor response to adefovir dipivoxil therapy.
    Liver international : official journal of the International Association for the Study of the Liver, 2009, Volume: 29, Issue:4

    Topics: Adenine; Adult; Aged; Antiviral Agents; DNA Mutational Analysis; DNA, Viral; Drug Resistance, Viral;

2009
Decision analysis model for hepatitis B prophylaxis one year after liver transplantation.
    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2009, Volume: 15, Issue:4

    Topics: Adenine; Administration, Oral; Antiviral Agents; Cost Savings; Cost-Benefit Analysis; Decision Suppo

2009
Spondyloarthropathy and chronic B hepatitis. Effect of anti-TNF therapy.
    Joint bone spine, 2009, Volume: 76, Issue:3

    Topics: Adenine; Adult; Antibodies, Monoclonal; Antirheumatic Agents; Antiviral Agents; Drug Therapy, Combin

2009
[Analysis of the cost-effectiveness of antiviral therapies in chronic hepatitis B patients in Korea].
    The Korean journal of hepatology, 2009, Volume: 15, Issue:1

    Topics: Adenine; Antiviral Agents; Cohort Studies; Cost-Benefit Analysis; Drug Therapy, Combination; Hepatit

2009
[Virologic response to adefovir dipivoxil monotherapy is not durable in HBeAg-positive, lamivudine-resistant chronic hepatitis B patients].
    The Korean journal of hepatology, 2009, Volume: 15, Issue:1

    Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B e An

2009
Anti-hepatitis B virus activity in vitro of combinations of tenofovir with nucleoside/nucleotide analogues.
    Antiviral chemistry & chemotherapy, 2009, Volume: 19, Issue:4

    Topics: Adenine; Antiviral Agents; Cell Line; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug

2009
Factors contributing to antiviral effect of adefovir dipivoxil therapy added to ongoing lamivudine treatment in patients with lamivudine-resistant chronic hepatitis B.
    Journal of gastroenterology, 2009, Volume: 44, Issue:6

    Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Hepatitis B e

2009
Can antiviral therapy for chronic hepatitis B enhance the progression to hepatocellular carcinoma?
    Antiviral therapy, 2009, Volume: 14, Issue:2

    Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; Drug Resistance, Viral; H

2009
Clinical usefulness of sequential hepatitis B virus DNA measurement (the roadmap concept) during adefovir treatment in lamivudine-resistant patients.
    Antiviral therapy, 2009, Volume: 14, Issue:2

    Topics: Adenine; Adult; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B Antibodies; Hepatitis B viru

2009
Current trends in chronic hepatitis B management: results of a questionnaire.
    European journal of gastroenterology & hepatology, 2009, Volume: 21, Issue:10

    Topics: Adenine; Adult; Antiviral Agents; Biopsy; Clinical Competence; Drug Administration Schedule; Family

2009
[Antiviral efficacy of lamivudine/adefovir combination therapy in chronic hepatitis b patients with resistance to lamivudine and adefovir consecutively].
    The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 2009, Volume: 53, Issue:5

    Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Fem

2009
[Treatment of hepatitis B virus resistant to lamivudine and adefovir].
    The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 2009, Volume: 53, Issue:5

    Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis

2009
Rapid HBV DNA decrease (week 12) is an important prognostic factor for first-line treatment with adefovir dipivoxil for chronic hepatitis B.
    Journal of gastroenterology, 2009, Volume: 44, Issue:8

    Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female;

2009
Characterization of hepatitis B virus reverse transcriptase sequences in Chinese treatment naive patients.
    Journal of gastroenterology and hepatology, 2009, Volume: 24, Issue:8

    Topics: Adenine; Adult; Antiviral Agents; Asian People; Base Composition; China; Computational Biology; Data

2009
[The clinical study of adding on adefovir dipivoxil to treat for lamivudine resistant patients with chronic hepatitis B].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2009, Volume: 17, Issue:5

    Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Resistance, Vir

2009
Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil.
    Hepatology (Baltimore, Md.), 2009, Volume: 50, Issue:3

    Topics: Adenine; Adult; Aged; Antiviral Agents; Cohort Studies; Creatinine; Female; Glomerular Filtration Ra

2009
[Therapy of chronic hepatitis B. Tenofovir--first choice in current EASL guidelines].
    MMW Fortschritte der Medizin, 2009, May-28, Volume: 151, Issue:22

    Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Drug Resistance, Viral; Evidence-Based Medicin

2009
Monitoring of therapy in patients with chronic hepatitis B virus.
    European journal of gastroenterology & hepatology, 2010, Volume: 22, Issue:6

    Topics: Adenine; Adolescent; Adult; Antiviral Agents; DNA Mutational Analysis; DNA, Viral; Drug Monitoring;

2010
Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B.
    Journal of hepatology, 2009, Volume: 51, Issue:4

    Topics: Adenine; Administration, Oral; Adult; Antiviral Agents; Cohort Studies; Cost-Benefit Analysis; DNA,

2009
Prevalence, viral replication efficiency and antiviral drug susceptibility of rtQ215 polymerase mutations within the hepatitis B virus genome.
    Journal of hepatology, 2009, Volume: 51, Issue:4

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Amino Acid Substitution; Antiviral Agents; Base

2009
Salvage therapy with tenofovir followed by adefovir maintenance in a cirrhotic patient with a lamivudine resistant HBV flare.
    Le infezioni in medicina, 2009, Volume: 17, Issue:2

    Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Hep

2009
Dynamic changes of HBV quasispecies and deletion patterns in a chronic hepatitis B patient.
    Journal of medical virology, 2009, Volume: 81, Issue:9

    Topics: Adenine; Antiviral Agents; Cluster Analysis; DNA, Viral; Epitopes, B-Lymphocyte; Epitopes, T-Lymphoc

2009
Different models of HBeAg seroconversion predicated by on-treatment ALT and HBV DNA profiles.
    Journal of viral hepatitis, 2009, Volume: 16, Issue:12

    Topics: Adenine; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Female; Follow-Up Studies;

2009
Tenofovir: new indication. In chronic hepatitis B: beware bone toxicity.
    Prescrire international, 2009, Volume: 18, Issue:101

    Topics: Adenine; Antiviral Agents; Bone and Bones; Bone Diseases; Double-Blind Method; Drug Approval; Europe

2009
Combination of Lamivudine and adefovir therapy in HBeAg-positive chronic hepatitis B patients with poor response to adefovir monotherapy.
    Journal of viral hepatitis, 2010, Volume: 17, Issue:3

    Topics: Adenine; Adolescent; Adult; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Drug-Related Si

2010
Lamivudine and adefovir resistance in children and young adults with chronic hepatitis B.
    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2010, Volume: 14, Issue:3

    Topics: Adenine; Adolescent; Antiviral Agents; Child; Drug Administration Schedule; Drug Resistance, Viral;

2010
Low efficacy of entecavir therapy in adefovir-refractory hepatitis B patients with prior lamivudine resistance.
    Journal of viral hepatitis, 2010, Volume: 17, Issue:3

    Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Follow-Up Studies; Gua

2010
Clinical outcome of lamivudine-resistant chronic hepatitis B patients with compensated cirrhosis under adefovir salvage treatment. Importance of HCC surveillance.
    European journal of internal medicine, 2009, Volume: 20, Issue:5

    Topics: Adenine; Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Drug Resistance,

2009
Chronic hepatitis B: update 2009.
    Hepatology (Baltimore, Md.), 2009, Volume: 50, Issue:3

    Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guide

2009
Chronic hepatitis B: update 2009.
    Hepatology (Baltimore, Md.), 2009, Volume: 50, Issue:3

    Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guide

2009
Chronic hepatitis B: update 2009.
    Hepatology (Baltimore, Md.), 2009, Volume: 50, Issue:3

    Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guide

2009
Chronic hepatitis B: update 2009.
    Hepatology (Baltimore, Md.), 2009, Volume: 50, Issue:3

    Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guide

2009
Chronic hepatitis B: update 2009.
    Hepatology (Baltimore, Md.), 2009, Volume: 50, Issue:3

    Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guide

2009
Chronic hepatitis B: update 2009.
    Hepatology (Baltimore, Md.), 2009, Volume: 50, Issue:3

    Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guide

2009
Chronic hepatitis B: update 2009.
    Hepatology (Baltimore, Md.), 2009, Volume: 50, Issue:3

    Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guide

2009
Chronic hepatitis B: update 2009.
    Hepatology (Baltimore, Md.), 2009, Volume: 50, Issue:3

    Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guide

2009
Chronic hepatitis B: update 2009.
    Hepatology (Baltimore, Md.), 2009, Volume: 50, Issue:3

    Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guide

2009
Chronic hepatitis B: update 2009.
    Hepatology (Baltimore, Md.), 2009, Volume: 50, Issue:3

    Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guide

2009
Chronic hepatitis B: update 2009.
    Hepatology (Baltimore, Md.), 2009, Volume: 50, Issue:3

    Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guide

2009
Chronic hepatitis B: update 2009.
    Hepatology (Baltimore, Md.), 2009, Volume: 50, Issue:3

    Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guide

2009
Chronic hepatitis B: update 2009.
    Hepatology (Baltimore, Md.), 2009, Volume: 50, Issue:3

    Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guide

2009
Chronic hepatitis B: update 2009.
    Hepatology (Baltimore, Md.), 2009, Volume: 50, Issue:3

    Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guide

2009
Chronic hepatitis B: update 2009.
    Hepatology (Baltimore, Md.), 2009, Volume: 50, Issue:3

    Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guide

2009
Chronic hepatitis B: update 2009.
    Hepatology (Baltimore, Md.), 2009, Volume: 50, Issue:3

    Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guide

2009
Chronic hepatitis B: update 2009.
    Hepatology (Baltimore, Md.), 2009, Volume: 50, Issue:3

    Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guide

2009
Chronic hepatitis B: update 2009.
    Hepatology (Baltimore, Md.), 2009, Volume: 50, Issue:3

    Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guide

2009
Chronic hepatitis B: update 2009.
    Hepatology (Baltimore, Md.), 2009, Volume: 50, Issue:3

    Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guide

2009
Chronic hepatitis B: update 2009.
    Hepatology (Baltimore, Md.), 2009, Volume: 50, Issue:3

    Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guide

2009
Chronic hepatitis B: update 2009.
    Hepatology (Baltimore, Md.), 2009, Volume: 50, Issue:3

    Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guide

2009
Chronic hepatitis B: update 2009.
    Hepatology (Baltimore, Md.), 2009, Volume: 50, Issue:3

    Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guide

2009
Chronic hepatitis B: update 2009.
    Hepatology (Baltimore, Md.), 2009, Volume: 50, Issue:3

    Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guide

2009
Chronic hepatitis B: update 2009.
    Hepatology (Baltimore, Md.), 2009, Volume: 50, Issue:3

    Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guide

2009
Chronic hepatitis B: update 2009.
    Hepatology (Baltimore, Md.), 2009, Volume: 50, Issue:3

    Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guide

2009
Chronic hepatitis B: update 2009.
    Hepatology (Baltimore, Md.), 2009, Volume: 50, Issue:3

    Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guide

2009
Chronic hepatitis B: update 2009.
    Hepatology (Baltimore, Md.), 2009, Volume: 50, Issue:3

    Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guide

2009
Chronic hepatitis B: update 2009.
    Hepatology (Baltimore, Md.), 2009, Volume: 50, Issue:3

    Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guide

2009
Chronic hepatitis B: update 2009.
    Hepatology (Baltimore, Md.), 2009, Volume: 50, Issue:3

    Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guide

2009
Chronic hepatitis B: update 2009.
    Hepatology (Baltimore, Md.), 2009, Volume: 50, Issue:3

    Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guide

2009
Chronic hepatitis B: update 2009.
    Hepatology (Baltimore, Md.), 2009, Volume: 50, Issue:3

    Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guide

2009
Chronic hepatitis B: update 2009.
    Hepatology (Baltimore, Md.), 2009, Volume: 50, Issue:3

    Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guide

2009
Chronic hepatitis B: update 2009.
    Hepatology (Baltimore, Md.), 2009, Volume: 50, Issue:3

    Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guide

2009
Chronic hepatitis B: update 2009.
    Hepatology (Baltimore, Md.), 2009, Volume: 50, Issue:3

    Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guide

2009
Chronic hepatitis B: update 2009.
    Hepatology (Baltimore, Md.), 2009, Volume: 50, Issue:3

    Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guide

2009
Chronic hepatitis B: update 2009.
    Hepatology (Baltimore, Md.), 2009, Volume: 50, Issue:3

    Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guide

2009
Chronic hepatitis B: update 2009.
    Hepatology (Baltimore, Md.), 2009, Volume: 50, Issue:3

    Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guide

2009
Chronic hepatitis B: update 2009.
    Hepatology (Baltimore, Md.), 2009, Volume: 50, Issue:3

    Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guide

2009
Chronic hepatitis B: update 2009.
    Hepatology (Baltimore, Md.), 2009, Volume: 50, Issue:3

    Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guide

2009
Chronic hepatitis B: update 2009.
    Hepatology (Baltimore, Md.), 2009, Volume: 50, Issue:3

    Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guide

2009
Chronic hepatitis B: update 2009.
    Hepatology (Baltimore, Md.), 2009, Volume: 50, Issue:3

    Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guide

2009
Chronic hepatitis B: update 2009.
    Hepatology (Baltimore, Md.), 2009, Volume: 50, Issue:3

    Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guide

2009
Chronic hepatitis B: update 2009.
    Hepatology (Baltimore, Md.), 2009, Volume: 50, Issue:3

    Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guide

2009
Chronic hepatitis B: update 2009.
    Hepatology (Baltimore, Md.), 2009, Volume: 50, Issue:3

    Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guide

2009
Chronic hepatitis B: update 2009.
    Hepatology (Baltimore, Md.), 2009, Volume: 50, Issue:3

    Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guide

2009
Chronic hepatitis B: update 2009.
    Hepatology (Baltimore, Md.), 2009, Volume: 50, Issue:3

    Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guide

2009
Chronic hepatitis B: update 2009.
    Hepatology (Baltimore, Md.), 2009, Volume: 50, Issue:3

    Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guide

2009
Chronic hepatitis B: update 2009.
    Hepatology (Baltimore, Md.), 2009, Volume: 50, Issue:3

    Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guide

2009
Chronic hepatitis B: update 2009.
    Hepatology (Baltimore, Md.), 2009, Volume: 50, Issue:3

    Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guide

2009
[Factors associated with response to lamivudine: retrospective study of 233 patients with chronic hepatitis B].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2009, Volume: 17, Issue:8

    Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Administration

2009
Hepatitis B virus in tenofovir-naive Chinese patients with chronic hepatitis B contains no mutation of rtA194T conferring a reduced tenofovir susceptibility.
    Chinese medical journal, 2009, Jul-05, Volume: 122, Issue:13

    Topics: Adenine; Adult; Drug Resistance, Viral; Female; Gene Amplification; Genotype; Hepatitis B virus; Hep

2009
Hepatitis B in HIV patients: what is the current treatment and what are the challenges?
    Journal of HIV therapy, 2009, Volume: 14, Issue:1

    Topics: Adenine; Antiviral Agents; Deoxycytidine; DNA, Viral; Drug Therapy, Combination; Emtricitabine; Guan

2009
[Telbivudine in the management of HIV/HBV coinfection. Treating hepatitis B without HIV trouble].
    MMW Fortschritte der Medizin, 2009, Apr-30, Volume: 151, Issue:18

    Topics: Adenine; AIDS-Related Opportunistic Infections; Algorithms; Anti-HIV Agents; Antiviral Agents; Comor

2009
[Non-standard discontinuation of adefovir dipivoxil causing acute exacerbation of hepatitis].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2009, Volume: 17, Issue:9

    Topics: Adenine; Adult; Antiviral Agents; Biomarkers; Critical Illness; Cytokines; DNA, Viral; Follow-Up Stu

2009
[The efficacy of nucleoside/nucleotide analogue on chronic hepatitis B].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2009, Volume: 17, Issue:10

    Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Guanine; Hepatitis B e Antigens; Hepa

2009
[Dissection of mechanism for the adefovir dipivoxil resistance in chronic hepatitis B patients].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2009, Volume: 17, Issue:10

    Topics: Adenine; Adult; Alanine Transaminase; Amino Acid Sequence; Antiviral Agents; Base Sequence; DNA Prim

2009
Evolution of hepatitis B virus mutation during entecavir rescue therapy in patients with antiviral resistance to lamivudine and adefovir.
    Antiviral therapy, 2009, Volume: 14, Issue:7

    Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Multiple, Viral; Evolution, Molecular

2009
Tenofovir disoproxil fumarate for the treatment of hepatitis B infection.
    Drugs of today (Barcelona, Spain : 1998), 2009, Volume: 45, Issue:9

    Topics: Adenine; Antiviral Agents; Clinical Trials as Topic; Hepatitis B, Chronic; Humans; Organophosphonate

2009
Decrease in viral load at weeks 12 and 24 in patients with chronic hepatitis B treated with lamivudine or adefovir predicts virological response at week 48.
    Revista espanola de enfermedades digestivas, 2009, Volume: 101, Issue:11

    Topics: Adenine; Adult; Antiviral Agents; Female; Forecasting; Hepatitis B, Chronic; Humans; Lamivudine; Mal

2009
Selection and counterselection of the rtI233V adefovir resistance mutation during antiviral therapy.
    Journal of clinical microbiology, 2010, Volume: 48, Issue:2

    Topics: Adenine; Adult; Amino Acid Sequence; Amino Acid Substitution; Antiviral Agents; Drug Resistance, Vir

2010
Serum levels of surface large envelope proteins: prognostic markers for hepatitis B e antigen-negative patients with adefovir dipivoxil treatment.
    Antiviral therapy, 2009, Volume: 14, Issue:8

    Topics: Adenine; Adult; Antiviral Agents; Biomarkers; Female; Hepatitis B e Antigens; Hepatitis B Surface An

2009
Hepatitis B viral surface mutations in patients with adefovir resistant chronic hepatitis B with A181T/V polymerase mutations.
    Journal of Korean medical science, 2010, Volume: 25, Issue:2

    Topics: Adenine; Adult; Aged; Amino Acid Sequence; Amino Acid Substitution; Antiviral Agents; Codon, Initiat

2010
Hypophosphatemic osteomalacia after low-dose adefovir dipivoxil therapy for hepatitis B.
    The Journal of clinical endocrinology and metabolism, 2010, Volume: 95, Issue:2

    Topics: Adenine; Adult; Antiviral Agents; Hepatitis B, Chronic; Humans; Hypophosphatemia; Magnetic Resonance

2010
Evolution of full-length HBV sequences in chronic hepatitis B patients with sequential lamivudine and adefovir dipivoxil resistance.
    Journal of hepatology, 2010, Volume: 52, Issue:4

    Topics: Adenine; Adult; Amino Acid Substitution; Antiviral Agents; Drug Resistance, Viral; Epitopes, B-Lymph

2010
Establishment of a new quantitative detection approach to adefovir-resistant HBV and its clinical application.
    World journal of gastroenterology, 2010, Mar-14, Volume: 16, Issue:10

    Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B virus; Hep

2010
Hepatitis B genotypes and response to adefovir treatment in patients with HBV chronic infection.
    The Journal of infection, 2010, Volume: 60, Issue:5

    Topics: Adenine; Antiviral Agents; Genotype; Hepatitis B virus; Hepatitis B, Chronic; Humans; Organophosphon

2010
Response to adefovir depends on mutation patterns in precore region, basal core promoter and reverse transcriptase, and on-treatment responses in Lamivudine-resistant chronic hepatitis B patients.
    Intervirology, 2010, Volume: 53, Issue:4

    Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B Core Antig

2010
Four-year study of lamivudine and adefovir combination therapy in lamivudine-resistant hepatitis B patients: influence of hepatitis B virus genotype and resistance mutation pattern.
    Journal of viral hepatitis, 2011, Volume: 18, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Fem

2011
Cost-effectiveness analysis of roadmap models in chronic hepatitis B using tenofovir as the rescue therapy.
    Antiviral therapy, 2010, Volume: 15, Issue:2

    Topics: Adenine; Antiviral Agents; Asia; Cost-Benefit Analysis; Decision Support Techniques; DNA, Viral; Dru

2010
Tenofovir/probenecid combination in HIV/HBV-coinfected patients: how to escape Fanconi syndrome recurrence?
    AIDS (London, England), 2010, Apr-24, Volume: 24, Issue:7

    Topics: Adenine; Fanconi Syndrome; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans; Male; Organophosphon

2010
Naturally occurring hepatitis B virus (HBV) variants with primary resistance to antiviral therapy and S-mutants with potential primary resistance to adefovir in Argentina.
    Antiviral research, 2010, Volume: 87, Issue:1

    Topics: Adenine; Adolescent; Adult; Antiviral Agents; Argentina; Child; Child, Preschool; Drug Resistance, V

2010
[Serological and sociodemographic differences in HBV-patients with and without migration background].
    Zeitschrift fur Gastroenterologie, 2010, Volume: 48, Issue:5

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Antiviral Agents; Comorbidity; Cross-Sectional Studies; Edu

2010
[Genotype distribution of chronic hepatitis B and hepatitis C patients and investigation of the resistance patterns in hepatitis B cases].
    Mikrobiyoloji bulteni, 2010, Volume: 44, Issue:2

    Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; DNA Mutational Analysis; DNA-Directed DNA Polyme

2010
Cost-effectiveness of nucleoside analog therapy for hepatitis B in China: a Markov analysis.
    Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 2010, Volume: 13, Issue:5

    Topics: Adenine; Antiviral Agents; China; Cost-Benefit Analysis; Guanine; Hepatitis B e Antigens; Hepatitis

2010
Long-term outcome of renal transplant recipients with chronic hepatitis B infection-impact of antiviral treatments.
    Transplantation, 2010, Aug-15, Volume: 90, Issue:3

    Topics: Adenine; Adult; Antiviral Agents; Biomarkers; DNA, Viral; Drug Resistance, Viral; Female; Guanine; H

2010
rtE218G, a novel hepatitis B virus mutation with resistance to adefovir dipivoxil in patients with chronic hepatitis B.
    Journal of viral hepatitis, 2010, Volume: 17 Suppl 1

    Topics: Adenine; Amino Acid Substitution; Antiviral Agents; Cell Line; Drug Resistance, Viral; Hepatitis B v

2010
Lamivudine-resistance mutations can be selected even at very low levels of hepatitis B viraemia.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2010, Volume: 42, Issue:12

    Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B viru

2010
Novel mutation in YMDD motif and direct neighbourhood in a child with chronic HBV-infection and clinical lamivudine and adefovir resistance - a scholarly case.
    Virology journal, 2010, Jul-21, Volume: 7

    Topics: Adenine; Amino Acid Motifs; Amino Acid Sequence; Antiviral Agents; Child; Drug Resistance, Viral; He

2010
Lamivudine plus adefovir or entecavir for patients with chronic hepatitis B resistant to lamivudine and adefovir.
    Journal of hepatology, 2010, Volume: 53, Issue:3

    Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Fem

2010
Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy.
    Journal of gastroenterology and hepatology, 2010, Volume: 25, Issue:8

    Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; Biomarkers; DNA, Viral; Drug Resistance, Vir

2010
The curative efficiency of tenofovir for patients with chronic hepatitis B after failure of nucleoside/nucleotide analogues.
    Hepatology (Baltimore, Md.), 2010, Volume: 52, Issue:2

    Topics: Adenine; Antiviral Agents; Hepatitis B, Chronic; Humans; Nucleosides; Nucleotides; Organophosphonate

2010
[A case of osteomalacia related to adefovir in a patient with chronic hepatitis B].
    The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 2010, Volume: 56, Issue:2

    Topics: Adenine; Aged; Alkaline Phosphatase; Antiviral Agents; Dietary Supplements; DNA, Viral; Hepatitis B,

2010
Management and treatment of chronic hepatitis B virus infection in HIV positive and negative patients: the EPIB 2008 study.
    Journal of hepatology, 2010, Volume: 53, Issue:6

    Topics: Adenine; Adult; Antiviral Agents; Female; France; Hepatitis B Antibodies; Hepatitis B Antigens; Hepa

2010
Cost-utility analysis of tenofovir disoproxil fumarate in the treatment of chronic hepatitis B.
    Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 2010, Volume: 13, Issue:8

    Topics: Adenine; Cost-Benefit Analysis; Guanine; Hepatitis B, Chronic; Humans; Markov Chains; Organophosphon

2010
Antiviral treatment including entecavir plus tenofovir disoproxil fumarate for HBV reactivation following a rituximab-based regimen.
    Antiviral therapy, 2010, Volume: 15, Issue:6

    Topics: Adenine; Antibodies, Monoclonal, Murine-Derived; Antiviral Agents; Drug Combinations; Female; Guanin

2010
HBcrAg is a predictor of post-treatment recurrence of hepatocellular carcinoma during antiviral therapy.
    Liver international : official journal of the International Association for the Study of the Liver, 2010, Volume: 30, Issue:10

    Topics: Adenine; Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Catheter Ablation; Disease-Free S

2010
[Antiviral treatment of chronic B hepatitis; 2010 - therapeutic recommendations].
    Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2010, Volume: 29, Issue:170

    Topics: Adenine; Antiviral Agents; Drug Administration Schedule; Drug Resistance, Viral; Guanine; Hepatitis

2010
[Treatment of chronic hepatitis B. High response rate in general practice].
    MMW Fortschritte der Medizin, 2010, Jul-22, Volume: 152, Issue:28-30

    Topics: Adenine; Antiviral Agents; Cross-Sectional Studies; Germany; Guanine; Hepatitis B, Chronic; Humans;

2010
Hepatitis B virus reverse transcriptase sequence variant database for sequence analysis and mutation discovery.
    Antiviral research, 2010, Volume: 88, Issue:3

    Topics: Adenine; Base Sequence; Databases, Genetic; DNA Mutational Analysis; DNA, Viral; Drug Resistance, Vi

2010
Impact of hepatitis B e antigen-suppressing mutations on the replication efficiency of entecavir-resistant hepatitis B virus strains.
    Journal of viral hepatitis, 2011, Volume: 18, Issue:11

    Topics: Adenine; Antiviral Agents; Cell Line, Tumor; Drug Resistance, Viral; Guanine; Hepatitis B e Antigens

2011
Persistence and adherence to nucleos(t)ide analogue treatment for chronic hepatitis B.
    Journal of hepatology, 2011, Volume: 54, Issue:1

    Topics: Adenine; Adolescent; Adult; Antiviral Agents; Cohort Studies; Drug Resistance, Viral; Female; Guanin

2011
Treatment of children with chronic hepatitis B virus infection in the United States: patient selection and therapeutic options.
    Hepatology (Baltimore, Md.), 2010, Volume: 52, Issue:6

    Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Antiviral Agents; Child; Child, Preschool; DNA, Vi

2010
Enhancing the antihepatitis B virus immune response by adefovir dipivoxil and entecavir therapies.
    Cellular & molecular immunology, 2011, Volume: 8, Issue:1

    Topics: Adenine; Administration, Oral; Adult; Antiviral Agents; Case-Control Studies; Cytokines; DNA, Viral;

2011
Initial virological response and viral mutation with adefovir dipivoxil added to ongoing Lamivudine therapy in Lamivudine-resistant chronic hepatitis B.
    Digestive diseases and sciences, 2011, Volume: 56, Issue:4

    Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combinatio

2011
Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B.
    Gastroenterology, 2011, Volume: 140, Issue:1

    Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Antiviral Agents; Biopsy; DNA, Viral; Drug Resista

2011
Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B.
    Gastroenterology, 2011, Volume: 140, Issue:1

    Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Antiviral Agents; Biopsy; DNA, Viral; Drug Resista

2011
Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B.
    Gastroenterology, 2011, Volume: 140, Issue:1

    Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Antiviral Agents; Biopsy; DNA, Viral; Drug Resista

2011
Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B.
    Gastroenterology, 2011, Volume: 140, Issue:1

    Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Antiviral Agents; Biopsy; DNA, Viral; Drug Resista

2011
Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B.
    Gastroenterology, 2011, Volume: 140, Issue:1

    Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Antiviral Agents; Biopsy; DNA, Viral; Drug Resista

2011
Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B.
    Gastroenterology, 2011, Volume: 140, Issue:1

    Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Antiviral Agents; Biopsy; DNA, Viral; Drug Resista

2011
Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B.
    Gastroenterology, 2011, Volume: 140, Issue:1

    Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Antiviral Agents; Biopsy; DNA, Viral; Drug Resista

2011
Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B.
    Gastroenterology, 2011, Volume: 140, Issue:1

    Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Antiviral Agents; Biopsy; DNA, Viral; Drug Resista

2011
Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B.
    Gastroenterology, 2011, Volume: 140, Issue:1

    Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Antiviral Agents; Biopsy; DNA, Viral; Drug Resista

2011
High rate of adefovir-lamivudine combination therapy in nucleoside-naïve patients with chronic hepatitis B in France: results of a national survey in 1730 patients.
    European journal of gastroenterology & hepatology, 2010, Volume: 22, Issue:11

    Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; Biomarkers; Cross-Sectional Studies; DNA, Vi

2010
Virologic and clinical outcomes in HIV/HBV coinfected patients on tenofovir-containing HAART.
    Gastroenterology, 2010, Volume: 139, Issue:6

    Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Hepatitis B, Chronic; HIV Infection

2010
Efficacy and pharmacokinetics of adefovir dipivoxil liquid suspension in patients with chronic hepatitis B and renal impairment.
    Journal of clinical pharmacology, 2011, Volume: 51, Issue:9

    Topics: Adenine; Adult; Aged; Antiviral Agents; Female; Follow-Up Studies; Hepatitis B, Chronic; Humans; Mal

2011
Liver fibrosis changes in HIV-HBV-coinfected patients: clinical, biochemical and histological effect of long-term tenofovir disoproxil fumarate use.
    Antiviral therapy, 2010, Volume: 15, Issue:7

    Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cohort

2010
Occult HBV infection in untreated HIV-infected adults in Côte d'Ivoire.
    Antiviral therapy, 2010, Volume: 15, Issue:7

    Topics: Adenine; Adult; Aged; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cote d'Ivoire; Cr

2010
[Analogs combination therapy in chronic hepatitis B: when and how?].
    Gastroenterologie clinique et biologique, 2010, Volume: 34 Suppl 2

    Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Guanine; Hepatitis B,

2010
[Long-term therapy for chronic hepatitis B in HIV co-infected patients].
    Gastroenterologie clinique et biologique, 2010, Volume: 34 Suppl 2

    Topics: Adenine; Antiretroviral Therapy, Highly Active; Antiviral Agents; Deoxycytidine; Drug Resistance, Vi

2010
[Treatment has a positive impact on the long-term evolution of chronic hepatitis B].
    Gastroenterologie clinique et biologique, 2010, Volume: 34 Suppl 2

    Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Clinical Trials as Topic; Guanine; Hepatitis B

2010
Th1 and Th2 immune response in chronic hepatitis B patients during a long-term treatment with adefovir dipivoxil.
    Mediators of inflammation, 2010, Volume: 2010

    Topics: Adenine; Adult; Antiviral Agents; Clinical Trials as Topic; Cytokines; DNA, Viral; Female; Hepatitis

2010
Characteristics of adefovir resistance in patients with or without lamivudine-resistant hepatitis B virus treated with adefovir: a 4-year experience.
    Liver international : official journal of the International Association for the Study of the Liver, 2011, Volume: 31, Issue:2

    Topics: Adenine; Adult; Aged; Antiviral Agents; Base Sequence; Cloning, Molecular; Drug Resistance, Viral; F

2011
Profile of HBV antiviral resistance mutations with distinct evolutionary pathways against nucleoside/nucleotide analogue treatment among Chinese chronic hepatitis B patients.
    Antiviral therapy, 2010, Volume: 15, Issue:8

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; China; Cross-Sectional Studie

2010
Evolution and suppression of HBV strains with multidrug resistance to lamivudine, adefovir dipivoxil and entecavir in a patient with chronic hepatitis B.
    Antiviral therapy, 2010, Volume: 15, Issue:8

    Topics: Adenine; Adult; Antiviral Agents; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Evolu

2010
Tenofovir for treatment of hepatitis B virus reactivation in patients with chronic GVHD.
    Bone marrow transplantation, 2011, Volume: 46, Issue:9

    Topics: Adenine; Adult; Chronic Disease; Female; Graft vs Host Disease; Hepatitis B virus; Hepatitis B, Chro

2011
Treatment of HBeAg-negative chronic hepatitis B patients with nucleos(t)ide analogues.
    Liver international : official journal of the International Association for the Study of the Liver, 2011, Volume: 31 Suppl 1

    Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic;

2011
Tenofovir salvage for nucleoside experienced patients: muddy waters?
    Gut, 2011, Volume: 60, Issue:2

    Topics: Adenine; Drug Resistance, Viral; Hepatitis B, Chronic; Humans; Nucleosides; Organophosphonates; Reve

2011
The level of HBV DNA at month 12 is an important predictor of virological breakthrough during adefovir monotherapy in chronic hepatitis B patients with lamivudine resistance.
    Digestive diseases and sciences, 2011, Volume: 56, Issue:4

    Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B virus; Hep

2011
Hyperlipidemic acute pancreatitis: a possible role of antiretroviral therapy with entecavir.
    Minerva anestesiologica, 2011, Volume: 77, Issue:10

    Topics: Abdominal Pain; Acute Disease; Adenine; Adult; Alcoholism; Antiretroviral Therapy, Highly Active; Cr

2011
Add-on adefovir is superior to a switch to entecavir as rescue therapy for Lamivudine-resistant chronic hepatitis B.
    Digestive diseases and sciences, 2011, Volume: 56, Issue:7

    Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Fem

2011
Circulating Tregs correlate with viral load reduction in chronic HBV-treated patients with tenofovir disoproxil fumarate.
    Journal of clinical immunology, 2011, Volume: 31, Issue:3

    Topics: Adenine; Adult; Antigens, CD; Case-Control Studies; CD8-Positive T-Lymphocytes; DNA, Viral; Female;

2011
[Efficacy and treatment strategy for drug resistances of nucleos(t)ide analogues for chronic hepatitis B].
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2011, Volume: 108, Issue:2

    Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Guanine; Hepatitis B, Chronic; Humans; Organophos

2011
[Efficacy of entecavir and adefovir combination therapy in patients with chronic hepatitis B refractory to lamivudine and adefovir combination therapy].
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2011, Volume: 108, Issue:2

    Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Guanine; Hepat

2011
HBV core region variability: effect of antiviral treatments on main epitopic regions.
    Antiviral therapy, 2011, Volume: 16, Issue:1

    Topics: Adenine; Adult; Amino Acid Sequence; Antigenic Variation; Antiviral Agents; B-Lymphocytes; DNA, Vira

2011
Comparison of multiplex restriction fragment mass polymorphism and sequencing analyses for detecting entecavir resistance in chronic hepatitis B.
    Antiviral therapy, 2011, Volume: 16, Issue:1

    Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Genotype; Guanine; Hepatitis B virus; Hepatitis B

2011
Defining virologic relapse in chronic hepatitis B.
    Digestive diseases and sciences, 2011, Volume: 56, Issue:8

    Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Female; Follow-Up Studies; Hepatitis B e Antigens; Hep

2011
Does the antiviral therapy of patients with chronic hepatitis exert nephrotoxic effects?
    Immunopharmacology and immunotoxicology, 2011, Volume: 33, Issue:4

    Topics: Adenine; Adult; Albuminuria; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis B, Chron

2011
Management of chronic hepatitis B patients: efficacy & limitation of nucleos(t)ide analogues.
    The Indian journal of medical research, 2011, Volume: 133

    Topics: Adenine; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Organo

2011
Tenofovir therapy in hepatitis B virus-positive solid-organ transplant recipients.
    Transplantation, 2011, Apr-27, Volume: 91, Issue:8

    Topics: Adenine; Adult; Aged; Antiviral Agents; Biomarkers; DNA, Viral; Drug Therapy, Combination; Enzymes;

2011
Medication nonadherence with long-term management of patients with hepatitis B e antigen-negative chronic hepatitis B.
    Digestive diseases and sciences, 2011, Volume: 56, Issue:8

    Topics: Adenine; Adult; Antiviral Agents; Asian People; Cohort Studies; Community Health Services; Drug Resi

2011
[Virological response to adefovir dipivoxil predicts the long-term development of resistance in previously untreated patients with HBeAg-negative chronic hepatitis B].
    Gastroenterologia y hepatologia, 2011, Volume: 34, Issue:2

    Topics: Adenine; Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Female; Hepatitis B e Antigens; Hepa

2011
Managing hepatitis B/HIV co-infected: adding entecavir to truvada (tenofovir disoproxil/emtricitabine) experienced patients.
    AIDS (London, England), 2011, May-15, Volume: 25, Issue:8

    Topics: Adenine; Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Deoxycytidine; DNA, Viral; D

2011
Proper antiviral therapy for hepatitis B virus-associated acute-on-chronic liver failure.
    Hepatology (Baltimore, Md.), 2011, Volume: 54, Issue:2

    Topics: Adenine; Antiviral Agents; End Stage Liver Disease; Guanine; Hepatitis B, Chronic; Humans; Liver Fai

2011
Adefovir-induced Stevens-Johnson syndrome and toxic epidermal necrolysis overlap syndrome.
    Singapore medical journal, 2011, Volume: 52, Issue:2

    Topics: Adenine; Antiviral Agents; Biopsy; Epidermis; Follow-Up Studies; Hepatitis B, Chronic; Humans; Immun

2011
Genotypic resistance profile of hepatitis B virus (HBV) in a large cohort of nucleos(t)ide analogue-experienced Chinese patients with chronic HBV infection.
    Journal of viral hepatitis, 2011, Volume: 18, Issue:4

    Topics: Adenine; Adult; Amino Acid Substitution; Antiviral Agents; China; DNA, Viral; Drug Resistance, Viral

2011
On-treatment monitoring of liver fibrosis with transient elastography in chronic hepatitis B patients.
    Antiviral therapy, 2011, Volume: 16, Issue:2

    Topics: Adenine; Adult; Aged; Alanine Transaminase; Antiviral Agents; Biopsy; Disease Progression; Elasticit

2011
Six-year follow-up of hepatitis B surface antigen concentrations in tenofovir disoproxil fumarate treated HIV-HBV-coinfected patients.
    Antiviral therapy, 2011, Volume: 16, Issue:2

    Topics: Adenine; Adult; Aged; Anti-HIV Agents; Follow-Up Studies; Hepatitis B Surface Antigens; Hepatitis B

2011
Outcome of patients suffering from a spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure and treated with antivirals.
    Hepatology (Baltimore, Md.), 2011, Sep-02, Volume: 54, Issue:3

    Topics: Adenine; Antiviral Agents; DNA, Viral; Female; Hepatitis B, Chronic; Humans; Liver Failure, Acute; M

2011
Long-term add-on therapy with adefovir in lamivudine-resistant kidney graft recipients with chronic hepatitis B.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2011, Volume: 26, Issue:6

    Topics: Adenine; Adult; Anti-HIV Agents; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy,

2011
Clinical course and predictive factors of virological response in long-term lamivudine plus adefovir dipivoxil combination therapy for lamivudine-resistant chronic hepatitis B patients.
    Journal of medical virology, 2011, Volume: 83, Issue:6

    Topics: Adenine; Adult; Aged; Amino Acid Substitution; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Com

2011
Development of immunity against hepatitis B virus after donor lymphocyte infusion in a peripheral blood stem cell transplantation recipient with chronic hepatitis B.
    Infection, 2011, Volume: 39, Issue:4

    Topics: Adenine; Adoptive Transfer; Antiviral Agents; DNA, Viral; Drug Combinations; Female; Hepatitis B Ant

2011
Two patterns of alanine aminotransferase increase to predict long-term viral response in chronic hepatitis B patients: virus- or host-induced?
    Antiviral therapy, 2011, Volume: 16, Issue:3

    Topics: Adenine; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Female; Guanine; Hepacivir

2011
Effect of antiviral therapy on the immunohistochemical expression of bcl-xL and bax protein in patients with HBeAg-negative chronic hepatitis B.
    Journal of medical virology, 2011, Volume: 83, Issue:7

    Topics: Adenine; Adult; Antiviral Agents; Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Biopsy; Fema

2011
Parallel decline of CD8+CD38+ lymphocytes and viremia in treated hepatitis B patients.
    World journal of gastroenterology, 2011, May-07, Volume: 17, Issue:17

    Topics: Adenine; ADP-ribosyl Cyclase 1; Adult; CD3 Complex; Female; Hepatitis B, Chronic; Humans; Male; Memb

2011
Hepatitis: PEG-IFN for the treatment of hepatitis D.
    Nature reviews. Gastroenterology & hepatology, 2011, Volume: 8, Issue:6

    Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Hepatitis B, Chronic; Hepatitis D; Humans; Int

2011
Predictors of relapse in chronic hepatitis B after discontinuation of anti-viral therapy.
    Alimentary pharmacology & therapeutics, 2011, Volume: 34, Issue:3

    Topics: Adenine; Adult; Antiviral Agents; Female; Guanine; Hepatitis B Antigens; Hepatitis B virus; Hepatiti

2011
Successful switch to tenofovir after suboptimal response to entecavir in an immunocompromised patient with chronic hepatitis B and without genotypic hepatitis B virus resistance.
    Infection, 2011, Volume: 39, Issue:4

    Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; Bone Marrow; DNA, Viral; Drug Therapy, Combi

2011
Changes of serum levels of keratin-18 fragments in hepatitis B e antigen-negative chronic hepatitis B patients under oral antiviral therapy.
    Antiviral therapy, 2011, Volume: 16, Issue:4

    Topics: Adenine; Administration, Oral; Antiviral Agents; Hepatitis B e Antigens; Hepatitis B, Chronic; Human

2011
Adefovir serum levels do not differ between responders and nonresponders.
    Journal of viral hepatitis, 2011, Volume: 18, Issue:7

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Antiviral Agents; Chromatography, High Pressure Liquid; Fem

2011
Large-scale survey of naturally occurring HBV polymerase mutations associated with anti-HBV drug resistance in untreated patients with chronic hepatitis B.
    Journal of viral hepatitis, 2011, Volume: 18, Issue:7

    Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Gene Products, pol; Gu

2011
Unsuccessful therapy with adefovir and entecavir-tenofovir in a patient with chronic hepatitis B infection with previous resistance to lamivudine: a fourteen-year evolution of hepatitis B virus mutations.
    BMC infectious diseases, 2011, Jun-22, Volume: 11

    Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Evolution, Molecular; Female; Guanine; Hepatitis

2011
Effect of HBV polymerase inhibitors on renal function in patients with chronic hepatitis B.
    Journal of hepatology, 2011, Volume: 55, Issue:6

    Topics: Adenine; Adolescent; Adult; Aged; Anti-HIV Agents; Antiviral Agents; Case-Control Studies; Female; G

2011
Nephrotoxicity, including acquired Fanconi's syndrome, caused by adefovir dipivoxil - is there a safe dose?
    Journal of clinical pharmacy and therapeutics, 2012, Volume: 37, Issue:2

    Topics: Adenine; Aged; Antiviral Agents; Dose-Response Relationship, Drug; Fanconi Syndrome; Female; Hepatit

2012
Serum HBsAg decline during long-term potent nucleos(t)ide analogue therapy for chronic hepatitis B and prediction of HBsAg loss.
    The Journal of infectious diseases, 2011, Aug-01, Volume: 204, Issue:3

    Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Female; Guanine; Hepatitis B e Antigens; Hepatitis B S

2011
Antiviral drug resistance testing in patients with chronic hepatitis B.
    Digestive diseases and sciences, 2012, Volume: 57, Issue:1

    Topics: Adenine; Adult; Antiviral Agents; Data Collection; Decision Making; DNA, Viral; Drug Resistance, Vir

2012
High frequency of CD4+ CXCR5+ TFH cells in patients with immune-active chronic hepatitis B.
    PloS one, 2011, Volume: 6, Issue:7

    Topics: Adaptive Immunity; Adenine; Adult; Alanine Transaminase; Animals; Antiviral Agents; Aspartate Aminot

2011
rtL180M mutation of hepatitis B virus is closely associated with frequent virological resistance to adefovir dipivoxil therapy.
    Journal of gastroenterology and hepatology, 2012, Volume: 27, Issue:2

    Topics: Adenine; Biomarkers; DNA Mutational Analysis; DNA, Viral; Drug Resistance, Viral; Genotype; Hepatiti

2012
Frequency and risk factors of renal impairment during long-term adefovir dipivoxil treatment in chronic hepatitis B patients.
    Journal of gastroenterology and hepatology, 2012, Volume: 27, Issue:2

    Topics: Adenine; Adolescent; Adult; Aged; Drug Administration Schedule; Drug Therapy, Combination; Female; G

2012
[Improvement of health-related quality of life in chronic hepatitis B patients treated with entecavir or adefovir].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2011, Volume: 19, Issue:4

    Topics: Adenine; Adult; Aged; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Male; Middle Aged; Or

2011
The efficacy of entecavir therapy in chronic hepatitis B patients with suboptimal response to adevofir.
    Alimentary pharmacology & therapeutics, 2011, Volume: 34, Issue:7

    Topics: Adenine; Adult; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Follow-

2011
The YMDD and rtA194T mutations result in decreased replication capacity in wild-type HBV as well as in HBV with precore and basal core promoter mutations.
    Antiviral chemistry & chemotherapy, 2011, Aug-23, Volume: 22, Issue:1

    Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Gene Products, pol; Genotype; Hep G2 Cells; Hepat

2011
High dose lamivudine in HBV-related cirrhotic patients with unsatisfactory response after adefovir add-on.
    Digestive diseases and sciences, 2012, Volume: 57, Issue:2

    Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Hepatitis B, Chronic; Huma

2012
Management options for lamivudine-resistant chronic hepatitis B patients with suboptimal virological suppression by adefovir.
    Alimentary pharmacology & therapeutics, 2011, Volume: 34, Issue:8

    Topics: Adenine; Adult; Antiviral Agents; Cohort Studies; DNA, Viral; Drug Resistance, Viral; Female; Follow

2011
Long-term efficacy of entecavir therapy in chronic hepatitis B patients with antiviral resistance to lamivudine and adefovir.
    Journal of viral hepatitis, 2011, Volume: 18, Issue:10

    Topics: Adenine; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Fe

2011
Long-term efficacy of entecavir in adefovir-refractory chronic hepatitis B patients with prior lamivudine resistance.
    Journal of viral hepatitis, 2011, Volume: 18, Issue:10

    Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Guanine; Hepatit

2011
Predictors of HBeAg status and hepatitis B viraemia in HIV-infected patients with chronic hepatitis B in the HAART era in Brazil.
    BMC infectious diseases, 2011, Sep-20, Volume: 11

    Topics: Adenine; Adult; Alanine Transaminase; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Brazil

2011
Optimization of adefovir therapy in chronic hepatitis B according to baseline predictors and on-treatment HBV DNA: a 5-year prospective study.
    Virology journal, 2011, Sep-21, Volume: 8

    Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; Biomarkers; China; Female; Follow-Up Studies

2011
Virological response to adefovir monotherapy and the risk of adefovir resistance.
    World journal of gastroenterology, 2011, Aug-14, Volume: 17, Issue:30

    Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B virus; Hep

2011
[A case with poly-bone pain, decrease of bone density and in crease of serum creatinine related to adefovir dipivoxil treatment in a chronic hepatitis B patient].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2011, Volume: 19, Issue:5

    Topics: Adenine; Adult; Bone Density; Creatinine; Hepatitis B, Chronic; Humans; Male; Organophosphonates; Pa

2011
Adefovir dipivoxil modulates cytokine expression in Th1/Th2 cells in patients with chronic hepatitis B.
    Molecular medicine reports, 2012, Volume: 5, Issue:1

    Topics: Adenine; Administration, Oral; Adult; Alanine Transaminase; Antiviral Agents; Aspartate Aminotransfe

2012
Adefovir-based combination therapy with entecavir or lamivudine for patients with entecavir-refractory chronic hepatitis B.
    Journal of medical virology, 2012, Volume: 84, Issue:1

    Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Gua

2012
Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: an international multicenter cohort study.
    Journal of hepatology, 2012, Volume: 56, Issue:3

    Topics: Adenine; Adult; Aged; Antiviral Agents; Cohort Studies; Drug Resistance, Viral; Drug Therapy, Combin

2012
[Lamivudine-resistant analysis and management for chronic hepatitis B patients with initial lamivudine therapy].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2011, Volume: 19, Issue:6

    Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Female; Follow-Up Studie

2011
[HBV resistance mutants before and after adefovir dipivoxil treatment and the relationship with HBV genotypes].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2011, Volume: 19, Issue:6

    Topics: Adenine; Adult; Drug Resistance, Viral; Female; Genes, Viral; Genotype; Hepatitis B virus; Hepatitis

2011
Canadian patients with chronic hepatitis B cannot access appropriate drug treatments: a call for change.
    Canadian journal of gastroenterology = Journal canadien de gastroenterologie, 2011, Volume: 25, Issue:10

    Topics: Adenine; Antiviral Agents; Canada; Drug Approval; Guanine; Health Services Accessibility; Hepatitis

2011
Cost effectiveness of tenofovir disoproxil fumarate for the treatment of chronic hepatitis B from a Canadian public payer perspective.
    PharmacoEconomics, 2011, Volume: 29, Issue:12

    Topics: Adenine; Adolescent; Adult; Antiviral Agents; Canada; Cost-Benefit Analysis; Female; Health Care Cos

2011
Molecular characterization of a novel entecavir mutation pattern isolated from a multi-drug refractory patient with chronic hepatitis B infection.
    Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2012, Volume: 53, Issue:2

    Topics: Adenine; Adult; Antiviral Agents; Cell Line, Tumor; Drug Resistance, Multiple, Viral; Fatal Outcome;

2012
A prospective clinical study in hepatitis B e antigen-negative chronic hepatitis B patients with stringent cessation criteria for adefovir.
    Archives of virology, 2012, Volume: 157, Issue:2

    Topics: Adenine; Adult; Antiviral Agents; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B Sur

2012
[New drugs of treatment of patients with chronic hepatitis B].
    Nihon rinsho. Japanese journal of clinical medicine, 2011, Volume: 69 Suppl 4

    Topics: Adenine; Antiviral Agents; Arabinofuranosyluracil; Deoxycytidine; Emtricitabine; Hepatitis B, Chroni

2011
Tenofovir plus entecavir as rescue therapy for multidrug-resistant chronic hepatitis B.
    Liver international : official journal of the International Association for the Study of the Liver, 2012, Volume: 32, Issue:1

    Topics: Adenine; Adult; Antiviral Agents; Drug Resistance, Multiple, Viral; Drug Substitution; Drug Therapy,

2012
Potent hepatitis B surface antigen response to treatment of hepatitis-B-e-antigen-positive chronic hepatitis B with α-interferon plus a nucleos(t)ide analog.
    Journal of gastroenterology and hepatology, 2012, Volume: 27, Issue:3

    Topics: Adenine; Adolescent; Adult; Antiviral Agents; Child; Child, Preschool; Drug Therapy, Combination; Fe

2012
[Adefovir dipivoxil-induced Fanconi syndrome and hypophosphatemic osteomalacia associated with muscular weakness in a patient with chronic hepatitis B].
    Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2011, Volume: 31, Issue:11

    Topics: Adenine; Antiviral Agents; Bone Diseases, Metabolic; Fanconi Syndrome; Hepatitis B, Chronic; Humans;

2011
Efficacy of entecavir and adefovir combination therapy for patients with lamivudine- and entecavir-resistant chronic hepatitis B.
    Digestive diseases and sciences, 2012, Volume: 57, Issue:5

    Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Monitoring; Drug Resistance, Viral; Drug Th

2012
Prevalence, virology and antiviral drugs susceptibility of hepatitis B virus rtN238H polymerase mutation from 1865 Chinese patients with chronic hepatitis B.
    Antiviral research, 2012, Volume: 93, Issue:1

    Topics: Adenine; Adolescent; Adult; Aged; Amino Acid Substitution; Antiviral Agents; Asian People; Child; Ch

2012
De novo combination therapy with lamivudine and adefovir dipivoxil in chronic hepatitis B patients.
    World journal of gastroenterology, 2011, Nov-21, Volume: 17, Issue:43

    Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Hepatitis B e Antigens; Hep

2011
Viral response at 6 months is associated with treatment outcome of adefovir add-on therapy for lamivudine-resistance.
    Journal of gastroenterology and hepatology, 2012, Volume: 27, Issue:9

    Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug The

2012
Peripheral blood lymphocyte dynamics and viral kinetics in patients with chronic active hepatitis B virus infection treated by tenofovir.
    Hepato-gastroenterology, 2012, Volume: 59, Issue:115

    Topics: Adenine; ADP-ribosyl Cyclase 1; Adult; Antiviral Agents; Biomarkers; CD28 Antigens; CD8-Positive T-L

2012
Antiviral efficacy of combination therapy with entecavir and adefovir for entecavir/lamivudine-resistant hepatitis B virus with or without adefovir resistance.
    Journal of medical virology, 2012, Volume: 84, Issue:3

    Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Resistance, Multiple, Viral; Drug Therapy,

2012
Transarterial chemoembolization for hepatitis B virus-associated hepatocellular carcinoma: improved survival after concomitant treatment with nucleoside analogues.
    Journal of vascular and interventional radiology : JVIR, 2012, Volume: 23, Issue:3

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Antiviral Agents; Carcinoma, Hepatocellular; Chemoembolizat

2012
Entecavir plus adefovir combination treatment for chronic hepatitis B patients after failure of nucleoside/nucleotide analogues.
    Antiviral therapy, 2012, Volume: 17, Issue:1

    Topics: Adenine; Adult; Antiviral Agents; Cohort Studies; DNA, Viral; Drug Combinations; Drug Resistance, Vi

2012
Quasispecies analysis and in vitro susceptibility of HBV strains isolated from HIV-HBV-coinfected patients with delayed response to tenofovir.
    Antiviral therapy, 2012, Volume: 17, Issue:1

    Topics: Adenine; Adult; Antiviral Agents; Cloning, Molecular; Coinfection; DNA, Viral; Drug Resistance, Vira

2012
An improved reverse dot hybridization for simple and rapid detection of adefovir dipivoxil-resistant hepatitis B virus.
    Genetics and molecular research : GMR, 2012, Jan-09, Volume: 11, Issue:1

    Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Genotype; Hepatitis B virus; Hepatiti

2012
HBV DNA level at 24 weeks is the best predictor of virological response to adefovir add-on therapy in patients with lamivudine resistance.
    Antiviral therapy, 2012, Volume: 17, Issue:2

    Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B e Antigens

2012
High-resolution melting and real-time PCR for quantification and detection of drug-resistant HBV mutants in a single amplicon.
    Antiviral therapy, 2012, Volume: 17, Issue:2

    Topics: Adenine; Antiviral Agents; DNA, Complementary; DNA, Viral; Drug Resistance, Viral; Guanine; Hepatiti

2012
Serum IL-33 levels are associated with liver damage in patients with chronic hepatitis B.
    Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 2012, Volume: 32, Issue:6

    Topics: Adenine; Adult; Enzyme-Linked Immunosorbent Assay; Female; Hep G2 Cells; Hepatitis B Surface Antigen

2012
Virologic response is not durable after adefovir discontinuation in lamivudine-resistant chronic hepatitis B patients.
    The Korean journal of hepatology, 2011, Volume: 17, Issue:4

    Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Follow-Up Studies; Hep

2011
Response to tenofovir monotherapy in chronic hepatitis B patients with prior suboptimal response to entecavir.
    Journal of viral hepatitis, 2012, Volume: 19, Issue:3

    Topics: Adenine; Adult; Antiviral Agents; Cohort Studies; Female; Follow-Up Studies; Guanine; Hepatitis B e

2012
Response to tenofovir monotherapy in chronic hepatitis B patients with prior suboptimal response to entecavir.
    Journal of viral hepatitis, 2012, Volume: 19, Issue:3

    Topics: Adenine; Adult; Antiviral Agents; Cohort Studies; Female; Follow-Up Studies; Guanine; Hepatitis B e

2012
Response to tenofovir monotherapy in chronic hepatitis B patients with prior suboptimal response to entecavir.
    Journal of viral hepatitis, 2012, Volume: 19, Issue:3

    Topics: Adenine; Adult; Antiviral Agents; Cohort Studies; Female; Follow-Up Studies; Guanine; Hepatitis B e

2012
Response to tenofovir monotherapy in chronic hepatitis B patients with prior suboptimal response to entecavir.
    Journal of viral hepatitis, 2012, Volume: 19, Issue:3

    Topics: Adenine; Adult; Antiviral Agents; Cohort Studies; Female; Follow-Up Studies; Guanine; Hepatitis B e

2012
Kinetics of hepatitis B surface and envelope antigen and prediction of treatment response to tenofovir in antiretroviral-experienced HIV-hepatitis B virus-infected patients.
    AIDS (London, England), 2012, May-15, Volume: 26, Issue:8

    Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; Female; Follow-Up

2012
Safety of long-term nucleos(t)ide treatment in chronic hepatitis B.
    Expert opinion on drug safety, 2012, Volume: 11, Issue:3

    Topics: Adenine; Antiviral Agents; Drug Administration Schedule; Evidence-Based Medicine; Guanine; Hepatitis

2012
Lamivudine plus adefovir vs. entecavir in HBeAg-positive hepatitis B with sequential treatment failure of lamivudine and adefovir.
    Liver international : official journal of the International Association for the Study of the Liver, 2012, Volume: 32, Issue:7

    Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Femal

2012
[Evaluation of the safety of pregnancy initiated by chronic hepatitis B fathers while taking adefovir].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2012, Volume: 20, Issue:1

    Topics: Adenine; Adult; Female; Hepatitis B, Chronic; Humans; Infant, Newborn; Male; Organophosphonates; Pat

2012
Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B.
    Alimentary pharmacology & therapeutics, 2012, Volume: 35, Issue:11

    Topics: Adenine; Adult; Aged; Antiviral Agents; Biomarkers; Creatinine; Female; Glomerular Filtration Rate;

2012
Similar risk of renal events among patients treated with tenofovir or entecavir for chronic hepatitis B.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2012, Volume: 10, Issue:8

    Topics: Adenine; Adult; Aged; Antiviral Agents; Cohort Studies; Creatinine; Female; Glomerular Filtration Ra

2012
Antiviral therapy against chronic hepatitis B in Brazil: high rates of lamivudine resistance mutations and correlation with HBV genotypes.
    Memorias do Instituto Oswaldo Cruz, 2012, Volume: 107, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Cross-Sectional Studies; DNA, Viral; Drug Resist

2012
High efficacy of adefovir and entecavir combination therapy in patients with nucleoside-refractory hepatitis B.
    The Korean journal of hepatology, 2012, Volume: 18, Issue:1

    Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Resistance, Multiple, Viral

2012
Commentary: combination therapy with two nucleos(t)ide analogues in chronic hepatitis B.
    Alimentary pharmacology & therapeutics, 2012, Volume: 35, Issue:12

    Topics: Adenine; Antiviral Agents; Drug Resistance; Drug Therapy, Combination; Guanine; Hepatitis B, Chronic

2012
Factors influencing inadequate or suboptimal response to adefovir with or without genotypic resistance.
    Journal of medical virology, 2012, Volume: 84, Issue:7

    Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Genotype; Hepatitis B

2012
Hepatitis B virus related membranous glomerulonephritis and proteinuria treated with lamivudine and tenofovir.
    BMJ case reports, 2011, Aug-31, Volume: 2011

    Topics: Adenine; Glomerulonephritis, Membranous; Hepatitis B, Chronic; Humans; Lamivudine; Male; Organophosp

2011
[Influence of adefovir dipivoxil or telbivudine monotherapy on renal function of patients with chronic hepatitis B].
    Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2012, Volume: 32, Issue:6

    Topics: Adenine; Adolescent; Adult; Creatinine; Female; Glomerular Filtration Rate; Hepatitis B, Chronic; Hu

2012
Another drug in the armamentarium to combat hepatitis B virus in adolescents.
    Hepatology (Baltimore, Md.), 2012, Volume: 56, Issue:6

    Topics: Adenine; Antiviral Agents; Female; Hepatitis B, Chronic; Humans; Male; Organophosphonates; Tenofovir

2012
Current practice of chronic hepatitis B treatment in Southern Italy.
    European journal of internal medicine, 2012, Volume: 23, Issue:5

    Topics: Adenine; Adult; Age Factors; Aged; Aged, 80 and over; Antiviral Agents; Female; Guanine; Hepatitis B

2012
Long-term hepatitis B virus surface antigen decay in HIV-1/hepatitis B virus-coinfected adults initiating a tenofovir-containing regimen.
    Journal of clinical microbiology, 2012, Volume: 50, Issue:9

    Topics: Adenine; Adult; Anti-HIV Agents; Coinfection; Hepatitis B Surface Antigens; Hepatitis B, Chronic; HI

2012
Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues.
    Gastroenterology, 2012, Volume: 143, Issue:4

    Topics: Adenine; Antiviral Agents; Cells, Cultured; DNA, Viral; Genotype; Guanine; Hepatitis B e Antigens; H

2012
Comparison of the efficacy of tenofovir and entecavir for the treatment of nucleos(t)ide-naive patients with chronic hepatitis B.
    The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, 2012, Volume: 23, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Female; Guanin

2012
Case report: management and HBV sequencing in a patient co-infected with HBV and HIV failing tenofovir.
    Journal of medical virology, 2012, Volume: 84, Issue:9

    Topics: Adenine; Anti-HIV Agents; Coinfection; Drug Resistance, Viral; Gene Products, pol; Hepatitis B virus

2012
Acute liver failure resulting from discontinuation of nucleoside analogues in chronic hepatitis B patients: a report of two cases.
    Scandinavian journal of infectious diseases, 2013, Volume: 45, Issue:2

    Topics: Adenine; Adult; Antiviral Agents; Guanine; Hepatitis B, Chronic; Histocytochemistry; Humans; Lamivud

2013
Pathological femoral fractures due to osteomalacia associated with adefovir dipivoxil treatment for hepatitis B: a case report.
    Diagnostic pathology, 2012, Aug-20, Volume: 7

    Topics: Adenine; Antiviral Agents; Arthroplasty, Replacement, Hip; Fanconi Syndrome; Femoral Neck Fractures;

2012
A case of adefovir-induced membranous nephropathy related to hepatitis B caused by lamivudine-resistant virus after liver transplant due to Byler's disease.
    Clinical and experimental nephrology, 2012, Volume: 16, Issue:5

    Topics: Adenine; Adolescent; Adult; Child, Preschool; Cholestasis, Intrahepatic; Drug Resistance, Viral; Fem

2012
Hepatitis B e antigen predicts delayed reduction of HBV DNA without viral breakthrough with adefovir dipivoxil and lamivudine: a 5-year study of patients with hepatitis B with lamivudine resistance.
    Journal of medical virology, 2012, Volume: 84, Issue:10

    Topics: Adenine; Adult; Aged; Antiviral Agents; Cohort Studies; DNA, Viral; Female; Hepatitis B e Antigens;

2012
Safety and efficacy of adefovir therapy for lamivudine-resistant hepatitis B virus infection in renal transplant recipients.
    Journal of the Formosan Medical Association = Taiwan yi zhi, 2012, Volume: 111, Issue:8

    Topics: Adenine; Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; F

2012
Outcome of lamivudine-resistant chronic hepatitis B after up to 5 years of combination therapy with adefovir.
    Antiviral therapy, 2012, Volume: 17, Issue:7

    Topics: Adenine; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Dr

2012
Comparison of rescue strategies in lamivudine-resistant patients with chronic hepatitis B.
    Antiviral research, 2012, Volume: 96, Issue:2

    Topics: Adenine; Adult; Antiviral Agents; China; Drug Resistance, Viral; Drug Therapy, Combination; Female;

2012
Tenofovir monotherapy and tenofovir plus entecavir combination as rescue therapy for entecavir partial responders.
    Digestive diseases and sciences, 2012, Volume: 57, Issue:11

    Topics: Adenine; Adult; Analysis of Variance; Antiviral Agents; Chi-Square Distribution; Drug Therapy, Combi

2012
Genotype-specific mutations in the polymerase gene of hepatitis B virus potentially associated with resistance to oral antiviral therapy.
    Antiviral research, 2012, Volume: 96, Issue:3

    Topics: Adenine; Administration, Oral; Amino Acid Substitution; Antiviral Agents; DNA, Viral; Drug Resistanc

2012
Long-term efficacy and safety of lamivudine, entecavir, and tenofovir for treatment of hepatitis B virus-related cirrhosis.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2013, Volume: 11, Issue:1

    Topics: Adenine; Adult; Aged; Alanine Transaminase; Antiviral Agents; Blood Chemical Analysis; Drug Therapy,

2013
The 2012 revised Dutch national guidelines for the treatment of chronic hepatitis B virus infection.
    The Netherlands journal of medicine, 2012, Volume: 70, Issue:8

    Topics: Adenine; Antiviral Agents; Drug Approval; Drug Resistance, Viral; Female; Guanine; Hepatitis B, Chro

2012
Letter: renal tubular dysfunction during nucleotide analogue therapy in chronic hepatitis B.
    Alimentary pharmacology & therapeutics, 2012, Volume: 36, Issue:10

    Topics: Adenine; Antiviral Agents; Female; Glomerular Filtration Rate; Hepatitis B, Chronic; Humans; Male; O

2012
Multidrug-resistant hepatitis B virus resulting from sequential monotherapy with lamivudine, adefovir, and entecavir: clonal evolution during lamivudine plus adefovir therapy.
    Journal of medical virology, 2013, Volume: 85, Issue:1

    Topics: Adenine; Adult; Antiviral Agents; Clonal Evolution; DNA, Viral; Drug Resistance, Multiple, Viral; Gu

2013
Blocking the natural killer cell inhibitory receptor NKG2A increases activity of human natural killer cells and clears hepatitis B virus infection in mice.
    Gastroenterology, 2013, Volume: 144, Issue:2

    Topics: Adenine; Adult; Animals; Antiviral Agents; Disease Models, Animal; DNA, Viral; Female; Flow Cytometr

2013
Effect of nucleos(t)ide analogue therapy on hepatocarcinogenesis in chronic hepatitis B patients: a propensity score analysis.
    Journal of hepatology, 2013, Volume: 58, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Antiviral Agents; Child; Ch

2013
[Clinical analysis of hepatitis B virus mutations related to adefovir dipivoxil among patients with chronic hepatitis B virus infection in eastern Zhejiang province].
    Zhonghua yi xue za zhi, 2012, Jul-17, Volume: 92, Issue:27

    Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; China; DNA, Viral; Drug Resistance, Viral; Femal

2012
The efficacy of adefovir plus entecavir combination therapy in patients with chronic hepatitis B refractory to both lamivudine and adefovir.
    Digestive diseases and sciences, 2013, Volume: 58, Issue:5

    Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Guanine; Hepatitis

2013
The short-term efficacy of entecavir in lamivudine-resistant chronic hepatitis B: influence of sequential adefovir-refractoriness.
    Hepato-gastroenterology, 2013, Volume: 60, Issue:124

    Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Guan

2013
Treatment of lamivudine-resistant chronic hepatitis B infection: a multicenter retrospective study.
    Scandinavian journal of gastroenterology, 2013, Volume: 48, Issue:2

    Topics: Adenine; Adult; Antiviral Agents; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy

2013
Clonal evolution of hepatitis B virus polymerase gene mutations during lamivudine-adefovir combination treatment.
    World journal of gastroenterology, 2012, Nov-28, Volume: 18, Issue:44

    Topics: Adenine; Adult; Antiviral Agents; Clonal Evolution; Drug Combinations; Drug Resistance, Viral; Drug

2012
Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy: finite treatment duration unlikely.
    Journal of hepatology, 2013, Volume: 58, Issue:4

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Femal

2013
Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy: finite treatment duration unlikely.
    Journal of hepatology, 2013, Volume: 58, Issue:4

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Femal

2013
Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy: finite treatment duration unlikely.
    Journal of hepatology, 2013, Volume: 58, Issue:4

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Femal

2013
Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy: finite treatment duration unlikely.
    Journal of hepatology, 2013, Volume: 58, Issue:4

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Femal

2013
[Outcomes of unexpected pregnancy during anti-hepatitis B virus therapy with adefovir dipivoxil: a report on safety and full-term infants].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2012, Volume: 20, Issue:6

    Topics: Adenine; Adult; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infant; Infant, Newborn; Ma

2012
Scar undone: long-term therapy of hepatitis B.
    Lancet (London, England), 2013, Feb-09, Volume: 381, Issue:9865

    Topics: Adenine; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Organophosphonates; Reverse

2013
Early viral suppression predicts good postoperative survivals in patients with hepatocellular carcinoma with a high baseline HBV-DNA load.
    Annals of surgical oncology, 2013, Volume: 20, Issue:5

    Topics: Adenine; Adult; Antiviral Agents; Carcinoma, Hepatocellular; Disease-Free Survival; DNA, Viral; Fema

2013
Management of chronic hepatitis B: Canadian Association for the Study of the Liver consensus guidelines.
    Canadian journal of gastroenterology = Journal canadien de gastroenterologie, 2012, Volume: 26, Issue:12

    Topics: Adenine; Allied Health Personnel; Antibodies, Viral; Antiviral Agents; Canada; Coinfection; Drug Res

2012
Osteomalacia due to Fanconi's syndrome and renal failure caused by long-term low-dose adefovir dipivoxil.
    Clinical and experimental nephrology, 2013, Volume: 17, Issue:1

    Topics: Adenine; Antiviral Agents; Fanconi Syndrome; Hepatitis B, Chronic; Humans; Male; Middle Aged; Organo

2013
Experience of anti-viral therapy in hepatitis B-associated membranous nephropathy, including Lamivudine-resistant strains.
    The Korean journal of internal medicine, 2012, Volume: 27, Issue:4

    Topics: Adenine; Adult; Antiviral Agents; Arabinofuranosyluracil; Drug Resistance, Viral; Female; Glomerulon

2012
The effect of HLA-DQB1 alleles on virologic breakthroughs during chronic hepatitis B treatment with genetically low barrier drugs.
    Clinics and research in hepatology and gastroenterology, 2013, Volume: 37, Issue:4

    Topics: Adenine; Adult; Alleles; Antiviral Agents; Drug Resistance, Viral; Female; Hepatitis B virus; Hepati

2013
Should chronic hepatitis B be treated as early as possible?
    International journal of technology assessment in health care, 2013, Volume: 29, Issue:1

    Topics: Adenine; Adult; Antiviral Agents; Belgium; Cost-Benefit Analysis; Early Diagnosis; Guanine; Health C

2013
Hepatitis B virus wild-type and rtN236T populations show similar early HBV DNA decline in adefovir refractory patients on a tenofovir-based regimen.
    Journal of viral hepatitis, 2013, Volume: 20, Issue:2

    Topics: Adenine; Adult; Amino Acid Substitution; Antiviral Agents; Deoxycytidine; DNA, Viral; Double-Blind M

2013
[Antiviral therapy for patients with chronic hepatitis B with multi-drug resistance to nucleoside analogues].
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2013, Volume: 110, Issue:1

    Topics: Adenine; Aged; Aged, 80 and over; Antiviral Agents; Drug Resistance, Multiple, Viral; Female; Guanin

2013
Kinetics and prediction of HBsAg loss during therapy with analogues in patients affected by chronic hepatitis B HBeAg negative and genotype D.
    Liver international : official journal of the International Association for the Study of the Liver, 2013, Volume: 33, Issue:4

    Topics: Adenine; Aged; Antiviral Agents; Biomarkers; Chi-Square Distribution; DNA, Viral; Female; Genotype;

2013
Patterns and causes of suboptimal response to tenofovir-based therapy in individuals coinfected with HIV and hepatitis B virus.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2013, Volume: 56, Issue:9

    Topics: Adenine; Adult; Aged; Antiretroviral Therapy, Highly Active; Antiviral Agents; Australia; Coinfectio

2013
Use of ALLGIO probe assays for detection of HBV resistance to adefovir in patients with chronic hepatitis B, Kerman, Iran.
    Asian Pacific journal of cancer prevention : APJCP, 2012, Volume: 13, Issue:11

    Topics: Adenine; Adult; Aged; Antiviral Agents; Biological Assay; DNA, Viral; Drug Resistance, Viral; Female

2012
Treatment strategies using adefovir dipivoxil for individuals with lamivudine-resistant chronic hepatitis B.
    World journal of gastroenterology, 2012, Dec-21, Volume: 18, Issue:47

    Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Human

2012
Outcome of various treatments for posttransplant hepatitis B virus recurrence.
    World journal of surgery, 2013, Volume: 37, Issue:4

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Biomarkers; Drug Administrati

2013
Quantification of hepatitis B e antigen between Elecsys HBeAg and Architect HBeAg assays among patients infected with hepatitis B virus.
    Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2013, Volume: 56, Issue:4

    Topics: Adenine; Adult; CD4 Lymphocyte Count; Cohort Studies; Coinfection; Female; Genotype; Hepatitis B e A

2013
Efficacy of tenofovir in patients with Lamivudine failure is not different from that in nucleoside/nucleotide analogue-naive patients with chronic hepatitis B.
    Antimicrobial agents and chemotherapy, 2013, Volume: 57, Issue:4

    Topics: Adenine; Adult; Anti-HIV Agents; Female; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged

2013
FDA notifications. New treatment approved for chronic hepatitis B.
    AIDS alert, 2002, Volume: 17, Issue:11

    Topics: Adenine; Adult; Antiviral Agents; Drug Approval; Hepatitis B, Chronic; Humans; Kidney; Organophospho

2002
From the Food and Drug Administration.
    JAMA, 2002, Nov-06, Volume: 288, Issue:17

    Topics: Adenine; Anastrozole; Antineoplastic Agents, Hormonal; Antiviral Agents; Breast Neoplasms; Chemother

2002
Adefovir (Hepsera) for chronic hepatitis B infection.
    The Medical letter on drugs and therapeutics, 2002, Dec-09, Volume: 44, Issue:1145

    Topics: Adenine; Administration, Oral; Controlled Clinical Trials as Topic; Creatinine; Drug Resistance, Vir

2002
Precore and core promoter mutations of hepatitis B virus and hepatitis B e antigen-negative chronic hepatitis B in Korea.
    Journal of hepatology, 2003, Volume: 38, Issue:1

    Topics: Adenine; Adult; Codon; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, C

2003
Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro.
    Hepatology (Baltimore, Md.), 2003, Volume: 37, Issue:1

    Topics: Adenine; Baculoviridae; Carcinoma, Hepatocellular; Drug Resistance, Viral; Hepatitis B Core Antigens

2003
Comparative effects of adefovir and selected nucleoside inhibitors of hepatitis B virus DNA polymerase on mitochondrial DNA in liver and skeletal muscle cells.
    Journal of viral hepatitis, 2003, Volume: 10, Issue:1

    Topics: Adenine; Antiviral Agents; DNA, Mitochondrial; Hepatitis B virus; Hepatitis B, Chronic; Hepatoblasto

2003
Suppressing hepatitis B without resistance--so far, so good.
    The New England journal of medicine, 2003, Feb-27, Volume: 348, Issue:9

    Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Hepatitis B e Antigens; Hepatitis B v

2003
Unsuccessful rescue therapy with adefovir dipivoxil for lamivudine resistant HBV in a patient with liver failure.
    Gut, 2003, Volume: 52, Issue:4

    Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Fatal Outcome; Female; Hepatitis B, Chronic; Huma

2003
Rapid hepatitis B virus-DNA decay in co-infected HIV-hepatitis B virus 'e-minus' patients with YMDD mutations after 4 weeks of tenofovir therapy.
    AIDS (London, England), 2003, Mar-28, Volume: 17, Issue:5

    Topics: Adenine; Adult; Anti-HIV Agents; DNA, Viral; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B,

2003
Adefovir dipivoxil for hepatitis B e antigen-positive chronic hepatitis B.
    The New England journal of medicine, 2003, Jun-12, Volume: 348, Issue:24

    Topics: Adenine; Antiviral Agents; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferon-alpha; L

2003
[The first nucleotide analog permitted. New hepatitis B therapy helps the problem patients, too].
    MMW Fortschritte der Medizin, 2003, Jun-12, Volume: 145, Issue:24

    Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Drug Resistance; Hepatitis B, Chronic; HIV Infections; H

2003
Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase.
    Gastroenterology, 2003, Volume: 125, Issue:2

    Topics: Adenine; Alanine Transaminase; Antiviral Agents; DNA-Directed DNA Polymerase; DNA, Viral; Drug Resis

2003
[New option for successful therapy of chronic hepatitis B].
    Deutsche medizinische Wochenschrift (1946), 2003, Jul-11, Volume: 128, Issue:28-29

    Topics: Adenine; Antiviral Agents; Clinical Trials as Topic; Drug Approval; Germany; Hepatitis B, Chronic; H

2003
Use of adefovir in the treatment of the chronic hepatitis B virus infection with resistance to lamivudine.
    Transplantation proceedings, 2003, Volume: 35, Issue:5

    Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B virus; Hepatitis

2003
Live-donor liver transplantation for acute-on-chronic hepatitis B liver failure.
    Transplantation, 2003, Oct-27, Volume: 76, Issue:8

    Topics: Acute Disease; Adenine; Adult; Antiviral Agents; DNA, Viral; Female; Follow-Up Studies; Graft Surviv

2003
Management of chronic hepatitis B in an HIV-positive patient with 3TC-resistant hepatitis B virus.
    AIDS patient care and STDs, 2003, Volume: 17, Issue:9

    Topics: Adenine; Adult; Anti-HIV Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B viru

2003
Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient.
    Journal of hepatology, 2003, Volume: 39, Issue:6

    Topics: Adenine; Amino Acid Sequence; Combined Modality Therapy; Drug Resistance, Viral; Hepatitis B virus;

2003
Treatment of pre- and post-liver transplantation HBV infection: Should we aim at combination therapy?
    Hepatology (Baltimore, Md.), 2003, Volume: 38, Issue:6

    Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B, Chronic;

2003
Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients.
    Hepatology (Baltimore, Md.), 2003, Volume: 38, Issue:6

    Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Child; Drug Resistance, Viral; Female; Genotype;

2003
Resistance of HBV to adefovir dipivoxil: a case for combination antiviral therapy?
    Hepatology (Baltimore, Md.), 2003, Volume: 38, Issue:6

    Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Gene Produ

2003
In vitro antiviral susceptibility of full-length clinical hepatitis B virus isolates cloned with a novel expression vector.
    Antiviral research, 2004, Volume: 61, Issue:1

    Topics: Adenine; Antiviral Agents; Cell Line; Cloning, Molecular; DNA, Viral; Drug Resistance, Viral; Geneti

2004
Antivirals for the treatment of chronic hepatitis B: current and future options.
    Intervirology, 2003, Volume: 46, Issue:6

    Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Hepatitis B virus; Hepatitis B, Chronic; Human

2003
Treatment of chronic hepatitis B in the human immunodeficiency virus-infected patient: present and future.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2003, Dec-15, Volume: 37, Issue:12

    Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Forecasting; Hepatitis B, Chronic; HIV; HIV Infections;

2003
[Adefovir].
    Revue de l'infirmiere, 2003, Issue:95

    Topics: Adenine; Antiviral Agents; Drug Monitoring; Drug Prescriptions; Hepatitis B, Chronic; Humans; Organo

2003
[Update in the treatment of chronic hepatitis B].
    Gastroenterologia y hepatologia, 2004, Volume: 27, Issue:2

    Topics: Adenine; Antiviral Agents; Drug Evaluation; Hepatitis B, Chronic; Humans; Interferons; Lamivudine; O

2004
The renal tolerance of low-dose adefovir dipivoxil by lamivudine-resistant individuals co-infected with hepatitis B and HIV.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2004, Volume: 19, Issue:2

    Topics: Adenine; Administration, Oral; Adult; Cohort Studies; Dose-Response Relationship, Drug; Drug Adminis

2004
Efficacy of combined lamivudine and adefovir dipivoxil treatment for severe HBV graft reinfection after living donor liver transplantation.
    Clinical transplantation, 2003, Volume: 17, Issue:6

    Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Hepatitis B, Chronic; Humans; Immunization, Pa

2003
[New antiviral agent. Hepatitis B therapy with slight resistance risk].
    MMW Fortschritte der Medizin, 2003, Dec-18, Volume: 145, Issue:51-52

    Topics: Adenine; Antiviral Agents; Clinical Trials as Topic; Drug Resistance, Viral; Hepatitis B e Antigens;

2003
Selective inhibition of anthrax edema factor by adefovir, a drug for chronic hepatitis B virus infection.
    Proceedings of the National Academy of Sciences of the United States of America, 2004, Mar-02, Volume: 101, Issue:9

    Topics: Adenine; Adenylyl Cyclase Inhibitors; Adenylyl Cyclases; Animals; Antigens, Bacterial; Antiviral Age

2004
Severe exacerbation of chronic hepatitis B after emergence of lamivudine resistance in a cirrhotic patient: immediate switch to adefovir dipivoxil appears to be indicated.
    Zeitschrift fur Gastroenterologie, 2004, Volume: 42, Issue:1

    Topics: Adenine; Adult; Anti-HIV Agents; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Genotype; Hep

2004
Tenofovir disoproxil fumarate for the treatment of lamivudine-resistant hepatitis B.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2004, Volume: 2, Issue:3

    Topics: Adenine; Administration, Oral; Adult; Aged; Dose-Response Relationship, Drug; Drug Administration Sc

2004
Adefovir dipivoxil: new preparation. A third-line option in chronic hepatitis B.
    Prescrire international, 2004, Volume: 13, Issue:69

    Topics: Adenine; Antiviral Agents; Clinical Trials as Topic; Cohort Studies; Drug Approval; Drug Resistance,

2004
[Adefovir dipivoxil--a further step in the control of chronic viral hepatitis B. There is still a long way to go].
    Vnitrni lekarstvi, 2004, Volume: 50, Issue:3

    Topics: Adenine; Antiviral Agents; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Organophospho

2004
[A case of liver cirrhosis B resistant to lamivudine showing the clinical effect of adefovir dipivoxil].
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2004, Volume: 101, Issue:5

    Topics: Adenine; Amino Acid Motifs; Antiviral Agents; Drug Resistance, Viral; Female; Hepatitis B virus; Hep

2004
Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy.
    Gastroenterology, 2004, Volume: 126, Issue:7

    Topics: Adenine; Antiviral Agents; Biopsy; DNA, Circular; DNA, Viral; Hepatitis B Core Antigens; Hepatitis B

2004
Practical management of chronic hepatitis B infection.
    Seminars in liver disease, 2004, Volume: 24 Suppl 1

    Topics: Adenine; Alanine Transaminase; Antiviral Agents; Hepatitis B Surface Antigens; Hepatitis B, Chronic;

2004
Haemolytic anaemia after nucleotide antiretroviral treatment discontinuation in a chronic hepatitis B-virus co-infected AIDS patient.
    AIDS (London, England), 2004, Jul-23, Volume: 18, Issue:11

    Topics: Adenine; Adult; Anemia, Hemolytic; Antiretroviral Therapy, Highly Active; Hepatitis B, Chronic; HIV

2004
Prevention of hepatitis B virus reinfection after orthotopic liver transplantation.
    Hepatobiliary & pancreatic diseases international : HBPD INT, 2004, Volume: 3, Issue:3

    Topics: Adenine; Adult; Combined Modality Therapy; Female; Hepatitis B Antibodies; Hepatitis B Core Antigens

2004
Lichenoid drug eruption to tenofovir in an HIV/hepatitis B virus co-infected patient.
    AIDS (London, England), 2004, Sep-03, Volume: 18, Issue:13

    Topics: Adenine; Anti-HIV Agents; Drug Eruptions; Hepatitis B, Chronic; HIV Infections; Humans; Lichenoid Er

2004
[Active prevention and treatment of superinfection with HBV, HCV and HIV].
    Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine], 2004, Volume: 38, Issue:5

    Topics: Adenine; Antiretroviral Therapy, Highly Active; Hepatitis B, Chronic; Hepatitis C, Chronic; HIV Infe

2004
[An attempt to approach an optional therapeutic regimen for chronic hepatitis B].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2004, Volume: 12, Issue:10

    Topics: Adenine; Animals; Antiviral Agents; Combined Modality Therapy; Genetic Therapy; Hepatitis B Antigens

2004
Tenofovir therapy for lamivudine resistance following liver transplantation.
    The Annals of pharmacotherapy, 2004, Volume: 38, Issue:12

    Topics: Adenine; Adult; Antiviral Agents; Chronic Disease; Drug Resistance, Viral; Hepatitis B; Hepatitis B,

2004
Chronic infection with hepatitis B viruses and antiviral drug evaluation in uPA mice after liver repopulation with tupaia hepatocytes.
    Journal of hepatology, 2005, Volume: 42, Issue:1

    Topics: Adenine; Animals; Antiviral Agents; Disease Models, Animal; DNA, Circular; DNA, Viral; Hepatitis B,

2005
Remofovir mesylate: a prodrug of PMEA with improved liver-targeting and safety in rats and monkeys.
    Antiviral chemistry & chemotherapy, 2004, Volume: 15, Issue:6

    Topics: Adenine; Animals; Antiviral Agents; Autoradiography; Carbon Radioisotopes; Dose-Response Relationshi

2004
Activity of adefovir dipivoxil against all patterns of lamivudine-resistant hepatitis B viruses in patients.
    Journal of viral hepatitis, 2005, Volume: 12, Issue:1

    Topics: Adenine; Alanine Transaminase; Antiviral Agents; Drug Resistance, Viral; Female; Gene Products, pol;

2005
Sustained HBs seroconversion during lamivudine and adefovir dipivoxil combination therapy for lamivudine failure.
    Journal of hepatology, 2005, Volume: 42, Issue:2

    Topics: Adenine; Adult; DNA, Viral; Drug Therapy, Combination; Hepatitis B Surface Antigens; Hepatitis B, Ch

2005
Adefovir dipivoxil added to ongoing lamivudine therapy in patients with lamivudine-resistant hepatitis B e antigen-negative chronic hepatitis B.
    Alimentary pharmacology & therapeutics, 2005, Mar-01, Volume: 21, Issue:5

    Topics: Adenine; Adult; Aged; Antiviral Agents; Drug Combinations; Drug Resistance, Viral; Female; Hepatitis

2005
[Therapeutic effect of adefovir dipivoxil on recurrent or de novo infection of hepatitis B virus after liver transplantation: a preliminary report].
    The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 2005, Volume: 45, Issue:3

    Topics: Adenine; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis B, Chronic; Humans; L

2005
[Advances in treatment of chronic hepatitis B].
    Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences, 2005, Volume: 34, Issue:2

    Topics: Adenine; Animals; Antiviral Agents; Drug Therapy, Combination; Genetic Therapy; Hepatitis B, Chronic

2005
Prophylaxis of hepatitis B virus recurrence after liver transplantation in carriers of lamivudine-resistant mutants.
    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2005, Volume: 11, Issue:5

    Topics: Adenine; Adult; Antibodies, Viral; Drug Resistance, Viral; Female; Genotype; Hepatitis B Surface Ant

2005
Summaries for patients. Antiviral regimens for chronic hepatitis B virus infection.
    Annals of internal medicine, 2005, May-17, Volume: 142, Issue:10

    Topics: Adenine; Antiviral Agents; Cost-Benefit Analysis; Decision Support Techniques; Hepatitis B e Antigen

2005
Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis.
    Annals of internal medicine, 2005, May-17, Volume: 142, Issue:10

    Topics: Adenine; Antiviral Agents; Cost-Benefit Analysis; Decision Support Techniques; Hepatitis B e Antigen

2005
Assessing the benefits and costs of new therapies for hepatitis B virus infection.
    Annals of internal medicine, 2005, May-17, Volume: 142, Issue:10

    Topics: Adenine; Antiviral Agents; Cost-Benefit Analysis; Hepatitis B, Chronic; Humans; Organophosphonates

2005
Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine.
    Hepatology (Baltimore, Md.), 2005, Volume: 42, Issue:1

    Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Female; Hepatitis B e

2005
Viral kinetics in patients with lamivudine-resistant hepatitis B during adefovir-lamivudine combination therapy.
    Journal of hepatology, 2005, Volume: 43, Issue:2

    Topics: Adenine; Adolescent; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Comb

2005
Antiviral effect of oral administration of tenofovir disoproxil fumarate in woodchucks with chronic woodchuck hepatitis virus infection.
    Antimicrobial agents and chemotherapy, 2005, Volume: 49, Issue:7

    Topics: Adenine; Administration, Oral; Animals; Antiviral Agents; Dose-Response Relationship, Drug; Hepatiti

2005
The maze of treatments for hepatitis B.
    The New England journal of medicine, 2005, Jun-30, Volume: 352, Issue:26

    Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B e Antigens

2005
[Influence of nucleoside analogues resistance on anti-HBV treatment].
    Zhonghua yi xue za zhi, 2005, May-11, Volume: 85, Issue:17

    Topics: Adenine; Antiviral Agents; Dideoxynucleosides; Drug Resistance, Viral; Hepatitis B virus; Hepatitis

2005
Chronic hepatitis B--treatment with nucleoside analogues.
    The Medical journal of Malaysia, 2005, Volume: 60 Suppl B

    Topics: Adenine; Drug Resistance; Drug Therapy, Combination; Guanine; Hepatitis B, Chronic; Humans; Lamivudi

2005
Association of polymorphism of tumor necrosis factor-alpha gene promoter region with outcome of hepatitis B virus infection.
    World journal of gastroenterology, 2005, Sep-07, Volume: 11, Issue:33

    Topics: Adenine; Adult; Case-Control Studies; Cytosine; Female; Genotype; Hepatitis B; Hepatitis B virus; He

2005
[Clinical outcomes after discontinuation of Lamivudine in chronic hepatitis B patients with Lamivudine resistant HBV mutant].
    The Korean journal of hepatology, 2005, Volume: 11, Issue:3

    Topics: Adenine; Adult; Antiviral Agents; Drug Resistance, Viral; Female; Hepatitis B e Antigens; Hepatitis

2005
[Adefovir dipivoxil in treatment of decompensated liver cirrhosis patients with YMDD mutation].
    Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences, 2005, Volume: 34, Issue:5

    Topics: Adenine; Adult; Aged; Amino Acid Motifs; Antiviral Agents; DNA-Directed DNA Polymerase; Female; Hepa

2005
Resistance to adefovir: a new challenge in the treatment of chronic hepatitis B.
    Journal of hepatology, 2005, Volume: 43, Issue:6

    Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B virus; Hep

2005
Risk of selecting K65R in antiretroviral-naive HIV-infected individuals with chronic hepatitis B treated with adefovir.
    AIDS (London, England), 2005, Nov-18, Volume: 19, Issue:17

    Topics: Adenine; Antiviral Agents; DNA, Viral; Genes, Viral; Genotype; Hepatitis B e Antigens; Hepatitis B,

2005
Impact of tenofovir-containing antiretroviral therapy on chronic hepatitis B in a cohort co-infected with human immunodeficiency virus.
    The Journal of antimicrobial chemotherapy, 2005, Volume: 56, Issue:6

    Topics: Adenine; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; DNA, V

2005
Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1.
    Journal of hepatology, 2006, Volume: 44, Issue:1

    Topics: Adenine; Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Drug Resistance, Viral; Fem

2006
Cost-effectiveness in hepatitis B.
    Annals of internal medicine, 2005, Nov-15, Volume: 143, Issue:10

    Topics: Adenine; Antiviral Agents; Cost-Benefit Analysis; Hepatitis B, Chronic; Humans; Interferon alpha-2;

2005
Treatment of lamivudine-resistant hepatitis B in HIV-infected persons: is adefovir dipivoxil the answer?
    Journal of hepatology, 2006, Volume: 44, Issue:1

    Topics: Adenine; AIDS-Related Opportunistic Infections; Antiviral Agents; DNA, Viral; Drug Resistance, Viral

2006
Heart transplantation in patients with chronic hepatitis B: clinical evolution, molecular analysis, and effect of treatment.
    Transplantation, 2005, Nov-15, Volume: 80, Issue:9

    Topics: Adenine; Adult; Alanine Transaminase; DNA, Viral; Drug Resistance, Viral; Female; Heart Diseases; He

2005
Virologic response and resistance to adefovir in patients with chronic hepatitis B.
    Journal of hepatology, 2006, Volume: 44, Issue:2

    Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Follow-Up Studies; Genotype;

2006
Clinical and virological effects during two years of ongoing adefovir dipivoxil in the treatment of lamivudine-resistant chronic hepatitis B infection.
    Transplantation proceedings, 2005, Volume: 37, Issue:9

    Topics: Adenine; Aged; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B e Antigens;

2005
Cost-effectiveness analysis of lamivudine and adefovir dipivoxil in the treatment of patients with HBeAg-negative chronic hepatitis B.
    Alimentary pharmacology & therapeutics, 2006, Feb-01, Volume: 23, Issue:3

    Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Cost-Benefit Analysis; Hepatitis B e Antigens; Hepatitis

2006
[Lamivudine and adefovir resistance in a patient with HBeAg negative chronic hepatitis B].
    Gastroenterologia y hepatologia, 2006, Volume: 29, Issue:2

    Topics: Adenine; Antiviral Agents; Drug Resistance, Multiple, Viral; Hepatitis B e Antigens; Hepatitis B vir

2006
Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil.
    Gut, 2006, Volume: 55, Issue:10

    Topics: Adenine; Adult; Drug Resistance, Viral; Female; Genotype; Hepatitis B, Chronic; Humans; Lamivudine;

2006
Adefovir dipivoxil-associated thrombocytopenia in a patient with chronic hepatitis B.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2006, Volume: 38, Issue:3

    Topics: Adenine; Antiviral Agents; Hepatitis B, Chronic; Humans; Male; Middle Aged; Organophosphonates; Thro

2006
Chronic hepatitis B: a critical appraisal of current approaches to therapy.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2006, Volume: 4, Issue:2

    Topics: Adenine; Alanine Transaminase; Antiviral Agents; Biopsy; Clinical Competence; Disease Progression; D

2006
Combination therapy for chronic hepatitis B: a one-two knockout punch, or a swing and a miss?
    Gastroenterology, 2006, Volume: 130, Issue:2

    Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Hepatitis B e Antigens; Hepatitis B virus; Hep

2006
Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants.
    Hepatobiliary & pancreatic diseases international : HBPD INT, 2006, Volume: 5, Issue:1

    Topics: Adenine; Adult; DNA, Viral; Drug Resistance, Viral; Follow-Up Studies; Hepatitis B virus; Hepatitis

2006
Replacement of tenofovir with adefovir may result in reactivation of hepatitis B virus replication.
    Scandinavian journal of gastroenterology, 2006, Volume: 41, Issue:2

    Topics: Adenine; Antiviral Agents; Follow-Up Studies; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male;

2006
[Chronic hepatitis B: from old braids and new brooms].
    Krankenpflege Journal, 2005, Volume: 43, Issue:7-10

    Topics: Adenine; Antiviral Agents; Germany; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic;

2005
Sensitive line probe assay that simultaneously detects mutations conveying resistance to lamivudine and adefovir.
    Journal of clinical microbiology, 2006, Volume: 44, Issue:3

    Topics: Adenine; Antiviral Agents; Base Sequence; DNA Probes; DNA, Viral; Drug Resistance, Viral; Genes, Vir

2006
First report of genotypic resistance to adefovir in chronic HBV in the Republic of Ireland.
    The Journal of antimicrobial chemotherapy, 2006, Volume: 57, Issue:5

    Topics: Adenine; Adult; Antiviral Agents; Drug Resistance, Viral; Gene Products, pol; Hepatitis B virus; Hep

2006
Antiviral options for the treatment of chronic hepatitis B.
    The Journal of antimicrobial chemotherapy, 2006, Volume: 57, Issue:6

    Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Guanine; Hepatitis B v

2006
Switching to adefovir monotherapy after emergence of lamivudine-resistant mutations in patients with liver cirrhosis.
    Journal of viral hepatitis, 2006, Volume: 13, Issue:4

    Topics: Adenine; Adult; Aged; Alanine Transaminase; Antiviral Agents; Bilirubin; DNA, Viral; Drug Resistance

2006
Tenofovir for chronic hepatitis B virus infection in HIV-coinfected patients.
    The AIDS reader, 2006, Volume: 16, Issue:4

    Topics: Adenine; Adult; Anti-HIV Agents; Clinical Trials as Topic; Hepatitis B e Antigens; Hepatitis B, Chro

2006
Variant of hepatitis B virus with primary resistance to adefovir.
    The New England journal of medicine, 2006, Apr-27, Volume: 354, Issue:17

    Topics: Adenine; Amino Acid Sequence; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Hepatiti

2006
Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B.
    Archives of Iranian medicine, 2006, Volume: 9, Issue:1

    Topics: Adenine; Antiviral Agents; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans;

2006
Adefovir dipivoxil monotherapy is a sufficiently effective treatment modality for Japanese patients with lamivudine-resistant chronic hepatitis B.
    Journal of gastroenterology, 2006, Volume: 41, Issue:3

    Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; Biomarkers; DNA, Viral; Drug Resistance, Vir

2006
Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy.
    Hepatology (Baltimore, Md.), 2006, Volume: 43, Issue:6

    Topics: Adenine; Adult; Aged; Antiviral Agents; Base Sequence; Case-Control Studies; DNA, Viral; Dose-Respon

2006
[The change of HBV nucleotide sequence during Adefovir dipivoxil treatment].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2006, Volume: 14, Issue:5

    Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Human

2006
[The use of nucleotide analogues in treating patients with chronic hepatitis B].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2006, Volume: 14, Issue:5

    Topics: Adenine; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Nucleosides; Organophosphonates

2006
[Problems of and strategies in nucleotide analogues therapy for chronic hepatitis B].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2006, Volume: 14, Issue:5

    Topics: Adenine; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Nucleosides; Organophosphonates

2006
Detection of rtN236T and rtA181V/T mutations associated with resistance to adefovir dipivoxil in samples from patients with chronic hepatitis B virus infection by the INNO-LiPA HBV DR line probe assay (version 2).
    Journal of clinical microbiology, 2006, Volume: 44, Issue:6

    Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Genotype; Hepatitis B virus; Hepatiti

2006
[To evaluate treatments of chronic hepatitis B].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2006, Volume: 14, Issue:6

    Topics: Adenine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Nucleos

2006
[Comparison of clinical outcome between patients continuing and discontinuing lamivudine therapy in acute exacerbation after viral breakthrough during lamivudine therapy in chronic hepatitis B].
    The Korean journal of hepatology, 2006, Volume: 12, Issue:2

    Topics: Acute Disease; Adenine; Adult; Aged; Alanine Transaminase; Antiviral Agents; Female; Hepatitis B vir

2006
Hepatitis B virus with primary resistance to adefovir.
    The New England journal of medicine, 2006, Jul-20, Volume: 355, Issue:3

    Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Guanine; Hepatitis B Antibodies; Hepatitis B e An

2006
Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B.
    Hepatology (Baltimore, Md.), 2006, Volume: 44, Issue:3

    Topics: Adenine; Adult; Antiviral Agents; Biopsy; DNA, Circular; DNA, Viral; Drug Carriers; Drug Therapy, Co

2006
Virological outcome of chronic hepatitis B virus infection in HIV-coinfected patients receiving anti-HBV active antiretroviral therapy.
    AIDS research and human retroviruses, 2006, Volume: 22, Issue:9

    Topics: Adenine; Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Chi-Square Distributi

2006
Favorable effect of adefovir on the number and functionality of myeloid dendritic cells of patients with chronic HBV.
    Hepatology (Baltimore, Md.), 2006, Volume: 44, Issue:4

    Topics: Adenine; Adult; Aged; Alanine Transaminase; Antigens, CD; Antiviral Agents; Cytokines; Dendritic Cel

2006
Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient.
    Gastroenterology, 2006, Volume: 131, Issue:4

    Topics: Adenine; Adult; Antiviral Agents; Biological Evolution; Cells, Cultured; Drug Resistance, Multiple;

2006
[A case of severe skin eruption caused by lamivudine in a patient with chronic hepatitis B].
    The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 2006, Volume: 48, Issue:4

    Topics: Adenine; Antiviral Agents; Drug Eruptions; Female; Hepatitis B, Chronic; Humans; Ichthyosis; Lamivud

2006
A novel hepatitis B virus mutation with resistance to adefovir but not to tenofovir in an HIV-hepatitis B virus-co-infected patient.
    AIDS (London, England), 2006, Nov-14, Volume: 20, Issue:17

    Topics: Adenine; Adult; Drug Resistance, Viral; Gene Products, pol; Hepatitis B virus; Hepatitis B, Chronic;

2006
Inhibition of viral replication reduces regulatory T cells and enhances the antiviral immune response in chronic hepatitis B.
    Virology, 2007, Apr-25, Volume: 361, Issue:1

    Topics: Adenine; Adult; Aged; Antiviral Agents; CD4 Lymphocyte Count; Cell Division; Cells, Cultured; Female

2007
Prevalence of hepatitis B virus genotype D in precore mutants among chronic liver disease patients from New Delhi, India.
    Digestive diseases and sciences, 2007, Volume: 52, Issue:2

    Topics: Adenine; Adult; DNA Mutational Analysis; DNA, Viral; Female; Genotype; Guanine; Hepatitis B Core Ant

2007
COBAS AmpliPrep-COBAS TaqMan hepatitis B virus (HBV) test: a novel automated real-time PCR assay for quantification of HBV DNA in plasma.
    Journal of clinical microbiology, 2007, Volume: 45, Issue:3

    Topics: Adenine; Antiviral Agents; Automation; Biopsy; DNA, Viral; Drug Resistance, Viral; Hepatitis B Surfa

2007
[The rate of hepatitis B virus resistance to adefovir dipivoxil (ADV) and the evolution of hepatitis B virus in lamivudine-resistant chronic hepatitis B patients with ADV monotherapy].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2007, Volume: 15, Issue:1

    Topics: Adenine; Adult; Antiviral Agents; Drug Resistance, Viral; Evolution, Molecular; Female; Hepatitis B

2007
Rescue therapy for lamivudine-resistant chronic hepatitis B: when and how?
    Hepatology (Baltimore, Md.), 2007, Volume: 45, Issue:2

    Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Guanine; H

2007
Why do we not yet have combination chemotherapy for chronic hepatitis B?
    The Medical journal of Australia, 2007, Feb-19, Volume: 186, Issue:4

    Topics: Adenine; Antibodies, Viral; Antiviral Agents; DNA, Viral; Drug Combinations; Drug Resistance, Multip

2007
Progress in the treatment of chronic hepatitis B: long-term experience with adefovir dipivoxil.
    The Journal of antimicrobial chemotherapy, 2007, Volume: 59, Issue:5

    Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans;

2007
Treatment of patients with lamivudine-resistant and adefovir dipivoxil-resistant chronic hepatitis B virus infection: is tenofovir the answer?
    Gut, 2007, Volume: 56, Issue:3

    Topics: Adenine; Adult; Drug Resistance, Multiple, Viral; Hepatitis B, Chronic; Humans; Lamivudine; Male; Mi

2007
In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants.
    Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:6

    Topics: Adenine; Antiviral Agents; Cell Line, Tumor; Drug Resistance, Multiple, Viral; Hepatitis B virus; He

2007
Tailoring antiviral therapy in chronic hepatitis B patients with lamivudine resistance.
    Journal of hepatology, 2007, Volume: 46, Issue:5

    Topics: Adenine; Contraindications; Dose-Response Relationship, Drug; Drug Resistance, Viral; Hepatitis B vi

2007
Early virological suppression is associated with good maintained response to adefovir dipivoxil in lamivudine resistant chronic hepatitis B.
    Alimentary pharmacology & therapeutics, 2007, Apr-15, Volume: 25, Issue:8

    Topics: Adenine; Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Female; Hepatitis B, Chronic; Hong K

2007
Decompensated lamivudine-resistant hepatitis B virus-related cirrhosis treated successfully with adefovir dipivoxil allowing surgery for hepatocellular carcinoma.
    Internal medicine (Tokyo, Japan), 2007, Volume: 46, Issue:7

    Topics: Adenine; Carcinoma, Hepatocellular; Cell Transformation, Neoplastic; Disease Progression; Drug Resis

2007
Characteristics of patients with chronic hepatitis-B virus infection in an urban hospital.
    Journal of the National Medical Association, 2007, Volume: 99, Issue:4

    Topics: Adenine; Adolescent; Adult; Black or African American; Contraindications; Female; Hepatitis B, Chron

2007
Optimal duration of therapy in HBV-related cirrhosis.
    The Journal of antimicrobial chemotherapy, 2007, Volume: 60, Issue:1

    Topics: Adenine; Antiviral Agents; Drug Administration Schedule; Health Planning Guidelines; Hepatitis B vir

2007
Recommendations for the treatment of chronic hepatitis B infection in children.
    JPMA. The Journal of the Pakistan Medical Association, 2007, Volume: 57, Issue:4

    Topics: Adenine; Antiviral Agents; Child; Child, Preschool; Female; Hepatitis B e Antigens; Hepatitis B Surf

2007
Reversibility of cirrhosis in HIV/HBV coinfection.
    Antiviral therapy, 2007, Volume: 12, Issue:2

    Topics: Adenine; Adult; Alanine Transaminase; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; DNA, V

2007
Adefovir dipivoxil monotherapy and combination therapy with lamivudine for the treatment of chronic hepatitis B in an Asian population.
    Antiviral therapy, 2007, Volume: 12, Issue:1

    Topics: Adenine; Adult; Aged; Alanine Transaminase; Asian People; DNA, Viral; Drug Resistance, Multiple, Vir

2007
Evolution of viral load and changes of polymerase and precore/core promoter sequences in lamivudine-resistant hepatitis B virus during adefovir therapy.
    Journal of medical virology, 2007, Volume: 79, Issue:7

    Topics: Adenine; Adult; Antiviral Agents; Base Sequence; DNA Mutational Analysis; DNA Primers; DNA, Viral; D

2007
[Recent advances in the treatment of the hepatitis HBV-related. Effectiveness and tolerability of adefovir dipivoxil].
    Recenti progressi in medicina, 2007, Volume: 98, Issue:4

    Topics: Adenine; Antiviral Agents; Hepatitis B virus; Hepatitis B, Chronic; Humans; Organophosphonates; Trea

2007
Viral genotype and baseline load predict the response to adefovir treatment in lamivudine-resistant chronic hepatitis B patients.
    Journal of hepatology, 2007, Volume: 47, Issue:3

    Topics: Adenine; Adult; Antiviral Agents; Cohort Studies; DNA, Viral; Drug Resistance, Viral; Female; Gene D

2007
Does pre-treatment with lamivudine prime for adefovir resistance of hepatitis B virus infection?
    The Journal of antimicrobial chemotherapy, 2007, Volume: 60, Issue:2

    Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B,

2007
[An economic evaluation of different treatments for HBeAg-positive chronic hepatitis B in China].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2007, Volume: 15, Issue:6

    Topics: Adenine; Antiviral Agents; Cost-Benefit Analysis; Female; Hepatitis B e Antigens; Hepatitis B, Chron

2007
Pre- and post-treatment predictors of the early achievement of HBeAg loss in lamivudine-resistant patients receiving adefovir therapy.
    Journal of gastroenterology and hepatology, 2007, Volume: 22, Issue:7

    Topics: Adenine; Adult; Antiviral Agents; Drug Resistance, Viral; Female; Hepatitis B e Antigens; Hepatitis

2007
Pradefovir, a liver-targeted prodrug of adefovir against HBV infection.
    Current opinion in investigational drugs (London, England : 2000), 2007, Volume: 8, Issue:8

    Topics: Adenine; Antiviral Agents; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dr

2007
[A case of chronic hepatitis B with primary adefovir resistance].
    Mikrobiyoloji bulteni, 2007, Volume: 41, Issue:2

    Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug The

2007
Hepatitis B virus and HIV coinfection: results of a survey on treatment practices and recommendations for therapy.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2007, Sep-01, Volume: 45, Issue:5

    Topics: Adenine; Adult; Anti-Retroviral Agents; Antiviral Agents; Drug Therapy, Combination; Female; Guideli

2007
Combination adefovir-lamivudine prevents emergence of adefovir resistance in lamivudine-resistant hepatitis B.
    Journal of gastroenterology and hepatology, 2007, Volume: 22, Issue:9

    Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Drug Resistance; Drug Resistance, Viral; Drug Th

2007
Antiviral efficacy of adefovir dipivoxil versus lamivudine in patients with chronic hepatitis B sequentially treated with lamivudine and adefovir due to lamivudine resistance.
    World journal of gastroenterology, 2007, Aug-14, Volume: 13, Issue:30

    Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy

2007
Adefovir for lamivudine resistant HBV: more than meets the eye.
    Journal of hepatology, 2007, Volume: 47, Issue:4

    Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B e Antigens; Hepat

2007
A novel mutation pattern emerging during lamivudine treatment shows cross-resistance to adefovir dipivoxil treatment.
    Antiviral therapy, 2007, Volume: 12, Issue:5

    Topics: Adenine; Adult; Arabinofuranosyluracil; Base Sequence; Cell Line, Tumor; Cloning, Molecular; Deoxycy

2007
Chronic hepatitis B: a wider range of therapeutic options.
    Prescrire international, 2007, Volume: 16, Issue:90

    Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Guanine; Hepatitis B, Chronic; Humans; Interferon

2007
Redetection of HBV lamivudine-resistant mutations in a patient under entecavir therapy, who had been treated sequentially with nucleos(t)ide analogues.
    Journal of medical virology, 2007, Volume: 79, Issue:11

    Topics: Adenine; Adult; Antiviral Agents; Drug Administration Schedule; Drug Resistance, Viral; Guanine; Hep

2007
[Effect of initial virologic response to adefovir on the development of resistance to adefovir in lamivudine-resistant chronic hepatitis B].
    The Korean journal of hepatology, 2007, Volume: 13, Issue:3

    Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female;

2007
Summaries for patients. Antiviral therapy for chronic hepatitis B.
    Annals of internal medicine, 2007, Dec-04, Volume: 147, Issue:11

    Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Biomarkers; DNA, Viral; Drug Therapy, Combinatio

2007
Evolution of primary and compensatory lamivudine resistance mutations in chronic hepatitis B virus-infected patients during long-term lamivudine treatment, assessed by a line probe assay.
    Journal of clinical microbiology, 2007, Volume: 45, Issue:12

    Topics: Adenine; Amino Acid Substitution; Drug Resistance, Viral; Evolution, Molecular; Gene Products, pol;

2007
[Recent therapies for hepatitis B (discussion)].
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2007, Volume: 104, Issue:10

    Topics: Adenine; Antiviral Agents; Genotype; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B

2007
The cost-effectiveness of long-term antiviral therapy in the management of HBeAg-positive and HBeAg-negative chronic hepatitis B in Singapore.
    Journal of viral hepatitis, 2007, Volume: 14, Issue:11

    Topics: Adenine; Antiviral Agents; Asian People; Cost-Benefit Analysis; Drug Costs; Female; Hepatitis B e An

2007
[Adefovir in reactivation of chemotherapy-induced hepatitis B in an anti-Hbc-positive patient].
    Gastroenterologia y hepatologia, 2007, Volume: 30, Issue:9

    Topics: Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Bleomycin; Dacarbaz

2007
Hepatitis B: explosion of new knowledge.
    Gastroenterology, 2007, Volume: 133, Issue:5

    Topics: Adenine; Antiviral Agents; Disease Progression; Drug Resistance, Viral; Genotype; Guanine; Hepatitis

2007
Long-term therapy with adefovir dipivoxil in hepatitis B e antigen-negative patients developing resistance to lamivudine.
    Alimentary pharmacology & therapeutics, 2008, Feb-01, Volume: 27, Issue:3

    Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combinatio

2008
Hepatitis B virus containing the I233V mutation in the polymerase reverse-transcriptase domain remains sensitive to inhibition by adefovir.
    The Journal of infectious diseases, 2007, Nov-15, Volume: 196, Issue:10

    Topics: Adenine; Adult; Aged; Antiviral Agents; Clinical Trials, Phase III as Topic; DNA, Viral; Drug Resist

2007
Tenofovir-based rescue therapy for advanced liver disease in 6 patients coinfected with HIV and hepatitis B virus and receiving lamivudine.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2008, Feb-01, Volume: 46, Issue:3

    Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Resistance, Viral; Hepa

2008
Switching patients with lamivudine resistant chronic hepatitis B virus from tenofovir to adefovir results in less potent HBV-DNA suppression.
    Journal of viral hepatitis, 2008, Volume: 15, Issue:2

    Topics: Adenine; Adolescent; Adult; Antiviral Agents; Cohort Studies; DNA, Viral; Drug Resistance, Viral; Fe

2008
Potency of tenofovir in chronic hepatitis B: mono or combination therapy?
    Journal of hepatology, 2008, Volume: 48, Issue:3

    Topics: Adenine; Antiviral Agents; Deoxycytidine; DNA, Viral; Drug Therapy, Combination; Emtricitabine; Guan

2008
[Protocol for the treatment of chronic viral hepatitis].
    Orvosi hetilap, 2008, Jan-20, Volume: 149, Issue:3

    Topics: Adenine; Algorithms; Antiviral Agents; Clinical Protocols; Hepacivirus; Hepatitis B virus; Hepatitis

2008
Evaluation of initial virological response to adefovir and development of adefovir-resistant mutations in patients with chronic hepatitis B.
    Journal of viral hepatitis, 2008, Volume: 15, Issue:5

    Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female;

2008
Lamivudine-resistant chronic hepatitis B: an observational study on adefovir in monotherapy or in combination with lamivudine.
    Journal of hepatology, 2008, Volume: 48, Issue:4

    Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Multiple, Viral; Drug Therapy, Combination;

2008
Tenofovir plus lamivudine as rescue therapy for adefovir-resistant chronic hepatitis B in hepatitis B e antigen-positive patients with liver cirrhosis.
    Liver international : official journal of the International Association for the Study of the Liver, 2008, Volume: 28, Issue:6

    Topics: Adenine; Adult; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B e Antigen

2008
Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study.
    Clinical therapeutics, 2008, Volume: 30, Issue:2

    Topics: Adenine; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Dr

2008
[Anti-viral therapy of type B chronic hepatitis. 3. Future of anti-viral agents].
    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2008, Jan-10, Volume: 97, Issue:1

    Topics: Adenine; Antiviral Agents; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Hepatitis B, Chroni

2008
[Factors affecting initial virologic response and emergence of resistant mutants after adefovir treatment in lamivudine-resistant chronic hepatitis B patients].
    The Korean journal of hepatology, 2008, Volume: 14, Issue:1

    Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; DNA, Viral; Dru

2008
Economic evaluation of chronic hepatitis B treatments in Taiwan.
    Journal of gastroenterology and hepatology, 2008, Volume: 23, Issue:4

    Topics: Adenine; Adult; Antiviral Agents; Cost-Benefit Analysis; Female; Hepatitis B, Chronic; Humans; Lamiv

2008
Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up.
    Journal of hepatology, 2008, Volume: 48, Issue:6

    Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Dose-Response Relationship, Drug; Drug Resistanc

2008
Europe extends Viread indication for chronic hepatitis B.
    AIDS patient care and STDs, 2008, Volume: 22, Issue:4

    Topics: Adenine; Antiviral Agents; Clinical Trials, Phase III as Topic; Drug Approval; Europe; Hepatitis B,

2008
Comparison of the Cobas Ampliprep/Cobas TaqMan HBV Test versus the Cobas Amplicor HBV monitor for HBV-DNA detection and quantification during antiviral therapy.
    The new microbiologica, 2008, Volume: 31, Issue:1

    Topics: Adenine; Antiviral Agents; Automation; DNA, Viral; Hepatitis B Surface Antigens; Hepatitis B virus;

2008
Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants.
    Hepatology (Baltimore, Md.), 2000, Volume: 32, Issue:1

    Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance; Female; Hepatitis B virus; Hepatitis

2000
Androgen-receptor gene CAG repeats, plasma testosterone levels, and risk of hepatitis B-related hepatocellular carcinoma.
    Journal of the National Cancer Institute, 2000, Dec-20, Volume: 92, Issue:24

    Topics: Adenine; Adult; Aged; Carcinoma, Hepatocellular; Case-Control Studies; Cohort Studies; Cytosine; Gua

2000
[Current treatment of hepatitis B].
    Gastroenterologia y hepatologia, 2001, Volume: 24 Suppl 1

    Topics: 2-Aminopurine; Adenine; Anti-Inflammatory Agents; Antiviral Agents; DNA Replication; Famciclovir; Fo

2001
Adefovir dipivoxil reduces HBV DNA.
    Newsline (People with AIDS Coalition of New York), 1999

    Topics: Adenine; Administration, Oral; Antiviral Agents; DNA, Viral; Hepatitis B, Chronic; Humans

1999
Successful treatment with adefovir dipivoxil in a patient with fibrosing cholestatic hepatitis and lamivudine resistant hepatitis B virus.
    Gut, 2001, Volume: 49, Issue:3

    Topics: Adenine; Antiviral Agents; Drug Resistance, Microbial; Hepatitis B e Antigens; Hepatitis B, Chronic;

2001
Human immunodeficiency virus (HIV) Type 1 reverse transcriptase resistance mutations in hepatitis B virus (HBV)-HIV-coinfected patients treated for HBV chronic infection once daily with 10 milligrams of adefovir dipivoxil combined with lamivudine.
    Antimicrobial agents and chemotherapy, 2002, Volume: 46, Issue:5

    Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B virus; Hep

2002